ࡱ> wyXYZ[\]^_`abcdefghijklmnopqrstuv bjbjcTcT  >>>>KKKK#N#N#N'O'O'OPX 'Oub,s~9u9u9uۀr1M 9tttttttF|~t#N1"ۀ11tKKKK9u9u t1KK 9u#N9ut1t~IN8 WM-q9u1<'O [Xmt ulu\Th lh-q-qh#NAq,111ttuj111u1111h111111111> J: Final Draft 9/14/09[Cover for 2010 EOC] January 1 December 31, 2010 Certificate of Coverage: Your Medicare and Medical Assistance Health Benefits and Services and Prescription Drug Coverage as a Member of [insert plan name] [SNPs with an arrangement with the State may revise this language to reflect, when applicable, that the organization is providing both Medicaid and Medicare covered benefits.] [Optional: insert beneficiary name] [Optional: insert beneficiary address] This booklet gives you the details about your Medicare and Medical Assistance health benefits and services and prescription drug coverage from January 1 December 31, 2010. It explains how to get the health care, services and prescription drugs you need. This is an important legal document. Please keep it in a safe place. [Insert plan name] Member Services: For help or information, please call Member Services or go to our plan website at [insert URL]. [Plan may add local phone number if desired] [Insert phone number] (Calls to these numbers are [insert if applicable: not] free.) [Insert TTY] users call: [insert TTY number] This plan is offered by [insert MAO sponsor], referred throughout the Certificate of Coverage as we, us, or our. [Insert plan name] is referred to as plan or our plan. [Insert Federal contracting statement.] This information [insert as applicable: may be OR is] available in a different format, including [list all available formats, including languages, large print, and audio tapes]. Please call Member Services at the number listed above if you need plan information in another format or language. Our Plan will accept all eligible people who choose or are assigned to the Plan. We will not discriminate in regard to your physical or mental condition; health status; need for health services; marital status; age; sex; sexual orientation; national origin; race; color; religion or political beliefs. [Plans offering the ANOC/EOC in Spanish (or other languages) should include the above paragraph in the English document in Spanish (or other languages as applicable).][Insert Language Block [insert Material ID number] [insert mm/yyyy] Table of Contents This list of chapters and page numbers is just your starting point. For more help in finding information you need, go to the first page of a chapter. You will find a detailed list of topics at the beginning of each chapter.  TOC \t "Chapter Heading,1" Chapter 1. Getting started as a member of [insert plan name]  PAGEREF _Toc110591470 \h 1 Tells what it means to be in a Medicare health plan and how to use this booklet. Tells about materials we will send you, your plan premium, your plan membership card, and keeping your membership record up to date. Chapter 2. Important phone numbers and resources  PAGEREF _Toc110591471 \h 13 Tells you how to get in touch with our plan ([insert plan name]) and with other organizations including Medicare, the State Health Insurance Assistance Program, the Quality Improvement Organization, Social Security, Medicaid (the state health insurance program for people with low incomes), programs that help people pay for their prescription drugs, and the Railroad Retirement Board. Chapter 3. Using the plans coverage for your medical services  PAGEREF _Toc110591472 \h 29 Explains important things you need to know about getting your medical care as a member of our plan. Topics include using the providers in the plans network and how to get care when you have an emergency. Chapter 4. Medical benefits chart (what is covered and what you pay)  PAGEREF _Toc110591473 \h 39 Gives the details about which types of medical care are covered and not covered for you as a member of our plan. Tells how much you will pay as your share of the cost for your covered medical care. Chapter 5. Using the plans coverage for your Part D prescription drugs  PAGEREF _Toc110591474 \h 66 Explains rules you need to follow when you get your Part D drugs. Tells how to use the plans List of Covered Drugs (Formulary) to find out which drugs are covered. Tells which kinds of drugs are not covered. Explains several kinds of restrictions that apply to your coverage for certain drugs. Explains where to get your prescriptions filled. Tells about the plans programs for drug safety and managing medications. Chapter 6. What you pay for your Part D prescription drugs  PAGEREF _Toc110591475 \h 86 Tells about the [insert number of stages] stages of drug coverage ([delete any stages that are not applicable] Deductible Stage, Initial Coverage Stage, Coverage Gap Stage, Catastrophic Coverage Stage) and how these stages affect what you pay for your drugs. [Plans without drug tiers, delete the following sentence.] Explains the [insert number of tiers] cost-sharing tiers for your Part D drugs and tells what you must pay for ([insert as applicable: copayment OR coinsurance OR copayments or coinsurance]) as your share of the cost for a drug in each cost-sharing tier. Tells about the late enrollment penalty. Chapter 7. Asking the plan to pay its share of a bill you have received for covered services or drugs  PAGEREF _Toc110591476 \h 98 Tells when and how to send a bill to us when you want to ask us to pay you back for our share of the cost for your covered services. Chapter 8. Your rights and responsibilities  PAGEREF _Toc110591477 \h 104 Explains the rights and responsibilities you have as a member of our plan. Tells what you can do if you think your rights are not being respected. Chapter 9. What to do if you have a problem or complaint (coverage decisions, appeals, complaints)  PAGEREF _Toc110591478 \h 115 Tells you step-by-step what to do if you are having problems or concerns as a member of our plan. Explains how to ask for coverage decisions and make appeals if you are having trouble getting the medical care or prescription drugs you think are covered by our plan. This includes asking us to make exceptions to the rules or extra restrictions on your coverage for prescription drugs, and asking us to keep covering hospital care and certain types of medical services if you think your coverage is ending too soon. Explains how to make complaints about quality of care, waiting times, customer service, and other concerns. Chapter 10. Ending your membership in the plan  PAGEREF _Toc110591479 \h 171 Tells when and how you can end your membership in the plan. Explains situations in which our plan is required to end your membership. Chapter 11. Legal notices  PAGEREF _Toc110591480 \h 178 Includes notices about governing law and about nondiscrimination. Chapter 12. Definitions of important words  PAGEREF _Toc110591481 \h 180 Explains key terms used in this booklet. Chapter 1. Getting started as a member of [insert plan name]  TOC \t "Section SubHeading 1 Ch 1,2,Section Heading Ch 1,1" SECTION 1 Introduction  PAGEREF _Toc110591772 \h 2 Section 1.1 What is the Certificate of Coverage booklet about?  PAGEREF _Toc110591773 \h 2 Section 1.2 What does this Chapter tell you?  PAGEREF _Toc110591774 \h 2 Section 1.3 What if you are new to [insert plan name]?  PAGEREF _Toc110591775 \h 3 Section 1.4 Legal information about the Certificate of Coverage  PAGEREF _Toc110591776 \h 3 SECTION 2 What makes you eligible to be a plan member?  PAGEREF _Toc110591777 \h 3 Section 2.1 Your three eligibility requirements  PAGEREF _Toc110591778 \h 3 Section 2.2 What are Medicare Part A and Medicare Part B?  PAGEREF _Toc110591779 \h 4 Section 2.3 Here is the plan service area for [insert plan name]  PAGEREF _Toc110591780 \h 4 SECTION 3 What other materials will you get from us?  PAGEREF _Toc110591781 \h 5 Section 3.1 Your plan membership card Use it to get all covered care and drugs  PAGEREF _Toc110591782 \h 5 Section 3.2 The Provider Directory: your guide to all providers in the plans network  PAGEREF _Toc110591783 \h 5 Section 3.3 The Pharmacy Directory: your guide to pharmacies in our network  PAGEREF _Toc110591784 \h 6 Section 3.4 The plans List of Covered Drugs (Formulary)  PAGEREF _Toc110591785 \h 7 Section 3.5 Reports with a summary of payments made for your prescription drugs  PAGEREF _Toc110591786 \h 7 SECTION 4 Your monthly premium for [insert plan name]  PAGEREF _Toc110591787 \h 8 Section 4.1 How much is your plan premium?  PAGEREF _Toc110591788 \h 8 Section 4.2 There are several ways you can pay your plan premium  PAGEREF _Toc110591789 \h 9 Section 4.3 Can we change your monthly plan premium during the year?  PAGEREF _Toc110591790 \h 10 SECTION 5 Please keep your plan membership record up to date  PAGEREF _Toc110591791 \h 11 Section 5.1 How to help make sure that we have accurate information about you  PAGEREF _Toc110591792 \h 11  SECTION 1 Introduction Section 1.1 What is the Certificate of Coverage booklet about? [SNPs with an arrangement with the State may revise this language to reflect, when applicable, that the organization is providing both Medicaid and Medicare covered benefits.] This Certificate of Coverage booklet tells you how to get your Medicare and Medical Assistance services and prescription drugs through our plan. This booklet explains your rights and responsibilities, what is covered, and what you pay as a member of the plan. You are covered by Medicare and Medical Assistance, and you have chosen to get your Medicare and Medical Assistance services and your prescription drug coverage through our plan, [insert plan name]. There are different types of Medicare Advantage Plans. [Insert plan name] is a Medicare Advantage HMO Plan (HMO stands for Health Maintenance Organization) [or insert other plan type]. Our Plan in is a part of a program called Minnesota Senior Health Options. The Minnesota Department of Human Services designed this project to provide special care for seniors. This program combines your Medicare and Medical Assistance services. It combines your doctor, hospital, home care, nursing home care and other care into one coordinated care system. This plan is offered by [insert MAO sponsor], referred throughout the Certificate of Coverage as we, us, or our. [Insert plan name] is referred to as plan or our plan. The word coverage and covered services refers to the medical care and services and the prescription drugs available to you as a member of [insert plan name]. Section 1.2 What does this Chapter tell you? Look through Chapter 1 of this Certificate of Coverage to learn: What makes you eligible to be a plan member? What materials will you get from us? What is your plan premium and how can you pay it? What is your plans service area? How do you keep the information in your membership record up to date? Section 1.3 What if you are new to [insert plan name]? If you are a new member, then its important for you to learn how the plan operates what the rules are and what services are available to you. We encourage you to set aside some time to look through this Certificate of Coverage booklet. If you are confused or concerned or just have a question, please contact our plans Member Services (contact information is on the cover of this booklet). Section 1.4 Legal information about the Certificate of Coverage Its part of our contract with you This Certificate of Coverage is part of our contract with you about how [insert plan name] covers your care. Other parts of this contract include your enrollment form, the List of Covered Drugs (Formulary), and any notices you receive from us about changes or extra conditions that can affect your coverage. These notices are sometimes called riders or amendments. The contract is in effect for months in which you are enrolled in [insert plan name] between January 1, 2010 and December 31, 2010. Medicare must approve our plan each year Medicare (the Centers for Medicare & Medicaid Services) must approve [insert plan name] each year. You can continue to get Medicare coverage as a member of our plan only as long as we choose to continue to offer the plan for the year in question and the Centers for Medicare & Medicaid Services renews its approval of the plan. Our Plan also contracts with the Minnesota Department of Human Services for Medical Assistance services on an annual basis. SECTION 2 What makes you eligible to be a plan member? Section 2.1 Your eligibility requirements You are eligible for membership in our plan as long as: You live in our geographic service area (section 2.3 below describes our service area) -- and -- you are entitled to Medicare Part A -- and -- you are enrolled in Medicare Part B -- and -- you do not have End Stage Renal Disease (ESRD), with limited exceptions, such as if you develop ESRD when you are already a member of a plan that we offer, or you were a member of a different plan that was terminated. : -- and -- you meet the special eligibility requirements described below. [SNPs insert this section as applicable to your plan type: Special eligibility requirements for our plan Our plan is designed to meet the needs of people who are age 65 and older and are eligible for both Medicare and Medical Assistance. Section 2.2 What are Medicare Part A and Medicare Part B? When you originally signed up for Medicare, you received information about how to get Medicare Part A and Medicare Part B. Remember: Medicare Part A generally covers services furnished by providers such as hospitals, skilled nursing facilities or home health agencies. Medicare Part B is for most other medical services, such as physicians services and other outpatient services. Section 2.3 Here is the plan service area for [insert plan name] Although Medicare is a Federal program, [insert plan name] is available only to individuals who live in our plan service area. To stay a member of our plan, you [if a continuation area is offered under 42 C.F.R. 422.54, insert generally here, and add a sentence describing the continuation area] must keep living in this service area. The service area is described [insert as appropriate: below OR in an appendix to this Certificate of Coverage.] [Insert plan services area here or within an appendix. Plans may include references to territories as appropriate. Use county name only if approved for entire county. For partially approved counties, use county name plus zip code. Examples include: Our service area includes these states: [insert states] Our service area includes these counties in [insert state]: [insert counties] Our service area includes these parts of counties in [insert state]: [insert county], the following zip codes only [insert zip codes]] [Optional info: multi-state plans may include the following: We offer coverage in [several/all] states [and territories]. However, there may be cost or other differences between the plans we offer in each state. If you move out of the state where you live into a state that is still within our service area, you must call Member Services in order to update your information. If you move into a state outside of our service area, you cannot remain a member of our plan. Please call Member Services to find out if we have a plan in your new state.] If you plan to move out of the service area, please contact Member Services. SECTION 3 What other materials will you get from us? Section 3.1 Your plan membership card Use it to get all covered care and drugs [Plans that use separate membership cards for health and drug coverage should edit the following section to reflect the use of multiple cards.] [SNPs may revise this language to reflect, when applicable, that the members will use the plan exclusively or the plan card and a Medicaid card.] While you are a member of our plan, you must use our membership card along with your Minnesota Health Care Programs card whenever you get any services covered by this plan and for prescription drugs you get at network pharmacies. Heres a sample membership card to show you what yours will look like: [Insert picture of front and back of member ID card. Mark it as a sample card (for example, by superimposing the word sample on the image of the card.] As long as you are a member of our plan you must not use your red, white, and blue Medicare card to get covered medical services (with the exception of routine clinical research studies and hospice services). Keep your red, white, and blue Medicare card in a safe place in case you need it later. Heres why this is so important: If you get covered services using your red, white, and blue Medicare card instead of using our membership card while you are a plan member, you may have to pay the full cost yourself. If your plan membership card is damaged, lost, or stolen, call Member Services right away and we will send you a new card. Section 3.2 The Provider Directory: your guide to all providers in the plans network Every year that you are a member of our plan, we will send you either a new Provider Directory or an update to your Provider Directory. This directory lists our network providers. What are network providers? Network providers are the doctors and other health care professionals, medical groups, hospitals, and other health care facilities that have an agreement with us to accept our payment in full. We have arranged for these providers to deliver covered services to members in our plan. Why do you need to know which providers are part of our network? It is important to know which providers are part of our network because, with limited exceptions, while you are a member of our plan you [insert as appropriate: must use OR may be required to use] network providers to get your medical care and services. The only exceptions are emergencies, post-stabilization (follow-up care), urgently needed care when the network is not available (generally, out of the area), out-of-area dialysis services, open access services and cases in which [insert plan name] authorizes use of non-network providers. [SNPs with arrangement with the State may revise this language to reflect, when applicable, that the organization is providing both Medicaid and Medicare covered benefits]. See Chapter 3 (Using the plans coverage for your medical services) for more specific information about emergency, out-of-network, and out-of-area coverage. [Plans with a Point-of-Service (POS) option may briefly describe the POS option here. The details of the POS should be addressed in Chapter 3.] [Dual Eligible SNPs should also describe their participating Medicaid providers here. You should describe if Home and Community based services are include in the Provider Directory and if not where they are included and how members and care coordinators can get a listing. The details of the Dual Eligible SNP providers should be addressed in Chapter 3.] If you dont have your copy of the Provider Directory, you can request a copy from Member Services. You may ask Member Services for more information about our network providers, including their qualifications. [Plans may add additional information describing the information available in the provider directory, on the plans website, or from Member Services. For example: You can also see the Provider Directory at [insert URL], or download it from this website. Both Member Services and the website can give you the most up-to-date information about changes in our network providers.] Section 3.3 The Pharmacy Directory: your guide to pharmacies in our network [Plans with combined provider and pharmacy directories may edit the provider and pharmacy directory paragraphs to describe the combined document.] What are network pharmacies? Our Pharmacy Directory gives you a complete list of our network pharmacies that means all of the pharmacies that have agreed to fill covered prescriptions for our plan members. Why do you need to know about network pharmacies? You can use the Pharmacy Directory to find the network pharmacy you want to use. [Plans may add detail describing additional information included in the pharmacy directory.] This is important because, with few exceptions, you must get your prescriptions filled at one of our network pharmacies if you want our plan to cover (help you pay for) them. We will send you a complete Pharmacy Directory at least once every three years. Every year that you dont get a new Pharmacy Directory, well send you an update that shows changes to the directory. If you dont have the Pharmacy Directory, you can get a copy from Member Services (phone numbers are on the front cover). At any time, you can call Member Services to get up-to-date information about changes in the pharmacy network. You can also find this information on our website at [insert URL]. [Plans may add detail describing additional information about network pharmacies available from Member Services or on the website.] Section 3.4 The plans List of Covered Drugs (Formulary) The plan has a List of Covered Drugs (Formulary). We call it the Drug List for short. It tells which Part D prescription drugs are covered by [insert plan name]. It also tells you how to find out which Medical Assistance drugs are covered. The Part D drugs on this list are selected by the plan with the help of a team of doctors and pharmacists. The list must meet requirements set by Medicare. Medicare has approved the [insert plan name] Part D Drug List. [SNPs with arrangement with the State may revise this language to reflect, when applicable, that the organization is providing both Medicaid and Medicare covered benefits]. We will send you a copy of the Drug List. To get the most complete and current information about which drugs are covered, you can visit the plans website ([insert URL]) or call Member Services (phone numbers are on the front cover of this booklet). Section 3.5 Reports with a summary of payments made for your Part D prescription drugs When you use your Part D prescription drug benefits, we will send you a report to help you understand and keep track of payments for your Part D prescription drugs. This summary report is called the Explanation of Benefits. The Explanation of Benefits tells you the total amount you have spent on your Part D prescription drugs and the total amount we have paid for each of your Part D prescription drugs during the month. Chapter 6 (What you pay for your Part D prescription drugs) gives more information about the Explanation of Benefits and how it can help you keep track of your drug coverage. An Explanation of Benefits summary is also available upon request. To get a copy, please contact Member Services. [Note: Plans may insert other methods that members can get their Explanation of Benefits.] SECTION 4 Your monthly premium for [insert plan name] Section 4.1 How much is your plan premium? [Dual Eligible SNPs should modify Sections 4.1, 4.2, and 4.3 to explain how premiums are paid for them on their behalf. If there is no premium delete 4.2 and 4.3] [Plans with a monthly premium:] As a member of our plan, you pay a monthly plan premium. [Select one of the following: For [insert year], the monthly premium for [insert plan name] is [insert monthly premium amount]. OR The table below shows the monthly plan premium amount for each region we serve. OR The monthly premium amount for [insert plan name is listed in [describe attachment].] [Plans may insert a list of or table with the state/region and monthly plan premium amount for each area included within the EOC. Plans may also include premium(s) in an attachment to the EOC.] [Plans with no premium should replace the preceding paragraph with: You do not pay a separate monthly plan premium for [insert plan name]. As long as you are eligible for Medical Assistance, you qualify for and are getting Extra Help paying your prescription drug plan costs and premiums. [Insert if applicable: Your coverage is provided through contract with your current employer or former employer or union. Please contact the employer's or union's benefits administrator for information about your plan premium.] Many members are required to pay other Medicare premiums [Plans that include a Part B premium reduction benefit may describe the benefit within this section.] In addition to paying the monthly plan premium, some plan members may be paying a premium for Medicare Part A and/or Medicare Part B. Many members do not pay premiums for Medicare Part A and/or Medicare Part B due to Medical Assistance eligibility. If you are paying for your Medicare Part B, you must continue paying your Medicare Part B premium for you to remain as a member of the plan. Your copy of Medicare & You 2010 tells about these premiums in the section called 2010 Medicare Costs. This explains how the Part B premium differs for people with different incomes. Everyone with Medicare receives a copy of Medicare & You each year in the fall. Those new to Medicare receive it within a month after first signing up. You can also download a copy of Medicare & You 2010 from the Medicare website (http:// HYPERLINK "http://www.medicare.gov" www.medicare.gov). Or, you can order a printed copy by phone at 1-800-MEDICARE (1-800-633-4227) 24 hours a day, 7 days a week. TTY users call 1-877-486-2048. Section 4.2 There are several ways you can pay your plan premium [Plans indicating in Section 4.1 that there is no monthly premium should delete this section.] There are [insert number of payment options] ways you can pay your plan premium. [Plans must indicate how the member can inform the plan of their premium payment option choice and the procedure for changing that choice.] Option 1: You can pay by check [Insert plan specifics regarding premium payment intervals (e.g., monthly, quarterly- please note that beneficiaries must have the option to pay their premiums monthly), how they can pay by check, including an address, whether they can drop off a check in person, and by what day the check must be received (e.g., the 5th of each month). It should be emphasized that checks should be made payable to the Plan and not CMS nor HHS. If the Plan uses coupon books, explain when they will receive it and to call Member Services for a new one if they run out or lose it. In addition, include information if you charge for bounced checks.] Option 2: [Insert option type] [If applicable: Insert information about other payment options. Or delete this option. Include information about all relevant choices (e.g., automatically withdrawn from your checking or savings account, charged directly to your credit or debit card, or billed each month directly by the plan). Insert information on the frequency of automatic deductions (e.g., monthly, quarterly please note that beneficiaries must have the option to pay their premiums monthly), the approximate day of the month the deduction will be made, and how this can be set up.] Option [insert number]: You can have the plan premium taken out of your monthly Social Security check You can have the plan premium taken out of your monthly Social Security check. Contact Member Services for more information on how to pay your monthly plan premium this way. We will be happy to help you set this up. What to do if you are having trouble paying your plan premium Your plan premium is due in our office by the [insert day of the month]. If we have not received your premium by the [insert day of the month], we will send you a notice telling you that your plan membership will end if we do not receive your premium within [insert length of plan grace period]. If you are having trouble paying your premium on time, please contact Member Services to see if we can direct you to programs that will help with your plan premium. If we end your membership with the plan because of non-payment of premiums, then you will not be able to receive Part D coverage until the annual election period. At that time, you may either join a stand-alone prescription drug plan or a health plan that also provides drug coverage. If we end your membership, you will have coverage under Original Medicare. [Insert if applicable: At the time we end your membership, you may still owe us for premiums you have not paid. In the future, if you want to enroll again in our plan (or another plan that we offer), you will need to pay these late premiums before you can enroll.] Section 4.3 Can we change your monthly plan premium during the year? [Plans without a monthly premium may delete this section.] No. We are not allowed to change the amount we charge for the plans monthly plan premium during the year. If the monthly plan premium changes for next year we will tell you in October and the change will take effect on January 1. However, in some cases the part of the premium that you have to pay can change during the year. This happens if you become eligible for Extra Help or if you lose your eligibility for Extra Help during the year. If a member qualifies for Extra Help with their prescription drug costs, Extra Help will pay part of the members monthly plan premium. So a member who becomes eligible for Extra Help during the year would begin to pay less toward their monthly premium. And a member who loses their eligibility during the year will need to start paying their full monthly premium. You can find out more about Extra Help in Chapter 2, Section 7. [Plans should include the following paragraphs if applicable to their territorial areas.] What if you believe you have qualified for Extra Help If you believe you have qualified for Extra Help and you believe that you are paying an incorrect cost-sharing amount when you get your prescription at a pharmacy, our plan has established a process that allows you to either request assistance in obtaining evidence of your proper co-payment level, or, if you already have the evidence to provide this evidence to us. [Note: Insert plans process for allowing beneficiaries to request assistance with obtaining best available evidence, and for providing this evidence.] When we receive the evidence showing your copayment level, we will update our system so that you can pay the correct copayment when you get your next prescription at the pharmacy. If you overpay your copayment, we will reimburse you. Either we will forward a check to you in the amount of your overpayment or we will offset future copayments. If the pharmacy hasnt collected a copayment from you and is carrying your copayment as a debt owed by you, we may make the payment directly to the pharmacy. If a state paid on your behalf, we may make payment directly to the state. Please contact Member Services if you have questions. SECTION 5 Please keep your plan membership record up to date Section 5.1 How to help make sure that we have accurate information about you [In the heading and this section, plans should substitute the name used for this file if different from membership record.] Your membership record has information from your enrollment form, including your address and telephone number. It shows your specific plan coverage [insert as appropriate: including your Primary Care Provider/Medical Group/IPA]. The doctors, hospitals, pharmacists, and other providers in the plans network need to have correct information about you. These network providers use your membership record to know what services and drugs are covered for you. Because of this, it is very important that you help us keep your information up to date. Call Member Services to let us know about these changes: Changes to your name, your address, or your phone number Changes in any health insurance coverage you have (such as from your employer, your spouses employer, workers compensation, or Medical Assistance) If you have any liability claims, such as claims from an automobile accident If you have been admitted to a nursing home [Insert for SNPs, if applicable]: If your designated responsible party (such as a caregiver) changes In addition, call your county worker to report these changes: Name and address changes When you are admitted to a nursing home or other facility Adding or losing a household member New insurance begin and end dates New job or income changes Read over the information we send you about any other insurance coverage you have Medicare requires that we collect information from you about any other medical or drug insurance coverage that you have. Thats because we must coordinate any other coverage you have with your benefits under our plan. Once each year, we will send you a letter that lists any other medical or drug insurance coverage that we know about. Please read over this information carefully. If it is correct, you dont need to do anything. If the information is incorrect, or if you have other coverage that is not listed, please call Member Services (phone numbers are on the cover of this booklet). Chapter 2. Important phone numbers and resources  TOC \t "Section Heading Ch 2,1" SECTION 1 [Insert plan name] contacts (how to contact us, including how to reach Member Services at the plan)  PAGEREF _Toc110591864 \h 14 SECTION 2 Medicare (how to get help and information directly from the Federal Medicare program)  PAGEREF _Toc110591865 \h 20 SECTION 3 State Health Insurance Assistance Program (free help, information, and answers to your questions about Medicare)  PAGEREF _Toc110591866 \h 21 SECTION 4 Quality Improvement Organization (paid by Medicare to check on the quality of care for people with Medicare)  PAGEREF _Toc110591867 \h 22 SECTION 5 Social Security  PAGEREF _Toc110591868 \h 23 SECTION 6 Medicaid (a joint Federal and state program that helps with medical costs for some people with limited income and resources)  PAGEREF _Toc110591869 \h 24 SECTION 7 Information about programs to help people pay for their prescription drugs  PAGEREF _Toc110591870 \h 26 SECTION 8 How to contact the Railroad Retirement Board  PAGEREF _Toc110591871 \h 27 SECTION 9 Do you have group insurance or other health insurance from an employer?  PAGEREF _Toc110591872 \h 28  SECTION 1 [Insert plan name] contacts (how to contact us, including how to reach Member Services at the plan) How to contact our plans Member Services For assistance with claims, billing or member card questions, please call or write to [insert plan name] Member Services. We will be happy to help you. Member ServicesCALL[Insert phone number(s)] Calls to this number are [insert if applicable: not] free. [Insert hours of operation, including information on the use of alternative technologies.]TTY[Insert number] This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. Calls to this number are [insert if applicable: not] free. [Insert hours of operation.]FAX[Insert fax number]WRITE[Insert address] [Note: plans may add email addresses here.]WEBSITE[Insert URL]In addition, you may use the following contact information for certain services. Chemical Dependency Services [insert contact information] Chiropractic Services [insert contact information] Dental Services [insert contact information] Health Questions Phone Line [insert contact information] Home and Community-Based Services [insert contact information] Interpreter Services [insert contact information] Hearing [insert contact information] Spoken Language [insert contact information] Medical Equipment and Related Supplies Coverage Criteria [insert contact information] Mental Health Services [insert contact information] Prescriptions [insert contact information] Transportation [insert contact information] [Note: If your plan uses the same contact information for the Part C and Part D issues indicated below, you may combine the appropriate sections.] How to contact us when you are asking for a coverage decision about your medical care You may call us if you have questions about our coverage decision process. Coverage Decisions for Medical CareCALL[Insert phone number] Calls to this number are [insert if applicable: not] free. [Note: You may also include reference to 24-hour lines here.] [Note: If you have a different number for accepting expedited organization determinations, also include that number here.]TTY[Insert number] This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. Calls to this number are [insert if applicable: not] free. [Note: If you have a different TTY number for accepting expedited organization determinations, also include that number here.]FAX [Optional: insert fax number] [Note: If you have a different fax number for accepting expedited organization determinations, also include that number here.]WRITE[Insert address] [Note: If you have a different address for accepting expedited organization determinations, also include that address here.]For more information on asking for coverage decisions about your medical care, see Chapter 9 (What to do if you have a problem or complaint (coverage decisions, appeals, complaints). How to contact us when you are making an appeal about your medical care Appeals for Medical CareCALL[Insert phone number] Calls to this number are [insert if applicable: not] free. [Note: You may also include reference to 24-hour lines here.] [Note: If you have a different number for accepting expedited appeals, also include that number here.]TTY[Insert number] This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. Calls to this number are [insert if applicable: not] free. [Note: If you have a different TTY number for accepting expedited appeals, also include that number here.]FAX [Optional: insert fax number] [Note: If you have a different fax number for accepting expedited appeals, also include that number here.]WRITE[Insert address] [Note: If you have a different address for accepting expedited appeals, also include that address here.]For more information on making an appeal about your medical care, see Chapter 9 (What to do if you have a problem or complaint (coverage decisions, appeals, complaints). How to contact us when you are making a complaint about your medical care Complaints about Medical CareCALL[Insert phone number] Calls to this number are [insert if applicable: not] free. [Note: You may also include reference to 24-hour lines here.] [Note: If you have a different number for accepting expedited grievances, also include that number here.]TTY[Insert number] This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. Calls to this number are [insert if applicable: not] free. [Note: If you have a different TTY number for accepting expedited grievances, also include that number here.]FAX [Optional: insert fax number] [Note: If you have a different fax number for accepting expedited grievances, also include that number here.]WRITE[Insert address] [Note: If you have a different address for accepting expedited grievances, also include that address here.]For more information on making a complaint about your medical care, see Chapter 9 (What to do if you have a problem or complaint (coverage decisions, appeals, complaints). How to contact us when you are asking for a coverage decision about your Part D prescription drugs Coverage Decisions for Part D Prescription DrugsCALL[Insert phone number] Calls to this number are [insert if applicable: not] free. [Note: You may also include reference to 24-hour lines here.] [Note: If you have a different number for accepting expedited coverage determinations, also include that number here.]TTY[Insert number] This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. Calls to this number are [insert if applicable: not] free. [Note: If you have a different TTY number for accepting expedited coverage determinations, also include that number here.]FAX [Optional: insert fax number] [Note: If you have a different fax number for accepting expedited coverage determinations, also include that number here.]WRITE[Insert address] [Note: If you have a different address for accepting expedited coverage determinations, also include that address here.]For more information on asking for coverage decisions about your Part D prescription drugs, see Chapter 9 (What to do if you have a problem or complaint (coverage decisions, appeals, complaints). How to contact us when you are making an appeal about your Part D prescription drugs Appeals for Part D Prescription DrugsCALL[Insert phone number] Calls to this number are [insert if applicable: not] free. [Note: You may also include reference to 24-hour lines here.] [Note: If you have a different number for accepting expedited appeals, also include that number here.]TTY[Insert number] This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. Calls to this number are [insert if applicable: not] free. [Note: If you have a different TTY number for accepting expedited appeals, also include that number here.]FAX [Optional: insert fax number] [Note: If you have a different fax number for accepting expedited appeals, also include that number here.]WRITE[Insert address] [Note: If you have a different address for accepting expedited appeals, also include that address here.]For more information on making an appeal about your Part D prescription drugs, see Chapter 9 (What to do if you have a problem or complaint (coverage decisions, appeals, complaints). How to contact us when you are making a complaint about your Part D prescription drugs Complaints about Part D prescription drugsCALL[Insert phone number] Calls to this number are [insert if applicable: not] free. [Note: You may also include reference to 24-hour lines here.] [Note: If you have a different number for accepting expedited grievances, also include that number here.]TTY[Insert number] This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. Calls to this number are [insert if applicable: not] free. [Note: If you have a different TTY number for accepting expedited grievances, also include that number here.]FAX [Optional: insert fax number] [Note: If you have a different fax number for accepting expedited grievances, also include that number here.]WRITE[Insert address] [Note: If you have a different address for accepting expedited grievances, also include that address here.]For more information on making a complaint about your Part D prescription drugs, see Chapter 9 (What to do if you have a problem or complaint (coverage decisions, appeals, complaints). Where to send a request that asks us to pay for our share of the cost for a Part D drug you have received [SNPs with an arrangement with the State may add language to reflect that the organization is not allowed to reimburse members for Medicaid covered benefits.] We cannot pay you back for most medical bills that you pay. State and federal laws prevent us from paying you directly. The exception is if you pay for Part D prescription drugs. If you paid for a service that you think we should have covered, contact Member Services at the number listed on the front cover. For more information on situations in which you may need to ask us for reimbursement or to pay a bill you have for a Part D covered drug, see Chapter 7 (Asking the plan to pay its share of a bill you have received Part D drugs). Please note: If you send us a payment request for a Part D drug and we deny any part of your request, you can appeal our decision. See Chapter 9 (What to do if you have a problem or complaint (coverage decisions, appeals, complaints) for more information. Payment Requests for Part D Drugs CALL[Insert phone number] Calls to this number are [insert if applicable: not] free.TTY[Insert number] This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. Calls to this number are [insert if applicable: not] free.FAX[Optional: Insert fax number]WRITE[Insert address] SECTION 2 Medicare (how to get help and information directly from the Federal Medicare program) Medicare is the Federal health insurance program for people 65 years of age or older, some people under age 65 with disabilities, and people with End-Stage Renal Disease (permanent kidney failure requiring dialysis or a kidney transplant). The Federal agency in charge of Medicare is the Centers for Medicare & Medicaid Services (sometimes called CMS). This agency contracts with Medicare Advantage Organizations including us. MedicareCALL1-800-MEDICARE, or 1-800-633-4227 Calls to this number are free. 24 hours a day, 7 days a week.TTY1-877-486-2048 This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. Calls to this number are free.WEBSITE HYPERLINK "http://www.medicare.gov" http://www.medicare.gov This is the official government website for Medicare. It gives you up-to-date information about Medicare and current Medicare issues. It also has information about hospitals, nursing homes, physicians, home health agencies, and dialysis facilities. It includes booklets you can print directly from your computer. It has tools to help you compare Medicare Advantage Plans and Medicare drug plans in your area. You can also find Medicare contacts in your state by selecting Helpful Phone Numbers and Websites. If you dont have a computer, your local library or senior center may be able to help you visit this website using its computer. Or, you can call Medicare at the number above and tell them what information you are looking for. They will find the information on the website, print it out, and send it to you. SECTION 3 State Health Insurance Assistance Program (free help, information, and answers to your questions about Medicare) [Organizations offering plans in multiple states: Revise this section to use the generic name (State Health Insurance Assistance Program) when necessary, and include a list of names, phone numbers, and addresses for all SHIPs in your service area. Plans have the option of including a separate exhibit to list the SHIPs in all states, or in all states in which the plan is filed, and should make reference to that exhibit below.] The State Health Insurance Assistance Program (SHIP) is a government program with trained counselors in every state. In Minnesota, the State Health Insurance Assistance Program is called the Senior LinkAge Line. . The Senior LinkAge Line is independent (not connected with any insurance company or health plan). It is a state program that gets money from the Federal government to give free local health insurance counseling to people with Medicare. Senior LinkAge Line counselors can help you with your Medicare questions or problems. They can help you understand your Medicare rights, help you make complaints about your medical care or treatment, and help you straighten out problems with your Medicare bills. Senior LinkAge Line counselors can also help you understand your Medicare plan choices and answer questions about switching plans. Senior LinkAge Line CALL1-800-333-2433 TTYCall the Minnesota Relay Service at 711 This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking.WRITEMinnesota Board on Aging PO Box 64976 St. Paul, MN 55164-0976 [WEBSITE www.mnaging.org and HYPERLINK www.minnesotahelp.info www.minnesotahelp.info SECTION 4 Quality Improvement Organization (paid by Medicare to check on the quality of care for people with Medicare) [Organizations offering plans in multiple states: Revise this section to use the generic name (Quality Improvement Organization) when necessary, and include a list of names, phone numbers, and addresses for all QIOs in your service area. Plans have the option of including a separate exhibit to list the QIOs in all states, or in all states in which the plan is filed, and should make reference to that exhibit below.] There is a Quality Improvement Organization in each state. In Minnesota, the Quality Improvement Organization is called Stratis Health. Stratis Health has a group of doctors and other health care professionals who are paid by the Federal government. This organization is paid by Medicare to check on and help improve the quality of care for people with Medicare. Stratis Health is an independent organization. It is not connected with our plan. You should contact Stratis Health in any of these situations: You have a complaint about the quality of care you have received. You think coverage for your hospital stay is ending too soon. You think coverage for your home health care, skilled nursing facility care, or Comprehensive Outpatient Rehabilitation Facility (CORF) services are ending too soon. Stratis HealthCALL(952) 854-3306 (Twin Cities Metro Area )or 1-877-787-2847 (toll-free)WRITE2901 Metro Drive, Suite 400 Bloomington, MN 55425-1525WEBSITE HYPERLINK "http://www.stratishealth.org" www.stratishealth.org SECTION 5 Social Security The Social Security Administration is responsible for determining eligibility and handling enrollment for Medicare. U.S. citizens who are 65 or older, or who have a disability or end stage renal disease and meet certain conditions, are eligible for Medicare. If you are already getting Social Security checks, enrollment into Medicare is automatic. If you are not getting Social Security checks, you have to enroll in Medicare and pay the Part B premium. Social Security handles the enrollment process for Medicare. To apply for Medicare, you can call Social Security or visit your local Social Security office. Social Security AdministrationCALL1-800-772-1213 Calls to this number are free. Available 7:00 am to 7:00 pm, Monday through Friday. You can use our automated telephone services to get recorded information and conduct some business 24 hours a day.TTY1-800-325-0778 This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. Calls to this number are free. Available 7:00 am to 7:00 pm, Monday through Friday.WEBSITE HYPERLINK "http://www.ssa.gov" http://www.ssa.gov SECTION 6 Medicaid or Medical Assistance (a joint Federal and state program that helps with medical costs for some people with limited income and resources) [Organizations offering plans in multiple states: Revise this section to include a list of agency names, phone numbers, and addresses for all states in your service area. Plans have the option of including a separate exhibit to list Medicaid information in all states or in all states in which the plan is filed and should make reference to that exhibit below.] [Plans may adapt this generic discussion of Medicaid to reflect the name or features of the Medicaid program in the plans state or states.] [Dual Eligible SNPs should modify this section to include additional language explaining that members are dually enrolled with both Medicare and Medicaid.] [SNPs may describe the Medicaid managed care program under which the organization contracts with the state Medicaid agency. Integrated SNPs may describe the Medicaid managed care program under which the organization contracts with the state Medicaid agency and should also describe their specific benefits.] [SNPs must, as appropriate, include additional telephone numbers for Medicaid program assistance, e.g., the telephone number for the state Ombudsman.] Medicaid is a joint Federal and state government program that helps with medical costs for certain people with limited incomes and resources. Some people with Medicare are also eligible for Medicaid. Medicaid has programs that can help pay for your Medicare premiums and other costs, if you qualify. In Minnesota, the Medicaid program is called Medical Assistance. To find out more about Medical Assistance and its programs, contact the Minnesota Department of Human Services. Our Plan in is a part of a project called Minnesota Senior Health Options. The Minnesota Department of Human Services designed this project to provide special care for seniors. This project combines your Medicare and Medical Assistance services. It combines your doctor, hospital, home care, nursing home care and other care into one coordinated care system. Minnesota Department of Human ServicesCALL651) 431-2670 (Twin Cities metro area) or (800) 657-3739 (outside Twin Cities metro area)TTY(800) 627-3529 or 711 This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking.WEBSITEHYPERLINK www.dhs.state.mn.us/healthcare www.dhs.state.mn.us/healthcare The Ombudsman for State Managed Health Care Programs, at the Minnesota Department of Human Services, helps people enrolled in a health plan in resolving service and billing problems. They can help you file a grievance or appeal with our Plan. The Ombudsman can also help you request a State Fair Hearing. Minnesota State Ombudsman for Managed Health Care ProgramsCALL(651) 431-2660 (Twin Cities metro area) or (800) 657-3729 (outside Twin Cities metro area) TTY/TDD711 or (800) 627-3529 This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking.WRITEMinnesota Department of Human Services Ombudsman for State Managed Health Care Programs PO Box 64249, St. Paul MN 55164-0249 WEBSITEHYPERLINK http://www.dhs.state.mn.us/healthcare/managedcareombudsman htt  HYPERLINK "http://www.dhs.state.mn.us/healthcare/managedcareombudsman" www.dhs.state.mn.us/healthcare/managedcareombudsman The Office of Ombudsman for Long Term Care can assist people with concerns about nursing homes, boarding care homes, adult care homes (i.e. housing with services, assisted living, customized living, or foster care), home care services, and Medicare beneficiaries with hospital access or discharge concerns. Office of Ombudsman for Long Term CareCALL(651) 431-2555 (Twin Cities metro area) or (800) 657-3591 (outside Twin Cities metro area) TTY/TDD(800) 627-3529 or 711 This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. WRITEOffice of Ombudsman for Long-Term Care P.O. Box 64971 St. Paul, MN 55164-0971WEBSITEHYPERLINK www.mnaging.org./admin/ooom.htm www.mnaging.org./admin/ooom.htm  SECTION 7 Information about programs to help people pay for their prescription drugs Medicares Extra Help Program [Dual Eligible SNPs may add language indicating that current SNP members have also been determined to be eligible for Extra Help, or the Low-Income Subsidy.] As long as you are eligible for Medical Assistance, you qualify for and are getting Extra Help paying your prescription drug plan costs described below. You do not need to do anything further to get this Extra Help. Medicare provides Extra Help to pay prescription drug costs for people who have limited income and resources. Resources include your savings and stocks, but not your home or car. If you qualify, you get help paying for any Medicare drug plans monthly premium, yearly deductible, and prescription copayments. This Extra Help also counts toward your out-of-pocket costs. People with limited income and resources may qualify for Extra Help. Some people automatically qualify for Extra Help and dont need to apply. Medicare mails a letter to people who automatically qualify for Extra Help. SECTION 8 How to contact the Railroad Retirement Board The Railroad Retirement Board is an independent Federal agency that administers comprehensive benefit programs for the nations railroad workers and their families. If you have questions regarding your benefits from the Railroad Retirement Board, contact the agency. Railroad Retirement BoardCALL1-877-772-5772 Calls to this number are free. Available 9:00 am to 3:30 pm, Monday through Friday If you have a touch-tone telephone, recorded information and automated services are available 24 hours a day, including weekends and holidays.TTY1-312-751-4701 This number requires special telephone equipment and is only for people who have difficulties with hearing or speaking. Calls to this number are not free.WEBSITE HYPERLINK "http://www.rrb.gov" http://www.rrb.gov SECTION 9 Do you have group insurance or other health insurance from an employer? [SNPs may, as appropriate, delete this section since beneficiaries covered under employer groups are not eligible to participate in dual eligible SNPs in some states.] If you (or your spouse) get benefits from your (or your spouses) employer or retiree group, call the employer/union benefits administrator or Member Services if you have any questions. You can ask about your (or your spouses) employer or retiree health benefits, premiums, or the enrollment period. If you have other prescription drug coverage through your (or your spouses) employer or retiree group, please contact that groups benefits administrator. The benefits administrator can help you determine how your current prescription drug coverage will work with our plan. Chapter 3. Using the plans coverage for your covered services  TOC \t "Section Heading Ch 3,1,Section SubHeading 1 Ch 3,2" SECTION 1 Things to know about getting your covered services as a member of our plan  PAGEREF _Toc110591890 \h 31 Section 1.1 What are network providers and covered services?  PAGEREF _Toc110591891 \h 31 Section 1.2 Basic rules for getting your medical care that is covered by the plan  PAGEREF _Toc110591892 \h 31 SECTION 2 Use providers in the plans network to get your medical care  PAGEREF _Toc110591893 \h 32 Section 2.1 You must choose a Primary Care Provider (PCP) to provide and arrange for your medical care  PAGEREF _Toc110591894 \h 32 Section 2.2 What kinds of medical care can you get without getting approval in advance from your PCP?  PAGEREF _Toc110591895 \h 33 Section 2.3 How to get care from specialists and other network providers  PAGEREF _Toc110591896 \h 34 Section 2.4 How to get care from out-of-network providers  PAGEREF _Toc110591897 \h 36 SECTION 3 How to get covered services when you have an emergency or an urgent need for care  PAGEREF _Toc110591898 \h 36 Section 3.1 Getting care if you have a medical emergency  PAGEREF _Toc110591899 \h 36 Section 3.2 Getting care when you have an urgent need for care  PAGEREF _Toc110591900 \h 37 SECTION 4 What if you are billed directly for the full cost of your covered services?  PAGEREF _Toc110591901 \h 38 Section 4.1 You can ask the plan to pay our share of the cost of your covered services  PAGEREF _Toc110591902 \h 38 Section 4.2 If services are not covered by our plan, you must pay the full cost  PAGEREF _Toc110591903 \h 39 SECTION 5 How are your medical services covered when you are in a clinical research study?  PAGEREF _Toc110591904 \h 39 Section 5.1 What is a clinical research study?  PAGEREF _Toc110591905 \h 39 Section 5.2 When you participate in a clinical research study, who pays for what?  PAGEREF _Toc110591906 \h 40 SECTION 6 Rules for getting care in a religious non-medical health care institution  PAGEREF _Toc110591907 \h 41 Section 6.1 What is a religious non-medical health care institution?  PAGEREF _Toc110591908 \h 41 Section 6.2 What care from a religious non-medical health care institution is covered by our plan?  PAGEREF _Toc110591909 \h 41  SECTION 1 Things to know about getting your covered services as a member of our plan This chapter tells things you need to know about using the plan to get your covered services. It gives definitions of terms and explains the rules you will need to follow to get the medical treatments, services, and other medical care that are covered by the plan. For the details on what is covered by our plan use the benefits chart in the next chapter, Chapter 4 (Benefits chart, what is covered). Section 1.1 What are network providers and covered services? Here are some definitions that can help you understand how you get the care and services that are covered for you as a member of our plan: Providers are doctors and other health care professionals that the state licenses to provide medical services and care. The term providers also includes hospitals and other health care facilities. Network providers are the doctors and other health care professionals, medical groups, hospitals, and other health care facilities that have an agreement with us to accept payment in full. We have arranged for these providers to deliver covered services to members in our plan. The providers in our network generally bill us directly for care they give you. Covered services include all the medical care, health care services, supplies, and equipment that are covered by our plan. Your covered services are listed in the benefits chart in Chapter 4. Section 1.2 Basic rules for getting your care that is covered by the plan [Insert plan name] will generally cover your care as long as: The care you receive is included in the plans Benefits Chart (this chart is in Chapter 4 of this booklet). Except in the case of preventive services, screening services and home and community based services, the care you receive must be medically necessary. Medically necessary means that the services are accepted treatment for your medical condition. [Plans may omit or edit the PCP-related bullets as necessary] You have a primary care provider (a PCP) who is providing and overseeing your care. As a member of our plan, you must choose a PCP (for more information about this, see Section 2.1 in this chapter). In most situations, your PCP must give you approval in advance before you can use other providers in the plans network, such as specialists, hospitals, skilled nursing facilities, or home health care agencies. This is called giving you a referral. For more information about this, see Section 2.2 of this chapter. Referrals from your PCP are not required for emergency care or urgently needed care. There are also some other kinds of care you can get without having approval in advance from your PCP (for more information about this, see Section 2.3 of this chapter). [Plans with a POS option may edit the network provider bullets as necessary.] You generally must receive your care from a network provider (for more information about this, see Section 2 in this chapter). In most cases, care you receive from a non-network provider (a provider who is not part of our plans network) will not be covered. Here are two exceptions: The plan covers emergency care or urgently needed care that you get from a non-network provider. For more information about this, and to see what emergency or urgently needed care means, see Section 3 in this chapter. If you need medical care that Medicare requires our plan to cover and the providers in our network cannot provide this care, you can get this care from a non-network provider. [Plans may specify if authorization should be obtained from the plan prior to seeking care.] In this situation, you will pay the same as you would pay if you got the care from a network provider. SECTION 2 Use providers in the plans network to get your care Section 2.1 You must choose a Primary Care Provider (PCP) to provide and arrange for your care [Note: Insert this section only if plan uses PCPs. Plans may edit this section to refer to a Physician of Choice (POC) instead of PCP.] What is a PCP and what does the PCP do for you? [Plans should describe the following in the context of their plans: What is a PCP? What types of providers may act as a PCP? Explain the role of a PCP in your plan. What is the role of the PCP in coordinating covered services?] How do you choose your PCP? [Plans should describe how to choose a PCP.] Changing your PCP You may change your PCP for any reason, at any time. Also, its possible that your PCP might leave our plans network of providers and you would have to find a new PCP. [Plans should describe how to change a PCP.] [Dual eligible SNPs that are obligated under state Medicaid programs to have a transition benefit when a doctor leaves a plan, may discuss that benefit here.] Sometimes a network provider you are using might leave the Plan. If this happens, you will have to switch to another provider who is part of our Plan. Member Services can assist you in finding and selecting another provider. If a provider you choose is no longer part of the Plan, you must choose another network provider. You may be able to continue to use services from a provider no longer a part of the Plan network for up to 120 days for the following reasons: an acute condition a life-threatening mental or physical illness a pregnancy that is beyond the first three months (trimester); a physical or mental disability defined as an inability to engage in one or more major life activities. This applies to a disability that has lasted or is expected to last at least one year, or is likely to result in death; a disabling or chronic condition that is in an acute phase. If your doctor certifies that you have an expected lifetime of 180 days or less, you may be able to continue to use services for the rest of your life from a provider who is no longer part of our network. For more information, call Member Services. Section 2.2 What kinds of care can you get without getting approval in advance from your PCP? [Note: Insert this section only if plans use PCPs or require referrals to network providers.] American Indians can continue or begin to use tribal and Indian Health Services (IHS) clinics. We will not require prior approval or impose any conditions for you to get services at these clinics. If a doctor or other provider in a tribal or IHS clinic refers you to a provider in our network, we will not require you to see your Plan network primary care provider prior to the referral You can get the services listed below without getting approval in advance from your PCP. Routine womens health care, which include breast exams, mammograms (x-rays of the breast), Pap tests, and pelvic exams. This care is covered without a referral from a network provider. Flu shots [insert if applicable: and pneumonia vaccinations] [insert if appropriate: as long as you get them from a network provider]. Emergency services from network providers or from non-network providers. Urgently needed care from non-network providers when network providers are temporarily unavailable or, e.g., when you are temporarily outside of the plans service area. Kidney dialysis services that you get at a Medicare-certified dialysis facility when you are temporarily outside the plans service area. [Plans may insert requests here, e.g., If possible, please let us know before you leave the service area where you are going to be so we can help arrange for you to have maintenance dialysis while outside the service area.] [Plans should add additional bullets as appropriate.] Section 2.3 How to get care from specialists and other network providers A specialist is a doctor who provides health care services for a specific disease or part of the body. There are many kinds of specialists. Here are a few examples: Oncologists, who care for patients with cancer. Cardiologists, who care for patients with heart conditions. Orthopedists, who care for patients with certain bone, joint, or muscle conditions. [Plans should describe how members access specialists and other network providers, including: What is the role (if any) of the PCP in referring members to specialists and other providers? For what services will the PCP need to get prior authorization from the plan? Explain if the selection of a PCP results in being limited to specific specialists or hospitals to which that PCP refers, i.e. sub-network, referral circles.] [Plans with referral models, insert: A written referral may be for one visit or it may be a standing referral for more than one visit if you need ongoing services. We must give you a standing referral to a qualified specialist for any of these conditions: A chronic (on-going) condition; A life-threatening mental or physical illness; A pregnancy that is beyond the first three months (first trimester); A degenerative disease or disability; Any other condition or disease that is serious or complex enough to require treatment by a specialist. If you do not get a written referral when needed, the bill may not be paid. For more information, call Member Services.] [Plans with direct access models, insert: If we are unable to find you a qualified Plan network provider, we must give you a standing service authorization for you to see a qualified specialist for any of these conditions: A chronic (on-going) condition; A life-threatening mental or physical illness; A pregnancy that is beyond the first three months (first trimester); A degenerative disease or disability; Any other condition or disease that is serious or complex enough to require treatment by a specialist. If you do not get a service authorization from us when needed, the bill may not be paid. For more information, call Member Services.] What if a specialist or another network provider leaves our plan? Sometimes a specialist, clinic, hospital or other network provider you are using might leave the plan. If this happens, you will have to switch to another provider who is part of our Plan. Member Services can assist you in finding and selecting another provider. If a provider you choose is no longer part of the Plan, you must choose another network provider. You may be able to continue to use services from a provider no longer a part of the Plan network for up to 120 days for the following reasons: an acute condition a life-threatening mental or physical illness a pregnancy that is beyond the first three months (trimester); a physical or mental disability defined as an inability to engage in one or more major life activities. This applies to a disability that has lasted or is expected to last at least one year, or is likely to result in death; a disabling or chronic condition that is in an acute phase. If your doctor certifies that you have an expected lifetime of 180 days or less, you may be able to continue to use services for the rest of your life from a provider who is no longer part of our network. For more information, call Member Services. [Plans should describe what happens when a provider leaves the network. (Instructing members to call member services for instructions is not describing the process.) Include detailed information on plan notification of members. Typical offers of replacement specialists and phone numbers to call if urgent situations arise.] [Dual eligible SNPs that are obligated under state Medicaid programs to have a transition benefit when a doctor leaves a plan, may discuss that benefit here.] Section 2.4 How to get care from out-of-network providers [Plans with a POS option include Section 2.4. Describe POS option here. Tell members under what circumstances they may obtain services from out-of-network providers and what restrictions apply. General information (no specific dollar amounts) about cost-sharing applicable to the use of out-of-network providers in HMO/POS plans should be inserted here, with reference to the benefits chart where detailed information can be found.] SECTION 3 How to get covered services when you have an emergency or an urgent need for care Section 3.1 Getting care if you have a medical emergency What is a medical emergency and what should you do if you have one? When you have a medical emergency, you believe that your health is in serious danger. A medical emergency can include severe pain, a bad injury, a sudden illness, or a medical condition that is quickly getting much worse. If you have a medical emergency: Get help as quickly as possible. Call 911 for help or go to the nearest emergency room, hospital, or urgent care center. Call for an ambulance if you need it. You do not need to get approval or a referral first from your PCP. [Plans add if applicable]: As soon as possible, make sure that our plan has been told about your emergency. We need to follow up on your emergency care. You or someone else should call to tell us about your emergency care, usually within 48 hours. [Plans must provide either the number to call or explain where to find the number (e.g., on the back the plan membership card).] What is covered if you have a medical emergency? You may get covered emergency medical care whenever you need it, anywhere in the United States and Canada. [If applicable, plans should describe their coverage for emergency services outside the United States where covered by Medicare, such as services received in Canada and Mexico in the case of service areas near those countrys borders.] Our plan covers ambulance services in situations where getting to the emergency room in any other way could endanger your health. For more information, see the Benefits chart in Chapter 4 of this booklet. [Plans that offer a supplemental benefit covering emergencies or ambulance services outside of the country, mention the benefit here and then refer members to Chapter 4 for more information.] If you have an emergency, we will talk with the doctors who are giving you emergency care to help manage and follow up on your care. The doctors who are giving you emergency care will decide when your condition is stable and the medical emergency is over. [Plans may modify this paragraph as needed to address the post-stabilization care for your plan.] After the emergency is over you are entitled to follow-up care (this may also be called post-stabilization care) to be sure your condition continues to be stable. Your follow-up care will be covered by our plan. If your emergency care is provided by non-network providers, we will try to arrange for network providers to take over your care as soon as your medical condition and the circumstances allow. What if it wasnt a medical emergency? Sometimes it can be hard to know if you have a medical emergency. For example, you might go in for emergency care thinking that your health is in serious danger and the doctor may say that it wasnt a medical emergency after all. If it turns out that it was not an emergency, as long as you reasonably thought your health was in serious danger, we will cover your care. However, after the doctor has said that it was not an emergency, we will generally cover additional care only if you get the additional care in one of these two ways: You go to a network provider to get the additional care. or the additional care you get is considered urgently needed care and you follow the rules for getting this urgent care (for more information about this, see Section 3.2 below). Section 3.2 Getting care when you have an urgent need for care What is urgently needed care? Urgently needed care is a non-emergency situation when: You need medical care right away because of an illness, injury, or condition that you did not expect or anticipate, but your health is not in serious danger. Because of the situation, it isnt reasonable for you to obtain medical care from a network provider. What if you are in the plans service area when you have an urgent need for care? Whenever possible, you must use our network providers when you are in the plans service area and you have an urgent need for care. (For more information about the plans service area, see Chapter 1, Section 2.3 of this booklet.) In most situations, if you are in the plans service area, we will cover urgently needed care only if you get this care from a network provider and follow the other rules described earlier in this chapter. If the circumstances are unusual or extraordinary, and network providers are temporarily unavailable or inaccessible, our plan will cover urgently needed care that you get from a non-network provider. What if you are outside the plans service area when you have an urgent need for care? Suppose that you are temporarily outside our plans service area, but still in the United States or Canada. If you have an urgent need for care, you probably will not be able to find or get to one of the providers in our plans network. In this situation (when you are outside the service area and cannot get care from a network provider), our plan will cover urgently needed care that you get from any provider. Our plan does not cover urgently needed care or any other care if you receive the care outside of the United States or Canada. [Plans with overseas care covered as a supplemental benefit: modify this section.] SECTION 4 What if you are billed directly for the full cost of your covered services? Section 4.1 You can ask the plan to pay our share of the cost of Part D Drugs only We cannot pay you back for most medical bills that you pay. State and federal laws prevent us from paying you directly. The exception is if you pay for Part D prescription drugs. If you paid for a service that you think we should have covered, contact Member Services at the number listed on the front cover. If you have paid more than your share for Part D prescription drugs, go to Chapter 7 (Asking the plan to pay its share of a bill you have received for Part D drugs) for information about what to do. Section 4.2 If services are not covered by our plan, you must pay the full cost [Insert plan name] uses Medicare and Medical Assistance coverage rules to decide what services are medically necessary except for home and community based services which do not need to meet medically necessary criteria You are responsible for paying the full cost of services that arent covered by our plan, either because they are not plan covered services, or plan rules were not followed. If you have any questions about whether we will pay for any medical service or care that you are considering, you have the right to ask us whether we will cover it before you get it. If we say we will not cover your services, you have the right to appeal our decision not to cover your care. Chapter 9 (What to do if you have a problem or complaint) has more information about what to do if you want a coverage decision from us or want to appeal a decision we have already made. You may also call Member Services at the number on the front cover of this booklet to get more information about how to do this. For covered services that have a benefit limitation, you pay the full cost of any services you get after you have used up your benefit for that type of covered service. [Plans should explain whether paying for costs once a benefit limit has been reached will count toward an out-of-pocket maximum.] You can call Member Services when you want to know how much of your benefit limit you have already used. SECTION 5 How are your medical services covered when you are in a clinical research study? Section 5.1 What is a clinical research study? A clinical research study is a way that doctors and scientists test new types of medical care, like how well a new cancer drug works. They test new medical care procedures or drugs by asking for volunteers to help with the study. This kind of study is one of the final stages of a research process that helps doctors and scientists see if a new approach works and if it is safe. Not all clinical research studies are open to members of our plan. Medicare first needs to approve the research study. If you participate in a study that Medicare has not approved, you will be responsible for paying all costs for your participation in the study. Once Medicare approves the study, someone who works on the study will contact you to explain more about the study and see if you meet the requirements set by the scientists who are running the study. You can participate in the study as long as you meet the requirements for the study and you have a full understanding and acceptance of what is involved if you participate in the study. If you participate in a Medicare-approved study, Original Medicare pays the doctors and other providers for the covered services you receive as part of the study. When you are in a clinical research study, you may stay enrolled in our plan and continue to get the rest of your care (the care that is not related to the study) through our plan. If you want to participate in a Medicare-approved clinical research study, you do not need to get approval from our plan or your PCP. The providers that deliver your care as part of the clinical research study do not need to be part of our plans network of providers. Although you do not need to get our plans permission to be in a clinical research study, you do need to tell us before you start participating in a clinical research study. Here is why you need to tell us: 1. We can let you know whether the clinical research study is Medicare-approved. 2. We can tell you what services you will get from clinical research study providers instead of from our plan. 3. We can keep track of the health care services that you receive as part of the study. If you plan on participating in a clinical research study, contact Member Services (see Chapter 2, Section 1 of this Certificate of Coverage). Section 5.2 When you participate in a clinical research study, who pays for what? Once you join a Medicare-approved clinical research study, Medicare will pay for the covered services you receive as part of the research study. Medicare pays for routine costs of items and services. Examples of these items and services include the following: Room and board for a hospital stay that Medicare would pay for even if you werent in a study. An operation or other medical procedure if it is part of the research study. Treatment of side effects and complications of the new care. When you are part of a clinical research study, Medicare will not pay for any of the following: Generally, Medicare will not pay for the new item or service that the study is testing unless Medicare would cover the item or service even if you were not in a study. Items and services the study gives you or any participant for free. Items or services provided only to collect data, and not used in your direct health care. For example, Medicare would not pay for monthly CT scans done as part of the study if your condition would usually require only one CT scan. [If your plan charges Original Medicares cost-sharing amounts for clinical trial services, use this language: You will have to pay the same coinsurance amounts charged under Original Medicare for the services you receive as a participant in the clinical research study. Because you are a member of our plan, you do not have to pay the deductibles for Original Medicare Part A or Part B.] [If your plan will cover all or a portion of the FFS coinsurance for your members participating in a clinical trial, say so here and/or modify the previous sentences. Also, specify the conditions (if any) under which such additional coverage is available (e.g., if the member participants in a clinical trial sponsored by one of your contracting providers).] Do you want to know more? You can get more information about joining a clinical research study by reading the publication Medicare and Clinical Research Studies on the Medicare website (http://www.medicare.gov). You can also call 1-800-MEDICARE (1-800-633-4227) 24 hours a day, 7 days a week. TTY users should call 1-877-486-2048. SECTION 6 Rules for getting care in a religious non-medical health care institution Section 6.1 What is a religious non-medical health care institution? A religious non-medical health care institution is a facility that provides care for a condition that would ordinarily be treated in a hospital or skilled nursing facility care. If getting care in a hospital or a skilled nursing facility is against a members religious beliefs, our plan will instead provide coverage for care in a religious non-medical health care institution. You may choose to pursue medical care at any time for any reason. This benefit is provided only for Part A inpatient services (non-medical health care services). Medicare will only pay for non-medical health care services provided by religious non-medical health care institutions. Section 6.2 What care from a religious non-medical health care institution is covered by our plan? To get care from a religious non-medical health care institution, you must sign a legal document that says you are conscientiously opposed to getting medical treatment that is non-excepted. Non-excepted medical care or treatment is any medical care or treatment that is voluntary and not required by any federal, state, or local law. Excepted medical treatment is medical care or treatment that you get that is not voluntary or is required under federal, state, or local law. To be covered by our plan, the care you get from a religious non-medical health care institution must meet the following conditions: The facility providing the care must be certified by Medicare. Our plans coverage of services you receive is limited to non-religious aspects of care. If you get services from this institution that are provided to you in your home, our plan will cover these services only if your condition would ordinarily meet the conditions for coverage of services given by home health agencies that are not religious non-medical health care institutions. If you get services from this institution that are provided to you in a facility, the following [insert as applicable: conditions apply OR condition applies]: You must have a medical condition that would allow you to receive covered services for inpatient hospital care or skilled nursing facility care. [Omit this bullet if not applicable] and you must get approval in advance from our plan before you are admitted to the facility or your stay will not be covered. [Plans must explain whether Medicare Inpatient Hospital coverage limits apply (include a reference to the benefits chart in Chapter 4) or whether there is unlimited coverage for this benefit.] Chapter 4. Benefits chart (what is covered)  TOC \t "Section Heading Ch 4,1,Section SubHeading 1 Ch 4,2" SECTION 1 Understanding your out-of-pocket costs for covered services  PAGEREF _Toc110591934 \h 40 Section 1.1 What types of out-of-pocket costs do you pay for your covered services?  PAGEREF _Toc110591935 \h 40 Section 1.2 What is the maximum amount you will pay for certain covered medical services?  PAGEREF _Toc110591936 \h 40 SECTION 2 Use this Medical Benefits Chart to find out what is covered for you and how much you will pay  PAGEREF _Toc110591937 \h 40 Section 2.1 Your medical benefits and costs as a member of the plan  PAGEREF _Toc110591938 \h 40 Section 2.2 Extra optional supplemental benefit you can buy  PAGEREF _Toc110591939 \h 62 Section 2.3 Getting care using our plans traveler benefit  PAGEREF _Toc110591940 \h 62 SECTION 3 What types of benefits are not covered by the plan?  PAGEREF _Toc110591941 \h 62 Section 3.1 Types of benefits we do not cover (exclusions)  PAGEREF _Toc110591942 \h 62  [SNPs may add a discussion to this chapter if they cover benefits under Medicaid, as long as the benefits are distinctly identified as Medicaid and not Medicare-covered benefits. This may include adding new language to the benefit chart itself as well as language to the related text in this chapter. This may be done in an additional column or additional rows or within existing cells of the chart or group together at the end and labeled as Medicaid benefits.] SECTION 1 Understanding your covered services This chapter focuses on your covered services. It includes a Benefits Chart that gives a list of your covered services as a member of [insert plan name]. Later in this chapter, you can find information about services that are not covered. [Insert if applicable: It also tells about limitations on certain services.] [If applicable, you may mention other places where benefits, limitations, and exclusions are described, such as optional additional benefits, or addenda.] Section 1.1 What types of out-of-pocket costs do you pay for your covered services? [Describe all applicable cost-sharing types your plan uses. You may omit those that are not applicable.] Because you are eligible for Medical Assistance, you qualify for and are receiving help to pay your out-of-pocket costs for Medicare. You do not have any additional co-payments for Medical Assistance. SECTION 2 Use this Benefits Chart to find out what is covered for you Section 2.1 Your benefits as a member of the plan The Benefits Chart on the following pages lists the services [insert plan name] covers. The services listed in the Benefits Chart are covered only when all coverage requirements are met: Your Medicare and Medical Assistance covered services must be provided according to the coverage guidelines established by Medicare and Medical Assistance. Except in the case of preventive services and screening tests and home and community based services, your services (including medical care) must be medically necessary. Medically necessary means that the services are an accepted treatment for your medical condition. Enrollment in [Insert Plan name] does not guarantee that certain items are covered. Some prescription or medical equipment may not be covered. This is true even if they were covered before. [Insert if applicable: You receive your care from a network provider. In most cases, care you receive from a non-network provider will not be covered. Chapter 3 provides more information about requirements for using network providers and the situations when we will cover services from a non-network provider.] [Insert if applicable: You have a primary care provider (PCP) who is providing and overseeing your care. In most situations, your PCP must give you approval in advance before you can see other providers in the plans network. This is called giving you a referral. Chapter 3 provides more information about getting a referral and the situations when you do not need a referral.] [Insert if applicable: Some of the services listed in the Benefits Chart are covered only if your doctor or other network provider gets approval in advance (sometimes called prior authorization) from us. Covered services that need approval in advance are marked in the Benefits Chart [insert as appropriate: by an asterisk OR by a footnote OR in bold OR in italics] [Insert if applicable: In addition, the following services not listed in the Benefits Chart require prior authorization: [insert list]]. Restricted Recipient Program The Restricted Recipient Program is a program for members who have received medical care and have not followed the rules or have misused services. If you are placed in this program, we may replace your regular member card with a Restricted Recipient Program card. You must get health services from one primary care provider, one drug store, one hospital or other provider located in your local trade area. You must do this for 24 or 36 months of eligibility for Minnesota Health Care Programs (MHCP). You may also be assigned to a home health agency. You will not be allowed to use the personal care assistance choice option or consumer directed services. Placement in the program will stay with you if you change health plans. Placement in the program will also stay with you if you change to fee for service. You will not lose eligibility for MHCP because of placement in the program. At the end of the 24 or 36 months, your health care services will be reviewed. If you still do not follow the rules, you will be placed in the program for an additional 36 months of eligibility. You have the right to appeal placement in the Restricted Recipient Program. See Chapter 9. The Restricted Recipient Program does not apply to Medicare covered services. [Instructions on completing benefits chart: When preparing this Benefits Chart, please refer to the instructions for completing the standardized/combined ANOC/EOC. All plans with networks should clearly indicate for each service applicable the difference in cost-sharing at network and out-of-network providers and facilities. Plans with a POS benefit may include POS information within the benefit chart, or may include a section following the chart listing POS-eligible benefits and cost-sharing. Plans should clearly indicate which benefits are subject to prior authorization (plans may use asterisks or similar method). Plans may insert any additional benefits information based on the plans approved bid that is not captured in the benefits chart or in the exclusions section. SNPs may modify the language, as applicable, to address Medicaid benefits and cost-sharing for its dual eligible population. Plans should also state that members should contact their Medicaid Agency to determine their level of cost-sharing. Benefits Chart Services that are covered for youCare Coordination Assisting you in arranging for, getting, and coordinating assessments, tests and health and continuing care services Developing and updating your care plan Communicating with a variety of agencies and persons Other services as outlined in your care plan [Also list any additional benefits offered.]Chemical Dependency Services See Chapter 2 for Chemical Dependency Services contact information. Covered Services Assessment/diagnosis Outpatient treatment Inpatient hospital and primary residential inpatient stay Outpatient methadone treatment Detoxification, only if required for medical treatment Room and board determined necessary by chemical dependency assessment A qualified Plan network assessor will decide what type of chemical dependency care you need. You may get a second assessment if you do not agree with the first one. To get a second assessment you must send us a request. We must get your request within five working days of when you get the results of your first assessment or before you begin treatment (whichever is first). We will cover a second assessment by a different qualified assessor not in the Plan network. We will do this within five working days of when we get your request. If you agree with the second assessment, we will authorize services according to chemical dependency standards and the second assessment. You have the right to appeal.Chiropractic services See Chapter 2 for Chiropratic services contact information. Covered services Manual manipulation of the spine for subluxation only X-rays when needed to get a diagnosis of subluxation of the spine Not Covered Services Other adjustments, vitamins, medical supplies, therapies and equipment Exams and consultations Office visits that do not include manual manipulation of the spineDental services See Chapter 2 for Dental services contact information. Covered Services Diagnostic services Comprehensive exam every five years Periodic exam once per year Problem focused exams Limited x-rays Preventive services Cleaning once per year Fluoride and varnish once per year Restorative services Fillings Sedative fillings for relief of pain Endodontics (Root canals) on anterior teeth and premolars Periodontics Gross removal of plaque and tartar in limited situations, once every five years Scaling and root planning once every two years only when provided in an outpatient surgical setting Prosthodontics Removable prostheses (dentures and partials) once every six years per dental arch Oral surgery limited to extractions, biopsies and incision and drainage of abscesses Additional general services Treatment for pain General anesthesia only when provided in an outpatient surgical settingDiabetes self-monitoring, training, and supplies For all people who have diabetes (insulin and non-insulin users). Covered services Blood glucose monitor, blood glucose test strips, lancet devices and lancets, and glucose-control solutions for checking the accuracy of test strips and monitors Therapeutic shoes for people with diabetes who have severe diabetic foot disease, including fitting of shoes or inserts within certain limits Self-management training is covered under certain conditions For persons at risk of diabetes: Fasting plasma glucose tests. [Insert frequency]Diagnostic tests and therapeutic services and supplies Covered services X-rays Radiation therapy Surgical supplies, such as dressings Supplies, such as splints and casts Laboratory tests Audiology Blood and blood products Other diagnostic tests ordered by your doctor [Plans can include other covered tests as appropriate]Dialysis (Kidney) Covered services Outpatient dialysis treatments (including dialysis treatments when temporarily out of the service area, as explained in Chapter 3) Inpatient dialysis treatments (if you are admitted to a hospital for special care) Self-dialysis training (includes training for you and anyone helping you with your home dialysis treatments) Home dialysis equipment and supplies Certain home support services (such as, when necessary, visits by trained dialysis workers to check on your home dialysis, to help in emergencies, and check your dialysis equipment and water supply)Doctor services, including office visits Covered services Office visits, including medical and surgical care in a doctors office or certified ambulatory surgical center Physical exam Preventive exam Treatment of illness and injury Consultation, diagnosis, and treatment by a specialist Hearing and balance exams Telehealth office visits including consultation, diagnosis and treatment by a specialist Second opinion [Insert in appropriate: by another network provider] prior to surgery Family Planning- open access service (For more information see Family Planning Services section. Gynecology (GYN) services You have direct access to GYN providers for the following: annual preventive health exam, including follow-up exams that your doctor says are necessary; evaluation and treatment for gynecologic conditions or emergencies. To get the direct access services you must go to a provider in our Plans network. Visits in the hospital or nursing home Outpatient hospital services Emergency Medical Services and Post-Stabilization Care (Follow-up Care) [Identify whether this coverage is limited to the U.S. or is also available world-wide.] Coverage is limited to services provided in United States and Canada. Covered Services Emergency room services Post-stabilization care (follow-up care) Ambulance (air or ground) Not Covered Services Emergency care or other health care services received from providers located outside the United States and Canada. Eye Care Services Covered services Eye Exams Eyeglasses, including identical replacement due to damage, loss or theft Repairs to frames and lenses for eyeglasses covered under our Plan Tints or polarized lenses, when medically necessary Contact lenses, when medically necessary under certain circumstances Glaucoma screening Outpatient doctor services for eye care. [Adapt this description if the plan offers more than is covered by Original Medicare.]Eyeglasses or contact lenses after each cataract surgery that includes insertion of an intraocular lens. Corrective lenses/frames (and replacements) needed after a cataract removal without a lens implant. [Also list any additional benefits offered, such as routine vision exams or glasses, either here or in Vision Care section later in benefits chart.] Not Covered Services Extra pair of glasses Eyeglasses more often than every 24 months unless medically necessary Bifocal lenses without line and progressive bifocals Protective coating for plastic lenses Contact lens supplies Family Planning Services Federal and State law allow you to choose any doctor, clinic, hospital, pharmacy, or family planning agency to get open access services. You can get open access services from any provider, even if they are not in the Plan network. Covered Services Family planning exam and medical treatment open access service Family planning lab and diagnostic tests open access service Family planning methods (birth control pills, patch, ring, IUD, injections, implants) open access service Family planning supplies with prescription (condom, sponge, foam, film, diaphragm, cap) - open access service Counseling and diagnosis of infertility, including related services - open access service Treatment for medical conditions of infertility Not an open access service. You must see a provider in our Plans network. Note: This service does not include artificial ways to become pregnant. Counseling and testing for sexually transmitted disease (STDs), AIDS and other HIV-related conditions - open access service Treatment for sexually transmitted diseases (STDs) - open access service Treatment for AIDS and other HIV-related conditions Not an open access service. You must see a provider in the Plan network. Voluntary sterilization (You must be age 21 or older and you must sign a federal sterilization consent form. At least 30 days, but not more than 180 days, must pass between the date that you sign the form and the date of surgery - open access service Genetic counseling - open access service Genetic testing Not an open access service. You must see a provider in the Plan network. Not Covered Services Artificial ways to become pregnant (artificial insemination, including in-vitro fertilization and related services; fertility drugs and related services) Reversal of voluntary sterilization Health and wellness education programs [These are programs focused on clinical health conditions such as high blood pressure, cholesterol, asthma, and special diets. Programs designed to enrich the health and lifestyles of members include weight management, smoking cessation, fitness, and stress management. Describe the nature of the programs here.]Health Services Covered Services Services of a certified public health nurse or a registered nurse practicing in a public health nursing clinic under a governmental unit Advanced Practice Nurse services: Services provided by a nurse practitioner, nurse anesthetist, nurse midwife, or clinical nurse specialist Community health worker care coordination and patient education services Tuberculosis care management and direct observation of drug intake Counseling and testing for sexually transmitted diseases (STDS), AIDS and other HIV-related conditions - open access service Treatment for AIDS and other HIV-related conditions - Not an open access service Treatment for sexually transmitted diseases (STDs) open access service. Medical nutrition therapy [Also list any additional benefits offered.]Hearing services Covered Services Hearing tests Hearing aids and batteries Repair and replacement of hearing aids due to normal wear and tear, with limitsHome care services Covered services Skilled nursing Home health aide Physical therapy, occupational therapy, and speech language therapy Respiratory therapy Private duty nursing Personal care assistant (PCA) services and supervision of PCA services Medical social services Medical equipment and suppliesHome and Community Based Services (Elderly Waiver) See Chapter 2 for Home and Community Based Services contact information. Covered Elderly Waiver (EW) Services: Adult Day Care: Health and social services given on a regular basis in a licensed setting. Adult Foster Care: A home that provides care in a family-like setting. Case Management: Management of your health and long-term care services among different health and social service workers. Chore Services: Services needed to keep your home clean and safe. Companion Services: Non-medical social support services for members who need supervision. Consumer Directed Community Support Services: Services that you manage yourself within a set budget. Customized Living/24 Hour Customized Living: A group of services given in an assisted living setting. Environmental Accessibility Adaptions: Physical changes to your home and vehicle needed to assure health and safety. Extended Home Health Care Services :This includes home health aide and nursing services that are over the Medical Assistance limit. Extended Private Duty Nursing This includes private duty nursing services that are over the Medical Assistance limit. Extended Personal Care Assistance Services: Help with personal care and activities of daily living over the Medical Assistance limit. Family and Care Giver Training and Education: Training for unpaid caregivers. Home Delivered Meals: Meals delivered to your home. Homemaker Services: General household activities to keep up the home. Residential Care Services: A group of services offered in a licensed board and lodge setting. Respite Care: Short-term service when you cannot care for yourself, and your unpaid caregiver needs relief. Specialized Medical Supplies and Equipment: Supplies and equipment that are over the Medical Assistance limit or coverage. Transitional Supports Services: One time costs related to setting up a household (such as when a person leaves a nursing home). Transportation: A ride to activities and services in the community. You must have a Long Term Care Consultation (LTCC) done and found to be nursing home certifiable to get these Elderly Waiver (EW) services. You can request to have this assessment in your home, apartment or facility where you live. Your MSHO [insert either care coordinator or case manager] will meet with you and your family to talk about your care needs within 10 days if you call to ask for a visit. Your MSHO [insert either care coordinator or case manager] will give you information about community services, help you find services to stay in your home or community, and help you find services to move out of a nursing home or other facility. You have the right to have friends or family present at the visit. You can designate a representative to help you make decisions. You can decide what your needs are and where you want to live. You can ask for services to best meet your needs. You can make the final decisions about your plan for services and help. You can choose who you want to provide the services and supports from those providers available from our Plans network. After the visit, your MSHO [insert either care coordinator or case manager] will send you a letter that recommends services that best meet your needs. You will be sent a copy of the service or care plan you helped put together. Your [insert either care coordinator or case manager] will help you file an appeal if you disagree with suggested services or were informed you may not qualify for these services. People who live on the White Earth, Leech Lake or Fond du Lac Reservations can choose to get their EW services through the White Earth, Leech Lake or Fond du Lac tribal services or through our Plan. These EW options may be expanded to other reservations. Contact your tribe or our Plan if you have questions. If you are currently on the Community Alternatives for Disabled Individuals (CADI), Community Alternative Care (CAC), Traumatic Brain Injury (TBI), or the Developmental Disability (DD) waiver, you will continue to get services covered by these programs in the same way you get them now. Your county case manager will continue to authorize these services and coordinate with your MSHO [insert either care coordinator or case manager].Hospice care You may receive care from any Medicare-certified hospice program. Original Medicare (rather than our Plan) will pay the hospice provider for the services you receive. Your hospice doctor can be a network provider or an out-of-network provider. You will still be a plan member and will continue to get the rest of your care that is unrelated to your terminal condition through our Plan. Covered services Drugs for symptom control and pain relief, short-term respite care, and other services not otherwise covered by Original Medicare Home care [Insert if applicable, edit as appropriate: Our plan covers hospice consultation services (one time only) for a terminally ill person who hasnt elected the hospice benefit.]Hospital care - Inpatient [List days covered and any restrictions that apply.] Covered services Semi-private room (or a private room if medically necessary) Meals including special diets Regular nursing services Costs of special care units (e.g. intensive or coronary care units) Drugs and medications Lab tests X-rays and other radiology services Necessary surgical and medical supplies Use of appliances, such as wheelchairs Operating and recovery room costs Physical, occupational, respiratory and speech language therapy Under certain conditions, the following types of transplants are covered: corneal, kidney, pancreas, pancreatic islet cell, kidney-pancreatic, heart, liver, lung, heart/lung, bone marrow, stem cell, intestine, intestine-liver and intestinal/multivisceral. If you need a transplant, we will arrange to have your case reviewed by a Medicare-approved transplant center that will decide whether you are a candidate for a transplant. [Network plans insert: If you are sent outside of your community for a transplant, we will arrange or pay for appropriate lodging and transportation costs for you and a companion.] [Plans may further define the specifics of transplant travel coverage.] Blood and blood products- including storage and administration Doctor ServicesHospital Outpatient Covered Services Urgent care for conditions that are not as serious as an emergency Outpatient surgery (including services provided at ambulatory surgical centers) Tests and x-rays Dialysis Emergency room services Post stabilization care (follow-up care) Interpreter Services See Chapter 2 for Interpreter Services for contact information. Interpreter services are available to help you get services. Oral interpretation is available for any language. Covered Services Spoken language interpreter services Hearing interpreter servicesMedical equipment and related supplies You need a prescription/doctors order. You may call the Medical Equipment and Related Supplies Coverage Criteria phone number in Chapter 2 if you need more information on our Plans durable medical equipment coverage criteria. (For a definition of durable medical equipment, see Chapter 12 of this booklet.) Covered services Prosthetics or orthotics Durable medical equipment (e.g.: wheelchair, hospital bed, walker, crutches, wigs for people with alopecia areata) Repairs of medical equipment Batteries for medical equipment Some shoes when part of a leg brace or when custom molded Oxygen and oxygen equipment Supplies you may need to take care of a medical problem Incontinence products IV infusion pump Nebulizer Nutritional/enteral products Colostomy bags and supplies directly related to colostomy care Pacemakers Family planning supplies open access service (See Family Planning services section)Mental Health Services See Chapter 2 for Mental Health Services contact information. Get mental health services from our Plan network of mental health providers. If we or your network provider decides no structured mental health treatment is necessary, you may get a second opinion. For the second opinion, we must allow you to go to any qualified health professional who is not in the Plan network. We will pay for this. We must consider the second opinion, but we have the right to disagree with the second opinion. You have the right to appeal our decision. We will not determine medical necessity for court-ordered mental health services. Use a Plan network provider for your court-ordered mental health assessment. Covered Services Adult Mental Health Crisis Services (Non-residential and residential): assessment, mobile intervention, treatment planning, and stabilization services. Adult Rehabilitative Mental Health Services (ARMHS): basic living/social skills, community intervention, medication education, and services to help you stay in the community. Assertive Community Treatment (ACT) Consultation between your primary care doctor and a psychiatrist about your care Crisis assessment and intervention in an emergency room or urgent care setting Day treatment and partial hospitalization Diagnostic assessment Dialectical behavior therapy for persons diagnosed with borderline personality disorder (This service is effective upon federal approval.) Explanation of findings Inpatient psychiatric hospital stay Intensive Residential Treatment Services (IRTS) Medication management Mental Health Targeted Case Management for persons with serious and persistent mental illness (SPMI) Mental health services provided via two-way interactive video, which would otherwise be covered as direct face-to-face services Neuropsychological services Psychological testing Psychotherapy: individual, family, multifamily, and group Not Covered Services Treatment at Rule 36 facilities that are not licensed as Intensive Residential Treatment Services (IRTS) Room and board associated with Intensive Residential Treatment Services (IRTS)Nursing Home Services Nursing Home Daily Rate Our Plan is responsible for paying a total of 180 days of nursing home room and board. If you need continued nursing home care beyond the 180 days, the Minnesota Department of Human Services (DHS) will pay directly for your care. If DHS is currently paying for your care in the nursing home, DHS, not our Plan, will continue to pay for your care. You may meet special criteria that enable you to get skilled nursing facility (SNF) coverage under Medicare. Our Plan will pay up to 100 days of coverage per benefit period. No prior hospital stay is required. Covered services Semiprivate room (or a private room if medically necessary) Meals, including special diets Regular nursing services Physical therapy, occupational therapy, and speech therapy and respiratory therapy Drugs administered to you as part of your plan of care (This includes substances that are naturally present in the body, such as blood clotting factors.) Medical supplies and equipment Use of appliances such as wheelchairs ordinarily provided by SNFs Generally, you will get your SNF care from plan facilities. However, under certain conditions listed below, you may be able to pay in-network cost-sharing for a facility that isnt a plan provider, if the facility accepts our plans amounts for payment. A nursing home or continuing care retirement community where you were living right before you went to the hospital (as long as it provides skilled nursing facility care). A SNF where your spouse is living at the time you leave the hospital.Out-of-Area Services Covered Services A service you need when you are temporarily out of the Plan service area A service you need after you move from our service area while you are still a Plan member Emergency services for an emergency that needs treatment right away Post-stabilization care (follow-up care) Medically necessary urgent care when you are outside of the Plan service area. (Call Member Services at the phone number on the front cover as soon as possible.) Covered services that are not available in the Plan service area Not Covered Services Emergency care or other health care services received from providers located outside the United States and Canada.Out-of-Network Services Covered Services Certain services you need that you cannot get through a Plan network provider Emergency services for an emergency that needs treatment right away Post-stabilization care (follow-up care) A second opinion for mental health and chemical dependency Open access servicesPodiatry services Covered services Treatment of injuries and diseases of the feet (such as hammer toe or heel spurs). Routine foot care for members with certain medical conditions affecting the lower limbsPrescription drugs - See Chapters 5 and 6 for Information on Medicare Part D Prescription Drugs Chapter 5 explains the Part D prescription drug benefit, including rules you must follow to have prescriptions covered. What you pay for your Part D prescription drugs through our plan is listed in Chapter 6. Medicare Part B Covered Drugs These drugs are covered under Part B of Original Medicare. Members of our plan receive coverage for these drugs through our plan. Covered drugs include: Drugs that usually arent self-administered by the patient and are injected while you are getting doctor services Drugs you take using durable medical equipment (such as nebulizers) that was authorized by the plan Clotting factors you give yourself by injection if you have hemophilia Immunosuppressive Drugs, if you were enrolled in Medicare Part A at the time of the organ transplant Injectable osteoporosis drugs, if you are homebound, have a bone fracture that a doctor certifies was related to post-menopausal osteoporosis, and cannot self-administer the drug Antigens Certain oral anti-cancer drugs and anti-nausea drugs Certain drugs for home dialysis, including heparin, the antidote for heparin when medically necessary, topical anesthetics, and erythropoisis-stimulating agents (such as Epogen(, Procrit(, Epoetin Alfa, Aranesp(, or Darbepoetin Alfa) Intravenous Immune Globulin for the home treatment of primary immune deficiency diseases Medical Assistance Covered Drugs Our Plan will cover some Medical Assistance covered drugs that are not covered by Medicare Parts B and D. These include drugs such as benzodiazepines, barbiturates, some over-the-counter products, and some prescription cough and cold medicines. The drug must be on our covered drug list (formulary). We will cover a non-formulary drug if your doctor shows us that: 1) the drug that is normally covered has caused a harmful reaction to you; 2) there is a reason to believe the drug that is normally covered would cause a harmful reaction; or 3) the drug prescribed by your doctor is more effective for you than the drug that is normally covered. The drug must be in a class of drugs that is covered. We will cover an antipsychotic drug, even if it is not on our drug list, if your provider certifies this is best for you. There is no co-pay for anti-psychotic drugs. In certain cases, we will cover other drugs used to treat a mental illness or emotional disturbance even if the drug is not on our approved drug list. We will do this for up to one year if your provider certifies the drug is best for you and you have been treated with the drug for 90 days before: 1) we removed the drug from our drug list; or 2) you enrolled in our Plan [Note: describe the formulary exception process, including authorization requirements.] If pharmacy staff tells you the drug is not covered and asks you to pay, ask them to call your doctor. We cannot pay you back if you pay for it. There may be another drug that will work that is covered by our Plan. If the pharmacy wont call your doctor, you can. You can also call our Plan Member Services at the phone number in Chapter 2 for help. Not Covered Drugs Drugs used to enhance fertility Drugs used to treat impotence Drugs or products to promote weight loss Drugs used to treat hair loss for a cosmetic reason Preventive Services Abdominal aortic aneurysm screening Bone mass measurement Procedures to identify bone mass, detect bone loss, or determine bone quality, including a doctors interpretation of the results. Colorectal screening Immunizations Covered services include: Pneumonia vaccine Flu shots, once a year in the fall or winter Hepatitis B vaccine if you are at high or intermediate risk of getting Hepatitis B Zoster vaccine Other vaccines if you are at risk We also cover some vaccines under our outpatient prescription drug benefit. Mammography screening Pap test, pelvic exams, and clinical breast exams Prostate cancer screening exams Cardiovascular disease testing Blood tests for the detection of cardiovascular disease (or abnormalities associated with an elevated risk of cardiovascular disease) Rehabilitation services Covered services Physical therapy, Occupational therapy Speech and language therapy Respiratory therapy Cardiac rehabilitative therapy Not Covered Services Vocational Rehabilitation Health clubs and spas [Plans that have included this as an added benefit under Medicare should delete here and add to additional benefits]Surgery Covered Services Office/clinic visits/surgery Outpatient surgery (including services provided at ambulatory surgical centers) Port wine stain removal Reconstructive surgery (e.g., following mastectomy; following surgery for injury, sickness or other diseases; for birth defects.) Anesthesia services Circumcisions when medically necessary Not Covered Services Cosmetic surgery Sex reassignment surgeryTransplants Organ and tissue transplants, including: kidney, cornea, bone marrow, stem cell, heart, heart-lung, liver, lung, pancreas, pancreas-kidney, pancreatic islet cell, intestine, intestine-liver, and other transplants. The type of transplant must be: 1) listed in the Minnesota Department of Human Services Provider Manual; 2) a type covered by Medicare; or 3) be approved by the States medical review agent. Transplants must be done at transplant centers that meet the United Network for Organ Sharing (UNOS) standards or at Medicare approved transplant centers. Stem cell or bone marrow transplants centers must meet the standards set by the Foundation for the Accreditation of Cellular Therapy (FACT).Transportation If you need transportation to and from health services that we cover, call the Transportation phone number in Chapter 2. The Plan is not required to provide transportation to your Primary Care Clinic if it is over 30 miles from your home. If you need a ride and closer clinic in our network is not available, please call the transportation number in Chapter 2. Covered Services Emergency ambulance (air or ground) - Covered services include ambulance services to the nearest appropriate facility furnished to persons whose medical condition is such that other means of transportation could endanger the persons health. Non-emergency ambulance Special transportation (for people who, because of physical or mental impairment, cannot safely use a common carrier and do not need an ambulance) Common carrier transportation (e.g., bus or cab).Urgent care An urgent condition is not as serious as an emergency. This is care for a condition that needs prompt treatment to stop the condition from getting worse. Urgent care is available 24 hours a day. Call Member Services at the phone number in Chapter 2 as soon as possible when you get urgent care outside the Plan service area. Covered Services Urgent care within our Plans service area. Urgent care outside of our Plans service area. Not Covered Services Emergency care or other health care services received from providers located outside the United States and Canada.Additional Benefits[For all additional benefits information, plans should include only applicable rows.] Dental services [List any additional benefits offered, such as routine dental care.] Hearing services [List any additional benefits offered, such as routine hearing care.]Vision care [List any additional benefits offered, such as routine vision exams or glasses, unless included in Vision Care section earlier in benefits chart.]Health and wellness education programs [These are programs focused on clinical health conditions such as high blood pressure, cholesterol, asthma, and special diets. Programs designed to enrich the health and lifestyles of members include weight management, smoking cessation, fitness, and stress management. Describe the nature of the programs here.][Include other additional benefits being offered.] SECTION 3 What types of benefits are not covered by the plan? Section 3.1 Types of benefits we do not cover (exclusions) [Plans may add references to optional supplemental benefits where applicable, using the following format: However, [insert item/items] are available under Optional Supplemental Benefits.] [SNPs may, as appropriate, remove or modify language regarding benefit exclusions when the benefits are covered by the plan under the Medicaid program.] This section tells you what kinds of benefits are excluded. Excluded means that the plan doesnt cover these benefits. The list below describes some services and items that arent covered under any conditions and some that are excluded only under specific conditions. If you get benefits that are excluded, you must pay for them yourself. We wont pay for the benefits listed in this section (or elsewhere in this booklet), and neither will Original Medicare. In most cases, Medical Assistance will not pay either except for those services listed at the end of this section. Another exception for both Medicare and Medical Assistance services: If a benefit on the exclusion list is found upon appeal to be a benefit that we should have paid for or covered because of your specific situation. (For information about appealing a decision we have made to not cover a service, go to Chapter 9, Section 5.3 in this booklet.) In addition to any exclusions or limitations described in the Benefits Chart, or anywhere else in this Certificate of Coverage, [mention any other places where exclusions are given, such as addenda,] the following items and services arent covered under Original Medicare, Medical Assistance or by our plan: [The services listed in the remaining bullets are excluded from Original Medicares benefit package. If any services below are covered supplemental benefits, delete them from this list. When plans partially exclude services excluded by Medicare they need not delete the item completely from the list of excluded services but may revise the text accordingly to describe the extent of the exclusion. Plans may also indicate if a service may be covered as an optional supplemental benefit.] Services considered not reasonable and necessary, according to the standards of Original Medicare, unless these services are listed by our plan as a covered services. Experimental medical and surgical procedures, equipment and medications, unless covered by Original Medicare. However, certain services may be covered under a Medicare-approved clinical research study. See Chapter 3, Section 5 for more information on clinical research studies. Private room in a hospital, except when it is considered medically necessary. Personal items in your room at a hospital or a skilled nursing facility, such as a telephone or a television. Emergency care and other health services received from providers located outside the United States and Canada Autopsies Elective or voluntary enhancement procedures or services (including weight loss, hair growth, sexual performance, athletic performance, cosmetic purposes, anti-aging and mental performance), except when medically necessary. Cosmetic surgery or procedures unless needed because of an accidental injury or to improve the function of a malformed part of the body. However, all stages of reconstruction are covered for a breast after a mastectomy, as well as for the unaffected breast to produce a symmetrical appearance. Self-administered prescription drugs for treatment of sexual dysfunction, including erectile dysfunction, impotence, and anorgasmy or hyporgasmy. Reversal of sterilization procedures and sex change operations Naturopath services (uses natural or alternative treatments). Services provided to veterans in Veterans Affairs (VA) facilities. Any services listed above that arent covered will remain not covered even if received at an emergency facility. These benefits are not covered by Health Plans, but may be covered by the State, County, or Tribe. To find out more about these benefits, call the Minnesota Health Care Programs Member Helpdesk at 651- 431-2670 or 1-800-657-3739 (toll-free). Case management for people with developmental disabilities Intermediate care facility for people who are mentally retarded (ICF/MR) Nursing home stays for which our Plan is not otherwise responsible. See Nursing Home Services in the Benefits Chart. Treatment at Rule 36 facilities which are not licensed as Intensive Residential Treatment Services (IRTS) Room and board associated with Intensive Residential Treatment Services (IRTS) Services provided by a state regional treatment center, a State-owned long term care facility or an institution for mental disease (IMD) unless approved by us or the service is ordered by a court under conditions specified in law. Services provided by federal institutions Job training and educational services Day training and habilitation In certain cases, mileage reimbursement for rides not otherwise covered by the Plan, to get to and from health appointments (for example, in your own car). Contact your county for more information Chapter 5. Using the plans coverage for your Part D prescription drugs  TOC \t "Section Heading Ch 5,1,Section SubHeading 1 Ch 5,2" SECTION 1 Introduction  PAGEREF _Toc110591974 \h 68 Section 1.1 This chapter describes your coverage for Part D drugs  PAGEREF _Toc110591975 \h 68 Section 1.2 Basic rules for the plans Part D drug coverage  PAGEREF _Toc110591976 \h 68 SECTION 2 Your prescriptions should be written by a network provider  PAGEREF _Toc110591977 \h 69 Section 2.1 In most cases, your prescription must be from a network provider  PAGEREF _Toc110591978 \h 69 SECTION 3 Fill your prescription at a network pharmacy or through the plans mail-order service  PAGEREF _Toc110591979 \h 70 Section 3.1 To have your prescription covered, use a network pharmacy  PAGEREF _Toc110591980 \h 70 Section 3.2 Finding network pharmacies  PAGEREF _Toc110591981 \h 70 Section 3.3 Using the plans mail-order services  PAGEREF _Toc110591982 \h 71 Section 3.4 How can you get a long-term supply of drugs?  PAGEREF _Toc110591983 \h 72 Section 3.5 When can you use a pharmacy that is not in the plans network?  PAGEREF _Toc110591984 \h 72 SECTION 4 Your drugs need to be on the plans Drug List  PAGEREF _Toc110591985 \h 73 Section 4.1 The Drug List tells which Part D drugs are covered  PAGEREF _Toc110591986 \h 73 Section 4.2 There are [insert number of tiers] cost-sharing tiers for drugs on the Drug List  PAGEREF _Toc110591987 \h 73 Section 4.3 How can you find out if a specific drug is on the Drug List?  PAGEREF _Toc110591988 \h 74 SECTION 5 There are restrictions on coverage for some drugs  PAGEREF _Toc110591989 \h 74 Section 5.1 Why do some drugs have restrictions?  PAGEREF _Toc110591990 \h 74 Section 5.2 What kinds of restrictions?  PAGEREF _Toc110591991 \h 74 Section 5.3 Do any of these restrictions apply to your drugs?  PAGEREF _Toc110591992 \h 75 SECTION 6 What if one of your drugs is not covered in the way youd like it to be covered?  PAGEREF _Toc110591993 \h 75 Section 6.1 There are things you can do if your drug is not covered in the way youd like it to be covered  PAGEREF _Toc110591994 \h 75 Section 6.2 What can you do if your drug is not on the Drug List or if the drug is restricted in some way?  PAGEREF _Toc110591995 \h 76 Section 6.3 What can you do if your drug is in a cost-sharing tier you think is too high?  PAGEREF _Toc110591996 \h 78 SECTION 7 What if your coverage changes for one of your drugs?  PAGEREF _Toc110591997 \h 79 Section 7.1 The Drug List can change during the year  PAGEREF _Toc110591998 \h 79 Section 7.2 What happens if coverage changes for a drug you are taking?  PAGEREF _Toc110591999 \h 79 SECTION 8 What types of drugs are not covered by the plan?  PAGEREF _Toc110592000 \h 81 Section 8.1 Types of drugs we do not cover  PAGEREF _Toc110592001 \h 81 SECTION 9 Show your plan membership card when you fill a prescription  PAGEREF _Toc110592002 \h 82 Section 9.1 Show your membership card  PAGEREF _Toc110592003 \h 82 Section 9.2 What if you dont have your membership card with you?  PAGEREF _Toc110592004 \h 82 SECTION 10 Part D drug coverage in special situations  PAGEREF _Toc110592005 \h 82 Section 10.1 What if youre in a hospital or a skilled nursing facility for a stay that is covered by the plan?  PAGEREF _Toc110592006 \h 82 Section 10.2 What if youre a resident in a long-term care facility?  PAGEREF _Toc110592007 \h 83 Section 10.3 What if youre also getting drug coverage from an employer or retiree group plan?  PAGEREF _Toc110592008 \h 83 SECTION 11 Programs on drug safety and managing medications  PAGEREF _Toc110592009 \h 84 Section 11.1 Programs to help members use drugs safely  PAGEREF _Toc110592010 \h 84 Section 11.2 Programs to help members manage their medications  PAGEREF _Toc110592011 \h 85  SECTION 1 Introduction Section 1.1 This chapter describes your coverage for Part D drugs This chapter explains rules for using your coverage for Part D drugs. The next chapter tells what you pay for Part D drugs (Chapter 6, What you pay for your Part D prescription drugs). In addition to your coverage for Part D drugs, [insert plan name] also covers some drugs under the plans Medicare medical benefits: The plan covers drugs you are given during covered stays in the hospital or in a skilled nursing facility. Chapter 4 ( Benefits chart, what is covered) tells about the benefits for drugs during a covered hospital or skilled nursing facility stay. Medicare Part B also provides benefits for some drugs. Part B drugs include certain chemotherapy drugs, certain drug injections you are given during an office visit, and drugs you are given at a dialysis facility. Chapter 4 ( Benefits chart, what is covered) tells about the benefits for Part B drugs. The two examples of drugs described above are covered by the plans Medicare medical benefits. In addition, the plan also covers some Medical Assistance covered drugs that are not covered by Medicare Part D. Chapter 4 (Benefits Chart) tells about the benefits for Medical Assistance covered drugs. This chapter explains rules for using your coverage for Part D drugs. The next chapter tells what you pay for Part D drugs (Chapter 6, What you pay for your Part D prescription drugs). Section 1.2 Basic rules for the plans Part D drug coverage The plan will generally cover your drugs as long as you follow these basic rules: [Omit if not applicable: You must have a network provider write your prescription. (For more information, see Section 2, Your prescriptions should be written by a network provider.)] You must use a network pharmacy to fill your prescription. (See Section 3, Fill your prescriptions at a network pharmacy.) Your drug must be on the plans List of Covered Drugs (Formulary) (we call it the Drug List for short). (See Section 4, Your drugs need to be on the plans drug list.) Your drug must be considered medically necessary, meaning reasonable and necessary for treatment of your injury or illness. It also needs to be an accepted treatment for your medical condition. SECTION 2 Your prescriptions should be written by a network provider [Plans should omit this section if not applicable.] Section 2.1 In most cases, your prescription must be from a network provider You need to get your prescription (as well as your other care) from a provider in the plans provider network. This person would often be your primary care provider (your PCP). It could also be another professional in our provider network if your PCP has referred you for care. To find network providers, look in the Provider Directory. The plan will cover prescriptions from providers who are not in the plans network only in a few special circumstances. These include: Prescriptions you get in connection with emergency care. Prescriptions you get in connection with urgently needed care when network providers are not available. Dialysis you get when you are traveling outside of the plans service area. Other than these circumstances, you must have approval in advance (prior authorization) from the plan to get coverage of a prescription from an out-of-network provider. If you pay out-of-pocket for a prescription written by an out-of-network provider and you think we should cover this expense, please contact Member Services or send the bill to us for payment. Chapter 7, Section 2.1 tells how to ask us to pay our share of the cost. If the drug is a Medical Assistance covered drug, we cannot pay you back for a Medical Assistance covered drug that you pay out-of-pocket. State and federal laws prevent us from paying you directly. If you paid for a prescription drug that you think we should have covered, contact Member Services at the number listed in on the cover. SECTION 3 Fill your prescription at a network pharmacy or through the plans mail-order service Section 3.1 To have your prescription covered, use a network pharmacy In most cases, your prescriptions are covered only if they are filled at the plans network pharmacies. A network pharmacy is a pharmacy that has a contract with the plan to provide your covered prescription drugs. The term covered drugs means all of the Part D prescription drugs that are covered by the plan. [Include if plan has both preferred and non-preferred pharmacies in their networks: Preferred pharmacies are pharmacies in our network where the plan has negotiated lower cost-sharing for members for covered drugs than at [insert either: non-preferred pharmacies OR other network pharmacies.]However, you will still have access to lower drug prices at [insert either: non-preferred pharmacies OR these other network pharmacies] than at out-of-network pharmacies. You may go to either of these types of network pharmacies to receive your covered prescription drugs. [Describe restrictions imposed on members that use non-preferred pharmacies.]] Section 3.2 Finding network pharmacies How do you find a network pharmacy in your area? You can look in your Pharmacy Directory, visit our website ([insert URL]), or call Member Services (phone numbers are on the cover). Choose whatever is easiest for you. You may go to any of our network pharmacies. If you switch from one network pharmacy to another, and you need a refill of a drug you have been taking, you can ask [insert if applicable: to either have a new prescription written by a doctor or] to have your prescription transferred to your new network pharmacy. What if the pharmacy you have been using leaves the network? If the pharmacy you have been using leaves the plans network, you will have to find a new pharmacy that is in the network. To find another network pharmacy in your area, you can get help from Member Services (phone numbers are on the cover) or use the Pharmacy Directory. What if you need a specialized pharmacy? Sometimes prescriptions must be filled at a specialized pharmacy. Specialized pharmacies include: Pharmacies that supply drugs for home infusion therapy. [Plans may insert additional information about home infusion pharmacy services in the plans network.] Pharmacies that supply drugs for residents of a long-term-care facility. Usually, a long-term care facility (such as a nursing home) has its own pharmacy. Residents may get prescription drugs through the facilitys pharmacy as long as it is part of our network. If your long-term care pharmacy is not in our network, please contact Member Services. [Plans may insert additional information about LTC pharmacy services in the plans network.] Pharmacies that serve the Indian Health Service / Tribal / Urban Indian Health Program (not available in Puerto Rico). Except in emergencies, only Native Americans or Alaska Natives have access to these pharmacies in our network. [Plans may insert additional information about I/T/U pharmacy services in the plans network.] Pharmacies that dispense certain drugs that are restricted by the FDA to certain locations, require extraordinary handling, provider coordination, or education on its use. (Note: This scenario should happen rarely.) To locate a specialized pharmacy, look in your Pharmacy Directory or call Member Services. Section 3.3 Using the plans mail-order services [Omit if the plan does not offer mail-order services.] [Include the following information only if your mail-order service is limited to a subset of all formulary drugs, adapting terminology as needed: For certain kinds of drugs, you can use the plans network mail-order services. These drugs are marked as [insert either: maintenance OR mail-order] drugs on our plans Drug List. ([Insert either: Maintenance OR Mail-order] drugs are drugs that you take on a regular basis, for a chronic or long-term medical condition.)] Our plans mail-order service requires you to order [insert either: at least a [XX]-day supply of the drug and no more than a [XX]-day supply OR up to a [XX] day supply]. [Plans that offer preferred and non-preferred mail-order services may add language to describe both preferred and non-preferred mail order.] To get [insert if applicable: order forms and] information about filling your prescriptions by mail [insert instructions]. If you use a mail-order pharmacy not in the plans network, your prescription will not be covered. Usually a mail-order pharmacy order will get to you in no more than [XX] days. [Insert plans process for members to get a prescription if the mail-order is delayed.] Section 3.4 How can you get a long-term supply of drugs? When you get a long-term supply of drugs, your cost sharing may be lower. The plan offers [insert as appropriate: a way OR two ways] to get a long-term supply of [insert either: maintenance OR mail-order] drugs on our plans Drug List. ([Insert either: Maintenance OR Mail-order] drugs are drugs that you take on a regular basis, for a chronic or long-term medical condition.) Some retail pharmacies in our network allow you to get a long-term supply of [insert either: maintenance OR mail-order] drugs. Some of these retail pharmacies [insert if applicable: may] agree to accept [insert as appropriate: a lower OR the mail-order] cost-sharing amount for a long-term supply of [insert either: maintenance OR mail-order] drugs. [Insert if applicable: Other retail pharmacies may not agree to accept the [insert as appropriate: lower OR mail-order] cost-sharing amounts for an extended supply of [insert either: maintenance OR mail-order] drugs. In this case you will be responsible for the difference in price.] Your Pharmacy Directory tells you which pharmacies in our network can give you a long-term supply of [insert either: maintenance OR mail-order] drugs. You can also call Member Services for more information. [Delete if plan does not offer mail-order service.] For certain kinds of drugs, you can use the plans network mail-order services. These drugs are marked as [insert either: maintenance OR mail-order] drugs on our plans Drug List. Our plans mail-order service requires you to order [insert either: at least a [XX]-day supply of the drug and no more than a [XX]-day supply OR up to a [XX]-day supply]. See Section 3.3 for more information about using our mail-order services. Section 3.5 When can you use a pharmacy that is not in the plans network? Your prescription might be covered in certain situations [Insert if applicable: We have network pharmacies outside of our service area where you can get your prescriptions filled as a member of our plan.] Generally, we cover drugs filled at an out-of-network pharmacy only when you are not able to use a network pharmacy. Here are the circumstances when we would cover prescriptions filled at an out-of-network pharmacy: [Plans should insert a list of situations when they will cover prescriptions out of the network and any limits on their out-of-network policies (e.g., day supply limits, use of mail-order during extended out of area travel, authorization or plan notification).] In these situations, please check first with Member Services to see if there is a network pharmacy nearby. How do you ask for reimbursement from the plan? If you must use an out-of-network pharmacy, you will generally have to pay the full cost (rather than paying your normal share of the cost) when you fill your prescription. You can ask us to reimburse you for our share of the cost. (Chapter 7, Section 2.1 explains how to ask the plan to pay you back.) If the drug is a Medical Assistance covered drug, we cannot pay you back for a Medical Assistance covered drug that you pay out-of-pocket. State and federal laws prevent us from paying you directly. If you paid for a prescription drug that you think we should have covered, contact Member Services at the number listed in on the cover. SECTION 4 Your drugs need to be on the plans Drug List Section 4.1 The Drug List tells which Part D drugs are covered The plan has a List of Covered Drugs (Formulary). In this Certificate of Coverage, we call it the Drug List for short. The drugs on this list are selected by the plan with the help of a team of doctors and pharmacists. The list must meet requirements set by Medicare. Medicare has approved the plans Drug List. We will generally cover a drug on the plans Drug List as long as you follow the other coverage rules explained in this chapter and the drug is medically necessary, meaning reasonable and necessary for treatment of your injury or illness. It also needs to be an accepted treatment for your medical condition. The Drug List includes both brand-name and generic drugs A generic drug is a prescription drug that has the same active ingredients as the brand-name drug. It works just as well as the brand-name drug, but it costs less. There are generic drug substitutes available for many brand-name drugs. What is not on the Drug list? The plan does not cover all prescription drugs. In some cases, the law does not allow any Medicare plan to cover certain types of drugs (for more information about this, see Section 8.1 in this chapter). In other cases, we have decided not to include a particular drug on the Drug List. Section 4.2 There are [insert number of tiers] cost-sharing tiers for drugs on the Drug List [Plans that do not use drug tiers should omit this section.] Every drug on the plans Drug List is in one of [insert number of tiers] cost-sharing tiers. In general, the higher the cost-sharing tier, the higher your cost for the drug: [Plans should briefly describe each tier (e.g., Cost-Sharing Tier 1 includes generic drugs). Indicate which is the lowest tier and which is the highest tier.] To find out which cost-sharing tier your drug is in, look it up in the plans Drug List. The amount you pay for drugs in each cost-sharing tier is shown in Chapter 6 (What you pay for your Part D prescription drugs). Section 4.3 How can you find out if a specific drug is on the Drug List? You have three ways to find out: Check the most recent Drug List we sent you in the mail. Visit the plans website ([insert URL]). The Drug List on the website is always the most current. Call Member Services to find out if a particular drug is on the plans Drug List or to ask for a copy of the list. Phone numbers for Member Services are on the front cover. SECTION 5 There are restrictions on coverage for some drugs Section 5.1 Why do some drugs have restrictions? For certain prescription drugs, special rules restrict how and when the plan covers them. A team of doctors and pharmacists developed these rules to help our members use drugs in the most effective ways. These special rules also help control overall drug costs, which keeps your drug coverage more affordable. In general, our rules encourage you get a drug that works for your medical condition and is safe. Whenever a safe, lower-cost drug will work medically just as well as a higher-cost drug, the plans rules are designed to encourage you and your doctor to use that lower-cost option. We also need to comply with Medicares rules and regulations for drug coverage and cost sharing. Section 5.2 What kinds of restrictions? Our plan uses different types of restrictions to help our members use drugs in the most effective ways. The sections below tell you more about the types of restrictions we use for certain drugs. [Plans should include only the forms of utilization management used by the plan:] Using generic drugs whenever you can A generic drug works the same as a brand-name drug, but usually costs less. When a generic version of a brand-name drug is available, our network pharmacies must provide you the generic version. However, if your doctor has told us the medical reason that the generic drug will not work for you, then we will cover the brand-name drug. (Your share of the cost may be greater for the brand-name drug than for the generic drug.) Getting plan approval in advance For certain drugs, you or your doctor need to get approval from the plan before we will agree to cover the drug for you. This is called prior authorization. Sometimes plan approval is required so we can be sure that your drug is covered by Medicare rules. Sometimes the requirement for getting approval in advance helps guide appropriate use of certain drugs. If you do not get this approval, your drug might not be covered by the plan. Trying a different drug first This requirement encourages you to try safer or more effective drugs before the plan covers another drug. For example, if Drug A and Drug B treat the same medical condition, the plan may require you to try Drug A first. If Drug A does not work for you, the plan will then cover Drug B. This requirement to try a different drug first is called Step Therapy. Quantity limits For certain drugs, we limit the amount of the drug that you can have. For example, the plan might limit how many refills you can get, or how much of a drug you can get each time you fill your prescription. For example, if it is normally considered safe to take only one pill per day for a certain drug, we may limit coverage for your prescription to no more than one pill per day. Section 5.3 Do any of these restrictions apply to your drugs? The plans Drug List includes information about the restrictions described above. To find out if any of these restrictions apply to a drug you take or want to take, check the Drug List. For the most up-to-date information, call Member Services (phone numbers are on the front cover) or check our website ([insert URL]). SECTION 6 What if one of your drugs is not covered in the way youd like it to be covered? Section 6.1 There are things you can do if your drug is not covered in the way youd like it to be covered Suppose there is a prescription drug you are currently taking, or one that you and your doctor think you should be taking. We hope that your drug coverage will work well for you, but its possible that you might have a problem. For example: What if the drug you want to take is not covered by the plan? For example, the drug might not be covered at all. Or maybe a generic version of the drug is covered but the brand-name version you want to take is not covered. What if the drug is covered, but there are extra rules or restrictions on coverage for that drug? As explained in Section 5, some of the drugs covered by the plan have extra rules to restrict their use. For example, [delete if plan does not have step therapy: you might be required to try a different drug first, to see if it will work, before the drug you want to take will be covered for you.] [Delete if plan does not have quantity limits: Or there might be limits on what amount of the drug (number of pills, etc.) is covered during a particular time period.] [Omit if plan does not use drug tiers: What if the drug is covered, but it is in a cost-sharing tier that makes your cost sharing more expensive than you think it should be? The plan puts each covered drug into one of [insert number of tiers] different cost-sharing tier. How much you pay for your prescription depends in part on which cost-sharing tier your drug is in.] There are things you can do if your drug is not covered in the way that youd like it to be covered. [Delete if plan does not use drug tiers: Your options depend on what type of problem you have:] If your drug is not on the Drug List or if your drug is restricted, go to Section 6.2 to learn what you can do. [Omit if plan does not use drug tiers] If your drug is in a cost-sharing tier that makes your cost more expensive than you think it should be, go to Section 6.3 to learn what you can do. Section 6.2 What can you do if your drug is not on the Drug List or if the drug is restricted in some way? If your drug is not on the Drug List or is restricted, here are things you can do: You may be able to get a temporary supply of the drug (only members in certain situations can get a temporary supply). You can change to another drug. You can request an exception and ask the plan to cover the drug in the way you would like it to be covered. You may be able to get a temporary supply Under certain circumstances, the plan can offer a temporary supply of a drug to you when your drug is not on the Drug List or when it is restricted in some way. Doing this gives you time to talk with your doctor about the change in coverage and figure out what to do. To be eligible for a temporary supply, you must meet the two requirements below: 1. The change to your drug coverage must be one of the following types of changes: The drug you have been taking is no longer on the plans Drug List. -- or -- the drug you have been taking is now restricted in some way (Section 5 in this chapter tells about restrictions). 2. You must be in one of the situations described below: [Plans may omit this scenario if they allow current members to request formulary exceptions in advance for the following year:] For those members who were in the plan last year and arent in a long-term care facility: We will cover a temporary supply of your drug one time only during the first [insert time period (must be at least 90 days)] of the calendar year. This temporary supply will be for a maximum of [insert supply limit (must be at least a 30-day supply)], or less if your prescription is written for fewer days. The prescription must be filled at a network pharmacy. For those members who are new to the plan and arent in a long-term care facility: We will cover a temporary supply of your drug one time only during the first [insert time period (must be at least 90 days)] of your membership in the plan. This temporary supply will be for a maximum of [insert supply limit (must be at least a 30-day supply)], or less if your prescription is written for fewer days. For those who are new members, and are residents in a long-term care facility: We will cover a temporary supply of your drug during the first [insert time period (must be at least 90 days)] of your membership in the plan. The first supply will be for a maximum of [insert supply limit (must be at least a 31-day supply)], or less if your prescription is written for fewer days. If needed, we will cover additional refills during your first [insert time period (must be at least 90 days)] in the plan. For those who have been a member of the plan for more than [insert time period (must be at least 90 days)], and are a resident of a long-term care facility and need a supply right away: We will cover one [insert supply limit (must be at least a 31-day supply)] supply, or less if your prescription is written for fewer days. This is in addition to the above long-term care transition supply. [If applicable: Plans must insert their transition policy for current members with level of care changes.] To ask for a temporary supply, call Member Services (phone numbers are on the front cover). During the time when you are getting a temporary supply of a drug, you should talk with your doctor to decide what to do when your temporary supply runs out. Perhaps there is a different drug covered by the plan that might work just as well for you. Or you and your doctor can ask the plan to make an exception for you and cover the drug in the way you would like it to be covered. The sections below tell you more about these options. You can change to another drug Start by talking with your doctor. Perhaps there is a different drug covered by the plan that might work just as well for you. You can call Member Services to ask for a list of covered drugs that treat the same medical condition. This list can help your doctor to find a covered drug that might work for you. You can file an exception You and your doctor can ask the plan to make an exception for you and cover the drug in the way you would like it to be covered. If your doctor or other prescriber says that you have medical reasons that justify asking us for an exception, your doctor or other prescriber can help you request an exception to the rule. For example, you can ask the plan to cover a drug even though it is not on the plans Drug List. Or you can ask the plan to make an exception and cover the drug without restrictions. [Plans that allow current members to receive a temporary supply instead, may omit the following paragraph:] If you are a current member and a drug you are taking will be removed from the formulary or restricted in some way for next year, we will allow you to request a formulary exception in advance for next year. We will tell you about any change in the coverage for your drug for the following year. You can then ask us to make an exception and cover the drug in the way you would like it to be covered for the following year. We will give you an answer to your request for an exception before the change takes effect. If you and your doctor or other prescriber want to ask for an exception, Chapter 9, Section 6.2 tells what to do. It explains the procedures and deadlines that have been set by Medicare to make sure your request is handled promptly and fairly. Section 6.3 What can you do if your drug is in a cost-sharing tier you think is too high? [Plans that do not use drug tiers may omit this section.] If your drug is a cost-sharing tier you think is too high, here are things you can do: You can change to another drug Start by talking with your doctor. Perhaps there is a different drug in a lower cost-sharing tier that might work just as well for you. You can call Member Services to ask for a list of covered drugs that treat the same medical condition. This list can help your doctor to find a covered drug that might work for you. You can file an exception You and your doctor can ask the plan to make an exception in the cost-sharing tier for the drug so that you pay less for the drug. If your doctor or other provider says that you have medical reasons that justify asking us for an exception, your doctor can help you request an exception to the rule. If you and your doctor want to ask for an exception, Chapter 9, Section 6.2 tells what to do. It explains the procedures and deadlines that have been set by Medicare to make sure your request is handled promptly and fairly. SECTION 7 What if your coverage changes for one of your drugs? Section 7.1 The Drug List can change during the year Most of the changes in drug coverage happen at the beginning of each year (January 1). However, during the year, the plan might make many kinds of changes to the Drug List. For example, the plan might: Add or remove drugs from the Drug List. New drugs become available, including new generic drugs. Perhaps the government has given approval to a new use for an existing drug. Sometimes, a drug gets recalled and we decide not to cover it. Or we might remove a drug from the list because it has been found to be ineffective. [Insert if applicable: Move a drug to a higher or lower cost-sharing tier.] Add or remove a restriction on coverage for a drug (for more information about restrictions to coverage, see Section 5 in this chapter). Replace a brand-name drug with a generic drug. In almost all cases, we must get approval from Medicare for changes we make to the plans Drug List. Section 7.2 What happens if coverage changes for a drug you are taking? How will you find out if your drugs coverage has been changed? If there is a change to coverage for a drug you are taking, the plan will send you a notice to tell you. Normally, we will let you know at least 60 days ahead of time. Once in a while, a drug is suddenly recalled because its been found to be unsafe or for other reasons. If this happens, the plan will immediately remove the drug from the Drug List. We will let you know of this change right away. Your doctor will also know about this change, and can work with you to find another drug for your condition. Do changes to your drug coverage affect you right away? If any of the following types of changes affect a drug you are taking, the change will not affect you until January 1 of the next year if you stay in the plan: [Plans that do not use tiers may omit: If we move your drug into a higher cost-sharing tier.] If we put a new restriction on your use of the drug. If we remove your drug from the Drug List, but not because of a sudden recall or because a new generic drug has replaced it. If any of these changes happens for a drug you are taking, then the change wont affect your use or what you pay as your share of the cost until January 1 of the next year. Until that date, you probably wont see any increase in your payments or any added restriction to your use of the drug. However, on January 1 of the next year, the changes will affect you. In some cases, you will be affected by the coverage change before January 1: If a brand-name drug you are taking is replaced by a new generic drug, the plan must give you at least 60 days notice or give you a 60-day refill of your brand-name drug at a network pharmacy. During this 60-day period, you should be working with your doctor to switch to the generic or to a different drug that we cover. Or you and your doctor or other prescriber can ask the plan to make an exception and continue to cover the brand-name drug for you. For information on how to ask for an exception, see Chapter 9 (What to do if you have a problem or complaint). Again, if a drug is suddenly recalled because its been found to be unsafe or for other reasons, the plan will immediately remove the drug from the Drug List. We will let you know of this change right away. Your doctor will also know about this change, and can work with you to find another drug for your condition. SECTION 8 What types of drugs are not covered by the plan? Section 8.1 Types of drugs we do not cover [SNPs may, as appropriate, remove or modify language regarding benefit exclusions when the benefits are covered by the plan under the Medicaid program.] This section tells you what kinds of prescription drugs are excluded. Excluded means that the plan doesnt cover these types of drugs because the law doesnt allow any Medicare or Medical Assistance drug plan to cover them. If you get drugs that are excluded by both Medicare and Medical Assistance, you must pay for them yourself. We wont pay for the drugs that are listed in this section . The only exception: If the requested drug is found upon appeal to be a drug that is not excluded and we should have paid for or covered because of your specific situation. (For information about appealing a decision we have made to not cover a drug, go to Chapter 9, Section 6.5 in this booklet.) Here are three general rules about drugs that Medicare drug plans will not cover under Part D: Our plans Part D drug coverage cannot cover a drug that would be covered under Medicare Part A or Part B. Our plan cannot cover a drug purchased outside the United States and its territories. Off-label use is any use of the drug other than those indicated on a drugs label as approved by the Food and Drug Administration. Generally, coverage for off-label use is allowed only when the use is supported by certain reference books. These reference books are the American Hospital Formulary Service Drug Information, the DRUGDEX Information System, and the USPDI or its successor. If the use is not supported by any of these reference books, then our plan cannot cover its off-label use. Also, by law, these categories of drugs are not covered by Medicare drug plans or Medical Assistance. Drugs when used to promote fertility Drugs when used for cosmetic purposes or to promote hair growth Drugs when used for the treatment of sexual or erectile dysfunction, such as Viagra, Cialis, Levitra, and Caverject Drugs or products to promote weight loss Outpatient drugs for which the manufacturer seeks to require that associated tests or monitoring services be purchased exclusively from the manufacturer as a condition of sale SECTION 9 Show your plan membership card when you fill a prescription Section 9.1 Show your membership card To fill your prescription, show your plan membership card at the network pharmacy you choose. When you show your plan membership card, the network pharmacy will automatically bill the plan for our share of your covered prescription drug cost. You will need to pay the pharmacy your share of the cost when you pick up your prescription. Section 9.2 What if you dont have your membership card with you? If you dont have your plan membership card with you when you fill your prescription, ask the pharmacy to call the plan to get the necessary information. If the pharmacy is not able to get the necessary information, you may have to pay the full cost of the prescription when you pick it up. (You can then ask us to reimburse you for our share. See Chapter 7, Section 2.1 for information about how to ask the plan for reimbursement.) If the drug is a Medical Assistance covered drug, we cannot pay you back for a Medical Assistance covered drug that you pay out-of-pocket. State and federal laws prevent us from paying you directly. If you paid for a prescription drug that you think we should have covered, contact Member Services at the number listed in on the cover. SECTION 10 Part D drug coverage in special situations Section 10.1 What if youre in a hospital or a skilled nursing facility for a stay that is covered by the plan? If you are admitted to a hospital or to a skilled nursing facility for a stay covered by the plan, we will generally cover the cost of your prescription drugs during your stay. Once you leave the hospital or skilled nursing facility, the plan will cover your drugs as long as the drugs meet all of our rules for coverage. See the previous parts of this section that tell about the rules for getting drug coverage. Chapter 6 (What you pay for your Part D prescription drugs) gives more information about drug coverage and what you pay. Please Note: When you enter, live in, or leave a skilled nursing facility, you are entitled to a special enrollment period. During this time period, you can switch plans or change your coverage at any time. (Chapter 10, Ending your membership in the plan, tells you can leave our plan and join a different Medicare plan.) Section 10.2 What if youre a resident in a long-term care facility? Usually, a long-term care facility (such as a nursing home) has its own pharmacy, or a pharmacy that supplies drugs for all of its residents. If you are a resident of a long-term care facility, you may get your prescription drugs through the facilitys pharmacy as long as it is part of our network. Check your Pharmacy Directory to find out if your long-term care facilitys pharmacy is part of our network. If it isnt, or if you need more information, please contact Member Services. What if youre a resident in a long-term care facility and become a new member of the plan? If you need a drug that is not on our Drug List or is restricted in some way, the plan will cover a temporary supply of your drug during the first [insert time period (must be at least 90 days)] of your membership. The first supply will be for a maximum of [insert supply limit (must be at least a 31-day supply)], or less if your prescription is written for fewer days. If needed, we will cover additional refills during your first [insert time period (must be at least 90 days)] in the plan. If you have been a member of the plan for more than [insert time period (must be at least 90 days)] and need a drug that is not on our Drug List or if the plan has any restriction on the drugs coverage, we will cover one [insert supply limit (must be at least a 31-day supply)] supply, or less if your prescription is written for fewer days. During the time when you are getting a temporary supply of a drug, you should talk with your doctor or other prescriber to decide what to do when your temporary supply runs out. Perhaps there is a different drug covered by the plan that might work just as well for you. Or you and your doctor can ask the plan to make an exception for you and cover the drug in the way you would like it to be covered. If you and your doctor want to ask for an exception, Chapter 9, Section 6.2 tells what to do. Section 10.3 What if youre also getting drug coverage from an employer or retiree group plan? Do you currently have other prescription drug coverage through your (or your spouses) employer or retiree group? If so, please contact that groups benefits administrator. He or she can help you determine how your current prescription drug coverage will work with our plan. In general, if you are currently employed, the prescription drug coverage you get from us will be secondary to your employer or retiree group coverage. That means your group coverage would pay first. Special note about creditable coverage: Each year your employer or retiree group should send you a notice by November 15 that tells if your prescription drug coverage for the next calendar year is creditable and the choices you have for drug coverage. If the coverage from the group plan is creditable, it means that it has drug coverage that pays, on average, at least as much as Medicares standard drug coverage. Keep these notices about creditable coverage, because you may need them later. If you enroll in a Medicare plan that includes Part D drug coverage, you may need these notices to show that you have maintained creditable coverage. If you didnt get a notice about creditable coverage from your employer or retiree group plan, you can get a copy from your employer or retiree plans benefits administrator or the employer or union. SECTION 11 Programs on drug safety and managing medications Section 11.1 Programs to help members use drugs safely We conduct drug use reviews for our members to help make sure that they are getting safe and appropriate care. These reviews are especially important for members who have more than one provider who prescribes their drugs. We do a review each time you fill a prescription. We also review our records on a regular basis. During these reviews, we look for potential problems such as: Possible medication errors. Drugs that may not be necessary because you are taking another drug to treat the same medical condition. Drugs that may not be safe or appropriate because of your age or gender. Certain combinations of drugs that could harm you if taken at the same time. Prescriptions written for drugs that have ingredients you are allergic to. Possible errors in the amount (dosage) of a drug you are taking. If we see a possible problem in your use of medications, we will work with your doctor to correct the problem. Section 11.2 Programs to help members manage their medications [Plans should include this section only if applicable.] We have programs that can help our members with special situations. For example, some members have several complex medical conditions or they may need to take many drugs at the same time, or they could have very high drug costs. These programs are voluntary and free to members. A team of pharmacists and doctors developed the programs for us. The programs can help make sure that our members are using the drugs that work best to treat their medical conditions and help us identify possible medication errors. If we have a program that fits your needs, we will automatically enroll you in the program and send you information. If you decide not to participate, please notify us and we will withdraw your participation in the program. Chapter 6. What you pay for your Part D prescription drugs  TOC \t "Section Heading Ch 6,1,Section SubHeading 1 Ch 6,2" SECTION 1 Introduction  PAGEREF _Toc110592012 \h 88 Section 1.1 Use this chapter together with other materials that explain your drug coverage  PAGEREF _Toc110592013 \h 88 SECTION 2 What you pay for a drug depends on which drug payment stage you are in when you get the drug  PAGEREF _Toc110592014 \h 88 Section 2.1 What are the [insert number of stages] drug payment stages?  PAGEREF _Toc110592015 \h 88 SECTION 3 We send you reports that explain payments for your drugs and which payment stage you are in  PAGEREF _Toc110592016 \h 89 Section 3.1 We send you a monthly report called the Explanation of Benefits  PAGEREF _Toc110592017 \h 89 Section 3.2 Help us keep our information about your drug payments up to date  PAGEREF _Toc110592018 \h 90 SECTION 4 During the Deductible Stage, you pay the full cost of your drugs  PAGEREF _Toc110592019 \h 91 Section 4.1 You stay in the Deductible Stage until you have paid $[insert deductible amount] for your drugs  PAGEREF _Toc110592020 \h 91 SECTION 5 During the Initial Coverage Stage, the plan pays its share of your drug costs and you pay your share  PAGEREF _Toc110592021 \h 91 Section 5.1 What you pay for a drug depends on the drug and where you fill your prescription  PAGEREF _Toc110592022 \h 91 Section 5.2 A table that shows your costs for a 30-day supply of a drug  PAGEREF _Toc110592023 \h 92 Section 5.3 A table that shows your costs for a long-term [insert number of days] supply of a drug  PAGEREF _Toc110592024 \h 93 Section 5.4 You stay in the Initial Coverage Stage until your total drug costs for the year reach $[insert initial coverage limit]  PAGEREF _Toc110592025 \h 94 SECTION 6 During the Coverage Gap Stage, [insert as appropriate: you pay the full cost of your drugs OR the plan provides limited drug coverage]  PAGEREF _Toc110592026 \h 94 Section 6.1 You stay in the Coverage Gap Stage until your out-of-pocket costs reach $[insert TrOOP amount]  PAGEREF _Toc110592027 \h 94 Section 6.2 How Medicare calculates your out-of-pocket costs for prescription drugs  PAGEREF _Toc110592028 \h 94 SECTION 7 During the Catastrophic Coverage Stage, the plan pays most of the cost for your drugs  PAGEREF _Toc110592029 \h 94 Section 7.1 Once you are in the Catastrophic Coverage Stage, you will stay in this stage for the rest of the year  PAGEREF _Toc110592030 \h 94 SECTION 8 Additional benefits information  PAGEREF _Toc110592031 \h 95 Section 8.1 Our plan offers additional benefits  PAGEREF _Toc110592032 \h 95 SECTION 9 What you pay for vaccinations depends on how and where you get them  PAGEREF _Toc110592033 \h 95 Section 9.1 Our plan has separate coverage for the vaccine medication itself and for the cost of giving you the vaccination shot  PAGEREF _Toc110592034 \h 95 Section 9.2 You may want to call us at Member Services before you get a vaccination  PAGEREF _Toc110592035 \h 97 SECTION 10 Do you have to pay the Part D late enrollment penalty?  PAGEREF _Toc110592036 \h 97 Section 10.1 What is the Part D late enrollment penalty?  PAGEREF _Toc110592037 \h 97 Section 10.2 How much is the Part D late enrollment penalty?  PAGEREF _Toc110592038 \h 97 Section 10.3 In some situations, you can enroll late and not have to pay the penalty  PAGEREF _Toc110592039 \h 97 Section 10.4 What can you do if you disagree about your late enrollment penalty?  PAGEREF _Toc110592040 \h 97  SECTION 1 Introduction Section 1.1 Use this chapter together with other materials that explain your drug coverage This chapter focuses on what you pay for your Part D prescription drugs. To keep things simple, we use drug in this chapter to mean a Part D prescription drug. As explained in Chapter 5, some drugs are covered under Original Medicare, Medical Assistance or are excluded by law. [Optional for plans that provide supplemental coverage: Some excluded drugs may be covered by our plan if you have purchased supplemental drug coverage]. To understand the payment information we give you in this chapter, you need to know the basics of what drugs are covered, where to fill your prescriptions, and what rules to follow when you get your covered drugs. Here are materials that explain these basics: The plans List of Covered Drugs (Formulary). To keep things simple, we call this the Drug List. This Drug List tells which drugs are covered for you. If you need a copy of the Drug List, call Member Services (phone numbers are on the cover of this booklet). You can also find the Drug List on our website at [insert URL]. The Drug List on the website is always the most current. Chapter 5 of this booklet. Chapter 5 gives the details about your Part D prescription drug coverage, including rules you need to follow when you get your covered Part D drugs. Chapter 5 also tells which types of prescription drugs are not covered by our plan. The plans [Insert if applicable: Provider/]Pharmacy Directory. In most situations you must use a network pharmacy to get your covered drugs (see Chapter 5 for the details). The [Insert if applicable: Provider/]Pharmacy Directory has a list of pharmacies in the plans network and it tells how you can use the plans mail-order service to get certain types of drugs [plans with no mail-order restrictions may alter text as appropriate]. It also explains how you can get a long-term supply of a drug (such as filling a prescription for a three months supply). SECTION 2 What you pay for a drug depends on which drug payment stage you are in when you get the drug Section 2.1 What are the two drug payment stages? As shown in the table below, there are two drug payment stages for your Part D prescription drug coverage. How much you pay for a Part D drug depends on which of these stages you are in at the time you get a prescription filled or refilled. [Insert only if you have a premium Keep in mind you are always responsible for the plans monthly premium regardless of the drug payment stage.] [Plans with no deductible and/or no coverage gap should revise the chart as needed to describe their drug coverage stages.] Stage 1 Initial Coverage StageStage 2 Catastrophic Coverage StageThe plan pays its share of the cost of your drugs and you pay your share of the cost. You stay in this stage until your payments for the year plus the plans payments total $ 4, 550. (Details are in Section [insert as appropriate: 4 OR 5] of this chapter.) Once you have paid enough for your drugs to move on to this last payment stage, the plan will pay all of the costs of your drugs for the rest of the year. (Details are in Section [insert as appropriate: 6 OR 7] of this chapter.) As shown in this summary of the two payment stages, whether you move on to the next payment stage depends on how much you and/or the plan spends for your drugs while you are in each stage. SECTION 3 We send you reports that explain payments for your drugs and which payment stage you are in Section 3.1 We send you a monthly report called the Explanation of Benefits Our plan keeps track of the costs of your Part D prescription drugs and the payments you have made when you get your prescriptions filled or refilled at the pharmacy. This way, we can tell you when you have moved from one drug payment stage to the next. In particular, there are two types of costs we keep track of: We keep track of how much you have paid. This is called your out-of-pocket cost. We keep track of your total drug costs. This is the amount you pay out-of-pocket or others pay on your behalf plus the amount paid by the plan. Our plan will prepare a written report called the Explanation of Benefits (it is sometimes called the EOB) when you have had one or more prescriptions filled. It includes: Information for that month. This report gives the payment details about the prescriptions you have filled during the previous month. It shows the total drug costs, what the plan paid, and what you and others on your behalf paid. Totals for the year since January 1. This is called year-to-date information. It shows you the total drug costs and total payments for your drugs since the year began. Section 3.2 Help us keep our information about your drug payments up to date To keep track of your drug costs and the payments you make for drugs, we use records we get from pharmacies. Here is how you can help us keep your information correct and up to date: Show your membership card when you get a prescription filled. To make sure we know about the prescriptions you are filling and what you are paying, show your plan membership card every time you get a prescription filled. Make sure we have the information we need. There are times you may pay for prescription drugs when we will not automatically get the information we need. To help us keep track of your out-of-pocket costs, you may give us copies of receipts for drugs that you have purchased. (If you are billed for a covered drug, you can ask our plan to pay our share of the cost. For instructions on how to do this, go to Chapter 7, Section 2 of this booklet.) If the drug is a Medical Assistance covered drug, we cannot pay you back for a Medical Assistance covered drug that you pay out-of-pocket. State and federal laws prevent us from paying you directly. If you paid for a prescription drug that you think we should have covered, contact Member Services at the number listed on the cover. Medical Assistance covered drugs will not be included or tracked to move you to the next coverage stage. Here are some types of situations when you may want to give us copies of your drug receipts to be sure we have a complete record of what you have spent for your drugs: When you purchase a covered Part D drug at a network pharmacy at a special price or using a discount card that is not part of our plans benefit. When you made a copayment for drugs that are provided under a drug manufacturer patient assistance program. Any time you have purchased Part D covered drugs at out-of-network pharmacies or other times you have paid the full price for a covered drug under special circumstances. Check the written report we send you. When you receive an Explanation of Benefits in the mail, please look it over to be sure the information is complete and correct. If you think something is missing from the report, or you have any questions, please call us at Member Services (phone numbers are on the cover of this booklet). Be sure to keep these reports. They are an important record of your Part D drug expenses. SECTION 4 During the Initial Coverage Stage, the plan pays its share of your drug costs and you pay your share Section 4.1 What you pay for a drug depends on the drug and where you fill your prescription During the Initial Coverage Stage, the plan pays its share of the cost of your covered prescription drugs, and you pay your share. Your share of the cost will vary depending on the drug and where you fill your prescription. The plan has [insert number of tiers] cost-sharing tiers [Plans that do not use drug tiers should omit this section.] Every drug on the plans Drug List is in one of [insert number of tiers] cost-sharing tiers. In general, the higher the cost-sharing tier number, the higher your cost for the drug: [Plans should briefly describe each tier (e.g., Cost-Sharing Tier 1 includes generic drugs). Indicate which is the lowest tier and which is the highest tier.] To find out which cost-sharing tier your drug is in, look it up in the plans Drug List. Your pharmacy choices How much you pay for a drug depends on whether you get the drug from: [Plans with preferred and non-preferred pharmacies, delete this bullet and use next two bullets instead:] A retail pharmacy that is in our plans network [Plans with preferred and non-preferred pharmacies, insert: A preferred pharmacy that is in our plans network] [Plans with preferred and non-preferred pharmacies, insert either: A non-preferred network pharmacy OR another network pharmacy] A pharmacy that is not in the plans network [Plans without mail-order service, delete this bullet:] The plans mail-order pharmacy For more information about these pharmacy choices and filling your prescriptions, see Chapter 5 in this booklet and the plans Pharmacy Directory. [Include if plan has both preferred and non-preferred pharmacies in their networks: Preferred pharmacies are pharmacies in our network where the plan has negotiated lower cost-sharing for members for covered drugs than at [insert either: non-preferred pharmacies OR other network pharmacies].However, you will still have access to lower drug prices at [insert either: non-preferred pharmacies OR these other network pharmacies] than at out-of-network pharmacies. You may go to either of these types of network pharmacies to receive your covered prescription drugs. Section 4.2 A table that shows your costs for a 30-day supply of a drug [Plans using only copayments or only coinsurance should edit this paragraph to reflect the plans cost-sharing:] During the Initial Coverage Stage, your share of the cost of a covered drug will be a copayment. Copayment means that you pay a fixed amount each time you fill a prescription. [Plans that do not use drug tiers, omit:] As shown in the table below, the amount of the copayment depends on which cost-sharing tier your drug is in. [If plan has any preferred pharmacies, the chart must be modified to reflect the appropriate member cost-sharing for preferred and non-preferred pharmacies. The plan may also add or remove tiers as necessary.] [If plan operates nationally or in multiple service areas, the chart may be modified to allow the option of indicating either within the chart, or by reference to a separate chart any variance in the cost-sharing levels for certain tiers for plans in different service areas.] [Insert if applicable: The chart lists information for more than one of our plans. The name of the plan you are in is listed on the front page of this booklet. If you arent sure which plan you are in or if you have any questions, call Member Services.] Drug TierMedicare Co-payment for Medicare covered drugsMedicare Co-payment for InstitutionalizedMedicaid Co-payment for Medical Assistance covered drugsGeneric$1.10 or $2.50 depending upon your incomeNoneNoneBrand$3.30 or $6.30 depending upon your income NoneNoneSpecialty Drugs$3.30 or $6.30 depending upon your income NoneNone Section 4.3 A table that shows your costs for a long-term [insert number of days] supply of a drug [If the share of costs for long term care drugs do not differ, plans may delete this section and include the information in the previous section. Or if plans call the tiers by different names, they may edit the table below to reflect the names of tiers used by the plan.] For some drugs, you can get a long-term supply (also called an extended supply) when you fill your prescription. This can be up to a [insert number of days] supply. (For details on where and how to get a long-term supply of a drug, see Chapter 5.) The table below shows what you pay when you get a long-term [insert number of days] supply of a drug. [If plan has any preferred pharmacies, the chart must be modified to reflect the appropriate member cost-sharing for preferred and non-preferred pharmacies. The plan may also add or remove tiers as necessary.] [If plan operates nationally or in multiple service areas, the chart may be modified to allow the option of indicating either within the chart, or by reference to a separate chart any variance in the cost-sharing levels for certain tiers for plans in different service areas.] [Insert if applicable: The chart lists information for more than one of our plans. The name of the plan you are in is listed on the front page of this booklet. If you arent sure which plan you are in or if you have any questions, call Member Services.] Your share of the cost when you get a long-term [insert number of days] supply of a covered Part D prescription drug from: Network pharmacyThe plans mail-order serviceCost-Sharing Tier 1 ([insert description])[Insert copay/ coinsurance][Insert copay/ coinsurance]Cost-Sharing Tier 2 ([insert description])[Insert copay/ coinsurance][Insert copay/ coinsurance]Cost-Sharing Tier 3 ([insert description])[Insert copay/ coinsurance][Insert copay/ coinsurance]Cost-Sharing Tier 4 ([insert description])[Insert copay/ coinsurance][Insert copay/ coinsurance] Section 4.4 You stay in the Initial Coverage Stage until your total drug costs for the year reach $4,550 You stay in the Initial Coverage Stage until the total amount for Part D prescription drugs you have filled and refilled reaches the $4,550 limit for the Initial Coverage Stage. Your total drug cost is based on adding together what you have paid and what the plan has paid: What you have paid for all the covered drugs you have gotten since you started with your first drug purchase of the year. (See Section 6.2 for more information about how Medicare calculates your out-of-pocket costs.) This includes: The total you paid as your share of the cost for your drugs during the Initial Coverage Stage. What the plan has paid as its share of the cost for your drugs during the Initial Coverage Stage. [Insert if applicable: We offer additional coverage on some prescription drugs that are not normally covered in a Medicare Prescription Drug Plan. Payments made for these drugs will not count towards your initial coverage limit or total out-of-pocket costs. [Insert only if plan pays for OTC drugs as part of its administrative costs: We also provide some over-the-counter medications exclusively for your use. These over-the-counter drugs are provided at no cost to you.] To find out which drugs our plan covers, refer to your formulary.] The Explanation of Benefits that we send to you will help you keep track of how much you and the plan have spent for your Part D drugs during the year. Many people do not reach the $[insert initial coverage limit] limit in a year. We will let you know if you reach this $[insert initial coverage limit] amount. If you do reach this amount, you will leave the Initial Coverage Stage and move on to the Catastrophic Coverage Stage. SECTION 5 During the Catastrophic Coverage Stage, the plan pays all of the costs for your drugs Section 5.1 Once you are in the Catastrophic Coverage Stage, you will stay in this stage for the rest of the year You qualify for the Catastrophic Coverage Stage when your out-of-pocket costs plus the amount paid by us has reached the $ 4,550 limit for the calendar year. Once you are in the Catastrophic Coverage Stage, you will stay in this payment stage until the end of the calendar year. During this stage, the plan will pay all of the costs for your drugs. SECTION 6 Additional benefits information Section 6.1 Our plan offers additional benefits [Optional: Insert any additional benefits information based on the plans approved bid that is not captured in the sections above.] SECTION 7 What you pay for vaccinations covered by Part D depends on how and where you get them Section 7.1 Our plan has separate coverage for the Part D vaccine medication itself and for the cost of giving you the Part D vaccination shot Our plan provides coverage of a number of Part D vaccines. This section applies only to vaccines covered by Part D. We also provide vaccines that are considered medical benefits. You can find out about coverage of these vaccines by going to Chapter 4, Benefits Chart, (what is covered). There are two parts to our coverage of Part D vaccinations: The first part of coverage is the cost of the vaccine medication itself. The vaccine is a prescription medication. The second part of coverage is for the cost of giving you the vaccination shot. (This is sometimes called the administration of the vaccine.) What do you pay for a Part D vaccination? What you pay for a vaccination depends on three things: 1. The type of Part D vaccine (what you are being vaccinated for). [Plans may insert the specific types of vaccines covered by this section] 2. Where you get the vaccine medication. 3. Who gives you the vaccination shot. What you pay at the time you get the Part D vaccination can vary depending on the circumstances. For example: Sometimes when you get your Part D vaccination shot, you will have to pay the entire cost for both the vaccine medication and for getting the vaccination shot. You can ask our plan to pay you back for our share of the cost. Other times, when you get the Part D vaccine medication or the vaccination shot, you will pay only your share of the cost. Remember, we cannot pay you back for most medical bills that you pay. State and federal laws prevent us from paying you directly. The exception is if you pay for Part D prescription drugs including Part D vaccines. If you paid for a service that you think we should have covered, contact Member Services at the number listed on the front cover. To show how this works, here are three common ways you might get a Part D vaccination shot. Situation 1: You buy the Part D vaccine at the pharmacy and you get your vaccination shot at the network pharmacy. (Whether you have this choice depends on where you live. Some states do not allow pharmacies to administer a vaccination.) You will have to pay the pharmacy the amount of your copayment for the vaccine itself. Our plan will pay for the cost of giving you the vaccination shot. Situation 2: You buy the Part D vaccine at your pharmacy, and then take it to your doctors office where they give you the vaccination shot. You will have to pay the pharmacy the amount of your copayment for the vaccine itself. When your doctor gives you the vaccination shot, you will pay the entire cost for this service. You can then ask our plan to pay our share of the cost by using the procedures that are described in Chapter 7 of this booklet (Asking the plan to pay its share of a bill you have received for covered services or drugs). You will be reimbursed the amount you paid Situation 3: You get the Part D vaccination at your doctors office. When you get the vaccination, you may have to pay for the entire cost of the vaccine and its administration You can then ask our plan to pay our share of the cost by using the procedures that are described in Chapter 7 of this booklet (Asking the plan to pay its share of a bill you have received for covered services or drugs). You will be reimbursed the amount you paid less your normal copayment for the vaccine (including administration) [Insert any additional information about your coverage of vaccines and vaccine administration.] Section 7.2 You may want to call us at Member Services before you get a vaccination The rules for coverage of vaccinations are complicated. We are here to help. We recommend that you call us first at Member Services whenever you are planning to get a vaccination (phone numbers are on the cover of this booklet). We can tell you about how your vaccination is covered by our plan and explain your share of the cost. We can tell you how to keep your own cost down by using providers and pharmacies in our network. If you are not able to use a network provider and pharmacy, we can tell you what you need to do to get payment from us for our share of the cost. Chapter 7. Asking the plan to pay its share of a bill you have received for covered services or drugs  TOC \t "Section Heading Ch 7,1,Section SubHeading 1 Ch 7,2" SECTION 1 Situations in which you should ask our plan to pay our share of the cost of your covered services or drugs  PAGEREF _Toc110592041 \h 99 Section 1.1 If you pay our plans share of the cost of your covered services or drugs, or if you receive a bill, you can ask us for payment  PAGEREF _Toc110592042 \h 99 SECTION 2 How to ask us to pay you back or to pay a bill you have received  PAGEREF _Toc110592043 \h 101 Section 2.1 How and where to send us your request for payment  PAGEREF _Toc110592044 \h 101 SECTION 3 We will consider your request for payment and say yes or no  PAGEREF _Toc110592045 \h 102 Section 3.1 We check to see whether we should cover the service or drug and how much we owe  PAGEREF _Toc110592046 \h 102 Section 3.2 If we tell you that we will not pay for the medical care or drug, you can make an appeal  PAGEREF _Toc110592047 \h 102 SECTION 4 Other situations in which you should save your receipts and send them to the plan  PAGEREF _Toc110592048 \h 103 Section 4.1 In some cases, you should send your receipts to the plan to help us track your out-of-pocket drug costs  PAGEREF _Toc110592049 \h 103  SECTION 1 Situations in which you should ask our plan to pay our share of the cost of your covered services or drugs Section 1.1 If you pay our plans share of the cost of your Part D drugs, or if you receive a bill for a Part D drug, you can ask us for payment We cannot pay you back for most medical bills that you pay. State and federal laws prevent us from paying you directly. The exception is if you pay for Part D prescription drugs. If you paid for a service that you think we should have covered, contact Member Services at the number listed on the front cover. Sometimes when you get a Part D prescription drug, you may need to pay the full cost right away. Other times, you may find that you have paid more than you expected under the Part D coverage rules of the plan. In either case, you can ask our plan to pay you back (paying you back is often called reimbursing you) for Part D prescription drugs. It is your right to be paid back by our plan whenever youve paid more than your share of the cost for Part D drugs that are covered by our plan. There may also be times when you get a bill from a provider for the full cost of Part D drugs you have received. In many cases, you should send this bill to us instead of paying it. We will look at the bill and decide whether the Part D drugs should be covered. If we decide they should be covered, we will pay the provider directly. Here are examples of situations in which you may need to ask our plan to pay you back for Part D drugs or to pay a bill you have received. 1. When a network provider sends you a bill you think you should not pay Network providers should always bill the plan directly. They should only ask you for your share of the cost for Part D drugs. But sometimes they make mistakes, and ask you to pay more than your share. Whenever you get a bill from a network provider that you think is more than you should pay, send us the bill. We will contact the provider directly and resolve the billing problem. We cannot pay you back for most medical bills including drugs covered by Medical Assistance that you pay. State and federal laws prevent us from paying you directly. The exception is if you pay for Part D prescription drugs. If you have already paid a bill to a network provider for Part D drugs, but you feel that you paid too much, send us the bill along with documentation of any payment you have made and ask us to pay you back the difference between the amount you paid and the amount you owed under the plan. 2. When you use an out-of-network pharmacy to get a prescription filled If you go to an out-of-network pharmacy and try to use your membership card to fill a prescription for a Part D drug, the pharmacy may not be able to submit the claim directly to us. When that happens, you will have to pay the full cost of your prescription. Remember, we cannot pay you back for most medical bills including drugs covered by Medical Assistance that you pay. State and federal laws prevent us from paying you directly. The exception is if you pay for Part D prescription drugs. Save your receipt and send a copy to us when you ask us to pay you back for our share of the cost of the Part D drug. 3. When you pay the full cost for a Part D prescription because you dont have your plan membership card with you If you do not have your plan membership card with you, you can ask the pharmacy to call the plan or to look up your plan enrollment information. However, if the pharmacy cannot get the enrollment information they need right away, you may need to pay the full cost of the Part D prescription yourself. Save your receipt and send a copy to us when you ask us to pay you back for our share of the cost. Remember, we cannot pay you back for most medical bills including drugs covered by Medical Assistance that you pay. State and federal laws prevent us from paying you directly. The exception is if you pay for Part D prescription drugs. 4. When you pay the full cost for a Part D prescription in other situations You may pay the full cost of the Part D prescription because you find that the drug is not covered for some reason. For example, the Part D drug may not be on the plans List of Covered Drugs (Formulary); or it could have a requirement or restriction that you didnt know about or dont think should apply to you. If you decide to get the drug immediately, you may need to pay the full cost for it. Save your receipt and send a copy to us when you ask us to pay you back. In some situations, we may need to get more information from your doctor in order to pay you back for our share of the cost. Remember, we cannot pay you back for most medical bills including drugs covered by Medical Assistance that you pay. State and federal laws prevent us from paying you directly. The exception is if you pay for Part D prescription drugs. [Plans should insert additional circumstances under which they will accept a paper claim from an enrollee.] All of the examples above are types of coverage decisions. This means that if we deny your request for payment for a Part D drug, you can appeal our decision. Chapter 9 of this booklet (What to do if you have a problem or complaint (coverage decisions, appeals, complaints)) has information about how to make an appeal. SECTION 2 How to ask us to pay you back or to pay a bill you have received for a Part D drug [Plans may edit this section to include a second address if they use different addresses for processing medical and drug claims.] Section 2.1 How and where to send us your request for payment Send us your request for payment for a Part D drug, along with your bill and documentation of any payment you have made. Its a good idea to make a copy of your bill and receipts for your records. [If the plan has developed a specific form for requesting payment, insert the following language: To make sure you are giving us all the information we need to make a decision, you can fill out our claim form to make your request for payment. You dont have to use the form, but its helpful for our plan to process the information faster. Either download a copy of the form from our website ([insert URL]) or call Member Services and ask for the form. The phone numbers for Member Services are on the cover of this booklet.] Mail your request for payment together with any bills or receipts to us at this address: [insert address] Please be sure to contact Member Services if you have any questions. If you dont know what you owe, or you receive bills and you dont know what to do about those bills, we can help. You can also call if you want to give us more information about a request for payment you have already sent to us. We cannot pay you back for most medical bills that you pay. State and federal laws prevent us from paying you directly. The exception is if you pay for Part D prescription drugs. If you paid for a service that you think we should have covered, contact Member Services at the number listed on the front cover. SECTION 3 We will consider your request for payment and say yes or no Section 3.1 We check to see whether we should cover the Part D drug and how much we owe When we receive your request for payment for a Part D drug, we will let you know if we need any additional information from you. Otherwise, we will consider your request and decide whether to pay it and how much we owe. If we decide that the Part D drug is covered and you followed all the rules for getting the drug, we will pay for our share of the cost. If you have already paid for the Part D drug, we will mail your reimbursement of our share of the cost to you. If you have not paid for the Part D drug yet, we will mail the payment directly to the provider. (Chapter 5 explains the rules you need to follow for getting your Part D prescription drugs.) If we decide that the Part D drug is not covered, or you did not follow all the rules, we will not pay for our share of the cost. Instead, we will send you a letter that explains the reasons why we are not sending the payment you have requested and your rights to appeal that decision. Section 3.2 If we tell you that we will not pay for the Part D drug, you can make an appeal If you think we have made a mistake in turning down your request for payment of the Part D drug, you can make an appeal. If you make an appeal, it means you are asking us to change the decision we made when we turned down your request for payment. For the details on how to make this appeal, go to Chapter 9 of this booklet (What to do if you have a problem or complaint (coverage decisions, appeals, complaints)). The appeals process is a legal process with detailed procedures and important deadlines. If making an appeal is new to you, you will find it helpful to start by reading Section 4 of Chapter 9. Section 4 is an introductory section that explains the process for coverage decisions and appeals and gives definitions of terms such as appeal. Then after you have read Section 4, you can go to the section in Chapter 9 that tells what to do for your situation: If you want to make an appeal about getting paid back for a Part D drug, go to Section 6.6 of Chapter 9. SECTION 4 Other situations in which you should save your receipts and send them to the plan Section 4.1 In some cases, you should send your receipts to the plan to help us track your out-of-pocket drug costs There are some situations when you should let us know about payments you have made for your Part D drugs. In these cases, you are not asking us for payment. Instead, you are telling us about your payments so that we can calculate your out-of-pocket costs correctly. This may help you to qualify for the Catastrophic Coverage Stage more quickly. The following is a situation when you should send us receipts to let us know about payments you have made for your drugs: When you get a drug through a patient assistance program offered by a drug manufacturer Some members are enrolled in a patient assistance program offered by a drug manufacturer that is outside the plan benefits. If you get any drugs through a program offered by a drug manufacturer, you may pay a copayment to the patient assistance program. Save your receipt and send a copy to us so that we can have your out-of-pocket expenses count toward qualifying you for the Catastrophic Coverage Stage. Please note: Because you are getting your drug through the patient assistance program and not through the plans benefits, the plan will not pay for any share of these drug costs. But sending the receipt allows us to calculate your out-of-pocket costs correctly and may help you qualify for the Catastrophic Coverage Stage more quickly. Since you are not asking for payment in the two cases described above, these situations are not considered coverage decisions. Therefore you cannot make an appeal if you disagree with our decision. Chapter 8. Your rights and responsibilities  TOC \t "Section Heading Ch 8,1,Section SubHeading 1 Ch 8,2" SECTION 1 Our plan must honor your rights as a member of the plan  PAGEREF _Toc110592059 \h 105 Section 1.1 We must provide information in a way that works for you (in languages other than English that are spoken in the plan service area, in Braille, in large print, or other alternate formats, etc.)  PAGEREF _Toc110592060 \h 105 Section 1.2 We must treat you with fairness and respect at all times  PAGEREF _Toc110592061 \h 105 Section 1.3 We must ensure that you get timely access to your covered services and drugs  PAGEREF _Toc110592062 \h 106 Section 1.4 We must protect the privacy of your personal health information  PAGEREF _Toc110592063 \h 106 Section 1.5 We must give you information about the plan, its network of providers, and your covered services  PAGEREF _Toc110592064 \h 107 Section 1.6 We must support your right to make decisions about your care  PAGEREF _Toc110592065 \h 109 Section 1.7 You have the right to make complaints and to ask us to reconsider decisions we have made  PAGEREF _Toc110592066 \h 111 Section 1.8 What can you do if you think you are being treated unfairly or your rights are not being respected?  PAGEREF _Toc110592067 \h 111 Section 1.9 How to get more information about your rights  PAGEREF _Toc110592068 \h 112 SECTION 2 You have some responsibilities as a member of the plan  PAGEREF _Toc110592069 \h 112 Section 2.1 What are your responsibilities?  PAGEREF _Toc110592070 \h 112  [Note: Plans may add to or revise this chapter as needed to reflect NCQA-required language.] SECTION 1 Our plan must honor your rights as a member of the plan Section 1.1 We must provide information in a way that works for you (in languages other than English that are spoken in the plan service area, in Braille, in large print, or other alternate formats, etc.) [Plans may edit the section heading and content to reflect the types of alternate format materials available to plan members and/or language primarily spoken in the plan service area.] To get information from us in a way that works for you, please call Member Services (phone numbers are on the front cover). Our plan has people and translation services available to answer questions from non-English speaking members. We can also give you information in Braille, in large print, or other alternate formats if you need it. If you are eligible for Medicare because of disability, we are required to give you information about the plans benefits that is accessible and appropriate for you. If you have any trouble getting information from our plan because of problems related to language or disability, please call Medicare at 1-800-MEDICARE (1-800-633-4227), 24 hours a day, 7 days a week, and tell them that you want to file a complaint. TTY users call 1-877-486-2048. Section 1.2 We must treat you with fairness and respect at all times Our plan must obey laws that protect you from discrimination or unfair treatment. We do not discriminate based on a persons race, disability, religion, sex, sexual orientation, health, ethnicity, creed (beliefs), age, or national origin. If you want more information or have concerns about discrimination or unfair treatment, please call the Department of Health and Human Services Office for Civil Rights 1-800-368-1019 (TTY 1-800-537-7697) or your local Office for Civil Rights. If you have a disability and need help with access to care, please call Member Services (phone numbers are on the cover of this booklet). If you have a complaint, such as a problem with wheelchair access, Member Services can help. Section 1.3 We must ensure that you get timely access to your covered services and drugs As a member of our plan, you have the right to choose a [insert as appropriate: primary care provider (PCP) OR provider] in the plans network to provide and arrange for your covered services (Chapter 3 explains more about this). Call Member Services to learn which doctors are accepting new patients (phone numbers are on the cover of this booklet). [Plans may edit this sentence to add other types of providers that members may see without a referral:] You have the right to choose where you get family planning services. You have the right to get a second opinion for medical, mental health and chemical dependency services. You also have the right to go to a womens health specialist (such as a gynecologist) without a referral. As a plan member, you have the right to get appointments and covered services from the plans network of providers within a reasonable amount of time. This includes the right to get timely services from specialists when you need that care. You also have the right to get your prescriptions filled or refilled at any of our network pharmacies without long delays. You have the right to get services you need 24 hours a day, seven days a week. This includes emergencies. If you think that you are not getting your care or Part D drugs within a reasonable amount of time, Chapter 9 of this booklet tells what you can do. Section 1.4 We must protect the privacy of your personal health information Federal and state laws protect the privacy of your medical records and personal health information. We protect your personal health information as required by these laws. Your personal health information includes the personal information you gave us when you enrolled in this plan as well as your medical records and other medical and health information. The laws that protect your privacy give you rights related to getting information and controlling how your health information is used. We give you a written notice, called a Notice of Privacy Practice, that tells about these rights and explains how we protect the privacy of your health information. How do we protect the privacy of your health information? We make sure that unauthorized people dont see or change your records. In most situations, if we give your health information to anyone who isnt providing your care or paying for your care, we are required to get written permission from you first. Written permission can be given by you or by someone you have given legal power to make decisions for you. There are certain exceptions that do not require us to get your written permission first. These exceptions are allowed or required by law. For example, we are required to release health information to government agencies that are checking on quality of care. Because you are a member of our plan through Medicare, we are required to give Medicare your health information including information about your Part D prescription drugs. If Medicare releases your information for research or other uses, this will be done according to Federal statutes and regulations. We, and the health providers who take care of you, have the right to see information about your health care. When you enrolled in the Minnesota Health Care Program, you gave your consent for us to do this. We will keep this information private according to law. You can see the information in your records and know how it has been shared with others You have the right to look at your medical records held at the plan, and to get a copy of your records. [Insert if plan charges a fee: We are allowed to charge you a fee for making copies.] You also have the right to ask us to make additions or corrections to your medical records. If you ask us to do this, we will consider your request and decide whether the changes should be made. You have the right to know how your health information has been shared with others for any purposes that are not routine. If you have questions or concerns about the privacy of your personal health information, please call Member Services (phone numbers are on the cover of this booklet). [Note: Plans may insert custom privacy practices.] Section 1.5 We must give you information about the plan, its network of providers, and your covered services [Plans may edit the section to reflect the types of alternate format materials available to plan members and/or language primarily spoken in the plan service area.] As a member of our plan, you have the right to get several kinds of information from us. (As explained above in Section 1.1, you have the right to get information from us in a way that works for you. This includes getting the information in languages other than English and in large print or other alternate formats.) If you want any of the following kinds of information, please call Member Services (phone numbers are on the cover of this booklet): Information about our plan. This includes, for example, information about the plans financial condition. It also includes information about the number of appeals made by members and the plans performance ratings, including how it has been rated by plan members and how it compares to other Medicare Advantage health plans. You have the right to get the results of an external quality review study from the State, if you ask for them. Information about our network providers including our network pharmacies. For example, you have the right to get information from us about the qualifications of the providers and pharmacies in our network and how we pay the providers in our network. You have the right to get the following from us, if you ask for it: Whether we use a physician incentive plan that affects the use of referral services; The type(s) of incentive arrangements used; Whether stop-loss protection is provided; and Results of a member survey if one is required because of our physician incentive plan. For a list of the providers in the plans network, see the [insert name of provider directory]. For a list of the pharmacies in the plans network, see the Pharmacy Directory. For more detailed information about our providers or pharmacies, you can call Member Services (phone numbers are on the cover of this booklet) or visit our website at [insert URL]. Information about your coverage and rules you must follow in using your coverage. In Chapters 3 and 4 of this booklet, we explain what services are covered for you, any restrictions to your coverage, and what rules you must follow to get your covered services. To get the details on your Part D prescription drug coverage, see Chapters 5 and 6 of this booklet plus the plans List of Covered Drugs (Formulary). These chapters, together with the List of Covered Drugs, tell you what drugs are covered and explain the rules you must follow and the restrictions to your coverage for certain drugs. If you have questions about the rules or restrictions, please call Member Services (phone numbers are on the cover of this booklet). Information about why something is not covered and what you can do about it. If a service or Part D drug is not covered for you, or if your coverage is restricted in some way, you can ask us for a written explanation. You have the right to this explanation even if you received the service or drug from an out-of-network provider or pharmacy. If you are not happy or if you disagree with a decision we make about what care or Part D drug is covered for you, you have the right to ask us to change the decision. For details on what to do if something is not covered for you in the way you think it should be covered, see Chapter 9 of this booklet. It gives you the details about how to ask the plan for a decision about your coverage and how to make an appeal if you want us to change our decision. (Chapter 9 also tells about how to make a complaint about quality of care, waiting times, and other concerns.) If you want to ask our plan to pay our share of a bill you have received for a Part D prescription drug, see Chapter 7 of this booklet. Section 1.6 We must support your right to make decisions about your care You have the right to know your treatment options and participate in decisions about your health care You have the right to get full information from your doctors and other health care providers when you go for medical care. Your providers must explain your medical condition and your treatment choices in a way that you can understand. You also have the right to participate fully in decisions about your health care. To help you make decisions with your doctors about what treatment is best for you, your rights include the following: To know about all of your choices. This means that you have the right to be told about all of the treatment options that are recommended for your condition, no matter what they cost or whether they are covered by our plan. It also includes being told about programs our plan offers to help members manage their medications and use drugs safely. To know about the risks. You have the right to be told about any risks involved in your care. You must be told in advance if any proposed medical care or treatment is part of a research experiment. You always have the choice to refuse any experimental treatments. The right to say no. You have the right to refuse any recommended treatment. This includes the right to leave a hospital or other medical facility, even if your doctor advises you not to leave. You also have the right to stop taking your medication. Of course, if you refuse treatment or stop taking medication, you accept full responsibility for what happens to your body as a result. To receive an explanation if you are denied coverage for care. You have the right to receive an explanation from us if a provider has denied care that you believe you should receive. To receive this explanation, you will need to ask us for a coverage decision. Chapter 9 of this booklet tells how to ask the plan for a coverage decision. To get help to identify services needed to help you stay in the least restrictive environment. To be free of restraints or seclusion used as a means of coercion, discipline, convenience or retaliation. You have the right to give instructions about what is to be done if you are not able to make medical decisions for yourself [Note: Plans that would like to provide members with state-specific information about advanced directives, including contact information for the appropriate state agency, may do so.] Sometimes people become unable to make health care decisions for themselves due to accidents or serious illness. You have the right to say what you want to happen if you are in this situation. This means that, if you want to, you can: Fill out a written form to give someone the legal authority to make medical decisions for you if you ever become unable to make decisions for yourself. Give your doctors written instructions about how you want them to handle your medical care if you become unable to make decisions for yourself. The legal documents that you can use to give your directions in advance in these situations are called advance directives. There are different types of advance directives and different names for them. Documents called health care directives, living will and power of attorney for health care are examples of advance directives. If you want to use an advance directive to give your instructions, here is what to do: Get the form. If you want to have an advance directive, you can get a form from your lawyer, from a social worker, or from some office supply stores. You can sometimes get advance directive forms from organizations that give people information about Medicare. Chapter 2 tells how to find resources from the Senior Linkage Line at  HYPERLINK "http://www.MinnesotaHelp.info" www.MinnesotaHelp.info. [Insert if applicable: You can also contact Member Services to ask for the forms (phone numbers are on the cover of this booklet).] Fill it out and sign it. Regardless of where you get this form, keep in mind that it is a legal document. You should consider having a lawyer help you prepare it. Give copies to appropriate people. You should give a copy of the form to your doctor and to the person you name on the form as the one to make decisions for you if you cant. You may want to give copies to close friends or family members as well. Be sure to keep a copy at home. If you know ahead of time that you are going to be hospitalized, and you have signed an advance directive, take a copy with you to the hospital. If you are admitted to the hospital, they will ask you whether you have signed an advance directive form and whether you have it with you. If you have not signed an advance directive form, the hospital has forms available and will ask if you want to sign one. Remember, it is your choice whether you want to fill out an advance directive (including whether you want to sign one if you are in the hospital). According to law, no one can deny you care or discriminate against you based on whether or not you have signed an advance directive. What if your instructions are not followed? If you have signed an advance directive, and you believe that a doctor or hospital hasnt followed the instructions in it, you may file a complaint with the Office of Health Facility Complaints at the Minnesota Department of Health at 651-201-4201 or toll-free at 1-800-369-7994. Section 1.7 You have the right to make complaints and to ask us to reconsider decisions we have made If you have any problems or concerns about your covered services or care, Chapter 9 of this booklet tells what you can do. It gives the details about how to deal with all types of problems and complaints. As explained in Chapter 9, what you need to do to follow up on a problem or concern depends on the situation. You might need to ask our plan to make a coverage decision for you, make an appeal to us to change a coverage decision, or make a complaint. Whatever you do ask for a coverage decision, make an appeal, or make a complaint we are required to treat you fairly. You have the right to get a summary of information about the appeals and complaints that other members have filed against our plan in the past. To get this information, please call Member Services (phone numbers are on the cover of this booklet). Section 1.8 What can you do if you think you are being treated unfairly or your rights are not being respected? If it is about discrimination, call the Office for Civil Rights If you think you have been treated unfairly or your rights have not been respected due to your race, disability, religion, sex, health, ethnicity, creed (beliefs), age, or national origin, you should call the Department of Health and Human Services Office for Civil Rights at 1-800-368-1019 or TTY 1-800-537-7697, or call your local Office for Civil Rights. Is it about something else? If you think you have been treated unfairly or your rights have not been respected, and its not about discrimination, you can get help dealing with the problem you are having: You can call Member Services (phone numbers are on the cover of this booklet). You can call the State Health Insurance Assistance Program. For details about this organization and how to contact it, go to Chapter 2, Section 3. Section 1.9 How to get more information about your rights There are several places where you can get more information about your rights: You can call Member Services (phone numbers are on the cover of this booklet). You can call the State Health Insurance Assistance Program. For details about this organization and how to contact it, go to Chapter 2 Section 3. You can also get help from the Minnesota Ombudsman for State Managed Care Programs. Contact information is in Chapter 2 of this booklet. You can contact Medicare. You can visit the Medicare website (http://www.medicare.gov) to read or download the publication Your Medicare Rights & Protections. Or, you can call 1-800-MEDICARE (1-800-633-4227) 24 hours a day, 7 days a week. TTY users should call 1-877-486-2048. SECTION 2 You have some responsibilities as a member of the plan Section 2.1 What are your responsibilities? Things you need to do as a member of the plan are listed below. If you have any questions, please call Member Services (phone numbers are on the cover of this booklet). Were here to help. Get familiar with your covered services and the rules you must follow to get these covered services. Use this Certificate of Coverage booklet to learn what is covered for you and the rules you need to follow to get your covered services. Chapters 3 and 4 give the details about your covered services, including what is covered, what is not covered, rules to follow. Chapters 5 and 6 give the details about your coverage for Part D prescription drugs. If you have any other health insurance coverage or prescription drug coverage besides our plan, you are required to tell us. Please call Member Services to let us know. We are required to follow rules set by Medicare and Medical Assistance to make sure that you are using all of your coverage in combination when you get your covered services from our plan. This is called coordination of benefits because it involves coordinating the health and drug benefits you get from our plan with any other health and drug benefits available to you. Well help you with it. Tell your doctor and other health care providers that you are enrolled in our plan. Show your plan membership card and Minnesota Health Care Programs card whenever you get your care or Part D prescription drugs. [Dual SNPs may edit or add to this bullet to indicate that members should also show their state Medicaid card.] Help your doctors and other providers help you by giving them information, asking questions, and following through on your care. To help your doctors and other health providers give you the best care, learn as much as you are able to about your health problems and give them the information they need about you and your health. Follow the treatment plans and instructions that you and your doctors agree upon. Establish a relationship with a Plan network primary care doctor before you become ill. This helps you and your primary care doctor understand your total health condition. If you have any questions, be sure to ask. Your doctors and other health care providers are supposed to explain things in a way you can understand. If you ask a question and you dont understand the answer you are given, ask again. Practice preventive health care. Have tests, exams and shots recommended for you based on your age and gender. Be considerate. We expect all our members to respect the rights of other patients. We also expect you to act in a way that helps the smooth running of your doctors office, hospitals, and other offices. Pay what you owe. As a plan member, you are responsible for these payments: [Insert if applicable: You must pay your plan premiums to continue being a member of our plan.] For some of your Part D drugs covered by the plan, you must pay your share of the cost when you get the drug. This will be a [insert as appropriate: copayment (a fixed amount) OR coinsurance (a percentage of the total cost) OR copayment (a fixed amount) or coinsurance (a percentage of the total cost)].. Chapter 6 tells what you must pay for your Part D prescription drugs. If you get any medical services or drugs that are not covered by our plan or by other insurance you may have, you must pay the full cost. Tell us if you move. If you are going to move, its important to tell us right away. Call Member Services (phone numbers are on the cover of this booklet). [Plans with a national service area can replace bullets with: We need to keep your membership record up to date and know how to contact you.] If you move outside of our plan service area, you [plans with a continuation area offered, insert generally here and then explain the continuation area] cannot remain a member of our plan. (Chapter 1 tells about our service area.) We can help you figure out whether you are moving outside our service area. If you are leaving our service area, we can let you know if we have a plan in your new area. If you move within our service area, we still need to know so we can keep your membership record up to date and know how to contact you. Call member services for help if you have questions or concerns. We also welcome any suggestions you may have for improving our plan. Phone numbers and calling hours for Member Services are on the cover of this booklet. For more information on how to reach us, including our mailing address, please see Chapter 2. Chapter 9. What to do if you have a problem or complaint (coverage decisions, appeals, complaints) BACKGROUND  TOC \t "Section Heading Ch 9,1,Section SubHeading 1 Ch 9,2" SECTION 1 Introduction  PAGEREF _Toc110592135 \h 118 Section 1.1 What to do if you have a problem or concern  PAGEREF _Toc110592136 \h 118 Section 1.2 What about the legal terms?  PAGEREF _Toc110592137 \h 119 SECTION 2 You can get help from government organizations that are not connected with us  PAGEREF _Toc110592138 \h 119 Section 2.1 Where to get more information and personalized assistance  PAGEREF _Toc110592139 \h 119 SECTION 3 To deal with your problem, which process should you use?  PAGEREF _Toc110592140 \h 120 Section 3.1 Should you use the process for coverage decisions and appeals? Or should you use the process for making complaints?  PAGEREF _Toc110592141 \h 120 COVERAGE DECISIONS AND APPEALS SECTION 4 A guide to the basics of coverage decisions and appeals  PAGEREF _Toc110592142 \h 122 Section 4.1 Asking for coverage decisions and making appeals: the big picture  PAGEREF _Toc110592143 \h 122 Section 4.2 How to get help when you are asking for a coverage decision or making an appeal  PAGEREF _Toc110592144 \h 123 Section 4.3 Which section of this chapter gives the details for your situation?  PAGEREF _Toc110592145 \h 124 SECTION 5 Your medical care: How to ask for a coverage decision or make an appeal  PAGEREF _Toc110592146 \h 124 Section 5.1 This section tells what to do if you have problems getting coverage for medical care or if you want us to pay you back for our share of the cost of your care  PAGEREF _Toc110592147 \h 124 Section 5.2 Step-by-step: How to ask for a coverage decision (how to ask our plan to authorize or provide the medical care coverage you want)  PAGEREF _Toc110592148 \h 126 Section 5.3 Step-by-step: How to make a Level 1 Appeal (how to ask for a review of a medical care coverage decision made by our plan)  PAGEREF _Toc110592149 \h 129 Section 5.4 Step-by-step: How to make a Level 2 Appeal  PAGEREF _Toc110592150 \h 131 Section 5.5 What if you are asking our plan to pay you for our share of a bill you have received for medical care?  PAGEREF _Toc110592151 \h 135 SECTION 6 Your Part D prescription drugs: How to ask for a coverage decision or make an appeal  PAGEREF _Toc110592152 \h 135 Section 6.1 This section tells you what to do if you have problems getting a Part D drug or you want us to pay you back for a Part D drug  PAGEREF _Toc110592153 \h 136 Section 6.2 What is an exception?  PAGEREF _Toc110592154 \h 137 Section 6.3 Important things to know about asking for exceptions  PAGEREF _Toc110592155 \h 139 Section 6.4 Step-by-step: How to ask for a coverage decision, including an exception  PAGEREF _Toc110592156 \h 140 Section 6.5 Step-by-step: How to make a Level 1 Appeal (how to ask for a review of a coverage decision made by our plan)  PAGEREF _Toc110592157 \h 142 Section 6.6 Step-by-step: How to make a Level 2 Appeal  PAGEREF _Toc110592158 \h 145 SECTION 7 How to ask us to cover a longer hospital stay if you think the doctor is discharging you too soon  PAGEREF _Toc110592159 \h 147 Section 7.1 During your hospital stay, you will get a written notice from Medicare that tells about your rights  PAGEREF _Toc110592160 \h 147 Section 7.2 Step-by-step: How to make a Level 1 Appeal to change your hospital discharge date  PAGEREF _Toc110592161 \h 148 Section 7.3 Step-by-step: How to make a Level 2 Appeal to change your hospital discharge date  PAGEREF _Toc110592162 \h 151 Section 7.4 What if you miss the deadline for making your Level 1 Appeal?  PAGEREF _Toc110592163 \h 152 SECTION 8 How to ask us to keep covering certain medical services if you think your coverage is ending too soon  PAGEREF _Toc110592164 \h 155 Section 8.1 This section is about three services only: Home health care, skilled nursing facility care, and Comprehensive Outpatient Rehabilitation Facility (CORF) services  PAGEREF _Toc110592165 \h 155 Section 8.2 We will tell you in advance when your coverage will be ending  PAGEREF _Toc110592166 \h 155 Section 8.3 Step-by-step: How to make a Level 1 Appeal to have our plan cover your care for a longer time  PAGEREF _Toc110592167 \h 156 Section 8.4 Step-by-step: How to make a Level 2 Appeal to have our plan cover your care for a longer time  PAGEREF _Toc110592168 \h 159 Section 8.5 What if you miss the deadline for making your Level 1 Appeal?  PAGEREF _Toc110592169 \h 160 SECTION 9 Taking your appeal to Level 3 and beyond  PAGEREF _Toc110592170 \h 163 Section 9.1 Levels of Appeal 3, 4, and 5 for Medical Service Appeals  PAGEREF _Toc110592171 \h 163 Section 9.2 Levels of Appeal 3, 4, and 5 for Part D Drug Appeals  PAGEREF _Toc110592172 \h 164 MAKING COMPLAINTS SECTION 10 How to make a complaint about quality of care, waiting times, customer service, or other concerns  PAGEREF _Toc110592173 \h 165 Section 10.1 What kinds of problems are handled by the complaint process?  PAGEREF _Toc110592174 \h 166 Section 10.2 The formal name for making a complaint is filing a grievance  PAGEREF _Toc110592175 \h 169 Section 10.3 Step-by-step: Making a complaint  PAGEREF _Toc110592176 \h 169 Section 10.4 You can also make complaints about quality of care to the Quality Improvement Organization  PAGEREF _Toc110592177 \h 170  [SNPs should revise this chapter, as appropriate, to incorporate information about the processes available to beneficiaries to pursue appeals and grievances related to Medicaid-covered services.] BACKGROUND SECTION 1 Introduction Section 1.1 What to do if you have a problem or concern Please call us first Your health and satisfaction are important to us. When you have a problem or concern, we hope youll try an informal approach first: Please call Member Services (phone numbers are on the cover of this booklet). We will work with you to try to find a satisfactory solution to your problem. You have rights as a member of our plan and as someone who is getting Medicare and Medical Assistance. We pledge to honor your rights, to take your problems and concerns seriously, and to treat you with respect. Two formal processes for dealing with problems Sometimes you might need a formal process for dealing with a problem you are having as a member of our plan. This chapter explains two types of formal processes for handling problems: For some types of problems, you need to use the process for coverage decisions and making appeals. For other types of problems you need to use the process for making complaints also called grievances.. Both of these processes have been approved by Medicare and Medical Assistance. To ensure fairness and prompt handling of your problems, each process has a set of rules, procedures, and deadlines that must be followed by us and by you. Which one do you use? That depends on the type of problem you are having. The guide in Section 3 will help you identify the right process to use. Section 1.2 What about the legal terms? There are technical legal terms for some of the rules, procedures, and types of deadlines explained in this chapter. Many of these terms are unfamiliar to most people and can be hard to understand. To keep things simple, this chapter explains the legal rules and procedures using simpler words in place of certain legal terms. For example, this chapter generally says making a complaint rather than filing a grievance, coverage decision rather than organization determination or coverage determination, and Independent Review Organization instead of Independent Review Entity. It also uses abbreviations as little as possible. However, it can be helpful and sometimes quite important for you to know the correct legal terms for the situation you are in. Knowing which terms to use will help you communicate more clearly and accurately when you are dealing with your problem and get the right help or information for your situation. To help you know which terms to use, we include legal terms when we give the details for handling specific types of situations. SECTION 2 You can get help from government organizations that are not connected with us Section 2.1 Where to get more information and personalized assistance Sometimes it can be confusing to start or follow through the process for dealing with a problem. This can be especially true if you do not feel well or have limited energy. Other times, you may not have the knowledge you need to take the next step. Perhaps both are true for you. Get help from an independent government organization We are always available to help you. But in some situations you may also want help or guidance from someone who is not connected with us. You can always contact your State Health Insurance Assistance Program. This government program has trained counselors in every state. The program is not connected with our plan or with any insurance company or health plan. The counselors at this program can help you understand which process you should use to handle a problem you are having. They can also answer your questions, give you more information, and offer guidance on what to do. Their services are free. [Plans providing SHIP contact information in an exhibit may revise the following sentence to direct members to it:] You will find phone numbers in Chapter 2, Section 3 of this booklet. You can also get help and information from Medicare For more information and help in handling a problem, you can also contact Medicare. Here are two ways to get information directly from Medicare: You can call 1-800-MEDICARE (1-800-633-4227) 24 hours a day, 7 days a week. TTY users should call 1-877-486-2048. You can visit the Medicare website ( HYPERLINK "http://www.medicare.gov" http://www.medicare.gov). You can also get help and information from the Minnesota State Ombudsman for Managed Health Care Programs The Minnesota Ombudsman for State Managed Health Care Programs, at the Minnesota Department of Human Services can help you file a complaint or appeal with our Plan. The Ombudsman can also help you request a State Fair Hearing. You will find the phone number for the Ombudsman in Chapter 2, Section 6 of this booklet. SECTION 3 To deal with your problem, which process should you use? Section 3.1 Should you use the process for coverage decisions and appeals? Or should you use the process for making complaints? If you have a problem or concern and you want to do something about it, you dont need to read this whole chapter. You just need to find and read the parts of this chapter that apply to your situation. The guide that follows will help.  COVERAGE DECISIONS AND APPEALS SECTION 4 A guide to the basics of coverage decisions and appeals [SNPs should revise the following language, as appropriate to incorporate information about the processes available to beneficiaries to pursue grievances related to Medicaid-covered services.] Section 4.1 Asking for coverage decisions and making appeals: the big picture The process for coverage decisions and making appeals deals with problems related to your benefits and coverage for services and prescription drugs, including problems related to payment. This is the process you use for issues such as whether something is covered or not and the way in which something is covered. Asking for coverage decisions A coverage decision is a decision we make about your benefits and coverage or about the amount we will pay for your services or drugs. We make a coverage decision for you whenever you go to a doctor for medical care. You can also contact the plan and ask for a coverage decision. For example, if you want to know if we will cover a service before you receive it, you can ask us to make a coverage decision for you. We are making a coverage decision for you whenever we decide what is covered for you and how much we pay: Usually, there is no problem. We decide the service or drug is covered and pay our share of the cost. But in some cases we might decide the service or drug is not covered or is no longer covered by Medicare for you. If you disagree with this coverage decision, you can make an appeal. Making an appeal If we make a coverage decision and you are not satisfied with this decision, you can appeal the decision. An appeal is a formal way of asking us to review and change a coverage decision we have made. When you make an appeal, we review the coverage decision we have made to check to see if we were being fair and following all of the rules properly. When we have completed the review we give you our decision. If we say no to all or part of this Level 1 Appeal, your case will automatically go on to a Level 2 Appeal. The Level 2 Appeal is conducted by an independent organization that is not connected to our plan. If you are not satisfied with the decision at the Level 2 Appeal, you may be able to continue through several more levels of appeal. As a plan member, some of your plan services may also be covered by Medical Assistance. Therefore, if you believe that we improperly denied you a service or payment for a service, you may also have the right to appeal this decision to Medical Assistance. We will let you know in writing if you have the right to appeal our decision to Medical Assistance. Section 4.2 How to get help when you are asking for a coverage decision or making an appeal Would you like some help? Here are resources you may wish to use if you decide to ask for any kind of coverage decision or appeal a decision: You can call us at Member Services (phone numbers are on the cover). To get free help from an independent organization that is not connected with our plan, contact the Minnesota State Ombudsman for Managed Care or State Health Insurance Assistance Program (see Section 2 of this chapter). You should consider getting your doctor or other provider involved if possible, especially if you want a fast or expedited decision. In most situations involving a coverage decision or appeal, your doctor or other provider must explain the reasons that support your request. Your doctor or other prescriber cant request every appeal. He/she can request a coverage decision and a Level 1 Appeal with the plan. To request any appeal after Level 1, your doctor or other prescriber must be appointed as your representative (see below about representatives). You can ask someone to act on your behalf. If you want to, you can name another person to act for you as your representative to ask for a coverage decision or make an appeal. There may be someone who is already legally authorized to act as your representative under State law. If you want a friend, relative, your doctor or other provider, or other person to be your representative, call Member Services and ask for the form to give that person permission to act on your behalf. The form must be signed by you and by the person who you would like to act on your behalf. You must give our plan a copy of the signed form. You also have the right to hire a lawyer to act for you. You may contact your own lawyer, or get the name of a lawyer from your local bar association or other referral service. There are also groups that will give you free legal services if you qualify. However, you are not required to hire a lawyer to ask for any kind of coverage decision or appeal a decision. Section 4.3 Which section of this chapter gives the details for your situation? There are four different types of situations that involve coverage decisions and appeals. Since each situation has different rules and deadlines, we give the details for each one in a separate section:  If youre still not sure which section you should be using, please call Member Services (phone numbers are on the front cover). You can also get help or information from government organizations such as your Minnesota State Ombudsman for Managed Care Programs or State Health Insurance Assistance Program (Chapter 2, Section 3 and Section 6, of this booklet has the phone numbers for this program). SECTION 5 Your medical care: How to ask for a coverage decision or make an appeal ?Have you read Section 4 of this chapter (A guide to the basics of coverage decisions and appeals)? If not, you may want to read it before you start this section. Section 5.1 This section tells what to do if you have problems getting coverage for care or if you want us to pay you back for our share of the cost of your care This section is about your benefits for medical care and other services.. These are the benefits described in Chapter 4 of this booklet: Benefits chart (what is covered). To keep things simple, we generally refer to medical care coverage or medical care in the rest of this section, instead of repeating medical care or treatment or services every time. This section tells what you can do if you are in any of the five following situations: 1. You are not getting certain medical care you want, and you believe that this care is covered by our plan. 2. Our plan will not approve the medical care your doctor or other medical provider wants to give you, and you believe that this care is covered by the plan. 3. You have received medical care or services that you believe should be covered by the plan, but we have said we will not pay for this care. 4. You have received and paid for Part D drugs that you believe should be covered by the plan, and you want to ask our plan to reimburse you for this care. NOTE: If the service or drug is Medical Assistance covered, we cannot pay you back for a Medical Assistance covered drugs or services that you pay for out-of-pocket. State and federal laws prevent us from paying you directly. If you paid for a prescription drug or service that you think we should have covered, contact Member Services at the number listed in on the cover. 5. You are being told that coverage for certain medical care you have been getting will be reduced or stopped, and you believe that reducing or stopping this care could harm your health. NOTE: If the coverage that will be stopped is for hospital care, home health care, skilled nursing facility care, or Comprehensive Outpatient Rehabilitation Facility (CORF) services, you need to read a separate section of this chapter because special rules apply to these types of care. Heres what to read in those situations: Chapter 9, Section 7: How to ask for a longer hospital stay if you think you are being asked to leave the hospital too soon. Chapter 9, Section 8: How to ask our plan to keep covering certain medical services if you think your coverage is ending too soon. This section is about three services only: home health care, skilled nursing facility care, and Comprehensive Outpatient Rehabilitation Facility (CORF) services. For all other situations that involve being told that medical care you have been getting will be stopped, use this section (Section 5) as your guide for what to do.  Section 5.2 Step-by-step: How to ask for a coverage decision (how to ask our plan to authorize or provide the medical care coverage you want) Legal TermsA coverage decision is often called an initial determination or initial decision. When a coverage decision involves your medical care, the initial determination is called an organization determination.Step 1: You ask our plan to make a coverage decision on the medical care you are requesting. If your health requires a quick response, you should ask us to make a fast decision. Legal TermsA fast decision is called an expedited decision.How to request coverage for the medical care you want Start by [insert if applicable: calling,] writing, or faxing our plan to make your request for us to provide coverage for the medical care you want. You, or your doctor, or your representative can do this. For the details on how to contact us, go to Chapter 2, Section 1 and look for the section called, [plans may edit section title as necessary] How to contact our plan when you are asking for a coverage decision about your medical care. Generally we use the standard deadlines for giving you our decision When we give you our decision, we will use the standard deadlines unless we have agreed to use the fast deadlines. A standard decision means we will give you an answer within 10 business days after we receive your request. However, we can take up to 14 more days if you ask for more time, or if we need information (such as medical records) that may benefit you. If we decide to take extra days to make the decision, we will tell you in writing. If you believe we should not take extra days, you can file a fast complaint about our decision to take extra days. When you file a fast complaint, we will give you an answer to your complaint within 72 hours. (The process for making a complaint is different from the process for coverage decisions and appeals. For more information about the process for making complaints, including fast complaints, see Section 10 of this chapter.) If your health requires it, ask us to give you a fast decision A fast decision means we will answer within 72 hours. However, we can take up to 14 more days if we find that some information is missing that may benefit you, or if you need to get information to us for the review. If we decide to take extra days, we will tell you in writing. If you believe we should not take extra days, you can file a fast complaint about our decision to take extra days. (For more information about the process for making complaints, including fast complaints, see Section 10 of this chapter.) We will call you as soon as we make the decision. To get a fast decision, you must meet two requirements: You can get a fast decision only if you are asking for coverage for medical care you have not yet received. (You cannot get a fast decision if your request is about payment for medical care you have already received.) You can get a fast decision only if using the standard deadlines could cause serious harm to your health or hurt your ability to function. If your doctor tells us that your health requires a fast decision, we will automatically agree to give you a fast decision. If you ask for a fast decision on your own, without your doctors support, our plan will decide whether your health requires that we give you a fast decision. If we decide that your medical condition does not meet the requirements for a fast decision, we will send you a letter that says so (and we will use the standard deadlines instead). This letter will tell you that if your doctor asks for the fast decision, we will automatically give a fast decision. The letter will also tell how you can file a fast complaint about our decision to give you a standard decision instead of the fast decision you requested. (For more information about the process for making complaints, including fast complaints, see Section 10 of this chapter.) Step 2: Our plan considers your request for medical care coverage and we give you our answer. Deadlines for a fast coverage decision Generally, for a fast decision, we will give you our answer within 72 hours. As explained above, we can take up to 14 more days under certain circumstances. If we take extra days, it is called an extended time period. If we do not give you our answer within 72 hours (or if there is an extended time period, by the end of that period), you have the right to appeal. Section 5.3 below tells how to make an appeal. If our answer is yes to part or all of what you requested, we must authorize or provide the medical care coverage we have agreed to provide within 72 hours after we received your request. If we extended the time needed to make our decision, we will provide the coverage by the end of that extended period. If our answer is no to part or all of what you requested, we will send you a written statement that explains why we said no. Deadlines for a standard coverage decision Generally, for a standard decision, we will give you our answer within 10 business days of receiving your request. We can take up to 14 more days (an extended time period) under certain circumstances. If we do not give you our answer within 10 business days (or if there is an extended time period, by the end of that period), you have the right to appeal. Section 5.3 below tells how to make an appeal. If our answer is yes to part or all of what you requested, we must authorize or provide the coverage we have agreed to provide within 14 days after we received your request. If we extended the time needed to make our decision, we will provide the coverage by the end of that extended period. If our answer is no to part or all of what you requested, we will send you a written statement that explains why we said no. Step 3: If we say no to your request for coverage for medical care, you decide if you want to make an appeal. If our plan says no, you have the right to ask us to reconsider and perhaps change this decision by making an appeal. Making an appeal means making another try to get the medical care coverage you want. If you decide to make appeal, it means you are going on to Level 1 of the appeals process (see Section 5.3 below). Section 5.3 Step-by-step: How to make a Level 1 Appeal (how to ask for a review of a medical care coverage decision made by our plan) Legal TermsWhen you start the appeal process by making an appeal, it is called the first level of appeal or a Level 1 Appeal. An appeal to the plan about a medical care coverage decision is called a plan reconsideration.Step 1: You contact our plan and make your appeal. If your health requires a quick response, you must ask for a fast appeal. What to do To start an appeal you, your representative, or in some cases your doctor must contact our plan. For details on how to reach us for any purpose related to your appeal, go to Chapter 2, Section 1 look for section called, [plans may edit section title as necessary] How to contact our plan when you are making an appeal about your medical care. Make your standard appeal in writing by submitting a signed request. [If the plan accepts oral requests for standard appeals, insert: You may also ask for an appeal by calling us at the phone number shown in Chapter 2, Section 1 [plan may edit section title as needed:] (How to contact our plan when you are making an appeal about your medical care).] You must make your appeal request within 90 calendar days from the date on the written notice we sent to tell you our answer to your request for a coverage decision. If you miss this deadline and have a good reason for missing it, we may give you more time to make your appeal. You can ask for a copy of the information in your appeal and add more information if you like. You have the right to ask us for a copy of the information regarding your appeal. [If a fee is charged, insert: We are allowed to charge a fee for copying and sending this information to you.] If you wish, you and your doctor may give us additional information to support your appeal. If your health requires it, ask for a fast appeal (you can make an oral request) Legal TermsA fast appeal is also called an expedited appeal.If you are appealing a decision our plan made about coverage for care you have not yet received, you and/or your doctor will need to decide if you need a fast appeal. The requirements and procedures for getting a fast appeal are the same as those for getting a fast decision. To ask for a fast appeal, follow the instructions for asking for a fast decision. (These instructions are given earlier in this section.) [Plans insert if applicable: If your doctor tells us that your health requires a "fast appeal," we will automatically agree to give you a fast appeal.] Step 2: Our plan considers your appeal and we give you our answer. When our plan is reviewing your appeal, we take another careful look at all of the information about your request for coverage of medical care. We check to see if we were being fair and following all the rules when we said no to your request. We will gather more information if we need it. We may contact you or your doctor to get more information. Deadlines for a fast appeal When we are using the fast deadlines, we must give you our answer within 72 hours after we receive your appeal. We will give you our answer sooner if your health requires us to do so. However, if you ask for more time, or if we need to gather more information that may benefit you, we can take up to 14 more days. If we do not give you an answer within 72 hours (or by the end of the extended time period if we took extra days), we are required to send your request on to Level 2 of the appeals process, where it will be reviewed by an independent organization. Later in this section, we tell you about this organization and explain what happens at Level 2 of the appeals process. If our answer is yes to part or all of what you requested, we must authorize or provide the coverage we have agreed to provide within 72 hours. If our answer is no to part or all of what you requested, we will send you a written denial notice informing you that we have sent your appeal to the Independent Review Organization for a Level 2 Appeal for decisions regarding Medicare covered services. Deadlines for a standard appeal If we are using the standard deadlines, we must give you our answer within 30 calendar days after we receive your appeal if your appeal is about coverage for services you have not yet received. We will give you our decision sooner if your health condition requires us to. However, if you ask for more time, or if we need to gather more information that may benefit you, we can take up to 14 more days. If we do not give you an answer by the deadline above (or by the end of the extended time period if we took extra days), we are required to send your request on to Level 2 of the appeals process, where it will be reviewed by an independent outside organization. Later in this section, we tell about this review organization and explain what happens at Level 2 of the appeals process. If our answer is yes to part or all of what you requested, we must authorize or provide the coverage we have agreed to provide within 30 days after we receive your appeal. If our answer is no to part or all of what you requested, we will send you a written denial notice informing you that we have sent your appeal to the Independent Review Organization for a Level 2 Appeal for decisions regarding Medicare covered services. Step 3: If our plan says no to your appeal, your case will automatically be sent on to the next level of the appeals process. To make sure we were being fair when we said no to your appeal, our plan is required to send your Medicare appeal to the Independent Review Organization. When we do this, it means that your appeal is going on to the next level of the appeals process, which is Level 2. Section 5.4 Step-by-step: How to make a Level 2 Appeal If our plan says no to your Level 1 Appeal, your case will automatically be sent on to the next level of the appeals process for decisions regarding Medicare covered services. During the Level 2 Appeal, the Independent Review Organization reviews the decision our plan made when we said no to your first appeal. This organization decides whether the decision we made should be changed. Legal TermsThe formal name for the Independent Review Organization is the Independent Review Entity. It is sometimes called the IRE.Step 1: The Independent Review Organization reviews your appeal. The Independent Review Organization is an outside, independent organization that is hired by Medicare. This organization is not connected with our plan and it is not a government agency. This organization is a company chosen by Medicare to handle the job of being the Independent Review Organization. Medicare oversees its work. We will send the information about your appeal to this organization. This information is called your case file. You have the right to ask us for a copy of your case file. [If a fee is charged, insert: We are allowed to charge you a fee for copying and sending this information to you.] You have a right to give the Independent Review Organization additional information to support your appeal. Reviewers at the Independent Review Organization will take a careful look at all of the information related to your appeal for decisions regarding Medicare covered services. If you had a fast appeal at Level 1, you will also have a fast appeal at Level 2 If you had a fast appeal to our plan at Level 1, the review organization must give you an answer to your Level 2 Appeal within 72 hours of when it receives your appeal for decisions regarding Medicare covered services. However, if the Independent Review Organization needs to gather more information that may benefit you, it can take up to 14 more days. If you had a standard appeal at Level 1, you will also have a standard appeal at Level 2 If you made a standard appeal to our plan at Level 1, the review organization must give you an answer to your Level 2 Appeal within 30 calendar days of when it receives your appeal for decisions regarding Medicare covered services. However, if the Independent Review Organization needs to gather more information that may benefit you, it can take up to 14 more days. Step 2: The Independent Review Organization gives you their answer. The Independent Review Organization will tell you its decision in writing and explain the reasons for it. If the review organization says yes to part or all of what you requested, we must authorize the medical care coverage within 72 hours or provide the service within 14 days after we receive the decision from the review organization. If this organization says no to your appeal, it means they agree with our plan that your request for coverage for medical care should not be approved. (This is called upholding the decision. It is also called turning down your appeal.) The notice you get from the Independent Review Organization will tell you in writing if your case meets the requirements for continuing with the appeals process. For example, to continue and make another appeal at Level 3, the dollar value of the medical care coverage you are requesting must meet a certain minimum. If the dollar value of the coverage you are requesting is too low, you cannot make another appeal, which means that the decision at Level 2 is final. Step 3: If your case meets the requirements, you choose whether you want to take your appeal further. There are three additional levels in the appeals process after Level 2 (for a total of five levels of appeal) for decisions regarding Medicare covered services. If your Level 2 Appeal is turned down and you meet the requirements to continue with the appeals process for decisions regarding Medicare covered services, you must decide whether you want to go on to Level 3 and make a third appeal. The details on how to do this are in the written notice you got after your Level 2 Appeal. The Level 3 Appeal is handled by an administrative law judge. Section 9 in this chapter tells more about Levels 3, 4, and 5 of the appeals process for decisions regarding Medicare covered services. Additional Appeal Rights under Medical Assistance As a plan member, some of your plan services may also be covered by Medical Assistance. Therefore, if you believe that we improperly denied you a service or payment for a service, you may also have the right to appeal this decision to Medical Assistance. We will let you know in writing if you have the right to appeal our decision to Medical Assistance. If you disagree with a decision or have a complaint regarding a Medical Assistance covered service, you can do any of the following: You can call our Plan to file an appeal You can write to our Plan to file an appeal You can write to the Minnesota Department of Human Services to request a State Fair Hearing. You may request a State Fair Hearing at any time during the Plans appeal process. You do not have to file an appeal with the Plan before you request a State fair hearing. If you request a State fair hearing instead of filing an appeal with the Plan, the timelines for appealing to the health plan still are applicable as described in the Appeal Level 1. Continuation of Services If we are stopping or reducing medical care, services or a non-Part D drug, you can keep getting the medical care, service or non-Part D drug if you file a health plan appeal or request a State Fair Hearing within 10 days after we send you the notice or before the service is stopped or reduced, whichever is later. The participating treating provider must agree the medical care, service or non-Part D drug should continue. The medical care, service or non-Part D drug can continue until the appeal or State Fair Hearing is resolved. If you lose the appeal or State Fair Hearing, you may have to pay for the medical care, service or non-Part D drug yourself. State Fair Hearing Process You may request a State Fair Hearing at any time during the Plans appeal process for services covered by Medical Assistance. You do not have to file an appeal with the Plan before you request a State Fair Hearing. If you request a State Fair Hearing instead of filing an appeal with the Plan, the timelines for appealing to the health plan still are applicable as described in the Appeal Level 1. A State Fair Hearing is a hearing at the State to review a decision made by us. You must request a hearing in writing. You may ask for a hearing if you disagree with: the delivery of health services; enrollment in the Plan; denial in full or part of a claim or service; our failure to act within required timelines for service authorizations and appeals; or any other action. You must ask for a State Fair Hearing within 30 days of the date of the Notice of Action or the decision in a Plan appeal. You can have up to 90 days to request a State Fair Hearing if you have a good reason for being late. Write to: Minnesota Department of Human Services Appeals Office P.O. Box 64941 St. Paul, MN 55164-0941 Or fax to: 651- 431-7523 A Human Services Judge from the State Appeals Office will hold a hearing. You may attend the hearing in person or by telephone. Tell the State why you disagree with the decision made by us. You can ask a friend, relative, advocate, provider, or lawyer to help you. The process can take between 30-90 days. If your hearing is about an urgently needed service, tell the Judge (see contact information above) or the Minnesota State Ombudsman for Managed Care Programs when you call or write to them. See Section 2 for contact information. If your hearing is about a medical necessity denial, you may ask for an expert medical opinion. This will be from an outside reviewer. There is no cost to you. If you disagree with the ruling of the State Fair Hearing process, you may appeal to the District Court in your county. Section 5.5 What if you are asking our plan to pay you for our share of a bill you have received for medical care? We cannot pay you back for most medical bills that you pay. State and federal laws prevent us from paying you directly. The exception is if you pay for Part D prescription drugs see Section 6 below. If you paid for a service that you think we should have covered, contact Member Services at the number listed on the front cover. SECTION 6 Your Part D prescription drugs: How to ask for a coverage decision or make an appeal ?Have you read Section 4 of this chapter (A guide to the basics of coverage decisions and appeals)? If not, you may want to read it before you start this section. Section 6.1 This section tells you what to do if you have problems getting a Part D drug or you want us to pay you back for a Part D drug Your benefits as a member of our plan include coverage for many outpatient prescription drugs. Medicare calls these outpatient prescription drugs Part D drugs. You can get these drugs as long as they are included in our plans List of Covered Drugs (Formulary) and they are medically necessary for you, as determined by your primary care doctor or other provider. This section is about your Part D drugs only. To keep things simple, we generally say drug in the rest of this section, instead of repeating covered outpatient prescription drug or Part D drug every time. For details about what we mean by Part D drugs, the List of Covered Drugs, rules and restrictions on coverage, and cost information, see Chapter 5 (Using our plans coverage for your Part D prescription drugs) and Chapter 6 (What you pay for your Part D prescription drugs). Part D coverage decisions and appeals As discussed in Section 4 of this chapter, a coverage decision is a decision we make about your benefits and coverage or about the amount we will pay for your drugs. Legal TermsA coverage decision is often called an initial determination or initial decision. When the coverage decision is about your Part D drugs, the initial determination is called a coverage determination.Here are examples of coverage decisions you ask us to make about your Part D drugs: You ask us to make an exception, including: Asking us to cover a Part D drug that is not on the plans List of Covered Drugs Asking us to waive a restriction on the plans coverage for a drug (such as limits on the amount of the drug you can get) Asking to pay a lower cost-sharing amount for a covered non-preferred drug You ask us whether a drug is covered for you and whether you satisfy any applicable coverage rules. (For example, when your drug is on the plans List of Covered Drugs but we require you to get approval from us before we will cover it for you.) You ask us to pay for a prescription drug you already bought. This is a request for a coverage decision about payment. If you disagree with a coverage decision we have made, you can appeal our decision. This section tells you both how to ask for coverage decisions and how to request an appeal. Use this guide to help you determine which part has information for your situation:  Section 6.2 What is an exception? If a drug is not covered in the way you would like it to be covered, you can ask the plan to make an exception. An exception is a type of coverage decision. Similar to other types of coverage decisions, if we turn down your request for an exception, you can appeal our decision. When you ask for an exception, your doctor or other prescriber will need to explain the medical reasons why you need the exception approved. We will then consider your request. Here are [insert as applicable: two OR three] examples of exceptions that you or your doctor or other prescriber can ask us to make: Covering a Part D drug for you that is not on our plans List of Covered Drugs (Formulary). (We call it the Drug List for short.) Legal TermsAsking for coverage of a drug that is not on the Drug List is sometimes called asking for a formulary exception.If we agree to make an exception and cover a drug that is not on the Drug List, you will need to pay the cost-sharing amount that applies to [insert as appropriate: all of our drugs OR drugs in [insert exceptions tier]]. You cannot ask for an exception to the copayment or co-insurance amount we require you to pay for the drug. You cannot ask for coverage of any excluded drugs or other non-Part D drugs which Medicare does not cover. (For more information about excluded drugs, see Chapter 5.) Removing a restriction on the plans coverage for a covered drug. There are extra rules or restrictions that apply to certain drugs on the plans List of Covered Drugs (for more information, go to Chapter 5 and look for Section 5). Legal TermsAsking for removal of a restriction on coverage for a drug is sometimes called asking for a formulary exception.The extra rules and restrictions on coverage for certain drugs include: [Omit if plan does not use generic substitution] Being required to use the generic version of a drug instead of the brand-name drug. [Omit if plan does not use prior authorization] Getting plan approval in advance before we will agree to cover the drug for you. (This is sometimes called prior authorization.) [Omit if plan does not use step therapy] Being required to try a different drug first before we will agree to cover the drug you are asking for. (This is sometimes called step therapy.)] [Omit if plan does not use quantity limits] Quantity limits. For some drugs, there are restrictions on the amount of the drug you can have. If our plan agrees to make an exception and waive a restriction for you, you can ask for an exception to the copayment or co-insurance amount we require you to pay for the drug. 3. [Plans without drug tiers should omit this section] Changing coverage of a drug to a lower cost-sharing tier. Every drug on the plans Drug List is in one of [insert number of tiers] cost-sharing tiers. In general, the lower the cost-sharing tier number, the less you will pay as your share of the cost of the drug. Legal TermsAsking to pay a lower preferred price for a covered non-preferred drug is sometimes called asking for a tiering exception.If your drug is in [insert name of non-preferred/highest tier subject to the tiering exceptions process] you can ask us to cover it at the cost-sharing amount that applies to drugs in [insert name of preferred/lowest tier subject to the tiering exceptions process]. This would lower your share of the cost for the drug. [If the Plan designated one of its tiers as a high-cost/unique drug tier and is exempting that tier from the exceptions process, include the following language: You cannot ask us to change the cost-sharing tier for any drug in [insert tier number and name of tier designated as the high-cost/unique drug tier].] Section 6.3 Important things to know about asking for exceptions Your doctor must tell us the medical reasons Your doctor or other prescriber must give us a written statement that explains the medical reasons for requesting an exception. For a faster decision, include this medical information from your doctor or other prescriber when you ask for the exception. Typically, our Drug List includes more than one drug for treating a particular condition. These different possibilities are called alternative drugs. If an alternative drug would be just as effective as the drug you are requesting and would not cause more side effects or other health problems, we will generally not approve your request for an exception. Our plan can say yes or no to your request If we approve your request for an exception, our approval usually is valid until the end of the plan year. This is true as long as your doctor continues to prescribe the drug for you and that drug continues to be safe and effective for treating your condition. If we say no to your request for an exception, you can ask for a review of our decision by making an appeal. Section 6.5 tells how to make an appeal if we say no. The next section tells you how to ask for a coverage decision, including an exception. Section 6.4 Step-by-step: How to ask for a coverage decision, including an exception Step 1: You ask our plan to make a coverage decision about the drug(s) or payment you need. If your health requires a quick response, you must ask us to make a fast decision. You cannot ask for a fast decision if you are asking us to pay you back for a drug you already bought. What to do Request the type of coverage decision you want. Start by [insert if applicable: calling,] writing, or faxing our plan to make your request. You, your representative, or your doctor (or other prescriber) can do this. For the details, go to Chapter 2, Section 1 and look for the section called, [plans may edit section title as necessary:] How to contact our plan when you are asking for a coverage decision about your Part D prescription drugs. Or if you are asking us to pay you back for a drug, go to the section called, [plans may edit section title as necessary:] Where to send a request that asks us to pay for our share of the cost for medical care or a drug you have received. You or your doctor or someone else who is acting on your behalf can ask for a coverage decision. Section 4 of this chapter tells how you can give written permission to someone else to act as your representative. You can also have a lawyer act on your behalf. If you want to ask our plan to pay you back for a drug, start by reading Chapter 7 of this booklet: Asking the plan to pay its share of a bill you have received for medical services or drugs. Chapter 7 describes the situations in which you may need to ask for reimbursement. It also tells how to send us the paperwork that asks us to pay you back for our share of the cost of a drug you have paid for. If you are requesting an exception, provide the doctors statement. Your doctor or other prescriber must give us the medical reasons for the drug exception you are requesting. (We call this the doctors statement.) Your doctor or other prescriber can fax or mail the statement to our plan. Or your doctor or other prescriber can tell us on the phone and follow up by faxing or mailing the signed statement. See Sections 6.2 and 6.3 for more information about exception requests. If your health requires it, ask us to give you a fast decision Legal TermsA fast decision is called an expedited decision.When we give you our decision, we will use the standard deadlines unless we have agreed to use the fast deadlines. A standard decision means we will give you an answer within 72 hours after we receive your doctors statement. A fast decision means we will answer within 24 hours. To get a fast decision, you must meet two requirements: You can get a fast decision only if you are asking for a drug you have not yet received. (You cannot get a fast decision if you are asking us to pay you back for a drug you already bought.) You can get a fast decision only if using the standard deadlines could cause serious harm to your health or hurt your ability to function. If your doctor or other prescriber tells us that your health requires a fast decision, we will automatically agree to give you a fast decision. If you ask for a fast decision on your own (without your doctors or other prescribers support), our plan will decide whether your health requires that we give you a fast decision. If we decide that your medical condition does not meet the requirements for a fast decision, we will send you a letter that says so (and we will use the standard deadlines instead). This letter will tell you that if your doctor or other prescriber asks for the fast decision, we will automatically give a fast decision. The letter will also tell how you can file a complaint about our decision to give you a standard decision instead of the fast decision you requested. It tells how to file a fast complaint, which means you would get our answer to your complaint within 24 hours. (The process for making a complaint is different from the process for coverage decisions and appeals. For more information about the process for making complaints, see Section 10 of this chapter.) Step 2: Our plan considers your request and we give you our answer. Deadlines for a fast coverage decision If we are using the fast deadlines, we must give you our answer within 24 hours. Generally, this means within 24 hours after we receive your request. If you are requesting an exception, we will give you our answer within 24 hours after we receive your doctors statement supporting your request. We will give you our answer sooner if your health requires us to. If we do not meet this deadline, we are required to send your request on to Level 2 of the appeals process, where it will be reviewed by an independent outside organization. Later in this section, we tell about this review organization and explain what happens at Appeal Level 2. If our answer is yes to part or all of what you requested, we must provide the coverage we have agreed to provide within 24 hours after we receive your request or doctors statement supporting your request. If our answer is no to part or all of what you requested, we will send you a written statement that explains why we said no. Deadlines for a standard coverage decision If we are using the standard deadlines, we must give you our answer within 72 hours. Generally, this means within 72 hours after we receive your request. If you are requesting an exception, we will give you our answer within 72 hours after we receive your doctors statement supporting your request. We will give you our answer sooner if your health requires us to. If we do not meet this deadline, we are required to send your request on to Level 2 of the appeals process, where it will be reviewed by an independent organization. Later in this section, we tell about this review organization and explain what happens at Appeal Level 2. If our answer is yes to part or all of what you requested If we approve your request for coverage, we must provide the coverage we have agreed to provide within 72 hours after we receive your request or doctors statement supporting your request. If we approve your request to pay you back for a drug you already bought, we are also required to send payment to you within 30 calendar days after we receive your request or doctors statement supporting your request. If our answer is no to part or all of what you requested, we will send you a written statement that explains why we said no. Step 3: If we say no to your coverage request, you decide if you want to make an appeal. If our plan says no, you have the right to request an appeal. Requesting an appeal means asking us to reconsider and possibly change the decision we made. Section 6.5 Step-by-step: How to make a Level 1 Appeal (how to ask for a review of a coverage decision made by our plan) Legal TermsWhen you start the appeals process by making an appeal, it is called the first level of appeal or a Level 1 Appeal. An appeal to the plan about a Part D drug coverage decision is called a plan redetermination.Step 1: You contact our plan and make your Level 1 Appeal. If your health requires a quick response, you must ask for a fast appeal. What to do To start your appeal, you (or your representative or your doctor or other prescriber) must contact our plan. For details on how to reach us by phone, fax, mail, or in person for any purpose related to your appeal, go to Chapter 2, Section 1, and look for the section called, [plans may edit section title as necessary] How to contact our plan when you are making an appeal about your Part D prescription drugs. Make your appeal in writing by submitting a signed request. [If the plan accepts oral requests for standard appeals, insert: You may also ask for an appeal by calling us at the phone number shown in Chapter 2, Section 1 [plans may edit section title as necessary:] (How to contact our plan when you are making an appeal about your Part D prescription drugs).] You must make your appeal request within 60 calendar days from the date on the written notice we sent to tell you our answer to your request for a coverage decision. If you miss this deadline and have a good reason for missing it, we may give you more time to make your appeal. You can ask for a copy of the information in your appeal and add more information. You have the right to ask us for a copy of the information regarding your appeal. [If a fee is charged, insert: We are allowed to charge a fee for copying and sending this information to you.] If you wish, you and your doctor or other prescriber may give us additional information to support your appeal. If your health requires it, ask for a fast appeal Legal TermsA fast appeal is also called an expedited appeal.If you are appealing a decision our plan made about a drug you have not yet received, you and your doctor or other prescriber will need to decide if you need a fast appeal. The requirements for getting a fast appeal are the same as those for getting a fast decision in Section 6.4 of this chapter. Step 2: Our plan considers your appeal and we give you our answer. When our plan is reviewing your appeal, we take another careful look at all of the information about your coverage request. We check to see if we were being fair and following all the rules when we said no to your request. We may contact you or your doctor or other prescriber to get more information. Deadlines for a fast appeal If we are using the fast deadlines, we must give you our answer within 72 hours after we receive your appeal. We will give you our answer sooner if your health requires it. If we do not give you an answer within 72 hours, we are required to send your request on to Level 2 of the appeals process, where it will be reviewed by an Independent Review Organization. Later in this section, we tell about this review organization and explain what happens at Level 2 of the appeals process. If our answer is yes to part or all of what you requested, we must provide the coverage we have agreed to provide within 72 hours. If our answer is no to part or all of what you requested, we will send you a written statement that explains why we said no and how to appeal our decision. Deadlines for a standard appeal If we are using the standard deadlines, we must give you our answer within 7 calendar days after we receive your appeal. We will give you our decision sooner if you have not received the drug yet and your health condition requires us to do so. If we do not give you a decision within 7 calendar days, we are required to send your request on to Level 2 of the appeals process, where it will be reviewed by an Independent Review Organization. Later in this section, we tell about this review organization and explain what happens at Level 2 of the appeals process. If our answer is yes to part or all of what you requested If we approve a request for coverage, we must provide the coverage we have agreed to provide as quickly as your health requires, but no later than 7 calendar days after we receive your appeal. If we approve a request to pay you back for a drug you already bought, we are required to send payment to you within 30 calendar days after we receive your appeal request. If our answer is no to part or all of what you requested, we will send you a written statement that explains why we said no and how to appeal our decision. Step 3: If we say no to your appeal, you decide if you want to continue with the appeals process and make another appeal. If our plan says no to your appeal, you then choose whether to accept this decision or continue by making another appeal. If you decide to make another appeal, it means your appeal is going on to Level 2 of the appeals process (see below). Section 6.6 Step-by-step: How to make a Level 2 Appeal If our plan says no to your appeal, you then choose whether to accept this decision or continue by making another appeal. If you decide to go on to a Level 2 Appeal, the Independent Review Organization reviews the decision our plan made when we said no to your first appeal. This organization decides whether the decision we made should be changed. Legal TermsThe formal name for the Independent Review Organization is the Independent Review Entity. It is sometimes called the IRE.Step 1: To make a Level 2 Appeal, you must contact the Independent Review Organization and ask for a review of your case. If our plan says no to your Level 1 Appeal, the written notice we send you will include instructions on how to make a Level 2 Appeal with the Independent Review Organization. These instructions will tell who can make this Level 2 Appeal, what deadlines you must follow, and how to reach the review organization. When you make an appeal to the Independent Review Organization, we will send the information we have about your appeal to this organization. This information is called your case file. You have the right to ask us for a copy of your case file. [If a fee is charged, insert: We are allowed to charge you a fee for copying and sending this information to you.] You have a right to give the Independent Review Organization additional information to support your appeal. Step 2: The Independent Review Organization does a review of your appeal and gives you an answer. The Independent Review Organization is an outside, independent organization that is hired by Medicare. This organization is not connected with our plan and it is not a government agency. This organization is a company chosen by Medicare to review our decisions about your Part D benefits with our plan. Reviewers at the Independent Review Organization will take a careful look at all of the information related to your appeal. The organization will tell you its decision in writing and explain the reasons for it. Deadlines for fast appeal at Level 2 If your health requires it, ask the Independent Review Organization for a fast appeal. If the review organization agrees to give you a fast appeal, the review organization must give you an answer to your Level 2 Appeal within 72 hours after it receives your appeal request. If the Independent Review Organization says yes to part or all of what you requested, we must provide the drug coverage that was approved by the review organization within 24 hours after we receive the decision from the review organization. Deadlines for standard appeal at Level 2 If you have a standard appeal at Level 2, the review organization must give you an answer to your Level 2 Appeal within 7 calendar days after it receives your appeal. If the Independent Review Organization says yes to part or all of what you requested If the Independent Review Organization approves a request for coverage, we must provide the drug coverage that was approved by the review organization within 72 hours after we receive the decision from the review organization. If the Independent Review Organization approves a request to pay you back for a drug you already bought, we are required to send payment to you within 30 calendar days after we receive the decision from the review organization. What if the review organization says no to your appeal? If this organization says no to your appeal, it means the organization agrees with our decision not to approve your request. (This is called upholding the decision. It is also called turning down your appeal.) To continue and make another appeal at Level 3, the dollar value of the drug coverage you are requesting must meet a minimum amount. If the dollar value of the coverage you are requesting is too low, you cannot make another appeal and the decision at Level 2 is final. The notice you get from the Independent Review Organization will tell you if the dollar value of the coverage you are requesting is high enough to continue with the appeals process. Step 3: If the dollar value of the coverage you are requesting meets the requirement, you choose whether you want to take your appeal further. There are three additional levels in the appeals process after Level 2 (for a total of five levels of appeal). If your Level 2 Appeal is turned down and you meet the requirements to continue with the appeals process, you must decide whether you want to go on to Level 3 and make a third appeal. If you decide to make a third appeal, the details on how to do this are in the written notice you got after your second appeal. The Level 3 Appeal is handled by an administrative law judge. Section 9 in this chapter tells more about Levels 3, 4, and 5 of the appeals process. SECTION 7 How to ask us to cover a longer hospital stay if you think the doctor is discharging you too soon When you are admitted to a hospital, you have the right to get all of your covered hospital services that are necessary to diagnose and treat your illness or injury. For more information about the plans coverage for your hospital care, including any limitations on this coverage, see Chapter 4 of this booklet: Benefits chart (what is covered). During your hospital stay, your doctor and the hospital staff will be working with you to prepare for the day when you will leave the hospital. They will also help arrange for care you may need after you leave. The day you leave the hospital is called your discharge date. Our plans coverage of your hospital stay ends on this date. When your discharge date has been decided, your doctor or the hospital staff will let you know. If you think you are being asked to leave the hospital too soon, you can ask for a longer hospital stay and your request will be considered. This section tells you how to ask. Section 7.1 During your hospital stay, you will get a written notice from Medicare that tells about your rights During your hospital stay, you will be given a written notice called An Important Message from Medicare about Your Rights. Everyone with Medicare gets a copy of this notice whenever they are admitted to a hospital. Someone at the hospital is supposed to give it to you within two days after you are admitted. 1. Read this notice carefully and ask questions if you dont understand it. It tells you about your rights as a hospital patient, including: Your right to receive Medicare-covered services during and after your hospital stay, as ordered by your doctor. This includes the right to know what these services are, who will pay for them, and where you can get them. Your right to be involved in any decisions about your hospital stay, and know who will pay for it. Where to report any concerns you have about quality of your hospital care. What to do if you think you are being discharged from the hospital too soon. Legal TermsThe written notice from Medicare tells you how you can make an appeal. Making an appeal is a formal, legal way to ask for a delay in your discharge date so that your hospital care will be covered for a longer time. (Section 7.2 below tells how to make this appeal.)2. You must sign the written notice to show that you received it and understand your rights. You or someone who is acting on your behalf must sign the notice. (Section 4 of this chapter tells how you can give written permission to someone else to act as your representative.) Signing the notice shows only that you have received the information about your rights. The notice does not give your discharge date (your doctor or hospital staff will tell you your discharge date). Signing the notice does not mean you are agreeing on a discharge date. 3. Keep your copy of the signed notice so you will have the information about making an appeal (or reporting a concern about quality of care) handy if you need it. If you sign the notice more than 2 days before the day you leave the hospital, you will get another copy before you are scheduled to be discharged. To look at a copy of this notice in advance, you can call Member Services or 1-800 MEDICARE (1-800-633-4227 or TTY: 1-877-486-2048). You can also see it online at http://www.cms.hhs.gov Section 7.2 Step-by-step: How to make a Level 1 Appeal to change your hospital discharge date If you want to ask for your hospital services to be covered by our plan for a longer time, you will need to use the appeals process to make this request. Before you start, understand what you need to do and what the deadlines are. Follow the process. Each step in the first two levels of the appeals process is explained below. Meet the deadlines. The deadlines are important. Be sure that you understand and follow the deadlines that apply to things you must do. Ask for help if you need it. If you have questions or need help at any time, please call Member Services (phone numbers are on the front cover of this booklet). Or call your State Health Insurance Assistance Program, a government organization that provides personalized assistance (see Section 2 of this chapter). During a Level 1 Appeal, the Quality Improvement Organization reviews your appeal. It checks to see if your planned discharge date is medically appropriate for you. Legal TermsWhen you start the appeal process by making an appeal, it is called the first level of appeal or a Level 1 Appeal.Step 1: Contact the Quality Improvement Organization in your state and ask for a fast review of your hospital discharge. You must act quickly. Legal TermsA fast review is also called an immediate review or an expedited review.What is the Quality Improvement Organization? This organization is a group of doctors and other health care professionals who are paid by the Federal government. These experts are not part of our plan. This organization is paid by Medicare to check on and help improve the quality of care for people with Medicare. This includes reviewing hospital discharge dates for people with Medicare. How can you contact this organization? The written notice you received (An Important Message from Medicare) tells you how to reach this organization. (Or find the name, address, and phone number of the Quality Improvement Organization for your state in Chapter 2, Section 4, of this booklet.) Act quickly: To make your appeal, you must contact the Quality Improvement Organization before you leave the hospital and no later than your planned discharge date. (Your planned discharge date is the date that has been set for you to leave the hospital.) If you meet this deadline, you are allowed to stay in the hospital after your discharge date without paying for it while you wait to get the decision on your appeal from the Quality Improvement Organization. If you do not meet this deadline, and you decide to stay in the hospital after your planned discharge date, you may have to pay all of the costs for hospital care you receive after your planned discharge date. If you miss the deadline for contacting the Quality Improvement Organization about your appeal, you can make your appeal directly to our plan instead. For details about this other way to make your appeal, see Section 7.4. Ask for a fast review: You must ask the Quality Improvement Organization for a fast review of your discharge. Asking for a fast review means you are asking for the organization to use the fast deadlines for an appeal instead of using the standard deadlines. Legal TermsA fast review is also called an immediate review or an expedited review.Step 2: The Quality Improvement Organization conducts an independent review of your case. What happens during this review? Health professionals at the Quality Improvement Organization (we will call them the reviewers for short) will ask you (or your representative) why you believe coverage for the services should continue. You dont have to prepare anything in writing, but you may do so if you wish. The reviewers will also look at your medical information, talk with your doctor, and review information that the hospital and our plan has given to them. During this review process, you will also get a written notice that gives your planned discharge date and explains the reasons why your doctor, the hospital, and our plan think it is right (medically appropriate) for you to be discharged on that date. Legal TermsThis written explanation is called the Detailed Notice of Discharge. You can get a sample of this notice by calling Member Services or 1-800-MEDICARE (1-800-633-4227, 24 hours a day, 7 days a week. TTY users should call 1-877-486-2048.) Or you can get see a sample notice online at http://www.cms.hhs.gov/BNI/Step 3: Within one full day after it has all the needed information, the Quality Improvement Organization will give you its answer to your appeal. What happens if the answer is yes? If the review organization says yes to your appeal, our plan must keep providing your covered hospital services for as long as these services are medically necessary. You will have to keep paying your share of the costs (such as deductibles or copayments, if these apply). In addition, there may be limitations on your covered hospital services. (See Chapter 4 of this booklet). What happens if the answer is no? If the review organization says no to your appeal, they are saying that your planned discharge date is medically appropriate. (Saying no to your appeal is also called turning down your appeal.) If this happens, our plans coverage for your hospital services will end at noon on the day after the Quality Improvement Organization gives you its answer to your appeal. If you decide to stay in the hospital, then you may have to pay the full cost of hospital care you receive after noon on the day after the Quality Improvement Organization gives you its answer to your appeal. Step 4: If the answer to your Level 1 Appeal is no, you decide if you want to make another appeal. If the Quality Improvement Organization has turned down your appeal, and you stay in the hospital after your planned discharge date, then you can make another appeal. Making another appeal means you are going on to Level 2 of the appeals process. Section 7.3 Step-by-step: How to make a Level 2 Appeal to change your hospital discharge date If the Quality Improvement Organization has turned down your appeal, and you stay in the hospital after your planned discharge date, then you can make a Level 2 Appeal. During a Level 2 Appeal, you ask the Quality Improvement Organization to take another look at the decision they made on your first appeal. Here are the steps for Level 2 of the appeal process: Step 1: You contact the Quality Improvement Organization again and ask for another review. You must ask for this review within 60 days after the day when the Quality Improvement Organization said no to your Level 1 Appeal. You can ask for this review only if you stayed in the hospital after the date that your coverage for the care ended. Step 2: The Quality Improvement Organization does a second review of your situation. Reviewers at the Quality Improvement Organization will take another careful look at all of the information related to your appeal. Step 3: Within 14 days, the Quality Improvement Organization reviewers will decide on your appeal and tell you their decision. If the review organization says yes: Our plan must reimburse you for our share of the costs of hospital care you have received since noon on the day after the date your first appeal was turned down by the Quality Improvement Organization. Our plan must continue providing coverage for your hospital care for as long as it is medically necessary. You must continue to pay your share of the costs and coverage limitations may apply. If the review organization says no: It means they agree with the decision they made to your Level 1 Appeal and will not change it. This is called upholding the decision. It is also called turning down your appeal. The notice you get will tell you in writing what you can do if you wish to continue with the review process. It will give you the details about how to go on to the next level of appeal, which is handled by a judge. Step 4: If the answer is no, you will need to decide whether you want to take your appeal further by going on to Level 3. There are three additional levels in the appeals process after Level 2 (for a total of five levels of appeal). If the review organization turns down your Level 2 Appeal, you can choose whether to accept that decision or whether to go on to Level 3 and make another appeal. At Level 3, your appeal is reviewed by a judge. Section 9 in this chapter tells more about Levels 3, 4, and 5 of the appeals process. Section 7.4 What if you miss the deadline for making your Level 1 Appeal? You can appeal to our plan instead As explained above in Section 7.2, you must act quickly to contact the Quality Improvement Organization to start your first appeal of your hospital discharge. (Quickly means before you leave the hospital and no later than your planned discharge date). If you miss the deadline for contacting this organization, there is another way to make your appeal. If you use this other way of making your appeal, the first two levels of appeal are different. Step-by-Step: How to make a Level 1 Alternate Appeal If you miss the deadline for contacting the Quality Improvement Organization, you can make an appeal to our plan, asking for a fast review. A fast review is an appeal that uses the fast deadlines instead of the standard deadlines. Legal TermsA fast review (or fast appeal) is also called an expedited review (or expedited appeal).Step 1: Contact our plan and ask for a fast review. For details on how to contact our plan, go to Chapter 2, Section 1 and look for the section called, [plans may edit section title as necessary:] How to contact our plan when you are making an appeal about your medical care. Be sure to ask for a fast review. This means you are asking us to give you an answer using the fast deadlines rather than the standard deadlines. Step 2: Our plan does a fast review of your planned discharge date, checking to see if it was medically appropriate. During this review, our plan takes a look at all of the information about your hospital stay. We check to see if your planned discharge date was medically appropriate. We will check to see if the decision about when you should leave the hospital was fair and followed all the rules. In this situation, we will use the fast deadlines rather than the standard deadlines for giving you the answer to this review. Step 3: Our plan gives you our decision within 72 hours after you ask for a fast review (fast appeal). If our plan says yes to your fast appeal, it means we have agreed with you that you still need to be in the hospital after the discharge date, and will keep providing your covered services for as long as it is medically necessary. It also means that we have agreed to reimburse you for our share of the costs of care you have received since the date when we said your coverage would end. (You must pay your share of the costs and there may be coverage limitations that apply.) If our plan says no to your fast appeal, we are saying that your planned discharge date was medically appropriate. Our coverage for your hospital services ends as of the day we said coverage would end. If you stayed in the hospital after your planned discharge date, then you may have to pay the full cost of hospital care you received after the planned discharge date. Step 4: If our plan says no to your fast appeal, your case will automatically be sent on to the next level of the appeals process. To make sure we were being fair when we said no to your fast appeal, our plan is required to send your appeal to the Independent Review Organization. When we do this, it means that you are automatically going on to Level 2 of the appeals process. Step-by-Step: How to make a Level 2 Alternate Appeal If our plan says no to your Level 1 Appeal, your case will automatically be sent on to the next level of the appeals process. During the Level 2 Appeal, the Independent Review Organization reviews the decision our plan made when we said no to your fast appeal. This organization decides whether the decision we made should be changed. Legal TermsThe formal name for the Independent Review Organization is the Independent Review Entity. It is sometimes called the IRE.Step 1: We will automatically forward your case to the Independent Review Organization. We are required to send the information for your Level 2 Appeal to the Independent Review Organization within 24 hours of when we tell you that we are saying no to your first appeal. (If you think we are not meeting this deadline or other deadlines, you can make a complaint. The complaint process is different from the appeal process. Section 10 of this chapter tells how to make a complaint.) Step 2: The Independent Review Organization does a fast review of your appeal. The reviewers give you an answer within 72 hours. The Independent Review Organization is an outside, independent organization that is hired by Medicare. This organization is not connected with our plan and it is not a government agency. This organization is a company chosen by Medicare to handle the job of being the Independent Review Organization. Medicare oversees its work. Reviewers at the Independent Review Organization will take a careful look at all of the information related to your appeal of your hospital discharge. If this organization says yes to your appeal, then our plan must reimburse you (pay you back) for our share of the costs of hospital care you have received since the date of your planned discharge. We must also continue the plans coverage of your hospital services for as long as it is medically necessary. You must continue to pay your share of the costs. If there are coverage limitations, these could limit how much we would reimburse or how long we would continue to cover your services. If this organization says no to your appeal, it means they agree with our plan that your planned hospital discharge date was medically appropriate. (This is called upholding the decision. It is also called turning down your appeal.) The notice you get from the Independent Review Organization will tell you in writing what you can do if you wish to continue with the review process. It will give you the details about how to go on to a Level 3 Appeal, which is handled by a judge. Step 3: If the Independent Review Organization turns down your appeal, you choose whether you want to take your appeal further. There are three additional levels in the appeals process after Level 2 (for a total of five levels of appeal). If reviewers say no to your Level 2 Appeal, you decide whether to accept their decision or go on to Level 3 and make a third appeal. Section 9 in this chapter tells more about Levels 3, 4, and 5 of the appeals process. SECTION 8 How to ask us to keep covering certain medical services if you think your coverage is ending too soon Section 8.1 This section is about three services only: Home health care, skilled nursing facility care, and Comprehensive Outpatient Rehabilitation Facility (CORF) services This section is about the following types of care only: Home health care services you are getting. Skilled nursing care you are getting as a patient in a skilled nursing facility. (To learn about requirements for being considered a skilled nursing facility, see Chapter 12, Definitions of important words.) Rehabilitation care you are getting as an outpatient at a Medicare-approved Comprehensive Outpatient Rehabilitation Facility (CORF). Usually, this means you are getting treatment for an illness or accident, or you are recovering from a major operation. (For more information about this type of facility, see Chapter 12, Definitions of important words.) When you are getting any of these types of care, you have the right to keep getting your covered services for that type of care for as long as the care is needed to diagnose and treat your illness or injury. For more information on your covered services, including your share of the cost and any limitations to coverage that may apply, see Chapter 4 of this booklet: Medical benefits chart (what is covered and what you pay). When our plan decides it is time to stop covering any of the three types of care for you, we are required to tell you in advance. When your coverage for that care ends, our plan will stop paying its share of the cost for your care. If you think we are ending the coverage of your care too soon, you can appeal our decision. This section tells you how to ask. Section 8.2 We will tell you in advance when your coverage will be ending 1. You receive a notice in writing. At least two days before our plan is going to stop covering your care, the agency or facility that is providing your care will give you a notice. The written notice tells you the date when our plan will stop covering the care for you. Legal TermsIn this written notice, we are telling you about a coverage decision we have made about when to stop covering your care. (For more information about coverage decisions, see Section 4 in this chapter.)The written notice also tells what you can do if you want to ask our plan to change this decision about when to end your care, and keep covering it for a longer period of time. Legal TermsIn telling what you can do, the written notice is telling how you can make an appeal. Making an appeal is a formal, legal way to ask our plan to change the coverage decision we have made about when to stop your care. (Section 8.3 below tells how you can make an appeal.) Legal TermsThe written notice is called the Notice of Medicare Non-Coverage. To get a sample copy, call Member Services or 1-800-MEDICARE (1-800-633-4227, 24 hours a day, 7 days a week. TTY users should call 1-877-486-2048.). Or see a copy online at http://www.cms.hhs.gov/BNI/2. You must sign the written notice to show that you received it. You or someone who is acting on your behalf must sign the notice. (Section 4 tells how you can give written permission to someone else to act as your representative.) Signing the notice shows only that you have received the information about when your coverage will stop. Signing it does not mean you agree with the plan that its time to stop getting the care. Section 8.3 Step-by-step: How to make a Level 1 Appeal to have our plan cover your care for a longer time If you want to ask us to cover your care for a longer period of time, you will need to use the appeals process to make this request. Before you start, understand what you need to do and what the deadlines are. Follow the process. Each step in the first two levels of the appeals process is explained below. Meet the deadlines. The deadlines are important. Be sure that you understand and follow the deadlines that apply to things you must do. There are also deadlines our plan must follow. (If you think we are not meeting our deadlines, you can file a complaint. Section 10 of this chapter tells you how to file a complaint.) Ask for help if you need it. If you have questions or need help at any time, please call Member Services (phone numbers are on the front cover of this booklet). Or call your State Health Insurance Assistance Program, a government organization that provides personalized assistance (see Section 2 of this chapter). During a Level 1 Appeal, the Quality Improvement Organization reviews your appeal and decides whether to change the decision made by our plan. Legal TermsWhen you start the appeal process by making an appeal, it is called the first level of appeal or Level 1 Appeal.Step 1: Make your Level 1 Appeal: contact the Quality Improvement Organization in your state and ask for a review. You must act quickly. What is the Quality Improvement Organization? This organization is a group of doctors and other health care experts who are paid by the Federal government. These experts are not part of our plan. They check on the quality of care received by people with Medicare and review plan decisions about when its time to stop covering certain kinds of medical care. How can you contact this organization? The written notice you received tells you how to reach this organization. (Or find the name, address, and phone number of the Quality Improvement Organization for your state in Chapter 2, Section 4, of this booklet.) What should you ask for? Ask this organization to do an independent review of whether it is medically appropriate for our plan to end coverage for your medical services. Your deadline for contacting this organization. You must contact the Quality Improvement Organization to start your appeal no later than noon of the day after you receive the written notice telling you when we will stop covering your care. If you miss the deadline for contacting the Quality Improvement Organization about your appeal, you can make your appeal directly to our plan instead. For details about this other way to make your appeal, see Section 8.4. Step 2: The Quality Improvement Organization conducts an independent review of your case. What happens during this review? Health professionals at the Quality Improvement Organization (we will call them the reviewers for short) will ask you (or your representative) why you believe coverage for the services should continue. You dont have to prepare anything in writing, but you may do so if you wish. The review organization will also look at your medical information, talk with your doctor, and review information that our plan has given to them. During this review process, you will also get a written notice from the plan that gives our reasons for wanting to end the plans coverage for your services. Legal TermsThis notice explanation is called the Detailed Explanation of Non-Coverage. Step 3: Within one full day after they have all the information they need, the reviewers will tell you their decision. What happens if the reviewers say yes to your appeal? If the reviewers say yes to your appeal, then our plan must keep providing your covered services for as long as it is medically necessary. You will have to keep paying your share of the costs (such as deductibles or copayments, if these apply). In addition, there may be limitations on your covered services (see Chapter 4 of this booklet). What happens if the reviewers say no to your appeal? If the reviewers say no to your appeal, then your coverage will end on the date we have told you. Our plan will stop paying its share of the costs of this care. If you decide to keep getting the home health care, or skilled nursing facility care, or Comprehensive Outpatient Rehabilitation Facility (CORF) services after this date when your coverage ends, then you will have to pay the full cost of this care yourself. Step 4: If the answer to your Level 1 Appeal is no, you decide if you want to make another appeal. This first appeal you make is Level 1 of the appeals process. If reviewers say no to your Level 1 Appeal and you choose to continue getting care after your coverage for the care has ended then you can make another appeal. Making another appeal means you are going on to Level 2 of the appeals process. Section 8.4 Step-by-step: How to make a Level 2 Appeal to have our plan cover your care for a longer time If the Quality Improvement Organization has turned down your appeal and you choose to continue getting care after your coverage for the care has ended, then you can make a Level 2 Appeal. During a Level 2 Appeal, you ask the Quality Improvement Organization to take another look at the decision they made on your first appeal. Here are the steps for Level 2 of the appeal process: Step 1: You contact the Quality Improvement Organization again and ask for another review. You must ask for this review within 60 days after the day when the Quality Improvement Organization said no to your Level 1 Appeal. You can ask for this review only if you continued getting care after the date that your coverage for the care ended. Step 2: The Quality Improvement Organization does a second review of your situation. Reviewers at the Quality Improvement Organization will take another careful look at all of the information related to your appeal. Step 3: Within 14 days, the Quality Improvement Organization reviewers will decide on your appeal and tell you their decision. What happens if the review organization says yes to your appeal? Our plan must reimburse you for our share of the costs of care you have received since the date when we said your coverage would end. Our plan must continue providing coverage for the care for as long as it is medically necessary. You must continue to pay your share of the costs and there may be coverage limitations that apply. What happens if the review organization says no? It means they agree with the decision they made to your Level 1 Appeal and will not change it. (This is called upholding the decision. It is also called turning down your appeal.) The notice you get will tell you in writing what you can do if you wish to continue with the review process. It will give you the details about how to go on to the next level of appeal, which is handled by a judge. Step 4: If the answer is no, you will need to decide whether you want to take your appeal further. There are three additional levels of appeal after Level 2, for a total of five levels of appeal. If reviewers turn down your Level 2 Appeal, you can choose whether to accept that decision or whether to go on to Level 3 and make another appeal. At Level 3, your appeal is reviewed by a judge. Section 9 in this chapter tells more about Levels 3, 4, and 5 of the appeals process. Section 8.5 What if you miss the deadline for making your Level 1 Appeal? You can appeal to our plan instead As explained above in Section 9.3, you must act quickly to contact the Quality Improvement Organization to start your first appeal (within a day or two, at the most). If you miss the deadline for contacting this organization, there is another way to make your appeal. If you use this other way of making your appeal, the first two levels of appeal are different. Step-by-Step: How to make a Level 1 Alternate Appeal If you miss the deadline for contacting the Quality Improvement Organization, you can make an appeal to our plan, asking for a fast review. A fast review is an appeal that uses the fast deadlines instead of the standard deadlines. Here are the steps for a Level 1 Alternate Appeal: Legal TermsA fast review (or fast appeal) is also called an expedited review (or expedited appeal). Step 1: Contact our plan and ask for a fast review. For details on how to contact our plan, go to Chapter 2, Section 1 and look for the section called, [plans may edit section title as necessary:] How to contact our plan when you are making an appeal about your medical care. Be sure to ask for a fast review. This means you are asking us to give you an answer using the fast deadlines rather than the standard deadlines. Step 2: Our plan does a fast review of the decision we made about when to stop coverage for your services. During this review, our plan takes another look at all of the information about your case. We check to see if we were being fair and following all the rules when we set the date for ending the plans coverage for services you were receiving. We will use the fast deadlines rather than the standard deadlines for giving you the answer to this review. (Usually, if you make an appeal to our plan and ask for a fast review, we are allowed to decide whether to agree to your request and give you a fast review. But in this situation, the rules require us to give you a fast response if you ask for it.) Step 3: Our plan gives you our decision within 72 hours after you ask for a fast review (fast appeal). If our plan says yes to your fast appeal, it means we have agreed with you that you need services longer, and will keep providing your covered services for as long as it is medically necessary. It also means that we have agreed to reimburse you for our share of the costs of care you have received since the date when we said your coverage would end. (You must pay your share of the costs and there may be coverage limitations that apply.) If our plan says no to your fast appeal, then your coverage will end on the date we have told you and our plan will not pay after this date. Our plan will stop paying its share of the costs of this care. If you continued to get home health care, or skilled nursing facility care, or Comprehensive Outpatient Rehabilitation Facility (CORF) services after the date when we said your coverage would end, then you will have to pay the full cost of this care yourself. Step 4: If our plan says no to your fast appeal, your case will automatically go on to the next level of the appeals process. To make sure we were being fair when we said no to your fast appeal, our plan is required to send your appeal to the Independent Review Organization. When we do this, it means that you are automatically going on to Level 2 of the appeals process. Step-by-Step: How to make a Level 2 Alternate Appeal If our plan says no to your Level 1 Appeal, your case will automatically be sent on to the next level of the appeals process. During the Level 2 Appeal, the Independent Review Organization reviews the decision our plan made when we said no to your fast appeal. This organization decides whether the decision we made should be changed. Legal TermsThe formal name for the Independent Review Organization is the Independent Review Entity. It is sometimes called the IRE.Step 1: We will automatically forward your case to the Independent Review Organization. We are required to send the information for your Level 2 Appeal to the Independent Review Organization within 24 hours of when we tell you that we are saying no to your first appeal. (If you think we are not meeting this deadline or other deadlines, you can make a complaint. The complaint process is different from the appeal process. Section 1 of this chapter tells how to make a complaint.) Step 2: The Independent Review Organization does a fast review of your appeal. The reviewers give you an answer within 72 hours. The Independent Review Organization is an outside, independent organization that is hired by Medicare. This organization is not connected with our plan and it is not a government agency. This organization is a company chosen by Medicare to handle the job of being the Independent Review Organization. Medicare oversees its work. Reviewers at the Independent Review Organization will take a careful look at all of the information related to your appeal. If this organization says yes to your appeal, then our plan must reimburse you (pay you back) for our share of the costs of care you have received since the date when we said your coverage would end. We must also continue to cover the care for as long as it is medically necessary. You must continue to pay your share of the costs. If there are coverage limitations, these could limit how much we would reimburse or how long we would continue to cover your services. If this organization says no to your appeal, it means they agree with the decision our plan made to your first appeal and will not change it. (This is called upholding the decision. It is also called turning down your appeal.) The notice you get from the Independent Review Organization will tell you in writing what you can do if you wish to continue with the review process. It will give you the details about how to go on to a Level 3 Appeal. Step 3: If the Independent Review Organization turns down your appeal, you choose whether you want to take your appeal further. There are three additional levels of appeal after Level 2, for a total of five levels of appeal. If reviewers say no to your Level 2 Appeal, you can choose whether to accept that decision or whether to go on to Level 3 and make another appeal. At Level 3, your appeal is reviewed by a judge. Section 9 in this chapter tells more about Levels 3, 4, and 5 of the appeals process. SECTION 9 Taking your appeal to Level 3 and beyond Section 9.1 Levels of Appeal 3, 4, and 5 for Medical Service Appeals This section may be appropriate for you if you have made a Level 1 Appeal and a Level 2 Appeal, and both of your appeals have been turned down. If the dollar value of the Medicare covered item or medical service you have appealed meets certain minimum levels, you may be able to go on to additional levels of appeal. If the dollar value is less than the minimum level, you cannot appeal any further. If the dollar value is high enough, the written response you receive to your Level 2 Appeal will explain who to contact and what to do to ask for a Level 3 Appeal. For most situations that involve appeals, the last three levels of appeal work in much the same way. Here is who handles the review of your appeal at each of these levels. Level 3 AppealA judge who works for the Federal government will review your appeal and give you an answer. This judge is called an Administrative Law Judge.If the answer is yes, the appeals process may or may not be over - We will decide whether to appeal this decision to Level 4. Unlike a decision at Level 2 (Independent Review Organization), we have the right to appeal a Level 3 decision that is favorable to you. If we decide not to appeal the decision, we must authorize or provide you with the service within 60 days after receiving the judges decision. If we decide to appeal the decision, we will send you a copy of the Level 4 Appeal request with any accompanying documents. We may wait for the Level 4 Appeal decision before authorizing or providing the service in dispute. If the answer is no, the appeals process may or may not be over. If you decide to accept this decision that turns down your appeal, the appeals process is over. If you do not want to accept the decision, you can continue to the next level of the review process. If the administrative law judge says no to your appeal, the notice you get will tell you what to do next if you choose to continue with your appeal. Level 4 AppealThe Medicare Appeals Council will review your appeal and give you an answer. The Medicare Appeals Council works for the Federal government.If the answer is yes, or if the Medicare Appeals Council denies our request to review a favorable Level 3 Appeal decision, the appeals process may or may not be over - We will decide whether to appeal this decision to Level 5. Unlike a decision at Level 2 (Independent Review Organization), we have the right to appeal a Level 4 decision that is favorable to you. If we decide not to appeal the decision, we must authorize or provide you with the service within 60 days after receiving the Medicare Appeals Councils decision. If we decide to appeal the decision, we will let you know in writing. If the answer is no or if the Medicare Appeals Council denies the review request, the appeals process may or may not be over. If you decide to accept this decision that turns down your appeal, the appeals process is over. If you do not want to accept the decision, you might be able to continue to the next level of the review process. It depends on your situation. If the Medicare Appeals Council says no to your appeal, the notice you get will tell you whether the rules allow you to go on to a Level 5 Appeal. If the rules allow you to go on, the written notice will also tell you who to contact and what to do next if you choose to continue with your appeal. Level 5 AppealA judge at the Federal District Court will review your appeal. This is the last stage of the appeals process. This is the last step of the administrative appeals process. Section 9.2 Levels of Appeal 3, 4, and 5 for Part D Drug Appeals This section may be appropriate for you if you have made a Level 1 Appeal and a Level 2 Appeal, and both of your appeals have been turned down. If the dollar value of the drug you have appealed meets certain minimum levels, you may be able to go on to additional levels of appeal. If the dollar value is less than the minimum level, you cannot appeal any further. If the dollar value is high enough, the written response you receive to your Level 2 Appeal will explain who to contact and what to do to ask for a Level 3 Appeal. For most situations that involve appeals, the last three levels of appeal work in much the same way. Here is who handles the review of your appeal at each of these levels. Level 3 AppealA judge who works for the Federal government will review your appeal and give you an answer. This judge is called an Administrative Law Judge.If the answer is yes, the appeals process is over. What you asked for in the appeal has been approved. If the answer is no, the appeals process may or may not be over. If you decide to accept this decision that turns down your appeal, the appeals process is over. If you do not want to accept the decision, you can continue to the next level of the review process. If the administrative judge says no to your appeal, the notice you get will tell you what to do next if you choose to continue with your appeal. Level 4 AppealThe Medicare Appeals Council will review your appeal and give you an answer. The Medicare Appeals Council works for the Federal government.If the answer is yes, the appeals process is over. What you asked for in the appeal has been approved. If the answer is no, the appeals process may or may not be over. If you decide to accept this decision that turns down your appeal, the appeals process is over. If you do not want to accept the decision, you might be able to continue to the next level of the review process. It depends on your situation. Whenever the reviewer says no to your appeal, the notice you get will tell you whether the rules allow you to go on to another level of appeal. If the rules allow you to go on, the written notice will also tell you who to contact and what to do next if you choose to continue with your appeal. Level 5 AppealA judge at the Federal District Court will review your appeal. This is the last stage of the appeals process. This is the last step of the administrative appeals process. MAKING COMPLAINTS SECTION 10 How to make a complaint about quality of care, waiting times, customer service, or other concerns ?If your problem is about decisions related to benefits, coverage, or payment, then this section is not for you. Instead, you need to use the process for coverage decisions and appeals. Go to Section 4 of this chapter.Section 10.1 What kinds of problems are handled by the complaint process? This section explains how to use the process for making complaints. The complaint process is used for certain types of problems only. This includes problems related to quality of care, waiting times, and the customer service you receive. Here are examples of the kinds of problems handled by the complaint process.   Section 10.2 The formal name for making a complaint is filing a grievance Legal TermsWhat this section calls a complaint is also called a grievance. Another term for making a complaint is filing a grievance. Another way to say using the process for complaints is using the process for filing a grievance. Section 10.3 Step-by-step: Making a complaint Step 1: Contact us promptly either by phone or in writing. Usually, calling Member Services is the first step. If there is anything else you need to do, Member Services will let you know. [Insert phone number, TTY, and hours of operation.] If you do not wish to call (or you called and were not satisfied), you can put your complaint in writing and send it to us. If you do this, it means that we will use our formal procedure for answering grievances. Heres how it works: [Insert description of the procedures (including time frames) and instructions about what members need to do if they want to use the formal process for making a complaint. Describe expedited grievance time frames for grievances about decisions to not conduct expedited organization/coverage determinations or reconsiderations/redeterminations.] Whether you call or write, you should contact Member Services right away. The complaint must be made within 90 days after you had the problem you want to complain about. If you are making a complaint because we denied your request for a fast response to a coverage decision or appeal, we will automatically give you a fast complaint. If you have a fast complaint, it means we will give you an answer within 72 hours. Legal TermsWhat this section calls a fast complaint is also called a fast grievance. Step 2: We look into your complaint and give you our answer. If possible, we will answer you right away. If you call us with a complaint, we may be able to give you an answer on the same phone call. If your health condition requires us to answer quickly, we will do that. Most complaints are answered in 30 days, but we may take up to 44 days. If we need more information and the delay is in your best interest or if you ask for more time, we can take up to 14 more days (44 days total) to answer your complaint. If we do not agree with some or all of your complaint or dont take responsibility for the problem you are complaining about, we will let you know. Our response will include our reasons for this answer. We must respond whether we agree with the complaint or not. Step 3 If you are not satisfied with our decision, you may call or write to the Minnesota Department of Health To file a complaint with the Minnesota Department of Health Write to: Minnesota Department of Health Health Policy and Systems Compliance Division Managed Care Systems P.O. Box 64882 St. Paul, MN 55164-0882 Or Call: 651-201-5100 (Twin Cities metro) or toll-free 1-800-657-3916 Section 10.4 You can also make complaints about quality of care to the Quality Improvement Organization You can make your complaint about the quality of care you received to our plan by using the step-by-step process outlined above. When your complaint is about quality of care, you also have two extra options: You can make your complaint to the Quality Improvement Organization. If you prefer, you can make your complaint about the quality of care you received directly to this organization (without making the complaint to our plan). To find the name, address, and phone number of the Quality Improvement Organization in your state, look in Chapter 2, Section 4, of this booklet. If you make a complaint to this organization, we will work together with them to resolve your complaint. Or you can make your complaint to both at the same time. If you wish, you can make your complaint about quality of care to our plan and also to the Quality Improvement Organization. Chapter 10. Ending your membership in the plan  TOC \t "Section Heading Ch 10,1,Section SubHeading 1 Ch 10,2" SECTION 1 Introduction  PAGEREF _Toc110592372 \h 172 Section 1.1 This chapter focuses on ending your membership in our plan  PAGEREF _Toc110592373 \h 172 SECTION 2 When can you end your membership in our plan?  PAGEREF _Toc110592374 \h 172 Section 2.1 You can end your membership during the Annual Enrollment Period  PAGEREF _Toc110592375 \h 172 Section 2.2 You can end your membership during the Medicare Advantage Open Enrollment Period, but your plan choices are more limited  PAGEREF _Toc110592376 \h 172 Section 2.3 In certain situations, you can end your membership during a Special Enrollment Period  PAGEREF _Toc110592377 \h 172 Section 2.4 Where can you get more information about when you can end your membership?  PAGEREF _Toc110592378 \h 173 SECTION 3 How do you end your membership in our plan?  PAGEREF _Toc110592379 \h 174 Section 3.1 Usually, you end your membership by enrolling in another plan  PAGEREF _Toc110592380 \h 174 SECTION 4 Until your membership ends, you must keep getting your medical services and drugs through our plan  PAGEREF _Toc110592381 \h 174 Section 4.1 Until your membership ends, you are still a member of our plan  PAGEREF _Toc110592382 \h 174 SECTION 5 [Insert plan name] must end your membership in the plan in certain situations  PAGEREF _Toc110592383 \h 175 Section 5.1 When must we end your membership in the plan?  PAGEREF _Toc110592384 \h 175 Section 5.2 We cannot ask you to leave our plan for any reason related to your health  PAGEREF _Toc110592385 \h 176 Section 5.3 You have the right to make a complaint if we end your membership in our plan  PAGEREF _Toc110592386 \h 177  SECTION 1 Introduction [Dual eligible SNPs may modify this chapter as necessary to reflect members continuous rights to change plans.] Section 1.1 This chapter focuses on ending your membership in our plan Ending your membership in [insert plan name] may be voluntary (your own choice) or involuntary (not your own choice): You might leave our plan because you have decided that you want to leave. You can end your membership in the plan at any time. The process for voluntarily ending your membership varies depending on what type of new coverage you are choosing. Section 3 tells you how to end your membership in each situation. There are also limited situations where you do not choose to leave, but we are required to end your membership. Section 5 tells you about situations when we must end your membership. If you are leaving our plan, you must continue to get your covered services through our plan until your membership ends. SECTION 2 When can you end your membership in our plan? You may end your membership in our plan at any time. You will be enrolled until the end of the month Section 2.3 You can end your membership during a Special Enrollment Period Members of [insert plan name] are eligible to end their membership at any time of the year. This is known as a Special Enrollment Period. Who is eligible for a Special Enrollment Period? If any of the following situations apply to you, you are eligible to end your membership during a Special Enrollment Period. If you have Medicaid. If you are eligible for Extra Help with paying for your Medicare prescriptions. If you live in a facility, such as a nursing home. What can you do? Our Plan currently provides both Medicare and Medical Assistance services. By disenrolling from our Plan, your coverage for Medicare and Medical Assistance services will change. In some cases you have choices to make. Coverage for Medical Assistance If you choose to leave our Plan, you will be automatically enrolled in our Plans Minnesota Senior Care Plus (MSC+) plan for your Medical Assistance services if our MSC+ plan is offered in your county. You can ask in writing to be enrolled in the MSC+ plan you were enrolled in before our Plans MSHO enrollment. If our Plan does not have an MSC+ plan in your county, you will be enrolled in the MSC+ plan that is available in your county. Contact your county financial worker if you have questions. If you currently have a medical spenddown and you choose to leave our Plan, your Medical Assistance will be provided fee-for-service. You will not be enrolled in another health plan for Medical Assistance services. Coverage for Medicare If you are eligible to end your membership because of a special situation, you can choose to change both your Medicare health coverage and Part D prescription drug coverage. This means you can choose any of the following types of plans: Another Medicare Advantage plan. (You can choose a plan that covers prescription drugs or one that does not cover prescription drugs.) Original Medicare with a separate Medicare prescription drug plan. or Original Medicare without a separate Medicare prescription drug plan. Note: If you disenroll from a Medicare prescription drug plan and go without creditable prescription drug coverage, you may need to pay a late enrollment penalty if you join a Medicare drug plan later. (Creditable coverage means the coverage is at least as good as Medicares standard prescription drug coverage.) When will your membership end? Your membership will usually end on the first day of the month after we receive your request to change your plan. Section 2.4 Where can you get more information about when you can end your membership? If you have any questions or would like more information on when you can end your membership: You can call Member Services (phone numbers are on the cover of this booklet). You can find the information in the Medicare & You 2010 handbook. Everyone with Medicare receives a copy of Medicare & You each fall. Those new to Medicare receive it within a month after first signing up. You can also download a copy from the Medicare website (http:// HYPERLINK "http://www.medicare.gov" www.medicare.gov). Or, you can order a printed copy by calling Medicare at the number below. You can contact Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day, 7 days a week. TTY users should call 1-877-486-2048. SECTION 3 How do you end your membership in our plan? Section 3.1 You can end your membership by enrolling in another plan Usually, to end your membership in our plan, you can enroll in another health plan at any time. One exception is when you want to switch from our plan to Original Medicare without a Medicare prescription drug plan. In this situation, you must contact [insert plan name] MemberServices and ask to be disenrolled from our plan. SECTION 4 Until your membership ends, you must keep getting your medical services and drugs through our plan Section 4.1 Until your membership ends, you are still a member of our plan If you leave [insert plan name], it may take time before your membership ends and your new Medicare and Medical Assistance coverage goes into effect. (See Section 2 for information on when your new coverage begins.) During this time, you must continue to get your covered services and prescription drugs through our plan. You should continue to use our network pharmacies to get your prescriptions filled until your membership in our plan ends. Usually, your prescription drugs are only covered if they are filled at a network pharmacy [insert if applicable: including through our mail-order pharmacy services.] If you are hospitalized on the day that your membership ends, you will usually be covered by our plan until you are discharged (even if you are discharged after your new health coverage begins). SECTION 5 [Insert plan name] must end your membership in the plan in certain situations Section 5.1 When must we end your membership in the plan? [Insert plan name] must end your membership in the plan if any of the following happen: If you do not stay continuously enrolled in Medicare Part A and Part B. If you lose eligibility for Medical Assistance - If you have Medicare and lose eligibility for Medical Assistance, our Plan will continue to provide plan benefits for up to three months. If after three months you have not regained Medical Assistance, coverage with our Plan will end. You will need to choose a new Part D plan in order to continue getting coverage for Medicare covered drugs. If you need help, you can call the Senior Linkage Line at 1-866-333-2466. If you do not pay your medical spenddown, if applicable. If you move out of our service area for more than six months. [Plans with visitor/traveler benefits should revise this bullet to indicate when members must be disenrolled from the plan.] If you move or take a long trip, you need to call Member Services to find out if the place you are moving or traveling to is in our plans area. [Plans with visitor/traveler benefits, insert: Chapter 3 and Chapter 4 give more information about getting care when you are away from the service area.] [Plans with grandfathered members who were outside of area prior to January 1999, insert: If you have been a member of our plan continuously since before January 1999 and you were living outside of our service area before January 1999, you may continue your membership. However, if you move and your move is to another location that is outside of our service area, you will be disenrolled from our plan.] If you lie about or withhold information about other insurance you have that provides prescription drug coverage. [Omit if not applicable] If you intentionally give us incorrect information when you are enrolling in our plan and that information affects your eligibility for our plan.] [Omit bullet and sub-bullet if not applicable] If you continuously behave in a way that is disruptive and makes it difficult for us to provide medical care for you and other members of our plan. We cannot make you leave our plan for this reason unless we get permission from Medicare first. [Omit bullet and sub-bullet if not applicable] If you let someone else use your membership card to get medical care. If we end your membership because of this reason, Medicare may have your case investigated by the Inspector General. [Omit bullet and sub-bullet if not applicable. Plans with different disenrollment policies for dual eligible members and/or members with LIS who do not pay plan premiums may edit these bullets as necessary to reflect their policies.] If you do not pay the plan premiums for [insert length of grace period]. We must notify you in writing that you have [insert length of grace period] to pay the plan premium before we end your membership. [Disproportionate share SNP w/grandfathering insert: If you enrolled after January 1, 2010 and you do not meet the plans special eligibility requirements as stated in Chapter 1, section 2.1.] [All other SNPs insert: You do not meet the plans special eligibility requirements as stated in Chapter 1, section 2.1] [SNPs can insert rules for members who no longer meet special eligibility requirements.] Where can you get more information? If you have questions or would like more information on when we can end your membership: You can call Member Services for more information (phone numbers are on the cover of this booklet). Section 5.2 We cannot ask you to leave our plan for any reason related to your health [Chronic care SNPs, delete this section.] What should you do if this happens? If you feel that you are being asked to leave our plan because of a health-related reason, you should call Medicare at 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048. You may call 24 hours a day, 7 days a week. Section 5.3 You have the right to make a complaint if we end your membership in our plan If we end your membership in our plan, we must tell you our reasons in writing for ending your membership. We must also explain how you can make a complaint about our decision to end your membership. You can also look in Chapter 9, Section 10 for information about how to make a complaint. Chapter 11. Legal notices  TOC \t "Section Heading Ch 11,1" SECTION 1 Notice about governing law  PAGEREF _Toc110592397 \h 179 SECTION 2 Notice about nondiscrimination  PAGEREF _Toc110592398 \h 179  [Note: You may include other legal notices, such as a notice of member non-liability or a notice about third-party liability. These notices may only be added if they conform to Medicare laws and regulations.] SECTION 1 Notice about governing law Many laws apply to this Certificate of Coverage and some additional provisions may apply because they are required by law. This may affect your rights and responsibilities even if the laws are not included or explained in this document. The principal law that applies to this document is Title XVIII of the Social Security Act and the regulations created under the Social Security Act by the Centers for Medicare & Medicaid Services, or CMS. In addition, other Federal laws may apply and, under certain circumstances, the laws of the state you live in. SECTION 2 Notice about nondiscrimination We dont discriminate based on a persons race, disability, religion, sex, health, ethnicity, creed, age, or national origin. All organizations that provide Medicare Advantage Plans, like our plan, must obey Federal laws against discrimination, including Title VI of the Civil Rights Act of 1964, the Rehabilitation Act of 1973, the Age Discrimination Act of 1975, the Americans with Disabilities Act, all other laws that apply to organizations that get Federal funding, and any other laws and rules that apply for any other reason. SECTION 3Subrogation or other claimsYou may have other sources of payment for your medical care. They might be from another person, group, insurance company or other organization. Federal and State laws provide that Medical Assistance benefits pay only if no other source of payment exists. If you have a claim against another source for injuries, we will make a separate claim for medical care we covered for you. The laws require you to help us do this. The claim may be recovered from any source that may be responsible for payment of the medical care we covered for you. The amount of the claim will not be more than Federal and State laws allow. [Note: You may include other legal notices, such as a notice of member non-liability or a notice about third-party liability. These notices may only be added if they conform to Medicare laws and regulations.] Chapter 12. Definitions of important words [Plans should insert definitions as appropriate to the plan type described in the EOC. You may insert definitions not included in this model and exclude model definitions not applicable to your plan, or to your contractual obligations with CMS or enrolled Medicare beneficiaries.] [If you use any of the following terms in your EOC, you must add a definition of the term to the first section where you use it and here in Chapter 12 with a reference from the section where you use it: IPA, network, PHO, plan medical group, Point of Service.] [Plans with a POS option: Provide definitions of: allowed amount, balance billing, coinsurance and maximum charge], and prescription drug benefit manager.] Action Our Plans denial or decrease of a requested service. This includes: the denial or decrease in the type or level of service; the decrease, suspension, or stopping of a service that was approved before; the denial of all or part of payment for a service; not providing services in a reasonable amount of time; not acting within required time frames for grievances and appeals; denial of a members request to get services out of network for members living in a rural area with only one health plan. Anesthesia Drugs that make you fall asleep for an operation. Appeal An appeal is something you do if you disagree with a decision to deny a request for health care services or prescription drugs or payment for services or drugs you already received. You may also make an appeal if you disagree with a decision to stop services that you are receiving. For example, you may ask for an appeal if our Plan doesnt pay for a drug, item, or service you think you should be able to receive. Chapter 9 explains appeals, including the process involved in making an appeal. Autopsy An exam that is done on the body of someone who dies. It is done to find out what caused a persons death. Benefit Period For [both our Plan and] Original Medicare, a benefit period is used to determine coverage for inpatient stays in hospitals and skilled nursing facilities. [Plans that offer a more generous benefit period, revise the following sentences to reflect the Plans benefit period.] A benefit period begins on the first day you go to a Medicare-covered inpatient hospital or a skilled nursing facility. The benefit period ends when you havent been an inpatient at any hospital or SNF for 60 days in a row. If you go to the hospital (or SNF) after one benefit period has ended, a new benefit period begins. There is no limit to the number of benefit periods you can have. The type of care that is covered depends on whether you are considered an inpatient for hospital and SNF stays. You must be admitted to the hospital as an inpatient, not just under observation. You are an inpatient in a SNF only if your care in the SNF meets certain standards for skilled level of care. Specifically, in order to be an inpatient in a SNF, you must need daily skilled-nursing or skilled-rehabilitation care, or both. Brand Name Drug A prescription drug that is manufactured and sold by the pharmaceutical company that originally researched and developed the drug. Brand name drugs have the same active-ingredient formula as the generic version of the drug. However, generic drugs are manufactured and sold by other drug manufacturers and are generally not available until after the patent on the brand name drug has expired. Care Coordinator A person who develops, coordinates, and provides supports and services stated in the care plan. This person works in partnership with the Plan. Catastrophic Coverage Stage The stage in the Part D Drug Benefit where you pay a low copayment or coinsurance for your drugs after you or other qualified parties on your behalf have spent $[insert TrOOP amount] in covered drugs during the covered year. Centers for Medicare & Medicaid Services (CMS) The Federal agency that runs Medicare. Chapter 2 explains how to contact CMS. Certificate of Coverage (COC) and Disclosure Information This document, along with your enrollment form and any other attachments, riders, or other optional coverage selected, which explains your coverage, what we must do, your rights, and what you have to do as a member of our plan. Chemical Dependency Using alcohol or drugs in a way that harms you. Clinical Trial A qualified medical study test that is: subject to a defined peer review; sponsored by a clinical research program that meets federal and state rules and approved standards; and whose true results are reported. Comprehensive Outpatient Rehabilitation Facility (CORF) A facility that mainly provides rehabilitation services after an illness or injury, and provides a variety of services including physicians services, physical therapy, social or psychological services, and outpatient rehabilitation. Co-payment or co-pay An amount that you are responsible to pay to the provider. Some adults must pay a part of the providers charges for some services. Co-payments are usually paid at the time service is provided. Cost-sharing Cost-sharing refers to amounts that a member has to pay when Part D drugs are received. It includes any fixed copayment amounts that a plan may require be paid when specific drugs are received. Cost-sharing Tier Every drug on the list of covered drugs is in one of [insert number of tiers] cost-sharing tiers. In general, the higher the cost-sharing tier, the higher your cost for the drug. Coverage Determination A decision about whether a medical service or drug prescribed for you is covered by the plan and the amount, if any, you are required to pay for the service or prescription. In general, if you bring your prescription to a pharmacy and the pharmacy tells you the prescription isnt covered under your plan, that isnt a coverage determination. You need to call or write to your plan to ask for a formal decision about the coverage if you disagree. Covered Drugs The term we use to mean all of the prescription drugs covered by our Plan. Covered Services The general term we use to mean all of the health care services and supplies that are covered by our Plan. Creditable Prescription Drug Coverage Prescription drug coverage (for example, from an employer or union) that is expected to cover, on average, at least as much as Medicares standard prescription drug coverage. People who have this kind of coverage when they become eligible for Medicare can generally keep that coverage without paying a penalty, if they decide to enroll in Medicare prescription drug coverage later. Direct Access Services You can go to any provider in our Plans network to get these services. You do not need a referral or service authorization before getting services. Disenroll or Disenrollment The process of ending your membership in our plan. Disenrollment may be voluntary (your own choice) or involuntary (not your own choice). Durable Medical Equipment Equipment that can withstand repeated use. It is used for a medical purpose. The equipment must be medically necessary and ordered by a doctor. Examples of durable medical equipment include walkers, wheelchairs, hospital beds and equipment that supplies a person with oxygen,. Emergency A condition that needs treatment right away. It is a condition that a reasonable person believes needs prompt care, and without prompt care, it could cause: serious physical or mental harm; continuing severe pain; serious damage to body functions, organs, or parts; or death. Emergency Care Covered services that are: 1) rendered by a provider qualified to furnish emergency services; and 2) needed to evaluate or stabilize an emergency medical condition. Exception A type of coverage determination that, if approved, allows you to get a drug that is not on your plans formulary (a formulary exception), or get a non-preferred drug at the preferred cost-sharing level (a tiering exception). You may also request an exception if your plan requires you to try another drug before receiving the drug you are requesting, or the plan limits the quantity or dosage of the drug you are requesting (a formulary exception). Experimental A service that has not been proven to be safe and effective. External Quality Review Study A study about how quality, timeliness and access of care are provided by us. This study is external and independent. Family Planning Information, services, and supplies that help a person decide about having children. These decisions include choosing to have a child, when to have a child, or not to have a child. Formulary See List of Covered Drugs. Generic Drug A prescription drug that is approved by the Food and Drug Administration (FDA) as having the same active ingredient(s) as the brand-name drug. Generally, generic drugs cost less than brand-name drugs. Grievance - A type of complaint you make about us or one of our network providers or pharmacies, including a complaint concerning the quality of your care. This type of complaint does not involve coverage or payment disputes Home and Community Based Services - Additional services that are provided to help you remain in your home.. Home Health Aide A home health aide provides services that dont need the skills of a licensed nurse or therapist, such as help with personal care (e.g., bathing, using the toilet, dressing, or carrying out the prescribed exercises). Home health aides do not have a nursing license or provide therapy. Home health care Care that is provided in your home that is medically necessary and ordered by a doctor. Inpatient Care Health care that you get when you are admitted to a hospital. Inpatient Hospital Stay - A stay in a hospital or treatment center that usually lasts 24 hours or more. Initial Coverage Limit The maximum limit of coverage under the Initial Coverage Stage. Initial Coverage Stage This is the stage [insert if applicable: after you have met your deductible and] before your total drug expenses, have reached $[insert initial coverage limit], including amounts youve paid and what our Plan has paid on your behalf. List of Covered Drugs (Formulary or Drug List) A list of covered drugs provided by the plan. The drugs on this list are selected by the plan with the help of doctors and pharmacists. The list includes both brand-name and generic drugs. Long Term Care Consultation A review done to find the type and level of services needed. Low Income Subsidy/Extra Help A Medicare program to help people with limited income and resources pay Medicare prescription drug program costs, such as premiums, deductibles, and coinsurance. Medically Necessary Care that is appropriate for the condition. This includes care related to physical conditions and mental health. It includes the kind and level of service. It includes the number of treatments. It also includes where you get the service and how long it continues. Medically necessary care must: -be the service that other providers would usually order. -help you get better, or stay as well as you are. -help stop the condition from getting worse. -help prevent and find health problems. Medicare The Federal health insurance program for people 65 years of age or older, some people under age 65 with certain disabilities, and people with End-Stage Renal Disease (generally those with permanent kidney failure who need dialysis or a kidney transplant). Medicare Advantage (MA) Plan Sometimes called Medicare Part C. A plan offered by a private company that contracts with Medicare to provide you with all your Medicare Part A (Hospital) and Part B (Medical) benefits. A MA plan offers a specific set of health benefits at the same premium and level of cost-sharing to all people with Medicare who live in the service area covered by the plan. Medicare Advantage Organizations can offer one or more Medicare Advantage plan in the same service area. A Medicare Advantage plan can be an HMO, PPO, a Private Fee-for-Service (PFFS) plan, or a Medicare Medical Savings Account (MSA) plan. In most cases, Medicare Advantage plans also offer Medicare Part D (prescription drug coverage). These plans are called Medicare Advantage Plans with Prescription Drug Coverage. Everyone who has Medicare Part A and Part B is eligible to join any Medicare Health Plan that is offered in their area, except people with End-Stage Renal Disease (unless certain exceptions apply). Medicare Prescription Drug Coverage (Medicare Part D) Insurance to help pay for outpatient prescription drugs, vaccines, biologicals, and some supplies not covered by Medicare Part A or Part B. Medigap (Medicare Supplement Insurance) Policy Medicare supplement insurance sold by private insurance companies to fill gaps in Original Medicare. Medigap policies only work with Original Medicare. (A Medicare Advantage plan is not a Medigap policy.) Member (Member of our Plan, or Plan Member) A person with Medicare who is eligible to get covered services, who has enrolled in our Plan and whose enrollment has been confirmed by the Centers for Medicare & Medicaid Services (CMS). Member Services A department within our Plan responsible for answering your questions about your membership, benefits, grievances, and appeals. See Chapter 2 for information about how to contact Member Services. Minnesota Senior Care Plus (MSC+) A program in which the State contracts with health plans to cover and manage health care and Elderly Waiver services for Medical Assistance enrollees age 65 and older. Minnesota Senior Health Options (MSHO) A program offered by the Minnesota Department of Human Services and health plans, including our Plan, for seniors eligible for both Medicare and Medical Assistance Network Pharmacy A network pharmacy is a pharmacy where members of our Plan can get their prescription drug benefits. We call them network pharmacies because they contract with our Plan. In most cases, your prescriptions are covered only if they are filled at one of our network pharmacies. Network Provider Provider is the general term we use for doctors, other health care professionals, hospitals, and other health care facilities that are licensed or certified by Medicare and by the State to provide health care services. We call them network providers when they [insert if appropriate: have an agreement with our Plan to] accept our payment as payment in full, and in some cases to coordinate as well as provide covered services to members of our Plan. Our Plan pays network providers based on the agreements it has with the providers or if the providers agree to provide you with plan-covered services. Network providers may also be referred to as plan providers. [Include this definition only if plan has preferred and non-preferred pharmacies. [Insert either:] Non-preferred Network Pharmacy OR Other Network Pharmacy A network pharmacy that offers covered drugs to members of our Plan at higher cost-sharing levels than apply at a preferred network pharmacy. Notice of Action A form or letter we send you telling you about a decision on a claim, a service, or any other action taken by our Plan. Nursing Home Certifiable A decision that you need a nursing home level of care. A screener uses a screening process called a Long Term Care Consultation to decide. Ombudsman A person at the Minnesota Department of Human Services who can help you file a grievance or appeal at our Plan or request a State fair Hearing. Open Access Services Federal and state law allow you to choose any doctor, clinic, hospital, pharmacy, or family planning agency - even if not in the our Plans network - to get these services Organization Determination The Medicare Advantage organization has made an organization determination when it, or one of its providers, makes a decision about whether services are covered or how much you have to pay for covered services. Original Medicare (Traditional Medicare or Fee-for-service Medicare) Original Medicare is offered by the government, and not a private health plan like Medicare Advantage plans and prescription drug plans. Under Original Medicare, Medicare services are covered by paying doctors, hospitals and other health care providers payment amounts established by Congress. You can see any doctor, hospital, or other health care provider that accepts Medicare. You must pay the deductible. Medicare pays its share of the Medicare-approved amount, and you pay your share. Original Medicare has two parts: Part A (Hospital Insurance) and Part B (Medical Insurance) and is available everywhere in the United States. Out-of-Area Service - Health care provided to an enrollee by a non-network provider outside of the Plan Service Area. Out-of-network Pharmacy A pharmacy that doesnt have a contract with our Plan to coordinate or provide covered drugs to members of our Plan. As explained in this Certificate of Coverage, most drugs you get from out-of-network pharmacies are not covered by our Plan unless certain conditions apply. Out-of-network Provider or Out-of-network Facility A provider or facility with which we have not arranged to coordinate or provide covered services to members of our Plan. Out-of-network providers are providers that are not employed, owned, or operated by our Plan or are not under contract to deliver covered services to you. Using out-of-network providers or facilities is explained in this booklet in Chapter 3. Outpatient Hospital Services - Services provided at a hospital or outpatient facility which are not at an inpatient level of care. These services may also be available at your clinic or other health facility. Part C see Medicare Advantage (MA) Plan. Part D The voluntary Medicare Prescription Drug Benefit Program. (For ease of reference, we will refer to the prescription drug benefit program as Part D.) Part D Drugs Drugs that can be covered under Part D. We may or may not offer all Part D drugs. (See your formulary for a specific list of covered drugs.) Certain categories of drugs were specifically excluded by Congress from being covered as Part D drugs. Physician Incentive Plan - Special payment arrangements between our Plan and the doctor that may affect the use of referrals. It may also affect other services that you might need. Post-stabilization Care: Also called follow-up care. A hospital service needed to help a persons condition stay stable after having emergency care. It starts when the hospital asks for health plan approval. It continues until: the person is discharged; the health plan doctor begins care or; the hospital doctor and health plan agree to a different arrangement. Prescriptions Medicines and drugs ordered by a medical provider. Preventive Services Services that help you stay healthy, such as routine physicals, immunizations, and well-person care. These services help find and prevent health problems. Follow-up on conditions that have been diagnosed (like diabetes checkup) are not preventive. [Include this definition only if plan has preferred and non-preferred pharmacies] Preferred Network Pharmacy A network pharmacy that offers covered drugs to members of our Plan at lower cost-sharing levels than apply at a non-preferred network pharmacy. Primary Care [insert as appropriate: Physician OR Provider] (PCP) A health care professional you select to coordinate your health care. Your PCP is responsible for providing or authorizing covered services while you are a plan member. Chapter 3 tells more about PCPs. Primary Care Clinic The clinic you chose for your routine health care. This clinic will provide or approve most of your care. The name of your clinic appears on the Plan member card. Prior Authorization Approval in advance to get services or certain drugs that may or may not be on our formulary. [Plans may delete applicable sentences if it does not require prior authorization for any medical services and/or any drugs.] Some in-network medical services are covered only if your doctor or other network provider gets prior authorization from our Plan. Covered services that need prior authorization are marked in the Benefits Chart in Chapter 4. Some drugs are covered only if your doctor or other network provider gets prior authorization from us. Covered drugs that need prior authorization are marked in the formulary. Quality Improvement Organization (QIO) Groups of practicing doctors and other health care experts that are paid by the Federal government to check and improve the care given to Medicare patients. They must review your complaints about the quality of care given by Medicare Providers. See Chapter 2 for information about how to contact the QIO in your state and Chapter 9 for information about making complaints to the QIO. Quantity Limits A management tool that is designed to limit the use of selected drugs for quality, safety, or utilization reasons. Limits may be on the amount of the drug that we cover per prescription or for a defined period of time. Rehabilitation Services Services that help restore or maintain a persons health function. These services include physical therapy, cardiac rehabilitation, speech and language therapy, and occupational therapy. Restricted Recipient Program A program for members who have received medical care and have not followed the rules or have misused services. If you are in this program, you must get health services from one primary care provider, one drug store, one hospital or other provider. You will not be allowed to use the personal assistance choice option or consumer directed services. You must do this for 24 or 36 months of eligibility. Second Opinion If you do not agree with an opinion you get from a network provider, you have the right to get an opinion from another provider. Our Plan will pay for this. For medical conditions, the second opinion will be from another network provider. For mental health services, the second opinion will be from an out-of-plan provider. For chemical dependency services, the second opinion will be from a different qualified assessor who is not in our Plan. Service Area Service area is the geographic area approved by the Centers for Medicare & Medicaid Services (CMS) within which an eligible individual may enroll in a certain plan, and in the case of network plans, where a network must be available to provide services. Service Authorization: Our Plans approval that is needed for some services before you get them. Standing Referral - Written consent from you Primary Care Clinic to see a specialist for more than one time (for on-going care) or written consent from us to see a non-network specialist more than one time (for on-going care). State Fair Hearing A hearing at the State to review a decision made by our Plan. You must request a hearing in writing. You may ask for a hearing if you disagree with: the delivery of health services; enrollment in our Plan; denial in full or part of a claim or service; failure our Plan to act within required timelines for service authorizations, grievances and appeals; or any other action or grievance. Step Therapy A utilization tool that requires you to first try another drug to treat your medical condition before we will cover the drug your physician may have initially prescribed. Subrogation Our Plans right to collect money in your name from another person, group, or insurance company. We have this right when you get medical care from our Plan that is covered by another source or third party payer. Supplemental Security Income (SSI) A monthly benefit paid by the Social Security Administration to people with limited income and resources who are disabled, blind, or age 65 and older. SSI benefits are not the same as Social Security benefits. Urgent Care: Care for a condition that needs prompt treatment to stop the condition from getting worse. An urgent condition is not as serious as an emergency. Urgent Care is available 24 hours a day. Urgently Needed Care Urgently needed care is a non-emergency situation when you need medical care right away because of an illness, injury, or condition that you did not expect or anticipate, but your health is not in serious danger. Because of the situation, it isnt reasonable for you to obtain medical care from a network provider.     MINNESOTA CERTIFICATE OF COVERAGE TEMPLATE 2010 Certificate of Coverage for [insert plan name] Table of Contents  2010 Certificate of Coverage for [insert plan name] Chapter 1: Getting started as a member of [insert plan name]  PAGE \* MERGEFORMAT 12 2010 Certificate of Coverage for [insert plan name] Chapter 2: Important phone numbers and resources  PAGE \* MERGEFORMAT 28 PAGE 180 2010 Certificate of Coverage for [insert plan name] Chapter 3: Using the plans coverage for your covered services  PAGE \* MERGEFORMAT 42 PAGE 180 2010 Certificate of Coverage for [insert plan name] Chapter 4: Benefits chart (what is covered)  PAGE \* MERGEFORMAT 64 2010 Certificate of Coverage for [insert plan name] Chapter 4: Medical benefits chart (what is covered and what you pay)  PAGE \* MERGEFORMAT 65 PAGE 180 2010 Certificate of Coverage for [insert plan name] Chapter 5: Using the plans coverage for your Part D prescription drugs  PAGE \* MERGEFORMAT 85 2010 Certificate of Coverage for [insert plan name] Chapter 6: What you pay for your Part D prescription drugs  PAGE \* MERGEFORMAT 97 PAGE 180 2010 Certificate of Coverage for [insert plan name] Chapter 7: Asking the plan to pay its share of a bill you have received for covered services or drugs  PAGE \* MERGEFORMAT 103 PAGE 180 2010 Certificate of Coverage for [insert plan name] Chapter 8: Your rights and responsibilities  PAGE \* MERGEFORMAT 114 PAGE 180 2010 Certificate of Coverage for [insert plan name] Chapter 9: What to do if you have a problem or complaint (coverage decisions, appeals, complaints)  PAGE \* MERGEFORMAT 170 PAGE 180 2010 Certificate of Coverage for [insert plan name] Chapter 10: Ending your membership in the plan  PAGE \* MERGEFORMAT 177 2010 Certificate of Coverage for [insert plan name] Chapter 11: Legal notices  PAGE \* MERGEFORMAT 179 PAGE 180 2010 Certificate of Coverage for [insert plan name] Chapter 12: Definitions of important words  PAGE \* MERGEFORMAT 188 *HITbp ÷ziUJ<h9h{56B*phh9h{B*ph&h9h{h9OJQJ^J_H aJ hUrh{6B*CJaJph*h9h{5CJOJQJ\^J_H aJ8#h9h{56B*CJaJ$phha,5CJaJ$h9h{5CJaJ$h7h{5CJ$aJ$h ,5CJ$aJ$h9h{5^J_H "h9h{5CJ\^J_H aJh}Ah{56B*phha"h+u*Ib % Y 4 YG7$8$H$[$\$gda, 7$8$H$gd{gda,gd{ [$\$gd{ & 0` P@1$7$8$H$gd{ & 0` P@1$7$8$H$$xa$gd{o  - 5 K # $ % & 6 7 H   " $ * + , 6 7 E X Y q ijӓӓumh7h{5hd;<h{6B*phh9h{h}A h9h{h}Ah{6B*ph h{5h}Ah{56B*phh}Ah{5B*phhVhJ5ha, hsG?h{ h7h{h9h{56B*phh9h{B*phh9h{6B*ph) 3 4 E F [ c f i XY0FGst̿̿׿׻teQ&hd;<hd;<5CJOJQJ\^JaJhw h{5>*OJQJ\hw h{5>*OJQJhw h{B*phh")ha,B*phha,B*phh}AhJ5hJ56B*phha"ha,B*phh{h}Ah{6B*phh}Ah{B*ph h7h{h9h{6B*ph h9h{h~-h{6 h ,6Gtfg  P ThTx[$]h^Tgd{hTx[$]h^Tgd{Tx[$\$]^Tgd{qgd1{$ % x[$\$]^a$gdd;<$7$8$H$[$\$a$gd{7$8$H$[$\$gd{efghʹypdXG j}h{UmHnHuh2Jh{mHnHuhw h{mHnHuhvKmHnHu jh{UmHnHujh{UmHnHu#hz;Jh{6B*mHnHphuh{5OJQJmHnHuh{mHnHuhw h{\jhw h{U\ h1{h1{h{CJOJQJ\^JaJ#hghd;<CJOJQJ\^JaJ  7I dh/0JKӵߦߕӵߦ߄vӵߦe jh{UmHnHuhw h{6mHnHu jwh{UmHnHu jh{UmHnHuh{5OJQJmHnHuh2Jh{mHnHu#hw h{6B*mHnHphuhw h{mHnHuh{mHnHujh{UmHnHuhvKmHnHu'KLNOP/0JKLNOP`yS!.ԈԈ}}}ԈԈlll hw h{B*mHnHphuh{6mHnHu#hw h{6B*mHnHphu jqh{UmHnHuh{5OJQJmHnHuh2Jhd;<mHnHuhw h{6mHnHuhw h{mHnHuh{mHnHuhvKmHnHujh{UmHnHu*P=*. r!Tx[$]^Tgd{ & F_x[$]^gd{Txx[$\$]^Tgd{Tx[$]^Tgd{Tx[$]^Tgd{ TTx[$]^Tgd{qhx[$]h^gd{.1K789;<=    #$%()*ĻĻsĻb jh{UmHnHu jkh{UmHnHuhvKmHnHu jh{UmHnHujh{UmHnHuh{5OJQJmHnHuh{mHnHuh2Jh{mHnHuhw h{mHnHu hw h{B*mHnHphu#hw h{6B*mHnHphu&* r!s!~!!!!!!!!!!!!!!""8"9":"=">"?"@"""ްޖޅxqdhw h{6B*ph hw h{jhw h{U\ j_h{UmHnHu jh{UmHnHuhvKmHnHu jeh{UmHnHujh{UmHnHuh{5OJQJmHnHuh{mHnHuh2Jh{mHnHuhw h{mHnHu'r!s!!!?"j"k""" ###$$$$-%%%=&&&'''^(pogd{x[$]^gd{T^Tgd{Tx[$]^Tgd{qgd{""""""####### #9#D#P#`#a#{#|#}#~###########ū⠒ūpūeh{_HmHnHu jh{UmHnHu jYh{UmHnHuhRh{6mHnHuh ,6mHnHuhvKmHnHu jh{UmHnHujh{UmHnHuh{5OJQJmHnHuh{mHnHuhw h{\jhw h{U\ ##$$$$$$ $!$"$#$M$X$d$e$f$$$$$$$$$$$$ŷŦŒŷsdTŷhRh{^J_HmHnHuh{5OJQJmHnHu jh{UmHnHuhRh{6mHnHuh ,6mHnHuhvKmHnHu jSh{UmHnHujh{UmHnHuh{mHnHuh{_HmHnHu'hRh{6B*_HmHnHphu$hRh{B*_HmHnHphu$$$$$$$ % %%(%)%*%+%,%9%f%g%h%%%%%%%%%%%%%%%%%%l[ j h{UmHnHu'hRh{6B*_HmHnHphu$hRh{B*_HmHnHphu jG h{UmHnHu jh{UmHnHuh{_HmHnHuh{mHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu jMh{UmHnHu#%%%&&&8&9&:&;&<&=&J&&&&&&&&&&&&'''!'"'#'$'%'3'7'I'r's't''ɯɯrɯ j; h{UmHnHuhRh{6_HmHnHu j h{UmHnHuh{_HmHnHuhvKmHnHu jA h{UmHnHujh{UmHnHuhRh{^J_HmHnHuh{5OJQJmHnHuh{mHnHu&''''''''''''''''=(>(?(Y(Z([(\(](g(h((((Ĵϣϒσs^H+hRh{6B*^J_HmHnHphu(hRh{B*^J_HmHnHphuhRh{^J_HmHnHuh{5OJQJmHnHu j h{UmHnHu j5 h{UmHnHuhRh{6_HmHnHuh{_HmHnHuh{mHnHuhvKmHnHujh{UmHnHu j h{UmHnHu((((((((((((((((((( )))A)B)C)])^)_)`)a)o))))))ԺԫԺ|kԺZ jh{UmHnHu j)h{UmHnHu$hRh{B*_HmHnHphu j h{UmHnHuh{_HmHnHuh{5OJQJmHnHuhvKmHnHu j/ h{UmHnHujh{UmHnHuh{mHnHu(hRh{B*^J_HmHnHphu#^(()b))'*****+,l-&./ & Fx[$\$]gd & Fxx[$\$]gd{" ) h8 xHX (#\$]gd{y z^`gd{pq))))))***!*"*#*%*&*'*4*u*v*w*************+++++}vqiv\vqivhw h{6B*phhw h{6 h ,6 hw h{hw h{CJ\jhw h{U\ jh{UmHnHuh{_HmHnHu j#h{UmHnHuhRh{^J_HmHnHuh{5OJQJmHnHuh{mHnHuhvKmHnHujh{UmHnHu#+,,,---!-W-i-j-k---.#.$.%.(.H...///////00D000000041?1K111P2g2h2ü~hw h{B*_Hphhw h{_H hJ5h{ h ,6hw h{B*phh ,h9h{6B*ph h9h{ hw h h")hhS hhhw h{6hw h{6B*phh hw h{hJ5-//D001W1111|zn\MM & Fx[$\$gd{$ & Fxx[$\$a$gd{  & F\$gd{y ) h8 xHX (#x]gd{ 7$8$H$gd{X & FhxEƀ [$\$]^hgd11D2{2k34I4l45c667P8888A9 & F xx[$\$gd{ d\$gd{z x7$8$H$gd{ 7$8$H$gd{xgd{ ) h8 xHX (#gd{y & Fx[$\$gd{h2x2y2z2{2I3T3`3k34414<4H4I4l4q4|44444595\5^5_5 626c66666(7+77ƾ˩ƾˈƾ{˾ti{ˈ{_hw h{h^hw h{B*ph hJh{hw h{6B*phhw h{5OJQJ^J$hw h{56OJQJ\]aJ(hw h{56OJQJ\]^JaJhw h{6 h ,6 hw h{hw h{aJhw h{_Hhw h{B*_Hphhw h{6B*_Hph$77O8P8Z8888888A9J9p9y9999:::::::::; ;9;m;ꪲꪢ}n}[Phbl'h{B*ph$hw h{5B*OJQJ^Jphhw h{6B*^Jphhw h{B*^JphhJ5h{^J hJ5h{hJ5h{]hJ5h{6hw h{]hw h{6%hw h{56OJQJ]^JaJhw h{_Hhw h{aJhw h{^J_H hw h{ hw hhh{A9p99:: ;9;;;}<=v==|?ACCC-Dzgd{\ & F dx[$gd{\ & F dx[$gd{ \d[$gd{y [$\$gd{xgd{ x[$\$gd{ & F x[$\$gd{m;;;;;;;;u==========6>X>Y>>>(?)???F?H?`?ҼɯғraTThw h{6B*ph hw h{6B*OJQJphhw h{6OJQJ^J$hw h{6B*OJQJ^Jphhw h{OJQJ^Jhw h{6B*_Hphhw h{B*_Hphhw h{OJQJaJhw h{_H hw h{hw h{B*phhB*phhbl'h{B*phhrB*ph`?k?w?{?|?}?v@@@@@@@4A@ADAQArAAACCCCD,D:D~DDEEFFGGfGhGGGGGHHII J׻׷צ}׻shw h{6_Hhw h{5>* hRh{6B*CJaJphh{6B*CJaJph hw h{6B*CJaJphhhw h{_Hhw h{^J_Hhw h{5 hw h{hw h{B*phhw h{6B*phh ,6B*ph--DDEEFhGHkII=JJK*LlLOgPQTcTHxEƀ"Fgd{gd{gd{0gd{xgd{y JY?YIYLYYYY Z ZZ:ZqZxZZZZZ[[[[[[[[[I\K\\ ]!]+],]}]~]]]]깯Ք깎 hJ5_Hh{6B*phh#hrhw h{CJ hw h{6_Hhw h{_Hhw h{B*phhw h{5hw h{6B*phhw h{6 hw h{hw h{5OJQJ^J8]]]]]_^f^^^^^_ _P_W_____/`G`````aaa.a/a=a[a\aaaaabbbbYbZbvb{b̿紥}s}̿̿hV6B*phh)6B*phh.;h{6B*ph hw h{6B*^J_Hphhw h{B*^J_Hphhw h{^J_Hhw h{6B*phhw h{B*phh#hw h{6hJ5 hw h{hw h{CJhw h{_H,{bbbbbbbb,c.cNc_cncccEdFdHddddddde e/e[eheiekelemeeePffff1g5g`gdgtguggƹƹ칆{{w{h{h'?@IJZ[uؾدؾدؾد|ؾد j5h{UmHnHu jh{UmHnHu j;h{UmHnHuh{5OJQJmHnHuhvKmHnHu jh{UmHnHujh{UmHnHuh{mHnHu h h{B* mHnHphpu,uvwyz{ "#$-.yzьҌFGabcefg| jh{UmHnHu j)h{UmHnHu jh{UmHnHu j/h{UmHnHuh{mHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu jh{UmHnHu-ghv[nˎΎ bcdeijwy "#&(-/IKLPQbdǿ}uhw h{\ hw h{B*OJQJhphhw h{6B*hphhw h{B*hphhw h{5hw h{5\^JaJhw h{hhw h{5OJQJ^Jhw h{B* phphw h{6B*ph hw h{jhw h{U.dy $Ifgd{8t<$If^tgd{ikd#$$Ifl## t0644 laldeiKsff $Ifgd{8tx$If^tgd{|kd$$Ifl40p#p0 t0644 lalKLPdsf xx$Ifgd{8tx$If^tgd{|kdC$$Ifl}0p#p0 t0644 laldek|sff xx$Ifgd{8tx$If^tgd{|kd$$Ifl0p#p0 t0644 laldejklz|}rƶoZSGhw h{6^JaJ hw h{(hw h{5B*OJQJ^JaJph#hw h{56B*^JaJph hw h{6B*^JaJphhw h{5OJQJ^JaJ h\4h'x|:;<A`dݗޗߗrs̿鿱鿡Կ鿱鿱ԱԱhw h{\ hw h{B*OJQJhphhw h{56B*hphhw h{6B*hphhw h{B*hphhw h{5hw h{5\^JaJ hw h{hw h{hhw h{5OJQJ^J5;ufYL xx$Ifgd{ $Ifgd{8tx$If^tgd{|kd4$$Ifl0p#p0 t0644 lal $Ifgd{;<@Aޗssf xx$Ifgd{8tx$If^tgd{|kd$$IflL0p#p0 t0644 lalޗߗssf xx$Ifgd{8tx$If^tgd{|kdj$$Ifl0p#p0 t0644 lalst+syp\<$If[$\$]gd{p]pgd{h]hgd'x|>B àĠȠ./0١ܡ>񻴦䞦䞖䞴|hw h{5OJQJ^JaJhw h{6\hw h{5hw h{\hw h{5\^JaJ hw h{ hw h{B*OJQJhphhw h{56B*hphhw h{hhw h{B*hphhw h{6B*hph.psfY xx$Ifgd{ $Ifgd{8tx$If^tgd{|kd$$Ifl0p#p0 t0644 lalssf xx$Ifgd{8tx$If^tgd{|kd$$IflL0p#p0 t0644 lal/sf xx$Ifgd{8tx$If^tgd{|kdL $$Ifl0p#p0 t0644 lal/0ܡ?pyp\<$If[$\$]gd{p]pgd{h]hgd{|kd $$Ifl0p#p0 t0644 lal>?opquvw¢Ǣɢ͢ |}~$&;<?AFGHL¤äȤ`abgļٯٯįٯٯxġxhw h{\ hw h{B*OJQJhphhw h{56B*hphhw h{6B*hphhw h{B*hphhw h{5hw h{5\^JaJ hw h{hw h{hhw h{5OJQJ^J hw h{6B*^JaJph/pqv}y $Ifgd{8tx$If^tgd{ikd!$$Ifl## t0644 lal}~ ¤sfY xx$Ifgd{ $Ifgd{8tx$If^tgd{|kd"$$Ifl0p#p0 t0644 lal¤äǤȤassf xx$Ifgd{8tx$If^tgd{|kd"$$IflL0p#p0 t0644 lalabhsf xx$Ifgd{8tx$If^tgd{|kd=#$$Ifl0p#p0 t0644 lalghxyz~^ 123789LOgi~ʧΧ/015׿woww^ hw h{B*OJQJhphhw h{5hw h{hhw h{5OJQJ^J hw h{6B*^JaJphhw h{5OJQJ^JaJhw h{6\ hw h{hw h{\hw h{56B*hphhw h{B*hphhw h{6B*hphhw h{5\^JaJ$ 2yp\<$If[$\$]gd{p]pgd{h]hgd{|kd#$$Ifl0p#p0 t0644 lal2380y $Ifgd{8tx$If^tgd{ikds$$$Ifl## t0644 lal015fsfY xx$Ifgd{ $Ifgd{8tx$If^tgd{|kd$$$Ifl0p#p0 t0644 lal56CDר٨efgl uvwժ+-ʫŷůŨ}oݨhw h{5OJQJ^J hw h{6B*^JaJphhw h{5OJQJ^JaJhw h{6\ hw h{hw h{5hw h{5\^JaJhw h{\hw h{56B*hphhw h{hhw h{6B*hphhw h{B*hph+fgklssf xx$Ifgd{8tx$If^tgd{|kd%$$IflL0p#p0 t0644 lalvsf xx$Ifgd{8tx$If^tgd{|kd.&$$Ifl0p#p0 t0644 lalvw.yp\<$If[$\$]gd{p]pgd{h]hgd{|kd&$$Ifl0p#p0 t0644 laly $Ifgd{8tx$If^tgd{ikdd'$$Ifl## t0644 lalʫͫ HLĬŬXZopsuz|}{|}aݼ󟗧󟵍hw h{6\hw h{5hw h{\hw h{5\^JaJ hw h{ hw h{B*OJQJhphhw h{56B*hphhw h{6B*hphhw h{hhw h{B*hph2@sfY xx$Ifgd{ $Ifgd{8tx$If^tgd{|kd'$$Ifl0p#p0 t0644 lal|ssf xx$Ifgd{8tx$If^tgd{|kd($$IflD0p#p0 t0644 lal|}sf xx$Ifgd{8tx$If^tgd{|kd)$$Ifl0p#p0 t0644 lal$ðypk[Rk $gd{7$8$H$[$\$gd)gd{p]pgd{h]hgd{|kd)$$Ifl0p#p0 t0644 lal #$°ð={krӲڲ߲#tu̳ǼyqgYhw h{5OJQJ^Jhw h{6\hw h{6hw h{5 h)6\h)h{6\ h)h{hXh] hw h{ h)h) h)5hm]Wh)5h{6B*hphh0h{6B*hphh{5OJQJ^JaJh]5OJQJ^JaJhw h{5OJQJ^JaJ #;=RSVX]^_cdqr "'()-.78IKLQRSacdeƵort´´´´´´›´´›´›|hc0>h{CJhw h{CJ h :h{ h{CJhw h{\ hw h{B*OJQJhphhw h{6B*hphhw h{B*hphhw h{5hw h{5\^JaJ hw h{hw h{hh]5OJQJ^J0 ^re $Ifgd{8t<$If^tgd{ikdU*$$Ifl## t0644 lal<$If[$\$]gd{^_c(sff xx$Ifgd{8tx$If^tgd{|kd*$$Ifl<0p#p0 t0644 lal()-Ksf xx$Ifgd{8tx$If^tgd{|kdu+$$Ifl00p#p0 t0644 lalKLRcs_ x$If[$\$^ gd{8tx$If^tgd{|kd,$$Ifl0p#p0 t0644 lalcdeƵt}ytyy`$If[$\$]gd{{gd{Y]gd{|kd,$$Iflc0p#p0 t0644 lalt|~׸ظٸ 9:;ӸӛӸsdsd[hw h{CJhw h{6B*CJphhw h{B*CJph h6h{h{B*CJphhw h{0Jhj/hw h{Uhjhw h{Uhhw h{\ hw h{hw h{OJQJhhw h{hhw h{5\^JaJhw h{5hw h{5OJQJ^J!}~ķyyy $Ifgd{8tx$If^tgd{ikdF-$$Ifl## t0644 lalpsfff xx$Ifgd{8tx$If^tgd{|kd-$$Ifl0p#p0 t0644 lalٸٺ sfff xx$Ifgd{8tx$If^tgd{|kdf.$$Ifl0p#p0 t0644 lal ;ytyyyy\ $If[$\$]gd{{gd{Y]gd{|kd/$$Ifl0p#p0 t0644 lal*+ܺܺܺܝ}ugu]Mhw hDhDB*hphhDB*hphhw h{5\^JaJhw h{5hw h{5B*ph$hw hD5B*OJQJ^JphhD5B*OJQJ^Jphhw h]B*CJph hzCJhw h]h]B*CJph h]CJ hDCJhw h{CJhw h)h]B*CJphh)B*CJphy $Ifgd{8tx$If^tgd{ikd=0$$Ifl## t0644 lal[\]cxy迷Ҭym`Q`Qhw h{6B*CJphhw h{B*CJphhD>*B*aJphj2hJ(hDUaJjhDUaJ hDaJhw h{5hw h{B*phhw hDB*phhw h{\hw h{hh")hDB*phhDB*phhw h{5\^JaJ hw h{ hw h{B*OJQJhph\sfY xx$Ifgd{ xx$IfgdD8tx$If^tgd{|kd0$$Ifl0p#p0 t0644 lal\]c|sfff xx$IfgdD8tx$If^tgd{|kd]1$$Ifl0p#p0 t0644 lalsf xx$Ifgd{8tx$If^tgd{|kd1$$Ifl0p#p0 t0644 lalx[vqhhh[JV & F x[$\$gd{m$ Y]gd{Y]gd{{gd{ h[$\$gd{|kd93$$Ifl0p#p0 t0644 lalZeZ[?ADSTUYZĺĶIJ{jĝbWhw h{B*phh6/B*ph hw h{B*OJQJhphh"B*hphh6/B*hphhw h{5\^JaJhw h{5hw h{5B*phh6/h{hw h{hN hw h{hw h6/h6/B*CJphhw h6/h6/CJ h6/CJh)B*CJphhw h{CJ [@ABDT$If[$\$]gd{Vh[$\$^hgd{m$ Vx[$\$gd{m$V & F x[$\$gd{m$V & F xx[$\$gd{m$o3&TUZy $Ifgd{8tx$If^tgd{ikd3$$Ifl## t0644 lalsff xx$Ifgd6/8tx$If^tgd{|kdY4$$Ifl0p#p0 t0644 lal,sf xx$Ifgd{8tx$If^tgd{|kd4$$Ifl0p#p0 t0644 lal*+,-.GHT߸߭tllgl[tlQjh{Uhhw h{OJQJh h{hhw h{hhw h{5\^JaJhw h{5OJQJ^Jhw h{CJ h6h{ hw h{ h{CJhw h{B*phhhh6/0J$j5hfh6/B*Uphhhh6/B*phjhhh6/B*Uphhw h{5hw h{\,-.Hyty`$If[$\$]gd{{gd{Y]gd{|kd<6$$Ifl0p#p0 t0644 lal4yyyy $Ifgd{8tx$If^tgd{ikd6$$Ifl## t0644 lal5TsffY $Ifgd{ xx$Ifgd{8tx$If^tgd{|kd\7$$Ifl 0p#p0 t0644 lalsf xx$Ifgd{8tx$If^tgd{|kd7$$Ifl) 0p#p0 t0644 lalhi]^_.6ƾzngXMEhVCJaJhh{CJaJhw h6B*CJph hw hh{6B*CJphh9gh{6B*CJphh{B*CJphhw h{6B*CJphhw h{B*CJphh6/ hw h{h{hw h{\hw h{hhh{0Jhjh{Uhj8hh{Uhh_JCh{h h{hh_/}xoooooXo & Fhx[$\$]^hgdY]gd{{gd{gd{|kdS9$$Ifl0p#p0 t0644 lal 6M`y89:>?+,-5Ƿzsk`YsQIhw h{\hw h{h h[Dh6/h[Dh6/B*phh6/B*ph hw h{ hw h{B*OJQJhphhh6/0Jhw h{5\^JaJhw h{5hw h{5B*phh6/5B*OJQJ^Jphhw hCJhhCJaJhh)B*CJaJphhh)CJaJhh{CJaJ9$If[$\$]gd{Y]gd{Y]gdJYEƀ"F]gd9:?y $Ifgd{8tx$If^tgd{ikd9$$Ifl## t0644 lal,sfY xx$Ifgd{ xx$Ifgd6/8tx$If^tgd{|kds:$$Ifl0@ #@ ` t0644 lal,-5sZM xx$Ifgd{$7$8$H$If[$\$^gd6/8tx$If^tgd{|kd;$$Ifl0@ #@ ` t0644 lal56_`aPQS[q鿷{qgWG:hQShQSB*aJphhQShQS5B*\aJphhQSB*OJQJ^JaJphhQSB*aJphhQSB*CJphhQS5B*\aJphhQS5B*\aJph%hQS5B*OJQJ\^JaJphhQSh6/ hh6/hw h{\hw h{B*phh6/h6/>*B*aJphj;hh!)UaJh6/h6/aJjh6/h6/UaJvfI $7$8$H$If[$\$]gdQS h[$\$gdQS h[$\$gd6/|kdX<$$Ifl0@ #@ ` t0644 lalR}d $7$8$H$If[$\$gdQS txx$1$7$8$H$If[$\$^tgdQSckd<$$Ifl##0#4 lalytQSRS[qjQQ ,xx$7$8$H$If[$\$gdQS ,txx$1$7$8$H$If[$\$^tgdQSvkd=$$Ifl0 # 0#4 lalytQSqGHOPQɽ֮hSA1jhY>*B*UaJph#hQSB*CJOJQJ^JaJph(hQShQS>*B*OJQJ^JaJph4j@hQShQSB*OJQJU^JaJph%hQShQSB*OJQJ^JaJph.jhQShQSB*OJQJU^JaJph *hQS5B*\aJph *hQSB*aJphhQShQSB*aJphhQShQS5B*\aJph *hQSB*aJphhQShQSB*aJphEGjQQQ ,xx$7$8$H$If[$\$gdQS ,txx$1$7$8$H$If[$\$^tgdQSvkde>$$Ifl0 # 0#4 lalytQSGHPfI $7$8$H$If[$\$`gdQS" txx$1$7$8$H$If[$\$^t`gdQSvkd>?$$Ifl0 # 0#4 lalytQSSy{ϿtibZLB7Zh[Dh6/B*phh8xh6/5\h6/B*OJQJ^Jphh6/B*ph h6/5\h6/5B*\ph!h6/5B*OJQJ\^Jphh6/hQSB*OJQJ^JaJph *hQSB*aJph *hQShQSB*aJphhJhhY0JaJjhY>*B*UaJph+j@hJhhY>*B*UaJphh5hY>*B*aJphhY>*B*aJphRSzl\\C$7$8$H$If[$\$]gdh7$8$H$[$\$gd6/ h7$8$H$[$\$^h`gdQSvkdQB$$Ifl0 # 0#4 lalytQSz{q$7$8$H$If[$\$gdtxx$1$7$8$H$If[$\$^tgd^kd*C$$Ifl##04 lalytvws^^^xx$7$8$H$If[$\$gdtxx$1$7$8$H$If[$\$^tgdqkdC$$Ifl0@ #@ `04 lalytuvwx~"#%&'|:NmoӾⰾwj`VOVOV h)5\h.+h)5\h{6B*phhh{6B*phh{5OJQJ^Jhw h{5OJQJ^J hw h{h{h6/B*phh8xh6/>*B*phjNFh8xh6/Ujh8xh6/U *h6/B*phh8xh6/5\ *h6/ h8xh6/h6/ h[Dh6/h8xh6/B*phwx~s^^^xx$7$8$H$If[$\$gdtxx$1$7$8$H$If[$\$^tgdqkdD$$Ifl0@ #@ `04 lalyt$%s^^xx$7$8$H$If[$\$gdtxx$1$7$8$H$If[$\$^tgdqkduE$$Ifl0@ #@ `04 lalyt%&'|:defzzulz` h[$\$gd{Y]gd{gd) 7$8$H$gd{{gd{gd{qkdF$$Ifl0@ #@ `04 lalyt cde`cijkstǹǛǏǣLJǛޱ}xpx`}V}hh{0JhjIhh{Uhh`m"h{h h{hjh{Uhhw h{6hw h{OJQJhhw h{hhw h{5\^JaJhw h{5hw h{5OJQJ^J hw h{h{5OJQJ^J h{\hw h{\hw h{CJh)h)5\ h)5\!+tk $Ifgd{8tx$If^tgd{ikdG$$Ifl## t0644 lal $Ifgd{gd{Gjsfff xx$Ifgd{8tx$If^tgd{|kd]H$$Ifl 0@ #@ ` t0644 laljkssf xx$Ifgd{8tx$If^tgd{|kdH$$Ifl0@ #@ ` t0644 lal,-vqeXQLLogd{xgd{ 7$8$H$]gd{ [$\$gd{{gd{ h[$\$gd{|kdTJ$$Ifl0@ #@ ` t0644 lalOt#-.kluv"#$>ypeWeh~h{_HmHnHuh{_HmHnHuhvKmHnHu jJh{UmHnHujh{UmHnHuhGMXmHnHuh{5OJQJmHnHuh{mHnHuhw h{\jhw h{U\hGMXh{hw h{5hw h{hN 6hw h{hN 6B*ph hw h{ -D.p*ZD.0x[$\$]gd{ [$]gd{|ogd{pq>?@BCP ()*,-ϳϤυtc j`Mh{UmHnHu jLh{UmHnHu jfLh{UmHnHuh~h{_HmHnHuh{5OJQJmHnHu jKh{UmHnHuh{_HmHnHuh{mHnHuhvKmHnHujh{UmHnHu jlKh{UmHnHu&-wxNOPjklnop| xg jTOh{UmHnHuh{_HmHnHu jNh{UmHnHuh~h{_HmHnHuh{5OJQJmHnHu jZNh{UmHnHuh~h{mHnHuhvKmHnHu jMh{UmHnHujh{UmHnHuh{mHnHu( $%&()34%hij׿tc jHQh{UmHnHuh~h{_HaJmHnHu jPh{UmHnHuh{_HmHnHu jNPh{UmHnHuh~h{_HmHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu jOh{UmHnHuh{mHnHu&89:TUVXYf"#$>?@BCDPt j*hDhAmhfHq hAmh56 hAmhhGMX hhhw h{6B*phhw h{6hw h{OJQJhw h{B*ph hw h{hw h{B*OJQJph0hw h{0J6:B*fHphq 5hw h{0J:B*OJQJfHphq S&;)ktfy & Fq[$\$gd 7$8$H$gd{ 7$8$H$gd & Fs[$\$gdgd & Fr[$\$gd()k*  !!!("5"a"b""##I$P$۽}qcZLD<hw h{\hw h{5hw h{5OJQJ^Jhw h{_Hhw h{KH\_HaJhw h{6OJQJ hw h{6B*OJQJphhw h{B*ph-hw h{0J6B*fHphq hw h{6B*phhw h6B*ph!hAmh0JfHq hAmh hw h{hw h{5OJQJ^JaJ hh{B !)"b""##$&7&\(~ x1$[$\$gd{gd{ & F 8x[$\$^`gd{x\$gd{ x[$\$gd{ x[$\$gd{}|Vx[$\$^gd{m$}gd{ h7$8$H$\$gd{ h7$8$H$\$gd P$T$$$$$$%&&6&7&&&&&'#'('@'Q'''/(0(\())*}*Ȳȥwplhp^^^pZpKphw h{0J6B*phhGMXh{6B*phh{h hw h{hw h{OJQJ^Jhw h{5OJQJ^J$hw h{5B*OJQJ^Jphhw h{6B*ph*hw h{0JB*fHphq hw h{B*phhw h{5B*phhw h{56B*phhw h{\hw h{6\\()*,:,-X..K////00;1!23\ ]\ gd{ & Fxx[$\$gd{} & Fh[$\$]gd{ & Fx[$\$gd{x\$gd{ x[$\$gd{gd{]gd{ x1$[$\$gd{}*****,:,--..W.X...//0;1223334o4y4 6*6,666667'7(7)777N8a8b888888}hvKhGMX hm]Whhm]Wh5 h5 h_Hhw h{_Hhw h{KH\_HaJhw h{6B*phhw h{5>*OJQJ^Jhw h{5hw h{6hw h{5OJQJ^JhXh hw h{/34566(7)7b8+9{9;,<h=>Y??A BCDEFZ[$\$]Zgd{xgd{7$8$H$[$\$gd}|gd{ ] gd{88899+979z9{999U:V:X::;;;;7<d<==>>>>>>ļߣ߼߇paTKhw h{0JPhw h{0JPB*phhw h{0JP6B*ph-hw h{0JB*]fHphq hw h{]hw h{h3u6B*phhx# hx#h{h hw h hm]Whhw h{6hw h{6B*phhw h{\]_HaJ hw h{ h6\hw h{6\hw h{\>>?X?e??A B)C,C9E*B*phhw h{6B*phhw h{B*phhw h{6hw h{^J_Hhw h{_Hhw h{KH\_HaJhw h{hQhT hw h{h{.WUWWXrYZZqqDD, & F" 8lH # kF!i!D#x[$\$gd{. & F" ;lH # kF!i!D#x[$\$gd{2 & F" ;lH # kF!i!D#x[$\$]gd{. & F" ;lH # kF!i!D#xx[$\$gd{Zk[l[[[?\\/]]^|^^7_________ h[$\$gd{pqogd{ $7$8$H$a$gd{% ;lH # kF!i!D#xgd{[[\\\9\:\;\=\>\?\K\\\\\\\\\\ ]]])]*]+]-].]8]9]B]X]]]]]عʰإؔʰإ؃ʰq]q&h,gh{6^J_HaJmHnHu#h,gh{^J_HaJmHnHu jUh{UmHnHu j0Uh{UmHnHuh{_HmHnHuhvKmHnHu jTh{UmHnHujh{UmHnHuh{mHnHuh,gh{^J_HmHnHuh{5OJQJmHnHu$]]]]]]]]]]^^^^^)^Z^[^\^v^w^x^z^{^^^^^^^^^^___1_2_3_ra jXh{UmHnHuh,gh{^J_HmHnHu jWh{UmHnHu j$Wh{UmHnHu jVh{UmHnHuh{_HmHnHuh{mHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu j*Vh{UmHnHu&3_5_6_7_C_[_^_e_r_s__________oayaaaa#b5bbbbbbbŵФЙvrggP-hw h{0J6B*fHphq hw h{B*phh)Ghw h{^J_Hhw h{6B*phh{ hw h{jhw h{U jXh{UmHnHuh,gh{6_HmHnHuh{_HmHnHuh{mHnHuh{5OJQJmHnHujh{UmHnHuhvKmHnHu______oaaucc2ddCeue1ffgh & F(1$[$\$gd)G & F( x1$[$\$^ gd{ & F(1$[$\$gd{ x1$[$\$gd{gd{ x]gd{~ [$\$gd{bscccc2d@d`dddddddeeeBeCeOeteyezeeeeeeeeee>f?fVfffff g0gWgXgYg]ggggghʼʳ߫}hFjh)G6h)Gh{fHq hw h{fHq h{hXhw h{6hw h{CJ hw h{6^J_HaJhw h{^J_HaJhhj?h)Ghw h{_H hw h{hw h{6B*ph1hhhhhiiNkdkkklllllllllllll7mBmEmFmcmqqrNrOrPrQr^rv\3hw h{0J56:B*fHphq 3hw h;F0J56:B*fHphq hw h)GB*phh)GhHyh)G>* h)G>* hHyh)Gh?Qh)G5OJQJ^Jh{B*phhw h{6B*phhw h{B*phhw h)GfHq h")h)GfHq #hhiMkFmcmPr}rrsDtt`uQvRvSvTvx1$[$\$^gd{gd{ & F%[$\$gd{ & F%[$\$gdc{ x1$[$\$gd{ > !gd)G & F( x1$[$\$^ gd{x1$[$\$^gd)G^r_r|r}rrrrrrrssCtDt_u`ueuuPvQvʹ|oaoaoT=o3Th{6B*ph-hw h{0J6B*fHphq hw h{6B*ph33hw h{6:B*phhw h{6B*phhRhc{0J*hc{0J6:B*fHphq 0hRhc{0J6:B*fHphq 0hw h{0J6:B*fHphq 3hw h{0J56:B*fHphq 0hw h{0J56B*fHphq QvSv_v`vnvovpvvvvvvwwAwBwvwwwwwwwwwwwww𽫽wphZOFhi{rh+/aJhj?5OJQJ^Jhg]hj?5OJQJ^Jhw hj?\ hUh3 8h]zh3 86 h3 86h hj?5 h hj? hj?5CJOJQJ\^JaJ hw hj?"hw hj?6OJQJ\^JaJhw hj?OJQJ\^JaJ hj?hj?CJOJQJ^JaJhj?CJOJQJ^JaJhj? hw h{hw h{6TvUvVvWvXvYvZv[v\v]v^v_vovpvvvHx<$If[$\$]^Hgd{Hx$If[$\$]^Hgd{$x1$[$\$a$gdj? x1$[$\$gd{vvvwBwwwwwg & F<$If[$\$^gd!) & Ft$If[$\$gdUYdd$If\$]gdUUkdY$$Ifs40'0000 tn(6YYYYYYYYYYYYYYYYYY4sa ytj?www4xFx[xpxvW> & Fu h!$If[$\$`gdU> & Fu h!$If[$\$^gdUh$If^h`gdUh$If^h`gd+/ $Ifgdj??kdY$$Ifs'n( tn(6YYYYYYYYY4sa ytj?ww3x4x5xFxoxpxxxGy | | |!|"|#|'|0|1|I|_|`|a|;vmcm]mOAh")hj?CJ \^JaJhO hO 5\^JaJ hO aJhi{rhO >*aJhi{rhO aJhO 5\^JaJhj?5OJQJ\^JaJ"h")hj?5OJQJ\^JaJhw hj?\&hw hj?5CJOJQJ\^JaJhi{rhj?CJaJhj? hg]hj?hj?hj?5 hwhj?h+/h+/aJhi{rh+/aJhi{rh+/>*aJpxxxyGy | |#|`|fUUO$If^O`gdO ?kd'Z$$Ifs'n( tn(6YYYYYYYYY4sa ytj?Y$$$dd$If\$]gdj? > & Fu h!$If[$\$`gdU > & Fu h!8$If[$\$`gdUa|q|r|t|||||||||}1}2}}}}}}}}}}}}~~~شrkck_k_VNJNhhhj?5hO hO aJhO hi{rhO >* hi{rhO &hhj?5CJOJQJ\^JaJhw hj?\ h!)hj?h]z h@Dhj?h@Dhj?5hhlhj?5h"h")hj?5OJQJ\^JaJ"hDhj?5OJQJ\^JaJhj? h")hj?h")hj?CJ h")hj?CJhUhj?5CJ`|t|||}K}c}}}P?kdZ$$Ifs'n( tn(6YYYYYYYYY4sa ytj? & Fv<$If[$\$gd!) & Fv<$If[$\$gdU p@ $IfgdU & Fd  ]]<$If[$\$^]gdUY R$If\$]gdU}}}~~8~T~j~y~~~~ll> & Fw !$If[$\$`gd> & Fw !y$If[$\$`gd> & Fw !$If[$\$gdU>$$ !hh$If^hgdUh$If^h`gdO Ydd$If\$]gdU ~7~8~S~T~i~j~x~y~~~~~~~~~~  FSTi456fghѿ}wmhi{rhj?5CJ hi{rCJh")hj?CJh")hj?CJ \^JaJh")hj?5CJ\^JaJ&h")hj?5CJOJQJ\^JaJ hw hj? hxT]hj?hvK hxT]hxT]hxT] hhj? hhhj? h5hhj?5hh5h'~~~ GT~Z$> & F{ !.$If[$\$^`gdF6> & F{ !$If[$\$^gdF6> & Fy h!$If[$\$^gd$> & Fx h!y$If[$\$^`gd> & Fx h!$If[$\$^gdUiڀ56`?kdZ$$Ifs'n( tn(6YYYYYYYYY4sa ytj? > & Fz h!8O$If[$\$`OgdF6 > & Fz h!8$If[$\$`gdF6 > & F{ !.y$If[$\$^gdF66b.΃ՃnXXYdd$If\$]gdxT]?kdh[$$Ifs'n( tn(6YYYYYYYYY4sa ytj? & Fd  ]]<$If[$\$^]gdxT] & Fd  ]]<$If[$\$^]gdUYdd$If\$]gdU bcق.NPnʃ˃̃΃ڷxj`ZQHA h")hxT]h")hxT]CJ h")hxT]CJ hxT]CJh]zhxT]5CJh")hxT]CJ \^JaJ&h")hxT]5CJOJQJ\^JaJ hxT]5CJOJQJ\^JaJhw hj?\"hxT]hj?5OJQJ\^JaJh")hj?6B*phh")hj?6]h")hj?]hj? h")hj?hi{rhj?5CJ hi{rhj?5CJhi{rhi{r5CJՃ2CMf˄̄qYdd$If\$]gdUDkd[$$Ifs'n( tn(6YYYYYYYYY4sa g"Fytj?Ydd$If\$]gdxT] & Fd  ]]<$If[$\$^]gdxT] BLRef}ʄ˄݄̄ׄ߄Uu\]#ϻqg^UNJNFNhj?h3 8 h")hj?h")hj?CJ h")hj?CJh]zhj?5CJh")hj?CJ \^JaJh")hj?5CJ\^JaJ&h")hj?5CJOJQJ\^JaJ hj?5CJOJQJ\^JaJ hw hxT]&h")hxT]5CJOJQJ\^JaJh")hxT]6B*phh]zhxT]7h!)hxT]7hxT] h")hxT]hxZ,hxT]7x˅8]$%cӇHnYdd$If\$]gdU?kdH\$$Ifs'n( tn(6YYYYYYYYY4sa ytj? & Fd  ]]<$If[$\$^]gd!) & Fd  ]]<$If[$\$^]gdU #$%+MNO_`ac҇abʈr|{ͽzmbm^ZRhw hj?\hDhvKh")hj?B*phh")hj?6B*phhDhj?7hj? h")hj?h")hj?CJ h")hj?CJ h]zCJh]zhj?5CJh")hj?CJ \^JaJh")hj?5CJ\^JaJ&h")hj?5CJOJQJ\^JaJ hj?5CJOJQJ\^JaJ hw hj? h!)hj?HbrŠp> !h$If^hgdU $IfgdU?kd\$$Ifs'n( tn(6YYYYYYYYY4sa ytj?Ydd$If\$]gdU & Fd  ]]<$If[$\$^]gdU OPQ1B^s   ön^TNE<h")hj?CJ h")hj?CJ h]zCJh]zhj?5CJh")hj?5CJ\^JaJ&h")hj?5CJOJQJ\^JaJ hj?5CJOJQJ\^JaJhShj?5hj? hShj?h]zhj?5hj?B*phh")hj?6B*phh")hj?CJ \^JaJh")hj?5\^JaJhj?5OJQJ\^JaJ"h")hj?5OJQJ\^JaJC^saٍ1 & Fd  ]]<$If[$\$^]gdUYdd$If\$]gdU> & F} !$If[$\$gdU> !h$If^hgdU> & F| !$If[$\$gdU 1<BYZ\|}~()>?OUZiߐϥi]Q]]iiihuB*\aJphh]zB*\aJph+h" hj?5B*OJQJ\^JaJphhj?B*\aJphhphj?5B*phhphp5B*phhj?6B*ph"h")hj?5OJQJ\^JaJhxZ,hj?67B*phh")hj?6B*phh")hj?6:B*ph hi{rhj? h")hj?hj?h]z1Z})?Ydd$If\$]gdU & F~($If[$\$gdU & F($If[$\$^gdU & Fd  ]]<$If[$\$^]gdU & Fd  ]]<$If[$\$^]gdi{r >R}XlƓǓFJ  ATUΖ  'Thiü hoN#5 hhj? huhj?hDhj?5hhj?5>*hhj?7huhj?5hhj?5 hhj?hhj?5OJQJ^J hw hj? hj?5CJOJQJ\^JaJ+h" hj?5B*OJQJ\^JaJph0Rlzzff & F$If[$\$gdU & F$If[$\$gdU $IfgdU> !h$If^hgdU> !hh$If^h`gdU?kd]$$Ifs'n( tn(6YYYYYYYYY4sa ytj?lǓ UԕϖTj() $IfgdU & F$If[$\$gdU $h$If`hgdoN#> & F !$If[$\$gdU> & F !$If[$\$gdU ()*PQR̛SgœӜKLͿte]UMhUhj?hh^hhj?hh^hhj?5hj?5OJQJ\^JaJhUhj?OJQJh]zhj?6OJQJhhj?5>*hhj?5 hw hj?hhj?5OJQJ^Jh")hj?6B*phh")hj?CJ \^JaJh")hj?5\^JaJhw hj?\"h")hj?5OJQJ\^JaJ hhj?h]z)*jN. p@  h$If] `hgd!) p@  $If] gd!)?kd]$$Ifs'n( tn(6YYYYYYYYY4sa ytj?> !hh$If^h`gdU?kd]$$Ifs'n( tn(6YYYYYYYYY4sa ytj?6Ú P͛h< hh$If^h`gdU> & F h!$If[$\$^gdF6> & F h!$If[$\$^gdF6> & F h!$If[$\$^gdF6 œӜLMH?kd^$$Ifs'n( tn(6YYYYYYYYY4sa ytj? & F<$If[$\$gdU h$If`hgdU & F($If[$\$^gdU?kd_^$$Ifs'n( tn(6YYYYYYYYY4sa ytj?LMV_`pqabÞ$̡1s3HYj{vn{f{b{^{b^W{b{b{^ hhY^yhY^yhj?hhj?5hhj?>* hj?>* hhj?hhj?5OJQJ^Jhw hj?\"h")hj?5OJQJ\^JaJhj?5OJQJ\^JaJ h@Dhj?h]zh]zhj?5h$~5OJQJ^JaJhj?5OJQJ^JaJh@Dhj?5OJQJ^JaJhw hj?6]M`rڝJba?kd5_$$Ifs'n( tn(6YYYYYYYYY4sa ytj? & Fd  ]]($If[$\$^]gdU & F$If[$\$gdU p@ $If`gd$~A$If^A`gd$~ $Ɵ@iJ> & F h!$If[$\$^gdF6> & F h!$If[$\$^gdF6> & F !$If[$\$^gdF6> & F h!$If[$\$^gdF6> !hh$If^hgdU> !h$If`hgdU p@ $IfgdUܠA"ie> & F h!$If[$\$^gdF6> & F h!$If[$\$^gdF6> & F h!$If[$\$^gdF6> & F !$If[$\$^gdF6> & F !$If[$\$^gdF6 iȤ40u R: $IfgdU"> & F h!$If[$\$^`gdF6> & F h!$If[$\$^gdF6> & F !h$If[$\$^gdF6 jCDӪԪv~ҫӫg "'F 789:;GHI˰̰ܰݰ߰kldz}vd"h@Dhj?5OJQJ\^JaJ h@Dhj?hDhj?5CJ hDhj?5CJhDhD5CJ hDCJh@Dhj?CJ h@Dhj?CJ&h@Dhj?5CJOJQJ\^JaJhw hj?6] hUhj?hj?h6GhY^yhM 6hM hhj?hY^yhY^yhY^y6':;̰߰bln[ p@ $Ifgd & Fd  ]]($If[$\$^]gd & Fd  ]]<$If[$\$^]gdYdd$If\$]gd?kd_$$Ifs'n( tn(6YYYYYYYYY4sa ytj?lmn*678lmnɸ~of`VND=9=hj? h")hj?hDhj?5CJ hDhj?5hDhD5CJ hDCJh")hj?CJh")hj?6B*CJph&h")hj?5CJ OJQJ\^JaJ"h")hj?5OJQJ\^JaJ&h")hj?5CJOJQJ\^JaJ hj?5CJOJQJ\^JaJhw hj?\hhj?5OJQJ^Jh@Dhj?6B*phh@Dhj?B*phh@Dhj?CJ nܲ9OY}̳.ٶ & F+  ]]<$If[$\$^]gd-Ydd$If\$]gd!)?kd `$$Ifs'n( tn(6YYYYYYYYY4sa ytj?/۵ܵض߶ )*+AHY5FGHI^bik"FGȾ񚊃{togt{thuAhj?>* hj?>* huAhj?huAhj?5 hw hj?hw hj?6h dEhj?>* h dEhj?h dEhj?5 h}hj?h dEhj?5OJQJ^Jhw hj?6]h-hj?7\h")hj?B*phh")hj?6B*ph hhhj?hj? h")hj?h]z'*+AYGnnnnnn & F($If[$\$gd!) $Ifgd!) p@ $Ifgd!)?kdv`$$Ifs'n( tn(6YYYYYYYYY4sa ytj? & F+  ]]<$If[$\$^]gd- GHI^"Gdjj> & F !$If[$\$gd-> !hh$If^hgd-> !$Ifgd-?kd`$$Ifs'n( tn(6YYYYYYYYY4sa ytj?$$$ & F<<$If[$\$^gd-GcdefopúĺԺֺػٻ{|żƼɻ~zsozhsozhsaP hj?5CJOJQJ\^JaJ hw hj? hxZ,hjhj? hxZ,hj?hjhDhj?5hDhD5h")hj?CJ h")hj? hpjhj? hShj?hShj?>* hVs:hj?h")hj?5\^JaJ"h")hj?5OJQJ\^JaJhj?5OJQJ\^JaJhw hj?\ h-hj? h=hj?depĺֺbٻyyYYY > & F h!8$If[$\$`gdF6 > & F h!8$If[$\$^gdF6 & F($If[$\$gd-> !$If^gd-?kdLa$$Ifs'n( tn(6YYYYYYYYY4sa ytj? ٻ.DU_|Ƽ > & F h!p$If[$\$^gdF6 > & F h!p$If[$\$`gdF6> & F h!$If[$\$^gdF6 > & F h!$If[$\$`gdF6 4rŽVb=$ ,A b"%W('+-03h$If^hgd-$ ,hA b"%W('+-03h$If^hgd-> !m$If^mgd- h$If`hgd-Y$$$dd$If\$]gd-?kda$$Ifs'n( tn(6YYYYYYYYY4sa ytj?$%*48?A˽NOrs"'>?TUMNcdIJ{|3ԻԻԻԻԻԱԭԻԻԻԻԻԭԻԻԻ hA|hj?hxT]hi{rhS 5 hi{rhS hi{rhj?5 hi{rhj?hj?h9hj?57h9hj?5hCh9hj?>* hj?>* h9hj? hj?5CJOJQJ\^JaJ&h")hj?5CJOJQJ\^JaJ2Os?UNdJf> & F h!$If[$\$`gdF6> & F !$If[$\$^gdF6> & F h!$If[$\$^gdF6> !$If^`gd-f|5oZYd<$If[$\$]gd-?kd"b$$Ifs'n( tn(6YYYYYYYYY4sa ytj?> & F h!$If[$\$^gdF6> !h$If^hgd-> & F h!$If[$\$`gdF635`ɷ{qg]QJBJ>J7 hjhj?hj?hKShj?7 h")hj?hjhj?56CJhjhj?5CJhjhj?5CJhjhj5CJ hKShj?hj?6B*CJph)hFjhj?57CJ OJQJ\^JaJ&h")hj?5CJ OJQJ\^JaJ"h")hj?5OJQJ\^JaJhj?5OJQJ\^JaJhw hj?\h-hj?5OJQJ hA|hj?hA|hj?5OJQJ;Zsal & Fb hx$If[$\$^gd- $Ifgd- & F`  ]]<$If[$\$^]gd-Yd<$If[$\$]gd-> & F+ !$If[$\$gd- `klGUVWo):uvƾ۾ueWh")hj?CJ \^JaJh")hj?5CJ\^JaJ&h")hj?5CJOJQJ\^JaJhm0hj?5OJQJ^Jhw hj?\hj?5OJQJ\^JaJh=hj?CJ hm0hj?hm0hj?5h=hj?5OJQJ^J hw hj? h-hj?hj? h")hj?hjhj?5 hjhj?hj""}p> !h$If^hgd- & F$If[$\$gd-> !hh$If^hgd-> !hh$If^h`gd-?kdb$$Ifs'n( tn(6YYYYYYYYY4sa ytj? VWo;}cDD> & F h!$If[$\$^gdF6> & F !h$If[$\$gd-> !hh$If^hgd-> !hh$If^h`gd-?kdb$$Ifs'n( tn(6YYYYYYYYY4sa ytj?Y & Fd<$If[$\$]gd@;v^mm & Fd  ]]<$If[$\$^]gd-Ydd$If\$]gd-?kdcc$$Ifs'n( tn(6YYYYYYYYY4sa ytj?> & F h!$If[$\$^gdF6]^_`qrIKļzmzd^zQC?hj?h")hj?CJ \^JaJhH.5CJ\^JaJ hjaJh")hjaJhr5CJ\^JaJhj?5CJ\^JaJh")hj?5CJ\^JaJ&h")hj?5CJOJQJ\^JaJ hj?5CJOJQJ\^JaJhw hj?\"h-hj?5OJQJ\^JaJ h")hj?h")hj?CJ h")hj?CJ hjCJhjhj?5CJ^_K%lttttttttt & Fd  ]]<$If[$\$^]gd- & Fx($If[$\$^gdjYdd$If\$]gd-?kdc$$Ifs'n( tn(6YYYYYYYYY4sa ytj? "$rs|}'BWŷxqmfRmHh & F !$If[$\$gd`ZYhdd$If\$]^hgd`Z.> & F 3!F.A b"%W('+-03$If[$\$gd`ZY & Fdd$If\$]gd`ZYdd$If\$]gd`Z Z\]klmǻߧo^P<&hrhj?5CJOJQJ\^JaJh=hj?5CJ\aJ hr5CJOJQJ\^JaJ hj?5CJOJQJ\^JaJ hw hj?&h")hj?5CJOJQJ\^JaJhjhj?5CJaJ&h*CJaJhH.>*CJaJh* h1=hj?hjhj?5OJQJ^JaJhChhj?>* hj?>*hhj?5OJQJ^J hw hj?hw hj?\ h`Zhj?h`Zhj?6hj?hhj?7 hhj?hhj?5hhj?5OJQJ^Jh=hj?CJ ,,K`zbY $Ifgd`Z?kdd$$Ifs'n( tn(6YYYYYYYYY4sa ytj? & F p@ $If[$\$gd`Z p@ h$If`hgd`Z & F| p@ $If[$\$gd`Z<&:av> & F h!$If[$\$^gdF6> !h$If^hgd`Z> & F h!$If[$\$^gdF6> !hh$If^hgd`Z BjkR?kdze$$Ifs'n( tn(6YYYYYYYYY4sa ytj? & F !$If[$\$gd`Z h$If^hgd`Z $Ifgd`Z?kde$$Ifs'n( tn(6YYYYYYYYY4sa ytj?k{R?kde$$Ifs'n( tn(6YYYYYYYYY4sa ytj?> & F h!$If[$\$^gdF6> !hh$If^hgd`Z$ ,FA b"%W('+-03h$If^hgd`Z> !hh$If^h`gd`Z4bQAkdPf$$IfsY'n( tn(6YYYYYYYYY4sa ytj?> & F !$Ifgd!)> !h$If^hgd!)> & F h!$If[$\$^gdF6> !h$Ifgd!) !h$If^hgd!) $Ifgd!)4012ӽqcZH:hw hj?5\^JaJ"hw hj?5OJQJ\^JaJhw hj?CJhw hj?CJ \^JaJhw hj?5CJ\^JaJ&hw hj?5CJOJQJ\^JaJhw hj?6B*CJph hw hj?#hw hj?5B*\^JaJph+hw hj?5B*OJQJ\^JaJphhw hj?\h!)hj?5 hj?5h1=hj?5 h1=hj?h1=hj?>*129?AkdSg$$Ifs'n( tn(6YYYYYYYYY4sa ytj?Ydd$If\$]gd{Pkdf$$Ifs['n(  t YYYn(6YYYYYYYYY4sa p YYYytj? & F($If[$\$^gd{89:EFG=>qrst~Bҽҽ˜whW hw h{6B*^J_H phhw h{:B*CJ phhw h{6_Hhw h{_Hhw h{^J_H hw h{hw h{CJ .hw hj?56B*OJQJ\^JaJphhw hj?5\^JaJ hw hj?"hw hj?5OJQJ\^JaJhw hj?6B*phhw hj?CJ \^JaJ9:>eAkd1h$$Ifs'n( tn(6YYYYYYYYY4sa ytj? & F($If[$\$^gd{Akdg$$Ifs'n( tn(6YYYYYYYYY4sa ytj?>?rstaUSQ~ [$\$gd{Akdi$$Ifs'n( tn(6YYYYYYYYY4sa ytj? p@  $If] gd{Akdh$$Ifs'n( tn(6YYYYYYYYY4sa ytj?BQ z" & F,d[$\$gd{" & F,dx[$\$gd{gd{& & 0` P@1$7$8$H$[$\$gd{ ) h8 xHX (#gd{BPKVbdeyzɼɡzkzXTPLPhvKh h{%hw h{B*OJQJ^J_H phh}c5OJQJ\^J_H "hw h{5OJQJ\^J_H hw h{6hw h{6B*phhw h{B*phhw h{6OJQJ^J_H h ,6OJQJ^J_H hw h{OJQJ^J_H hw h{hc^J_H h ^J_H  hw h{hw h{^J_H ,<il/09»泻xxoh{mHnHujhw h{Uhw h{\ hw hX,hX, hTQh  hTQhTQ hTQh}ch h}c7h h}c>* h h}ch h}c5 h}c5h{hw h fHq h}ch hoN#h hw h{ hw h 'L4eLv "dx[$\$gdX,> & F h![$\$^gdF6> & F h![$\$^gdF6 > !gd}c" & F,dx[$\$gd " & F,dx[$\$gd{ogd{ "dx[$\$gdX,h(},~D  pq # b0xx[$\$]b^`0gd{ogd{9:FGHbcdfght"#$&'126lmnعʰإؔʰإ؃ʰrʰإ jjh{UmHnHu jxjh{UmHnHu jih{UmHnHuh{_HmHnHuhvKmHnHu j~ih{UmHnHujh{UmHnHuh{mHnHuhq2h{^J_HmHnHuh{5OJQJmHnHu,[\]wxy{|}   &'(*+8\]^x׿q jlh{UmHnHu jllh{UmHnHuh{_HmHnHu jkh{UmHnHuhq2h{^J_HmHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu jrkh{UmHnHuh{mHnHu'xyz|}"#$>?@BCMN}~ϳϢϓr jnh{UmHnHuhq2h{^J_HmHnHuh{5OJQJmHnHu j`nh{UmHnHu jmh{UmHnHuh{_HmHnHuh{mHnHuhvKmHnHujh{UmHnHu jfmh{UmHnHu&    . / _ ` a { | }              & ' ( B ıό{lZ#hq2h{^J_HaJmHnHuh{5OJQJmHnHu jTph{UmHnHu joh{UmHnHu'hq2h{6B*_HmHnHphu$hq2h{B*_HmHnHphuh{_HmHnHuh{mHnHuhvKmHnHujh{UmHnHu jZoh{UmHnHu  H   B  J  Q  p)wT  # b0xx[$\$]b^`0gd{qpB C D F G H T x y z                 ! " < = > @ A K L     ohq2h{^J_HmHnHu jHrh{UmHnHu jqh{UmHnHu jNqh{UmHnHuhq2h{_HmHnHuh{mHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu jph{UmHnHu&       ( ) * D E F H I V          / 0 1 K L M O P Z [     tb#hq2h{^J_HaJmHnHu j* hX,5>* hvK5hy&hX,5 hX,5hnhX,5h{OJQJ^Jhw h{OJQJ^J hw h{&$!y"z"" ##&'9'')))Z)k***+ & Fhxx[$\$]hgd{ h\$]hgd{ hx]hgd{ h[$gd{ xgd{ hx]hgd{ x7$8$H$gd{ 7$8$H$gdX,'9'N'`'t'u'v'''(((((())Z)W*i*k*~*******.++,N-5..x///////00100.1<1=1ζ菆vhw h{h_u46B*phhw h{CJhw h{_Hh{h{5OJQJ^JaJh;F5OJQJ^JaJh@h{B*phhw h{6B*phhw h{B*ph hh{hw h{6 hw h{hw h{5OJQJ^JaJ.+O-.l///00 22B3!44569;;)<= 7$8$H$\$gd{ 7$8$H$\$] gd{ & Fx\$gdqgd{ xgd{ x]gd{x\$gd{gd{ & Fhx\$]hgd{=1K1M1O1Z1\1a1}1111 2>2?2N2V2y22222222B3I3J3_3p33333e4i4p4q444444555[5\5r5y5{5555555555556666666ԽԳԳԫhw h{5h{ h{_Hhw h{_Hhw h{56B*ph hw h{hw h{B*phhw h{6B*phhw h{5B*phC66666666774797J7K7a7j7l7|777777777777)8?8F8H88888889J9S9^9_9m9z9|999997:K:f:g:u:::::::;+;>;@;Y;Z;ıııııhqh{B*phhqh{5hqh{6B*phhqhw h{6hw h{6B*phhw h{B*ph hw h{h{CZ;[;;;;;;)<*<?<<<===>>>>>?6?d@e@@@@@(AAAMASAAȽzrje]e]eXe] hvK5hy&hX,5 hX,5hnhX,5hX,hX,5hw h{5&hw h{h6B*OJQJph#hw h{hB*OJQJphhw h{6hw h{6B*phhw h{B*phhw h{5OJQJ^Jhw h{CJhw h{_H hqh{ hw h{hw h{h =>?6?AAA5BBrCDDEEFz\$gd{O Eƀ[$gd{ 7$8$H$gdX, x7$8$H$gd{gd{V & F xx[$\$gd{m$AAAAAAB4BEBhBqB|BBBBCC_DDDDEEEEG"G#G9G:GjGkG甂ufu]hw h{CJhw h{6B*_Hphhw h{B*_Hph"hw h{56OJQJ^JaJhw h{5OJQJ^JaJ h. h{hw h{h~hw h{5 h ,6hw h{6hw h{_Hhw h{CJ hw h{^J_H hw h{hy&hX,57>* hX,5>*FF GkGGVHHOIIJ9JrJJKKK$MNN "d^gd{ & F x[$]gd{gd{ & F xx[$\$gd{\$gd{ & F x[$]^gd{kGGGGGGVHHHCILIIIIIIJJJJJJKKKKKNNNOOOPRP쪷쒀o`Xhw h{\hw h{0JIOJQJ^J hw h{0JI5B*^Jph#hw h{0JI56B*^Jphhw h{0JI5^Jhw h{\]_Hhw h{^J_HaJhw h{CJ hw h{_Hhw h{6hw h{hf]6B*phhw h{B*ph hw h{hw h{6B*ph"NOOPQQSSUUVVXuXXYZ\Y^_Vx[$\$^gd{m$V & F xx[$\$gd{m$gd{]gd{gd{D^gd{RPPQQORZRnRoRSSSTT U UUUUVV X XXX$XtXuXXXYZZ[[[𧚧zozo^ hw h{6B*OJQJphhw h{OJQJhw h{5OJQJhw h{CJ hw h{^J_Hhw h{6B*phhw h{B*phhw h{\]_Hhw h{0JIOJQJ\^Jhw h{0JIhw h{0JI5hw h{0JIOJQJ^J hw h{hw h{5"[=\k\\\\ ]7]8]I]]]]]]5^F^X^Y^^^^_______K`W``ñàshhaaXhw h{_H hw h{hh{B*ph hh{6B*OJQJphhh{B*OJQJphhh{5B*ph hh{5B*OJQJph#hw h{56B*OJQJph hw h{5B*OJQJphhw h{OJQJ hw h{6B*OJQJphhw h{B*OJQJph__K`` aaa b6bBccc*ddde & F\$gd{ V & Fx\$gd{m$V & Fxx[$\$gd{m$\$gd{xgd{ h[$]gd{V & F xx[$\$gd{m$V & F xx[$\$gd{m$oeӆ`` aa b b6bRbSbccd(dTdoddd^e_eeeff4f6fJf{f|ffff#gwgggggghChDhzh{hhi%i&i3iܾ㾥ܾxܾܾܾ hRh{hw h{B*phhw h{56B*phhw h{5B*phhw h{6B*phhw h{5OJQJhw h{5hw h{6hw h{5OJQJ^J hw h{hw h{OJQJhw h{^Jhw h{CJ/e$gwghijfk4lllnnpp Vx[$^gd{m$gd{ gd{ojҦV ,xx^gd{m$V ,xx^gd{m$ohӦ & F*\$]*gd{ & F\$gd{ & F\$gd{ x[$^gd{ 3iDiEisiiiiiinjojjjjjkkHkLkekfkxkykkk4llnnppp]qrrrtttttʽʽʽսՏ՝~oghw h{6hw h{B*OJQJph hw h{6B*OJQJphhw h{5OJQJ^Jhw h{OJQJh;h{5 h{5h7h{5hw h{6B*phhw h{B*ph hw h{hw h{56B*phhw h{5B*phhw h{5(prtwuu vbvvwwyy$zYz#{f| & F x[$]^gd{ $dN V^gd{m$ V[$^gd{m$ gd{ojҦ\$gd{ [$gd{ Vx^gd{m$Vxx[$\$^gd{m$ttuuu vv/vEvbvvvv wwwx-x]xyPyQyaycyyy#z$z0zXz#{I{f|g|}|||𴨴}p}chh{5B*phhw h{6B*phhw h{5B*phhw h{5hw h{CJ hw h{^J_HaJhw h{6OJQJhw h{OJQJhw h{5OJQJ^Jhw h{h)Yyhw h{h)Yy6B*phhw h{_H hw h{hw h{6$f||;}k}}~Y~V.? & F x[$]gd{ x[$\$]gd{ x[$]gd{ [$]gd{gd{ & F x[$]^gd{|||;}k}}~~Y~z~~~~.V./TUv>?<;<,-/0DUw察}rhw h{h~6hw h{h)Yy^Jhw h{hf]5hw h{B*phhw h{hf]6B*phhw h{hf]B*phhw h{6hw h{5OJQJ^Jhw h{CJhw h{_H hw h{hw h{5hh{B*ph)<0mӇlO#| x[$\$gd{ "d^gd{ ) h8 xHX (#gd{ & F x[$]gd{ & F x[$]gd{ohӦ & F x[$]gd{ w҇Ӈl4q!#BC~RST^ՑّQ*sٿٻٻٳٻ٥ٜٜ٘ٻٻَ}}uuhw h{5hw h{6hw h{CJhw h7dh7dh{hw h{aJhw h{hc56]hw h{]h7d hw h{6B*^J_H phhw h{_H hw h{hw h{CJ hw h{6^J_Hhw h{^J_H.CȌ7ĎxRTRxgd{ h[$]gd{gd{ "d^gd{" & F%d[$\$gd{" & F%d[$\$gd{" & F& 8dx[$\$^gd{[r~ƔߔIVWXc`a֗!dԚDUtuynahw h{6B*phhw h{B*phhw h{5OJQJhw h{OJQJhw h{^Jhw h{5OJQJ^Jhw h{6hw h{56hw h{_H hw h7dhy&h7d57>* h7d5>* hvK5hy&h7d5 h7d5hnh7d5h{ hw h{&WXWɚН(wx7$8$H$]gd{V ,xx^gd{m$Vxx^gd{m$Vxx]^gd{m$ "dh^gd{ "dd^gd{xgd{ 7$8$H$gd7dST34&%v$R~T}'˥ե֥ͷ堙zhw h{6]hw h{]hw h{OJQJ^J h~h{hw h{5OJQJ^Jhw h{_Hhw h{6hw h{hOJQJhw h{6B*phhw h{B*ph hw h{hw h{OJQJhw h{5.S~U iC)*xgd{h[$gd{h[$ & F xx[$\$gd{\$gd{xgd{ 7$8$H$gd{ x7$8$H$gd{')*]  FGHIƸ屭哊{k]L j |h{UmHnHujh{UmHnHuh/ nh{^J_HmHnHuh{5OJQJmHnHuh{mHnHujhw h{Uhw h{\ hJ h{h{ h/Oh{hdDDh{6B*]phhdDDh{B*phhw h{B*phhw h{_H hw h{hw h{CJ hw h{^J_H* GH;ů.$*ܵhݶ^<pq # xx[$\$]^`gd{ogd{xgd{ˮ5679:DEïįůѯޯ߯  ()*ѵڣђkZ j}h{UmHnHu'h/ nh{6B*_HmHnHphu$h/ nh{B*_HmHnHphu j}h{UmHnHu#h/ nh{^J_HaJmHnHu j|h{UmHnHuh{_HmHnHuh{mHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu#*,-78 "#0pqrܱݱޱ @߯ߤߓߤ߂qߤ jwh{UmHnHu j~h{UmHnHu j}~h{UmHnHuh{_HmHnHu j~h{UmHnHuh/ nh{^J_HmHnHuh{5OJQJmHnHuh{mHnHujh{UmHnHuhvKmHnHu,@AY[ijk'wxyŷŦŎ~ŷmŷ\ŷ jh{UmHnHu jqh{UmHnHuh/ nh{^J_HmHnHuh{5OJQJmHnHuhvKmHnHu jh{UmHnHujh{UmHnHuh{mHnHuh{_HmHnHu'h/ nh{6B*_HmHnHphu$h/ nh{B*_HmHnHphu$<=RTdef  $%&()34Tıόı{l\h/ nh{^J_HmHnHuh{5OJQJmHnHu jeh{UmHnHu jh{UmHnHu'h/ nh{6B*_HmHnHphu$h/ nh{B*_HmHnHphuh{_HmHnHuh{mHnHuhvKmHnHujh{UmHnHu jkh{UmHnHu Tkֵ׵صڵ۵ܵ12EFGHbcdfgt׶նǭǞՓl[ǭՓ j_h{UmHnHu'h/ nh{6B*_HmHnHphu$h/ nh{B*_HmHnHphuh{_HmHnHuh{5OJQJmHnHuhvKmHnHu jh{UmHnHujh{UmHnHuh{mHnHuh/ nh{^J_HmHnHu"h/ nh{6^J_HmHnHu׶ضٶ۶ܶ<=>XYZ\]^jϷзѷ678:;<Hklmϟϔσrϔ jSh{UmHnHu jքh{UmHnHuh{_HmHnHu jYh{UmHnHuh/ nh{^J_HmHnHuh{5OJQJmHnHuh{mHnHuhvKmHnHujh{UmHnHu j܃h{UmHnHu(ڸ۸ܸ|}~ VWXrϟϔσϔr jGh{UmHnHu jʆh{UmHnHuh{_HmHnHu jMh{UmHnHuh/ nh{^J_HmHnHuh{5OJQJmHnHuh{mHnHuhvKmHnHujh{UmHnHu jЅh{UmHnHu'xԺ2 !"#:H [$\$gd{ h[$\$gd{ # bxx[$\$]b^`gd{ # xx[$\$]^`gd{pqrstvwxκϺкҺӺ,-.01?q jh{UmHnHu j;h{UmHnHu jh{UmHnHu jAh{UmHnHuh{_HmHnHuh{mHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu jćh{UmHnHu*-9:FHLWyznv9>퓆tle hh{hw h{6hw h{56B*phhVVIhw h{6B*phhw h{B*phhw h{56hw h{5hNh{6B*_HphhNh{B*_Hphh7dhw h{_Hhw h{CJ hw h{^J_H hw h{jhw h{U#HLj ^QxEƀ [$\$]gd{ & F2xh[$\$gd{ & F2xx[$\$gd{ & F2x[$\$^gd{ & F2x[$\$gd{ [$\$gd{ > ijv ' :Qɿ췭줟줍sh]hn5OJQJ^Jhw h{B*phhdDDh{6B*phhw h{6B*phha6B*phhVVIh{6 hVVI6hVVI hVVI\hnB*\phhw h{\hnB*_Hphhw h{_Hhw h{CJ hw h{^J_HaJh{ hw h{hh{6B*ph 7_RRR x$If[$gd{|kd5$$IflH0 t0644 lal$x<$If[$\$a$gd{x[$\$]gd{ 74EIUVWB\ŵШyyttyymimah <h{5hn hw h{ h85hvhn6B*phhvhnB*phhnB*phhvhn5 hvhnhvhnB*\phhG`hn6CJOJQJ^Jhn5OJQJ^Jhvhn5OJQJ^J#hvhn6CJOJQJ^JaJhn6CJOJQJ^JaJ&=cSQOLx[$\$]Lgd{zkdЊ$$Ifl0 t0644 lal x$If[$gd{x$If[$\$]gd{\<gnxy_l )~*=&,c| hvK5hy&h!b5 h!b5hnh!b5 h{\hw h{5\hw h{\h/Oh{6 h/Oh{h{hw h{5hw h{7hVVIhw h{_Hhw h{CJ h{^J_Hhw h{^J_H hw h{.=y_5K & F3x7$8$H$[$\$gd{" & F3d[$\$gd{ 7$8$H$gd!b\$gd{ & F0x[$\$gd{ & F0xx[$\$gd{x\$gd{ & F0hxx[$\$]hgd{ x[$\$gd{c5Kp\]efi%;վնծժ՟ժՅՁվվshw h{5OJQJ^Jh{hw h{_Hhw h{CJ h{^J_Hhw h{^J_Hhlhhw h{6hw h{5hw h{\hnh!bh{57>* hw h{h857>* h85>* h!b5>*hy&h!b5 hV5&K]e%*;  \$]gd{ [$\$gd{ & F*xx[$\$gd{ & F xx[$\$gd{\$gd{gd{ & F0gd{ABXYd!$%&+g )*ʾyogooggyhw h{5h{6B*phhw h{6hw h{hf]6B*phhw h{B*ph hw h{hw h{6B*phhw h{5OJQJ^Jhw h{5OJQJ hw h{5B*OJQJph#hw h{56B*OJQJph$hw h{5B*OJQJ^Jph(-GI:;< ^_`a}~ö۲۪۪öۑ|ulhb h!bCJh!bh!b5CJ\ h!b5CJhw%h!b>*hw h{B*]phhw h{6B*]phhw h!bh!b5hw h{5h{hw h{6B*phhw h{B*phhw h{_Hhlh hw h{h`sh{B*phh`sh{6B*ph h{6$ ^D} <<$IfgdTgd!b "d^gd{ & F*xx[$\$gd!b & F*xx[$\$gd{ }~) <<$IfgdTkdg$$IfTl4\ YS  (%%%%0J"64 lauf4p(%%%%ytTT2<=>?GHKoxyz:Qʽxtdtthw h{6B*\^Jphh{hh6B*phhhc6B*phhw h{^Jhw h{6B*_Hphhw h{B*_Hph h{_Hhw h{_Hhlh hw h{hw h{OJQJ^Jh;F5CJOJQJ\^Jh!b h!bCJh?]O?5-[$gd{ $dN"[$\$]"gd{ "d^gd{kdP$$IfTl\ YS 0J"64 lauytTTxyx$If[$\$gd{ $Ifgd{ <\$]gd{]gd{[$gd{-EwxyɼɱrbR@R@Rb"hw h{5CJOJQJ\^Jhw h{5OJQJ\^Jhw h{CJOJQJ\^J hDh{5B*CJaJph2hDh{56B*CJOJQJ\^JaJph&hDh{5CJOJQJ\^JaJh{6B*]phhw h{B*]phhw h{6B*]ph"hw h{6CJOJQJ\^Jhw h{6B*\^Jph hw h{ iQ933$IfHZ(x$If[$\$]H^Zgd{ZZx($If[$\$]Z^Zgd{kd$$$Ifl44   F~ &$~  j t0       44 lalf4yt;F   !"#5678STopq78BCFVlŹծծŹծծŹծծŹծծ h{_Hhw h{_Hhlhhw h{5OJQJ\^J hw h{hw h{B*phhw h{5CJ\hw h{CJOJQJ\^J+hw h{6B*CJOJQJ\^Jph(hw h{B*CJOJQJ\^Jph3  !8TpkS;55$IfZ(x$If[$\$]^Zgd{ZZx($If[$\$]Z^Zgd{kd$$Ifl4   F~ &$~  j t0       44 lalf4yt;FpqkS;55$IfHZ(x$If[$\$]H^Zgd{ZZx($If[$\$]Z^Zgd{kd$$Ifl4   F~ &$~  j t0       44 lalf4yt;F8kS;55$IfHZ($If[$\$]H^Zgd{ZZx($If[$\$]Z^Zgd{kdU$$Ifl4   F~ &$~  j t0       44 lalf4yt;F89:Vk_]QE6 & F1x[$\$gd{ x[$\$gd{ x[$\$gd{ [$\$gd{kd$$Ifl4   F~ &$~  j t0       44 lalf4yt;F()/=S G]_`vb{12OP ()*234?hw h{^J_Hh Y hnhn hnh{hvKhw h{6hw h{6B*phhw h{B*phhw h{5>* h{5hn5B*phhw h{5hsh{ hw h{hnB*_Hph3_{c*Z9(K & F.xh[$\$gd{ & F.x[$gd{\$gd{xgd{gd{ "d^gd{ & F1x[$\$gd{ & F1x[$\$^gd{?Zjnyz+Idghv}8<HIbcd9ABCasվպպղվծծգȈȈ h!K5_Hh!K5^J_Hhw h{6B*phhw h{B*phhshB*phhch{ h{_Hhw h{_Hh Y hw h{hw h{CJ hs^J_Hhw h{^J_Hh{^J_H5'RYc'57GIKry*I 34{|}W^<Cv;BU·в𮦮𗒊 hw h'hm]Wh'5 h'5h{ hw hhh'h'6h' hj5h!K55OJQJ^Jhw h{5OJQJ^Jhw h{5hjhjhj6h!K5h!K56h!K5 hw h{hw h{_H2}<UDnyy & F7 <[$\$^ gd{`\$^``gd{ & F6xx[$\$gd{ & F6xx[$\$gd\$gd{x[$^`gd{x[$\$^`gd{x[$\$^`gd{gd{Uaovx&''/012<=>KReԓۀyuyuyukyhw hz5\hz hw hzhw hz6hw h{B*phhzhzB*phh$h{5\hw h$\ h$6\hw h$6\ hw h$h$h'B*ph hw h{ hz6hw h{6hjh' hjh{hjh{6'n'12x565   & F/xx[$\$gd{\$gd{gd{ & F7 <[$\$^ gdz`\$^``gdzp<[$\$^pgdz & F7 <[$\$^ gd$ & F7 <[$\$^ gd{e 45674 5           ֵΪynneVh{5OJQJmHnHuh{mHnHujhw h{Uhw h{\hw h{5hw h{_Hh Y hw h{hw h{6B*phhw h{B*phhw hz5B*\phhw hzB*phhzB*ph hw hzhw hz5\hw hz\ hz6\hw hz6\ ( )   e    G  L`bcdel # xx[$\$]^`gd{pq # xx[$\$]^`gd{ogd{xgd{ & F/gd{ C D E _ ` a c d e q           \ ] ^ x y z } ~             $ % & @ ؾدؾؾدqؾ j@h{UmHnHu jÓh{UmHnHu jFh{UmHnHuh{_HmHnHuh{5OJQJmHnHuhvKmHnHu jɒh{UmHnHujh{UmHnHuh{mHnHuh Vh{^J_HmHnHu,@ A B E F G S          )*+EFGJKUV>?YZ[^_`q jh{UmHnHu j4h{UmHnHu jh{UmHnHu j:h{UmHnHuh{_HmHnHuh{mHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu jh{UmHnHu)`ap=Okl$U\gny9Jnop"67햋|hw h{OJQJ^JaJh45OJQJ^Jhw h{5OJQJ^Jh4hGVhz hm]WhGV hGV5hm]WhGV5 hV_H hGV_Hhw h{_Hhw h{CJ hw h{^J_H hw h{jhw h{U.lo>xnhx7$8$H$[$\$^hgd{ & F8 x[$\$^gd{hxx[$\$^hgd{ hhhx7$8$H$[$\$]^h`gd{ x7$8$H$gd4x[$\$]gd{ x7$8$H$gd{7$8$H$[$\$gdGV 7diQb=>?;wapw)W0QX  !!!!!!:"ȺײȺȺӲȺȺףיhw h{h. hw h{6 hw h4h4h45hw h{5OJQJ^Jh45OJQJ^Jh4 hw h{hw h{OJQJ^JaJ h45 hz 5hm]Wh459M9N9˿íhw h{6^Jhw h{5h{hm5OJQJ^Jhw h{5OJQJ^JhmhVhw h{6h% h%_Hhw h{_Hhw h{CJ hw h{^J_H hw h{ hm]Wh%72g33745 6d6c77N9:::B:C::q # bxx[$\$]bgd{ogd{ x]gdm & F8x^gdm hx^hgdm hhx7$8$H$]^h`gdmxgdm & F;xx[$\$gd{N9:!:A:B:C:D:::::::::::::::;;;;;;;;;<<<5<6<7<:<;<H<<ʺ٬ٛه٬vه٬eه j(h{UmHnHu jh{UmHnHuh{_HmHnHuhvKmHnHu j.h{UmHnHujh{UmHnHuh6h{^J_HmHnHuh{5OJQJmHnHuh{mHnHujhw h{Uhw h{\h1{ hw h{':;<<<%==>>8???E@G@H@@@@@@@ArBBkD]gd{gd{ # bxx[$\$]bgd{qp<<<<<<<<<===== =#=$=1=============>>>>>+>>>>>>>>>>???1? jh{UmHnHu jh{UmHnHu jh{UmHnHu j"h{UmHnHuh{_HmHnHuhvKmHnHu jh{UmHnHujh{UmHnHuh{mHnHu01?2?3?6?7?D?q?r?s?????????????????@"@#@$@>@?@@@C@D@E@F@H@ϳϤσrg` hw h{jhw h{U jh{UmHnHu jh{UmHnHuh6h{^J_HmHnHuh{5OJQJmHnHu jh{UmHnHuh{_HmHnHuh{mHnHuhvKmHnHujh{UmHnHu jh{UmHnHu$H@I@M@N@O@@@@@@@AArBCCEEEF2FhF|FJGaGHH%I&I[$\$gd{ & F> x[$\$gd{ & F>xx[$\$gd{x\$gd{[$gd{ gd{gd{gd{MMGNNPPQUQRPRTTUPVVV WXXX'Y3YYY9Z[\\B]]]]]]]^F_G____Ÿ򫒫х~z~sk~g~g~h9hw h{] hw h9hp\] hxx[$\$gd} & F>xx[$\$gd{^F_r___X``]aadbc7ddegRhShhiigd{@ ]@ gd{ xx[$\$gd{ & F=xx[$\$gd{ & F=xx[$\$gd{ & F= [$\$^gd9__2`3`:`T`U`W`X````OaPaZa[a\a]aabbc1c7ddReSe_hhhiiijjkkl򵨵ȗ~ug_hw h{5hw h{5OJQJ^Jhw h{_Hhhw h{6\]hw h{\]!hw h{5OJQJ\]^Jhw h{6B*phhw h{B*phhw h{6hw h{]h{6B*phhzh{6B*phhzh{B*ph hw h{ h9h9%ijlmnoNpp5qqrpstPuuwbxyy z & FCxx[$\$gd{gd{ & FBxx[$\$gd{]gd{ & FAxx[$\$gd & FAxx[$\$gd{x\$gd{l'lm-mnnooMpNpfppppp5q6q* h%M>*hhz h5hz h{5 hz h{hw h{6hRh{6B*phhRh{56B*phhRh{B*phhw h{5OJQJ^J hw h hV5 h+=?h h5h{ hw h{hw h{5*vvvvw w!w7w8w:w;w*mHnHu jPh{UmHnHu jӡh{UmHnHuh{mHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu jVh{UmHnHu$fgŠ12367o١ڡۡޡߡ23478ǢȢɢ̢͢עпгТгБЀo jh{UmHnHu j>h{UmHnHu jh{UmHnHu jDh{UmHnHuhQh{mHnHu jǣh{UmHnHuh{mHnHuh{5OJQJmHnHujh{UmHnHuhvKmHnHu+89΢O? ---hA  gd{gd{qpעآ,-.HIJMNO٣ڣ89:=>Pعʰ؟ʰ؎ʰ}ʰlʰ j,h{UmHnHu jh{UmHnHu j2h{UmHnHu jh{UmHnHuhvKmHnHu j8h{UmHnHujh{UmHnHuh{mHnHuhQh{^JaJmHnHuh{5OJQJmHnHu'P  xyz  &'(+,ꢔܢra jh{UmHnHu j h{UmHnHu jh{UmHnHuhQh{^JmHnHuh{5OJQJmHnHu j&h{UmHnHuhvKmHnHu jh{UmHnHujh{UmHnHuh{mHnHuhQh{mHnHu&  &'(+,wx   &'(+,-9^bd٩߽߱ߢ߃ufuZhQh{mHnHuhQh{6>*mHnHuhQh{6mHnHu jh{UmHnHuhQh{^JmHnHuh{5OJQJmHnHuh2Jh{mHnHu jh{UmHnHu jh{UmHnHuh{mHnHujh{UmHnHuhvKmHnHu#٩ک۩FGabcfgҪӪ^_yz{~ʫ˫ :{mhQh{^JmHnHuh{5OJQJmHnHu jh{UmHnHu jh{UmHnHu jh{UmHnHu jh{UmHnHuhvKmHnHu jh{UmHnHujh{UmHnHuh{mHnHu):;<?@A    )*vhW jyh{UmHnHuhQh{^JmHnHuh2Jh{CJ mHnHuhw h{mHnHuhw h{CJ mHnHu jh{UmHnHu jh{UmHnHuh{mHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu jh{UmHnHu"ڮdf+,-89P\$gd{gd{ # xx[$\$]^gd{ # xx[$\$^gd{  xx[$\$]^`gd{pqgd{hiӮԮծخٮBC]^_bcdeg+,-89slc\c hw h{hw h{CJ hEwVh{hEwVh{6B*phhw h{B*phjhw h{B*Uph jmh{UmHnHu jh{UmHnHu jsh{UmHnHuhvKmHnHu jh{UmHnHujh{UmHnHuh{mHnHu$9CDOP #%ڳ۳ݳ *Bz,yzػ ܼPiܾݾ!"#ΐytiah{CJaJha@<h{OJ QJ h{6h2Jh{6B*phhw h{5CJhw h{CJhw h{aJhw h{^JaJ hC5hw h{5hw h{0Jc5CJOJQJhChw h{5OJQJ^Jhw h{CJ hw h{^Jhw h{^J_H hw h{$.yݳD/µm"zػ P"#W Y\$]Zgd{Y]gd{[$\$gd{gd{ & FHx[$\$ j\$]j#W~+,0:.MYjku콲}}}yuncZnhw h{CJ hw h{^JaJ hw h{hYh+u hh0h0B*CJphhjRh0B*CJphhjRh05B*CJphh0CJaJh")h0CJaJ h{CJh ^h00Jjh0Uhw h0CJh0jh0Uhw h{CJhw h{CJaJZ,jk. ?@C]gd{gd{gd{[$\$gd{gd{Yh[$]^hgd0 h[$\$gd0Zgd0 Y & FJ[$] Y & FJ[$] ?@JB"'Eauvd7 Gտ𤞤𤘑xnhw h{5\hRh{5\hw h{5 hw h0 hAz,h0 h{CJ h,CJhw h{CJhw h{5OJQJ^Jh0hw h{6B*phhw h{^Jhw h{CJ hch{jhIhgU hw h{hch{CJ(Y"v`g & FM[$\$gd{ & FI xx[$\$gd{\$gd{gd{gd0 Y[$]gd{gd{ Y & FJ[$]Y & FJ[$]gd{ dgd{G}~fg#]+P|F56 #cdTa8W漳抝~y~y h9 5h9 h9 5h9 h06hw h{5OJQJ^Jhw h{6hrh{5CJHOJQJhw h{CJ hw h{^JaJhYh0j"!hIhDUh{hw h{>* hw h{hw h{5\hw h{\/$<6 $Ifgd{$Ifx[$\$gd{ [$]gd{\$gd{gd{ & FI x[$\$]gd{ & FMZx[$\$]Zgd{ 67BnO & F Lxx[$\$]L^`gd{ & F Zxx[$\$]Z^` \$\$gd{gd{_kdT$$Ifl0   t 44 lalp 2IMrrW & FT 8L8xx[$\$]L^8gd{ & FU Txx[$\$gd{ & FT 88xx[$\$]^8gd{ & F xx[$\$]^`gd{ 7$8$H$^gd9  & F xx[$\$^` & F #x[$\$^#`gd{W;HI cM%'23Yrtu  aѲљѐ{qiѐhw h{>*hw h{hLahw h{hLa>*hw h{5PJ hw h{PJ hrbeh{5OJQJ^JjՈh=hgUhw h{CJ OJQJ^Jhw h{6hw h{5 hw h{h9 h9 57>*h9 h9 5>* hvK5 h9 5h9 h9 5)&'-3$If[$\$gd{$$If[$\$a$gd{[$\$gd{x[$gd{ R [$\$]R gd{{vccS$If[$\$gd{$$If[$\$a$gd{gd{kd $$Ifl0 X$8 t0644 la p9:OZa8  %&D!XY OSz>$+L~ ip|Ƴ hdDDh{ hp*h{hw h{hLa>* hRh{hw h{56hY hHBz5hw h{5hw h{6hw h{6B*phhw h{B*ph hw h{hw h{5PJ 80.{vbbvYMb & FVxx[$\$ hx\$^h & F 8xx[$\$]gd{kd $$Ifl0 X$8 t0644 la p!Y3> $zgd{ & F 8TV[x[$\$]V^[gd{ & F 8TZTxx[$\$]Z^Tgd{ & F 8xx[$\$ & F 8TTxx[$\$]^Tgd{ & F 8xx[$\$]gd{L~)efg & F 8xx[$\$gd{gd{ & F 8xh[$\$gd{gd{ & F 8x[$\$gd{ & F 8TTxx[$\$^Tgd{ & F 8xx[$\$|} /enP$rqfgLtvʼ먟Ջ~vk~k~k~khw h{B*phhw h{6hw h{6B*phhw h{hLahw h{5PJ hw h{PJ 'hw h{5CJOJPJ QJ^JaJhrbeh{5OJQJ^Jh{5OJQJ^Jhw h{hLa>* hdDDh{h hw h{hw h{5 hY5*$$If[$\$gd{Zd$If[$\$^gd{$$If[$\$a$gd{[$\$gd{g<{vqZZFF & F 8xx[$\$] & F 8xx[$\$]gd{gd{gd{kdX $$Ifl0 X$8 t0644 la p;-45- Y  %   $ % & ·뙏τzme^e^ h=h{h=h{5hw h{OJQJ^Jhw h{hLahw h{hLa>*hw h{5PJ hw h{PJ hrbeh{5OJQJ^J h2Jh{h2Jh{B*phh2Jh{6B*phhw h{6B*phhw h{B*phhOG hw h{hw h{5 hOG5$<Z$If[$\$gd{$$If[$\$a$gd{gd{ & F 8TTxx[$\$]^Tgd{-pc{kkkfO & F 8xx[$\$]gd{gd{ & F 8xx[$\$kd $$Ifl0 X$8 t0644 la pc &  & % G XZgd{ & F 8xx[$\$]gd{ & F 8xx[$\$gd{ & F 8TTxx[$\$^Tgd{ & F 8xx[$\$gd{ & F 8x[$\$gd{& `    # $ % 5 ? @ G   Z>hi ?LFGxLWhrbeh{5OJQJ^J hOGhOGhw h{\] hOG5hw h{6hw h{hLa>*hOG hzh{hw h{h+}hw h{5OJQJ^JhY hRh{ hp*h{ hw h{hw h{54LRX>kd $$Ifl0 X$8 t0644 la p$If[$\$gd{$$If[$\$a$gd{gd{ & F:8x[$\$^8gd{/jkm|7UWXY3Jjk#%&-.JZ㼸㼸㫤㼸㤜ۈ h6ah{ hRh{hw h{OJQJ^Jh>Nh{5 h7h{hp*h{OJQJ^JhOG hOGhOGhw h{6B*phhw h{B*phhw h{5 hw h{hw h{hLahw h{hLa>*.dY&jh[$\$^hgd{ & F: 88xx[$\$^8gd{ h^h`gd{gd{ & F:8x[$\$^8gd{ & F:8xx[$\$^8gd{gd{!!S"T""""""!#q#r###^$_$$$$$%&*&&&&(((w+x++G,d,e,,#-￸ﴢ}voovvv hThT hrhThAz,hTCJ hThTCJOJQJ^JaJhT hAz,hT#hThT5CJOJQJ^JaJh{ hdDDh{hdDDh{hVhw h{6hOG hOGhOGhw h{hLa>*hw h{5 hw h{hw h{hp*(!!"#$$*&&&'((x++$--- & F[$\$gdT & F[$\$gdTgdT & F:8x[$]^8gd{ & F:8xx[$\$^8gd{gd{ & F:xx[$\$^gd{#-$-3.?.\.{.....000011112 2 2#2$2T2s222=3>3?33,4~44455 5_5`5a5c55ƻzlhrh{5CJHOJQJhw h{CJ hw h{^JaJh9 hT57>* hm]WhT hT5hm]WhT5 hw h{ hw hThThTCJaJhAz,hTCJaJhY40hT>* hT>*hThrhT5hY hrhThrhTCJ aJ *-.3...///// 0001$22>3 & F[$\$gdT ^`gdT > !gdTgdT & F[$\$gdT & F[$\$gdT & F[$\$gdT & F[$\$gdT>3?3355`5a5c56 6R_kdS$$Ifl0 B  t 44 lalp $Ifgd{$If x[$\$gd{gd{ 7$8$H$gdOG7$8$H$[$\$gdTgd{x[$]^gdT 5566"6+6,6x778/8 99i99999999999:::::;v;;;;M<b<q<w<===%===>???۵۬ۚۖۏxjh2Jh{Uh2Jh{6hx' h2Jh{h^hY h{6hY h{5PJ hY h{PJ hrbeh{5OJQJ^JhY h{5OJQJhw h{5h{ hY h{hw h{5OJQJ^J hw h{hw h{6/ 668899::::;$If[$\$gd{$$If`a$gd{$$If[$\$a$gd{gd{ & FPx[$\$gd{ & FPx[$\$gd{ ;;;<d<<*=>>{sdQQQdd & FP x[$\$gd{ & FPx[$\$gd{\$gd{kd$$Ifl0 ," t0644 la p>>>????@BBBBBBCx<$If[$\$]gd{ $If`gd{$$If[$\$a$gd{ & FW hhx\$^hgd{  $dNgd{ [$\$gd{ [$\$gd{???2@AfAgAAAAAAABBBKBnBBBBCCCCCCC EIEEEEEZFpFFFFFG G򧚧zrhw h{\hw h{6\hw h{6B*\phhw h{6hw h{6B*phhw h{B*phhrbeh{5OJQJ^Jhw h{56hw h{5hY h{5hY h{6B*phhY h{B*ph hw h{ hY h{)CC`D EEEo[F3$$If[$\$a$gd{ & FW hhx\$^hgd{ & FQ 8x[$^8gd{ & FQ 8xx[$\$^8gd{ykd}$$Ifl0~ #r t044 la EEqFrFFAGGHiUAAA & FQ x[$^gd{ & FQ 8x[$^8gd{ykd;$$Ifl0~ #r t044 la H<<$If[$\$]Hgd{ $Ifgd{ G@GAGqGGGGHIHHHHHII/K0K6K*hY h{5OJQJ^Jhw h{6hw h{5OJQJ^J hY h{hw h{6B*\phhw h{B*ph hw h{hw h{6B*phhw h{B*\ph+7RR1SSTTUWXXY[\\\Q\$If[$\$gd{ $Ifgd{$$If[$\$a$gd{ & F 8xx[$\$] & F 8xx[$\$]gd{gd{gd{gd{x[$gd{ & FRx[$gd{ TTTUUUUdVVVVSWTWUWWXXXXYY0ZUZ[[[[\\\;\P\m]n]]]]]^R^S^d^^^^^೯س~tpೆhp\]hw h{56hw h{5hw h{6hw h{5PJ hw h{PJ hrbeh{5OJQJ^Jh{ hw h{hY h{6\hY h{5hY h{6^JaJhY h{6 hY h{hY h{6B*phhY h{B*ph,Q\R\n]]d^^_:`{ggNNg> & F 8xx[$\$ & F 8TTxx[$\$^Tgd{ & F 8xx[$\$]kd$$Ifl0 X$8 t0644 la p^__`b=cHcOccccdCde:fuff gCgggggh h4jpjqjjjjjk-k0kkkkk llClllll)mmmmmmnn~nnллзhw h{PJ 'hw h{5CJOJPJ QJ^JaJhrbeh{5OJQJ^Jh{hY h{5 h{5hy5h{5 hy5h{hw h{hLa>* hwU0h{ hY h{ hw h{hw h{57:``|aHcccd"e:f ggg{{ & F 8xx[$\$ & F 8TTxx[$\$^Tgd{ & F 8vxx[$\$]vgd{gd{gd{ & F 8TV[x[$\$]V^[gd{ & F 8TZTxx[$\$]Z^Tgd{ g h$i4jqj0k lllmmmv[$\$gd{ & F 8xx[$\$gd{gd{ & Fo 8x[$\$gd{ & Fo TTxx[$\$^Tgd{ & Fo 8xx[$\$gd{ & Foxx[$\$gd{ & Fo 8xx[$\$]gd{ mnn~nnnfo:5gd{kd6$$Ifl0 X$8 t0644 la p$If[$\$gd{Zd$If[$\$^gd{ $Ifgd{$$If[$\$a$gd{nnnnoWoeofoqoopp q qIqJqqqrrqrtrurrss1t2tOttEuPuQuruulvvvvfwx:xHxxxyy-zhzzzzzz^{o{{{}ۻλλλλhY h{6 hY h{hw h{PJ hrbeh{5OJQJ^Jhw h{B*phhw h{6hw h{6B*phhw h{5hw h{hLa>* hw h{hw h{5PJ :foqoo qursstuEuKuQuu$If[$\$gd{ $Ifgd{$$If[$\$a$gd{ & F 8TTxx[$\$]^Tgd{ & F 8xx[$\$] & F 8xx[$\$]gd{ uu7vvv*x{kTO8 & F 8Lxx[$\$]Lgd{gd{ & F 8hxx[$\$]hgd{ & F 8xx[$\$kd$$Ifl0 X$8 t0644 la p*xHxx-zzN{p{e|}}~OfW 8x[$\$gd{gd{gd{ & F 8xh[$\$ & F 8x[$\$gd{ & F 8TTxx[$\$^Tgd{ & F 8xx[$\$gd{}}}}~~#~b~e~~~~)NOV]VWab8W9UqwyKw9 !=bLJc򟒟hw h{6B*phhw h{B*phh{hrbeh{5OJQJ^Jhw h{CJhw h{6hw h{hLahw h{hLa>*hY h{5hw h{5 hw h{ hY h{7xy+OJ7 & F:8x[$\$^8gd{gd{kd$$Ifl0 X$8 t0644 la p$If[$\$gd{ $Ifgd{$$If[$\$a$gd{+bdh[Y \$gd{\$gd{xx[$\$ & F: TTxx[$\$^Tgd{gd{gd{ & F:8xx[$\$^8gd{cdrm|ʊIX2Hh)Wf"MZ[bf"XYsΓ1˕̕ݹ쨜݀wr hT6hRh{^JhY h{6hw h{6hY h{5OJQJhw h{5OJQJ hw h{hLa5>*OJQJhw h{5OJQJ^JhY h{5OJQJ^JhY h{5 hY h{hw h{5 hw h{hw h{OJQJ^J,'>O^  & FO xx[$\$ \$^`gd{ & F8x\$ & F8xx[$\$\$! ) p@ P ![$\$gd{gd{ & F:8x[$]^8gd{ ̕9AX[ftҝdilqszϢ0DԣG&ݦ  ݳ𦑦hw h{5PJ hw h{hLa>*hw h{PJ h{hw h{56hrbeh{5OJQJ^Jhw h{\hw h{6]hw h{5hw h{B*ph33 hw h{hw h{62 [agst<kd1$$Ifl0 X$8 t0644 la p$If[$\$gd{ $Ifgd{$$If[$\$a$gd{ & FO xx[$\$gd{tҝ<РϢ0r & FG hx[$\$]h^gd{ & FG hxx[$\$]h^gd{ hx\$]hgd{gd{ [$\$]^` & FG rx[$^rgd{ [$\$^` 7kd$$Ifl0 X$8 t0644 la p$If[$\$gd{ $Ifgd{$$If[$\$a$gd{ x[$\$gd{ [$\$gd{  ;JEgd{kd$$Ifl0 X$8 t0644 la p$If[$\$gd{ $Ifgd{$$If[$\$a$gd{gd{;ũ\:SEKQ$If[$\$gd{ $Ifgd{$$If[$\$a$gd{ & F 8xx[$\$ & F 8xx[$\$gd{ & F 8xx[$\$gd{ & F 8xx[$\$gd{ ۨĩ2\,:REPT_t}~αٱ p;rֶ׶$߶߲߶ߨhw h{\]h{hw h{hLa>*hrbeh{5OJQJ^Jhw h{5hw h{6 hw h{hw h{PJ hw h{5OJPJ QJ^JA7Ѱα{vqaM9 & F 8xx[$\$] & F 8Lxx[$\$]L & F 8xx[$\$gd{gd{kd,$$Ifl0 X$8 t0644 la pαԱڱɳOJEgd{gd{kd$$Ifl0 X$8 t0644 la p$If[$\$gd{ $Ifgd{$$If[$\$a$gd{ɳqFh׶ dκ)"#x{ & F 8x[$\$gd{ [$\$gd{gd{gd{ & F 8xx[$\$gd{gd{gd{ & F 8xx[$\$QTκպFT"*j9\ DMV@KLHtu]dqxĴ❓hw h{6B*phhw h{5PJ hw h{PJ hrbeh{5OJQJ^Jhw h{56OJQJ^Jhw h{5OJQJ^Jhw h{5hw h{6 hw h{hw h{hLa>*hw h{56]4վ+OW9\ V@gd{gd{gd{ & F:xx[$\$]gd{gd{ & F:8x[$\$^8gd{ & F:8x[$^8gd{gd{ & F:8xx[$\$]^8gd{ & F:8xx[$\$^8gd{@FLOJ6 & F 8xx[$\$]gd{kd~$$Ifl0 X$8 t0644 la p$If[$\$gd{ $Ifgd{$$If[$\$a$gd{]q-17q$$If[$\$a$gd{ & F: 88x[$\$^8gd{ & F:8x[$\$^8gd{ & F:8xx[$\$]^8gd{ & F:8x[$^8gd{ & F 8xx[$\$gd{gd{ & F 8xx[$\$ xy,4FHmzHo|'|1<~%!$5"ݼhw h{56 hRh{hrbeh{5OJQJ^Jhw h{56OJQJ^Jhw h{5OJQJ^Jhw h{hLa>*hw h{6hw h{\]hw h{5 hw h{hw h{hLa77=%ob]J]JJ & F:8xx[$\$^8gd{gd{kd'$$Ifl0 X$8 t0644 la p$If[$\$gd{ $Ifgd{\Q({c & FF xx[$\$^gd{ h\$]h &dPgd{gd{ & F:8x[$]^8gd{ & F:8xx[$\$^8gd{gd{ & F:x[$\$^gd{ & FN8xx[$\$^8gd{ & F:8xx[$\$]^8gd{ "$IMO(=;Y\->@IR]pq|}}}hrbeh{5OJQJ^J hp\]5hw h{B*ph33hw h{5hw h{6hhw h{hhw h{5hhw h{6hw h{56>*hw h{56hw h{CJ hw h{^Jhw h{hLa>* hw h{1(\nnwdW $If`gd{$$If[$\$a$gd{ & FG rxx[$\$^rgd{ [$\$^`gd{gd{ ) p@ P ! & FF xx[$\$]^gd{ & FF xx[$\$]^gd{ RX^kTA4 $If`gd{$$If[$\$a$gd{ & FG rx[$\$^rgd{kd$$Ifl0 X$8 t0644 la p$If[$\$gd{^opqw}k[H; $If`gd{$$If[$\$a$gd{ [$\$gd{kdy$$Ifl0 X$8 t0644 la p$If[$\$gd{t0PacjRSyRl,x%F'>@VǶhw h{hLahdDDh{6hw h{5OJPJ QJ^J h{PJ hw h{hLa>*hw h{PJ hrbeh{5OJQJ^Jhw h{5>*hw h{6 hw h{hw h{5:u8tydPPK; hx\$]hgd{gd{ & FG rx[$^rgd{ [$\$^`kd"$$Ifl0 X$8 t0644 la ptPb$If[$\$gd{ $If`gd{$$If[$\$a$gd{ [$\$gd{ & FG hxx[$\$]h^gd{bcSzSl{vq^q^qN & F 8xx[$\$ & F 8xx[$\$gd{gd{gd{kd$$Ifl0 X$8 t0644 la p-%Fa$If[$\$gd{ $If`gd{$$If[$\$a$gd{ & F 8xx[$\$] & F 8xx[$\$gd{ & F 8xx[$\$gd{gd{ g)){vvvqaaq & F 8xx[$\$gd{gd{kdy$$Ifl0 X$8 t0644 la p)0gN{;" & F:8xx[$\$^8gd{gd{ & F 8x[$\$gd{[$\$gd{gd{ & F 8xx[$\$ & F 8Lxx[$\$]Lgd{ejNUV{;VGNOn"+4Q \ ]       ﴤhw h{5PJ hw h{PJ hrbeh{5OJQJ^Jhw h{56OJQJ^Jhw h{5OJQJ^Jhw h{hLahw h{>*hw h{hLa>*hw h{5hw h{6 hw h{hw h{\]3oG$n4 Q W ]  $If`gd{$$If[$\$a$gd{gd{gd{ & F: 88x[$]^8gd{ & F: 88x[$^8gd{gd{ & F 8x[$\$gd{]      o kb]I9 & F 8xx[$\$ & F 8xx[$\$]gd{[$\$kd"$$Ifl0 X$8 t0644 la p$If[$\$gd{   Z      o v 9@])*.5GIn{Dkx#x-8zȧhrbeh{5OJQJ^Jhw h{56OJQJ^Jhw h{5OJQJ^Jhw h{CJ hw h{\]hw h{5hw h{6hw h{6B*ph hw h{hw h{hLa>*hw h{CJ4o   9]*.-39 $If`gd{$$If[$\$a$gd{ & F:8x[$\$^8gd{ & F:8xx[$\$^8gd{ & F:8x[$^8gd{ & F 8xx[$\$gd{ & F 8xx[$\$gd{ 9 jkfSfSSS & F:8xx[$\$^8gd{gd{kd$$Ifl0 X$8 t0644 la p$If[$\$gd{   H!c!""#u#v#w#򭧞r`#hp*h{5CJOJQJ^JaJ hp*h{CJOJQJ^JaJhp*h{CJhsn hdDDh{ hp*h{hw h{CJ hsn^Jhw h{^Jhw h{hLa>*hw h{56hw h{5hw h{hLah2Jh{hLa>*hw h{\] hw h{ h7h{##y )"""v#iZd$If[$\$^gd{Zd$If[$\$]gd{\$gd{gd{ & F: 88x[$]^8gd{ & F: 88x[$^8gd{gd{ & F:x[$\$^gd{ & FN8xx[$\$^8gd{ v#w#$%%1&&|eSJ5 & F:x[$^gd{oF & F:x[$ & F:x[$^gd{ & F:x[$^gd{owF & F:[$gd{vkdt$$Ifl0h` $0 t044 law######$$%&&&&&.&'''''''((()(((((())******-)-8-N-I/d/001v1w1x111 2 2222z33żżŏżżhw h{hLa hw h{CJOJQJ^JaJ#hw h{5CJOJQJ^JaJhw h{CJ hw h{hw h{56hw h{5hp*h{6 hp*h{hp*h{56hp*h{58&''(()()F: & F:[$gd{vkd$$Ifl0h` $0 t044 laZ d$If[$\$^gd{Zd$If[$\$]gd{ & F:x[$^gd{)9***`+-)--~ $If[$gd{Z d$If[$\$]` gd{ & F:x[$^gd{ & F:x[$^gd{oF & F:x[$ & F:x[$^gd{ & F:x[$^gd{owF---..*000|wrrpYZd$If[$\$]gd{\$gd{ & F:[$gd{vkd$$Ifl0h` (# t044 la0w1x11"22z3qe\G7 & F:x[$^gd{ & F:x[$^gd{oF & F:x[$ & F:[$gd{vkd!$$Ifl0h` $0 t044 laZd$If[$\$^gd{z3344~44VJA & F:x[$ & F:[$gd{vkd$$Ifl0h` $0 t044 laZ d$If[$\$^gd{Zd$If[$\$]gd{33333444G4~444444666 777777888{8899x:y:}:~::::;;;1;E;I;ĺḻ̨̱́̒̒̇̚|nhBh{5OJQJ^Jj hahgUjO!hahgUhw h{6h~-h{5CJHOJQJhw h{^Jhw h{CJ hw h{56hw h{5 hw h{hw h{CJ hw h{CJOJQJ^JaJ#hw h{5CJOJQJ^JaJ+4!566U7V79vkd? $$Ifl0h` (# t044 la $If[$gd{Z d$If[$\$]` gd{ & F:x[$^gd{ & F:x[$^gd{oFV777778888=9b]gd{_kd $$Ifl0z  t 44 lalp $If $Ifgd{gd{gd{ ^`gd{x[$gd & F:[$gd{ =9x:z:{:|:::::: ;`;; & FKxx$If[$\$gd{ $Ifgd{[$\$gd{x[$\$x[$\$ [$\$gd{ I;^;t;;;;;;;;2<e<<<<<b====*?t????}@@@@@@@@@ AA,A.A/A6AlAA@BB2CDC8DȻȢȕȏшȢzu h{>*hBh{5OJQJ^J h{F5CJ h{FCJhw h{6B*phhw h{6CJhw h{6B*CJphhw h{B*CJphhw h{CJhw h{5CJhw h{hLa>*hw h{hLa hw h{hw h{5.;;;;2<<=*?{rmhcWK & FExx[$\$ Y & FLx[$\$Y & FLgd{gd{[$\$kd%0$$Ifl0 X$8 t0644 la p*??@@@-A.A/AGBgd{kd0$$Ifl0 X$8 t0644 la p$If[$\$gd{ $Ifgd{ Y & FLx[$\$Y & FLx[$\$gd{/AlA@B2C9DDDEAEYEkEEEE7F8FF Gddx[$dx[$\$gd{Yhx[$\$^hgd{F^gd{Fgd{FY & FLx[$\$gd{Y & FL[$\$gd{ Y & FL[$\$gd{8D9DDDEE8FFF G GMGGGHIIIIIII JJJJwieZZQBh{5OJQJmHnHuh{mHnHujhw h{UhU4hw h{5>*OJQJhw h{5\hw h{5hw h{6CJhw h{CJhw h{5CJhw h{6OJQJaJhw h{OJQJaJ hw h{hw h{FCJ hrh{F#hTh{F5CJOJQJ^JaJh{Fh{F5OJQJ^JaJ h{CJ GHIIIIGJJ KxKLLMtMMoNNVOO*PPPPpqogd{Yh[$\$]^hgd{Y & FL[$\$]gd{Y & FL[$\$]J$J%J&J@JAJBJEJFJGJSJJJJJJJJJJJJJJKKKK K KKUKVKWKqKrKsKvKwKKKKKLؾدؾؾدqؾ j2h{UmHnHu jq2h{UmHnHu j1h{UmHnHuh{_HmHnHuh{5OJQJmHnHuhvKmHnHu jw1h{UmHnHujh{UmHnHuh{mHnHuh2$h{^J_HmHnHu+LLLLL+LLLLLLLLLLLLLMMMMM%M&MQMRMSMmMnMoMrMsMtMMMMMMϳϢϓr j4h{UmHnHuh2$h{^J_HmHnHuh{5OJQJmHnHu je4h{UmHnHu j3h{UmHnHuh{_HmHnHuh{mHnHuhvKmHnHujh{UmHnHu jk3h{UmHnHu&MMMMMMM;N*_HmHnHuh2$h{6_HmHnHu jS7h{UmHnHuh{_HmHnHuh{mHnHuh{5OJQJmHnHuhvKmHnHujh{UmHnHu j6h{UmHnHu$PPPPPPP1Q=QwQQQQQQQRR)R-R9RoRRRT(TaTTTTTTTUU?U@UAUKU]U햻}nhw h{6B*^Jphhw h{^J hS^Jhw h{5^J hS_H hw h`hSh`hw h{6hw h{5hw h{_Hhw h{6B*phhw h{CJ hw h{^J_Hhw h{\ hw h{jhw h{U'PP1QxQQ9RpR%SSWTTT@UU[$\$gd{l`2 x\$gd{ & F\x\$gd{o& & F\x\$gd{ & F\x\$gd{o& & F\x\$gd{o& \$gd{ [$\$gd{ ]U^UbUUUUUUUW$W%W-WgWWX X$XAXTXsXtXXXXXXXXYY-YJYMYjY{YYYYYYIZfZZZ [[[[[\\\\\\]]J^ƿƿƿƿƿưưƿƿƿƿƿƿƿƿƨʡʙʙʙhw h{6 hSh{hShS5 hBhShI!hS5 hI!hShS hw h{hw h{5hw h{5^Jhw h{^J hS^Jhw h{B*^Jph:UyVVVWX"XZZ [[~\\]K^^3_hx[$\$^hgdSl`2x[$\$^gd{l`2h^hgdSgdS & FZx[$\$gd{l`2 & FZ[$\$gd{J^K^i^^2_3___````M`[```aaa&a'asataaab,b-b9b:b=bAbqbbbbbc%cmcccccꭻ꘏xq hw h]Uhw h{6B*phhS hS_Hhw h{CJ hw h{^J_Hhw h{hij8hw h{Ujhw h{Uhw h{6hw h{56hw h{aJhw h{_H hw h{hw h{5 hw hS+3___#``uaa-brbcc(dsdefgg.hhh & F[[$\$gd{l`2gd{ & FZxx[$\$gd{ & FZxx[$\$gd{[$\$gd{l`2ccccdd'd(d4drddddd{eee0ffffffVgggggh-h.h@hhhYjfjj笻盐އwmib^h hpHh{~h{~hw h{5^Jhw h{56B*^Jphhw h{aJhw h{^J_H hw h{6B*^J_Hphhw h{B*phhShw h{6B*phhw h{CJ hw h{B*_Hphhw h{_H hw h{hw h{5hw hShS$hhjjk)llXnnwo:p||ccc||| & F[[$\$gd{l`2 & F[[$\$gd{l`2 & F[[$\$gd{~ZhEƀ"F[$\$^hgd{~l`2 jjjjj kkkkk)l*lXllmjmmmXnnnnnwoxoooppppqqlrmrnrrrrrrrss9s:s;sosssstst浨浨浨浨明浨浨悵hw h{5OJQJh{6B*phh{B*phhw h{6hw h{6B*phhw h{B*ph hRh{hRh{6B*phhRh{B*ph hh{ hw h{hpHh{~6h{~ hpHh{~3:ppqqr:ssttttJuuv.vRv=wwx[$\$gd{l`2 & F[[$\$gd{l`2oJצ & F[[$\$gd{l`2 & F[x[$\$gd{l`2stttutttttWuguuuuuuuvv.vRvvvIwwwxxxxxxxxyտնն|xpccZh{mHnHujhw h{5Uhw h{\hh{hw h{aJhw h{6B*^Jphhw h{5^Jhw h{>*_Hhw h{6_Hhw h{_Hhw h{5OJQJ^Jhw h{5 hw h{hw h{5OJQJhw h{B*phhw h{6B*ph xxxx?yyy]z^z_z`zazbzczdzezfzgzhzizjzgd{ h[$\$gd{h[$\$gd{l`2 T# hx[$\$gd{qogd{xgd{yyyyy8y9y:y=y>y?yHyIygyhyiyyyyyyyyyyy]zuzzzzعʰ؟ʰؐykyb[P[hw h{^J_H hw h{hw h{CJhw h{56B*phhw h{6B*phhw h{5CJjhw h{5CJU j9h{UmHnHuhvKmHnHu jk9h{UmHnHujh{UmHnHuh{mHnHuhP/h{^J_HmHnHuh{5OJQJmHnHujzkzlzmznzozpzqzrzsztzuzz||+ $Ifgdr x$If[$gdr h[$\$gd [$\$gd{l`2gd{gd{zzz||+,kxRgIg;hw h{0J56:B*OJQJfHphq 8hw h{0J6:B*OJQJfHphq hw h{\hhw h{56B*phhw h{6B*ph hw h hK h h")h 5#h h 5CJOJQJ^JaJh")h CJ h{hw h{^J_H hw h{hw h{6 h ,6+,jkxcN99h[$\$gd{l`2[$\$gd{l`2h[$\$gd l`2kde:$$Ifl00p  t0062V2 s44 laytrkSم(\؆R}``>$ & F h![$\$^a$gdF6$ & F h[$\$^a$gdF6$ & F h[$\$^a$gdF6$ & F h[$\$^a$gdF6$ & F h[$\$^a$gdF6$a$gd gd{o gd{ RSYQRS])̵ױחv`I-hw h{0J6B*fHphq *hw h{0JB*fHph33q *hw h{0JB*fHphq hw h{B*ph hw h h{ hw h{hw h{5h -h h 0J:B*fHphq h h B*ph hK h hK h 52h{0J6:B*OJQJfHphq RS]:def > !hgdm ) h8 xHX (#gd{ 7$8$H$gd   p@ Pgd{ > !hgd gd{>$ !h[$\$^ha$gd $%<=]l{Z[npɑ%34Sxshhc[c[h")h 5 h 5hw h{B*ph h{5 hw h h hK h hK h 5h{hw h{5hw h{>*hw h{B*ph33hw h{]hw h{6 hw h{hw h{6B*]ph33hw h{6B*ph8hw h{0J6:B*OJQJfHphq S˒̒9:M~d'()0efrtu789Jؙ4Dٚļĩuhw h{6B*phhw h{OJ QJ ^J aJ h aJhw h{aJhw h{aJhw hm5h{ hw h{hw h{5 hrhmhmhm5hm hK h hMI\h hMI\h 5h h")h 6 h")h .f9ؙ4Z آn6_7 >$ !hgd5} > !hgdm > !hgd5}gd{ ) h8 xHX (#gd{ 7$8$H$gd{ٚYZp #˝͝Ǡ/1עآn}6@B^_k7@9ȧ üüüü˪Ӣ h5}]hw h{]hw h{5] h^h5}h^h5}5 hw h5}hm h5}h{ h8"h5}h8"h5}5hh]Uh5}hw h{5 hw hm hrhmhmhm5h{ hw h{4!pۨ58(E­!ITD   7$8$H$gd{ >$ !ha$gd5}gd{ ) h8 xHX (#gd{ > !hgd5} ) h8 xHX (#gd5} >$ !hgd5} !/op٨ڨۨ25K`awΩϩ8h'(CDX[\HIQSqD|Dy˷˷Ǣ҂{tt h)h5} h5}h5})hw h{B*CJOJ QJ ^J aJph! hw hmhmhmhm5hw h{6B*phhw h{B*ph h{5h{ hw h{hw h{5h5}h{B*phhw h{] h^h5}h^h5}5h5}-y 29 &89&'Ͷζ·hiy{|úA¼üżƼܼݼlm}:;OĽӝh5} h7h5}h7h5}5hw h{6B*phhw h{B*ph hw hm h7hmh7hm5h{hw h{6hw h{5]h$ah{5hw h{5 hw h{7 ζiAm;,YQgd5} > !hgd6Ggd6G > !hgd5} > !hgdmgd{+,FXYPQhkǿҖފǂ{{{{ h=h5}h=h5}5 h5}5 hw hm h'hmhmhm5hw h{\ h6Gh6Gh6G hw h6Ghw h6G5h5} hlh5}hmhlh5}5h{hw h{] hw h{hw h{5 h5}h5}/eg"#9DFPV#$7RfY[XYͿիՑՉ}yummyh=h5}5h{h5}h=h5}OJQJhh=h5}hhw h{B*ph33 h'hmhmhm5hmhw h{56B*]phhw h{5B*]phhw h{5 hw h{hw h{6B*ph hw h5} h=h5}h=h5}6*$fYiZ{+J > !hgdm> & F ![$\$^gdF6 > !gd5} > !hgd5} >$ !hgd5}gd{Yehi~IJV     +4»쬥섀|x|tphhxahC hAhLjhLU hZh{ hHh{h2|A h5}h5} h0h5}h0h5}5 hmhm h'hmhmhm5 hw h5}hmh5}5h5} h=h5}h=h5}5h{ hw h{hw h{5,  56789:;<=>?> !#x[$\$gd{(Zgd>xgd{ ,gd5}46789:;<=>@as<N}u}mje<h}Uj;h}U(jh h}CJOJQJU^J*$h-UCJOJQJ^JmHnHu*h h}CJOJQJ^J%jh h}CJOJQJU^Jj;h}U,hh}6B*CJOJQJ^JaJphh}CJOJQJ^JaJhC hAh}'?@tPJ(&`#$Eƀr&>gd{> !#x[$\$gd{> !#[$\$gd{&'(?@BCDGHNORSTYz һਙqiһਙqaһj=h}Uj =h}U(jh h}CJOJQJU^J*$h-UCJOJQJ^JmHnHu*h h}CJOJQJ^J%jh h}CJOJQJU^J,hh}6B*CJOJQJ^JaJphh}CJOJQJ^JaJh}hR0J?mHnHu h}0J?jh}0J?U&EFywoo^MM> !#x[$\$gd{> !#[$\$gd{$a$gd{C(Eƀr&C(Eƀr&FGTUVk(C(Eƀr&C(Eƀr&J(&`#$Eƀr&>gd{VWXYqrs>gd{> !#x[$\$gd{> !#[$\$gd{> !#x[$\$gdr> !#[$\$gdr$a$gd{ RSTklnopstz{~!BTU۹j۹bjM)hh}B*CJOJQJ^JaJphj?h}U,hh}6B*CJOJQJ^JaJphhR0J?mHnHu h}0J?jh}0J?Uj]>h}U(jh h}CJOJQJU^J*$h-UCJOJQJ^JmHnHu*h h}CJOJQJ^J%jh h}CJOJQJU^Jh}h}CJOJQJ^JaJsr/-C(Eƀr&C(Eƀr&J(&`#$Eƀr& !UJ(&`#$Eƀr& >gd{> !#x[$\$gd{> !#[$\$gd{$a$gd{ U\]^uvyz{~۹j۹bjjU@h}U,hh}6B*CJOJQJ^JaJphhR0J?mHnHu h}0J?jh}0J?Uj?h}U(jh h}CJOJQJU^J*$h-UCJOJQJ^JmHnHu*h h}CJOJQJ^J%jh h}CJOJQJU^Jh}h}CJOJQJ^JaJ$|}ywoo^MM> !#x[$\$gd{> !#[$\$gd{$a$gd{C(Eƀr& C(Eƀr& }~k(C(Eƀr&C(Eƀr& J(&`#$Eƀr& >gd{J(&`#$Eƀr&>gd{> !#x[$\$gd{> !#[$\$gd{$a$gd{   &GYŶţ|v|k|vTŶţL|jAh}U,hs,h}6B*CJOJQJ^JaJphhR0J?mHnHu h}0J?jh}0J?Uj@h}U(jh h}CJOJQJU^J*$h-UCJOJQJ^JmHnHu*h h}CJOJQJ^J%jh h}CJOJQJU^Jh}h}CJOJQJ^JaJ)hh}B*CJOJQJ^JaJph !"#$%&[ywoomw\> !#[$\$gd{>$a$gd{C(Eƀr&C(Eƀr&[ZC(Eƀr&J(&`#$Eƀr&>gd{> !#x[$\$gd{*[\]tuxyz} 2^ӼᩚrjӼᩚrbӼjBh}UjMBh}U(jh h}CJOJQJU^J*$h-UCJOJQJ^JmHnHu*h h}CJOJQJ^J%jh h}CJOJQJU^J,hs,h}6B*CJOJQJ^JaJphh}CJOJQJ^JaJh}hR0J?mHnHujh}0J?U h}0J?&,m\> !#[$\$gd{C(Eƀr&>$a$gd{C(Eƀr& ,{|}J(&`#$Eƀr&>gd{> !#[$\$gd{> !#x[$\$gd{3~ywoo^MM> !#x[$\$gd{> !#[$\$gd{$a$gd{C(Eƀr&C(Eƀr&^_`wx{|}Dzh{hLjCh}U(jh h}CJOJQJU^J*$h-UCJOJQJ^JmHnHu*h h}CJOJQJ^J%jh h}CJOJQJU^Jh}  $7$8$H$a$$a$J 00P1h/R :pa,BP/ =!"#`$%k DpF 00P1h:p{BP/ =!"#`$%k Dp=0P1hBP/ =!"#`$%k Dp< 001h:p{BP/ =!"#`$%k 61h:p{BP/ =!"#`$%k 61h:p{BP/ =!"#`$%k G0P'1h/R :p}cBP/ =!"#`$%k Dp'01hBP/ =!"#`$%k 9 01h:p{BP/ =!"#`$%k 61h:p{BP/ =!"#`$%k @1h:p{BP/ =!"#`$%k Ca&61h:p{BP/ =!"#`$%k 61h:p{BP/ =!"#`$%k 61h:p{BP/ =!"#`$%k 61h:p{BP/ =!"#`$%k 61h:p{BP/ =!"#`$%k `!dM1 A  8cM6x} UŵڻԆwM⋍#qOE$bOcnƆh.@(WžJ4?AF_C#9|Ԁ+Y5>}q{33WUU>gջ((2ѕ~*T]F!KwG5jjh\I޽;3(Ƚkt %9.~D sqs4":0k}K5oIGь*ҏi!Ct-mMR?T CZ:xrOgkW삥}Ȩ}]ω$#l\h;}^{˼ݳ絴uo=)et^=ؽk=i9+ͦ8X.HFxoUy9-t#s;&e֭޾}{ \x~yfiosS6hr9cғ7xU\F6}}y--Sv|ynkSs,#l#WWg/GcL:,KǙEә~~ɜd&gwLsp|*TҫͰtn4t1ܫۖ!vXzwvrG{jw{vLEI6OC eQ6i[))h/.^Q/ή)YR^o-h(_i,>Uv_'[||Ь)4+g'L[ sBy_k)1YMчF7j"#QnǏ'؋1nEFct/#ʹm+M+6$Qi&yQ'/# se״xQ~` L*o(SW^F5m>)mot)@&g+v2m)#Ŷh;#>e&[5<`J;-nj(S,ǖ(S[J2m$O`-c(SXQbcDz22-b:g0Ňk(S:"ʔu bx^nWN8N.TQDv5AvH2AevALg:qSteL5^F9eD%p)b!vn2LheDջr{)?ammaeD{u2>S|XNL[xl nj(SW-ΆmLi ViùaD8;D8cD: cg2QqhTr;@sn!Qn.O`J;G[C#ݭ2Ah{Q]M]L!0Ňejb͘LigiGc}=uv n?fDY-b{̷Ck(S͏(Sۼ(S܇p_V͹30 )t֘s;SV}fowc0Egy*nq/#žIe%ԕS} p-0Ev} *s^ˬVw{#d[]9euf;Zi?%;{Fz~ốCtii )Z=Up98G~>Lh?ꨖs-׍/٬ۆgu#vt1oo$ަv,P Tg:W.Tej|z:"Iީ>ޯ*SjX;_Ut;ؤt)tOt>"}DO֓_SgНzQ^=}H==>KQ~K=?(Zkʏ;˛=|~L?Q^,OW?Yީ(-RWwTk75eŪP3j|]RnSm UV7^ܨUQཡBtvfQ{Q"_8xs`JۋDZ&2R1I<(S)2u:>)~=gL=% .oLiU6Qv"O=x߬0$};D,ҔeSm}S^#Q뢯SڹNs̈2ueV-#_ɑ7x؂)ӌ LB3v\S3ƈ2{X$EL 7͵A>]ﺻGvbLi}+Q''`·nDj"#9&L}%sTQw }.]vY(S^F9b>sY{bE}o<&Qw!V_`[O=" i2uf>k LHp):yl"1we*)#žF]L ~)>NL[8vnj(SO(-Ά}cSھM ViùbLblcej*b5?0Ň1O3k(S-P)-D!T|>/xS9bLn5 Bܳfw7uVC/`]y_25fLsӫ0 )t#Ub [DZ~Tը(Sw)2W~S|xZ+Z?f`BUqL8yl"waϤ2ej@~)>,E_\0 )thz_9Sl?D>D.DڡL"uLiV'lK])`jdStܙ LwJLsc ;px|+'V?̉ѷBx0ŷZyu=$B<"jVch2uW/`J;:1+t"/]0"]cASLigYq-?&ە)۩>)m**+Lii[}-ݿ;KëV- >fzEjmu}jn{뒜{7sU[mbZILOZ"Q=t`s#}NMUb*[i; ̑o37{2C^e}:`R*絠̡Q nckS^!Թ o(Sms^FyV)^~ ^S/`,m&ɜ|[ikƘǣhq4G8:̍sNaN晓K 39Zm&Fc16Z`ډ*;9Şm'Gӣg9ы#z΍ް#ǑIlx44}>i<}##4i߰7ƯuvC?j7[S*-^j6-<nWfs|3sc|:j' )+h΍'qfr<֌cGƎ_2OT#/Sͽo ޏQ0e^1ls,`VsvZ/#w˼(s^9G0i۷Co6/#TS|p+} -r̈2ueq9 \cL2&2!ryr#ԻB?DZ`S "P_)mb͇cL?5;F]V\e q(2AeD?-fS|wrp):js8o;'`J|;DU^Fعˈ\eDջ1@W`_ڭLmyQ)msp):K/m"1z"ʈ2P(Sw‡p)>v'*G0EgaOL1GSڞc8D8cB3C cge LaHS1} J2wk1<`93j6xd܋P=(.jKz* nT5?0j$c`ffngmNgs:_1 2uY[0*neD xQ^F܇p_V֬𘁹NN<0θ[x0EgYUn'{^F=2"˨K{YCo0Ň[5<>`Άip_cLѹF'lLy1S0Egee7vn%Ge ,cݭJ\]u/`_mvc&u="lgu⚻R8;N6طStvDKg"s&Bq7 ܁&N>ްB}"]0ŷ%UXeDݙ^F?ˈ^bL!{o}?m30 5:a`΀rn'`6 .NEaa/R^ZLa)0EgitS'lYbD8ËX 3bØ$K3 cwKy S]W bgBM.`nK{}& |9gޟ^Jꣷ ɻ#"T췸2EA-٥՜*ɒNМ޾9y:o䬨䟑͙|O紴紌:c5FS{[{&3Zz[̬mV߾gpW#4D*?jj7?jlG@7JQG _ϝ2gǣhqԫ>uytZ-Ss#A ӣauB]M^RԱ.uLuc>=1Z'G}rt>=zDm zn^/]c{Q>!EsK.ޮ7ďx@?_mq~:vuqs-ޥ_S/jsoTuc|:^ԅŪ+SƽxVcYhV^_N**jbnK5zSFgHx):ݬm"Gk˼(SF`9GL66˾eD*r)P'v2s5ˈ2]}ˈ2HxB0)6Mr|1sDw(S}D-| V[0Eg@s̈Pϱ%B3\a0޳1AH3v c(S1&ۺѼ6{km" qG$?G\$" y#LF`"0E} U {ˈ0G%CXq.1#bfo(S;\'bș u&r9lН<r= ;`NM=9l"E)VS|xɝkxcF=cKT1G=Li'sM?ND8;DQ#h^LaHS1@qmw鸆P^)-s0Eg"5Mc2MSQsC%TOn=p_ՌI8} oN ۹Huz%ym"j4 ؾF]UEE ^F}d(SGMe/`֬qT?f`S輤\o8;[{c1輣~VE ^6Lʈp/.eau):kkΦ<):kjtv <kDnw+9Bc=D3Ɖi浉2gh^Lm]Ibzy0LHs&ԿkDq&x2MtG8<>`rLso؋NNgh^LU-:Wbr~J31"j\do0Ň 46{Ίn4 F'lLE7`6`Nfn{,sD؋)#½D>S|xI} jtS'l٪D8ËX `cw.'Ѽ6boTqU\SF;NNx E5p )vzkrpτd+sydaїQ/ݕLw>e]nTb?yn\zwt\^eQ{yOg9/4Sګ$,qryfKS%GU׏gҸ0b=wI4WNᾀ):lT&>ojǒ1fS2֬Mƙk fi2%<9ɜL5g&瘓3%gM.1G%+d9"oK{x[Q&{l򨝒Q鵉I&6ݔ MK-9t{)Ƥgv|a0UE{yƮ3fdnUvYj7 kl7&ڬ7+:s3Lœc~`$iDs`&qfkZ`L_X(sw"s4ܒ%2u0aZsh"Oxx*;s{L4soS_2"T L!BX/#B5/#B5)0:s)>4\D_&B5}s]N50EgTv Tsv=jzAo1 B5h/#B5| `SsStۅ")"=ˈ0G]y8S~.!&.2"U^Fj뽌ˈӷ~ u!B5F/#B5}y9S^e:Stm"1y"ʈPD]"T->S|XN0EgaOp)m1k"E1!™!B5=cgL B5=鋵0hwKcLn5@+>P9eDq/"B5=8.i)W3& oǘgNa;Ǜi^+fzL>/q >|߷Cʸ˼x*V{o}LaezGc:a;jܷp )vpbLb"T ^xaϤ2^VLa} l sWN-b$`6X#B5wQM/Ɍ]"T.3ƉPM/+\ \k7{n{^tv Ep)e&1eDݳ1u/#r{=!!7CvovcF'lLr;StOTӏ:K*B5 Gzbʈp/.aWStVF=uv %1@3p<)/0I"Dgҝko0W$u7w0ZB縚X8;jrpU D>Fu@?󖛡5ry?]:+=~^~g%nݓ{2Ws;uO־u;EwY)b |_7|2c,)&sԵIZU'yJufr:9PSauT]N^RG$Ó]갤9>,ԇ'}d\JzJ>9ٮL^%/uݗd6@M>֛EA>D>ҝozy]0/Uf<יz37}flӽfϼ6z]3F + ŭT2i.Vg>̞^5qOiZ,׾HF5I]ѳLYe^`|7+bK }{+D&&B׼E2?0h%z*x*lxS콮$?\"9\Ǻ%ۅP/z\4dP/1뢯St֜MySt):t#LyP3ֈP|M]T B1cƌq"T3M Fs`_ob L{DxgywjJS|=oo90E#ͽc L xDo(;5w1m47l/:a;Οuh0ŷWdPou[]T BeDqP_~)>lГ|Do4 F'lLE~6`6`Nf>{,D؋)#½D>S|xI} jtS'l٪D8ËX `cw.*D4S-QP5ujt)ǬYT b&wnKmh6Y J<7ayJUVWBT[]mM$;;{.7j;{Wb{vExozO,<ּÝy;40w*ne=}f7_`R*3diKن|6tU="}gΙ3wx_3}g)Bg!t cDc,"Bg0ֵ=I&=鬬ILZϺ -f]gb߂iP!Bx#Bg0FCa,lHLh-=sLZO-`)Wq0MmxC cD#B^FY"eц` g\\kz4KϦ9i2,ɤi2]i2u5"t kxC. >NxV]6g^ fׂw7g`R&ƈdJR4=RNضu`Lw 1cDg|&Bg|Mvi6tr=/rk! n|(sÍzҾ v=F5C'|?ǿƈ|,qk vi6\t}a"t[̓30mK2i`Г0MUT3'F7{g#B,R!/6잨ǵL9Zz`.I2"<ã/L=RO!g3>N\vi&!ZWzy2iQfm60MC{w4ܖ vvVΗC(v3~YO=?ln?3;ɪoY__mkwԳþ\*u[--}wuvwϮ ;7muӥ? ʩlHe[e6"Oe-dsGϞGcp6!d'lFVeٜܞ} YKWe{';dz>gh>Y>ҧ9ݟ]c5=}]k]ܜnr頛Ֆ{[uo7ݫkN =WϺsrzrȄ9+r؝nBuǤ垓AG61y̵d>UzܐtY|ǍhHSX"Us0>a9i2TL7Q.eg#BgP#oo*(H~(P#u4}/7ˀD@lxgAw4jL7"ip4DΧ"_-ٚ^fҞ} L%7ٓ u]º3š6Q.?5m0M!F f(_x#夰~Hˡ#zez-` JmuKež:o4=>k`̼nv Y&B2!/6l8qdNMsddz4}$_4Fck(P.S.Q.o)}(5m\>Ԫ5m0ͮ+nzL=Af+}Ls-|RvD0L'ENIvPMvi6̗r=Z㺢ȤDjML=\{toO; w|C\^5w` g/MqZK9QIdh}LAզZdZʺ4b,D#B^JY"ц` 3ך0MT=0ʤD B 3@r'E-܋"i?s[s#Թ j{c9v]^+kKÏZC .g3Ѕ  cC{?KEg¶k8cM-x[ XW&03 ZЯD,@&$UOD a nUqHRźQե">*֊ u[EEIRCϓdN{&9}CE es\/LD萇| |tP#8`7#yRRRXрo mP57qϚNkqhJQC7s.3j|nG?s4xhώ3^zBuSo>^٭CZywÆFN,\}'JvqX%UF*IF[OM:1ѐcUM}#^tzv! QRH5jJ."Dp-V D×èc!9$roo)ŷm5 `z'bS4߆v9j.\+Whob }Cߐ=v2Ruޒ{{~nohơ.N6T~pzab$leڡ)'NՏ0^jv lDbc}!U?>Ý?x&KW:6Yu++f޶i&*gMK~r|qT4zfqt.^c2^eK];4TuF` &=\|srv:w-3]K\)\8o Q]zB3kJ &wKez}`Q.ӯޱfvke 7~=6]yn=q|woյ_O6n5az;#=.:-A:39\X0]7[EFrȁ$vX_k[/q ^SkxglԒ*.0oȢ}v/3I ?4O.8_/J#{R!Qj2≉c|NA l>4;B3&!lh[tKž9RBq-Q()liťcXސ7π2T#UɥFU7?/H&IKDREҧ(r%EhKny'N*gu\.d6:Zck'6dTflT6 ΔdKC388^8 Jm(Ez@Z2ZZŨT2*pH:R9VQ1ུf`=<&jݓ`q!u=!OtSq?-"Ed)̂Pw!BipGx H WoDh6Z Xt C:xkc(CeeԛR,H#ij!'j#>].pν.gFP^#*wn4]f/|wWq#Zw}=lb۪FӤ^U]Q -}u0FEɥJ(rvc1vc116 ;y Զ`Df PhBR@F&mȥhTn n U )RЬ4crR ɰ*Rd^hb dd'@:ߣEH!~188ҭZa)DyXF_yEmY( i&V)~S˧ yX CHnݻǴ/>\<`s~,eoAoeqsiǝ:ۏHn9i.7!ܦeXןHhv`v`/v?.Hl^? ~SHmLh?~`FchF#c9Re\LiX) :^hbg.tq;d9x@8qk%TKx8 ~uluuV Moc)DaOpB'KVj\<-W:WJcdWTjV+)4ыm#tжFhlJH.]yQ(m|rT)k#.)idJNYiVRs: ԱQH" "IyV+)S^i1Y [p`!i 00 <S;>ᫀ+ !~, $G;DZ `A8pz= `!p9@ \zg9 dp uC2#gL!ΑQ,$uAbYL"KY(|YU>|Yx,O&s02Ad܏j2 Wp4ٛC(lYDR Z|Jp ViW#HPXHx]O0Ky jB1CвzhzFz#0h yPPaeL11P'26^@l oaPK`zJfj׽Il UZ~6 0r5aU,1T*17[-1* 66XkTk o uͰ^j,U%PXo.h?02 VR;r2T .cH`^nĹg.6DF:!(׃h0ސBiD*օ>"e86އ Z Ў M4V/+ڌ'݅eqh*H :<6vf|۵˚hdidN/WjXPJ=szpzhL=/NPXWD3<nA|FFV <(M=hÔFhZJԘ[&٢cta Rvj >pѻA>ܟǞ)*t-[Zgl}#VٶZl6'Y&ϊ\W EUY+{)3:+K^k' K&l Js#Uaz6fis{^͵mc?)1s]^+W;T(dW7'_٦1\a9$/9ҪzM#!D(*v-g33Dl٘ -C1]{!cG@ŷ2ODmqm_ w.Qm2~t孭#Z{m%:8jg ʖ#"k'|?N?M?Sk=%JF`* b4ZEx"hQoѩBoAXhL X0 .Y{<{d<x)y Ҡ2`'ԁ 0d8PA(p&~c?ЋJD- S Z\ЏQGA0uRA8uRw@2UH1R )vJe)Sh,J R)I1Z厝fQdϝosy̍6v*sE-wo;ܹ=wsgqzq+;Ws [s}Bݷ2{Lsglbf-e+x׳ /.j"܊E娻ezp\岭l1k'wh+r{fٗfܛmmG#<p&Q$*K3b*R޼;"qMqvwg`On>KUznaoBƃс mYF/U'%)7{zA-tـ7Ce۾|FM *M8(O;uoț_Uٲ.>r~Nfτ/[YkVP56[otCuq{Owhor'5[ep7jwvθ[>n˪?Wi[Zxnj->Жc(uR 9s39sF͙E75th`uӞK89fj>3{36)y4j50VcZMzEviܛbGIoM/E?Oa@1vb `Vb)`6$cK@,cY X!~w  JA/2$O Hf~0 2J9K^ +jE~ _(BP|Z|Y#+(>ei<,óɽvrOf &2/|*2~/BrX3%2l.Ӱ$< Ka1lMĕ|8\K]i\{24[nO\T^î Ի24ќ6\H ܛǕUʸY|*Wv]vݑ}}]*D5FˮD[98?βθL&?nG޵.jc{sN79 ݥ87d8 FmՀўn lnC>;EmTrg%Crk6jf4Y^X ntl4ņ cXpg&_E^ a.\0õ0P0N`! P |Ķ!z $za$zaAsDa=KМD/iNi?KR#Ԉ JR1D5ږʀc_3[(SBu|O[u|u踉)~χ!'N~ὡB[?ˤc2F\xhO >߷ڔ5茣ؑKWT#6dZ49IN"鯜鯚N{^_"ۧxU ?nW(^1z m65"L2[hBb̴UКT +F+ófBLll|]a (g6buXK"Ұ" KDaKjb$E rVHceP` ?ńZK#"ŸK2byI#ƓW(DVid5E g'BO &`7`yN&T4\Htr/\KdB0 `.V`0ˁk, %0 'c)0K!X$&B9;Ln꩘\W5lIW5*4hNUOr٘fU,>j& ژ7 .K\4^F-soAis:+-"1@V9:k+O+e\\.:|oU]7ݻeqbLOaؕl,'}~~D.[no՗l{4+ ggo?q8ƘDc*;Ӻ5.z"8#u:C#svs2`ԫtVUXaE7*tf]QқtJ]hJGK\d%hg1Ygm_[WWm]bwCu~ںMas%kd m)67wnʡTkGfMQ\yi3z6˥nIg;<?mPTǗ}ijHv`50Yv/k,5UBm H. `# 38ۮ%2PǷuVIJlFNR\SqbAKJ^@5~̹=}3ok|) ߜܭ*,:V\8JgIo5LQ%?ڙ]OM5Gzk:oN>Dn.i8Ӟ5'Ξ^[C_nmsZ߬J8>oۿYVݓw"W_2yZ/ҦާI^ϟ%_l\ٴ̄i7T nk}:ɯZY7W5.r]o[çioNk'=<׊+wnOv~ݶ%,~zϸU1}֔˞;XɽY\´2 kѸ-Uv{!>,-n&u ӛr\ntH YQnE$Rn>Vyz˵[&լXK.(7j 6c">9|sC b0H`vA" ,3S09Ld2ub/ >~.Ljn2q&smE`cΠ9L;V3X:ƃ:ldoWFr=H3VZ,'M"G0Fp&G-qp- 7{67Kla~ fRGzǤF~_=f-\al*INjwbE)݇_L}ų h5QuFVPr"rQ+̣Q(_'*_k^u-+_9~e8Ǐ{"}[p zZҢk2v j~@Fr7:(de(W#zD! `ӛCDJhi($Qbx…5J6{g4-.%7טg/brq&3d.Pʍn=CT.e/ߴoK[p ]eul[_egkj-gv6gw_Z[:X퉹G.fOYl]tt6&4#GD(AQ^z:e*WA*x}pCpgPr J*g8*|4CoLrkw|(? UP5#RwA4b9R8ӁwF#=iiisnxxm }DyK _Toc110591470}DyK _Toc110591471}DyK _Toc110591472}DyK _Toc110591473}DyK _Toc110591474}DyK _Toc110591475}DyK _Toc110591476}DyK _Toc110591477}DyK _Toc110591478}DyK _Toc110591479}DyK _Toc110591480}DyK _Toc110591481}DyK _Toc110591772}DyK _Toc110591773}DyK _Toc110591774}DyK _Toc110591775}DyK _Toc110591776}DyK _Toc110591777}DyK _Toc110591778}DyK _Toc110591779}DyK _Toc110591780}DyK _Toc110591781}DyK _Toc110591782}DyK _Toc110591783}DyK _Toc110591784}DyK _Toc110591785}DyK _Toc110591786}DyK _Toc110591787}DyK _Toc110591788}DyK _Toc110591789}DyK _Toc110591790}DyK _Toc110591791}DyK _Toc110591792DyK yK 0http://www.medicare.gov}DyK _Toc110591864}DyK _Toc110591865}DyK _Toc110591866}DyK _Toc110591867}DyK _Toc110591868}DyK _Toc110591869}DyK _Toc110591870}DyK _Toc110591871}DyK _Toc110591872$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l4 t065p50al$$Ifl!vh5p50#vp#v0:V l} t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l. t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V lL t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V lL t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V lL t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V lL t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V lL t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V lD t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l< t065p50al$$Ifl!vh5p50#vp#v0:V l0 t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V lc t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50alDyK yK 0http://www.medicare.gov$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50alDyK Fwww.minnesotahelp.info$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l t065p50alDyK yK <http://www.stratishealth.org/$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5p50#vp#v0:V l) t065p50alDyK http://www.ssa.govyK &http://www.ssa.gov$$Ifl!vh5p50#vp#v0:V l t065p50al$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5@ 5`#v@ #v`:V l t065@ 5`al$$Ifl!vh5@ 5`#v@ #v`:V l t065@ 5`alDyK yK >www.dhs.state.mn.us/healthcare$$Ifl!vh5@ 5`#v@ #v`:V l t065@ 5`al$$Ifl!vh5##v#:V l0#5#/ 4alytQS$$Ifl!vh5 5#v #v:V l0#5 5/ / /  / 4alytQS$$Ifl!vh5 5#v #v:V l0#5 5/ / /  / 4alytQS$$Ifl!vh5 5#v #v:V l0#5 5/ / /  / 4alytQSDyK yK vhttp://www.dhs.state.mn.us/healthcare/managedcareombudsmanSDyK 4www.dhs.state.mn.us/healthcare/managedcareombudsmanyK vhttp://www.dhs.state.mn.us/healthcare/managedcareombudsman$$Ifl!vh5 5#v #v:V l0#5 5/ / /  / 4alytQS$$Ifl!vh5##v#:V l05#/ 4alyt$$Ifl!vh5@ 5`#v@ #v`:V l05@ 5`/ / /  / 4alyt$$Ifl!vh5@ 5`#v@ #v`:V l05@ 5`/ / /  / 4alyt$$Ifl!vh5@ 5`#v@ #v`:V l05@ 5`/ / /  / 4alytDyK yK @www.mnaging.org./admin/ooom.htm$$Ifl!vh5@ 5`#v@ #v`:V l05@ 5`/ / /  / 4alyt$$Ifl!vh5##v#:V l t065#al$$Ifl!vh5@ 5`#v@ #v`:V l t065@ 5`al$$Ifl!vh5@ 5`#v@ #v`:V l t065@ 5`alDyK http://www.rrb.govyK &http://www.rrb.gov$$Ifl!vh5@ 5`#v@ #v`:V l t065@ 5`al}DyK _Toc110591890}DyK _Toc110591891}DyK _Toc110591892}DyK _Toc110591893}DyK _Toc110591894}DyK _Toc110591895}DyK _Toc110591896}DyK _Toc110591897}DyK _Toc110591898}DyK _Toc110591899}DyK _Toc110591900}DyK _Toc110591901}DyK _Toc110591902}DyK _Toc110591903}DyK _Toc110591904}DyK _Toc110591905}DyK _Toc110591906}DyK _Toc110591907}DyK _Toc110591908}DyK _Toc110591909}DyK _Toc110591934}DyK _Toc110591935}DyK _Toc110591936}DyK _Toc110591937}DyK _Toc110591938}DyK _Toc110591939}DyK _Toc110591940}DyK _Toc110591941}DyK _Toc110591942$$If !vh55#v#v:V s4 tn(655/  YYY0/ YYY0/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?s$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa g"Fytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?i$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?m$$If !vh5n(#vn(:V sY tn(65n(/ YYY4sa ytj?$$If !vh5n(#vn(:V s[  t YYYn(6,5n(/ YYY4sa p YYYytj?m$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?m$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?m$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?m$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?m$$If !vh5n(#vn(:V s tn(65n(/ YYY4sa ytj?}DyK _Toc110591974}DyK _Toc110591975}DyK _Toc110591976}DyK _Toc110591977}DyK _Toc110591978}DyK _Toc110591979}DyK _Toc110591980}DyK _Toc110591981}DyK _Toc110591982}DyK _Toc110591983}DyK _Toc110591984}DyK _Toc110591985}DyK _Toc110591986}DyK _Toc110591987}DyK _Toc110591988}DyK _Toc110591989}DyK _Toc110591990}DyK _Toc110591991}DyK _Toc110591992}DyK _Toc110591993}DyK _Toc110591994}DyK _Toc110591995}DyK _Toc110591996}DyK _Toc110591997}DyK _Toc110591998}DyK _Toc110591999}DyK _Toc110592000}DyK _Toc110592001}DyK _Toc110592002}DyK _Toc110592003}DyK _Toc110592004}DyK _Toc110592005}DyK _Toc110592006}DyK _Toc110592007}DyK _Toc110592008}DyK _Toc110592009}DyK _Toc110592010}DyK _Toc110592011}DyK _Toc110592012}DyK _Toc110592013}DyK _Toc110592014}DyK _Toc110592015}DyK _Toc110592016}DyK _Toc110592017}DyK _Toc110592018}DyK _Toc110592019}DyK _Toc110592020}DyK _Toc110592021}DyK _Toc110592022}DyK _Toc110592023}DyK _Toc110592024}DyK _Toc110592025}DyK _Toc110592026}DyK _Toc110592027}DyK _Toc110592028}DyK _Toc110592029}DyK _Toc110592030}DyK _Toc110592031}DyK _Toc110592032}DyK _Toc110592033}DyK _Toc110592034}DyK _Toc110592035}DyK _Toc110592036}DyK _Toc110592037}DyK _Toc110592038}DyK _Toc110592039}DyK _Toc110592040$$Ifl!vh55#v#v:V lH t0655al$$Ifl!vh55#v#v:V l t0655al?$$Ifu!vh55 55#v#v #v#v:V l4 (%%%%0J"6,55 554auf4p(%%%%ytTT$$Ifu!vh55 55#v#v #v#v:V l0J"655 554auytTT$$Ifu!vh55 55#v#v #v#v:V l0J"655 554auytTT$$Ifu!vh55 55#v#v #v#v:V l0J"655 554auytTT$$Ifl!vh5~ 5 5j#v~ #v #vj:V l44 t0   5~ 5 5jalf4yt;F$$Ifl!vh5~ 5 5j#v~ #v #vj:V l4 t0   5~ 5 5jalf4yt;F$$Ifl!vh5~ 5 5j#v~ #v #vj:V l4 t0   5~ 5 5jalf4yt;F$$Ifl!vh5~ 5 5j#v~ #v #vj:V l4 t0   5~ 5 5jalf4yt;F$$Ifl!vh5~ 5 5j#v~ #v #vj:V l4 t0   5~ 5 5jalf4yt;F}DyK _Toc110592041}DyK _Toc110592042}DyK _Toc110592043}DyK _Toc110592044}DyK _Toc110592045}DyK _Toc110592046}DyK _Toc110592047}DyK _Toc110592048}DyK _Toc110592049}DyK _Toc110592059}DyK _Toc110592060}DyK _Toc110592061}DyK _Toc110592062}DyK _Toc110592063}DyK _Toc110592064}DyK _Toc110592065}DyK _Toc110592066}DyK _Toc110592067}DyK _Toc110592068}DyK _Toc110592069}DyK _Toc110592070DyK www.MinnesotaHelp.infoyK >http://www.minnesotahelp.info/}DyK _Toc110592135}DyK _Toc110592136}DyK _Toc110592137}DyK _Toc110592138}DyK _Toc110592139}DyK _Toc110592140}DyK _Toc110592141}DyK _Toc110592142}DyK _Toc110592143}DyK _Toc110592144}DyK _Toc110592145}DyK _Toc110592146}DyK _Toc110592147}DyK _Toc110592148}DyK _Toc110592149}DyK _Toc110592150}DyK _Toc110592151}DyK _Toc110592152}DyK _Toc110592153}DyK _Toc110592154}DyK _Toc110592155}DyK _Toc110592156}DyK _Toc110592157}DyK _Toc110592158}DyK _Toc110592159}DyK _Toc110592160}DyK _Toc110592161}DyK _Toc110592162}DyK _Toc110592163}DyK _Toc110592164}DyK _Toc110592165}DyK _Toc110592166}DyK _Toc110592167}DyK _Toc110592168}DyK _Toc110592169}DyK _Toc110592170}DyK _Toc110592171}DyK _Toc110592172}DyK _Toc110592173}DyK _Toc110592174}DyK _Toc110592175}DyK _Toc110592176}DyK _Toc110592177DyK http://www.medicare.govyK 2http://www.medicare.gov/amDd !E9~  s d<A2O 1To figure out which part of this chapter tells what to do for your problem or concern, start here. Is your problem or concern about your benefits and coverage? This includes problems about whether particular medical care or prescription drugs are covered or not, the way in which they are covered, and problems related to payment for medical care or prescription drugs. If yes, go to the next section of this chapter, Section 4: "A guide to the basics of coverage decisions and making appeals." If no, skip ahead to Section 10 at the end of this chapter: "How to make a complaint about quality of care, waiting times, customer service or other concerns."C"`PK!%>[Content_Types].xmlN0 HC+jRv@݁# 4J6ZDq(ۓn쀄8&jF1cd穖x먯,U=dĵR ZpV> J)?cWey0dSǘfON\S2 lT/UT/xt+ S6ƕoQ3Y5qTmQuO8fg/Gʋݟߙ<ƒ |jPK!8! _rels/.relsj0 }qN/k؊c[F232zQLZ%R6zPT]( LJ[ۑ̱j,Z˫fLV:*f"N.]m@= 7LuP[i?T;GI4Ew=}3b9`5YCƵkρؖ9#ۄo~e?zrPK!oh+drs/e2oDoc.xml][o8}_`]lZK0 lg0GZmmeI+q2OCvxŎ*Ja %M?>.}@ aNz|lzbh$Ł0 c$Əo%E$FPH\H͛Y%N^ ,8?7k(}鿱:uQ:$I՟I-+6#N,!)F3(Pɘo/1#jϨ{oVO8h{gNH߹,";__2 >$i͝y.&Kx^8!.l5 xKZP8GVS0yL/{ΰs]{h]}5+Цg,UUB!׎Z 7c"n6?Y3<Ðò4]$^!h h׵6qu5e}zL <[l7 @[w]g$1~] \;gp0 gp@oYH">ig0 }4q`e+vO<0*/8I?p؀~"I]^G~|AYޏq:7E)]h #5"g*y㄁> 'Z"Ic^8LpyZ^DZ'%[>ml׉h|~×F 04 8 H9Ȍ9N!etjNՃ/(@_HL\g`S/@SDf؁OE_''dㄓx g(^K={@+ѓx@B&`z(d^l?þ>.7lLS=N~GEUB] l jJs z7 FMZpp0O-l/gC)/gToʃ"g^y-NSM0Ǘ$poq7g T?ӌ|`?bW y"b>_%dQ&'rwd2eD`!c٩v Lwp$h0lQ"U[ L{읁d7/ X9gBJSva9 )P_#*`7$^qH C|u&'qb׼+)-'MQex˥"{˱s %:p٧*ŞϏ:m ̷Rnmr۫@#/uAX0MQ9 KJG=lËöEY=p[ĩ1[=Ճ1l]=Ճn6z}o{GL n/`;Q`Py} "w=8 2+C2d{! ղqb;-™)XSLSvv(*pK+pJ|xBø F4N?amxW=l5խNTBKS T7*HTl4=:Muφn/e`9,WWBPGX]Gbʦ1D3O 9)8)%I Yp#.΢QPMڸ}f|R% 8E /1(S \Sȅ=e8N8}X9*vCCϪ|}wю\bx!3\A16038_1`w3c W tX& #`CFx/L)[GPd.{P&%t$t?Hi7o+/P-%7\Lڦ?*ڣԁ^:kQ|Q-1D4Fyh uW=ЖV[0'2lqv^g|#@N[ȭ|يz1k.f^m;Vqgm Vnk +Wpv/'(0 )iXqj0KUmMS]?eAC ;#LVhA9 tօ<_==W=lCöEX=p[D1Z=CՃ1\=CՃn7o`ŋ!D_ S7y`v-Q8@T5l&l_zBA32a/)$LOZc6cfyUK葐s GB+ޑPEqJ6 }r^Jm2yдMyV2IHjrui-lcVYmxF=hUzћ@ERH3ƨBuݧpNc:٭hE7z:M.z4$mL tܕQ-̔:E9/l_9-""!Aڭt!Aʮt{ = r'i§4-vn EXOE=NќI4u"#Nc:iTR8CgܡF|W^N; Q_&E\QRX2*.Y_*CA+8o C+sX4]dlUAl'i'IDh{&{ !3یVa'2dR֯̿p@@j&%=/piݗMXSCgöEdW=p[D1DY=CՃ1$[=CՃn?A_ K<5Pظ/0 '3쫐ǀ [cۛzsl׉߁6 =]n݅K>?X-fYY$ "gf(.Peӹ\Qr 5-MX- {m.%oHݵ$F\T[eKC sqb$"g+xsqHDDr" ly*غU؝~/HIꎺau 7~ģ-i PK!7drs/downrev.xmlLAK@a54R*Ղ zf$tw6dm׻{M9'|~ A.r>(8&/0JUhw56}BJ_d8zn*D94R˭idҪBzZT6G|_WzV1>ooD1ѡL{wdA<{@dUPK-!%>[Content_Types].xmlPK-!8! 0_rels/.relsPK-!oh+/drs/e2oDoc.xmlPK-!7drs/downrev.xmlPKbPЧE}ekkPncPЧE}ekPNG  IHDR)%iCCPICC ProfilexMHaї$T& R+SeL b}wg-E"u.VDNC:DuE^";cT03y|URcE4`λޘvztLUF\)s:k-iYj6|vP4*wd>,y vڴ=S԰79 ڸ@`ӋmvUl5`P=Gj)kP*}6~^/~.~a2 nײ0%f|U 9l7?j`l7"tiNf]?uhgM Zʲ4i[&LY_x {xO$̥߬S]%֧&7g̞>r=g8`候 8rʶ<dWT'<eL~.u"A=9뗚]>313X3-$e}u,gmg664$ыEzL*LZ_j_]Xy[?Xs N/ ]|msϚƫk_WfȸA2)oz-di2|m٣j|5ԥej8ɮeE7[Q|IM%ײxf)|6\ k`Ҳ䍐. s9g,`7Mq_S~?N?nx+Χ:3Ңө?VZ]jW[vc+'.g}:{~[ߪïkk 'P]z㉝K>zv%;g >V&Оd->T^'?r'VVHy,W8.o<|U,?Ի?i_JSu_u]RpD`!T3ݯ׽zȳ^{ՁyユS OxBt~34Na9 H >t{w4LJ3}{wO~?O3ZZk_W~KỺ9묳߿?];`8W2?X1~C=O^ #H#pMwqN?я8Hs@Wj;U¹3\&_?{;va=qVէ]|+ n]Sa3XW٢{3YWO!/=FG:|4Alg]&z׻vni)}2_| 0[|qI%H *(]C3 3wӝ&u8|ecwtMT oX; [ V_oM6Yy%􃇳KtZm!YBDG𙔧?tD'N-=C+rU~mY't2KqA,7| oxC]!T6<^_"o˯\hDcii5g`Sy|A:O㋶?񏵸׽nmV. oYCʇ~7>~Kmhwݻ=أn)Q~m8g6_|sqneGBO3Y9b+o{z_>]-]*Ёe8![o=< ^RKÍ0?"W9 &ɪ쮻ZWAßʄ,o<~{= Lf{O#G?ަ!9"{}h(Zz|ѓ/D^|}~rwףlݓZsemާ~dU\*Uv6&rCSdM` .-آP_f+¦x -+zQ^Rg-fW<-`޶MsFtπOym,{-G›hgxQnQg H |'Z"7tږ#/,`䐷W>:mN”U2&aG./aQ=F@);l?nڞF >5mY]sղ>Z{&Agͦ r^CNF״ It`q=䠓z7(Af /S7uK )'c_Ӂx_EgXrO6ښg`>FL"_;`NvvK=uO}z)dQGV6saS>r#?,.=–`aS[v3Ks0dT#m~.oPF?W_/ջprh'd'nq[TcUЁ]˶Q0F_أ>vuJ㨣Fmov.7y\.P裏A樼dTc?NysT_ŭ8Qy Ѩ FeM{ֳ56ySTՃ.9GYœe먼XNqޕNq׾2}?W0Ѧ٧ `kW;2_糫vNWɇw+HKLo]^x, '}e24׽_)\x;VoGC W;pRG|Wy>ڒvmI&[vn ,#:!vgó_]ͫ~ԟ/4#:./K$ G>C-go+.-ߨhlYD`c kߊ;9`VV4ȣ7嫏)ۯQ/7}',50VO֠^ Lc|oEH6P^ҲV{mGꇬe^u*o{M&DX}_ӖmC2?.ϙVVmUϗ%fy}Tz=FVcx'_ɏ^zTvuZȯ`TA}}llʧ՟O2n \؅dWCl];Shձb}y9Wm7iEWZ,x{S9k/ڤW>c Qρoyld?C>c3cvމ8WOa/dVȃNȘؤXͱ͚ RJf<2X14R/(3kf5dl#Rg>T:5fQEËJìn|/C@̐si(5)LӇ?:Cw޶xeiǗ]6Z0^wf&μ+΢Tg5ueP V:22)4 rzvt],t4Qʒ8ˊa묗Y&)%RqZfԫa1.8΋0}_6๜:A!s)OyJR Ey-e|-Q}Sf(v033Wu8) sܺŒ +/VM8t*mq$ʀڽ6/[ou3 6:v-Sm׍+tɆnյN̪i~ ?&9{q=ǙMƏ](>م>UҶ")?_Y*?z 2Xg`Ņ}㾼2pśu HƆM2T4$/22G<ڥ2 X_΢$`}{@dzR pǫjte?^28O|$JPq`h+EfX}?z jmI}x>S5mŝh0+>,e[1Xnc[|[cd:E;:Nٚ7uVd漁USr],fu%[n?K~ m[/;%覾jI}__h7lFV%t_-V&T} Vh<[<e$SՋ06°ΏA`ɭ=YzPf4FRgʠFfo/:0g%:*8* Τ'ZgnVX)Dٖ̓ՙXV[:J GVwEjofKQe1L3FIYxHfǬ^gvF~]8z vjk+t-xg4LWC~V\Ni<ۅY2X|_:C޸.Bwqv<3k_u4kVɌ"X6UtU RRX(NEfϬj]@Y%K\C6§o3Y7@Wf:B!纕&y /u@&3trcT92IT:#gqU3V!U1k̞\u[QyCa] Z ^U*+4!垕02K3f0OU|&ѭ *f\u X)cgk%:-̨? ^:ɪ):3^U..N] &ɆƑGYw&X)0?9`\:Gi6]]cؠY1VA.z;sؕlJp4w(jȏ'RɎQd+&| < K{~tҕ/7s'y 6T`+ StڰjSvFOi+lF;bc|n/P;Jrj]Xm%]4ִAװQ7vqv/j,;=Гh'VW3]&4H|캐O~+ V-B |{] 7r?`X '/ёWoY)${W\h;]?c :v XIad||Cزs{VvryXՏ[Ċ Ƹ7+UVp 䳭ฦ<[ؙ{ʫBvhMY偁 p1;MؚX+GWyȁ<6[r_×Oz joWe ,?Fȯ^ [eJ!0>L?<<@O{Zdf IDATFՇ}Uڮvִ~앿/n{lJZy4.c&zeBoe8`ERlfg5gڑ Zӆ"9l}6o o_OI+ʫXuQ&Q2VL{ :ޘm 'aއV |HRJf8*FZWY&fGPlH_73VẐKf̊be̤e?|`݌|%rf̢)N̙a3CIW26d4:HdV4:b 'OYt̒ kf0P"xLJV`W:W3߲23^V^BJZI]VXٖq.Y}fN^0mJ c~qnr +/f&%4lֵ ,+<`Sެ'٬89_GE9j 0j68Iu:zظWT: P*O:L&Pr])#/m:b=rR?mw`fEج/$ynxYYxV|Y[F>URkktnUSc[l௽R]ŃQ[e-DׂJ$aՄL6?~X[`+^%|~UvWBNk#!k5>v?+|IWd5COعLוNmNC6v'G~m=h|* ۇd?Vp݊3[z#c+hI{ǩ'6Ucw SK;?R/%А4@F 8&K ~?Ah4jGlQC45,lSWM' }&5u !%uI6=K AUϕ@@=zuؕkd#$> 9u{}`&x::l]f}?WW}[xxHן>K ;jO,l -m8I.R}v3<^|5 [$4؅mϐLX8G$93[B(,_[a3tߖWjѠt'cfh@\10F'gӿ>״|>=ix$~ɠaY)y׉hB#1tI@ì6<KNu 1[ɔ 0` 8y9;9': Ig峊bj=lщCuҏ9Ö ><`&M͆\~sI=J>+zll=|=_yF‹xlxJϳ1!@ߧW6bJ]b;_b֖ERGڹN{c?M @<8l>m6)b?RN;÷Qm.V^+|$2\׶=FMF?Fٴxak LCfŢg& oLB)o'##p۪V;;7ВUj{>$`cBp}ۀ!E>2<^KMё>^N dGM~W^[[k&&lIg 尠o Y_#Ogx}ں&LH]@]gZZUŪ2c ^i$ɡ<ܴ39n[)^yo65%O$ylmHY!S" ̤0yz= u+`<0YC P-Al3|jj@ 7 WyRݐ?ylKU4騾C%Ҫb"l塌 :rAko٪_du&icQ9;9 Cl1 Fo=tlP 4B'P#VUL,~]6Տ $6 %Ec>&ۿzNF.0~&%.MY꿤Nk)~ cor0zUF MkdaM\'Ȇ  & xijm!:\S?KI~\փ .|lP9h˙7<ɶ.WD 4ֽEI ;hm9X݆}Ǜ_"\M~+ ?2K0dtT7kw=Lp2MDг9:χw^zu3u,pwe ՙn pu~CS|倠][卾@w"}v1 =N?&~`Bi=赬ML, n3Q.Lpx5zyaN>fgv |d੮7A?as3a.ɩM0!v1ˢ‹lzhKx +cGHE][3lݜ2LD{N/WLclY=G^}/Cư3)/Z>'I|W#E#߫K4arHn4I)h9^7V+# szf4j '6x :t2fulvrpަ%,1PG6@זf ?gñ qf~JK~=^A  .9h)Ӭ^ȫ:0` vtTW7C~__> ^fW'x5A ̐s | &dU8I2o j^6b,+m,ʠVLG`:w8؏7yXCnQ=r?P:>+D6} i* wU07:gyԏ @PMߡcC}'Zڿf `m忻FUog~ѠЀC}*gP>`f[>Hy[|{oAm8\f ?+e@-;ap5 x8)iCgmrPv3h'vﰛM ՟zu?)x+tL-Oo Mx=a2pu?h;̪2?آ -ˡX~WfRnI~IA^8ZhNش~V^>~^. [d avY €?!;[ט >k9^T}=~ –0rO_ )(L@A}(v2>_dSܽF[4kh Ɏ~Ўs{CR]@}Jt=an|˖c>@ńE>A{ˋY+u69ZyB(ؖ cTϠ^a!^$pS@Uc&޽i D6G"]c"h̾Aw{Ev8 3fQ/f N-ԼPC؋:#\U"ȶ6Ь5;SRo7}7(p6CW :ok0\Bފx(ѵ lm vo<8e1e`ՇB]ы!W{kw]L9I1h[ 㴄f T՗DMh=ȃr@<ډN.~u9xIp҃&p )9WHmeo1xbkޔ[lc3%a`n&r6kR ГЖs ͔`V4:n9m5)[gBʎpxGVwaϾ7xipdTVݘ=Iv+Vn lnb2]KwMd$?D^}Oʫ m w%bJ 0ھ"xR~@0KٕUX}_xG]~&vmi@JOԏEHARWv|~Y1~$$~I"oP3C%|ЅjA5$U/]VlԄ4Ce>$FUd;Vyl5oV&دA==i}r Vե ?öK^v3kݳ?ufaGum}{`[ߑQ;z)m5{_g!1L@Y-{`&Z/oEO< 2`\fu< cvvdA=s2-sRL>M'1s+{;ahWB?+ q_zq{p Zx͘0E<i ?/%jݩDe}C`$if\H04y9hlE:: W^6Y*r-^ Ywfa aӖm@@Ij|O!}oV7 b̞3ST)?5t/S6E^Xl <"ϐhMc왭;>1@(G?B.ȶ]_p_%njus<#E7nFu^ju[C;zR[mvF%)TY]&mBS6F8Kkmm<d!$YhTS>c7_m+']T11?a _߾ ~_0&hf ?l 6GѮMD]*3D 4wZNF^U1nzq#;A}~==>\7bryM=tm˩o&\Lj?-/26lƤeϴBse1~231Z#|h hd{VFz`|lT @^KPOgl{-p:V=ˤ@@ %1)O$W?hO*7to:s<|2MiL6+zAX_>OJCO,yog{^hK9 &Ƶ~`1ӵ(WL̵~:MP9| `,(w ]r+i(OuRȪ3}WFf[4/yb+O3J~я|As6g~V<;gRJޡDWE9SMRtx<Wan-~Ch#w | ~;nK#щ{Cώc|o1گ*QD &Ϥ{AxžO(s"_{-ON3\Lqb' 6M<%Vi6[ixxV7Fm^j5nh61$s>U;>!l1me&|'c]\+ٖ;?䙭M,,s?zR>pGNI.*(\JXNxOagYy/p}jˉ^j"? !{ {=o` FW4\]^oZ^Zз/GVϚϩo%D|B …:u5د+Hk;+T},lџ6љŃ^F&FmTu}G˳ p8D>~wHy/ w"$@"$@"7f7s.-X|<3ΨxK\j!/K?:kVdw'0Dsw 'tsN zjWZs/u&ZK_կ~ZZ]vءWR\3>@?^Mo'2<#?;n[7ٝ~k7z/F!7z&Eq7qy\noD HD HD 8,0Нvik o}[wO|k$h|3}ߟ =5P yCj|;ע'YzVw)u@HPxݬ{ғTyW:Xn+_ZA$g{O<ԧ>U6V\J?;餓j@~uycjCl׺뮻vx`w/g<ݏ~#/[Vʡկ~uw_׽%/_߉@"$@"$@"0O,P#hg>Sw5l&5?~wԥ?5`2gE.J$HI&EpuGB׏??A6یW\\$FNprHEVN@M!g{my{Z݃C mjy O5贲JK[5'u/S"$@"$@",n}gw';j}v}wwk񖷼_e/otiM-nQWc`O軭V$jG>RWە| Wk<+hzc+W<9m"[8_Vt٪h+yڽ~yS7řdlQV7l=O>ug+&G}t }kW<,}cիW]r5ω@"$@"$@",P`UVNɳo{W} 5yxstVF]z{2h8;S}&QPF߯~3|hzOP 4 t-zo=?GFA!b5̖KMCk] ׺1.5g 7gF>wy窳gzjIw׺ֵjЮއ,k@"$@"$@"0wr:Ng֬8y1lIXxo~s]U22{)C= O輌E/zz0#1g ^"ዏ~/2gsljD HD HD X]P蹵?  .~ ry">sn |q{tz׻)0s(pۛ8.$vIAw]sʯr^2$#XǤȡԏUЙ?OjЮ=UPmJ _qk\B>}߭aUp Iԧ>'dWyq{\}a Y= O;.ho'o緾g~e6*G=t"O~gݓ&Жmy549"B3@"$@"$@"0YmX[]t+!! E`12YIf 3: ׇ$"$ql䘔g.8rVI']oyD HD HD 8XAa "S"$@"$@"$#bK@"$@"$@"$Ƞp:y/HD HD He@˼SD HD HD H!A4t^"$@"$@"$ yz@"$@"$@"LC iD HD HD H9. ND HD HD @{@"$@"$@",s2(\%@"$@"$@"0 D HD HD XdP+8KD HD HD`NC'%@"$@"$@"ȠpWp$@"$@"$42(NKD HD HD`#A2T/HD HD HidP8 $@"$@"$2G e^^"$@"$@"$Ƞp:y/HD HD He~sVeFXFHD HD H1zۍ#ZgF`aPk?;ss=vo<3#HD HD H  7ܰ` q\.m%/yz_W.̡VlPل_Eo~g?Y5HD HD HXte/mUrz׻^[vWҕY(@IȠЬŸ+_JwQGAffnvsDwы^>XM̔$@"$@"$s]9DgߪUmݶy睻=أ?/Z;cm'xf7Ywoyfuni od@"$@"$E:3Ϭ;N8?裏=wCw;߹n/]hM| ?awYcyyvu:{ ̔$@"$@"$K _5,Aw߽w}o!}AG>nmF, MVeygt{7Z׺V?e]_]n ]X#K@"$@"$G<_G<;#8{PBA㵯}/\ibN:{+^y[o=&OD HD HexD|go| ^nup?o,ߜ[/՗Ƽt.붟%@"$@"$k!pݮ?X/ytA?Uh\XvA !zիw]Rf"$@"$@"}s;^W+ɕ.ү_Wx_> }߉@"$@"$@"MnRҏ|#ݳ[p^??n}^Z+yƉ@"$@"$vz7ZAWN;uy{hEPI?50׽:ND HD H! 0u׸5uQ|P?׿?wJL]D HD HD`~EŦ8;SWT` 6ؠn{v/| keIdD HD HD XiNwo+_J>{l#]AUŸuwM7'weV@"$@"$@"petnpt}{)B?/|;7_:ȧ@"$@"$@"/]E_/YT-0K6(F3<{[]o]i.Q$D HD HD`"`7qwGw|'@\i*cN9nvm*KD HD HFh?x/0EA~Io~X]h@"$@"$@"u'x -|~n˻KRD HD HD Xk 7z.Z #8?Fmˑ?D HD HD XwkZs;|\ӒKfqyv[uz%@"$@"$zB WB;v/o}[\Ph駟ޝvi? ~d&6HD HD H+v'V~fP*YP}\#w}3%@"$@"$@"0;vio[}]5-ɕŸ'^˵^RD HD HD X\׬׿d\%z?y׿yt=IOD HD He.vn7?tguֲ}̒ E*e4u̔$@"$@"$B ֘_S{up!oK2(_Rql7~5E!P 1okF9LrD l|9RtZus~8tn3Be_S}_Z? RtMsonx83r{JoRӟ3<6>x^vYv[l_?g`l-/uKug[4%wnm{=yvs_?qK\sXvyǬ>}\3_=׿U+!y;!]r.zы;7es9>o~jrT@̡D{YH~ u^!i1ycX7>xի^{_]W^_| 6|;׽=Ua@^&H-ԧ>Uҗ+z{|տ=Ll IDATЇ. >o|c}Рxww}k /}K ՕƳK4vG=ʂ׼53-M_~{ϻWmpW!f:u/b_rc5V1q2Xp'X7\c 4mXf2%  'PU2XNR;s -Vy/SO=7QY K=iOel!8I{_8x;Y'ule'v;[$&VG:; ZĘ>#c={ysr jf-3(eyЈA$C)pr/tT>S>BWףL?? }9Bِ+a8{!g`$9A52{+3ׄ 瘋GfNbضƤ!g3  ZOa.24}B.Z\y߰ZkЍ:+}v9M!XWz`iG毋N-+b$[KkW`{R?~/Ew_(@[qAoHO.XE{(?FyXJCB;3ȁn[)2/C7M  W.|94^!z;Ðg[!-9ZȄtrʐ̐mb>m>fnULt"_`*?1혔Z[?7Yt~ֽ=ND?UlїnuGGvV@=@'gw[gxi&lRa+JpGT&FgAvmqFd m4Wջ+]J̤ΌPS;3s1U\N;Td56Zznwl2#{߼ծ6v}}fvi2~;N>*u*jpds_rnqvPIU|jnVZ!ۤ@fʎӈdPkۇȋn֧l׿~'XlAWv1D>ۉ،V-آzmf =W6.:GEvuؗuSmS4" (AB<Orq؇؂?e4ؐ:QʰWr֧\`O_sxkl.R\BsuA&ϱi-&ۊkt[jS]k]v*g [cu,dt&VI+/욝h{| laO[Eᣎ47[~1?1RDY+7MexCؽhfL}ѷ8|:C_V2%ئh=KFC[TGq$Fmїv~SyP}TU(GWJr!29*N.y׿~TTC2]zK;yJG0*ݨmUTGE*/GAWC>8nsٚ3._7(z GejTv5|Tkj<w}G噐k+o}QFt,Awqcj~JSg8rt#Xc~ы^4UfFemDosی>5t+Qq5OGtИ.([9F+te5*oΫyK3*/5:V~U[cC kGX϶sQ RFT::ǯtH?6ZyyD8igQTD;Qf7٨LDAC(s{޳+|wGe`F)䑶2ݦֿ<[9=9Y񇓒:S:>?2v^{U; W2WYeZǟ~x;K#u|[Ƶ|c|k_;ge>q28f|-ǹUbٞWqfr-r5|TG;o' [qۑ_; - bjs|>Me2DT-^lf%HO-:+^XAِq<.ub(Vm07xǭڳ6ǷDvcy(ZLm?}~L -F']w9g{fnx.d\T>bc"H!kARSv*6׵h1XZt7c-E ~UHghCUo4)$7 leksU^*zٽ;E.E5leYAr5S ._1x g'7?Z:|T JT9Wס#TxYRxlkg$$&q>s~sdD`$k~VrV rjNDc#(̴Ik9=qYUlps?$Itܬ@ & pe6G՟J #x^9;'#@O#\'PqMlM (0cȎ@_$e?  X+ hB" EhE URqUcTLZjũY-N@*Yd $%xiX{R:XmPI>Ţ }"]l]ε39URhBKF^zs6]Ig_,K\)@[l@~hBV%VtRHkNx-BkvY{Wɝh#g_)RDRVAI(P2FI!\'kXqMskL,1>:?_ѮvU\Mmg>{aMRjeV<ˮẅ́N1o3D%= bN6JrP!!I8Gǝtp&З(Bo7i.7GӞgE"0Cl~yMa$wyH+<]+j~g!<FB<-"yѱb=o hIZ>#XpFear!󻱫|uHp#χ%ԁH6<` <$l [n6\X$UCnUKX$OyAT)DОh U )y] y{M*C6*9O#xZ<(|-"ʇUX}]l"܀cq)C:6_F}]|F@/-ӡ6A"P"ɇUAuڍr![;M"0ŧЏEЛĪ.lceüx%HN Q,D.z:(-?J.#L"^ЦhK|('DRݍRAٱ~:rڳH|jy  V~aa7ؑiOY$yg.z+mGB~H3!:6fWsR@!*C+s4(PjNWOIsmQqΧq8~cq@VF%ϓ $ ygL[h{$Nϭ O` t/}J frqF;'!JP>]lniJz8Ֆm=VpHXSsP 1U0.C߫>ѪTf&q*XS>ФuN?9)H0-B<=cbmqX.Ɨ) 5V+9~z.8_lf@V&殙J;2"c{zZYlgr}OMǵh?M _ϜNor!XT!V>:nQLjeF@^@{ڮ;V#6k FċKEklk-p>TfrNf[zUO:c#t_<}_d7Mgmb OzHOW / +Jbs>[j۶]+C f7aW٤KTk[_Rוu~c+ hLѼ=!\ل=)܄8{#-*iDTTQX"s {3(u JU 0Sgܪ oەkցvچS([K`:u<3eXPFbH^ԼԮ P:נ# ŏ3@(os2oS6IN@]-lhVst듌+RŁh3ؒØS>;V>}+Y6~Ks)]S̘<*XwCII[.Pm,+٩b MX˹wE+m}צ,6}]H܃_$]5^UV b%HnxQ ):2E9ۡ$IBQozҰG2 6έ pj|OZю{+yb/״;nbqi%>?gELdvΑ+SϜ"UR+Ʒs Ѧ&m<@-hA;nn IDATV. oǫO fuo*vXE3!چaTaU8B0@it#fQϙبe@Uˉ 2'@Զ7ĸ#h GΫ Nv:u6*|c0OAYPB>-kˉᇿ!X GXK26{mJu𭱧p]%qb[!8N8sOVXr^ X!ݸ.$#Rk_{&8z[?o2n5<-hB^$3%0'qxlS(4 8}j}Yo{/O@NO:i,J>)\"HlB>}2XR>VR[  !/ _>Ab+|nJ\ѡxͺ57KZj_t(AV]#䧠SD{ro^:n~䞮>O¡ScNe8޲(f'Dl9RfAmՠ=1Wa-c0C$Wmu@gk 6+޹sgVV\H`p(yh:6s$(O[/usc2M8eCBsbmxHX^G2U G_ _xIY̼ٹFa0$lʱbB#Ng赱m$[Ɠ]ɗ~JF Z%ɔ9$`4ʟ>]ˮZLVWgH^O[AZJ%U "/xz~sȴKfh: RV᰽M{\R]'nxU;LBN6Uobbg*dt۵xTpʓQNu(W סҚm FsD>Is V8KVuUW #`l70`U0R}XP0ʤ`RupcpPcT*A4?[nWx &FuÔsB%yEep ; ?c\?juռq|gmdͫZ ͕l ɚmr9@+dsݷ;E']TU1i;=c$|q]K.v!ly!S\}dVR8@b>c+"\~S(Г¢6?os #&h [-*/-.0zHC5OuSVN>PF1 U p0&X)Go^9WUc9:wWV*_,@sYqp^0q,& ھ%'(U JkeGA0m^p*%3mDEu׹ꫥNj8]F81۟-3E'Nű~5 Pq?Gm#*=]c##4wAK)/4قD+$HL p;W1%;#': $$85U6^wt0 LEd[U  -Ȳ`GO:@QB`LvQIV$COkhe%5+tX+o E$|*+u\ڎL`BM~Z ъ'$cd@2ɓ=AWeRL?[9piȵ:IEZ7rm~ c\ -\;T&/wal 9;*8;k,J#neXVi$Jzv^{d >C׽_ vxDtd$] %+E#7!W~VP!m7[V'ъ_ƕlI9'8؜ 'nk *؎H8+("/^2cݺ5b~+p ҶIZ|#g@>7'oҒ{BX;)柶T6z60~a%^ ʍ+  8 %/hup%L 5P2>F!`q*`S8c 11P% O  3zp<ښ0cm岺4+>܂Ζ ]~8:rTGDV-D#mZ&ɟB0]6^=Z},Er4c X)bYy+u#W 'Z޼=D%1%V̺cE2(gQU?6k|#zA'Tgk:Ϲ:G}ᏀP@ZПby< Kx]clks}HJZ/`+V}rסo~MC}ciKG}>L(#9MS-UwzVx; Y@#V4`Q0W&Q!H$_Us,TRh|EڒZ'-y8Z)dmS{17v%5eZ=[h]Mb_V$ͫݪ2(GC66<#䩕k'e">KfѪlrx!36x(fZI-ڐS:.4#hf+Y|e'~+{[}.t+*21GJN_l.% I?*VQ8Vt*UQN\?%=\o\6L,0D-wk zW 6w*uPLO򩀄h̦Fh.-O.O'|I\0#V2)zoJ\ \h:{^ro^?$C:Z4많y1pT %d$'E ߲y"%R|Hs^c[٭\sT a&O?>ʋuޝOp{lEfD:%LVǃ@O?^ m[W.B_pqyvLV(x?[[?WzǪk^WWp6Vd\G{O$j+DmٵKݝ󪱖b:4o2q⻧e"TUd0ghJXmk~OOϡS@1E2nErp@Ȥ`ɶ[\2/ɯmL*RVHUօ{w\7 * ,ץ8iY[ xngk;<۝kVVB} JYׯ{`65+ pVNAr+;csv J]v:׏cZvv$l;vc_{Oَ̺>H Lv+0Y=fEwx[t t t l3-VvĮ [6g{::F (rTg{=d_(ޜzRx̍v[gܔ=`*KQ@/-w?$C@@qA~=7|81;:< (0y5Ɩtԃ~$biׁǡ=)Rd?iXv0 |s8p( c))?R?@GtQGNNNNNNNNNNNNC=)<$')))))))))))0Oӥ8$(ГC}I<]NNNNNNNNNNNC=)<$')))))))))))0Oӥ8$(ГC}I<]NNNNNNNNNNNC=)<$')))))))))))0Oӥ8$(ГC}I<]NNNNNNNNNNNCuHrMrxoo ~ WW]s0 {sEM=V{ )6Ḙ,k=W4bt[k^toܱ5}9ޚCwS`oq#==)܃2`x?\R~?O" g~OO^?? g>۴'ӟ7dxu/V_÷77c/>\o<}կ~td/eaD'Z`i@oog9Yiqq15b '< @_Ùt8~(A#[k??=iS{51d'/8Ik~x,g ^ {H(x@.rl.6\pL^ë_:*Ͽ}[x3 _G>m`_Ν;׽d>׼5If.dn}[%G3-Cw]]r'?ɵ&UrA2y(g?ٜnwbdW.&$qk Gq^??~op\f>?WjW /| @8y>걏}lD&e/{,BZ@|pUE96px;??߫( <7@}["Z A6|]\\x~~^W 89reJ*>(4@b[f'8pS:W_ 1׍Ib\(wc;2ّG9=..n6:I`nw[*-oyQrXہD}ksU7bd$r8κ]7p_>ǮkY}UVc-8<:}ncn?5\p1|j[ܹU}߹Ҫ]վS8VsE[ݺ~SX% ڬj|eKr;S_[GGcU2Mܼ”nЇ27T2je:V5M{n>"S>Oyxӟ~xS>zYv+^w[x]&c뎹5Vnx[`λ\wn~yi[= Oȭ9i&,q=tK꺴hqM;N{?n(Г=@-ǖJZ^C;6"ٴD@eN՘C~ Ե tKkNɽd-Vl(`u/wSyYUx0V*7{U]8s÷V\VB.s)g?[E#>GnVmi4 M2{FN~g?N<3~Qt%hd2|7:`~u=r߫ɞ1[ܵ͝|ޡ;T.-~ٞ6wws.-]JХ[}ED6mɋBqPr47&zozigΫ-Cs}7pՇ9Lq6߸[mK5_8ܹttEV'/qJ7ȷЈ]ۜ.˿˿3tk髯`T:.xj ][ ~Fkgvp342?וsگk߲[eWٗ)/_K1˯8/_<#Wt;gwz6dS߮)F2ӭ>K{}]2}U[4P9ß|zM~ڕ^|nF'}7t+ф|zic|z\m%Oڡqܦ+7!pwup{gnDOB<WƸf{x8Bq v(l?ύ*9CGO|nٗymo{E[Vc81pqǎ t+l! gmn3‰|0Ncl o9=iOѷآ;V1/kwww) SO IDATc/x a0XaO|㕯|1 XVq7i #hq?mg]zHZ9>!F .tZٍѸw.>MozxpTځp)ӮkN)~k!yPy~sl9mb .tycZѧ(?2Go<}1򓎔qDox?߅>5'N;-="st44_#͞1s Ϯv 2'=Ic$%} O|sb/9qh+Ir5vac$#f=A9^agݞ;L/><|&Ǐj.!s2^Qe{܏8lgK[ oc]e]KYpF7Q׾+=䑏|6u;|{|1jlK__|p ]~k^2E1 ܑٖ%|pn3?y76:$t5/~~oBn2Q9%ޖ %/oN?D_OTǦs1qk]+uA?o{pEU6|iD^%_͝\9v.d@[h>pOū4dWfwCq{2n?R:_ca#ƜocX|s i}^בgD'-c'6NwSA6|97Cvo1:l9r<>c?W na c(tV5>OVf<$E֢p~!0@3HV;Rc[A$d#NYU2TwUHTRk˪JPJe5*aXg7(pJY@)硲4,}w>m׹u*QkD?͊\!3h>'HVG""ʧGb|Y!. 5Hl'Fuv>[{S[7g6 P/t_4!xk0 ^hpsގO-jʤ c+@CC{VUo[xbyPx8m{f7 |Fғ9[y$C$i?=n@.mU>L'4){IK~ih@n|7f$?){&ly,=Oy ~?N;G8z^NA ewdl+IlbO?zlDlŪ yO6M<\9 [^@{#|_?Dʖ9 +G2'4+}`A [9 "| {fj7= Vg^plu%Ks@g*6-]MK3p&h ȷs73>ha<,<ttqٜ<Oƒ}̎s8}?h џV%ыgso27%/|8FH80?|f۬ Cl}G/?Мh"E |I8e =$o4̊HRg>ͬ\_:]Xe&[/S>1i$j;^(@4D5e],D?2{ m"TvT|UV:+gRle($υ㡨YpF5-4g5JE=]YF~Q1V;U V-zaΥa0`Ҥrծ>0k}QWAU$OUœ4H_+ar-ƶg8\ASU*4".ax*cLQeC'.h4U6+歒3B]2!ϕNUC՟C}Yh &RJ] 譚fQQ,plWs?*X &U܍r)Ű\T"76jaZEj XUZ)#Ws[!'!Eu<.{\@|'k<nn|[vՊ#yK-#)P39Z|yJKVK'%ӑ৭ku| o|)Lc:|CaxA+;v؍^vkT TZU2P EʣŨtj+kJo <I= nWSA(Uשm}c2}*gqReTIVky _.(qV;~=CJz*V2 \ge UUB[uxVT =QJTh)Uyj#cU%jglX5WhjcV '9y=K.1gt N%/P #XK;T+Uϫ36pClJ`2zom2~ U`[jcvjzKUws+t* U+**@_*VܭWRPPbY%:6 f—LBJU6VzjXE@%WMl6++$5.Y3$hAGtB$edOzc BkTU#^عOάhd kuﱥz8"Vdp%ծ5EVvX owUD,LYw7hn|!HdtП++,O+(h\@зLOdg$M)cVP# *K ,_ >G+ Ղh :F8Ytg?VZe3 f/w*NK<݌h[1NVtzߢ$vs~j?v]x.:Of.}Ƕ:7ٹ Ŷ$nwR}kx25gV"AHϏ]dbsjZZqGqV5a˟[m؎cZ+[|>ˤ@{ HVN xiQ4F޷1$aoŊyE-$FPJmm`YC)9/8eL(UҨV)^+7Glu|Iƨ`>9eVi Y 0@?mT`2pdU0艱ڕc1-l m5i;ڴЌAl+p ֖7YMA{lՐ ZGSqdMK)`UR\[;6UƜ/0GIf[rhB%!1۹51r-ps}rLkyp^Jlo tNIP p{ݦ -1{v{8r/0ѵfB 3ID !N xHGЉ~Q[l5t?r̀Nm [P!UU}a`n~̱թjӵҝj'ZlnHt'*I{^E_h*qOrHn&%S`*n vtqmQ7?A;U0NK/4sx\BBE6cv ъTĵ|c;sdC_s OqsMɋklcKKN|B Z[VC*:a:< ?36X/ȕk-ݶx9-/~<H;ɗd ?m]@a#p=.+>h"TkG'/2p XLT0l?5 8kp$b,A^XJ}(Ali X=)M[-`jݖѫp>uL VT4s©Ygƥ5s Ҝv橿Bѧ*#>96p##^ *ut=U89f3hqU|k8tΞwLe?so`T`d:WAU`FٌezX{Sr~_tܜ9NmBYs}.;FfLZKr/kAxE oLԞ۾|w$,i`wbwILdut̹AkWxExyTܻ{mc'Q{́lXBj[FWmBv9ӷ?p"pL(d/%s*VsymS6cb1(vDhEZQ3cO˼/put"5E{f=o~ڞoks.6{P`c4oW:nAΕ5k8ƻ*VQ=Spk>!PfAIWN6'Fqԁk99c V?J[9C0sAlخj+kѽ e;Ƕ]ՔTl<:HzTvj≶vrж]eeTSV[ͥ9Ѿ #=ez2mo t['iAϪTOpEYz0 ɥv>W:zNά*vYuiA56p|NWkT*)b?aFm+Uf[l'pUٶ~$S٪ =>h&Lhe*J++H˞B1?kk8HOmsd\MF$傻͒up1&[GkA`O=TQZP@KL\c~*,a"k0!l9;4j]+6O{۬ͲkU| OtϽ|: 5REY"^ٮ qo$*oV|+[&pB_s_Ƶ·F%l\Pkn6d}S+ =k7ZZO;g2ƶ_[L|bg.+p-Jr4~d"/}j`mtܦ UQEzR9^`iP IUUI fջ=1Ud} T<Pr"9'PB~+(yPqNQɉv2m xr0,, nnxG?x6FFU;K)HdFo?GA*p/^^@O`a$$`ص$ c%XK $ ZJGDչUsXux+v`xdl+rYbSA6ءX5C0 9O1=4 _^$?tOL9Jѩ "ԯ`kZUE gͧe[\CUwD6+4W?z=Pt^?@Aɂ"lz\VvI4>bA<J$1bSRtb 5`n1(Ӝ<9-+{ o׉EȚXDo8 qV+l=-aWW<q33;1hV8?N[0s%ym<O ֮ Ќsz"䩂cOjN$ZAdOU D+GEɱL;D0!iu$-q g*|+:i>~)w6VI̓O͗ Y) N='o SV#ח @{OLRhkYr\a2h&t,7* h/A? ^K8<<Dd*^x5;#)dWR~(xBFƫo%CdZ=\1^KvQc IDATa䵕DIV"g+@lo ?F<"ybj3l.]`JK '=I 8 9EEvB=V,W4v|Ʉc?H"Sh1 [@$wk]?d bI'OE-q=@#}L X;%"wDk_>h{i^3>X%jrSd(VƨXͶ w iA.m˹d0c<}>|?V|Y'λp\cEe_'f$d_ejqSwEQ3*cω_8|'T|R8l2r{+߃p`(K|OU;ád]Cڨj.[јh7tuIE hK1~^w,#H0zcO©l/e}6W#w9 >F"5F定g8|P8gxC"~(*|_a+*Npw-iAŒ|D-V|D }Rp`I'xHX]mCG͏0燷j:3zGăr}PZ g-D9$=|<߿ٶ=gcJB/#Xm< b%*чK$'uzEpjF_q:[X|A;6J-'<^3|bC|yF4mce}o p5ySW+m_Qʾ"E5cHS'ؗn˜c$ZG:"k2= 䭅(HaO b"itKg5l3_$OD\4 ;|W4&vlxb;,iG.BAf<: QL :h+ƜD}T_l=NG* CD8 ǖD?S"f|7ciq͗xG4$1i@w@ Ox~@WFzy*K  *V8뺽zN*+-aP=ñJ7V+[JJ;vKah[ M8ǪmɶڇPu*mƲVX}}:T~ek@]sUFTTeہU+@ƌt1mSAuj :ZyKZʠN2̅˾' b̺FV\nso8v-cےg>qX9RڧKvUC\j,x (OqGpdFVTm{Gsig8iu}nL"m':F&[@C0nxg]Ѵd [FU5p)CTz;(\g'\h:m GFWrLimk8O><ͽVjS{4tp-0^R:܌ 6dԜɲA܍O%#ϩܢk_ xWNΌV7+m_wmVjEO4mZreCC89\+IZA#d1_<ҡd|Vt(Α Gek_\81G4CzUN)^tqyv}j1/u=Lmu_yhok-_c-\ bЍ qcȮy2_/kg $Wh/Ckt߲ťnlrV_HZyhj cW9AD[m_w=_.KedǎmG>sG ЖεDoxML s$7cJRH5ߴqLOsz 93LwJ #sx#E9WN2e7ns^Zɶ"{RPc_+A66Ynھb:}IAJ 9{۱::\ TR(IP*vNa8TJ,UVU)0G.sT: Ѯ?:&CC]pq݃0ܰu( j4ݲWg@A[vNNRCmtϿ?ק6[޲ `NڡS(\C9-gJx:{Zb8w::S}s/yK~W\g<}c}zpэ^eރD=0))RVp:t t |m:TCa.vzR mvI_ ڌ:\@@@@@@@@@F~OƑO@@@@@@@@@@>@O "sƻW|vN@w(=}lOuڏ<ݟ,k^]ksG} (\σeOWdfoڏ}KEz{ڿ}ۋ;)'=io=G?op p^ܼ;) 4' w9fWx|*/}Kvx]`m׼5Zy.^] Ӄpnu[;Vvt lBv#i ?}Eo~s%g{8LʋzN=HAbN?<<|J{PMozp~O;.ַ5_җ2x_F0,<C_@`%Q{s!__7_pQG  _Yw0'>1E/گhքz*b$ 8oy[;Bo~ZK\`?\ۡS`_S'{:9⣐"Y{kRPx|5k3WO В.wXNK_3Lga:?O~-c[:W[ {2mnū_wpQ@k]eVIOͩ|U~S`OSG9{*;2.%aa8܁9 suzǦYS< ߹OxC_W '9m:|\W=OĿ2E˺>ί;w_#<6k8Vi{䳅56֗N~/hd̚[З6Ο'hTr⿾O§p9Vj[}εcE/cNh1#kԾΛU}w:&7ph{K7Ǧg_V879:5m>PtзR\{d]? m_s^"9tcSJ?.EVxy}X>iv;V)nm_S}.^cC7+ܧk^>/|پvp(նS8_~.Yt1N|Ys|1]Wo֮O?2'Ըշ~ikuou_lfX5j̶m'Wg UtlN[v@O />تcǎ".=`Kܟ'>@G\:w3ػڗ'3`GK\NvE߶8}C>ϧ{Y.pᗿ`+Ql?>7?NqS ?sNwY/o|cWWYQ~Ӟ ( ]x*wUЭ/˹ߞsuN_W~.zыXFկ~5|*ԧαFpƊk-}<) ]BG?웱5׳HV\DD;clC3Tx3|S8+lg;[Ժӏ܏O:w_8=,gNxp9.yK&9@k&9iRf|/8T074DO}S9ڑSOt*пcl%zmBq.uKT-8޳-dΙ-aSN?Yl{"z]2.NwnҖjk@&ɛ'>qڡˮz$'Iyη]t~ޣ=?w /`WW6d6ã'#UtSAx䄍;1گ}k930c >=6^2gSڢ?닽+%e7hS_V.\Ο؂ 0?RsC7 ''-__> gH>W.xIvh/B'v鳟lo|*[9m Fo ZC;8l5^]6Wt')׏-!ӎ>̏keŵ?8(pXqx _ PЁ8}c0c(#C)pc<#dd c9F:31d;cc11xä9Ǐsa`c1 Dn`=glee$nccE?_.]%?~ ×S8`׼50>yy1 7<7 xDa Ǟ}90id 5q!7pɧHRx2e\;?IxԆ׹urHb8{F0FFbfg$8yԝ:I]gk+{t{#jky&#paȕG=#rp#~xv~G<y|3>SH$w16=a91U&Es6-t 71._||=_48~Et&l1[UzՅ-4^o|S/͏s7<1c(}'tCWE`5Ƌ}bK=yό?4蕶7j`!y{^6ח%|ோGil{+])yW8 T1Om-C]oA|ʢ6pЃ=5vA@ލ#(Q^t;ڛל/s 2!2 N t7AʤV9Crd1}[1z.vog<نN2}XZ}|=+>c6&0Y#l$_H[G+#o͟\0'xh(!*T10JH*)Eu,<)OcA$Qs~ dQ@ q;#Ƞtd m *+ 08He%g4B286&9 gGuӉ/kΜ9K'*pgZNQ 93p @ajX~,6|8 pIh7}fxq<UtQM0h90|DeFT3&q[L2LfГlQ ' ̣$S/ڐIƒ_A#xd<@/֏>90OǞ϶F bpt 7w|v̼ %sl$ د vgdߪ80['[͞h.Еl|#9`KZݘ<GeP|X}ǻXO5_ !ߊo[ִh.G+rIӜ[7WТ@ы ?(nv/%p$G䀽pZ'tiݤ?+;-eC]jW%䇌Jf׽u)Esܥ™En'x6گJ<9| *G}r# 7MsU>1 N9rUU~9IzU (x;WL{p"$dki~)a,=)U/<>|:"X嘐1] ቎Sp_\O:J B΅\{"< O9O o&&X[ȷ "; ) @ 9B# ~Hz@pLuqL҃E { *O Z"Ⱥ2"(+j5(5&(buψEp'S_@]\ş8GG}e~)`Lw,=(E\iRhK0OQ:;bL^mֿ||GeB15frSW$^O/- g_Gx73"c]WԵ?u|D^/c^+ b݃Rٺoľ"9Q]/җd(Eq)FO=X( ?^:cޞqT:.T :T()z mYfK>c.ڢd'Bߞ%g&C 'Pax_VBmڈGk s DBUٚX=E0~2BD:r rWgʃyͷwЕ*'aYV[ʼو~~`+s%~}oҷeG;s) :> :Ev `"b^7iص~_^d9O TؘWktF/h^)/%Y1(% }я(WT{zY>6Y%ꤜPNt0Ө_Ga(mt-ۦ_;zimv=~_0]klphOPۏ l9&'(V)-y9<(V%|Ew(#eKXP=Ϙ)<ŌȲ-RnUw"(g: G{afKc#`P/M{E^PJ%D[SƦ6"3 {^ޱ"GIM8?P21rVZ8[y1^Š:h2I>j ɓQPl)_p5Kc ~[ &tx0QXI;J#0R c8+iùN}q@'odr_侹Ęr`l4_G&H0FqȰFzD_kCi?M=ϰr/!$p_Y #V~ZWG8#nylkV&>iΡJuXi!| ,_-}q_޼ t`%ZE0ځϻ%Dʈ@ӪcxS'~HGwߕC!$4mkp s/m U PPbg\!f-KX)}mDDֆhrGWn[VVVi(JKa~I)J[;[6cԦ[ߓ?V7M.~XضuC3Օ?uqQ>xvçNPER XƱq OkVkƿ2f(0]V|e\}0e@!myzꂕZj@-9D.Ľxv.Y<8jIΆ|[9#3 19kVyI:g%;Gk}R.!MZ'm{r8gXw<ʓj D Ͷ|ni!0ܕdkc2Akz(SBp\c jay!`!Ӏ GJ[ibZeaFgzSw^z2>УGg !Hqe3f7A ozŤ'u")6voR{ s2p<Falm}aAɰA'"x6S~`)*IRUN2Q>= [jTcj C݄ɸUu YRbO3^ ‡&&Ⴜҡ8+S9D_[ ˧npKlr}SA#GtgoYPD(&~S6%ϭEϸZ3 BOjʹ1jlQP\03_$d"g'8Cf{m q&yAW\69!\DY Vc|? 4/jynX>UNWiCAƑ] S#-,ErACg9ؖg̘f;1(sRk>M+~{xk y V>A!#-0axOʘG%s:cɃ۹ld.'!R|E 9Wr^ޕUCfn bEo'T n|r\5LNA&y`tj"P`B0|Lx9% V 1`0(?pUN<]cQh[ö_7}PtxDɽ$W5cRP&ʻjr0sJAJgʡԯjX ؚt[{I lx!~||תx"'Xu'S/&|WN{Xoi0>x!)/ETڟH!Bl[=ރR讕ڨ,lP;|Q(0~J B q+Fz'q->?v, XT0#OrcQQtUH9jIaIA&F\qTcR^ЕWtT9H$19?U%2Ҋ<|m2𗱅Ok3B$9Yɤ'xRoXέ'#/ژρj?ZC6)UNNFy&ʸ2q>=Ϩ6//NQGQ~TA'G:Ɓ/4(ϛe(L>`CUyHajIo>F(dѯx K:"y3D׵a#M& uԷɱp"pI+ c#$C&BC0`n   Y3Ĕ;/aD>F:d1dgTOĐ"#Ƒ}n1B#ҙ,S}|Zr}Dd#LQNcJ~1<0 I#˪!AF1 ={N`ϱC:}:M u,}|F0p( (Ǥ#̧#׷&JdƑ e,Zdf  ՟kQ/|J`8q(Ow)J xol_k{8(5>pPoW?W :5]a܏łhqD1F@mnqjR1LM-Q,왥r%0n 7*p>7E14D*Ѣ~xz1{xWp% J7E NmJ rHׇ}Þ#@ ESÁ #JjolYh%ʜ?'~$۬8%T:p18L)B2)U㿖g[!<[9"<ayNBNQ+W$5`P:h_tLbw͉^p66cQZ~kҭ̫02{Vh19*6_'~,yrBrz atA0_G<%Y\9094#/c]ɇeT^Q^~/?QuaFMrx Є1ņ:QLℼɎfRoîAl01). ZaZh1ƊAkf} KyKqRʸ}O_I2C"R_ȡGW[ &qXAݭESJgf"#`-|,i4ҷ: d|(K;K 'eZ"&t/iu!,RhJ!>X_)e;V'i.~'쩠1ywf3$G^!hVupyz&#(D (wC~;#j|ndىB!FB!rVAt`UFbN~ !wxilʿpSgL&^Xi IDATzD 4 hɧ&+L%EpL"랭yTf$@"hL~ߢU) JD HD HD X,(\,D HD HD H i.N~(N#𮣤~^ܺ[}vm\dB? ţ_gOR ^rxc#X%3ַ+6&AG;tf>oy9Sl6qy7=ɋ6,3 ԏ?y=vyi_a[9|+e7 kwzmBq} 1 Aʕ~V.Hد(z+gu•Lxpw{msI$|;nlDðoy^8a3?G=~tGIxSĽd4L./}&߶6G}'/ʜ_uR^j1URA^FH0޻KjȢU~Ǿb<0FeXK3z}$^iѧ7ZI@"i&tV`XM'Z_UYڍ7x}v履WL Wҕ:/izMJ&F!gQVL漦{ɤQHp䔩M/_L'!KDP/~ 1N?bM2*Vm6b-j>mzU H>pOWaQG.>{lD?wy~~_o_V1^#-anCH1o;ZOrCҩC`!O6Ř"<Rz"C /A?鐁Ƥ}碿3QԷ> #6XIjż<~|<[/]'a<O򗿼{_xMD Hf@3E*{^nl(p C!{'>:18LvûL&N:{[ZdϛM||p=9ϩnvuw\5,(6ЇWu3Y'<c֞wU957nw zw_bEE>ڰN;ZHI~P()zЃQZ(ap'?랾qMozS?PǾݭnu;E/zQڇL;N}gɗ%Ä(xǁLҗ=ϭ|DIdmuoFc=5X*Cʉ'}>U\] _ chk^l{^ZL]׎蛂mi3~CdGC7\?p Yc&7Ijjq m3cws$_!ȃۯ6[!-WU9w^I`79hvPLjF@(k&I?_[UqqU7c *HX;)F^e d8aw#׺ֵ*&|Q(b}uS^4F!e3Ϭ8SyCPg)9@KKLs{ 0,r!aJKi|[R |COrPv))2MQ.ME}}CƮQ/7_L |)}:[&ϻPm7#AiP)d/˵N@#)nևS=#`R86nP d|%X*?3%p]vc|uQu<0)AȐe34VҧgB0ʛbLEA)g}vUAv0B{/0pcy#Y t N&xhD_k>VO wocL>0Y݌%>d(2nWDB9gX0|3Xp=oʾrZ0Y -X%5H1GTO~ %`(S>U u?QT[Vyɧ(fSE*^֊{/JTQl25Se2*JT18"i.TBQŢ|MIa鍋~ҏx+&EѮEֱ(VQTrX)wVTLe{p( SEy*~UqEr(S *ƅSp* TQʫqb7U QI[- ƒH* _-jچ\ wY<TVjdڬb{d*TQ\ _ީ*U\ OE\]#|zh(g3U r3?W$ԥ(Sŀ*+~c$8.ʊT1yGY)T1w(o'[Vk p~p*+ubU4^ʊYdSDsj:yŘu,:'EcP1TbMcu2?x6Unx"ws^.U1*Ϲʞ۩bTȋ:bpLCe|?D/TTVQQ>j!-/#9ũW/Scm*L5|T%v+s1d?8j?+Vڀ|{X88;iO>C|BF<;sYu}hrSkiWqBvjOcƒR O1j[w):L*N*KƟүU'hcp qoԷ7W'I@"Wv:&l\nZGV&.;xJ~&2m 7//B y_(0B!3HBD#A^I!m#9a gEEX!]Xr,i֖\~$p^y{-V܅([gֻ(uܓE F5NkR"$e#̣!-BsL-ƈ#`D&> k;F:iJ8CVUECژxwM&vSG=$=EU#O!As!JŊrJ}H;)!jio2 }YaxI{S8 :Q>Q(BK{'aG0B/ A"ʆ(-Q6x>W F 3R4o b=oH?)ٯ7 ՚  %)ᑖmTNK8cOZ}aS=0o`ZoڐH&%ƮqM%+Pf?<ܯs.?>AxاTzX_>7Ce}d[H4~ R;Hx:酷3T\nn̰ #ג> N 7$;?BBWgaowJ]e<aZ^cط!k#_fw𝽥j*K^xK7-kmzX觖I; 4$_~kq#O WrPU3yI>xR;2 13)H"F\ xL>OBi!NfR<ՆL_~ںD&IEһ>l46za?VmFF21X0%$8QP K+0݌3mO& ={m] ~_z~S߶rH"ʥUV4L$=emO{z2|(;V좎qT}F=}6G og Ifq H3G%e6"Vj`j*>tΔ1:ں1Z^oyJ'֒zýJHٔ'?Xb #2C=yi(0G;(nh d :@qZ`%\lx+Ȑl;<538F6wpS>Ir8K?ͰwuUj P>fcMBdk8g( c$沸~umk &/vѶxFNƼd}w{Ojث`JJD`6L&yg*{5ddĺkpm$Lѡ &$E搃Ieb,(-ݦ=BdR )CMfÈbK lgAaFu(10/BPRxFCZx2xr>YBql1l(SD=D[] X)?<gR/"nT9&KO  3k8:0J$uUg+ ̙gŊneL0 C?- HXsiW.pc'IJ?n+ sD 0Hi.ׯWNaķCMf8weŘ>\Ko\Xt ^`QB"|_HÎiHͨ'#]:Fx_>À \#mi}g>MZ`CڰϏmXѶ>Uף qcH 'z(=1gx+I@"W磴URKI}P:+Fƨ>wQxMufBmA:Jz7R"/IʡB<䷓>'Nʒ=+}ׅ)t&_d~F{ ;P'>[Fm{)vx}L( శuoyY}Voԩ#p.^elI9mf /YEQ/s>fZ~z79joYၻqEYZon 1UZ]vqgQteenH>vP>ʞ*Q{6C^#N$c՘Xd Chqvh'3=2"h /qchcm7L8YHm ӕ-}V 6DK!MU$8SRgc5xו?,s\Y亾+Ǒ:\tdϫy5 SiSW;3 #,M n6yL?w 1Ye SoSCSÙ;H"Fl9VQ& !&{ LAYbɕe0f)ɡU5P;3Lb<d&M[Tb2 y{GCRZ&Ir|mQO'ȞaP2Y0#aP^GIuRf`),W`Vߖq@UWe-VZR|.9XU'v3U[i}( YN LU\xK{^cl{g =b[y IDATrƸ1b\z( F^Z9Q'"uq~72QcXƭ<9LuQ}>VVZ2.dA( 1n̏#ZF+X /5eehG ' N01)H0H}W2fk9maL[y$|D79ƒ VG}7}5;*V[Ş]</uF.0cGFy͊/}9;,I1n5v9'e\09n?Ҝ5OƙLZ̈́(Net[m8oF2WV5MkYt,8 #iSGY.c6A/^N5sƆygy#qˈ̒ k,D{hG̸5veP} 7V[Jpa0R9M#4yNyr!'V.YSpwwȩAv0Z6vmw+_(6mTWuvJ(aL'VNMBr/ szaQGs?u$`+!dE݆ouRdhh0R'Gh V04 >$;QkQd}MaÊqqy)f|FAsR5idʱhp\׭*>kx9!߮@&=)H@ 9~>yu47QVz23_!0 we6RL&@S1nkW\XPϛm2 {`xPgF r;adR2ca1&Vdz!UH0.Lj8eQO ([ %@QO4ClSTFNg[rø緽Iᰊd5yQ7N2O 뫡C!x~$84R !VRC+( BNpPNx0ʠ 2>5fBd(YH68 m2K{)0y/,x.=W}Dum." O}$_iruV?;}Z׮@|o *>SNhg9,j0H2_0z6j9׵S.q ){R>CX|n>Ƭ:s!}L=c9 ;Eƃz6![H)ꁔˁ^ѧgǁRnVgacJJD`WިP2<72XKc8 q$B'I;u @ٴZ`a < `L0L|xP@BJ"L4L{LF5DꭾRi$ʘ+VBLюh{[op8pNVM~D #:CѦYw1}B[6P2$|S0`C bgXJG{6^܋L׬y󾥍Pa%R]]#{>l<)nm_6\/,>reCxRuO2Ǘ~HaI?nW#[~ॾ b^>m_嶿YxuBDZm GŊ f#}iKk[^ y/s qmu$7Mnʻ/7W &^,RZ /{ #Z}D{OlߩCi&9{>μD`u FJ8Qtȁ IJkVb zB ih_ אC6P~?H G%|6HD HUB ى"!F"$@"$@"$@"XvFB{b'eD HD HD X(Q(fa_(|D HD HD`s?;+ײ2 qѥ^ZO"$@"$@"$a_/;$滜 ߲3 FUܼ()HD HD H@g})p%Bֹ /p!>LD HD HDc9+r܊])\v)7߼?Aj",cr_d1LH<=Y?%OOSJ _׿u[wW*痝Q#uk}{S@"01Vo?w\rIM*LHy+^v_ XMx?1yzBm I@",E߻\*v_b5\egZfmj|K_$K ziugyf Vc:i4@wuw]wݵҕo4lrӟ>}~_VGxh9#;iNἦ W+_x_$G xZ*<~׿=98rsɻ@",,~_k\o_H 4 Y{]y5aTD`$Nzݽ=a?tի^*~+xAloj؏8U~[PT>:˱;H9+$OO ~WW\Fo=|p3^^LDSTs=-ܲʮ,1ZFBLXg}v=tm]LܲD ooZ1!mnS;4+NB)sNݷfp\+]tQ?uN3ɫ󆀃N8te]^ \-@K}~mݝt&X$EN::w{h1.,sq<c^裏;ccvVk!`%3Lw{ܣp2L>tBK9NYJp=iO|+o~'@" P߿:`qYGu{SH8ǀ꼗,d)OyJaށ쿅%xE7}k!a'& <}{߻kYA*R6hhH%O~5ynwے/Q˟#/|^-2D`nx~A&vm"$c&VܸC 4~vJo^CI n^rfI@",&Nv2ŰW ỬB䀅C="7Բd,+HG[o] Wh/9"p߸o؆~8^:y@:F!ЭD H NV_bjeoڏ=]׿7 v.UZY;#i򕯼ɭN)Mz$ '/Br Kr[H߉@"Xl~нe/{RkV -kP'1]' e_mo5XF!&֩N,~ُx#:/x^mu9HD HD FG}t=<̻gWy5+(: GqD}`2D HD HD X8k:/xA6t › Yi,0dM#<.SO= ;o]WSWZg{D HD H n׼;S:yΫ ۊ3 5ի^Z׾c={#Y_]4]z`6)HD HD HV6ߺ/k6vAzP[jPϯHPcE/zQowݯ(z/RXw'%@"$@"$E@0m+{+^}6hq{\qaWWQV /stKwwo}[w݋_~w#0 _ݯzi}6t*3z׻vT_"=yg?cXo}Fs' f7YU*~wV.0TKA1a3y"AZ?-oyK*K.m/TĩwQx;ݩNf%|[ =3Dn%k)7Ar饗vwܠ75q5?.-5 9s/u u9I9AMUt_W!Hw'#r&cz)SgUcF#f6M uz :'>QCoxZ1Fa߉xgA}Cs=;j( xJg]׭=+ԧ>:rߞX<=qO^W#P.{dgC=-y::=D`}2 }dލo|j!h뭷:I.2}#€gfՐQ^tEe?;wҦw"0u,O5V?3Lgxu3f8㌺Xi A.uNŤdR+&Q8KUmo7E'?I=n_{ڷ-g)>=~-wܱO^@3D`"Уr] jmc^Mg6ʧUk)"7b8bLgHtIu}1а b}ckhw{߻/| uz'"$:ZȉEFD`ijdV[LB ({/$7.cg{|XJW!M%<, #alvCv:'o:d@"t0rjc+[qL3UmP(}AI@"0s{ẋ?Άr&i|uOPx;]ӈLsb/=\%i3&&8=auVSNfoPA<ȺI w5EQp"'w^}樣A9̊bZjrZI!:r8b}ɻm8ʢ)`?}s%bNJD X8cΜD X<l(#1XqR8 ;C5 E+Ȼb OxB vWB%USN9Ϻzh%5yMMG=:r#{),~5kz-}{_=}=A5#wqs_lz"$ D W W`fՈC9~+ 97{Nn'u=3{g]Ǩ_ky-lq)RkT 7e&% ~sړN޵v7jrrs1eA5 ycÉܯ}k3e/\(,3D H!0ڥ%@"`1 7xZs&ZiR_6+ IDATɉß3I* ~XdMV?<裻:)4BSٶ-8&z<;)xE‰?O%'~ExG/E4G"$+\)\}-LVV:U4vPGdY)"Zxi<` 8cϊ}\N*eXڿHf8 E*ϯ*𳱋^а1Qqꩧ}[կ~58HWz/Wq +R:`g͂D XQ ;=&b6 ir04bwuz0;Ϯ`4 Ge\uYBJ30)Xhܽ/΋7M5_ic!'ǰ} m~^"$C •ק٢D +%VE+t]v DR"$S:9[$  g;餓1gH~vzǧ&w]|D H@+OEFla >v[ߺ۫'|cK9XFh(5|gp='ZM¨L'8:fv'sBi{ 9-P > z?Sq(w߽aMI@"$4 WO_gKUXcmC-X9; w!yH}EH!OQ%)HD`u!Flm"@/C9+~N-~À WիR=I& ޥ9GQ?IiRf <πLJD XQz>[$ V^w5WH$%{f}D H<}4y HD HD HU@@"$@"$@"Q<$@"$@"$*F UD HD HD HD wG?}tџvzW" \xԒ .4OYD HVi$K޷m^Gݥ^K۲6o Fm]]zHlۻJ{[jO\1~ /p|>N).N\(b Aޟ$@"8]D` +_y?1e׹>>t}kbx'< 3mތ򗿬`KqX'/_.wk7MIWOi Rɼh-`_;}꺂ar!x4~~}ްQxӛ޴+ xf$@\)&uܥw[oVax-wCwg0R!|V(ϋEV/~ ~n_*(Sx_v]*Wx;{~&Tk_Z e(t;uxַuw~fnV#D֪{=a[oe }_ޝuYOw[޲/\@"$ @ kZ(yVozjbaܣ#(V(a}C.>w7RGE]tQ5 <+w6c( O>/}QQwaf7k O}Sw~|f5kpO{jn衇v_򗻳>3,p80 >i{IqpiXV\_Wvaq npu;HD`mlےqW=᱌$$Ph}>v~xwJߚ:FFus?MCI~R"巐JvQovӟjozӛ8`=7E؞4{,Wy#Bwgcj W{\=W=cƓU_?n|i<ߊww1x]x9c;LUFz ś HC oؽ%/!s 9|;HD_p^]l+-;H"n}JI']r%h@ +}giy _nw\ǀrosN|sh El`Zոnc xiO{Z|yzzN8( <)[l-8 Z+ksOs(Vk__bh^FNg9>u<3&!qi%'>@iH7G]zױwG}t|ߎ->kƱvQcDD Hx[|:6W 4g"? ~,2We9zr)a֒O?pU$ i51Pkv?RGL[C _B$ei/njXn`敿_u{]/~cY=cߏ* }xBF[C:㏯FTQyOz]YJ6*$wQhZr9{rpw:fZVOD  4 ')S%(Soc) ,+,ӑg*XqВMx^$.4QQJU~^j>dZ=zs;8, s7&lX^ym~V֜c'c=dT[8ҷA#H54]gY-R^QW:!Cey?9* OeR"$C }:(aXY 4%YKSZϧKwy0xJ\V(шq㌁q. _-iؤ@x&<50h^':3A<۹ W)BsxZt{7ycJy/HC`xmʒD` @)R2';2'fU9ʞB(vmG8|0N5>i[<M?{?iv!ԓm#7D8VY7MMV%px:z.=&@"0Q8xfn@"0(p33 zDaF-YIJ '= ,<\ʞm^mͭ:z'nt.\ʘ06b )Kb4\P^OD`y#F}"*2 P PzKc [Yg}S؅",;Nn\q{+ |}խn=!Z8)": Y<:+O8.%@",O(\NV=hWD }zw_?t6 袋~+d8~^O!0tÖun6p2xgx3%'zFжn[WaxZfSްZ"$C ¥'YD =V閜=kmYlϋ)ÓIg%*c9mIOzR[ŭ[]u?˪\CN#>=4oӍvpZs>ϯ$:^o"$2@ eIYD X *EUi?mysJ(r_ex:}Y!AFozaeTIM^JapuJ߼+p;#fp"akaIK8ؿ;ݸG^OD XQ<)k$CJF{0Rt8?IV 'YY[%:ad5A+0D`R(~׽U_v64BN^Ї>t$OeGJ߉@"$4 oeD 0 ]5|ͻ#8O P9qq0"4/><)ݚ5kdI')fc _Ogu%FF#]|݆AV47噑9lD`R8;דBh_k<6D=أ;xc:4q^LD X1Qb2n(DڶQ5vaH+*(O`=)bXIH 5526mi-kq9wUks-#YoDњc/u]˓)7tkV'c9mdܒ~!̷!c;;}s ӲFF}iK +]Jݓn=lmO9k !mjXr9qw}<1 Hq%vs~-85W9I5G٬t̓><W݂d^Ch<`9]㖍/2F nmXo (~^_Ѝo|#|+·K\hXBi-K=~X Ph)kH,ֵ=yKeVA7эO<5YQk<0=輪"T?]׽ny>y n88888@aƁƁ5`v~-#=>ú(ˣ~׏oKY?\# 2ke)7?544u$Ry=ejWebl+q`p [Fl#3L|8Ůdy+vIբjw>u}oB,$;<##v뒖?ww\owSw7]hwoۻ.h- k,''݆ \*կ~&W(sD'{0-b9""+\ ݽ}LAKdUB/E/(J# `N;T@&o%e{/%\R7{De8>ovGSO-r /:}h}iY~;3ouQqqq`sΗK`Ewӝ]v٥,g#fn݀8u^ K/8~w''WUqVhoh'tRqyOoCCyk-9jc؀@F9>]znv׾v"=뙢- %_җ/~۲c&{]UB[#q6=T樣~wOzғ.,;8O;˝k $voNW<Ə~__[{t{g,zkZü:Kr^!yȚyA& ?% -oy˒^f0E {QFkt}s:׹N G!NeSs|pAdL ,)t\?* 'sZ4~czYg;-_@ L22~~V?Q*&`r>Z^'>>xe ku[]zׂ <_+^C}>5 BEEO8%/Wh? @{|;e[l>Ph9j^>;i rO?{^u6mj`pڹƁƁƁ5vC#+_JKa^| IDATWW PhP93%?LQ@@@ kJvooʾC72 lܸd }7jhhhXIM?Ot_׺w޹LiКx+_vhqG@rp!׽ַ.Fл켢Þ?c#,}X ["Ԩqqqqq쫷Wj{nYQ#kƁ5{ t/Cb'7g}ص>444lx"xۇ?l[Pןmmns/yk]*ihhhXUj7)RVmXIz ! -nLƁƁƁƁ8` ^^iz :'tRyG|iW7444XAsvvXl5ص?K/{P88880#9yN1~OU e@󟗧P{@ƁƁƁƁƁI}bxdI@ 2 jP{j޻cd9Ins/}{l6Cy𨣎vE@@@@J "<.õ-\ՠВ&Q:;ȵ?@eC*DMW0der $l888880+{N@fO}ܶ %A,Q9#Y]88880g>[-P;mwY띄'rHyUs 6[8O?W5(rɯ~ehvƁƁƁƁ=x`wt~Y6?Sy8~衇$K+ƁƁƁu/\=o~JPg׿5}k%kRZVWa|It]c.+IZ}}|]9k\+_,RWUzHÃtH3p򓟔A6{6jhhhX~pe :xv[Jg L3#Z}1]؊" qL>ϖLWsrP^a?;w~pc9u~WUwk]l9V&C?.`BrL(-1lhhX d7BҕIKIr/~{ի^U!'o8x<x 't?S'B{4_4֏{?<{%BO|ӟ=1 '??i'>qeuַ:}IzЃ3IMӾ(>=%$җ?y̹瞻 ^-9yNe?@>^ve;CPg} 4/ҽ/s~nZɆڅu>3nYD{Ӟ|]!E^cmkcK5 hՁBam}hhhXjpR,k0+d4r !}K]׼8:CKvB@5<r{q{L;gqЌpKM|;SN9A,+@ؖ;va nG]Y./rV+Ew|飹\o|9|k_["}_oԧvOxJoZ^x≝lJׯi~ FЇyzmٲ5B$;hΰ3kV($8 嬥Ai}ihhX`9 JwZԤlhNcح2W21o}[+imذ{_\z}v2O5Ce;q8i8q=<ǕiV^T_;8fIP_m|˭e ~Wޕ!yٽ=)g>w n\ﺡ=g>O]oldS} G^|+墺IvYr 0/|abw]g=YwOzғ .owgVc+$,.}[k/WSu N?8=9-1Vu[`\{ھM)?s-i,kߣ}2#fqۿv1G7ZJL4M)30J K)dKXޚijؿfs<]chGNy0u=_ ?d!3u!sR9u D{Xvz\Ƞh*"d)a飌LU^K#N7feVА6V8h叵-4w,w_~7,f].yL`rFVivzekf7Y.գ.Y;u}k.ަ|mEݞo}od-c_JroՔv5hp^%~5SuXl14 b]J|AGj Zɱ]db>:}Ѷie|ɥ&9P:?t9,m$D=-LYՍN|%7˸F/!`6 &<xDV?97 Q1T,sT0Gܯ:Q]'僇H!7dB_/}hegֺci |$KN^^79n~xjogVAg(lRf"$SP"k~ Nf)ɤD^/OI3Zw]:u(d#<KPoWZʝ|U9aT~ˁ\c 0Еԧe 8FΛ{պ7sH+)S#kcɀXwqu_׊ũڛdӜ]O/67%pu}pI<j o||  @iӦ*7 E]T$gWZwF/ґk`65ޫ/yò??/{?_Wgu3Gn-|VY,ʲ (wKPe `M7טoy޷3/!?~ \s=<)ŮrGq.mA3$jcw\Zd<⏺ԩ~іa"F.mx ^Pz|YnEH_,7G k2/^* h82#ٵƆO|3x~ˊe}-YM}!<2??`5{'Ӈ'?~9&3:\o_~̵R `#)S';n,ɒcu9$a*~ry^2/TOWBGmT~rpm_fRzfU,W˄)oD41X6m)`/|CR>KY/g\א/-s||!J J;gX"g警y͑t3R;G?Nyp}8ل8}ΐ)' ܔ]A)kBdTԛs>PFMP|㨝zA ٖ\ xpe8W]GJQ?N{]@C"pRzױLx(>l61祀`eo) 5<͛7k8−%WRD6  7锳:e_Ȇvేn|K_*6Y<< ?V@Nt3@'TO<";ƸÑvMڔoבpIX;JKş/e)|ܛW< {ȶ@> ԖPm 4l$ym,<(6`no+C#<|$7U6ȃ25cjn慹6ǴE&VRK"}`|:4"I'T x#JRFp7g_ H_(MFd4P8dDNDaHTx8vil&NÉԠ1~=jh)CTBR2SI`yZaSEf̰;NlQ?8~;{!ŹIāR(DWSĎ[XrD=h^lWB灆>;c pQr9@w{޳8d{d}<֝qCqdBmNzcp)c#ϩL8y >7Ygq{Mo*GP}/hp9߂{ ' :e&J@-#r^)3g HOEf@smE 2y'W@l'02@!J2kl[r l/mGX_w9YoIF,{ RS 2o-(6g&Kfܦ:8FA>MlgT ʙ9H"-qc1 5%F~I # m d#""o$>PPc8/=% P#t$"o6&}1|Df{"muÿi8כ[=N#V ~'g᯾Mk);me3 S% Y5@,0k~ xs>DӈܲтJ5 t6  x|_hfiue׍ 瀥/:I)>ˆ3$ Q WlR~ZgÆ wqS2F9C9AT%80!/:ԏ^ks;AA0n3#1RR"uyߌ"E2 "ʎz pj>/W=Ǯe( 7}|x^r.Oݵkx2+ㅱwe9uwm0_|dn9^۴7Q>dl럱v=G%lއפڀx63v%˜m$˲+c/;j#^Efeh?^Ox9f 'K~s#GVU &y4x=d\D79W^rg-8)3WNN%o40teMt9e!ơђc漺Cy&dMNǔOoCڦ>Y`|`x? l#0"z G e\ƑӎͧCI-5E@Ra-uGP| md4&[Sˎ5t>eNa|aK1X9+72l\l5^?&8P\/$ a\:;e{! m$޺'m1>ln (S94lMxXx Eo(#.xk+KD?L"J-"u"4+qIda`(C0"."t(#b~FG_}^Яd3eKQ=uZ\C٢`1&)_ߌc`i iGEŮUNFY$D L0৥8gYC+>[۵"{"hYy%W9g~KR,˰F^_\/JnD4޸pY1c=uvp"+˸r=yV7c`ƑB,հdI[# cb4!]?(,+'Od(|5)N>r,6 u?y"#x,R>'2ueSVnlF [`p\$#f VnΏ#:7D׎Ga8.@c5)ORݓ3,3/'mTaϝ9Nfۀ8ghm-pU)u2r2I&ȥq1Axu'6{3'ת-wP|M5 ! spfCc@E%;&2fL[&K3jON#+I`IJD͆wFʉleʃ“F`^H>Y=d,Iq hmzY΀9.ZNFSPC_-Eѕ hDR h—ƒQ=`CQ[[b T=Jlr`q/}#K$UY6T[=Q,Q%^Cm8L/SS~Ƃs@A! ڋ CΡ:ci> < z IDATO} F"zUem\ gi)3g-g Ii?}̉̚W"q{+^Q!0nsnaTw;9`[z ё5 "t9! ;ɵy@ d. xI!6Am{r90Ble9Vj`LM-@ݦ!eҵs̝c/-:Ex+& @ү2/)7=J]6a54}8IJ65.>쳠PH!#χ]&ct܏t-[jV>BfeYl_ݎ:o|| '}q5G&\kYڸQvRJnܷ9eI}9w96gɚ9hXkNUt` e8R I`|e8@C1e9˙@+ .F 'GxJqN|d9uJ# T~_qdB9ތ`m80خ8dj u%T@m|,} Z &QJ2€+e. pFChÊJMp@#ڰeqxYR\@̆'Ld4usFBc lE33 Y*‘FriyGx#XQЬet#y(l-xs#SYpqR^12D3~H>/m7sc2l>?q8{13\#8l8vk'|[@w>HD2uN Jd}~6\Wc<Ü C @qsv-I2C'P(+E C.:]|Bt gs=%u ˵u׹>17f:~ +cy0pt<}ӯt w v_ FF]@M}8l8޴Kmvdt\yyE[O5o`[®MŖ_j02{sMd{qϮ2׬_cO6ȷ97U?. /sW/MOb!k}!\A2r'|׾9@a/&eIt1h>QIʲDԳh!Xj(dD8 FKXkC<`P(B! (Ib@".9!rE g: 9:=};s%dϐ"|ahzy @ pC H/]u>x WT b$@H} ?8c8i+̀Gqsȴ(r`RDpOjz''MjLz$}eLP zQ`py{O+t.PV1ൾqɀ1%-@46_,Uh :ydb(g, j.-xgʗdōǎ },p OV93m%拲Ef"~@,GFR&?kZrʟq;{&(0D|+6>|yIƄ|*]:;=ț$14t@- xG`)ghbF\G Pfe&<0 V?2p%=!`0k~SX/۽&" 0FۼmonO"m) 7Ktr=͹@eh soJך;?xrbBv2@Fup\d) 8f)IR30*ͪiP( hqJ[m?/e[V&6yo2kL8*u&$,yfr}7LEVX=A6}8AʊΏWHA |_:nq3f#G`se 6\s|ƕxyT. [ pZ~7@B:@@#@s;d* ^wz(Ϟ [`NY0-SVO+}}гʶ([c ph s@(!}@70DG{7x .e42I#cVZh3;!:Lec/5x/N e}7~O"|fc}TrȄ|rI7^ԯ1l2Ƣ=0i k$J`J^`N0Kc͎YV.gqFY54Oּ7֗VEsPhs]=F|ʏ-/ʱM06"Gr/~RxN"SP [^'Qs=Ya@JȀs!mE#YebhD-}΂v*v8$,}qš &\!>Mo~Efo'>倹F ^XI4Γ% =#dP$rs%lC?vNe'r9tȸ)4oih3HtOYh_oB4@Dw4tc% J _ iedkc`i@]YJe#ݸ+VnGKl-VƚRa<2kM911ؙ PS.BC"FRٹ.P}Jg_$rʢlJ~e9oJ1:?3F]GM#u[:&R%BGiZQ Gs8G20uzbʚ# Rf?`"&%NHh' Gr|c)qhy0Ļ;2jN Qq5Cc놾9u/ l^6jX 8n pe}sp;ȸ?/3#p,1d|lrn߲Wsh_2+]N=ǕNog-~]sHVWFPQFÃr=w2{еuEKK¹ exNc \h+>( AS}}R4'Uƨ?o hד zP-éϹDƆN_Z(c_H%dȗ4]_(/`cW$@.͖[j2dg}N_gk)g[{5~9䨮Ͻ&}}͟?2o1MNor:F6"1Fː ^!Pt͹^8~L@K$lVe:'t4YD @$ /zJ|QL$UOJG8,5 $8ær2'! !wg_r< qqQ{h)HEdeDDjeH,aHQr-:E-K=pp^R<|CRC$ /z.Mq9˗DjQfC@nE{-SyFJkp\:c D*,˞N c(jẬyڒYArb\B i2wv4Y2DRFRs5Rnפk)kÆ >ն>֧Ll izRlPۆC}412-C:)A~Mläqt.gY׆qWn8~wj' <w>~:QƸ>sV͵)BfɈ@OMCӡ>rMeo90~:搨(L`aW`%m8&,p/9ߢrF1޸GDPCy8z 1 9 {(C;DB%_\2"p ={!@+d*ȳ ݖ*_SO891i Y$x)uc{ 5ˉRGYDQtrZf=Yz.UZ9ʁZ) 'oN t5g̱/APFuY "%2->N"N2Zth%I@a$Cs-_62 \K@i.YM]Wu%Y(Od!RoU]~\Y8p2SNnX)a gv4444|4P8f=K82slv2C2 y`Ffp>2u7N;([hXZN9&-,X]g %KRe==#˜&m=~'a2k GeηmNM*C]i{P)#$c o,cdcl-|?(G}e%5qci#Y\8FQk%@kӦM`ɢwṀ,)lNmo`'{ ` ̸#m )s>Hg#rsj_YP%yA#X; HkـY g\8}@&? kAYJcz G[CK&5l]6Axqqq`}q7}/<)MDBN5ǡ0eR2RZmoK6#,A'p9\S>+\L*-[ D6;V2k),T_g!eVy'eoU3KyoYv&c4A^}O~D+dM6>SmzLKV𥿿@p"i+~L$҇ݒPK ݇7Ƀ>#K=f,}v;~r>m.cY;j\^_ﷶx#+n댇9x@~@e0+AvO~Tn88888"˖Okʦk9&$IQ-VEZ~r}ycC`K$2+h8}i>@]܍S K8A'4Ү4C K.X00*[=~h, 885=n\.K]{&L0%[z۹ƁƁƁƁƁƁƁSVG3se gfUqqqqq`kXje̖t[ljreOe5Hޥ_ݞ*-C.RznS+cV.dE-mUVڴr{,-_kW· 7y.٦`5wLzƁƁƁƁ9`ϰڗMOi>ʃ>5ˁ Xqqqq`]sȫX$Ag}vyMVl'0ztGwz2,r/K-`!`2|y8k$x*fIf6xHE_^$kk7_F]@aƁƁƁƁƁ98`ɨWSIEƻMK\%uO] WykY6Wx2z~\s+6+ȥwᮔj8x[=vRfq`s)\#8888]9`I:}"yK)S$qykk[SZo{ɸ^3ϫUe2E¼gujk׫Y\M4=Dܣ_<5|ka=^22hxz?O1kS1+v}eϥS2~a9(`?ϫY@ݯQ]UCƳ~=\f'A>$韥A _]q2^/"xB/m4wώ˹s}ǔ\uh ]߿{^Ykks/Ob/2^m .e@Q6S>*ieO; ! J2F7 6ۻ q>Kv^) .5c=[E h|ӟ~w{gaXZhY1{ͭnuwsi}+_)G?_n+czԻlH24nw+QI:_9Βa5?A^tcK/-|N^+ͻyC Hi Hx>S8i Cf9y睻~NK9N6^udNiKŴi[ی>O s^+ /,sp37":MozSЇ>;l ]r^,8vJxm@@Pҿ5??y` wv7o.`?k{q 夓N*6]5[-)}D钗eG@sNN& 974O.!re3f揨=vۭO1\ `'k ѕzֳWU~LOp8 w(e:ٓcBk?nӦMUtWOH2&kE!Az{h%ԟdt/NQGUaƓ1"v@H{8Jg[ > H&Id4PXطdo^җx biC@+,q{B?z' ۣ{ـ.X2U 'PуR ]*IB??YJ pxeeȌ>я.@ #@[_'['>7-O>d.2)j`% hɦK<;'.H)&s?'XR?sA`9~ h'( +d~ i[뮻L8P;AsX4jhpULAE$ t։Jpee=Eel)rJ1y W/% pfHX8"Ƒa4d{#aZB΃ J$,z̛Ŷ69x&ɼ#S}Ɨ>l/}[vŹB~BCYkN9׈6"N2P$̏!,C( Pj:JE-L& Z KP&*9ɺq=e#PhXagÇRNu 8:0o,*x T#g_ϐK222u.SO-:2'day5 ΢f~1#(ǔ941^iKd7?YQ|F2`cZG @wP$6AOm2Vd Nc8u@征D 0v:QX2dƍ~d0ߘgR?͛7mOv X8'PE !z< %@ ?@v9 '@[Ff\Kc2:O^x,P.é|`oҨq`{sŠ BR&&S;!"3EZO+Ski[eP1.1b\Nק˥m\O19,v} 9QzD Ǘɽ,}>cZ*׏-""«_0 KDfE_E>9,0T~"Wf_IR{ܫl݋^qK"[۴|v Jԅ/G߀h>i9A]CXpQWkW:8P<Pidڣ[,:2#1o\2g=?~Zp|d˳3mj]dP߲^S@8䟞=nqɫi=G/kҵVq<=\ Wx>OپO:P;궔 QVZuod]3zP=@kOV H*DAdM:yR'Q.Ӑ,];Zj6\̡o s p*7<qo< x'Q`,Cysvi>_6ZbEY͏rAG@T@Q H0rb./v(n&@$aIC@c(%jDp) Q?T)c('QlmOjOpH0@ \@1CD9B0V%AW"e),JJ8V9K;\µ|Oi2 E~Q3cÁI=)]J[8\)(p|a(8ax@RiW׈6)H ~eGO<n ދ3f -c`Úؑ9u[)Hv]"{qLa'G2DU&~zciO{ڂܐ5D%.b Y~uoc9}gǁGl;~sG92RQls%omu(;Ζ,_:Զ sfh3K-##y1o&rBO -R EF~@ >޷r؅>xB_ѫ}'qs=o:Ws{֌{Yoc%Gk;bCT5?kGm+[&=k7V1; =b|L(:ЉO3ud#}Kj$J~7D.2_c-_rPk72z| H}l<]!lk ?O"e54~~;vq`[9@aAΟ#gA>QҜg`uLP׈͡rBX(sQ"ܤY ?)WŹ(8}Pa_Gll1QzB4LEhS&0DjHɰc Zh5$H7o.˵xQA[RƂjɉ+ڧ^>gmW7 }Phq@uY%hQg.hph=H(rD-e\7JE_@(үj$tG%C7G^E^X-'?jg+׼P~yc eY28'G1}tc5_4⃱?DÏohl,_x@)2FG,GȃjPh|ryx +07,"ָ?<q[i%R,2hD #%zY;a[1K{KE[`'~TiK;gao}KDLsuG9 u {]-:L_|})2BE<㢌Ԇ;e#munraL| _X@BH#= U> {~8MS>{`c?~3WLy}7l/lMmZWh= ,q쬣ghD9ff`s:{)(yLnřBDDG)B'qġVeo1%Y[#XgA[ӵ TzJs8oy[ H,VTooCIFq <(@;bN8"y O׾ >|iY@]Nl#8&f]7FlaCxxXM􀩨l>O國lXo7Fx bq#K-Hoj&:Ix62 ڦ~%me@P0Q$1<2lɖ1Pb8bpqVe9h1ʀeUN?# :Ρf`9Hq$\$q&H]S=[(GN5~9197DOMCS&9-0yx9e[h$q"-]77]6L`dIP<NM䈍s<$@ʆXgeAEwle6]esni?u\E˭- t1@S%*K2yGpе ^[ D!<.qpn3lz xb'Kdڐ1\?u}qZ@X,y7|>)@8Wڐ'"xI'v\ k42۹Ɓ@7MT#<ʏCQtJxrbFF8 h7*e0,7 x xN"mVDPp(s`j(^dLpxhP,?r!\`ON(Oy$R ^ Bo܀d ͝i sdd)O2ҞΦa 9IO 2I"3ʀv#<ra32+:h^fD!Ɛ#~^3~gioo+O5OȚ ! xr-8Ƌ/+n(An04zD3_4AirX^Е ]mT NyWyL{sI=xn7lxzu,T .s $ڒL~{l~ 5`_sVZЩ!W|&+5 ?Dɶ#n[O#RXf YN #+-#@M}#g^ur󄜳#i/ 'VѓH@%ڪ.z>m3|5vDkVHhB(?L ZtoQLZ6FFۺ,m9!\#PT_2 t2JAE;nAqR\ 'x3!^m (.c Qxȁ"@Q1٩A!IN}`PLȺ0@="yHF=P/*aq8 >1Txk#+'f|;f!_n6o!) ;I #v\akvz{ƹ 5r.yAd LӑmVcNs$8lgArI pG&qP.n>a:|7vkZYk8hpNԷ4(\~s=RHN7€HQ㈣`9"U\h)(!?Ƈ)VHd)ʲ<L"΃rDJ;j'J}1> #GƗ[- 0(Ƚ%05@%?xiOǵC?`e o^eBYqtcxd 4'd/h1n/uYK[`ɸK<HVX5˽kCe'8ڀ8=@O|Ng^N:FjqLK0rVv.sƣϙ_,~6tuos28+d z\fC(Dq YzlؗJ?s)T[U"FGLX-@X W!@M@쯥}%Fz;淺݇ԋ>}vT9xտn1c GsBdR}mG5|*CTb,$7sr+ EvLlW`1|`@4T'VX#EGN[Ʌ̪ Y-eE].Ȝ`bCA|ŎZ^*P  3{n2|cn5lo4P8'漭(LNNĖrk)shm*αkk)k`$J2a]y@E0])#pZn_2|jc7q Dv;刮cQ7@p\}DEFe kZ&᣽ATq|j2g=u1W jҞ\)mm/ #x&.bɶȪr$mQG&dN *МzZmyn1t-}͵Lԍ'9G90(-x!EA_5dAiD$ˀzL; 8OWə:%hA+ȗʐ2b֬\pF}#YL/cKI3DsF; N٧ckD*DǒW^&Y1H %]_7?Hʐ@S 8j'1y#?NP}-ŬrJʹF5Ʀ;[p UZ ;'Ƅqc5 `,DiqRTVxaD-Ƭ>ў:(z x1>b@ٴ:]8d1HL͌a,f2> ^(|? AƓ#P;])\[g"D#g%R<$,Κ̓#ODQem&2ehJ;ȓὌO/',k56]Y-"z$+C?:ddy7_$3D`a9FѮ:Ȣ,4zDη]]d}\g'Cdx>tǀH2&7EwO!*,6@_Pk ZI&<lnA!"G>}הG lvr>a!b߇#y@6=>v$(~ QہKf>GACT2{8e>s88Жs04SGHk068GղȾl΄dd)c, XE1Y"I/8P^^O]U.3b/q2}ȵ MTXq6D)gcI<ҦDt)ra*r/esXȏp?c>;Z>hAN IDAT~(x^JȄچW:DSVy@-!LBqH*'K].0bESsYN`x~@,jWt;s3cȂ>qh\4bsfV3sMWslZz AD9=)}ǁzw䫇w\,%]b+>7]i./4! lJyesY2X޶v(=%ȡ5. sogRȞ @@ĉdsDqUTbsluJԹnK̜˷8p_vd-@{ded<%Q2VW< .@@iu^ ظN8^10Z3NfG0&h4PsG1/G}FI_-Ԅ#@y,1T`2Zb 8⑇;/Xb)XEVei\RAO}]TדR0U<!es\`hJFRu\UE i,ŭ7?-r"gqNl~3b Bob mw9(-! icen{ H>>Y{d~׾No9he6444, (#GCmOe~VrEA8ps+X")Le$@uyWV2 e Р-;d̑FeL#'[`^-N~4 xp9׾:(?GY=6m*{?8nuD׬^}JY; &Bؗ\J/2x Xqݏxk"2el܃o\7,>^ Fd/=Ց_"E\O˖cq2m'Hhy'uU ߓ圌V>qP1pO&0t3@s鳽Ax+JSX;sk;hy$gX(+odɆ}jN6<~7,tl88889@$82p08 xT$Kz3, < DMT~ 6Ou  %iJdR%GON Nk/t+ZTM@֚8u-8ϲxqW_b@Z# ?# \@aDʞJ_x+`bd,y/ڱs@Z pl{(זkyT':P2Umɹ0%2`eÓa -U-1Kb;>= M-m%^Ч>5Bvʒ9ԋe!>BhVOyS|&_պ5-c=BS79Ȟ<=-`{+O6'< mU]\ct5O[n8G 89^4&}#8b6ַ*Z[hex81S⮻[3ȟyC?݇lx XgۯگUۺqW<oۮͷ;8 _~˚eN˂XWtyϲ(X(Nٴa6.+o|bSzLM_9mj;5_i1kS OqJ^cx<6UlK\>y4F9-GuT-9+g;+gˮ y0to-r×ܚ[roVkq^GVZ(W:F e:d%<omT:=8+W8;Tp~- ~̣*W+Yx$8/}36%:+W+;Vv/ć+Nܴ̏^ BL뺶o.*lw].ޕv@/PΒNKeV/Eh>4PfA!\9X+ wȗ(We"Ѹ"'g}v;__0n<ٷUW'9 ׾ E+qo=kDQD)![2?)]է."ywL6ܡ[̇eWF w8Ut)c g[.Eլ:] }mÕ=X<Яo1b+nhVIq jMO}[ˇ)khDh,;d8ewfho+i2qʼnvG<䲥J@f^@'*? deo)KfWMxz+xni[xUd}fy.~i&-x^V_F: Ct5Wq&hꝹi.6>OԵ 3P߿K>o{j;'| g_xNȜdtj^ =db!˂',VP6 ,}?(f}ۂ)sFF/TuO@W#[[n><F ٵg>s9n? <ıhqbva!{N`.jD[Ody DEkn[IA69=Z(gdR&%c9a,!!n牤 nN'dܪʡX鋑PDTEA5F0r KkR2u[(C|ޒ[+guV5͕9LDs tcꐘwɍ78y=9SVԄ:zGdx=yxEzaƟn;Hr]Vs_qg`p9ϩ0v'[3S/.|s9<snf:9N:INWGނ&)~KfpoٲeR2Hћ՗9NUИ1o?<[ddzwҸ22*Vxd)Q;&Dq%H]=^|j̰N`)" 0gؖ{5/Sʗ-창1N|OVi{_AJ r]ƃc;/B}miǘrmϚ97|+cԧOێ6> ||/mou̍531C}ؘҿPc8e]lg+xq*c)ptKEuRUc*)8xs[ t ׼f_j20)dlȎ0os2^60x8A>ɴp  !0999 _z͸FOt"9'+[Wh_ -,K'U6_ɷ7|T֌StӼ݃@'fd[ϳgp88@]g0Oˠ XG ^f_^H3:Y9NP؈u@Q̓d^Ɏ98t圙gN_4ҕNڅWdgZKg[i.:v/2ۿZt".P V:Fy4v'b"'PZiË` "BYcò="!Iޢd@@RĄ!^a1AcCȷevO`>֎(e]d t0fJZyN#zg194gm0~g)׏GwNPș։Ë{LSAM׬2:[3\ o4z) Xk)g\cZ~/]Cc%C[lUoy0r9&;@d>/ؽꫫ\#?5!?? vqNpwL1YCdzC#Ʈ5r>l<5:썌Zؼzs4:_ԭ`b[ |ߨ!tw8jy~?Y@0eeye?IsO [jy>je+zPPm|]jGt lG/ѺrG6sΙzի^U˄m f9P],:TN78M+? JD08j,{M 8` E˶[?N:胠!"Pxղ`;%fK!=[+ >@Q,.cUd\lH0O ]hRj{mm*M/nІ`U_:Bd" Zh˜͜Èx_qDU Y LKk9_v_/*kc2N%!m[CΥM ou܏=JWbq.^s˦ѓ-hE:k[1dYց-wqG b@Zrv2g-C5@z5ɺ 鰱)Нf~ t>"dԺGr",ru̢=blmWW?.`u Ef'ɐp9 ,t23J#p͈1T8`*'z/3na>Dl!l8Ɣ9b22=:* (GX;eg̲"|N9p^99(#'5S.>R8"`p!̓$!k()[IS/zq2l,KQEX*9#+mp=`%l2Čg̟܇6_}h'q!֭3>4Hi  ;t ,K6G^_j]ݲ^Q8Š+&˔Ձmq"@ !&:-^ ?n2s[!omrpЙk/05PO߄8L?(C_ maP8͐">Gyd쳄0(ܐԷHT!i[MxSV3e;:v$elq];' ~a,@zȂHECTE&,d9 #ky47 888C2xYE 9dؑYZ g3^c 6J >)rVVRA kW`20 K!AKcq\Gۺ%ƀ"gKSDnym۠K9/]Yb rp8YCџeO$=l{OV_?㢋ƀ.[&{ |t;:™]D_𶳗G=<7'-ƭ_θ{ xڸ'GkN9peC+vtkˋˌ!eG:$?4!Y@\Aw;^7ƿ( 7=r8kCdb8pgpsv8J ΄cZ# L(8RY_5GHP^{T,gIP`lEAM kJnoD?[|l'ؙO j.RyUyBAwmpy\[1Df[N+~?ޔ9o44Wx|c-82O0ιn:|Q2ǵB6ióqƙOp/<l * M9Z@kh Lc8pfD.ֽtX5A@/6o\BYG.-a1$]A1n'9cd2[028 iБ9.<Ʌ8)?~dFY:Z@FkDc@!PGP +##@dtf.ϼu_N6м +xsGjM[F{vGcr,g3ɳY@YpӇ@~{CD/=cAK4OV=3]Bא'+K9XҹmgoǗGc:3kB_l8F`_fs`k]>dgcnE}a7<{(Qt_ xet37vGr9.8ubGrBzpؑ6vn@l3V"*5QMP>v ǀY<1 J ,aÃŰ U+L 3T) @6G[#g $x6cBiǙvMfK,gn/܃( [`eU9iitgy-pt_^vX @;ׄ"`dy[%ɣ)@rMPqM@xoJP9ؾ}{5< 8k)J."_y۲-Pd2'++(@91[Q%s%cuX1`O 1ʻnP:u&G  d_$CQ߭a!ßIAY[9jYeiN;&uNZW2aMJ?Z0)= BXֵk♶kxU[h<)@M):eldL1}el (Jj[$NvUShK1΀Gmv)J$Ҿl*4]Fs ^Ύ`q82^ćCDǨWю=e`'؆@{xG`C7'4;!z8mԆʟw枮`sqP xIA;YA[3sg3J]Pz(hmˬ;?#Оg./lsRm Ƨ6P΢~Lۡ+u FraFk=8n@Mb~ @ Nu` 02-E2|[1^ۦ>|ۋq-}$D- d[G},` e(B0aIAQ62A#"'(F1R c`8CҖH9% +(|F JYD u6E5|?pRfocCo03c }|Cю orR*k̨3 -99eT@Q6x2Yuk5s0P? R8ӆ9?}^)Z 0e -'[-ٶAc<ψ 28@֠o'ݬ9g=šmf 19vd6cfF~83N8lq4emd'`q. 1GA9nWo,@b t-LƜ}5+dYh&0g+К liKWtcd~ǙMc4~~`#=!P? T '[{n[M03:gl >xxL5q׷1[wC<P`4'ff!ILvfP;  d37גRGB^,1̽\S7Nmv s2>DƀN&RJ;A<Ҷ,d|ɘm)'8}CF[:/Bz ЖP'uAQZp?1_P~'@XrjCqrr gФj 8e}`2^Dc9(RmPxo*L\qh/˴KYQ*1"3c,Ʊϻ́9Ӫm[1(2Ԕrկ9eD~Ne(@'ضlɄ'"|7ls%/󶼵 o0\Jްv\N9GCӶ,<h26+1AL8nݺ2Gms@{t,ZG#Ɯ"N:tBkzKGc<գG>d& oH[`dhNTʢׇ`*(rE=2ԣG s!6vOKԴ&OFP: >!]VԾFqtm/9̵k_HM\9فPvX_SN:m'C Z8{fW,6Nj-dו"Ʀ^ƦB"l(nlyE$&@P22ݶ"p$CQ}#DmE! dq.C`#cp!B@;ZJt1#+qf#G)OPpu\<~k8vQ7!H.NG@1&Us7aaqXD(DP8ڙG4DOlw师.RSv1]Ds޴$[Bf07 CBCD[J#`h1,mF:hڠ B(( |OD]= hPpR_x%[RG;̔k]K#wW e &ME1, 1w-õYs]{&k|VO c ?d]tʴɰrl,7ke]:p0 7R~XgHS]w=ͶF\M!n2nth}h{8Wee{ΧǮu Kl6xcp ΄t1?:Fr*#!PCp"lcYqX9qCMd #+ eьQ-cW? 6J DYNE;8>}[@Z d()NQcplcF _ʈ(p H!σEl}D)s83‘D1΅p( 'I_xd%d9ϜWtOKr&;/&,\UDL5S¶k=M78ƌm:g\fS?橩ߵ10^k)pV q:t ld ;[62M~XWiAۺJ ҿl}ulol)_[#2lNE4e֭p̐ G|'pny d2-^fϵW8-kO@<+*;n83b( vuВë6@~d./k{pv3E<>Ul ̉uW/nCCF9L.Y__}\] HG 2&]k}]agؙC RyvF|6>S82[ʾ{dň$p:'mc6>8,L4E9'P;ÞKPqJmmk\3ir@rϷk9Ku͗`Ex&}79̈́Lpݵ!๭xrxT=\ϼ%+޶i|teyd9'/Z6кȖ^ gv]t͓8.%|͙U&֡S`#S^A+36St~[%4 q0vdFpk4qcQ4SCdLp67q2:qD8\=-0~'?ΙY/4x-˛/e3Y5w想f<q?yed %Z[E'ʡl!FC^kߏ2v4@xn[gǩSSSS`ߣFv fٗY >5zɸ] `Ϯ=㕶|36 CYg\C>I<UÓ0 d|<9> ƱY谨.gjys5Ɣrg+sugdmUW c ekCpY7cX)))))))?P;,1v l 8=&*B's* m"x::::::::@w U/)))༦l'ٞA@utѓzם;Mܔ#Hgu:=_8=vV8eƷlg7=Ivy;Dӎ{ǑMupn1)Z tp;: u%9?\(CזRggwǶ2i p'N l~-Ү˨{}3^,.h7;O˽69~ٙ=c;?ajDO')Z tp;:2y -e={ H{RZk˫\y[S8y)^]^G {믯O9Xm("A`:v):!\Б X!U&#W56W0w[ꃢ<9;Im5xߋxk_Z}ۖgooE)0)E~SSSSS`@횲ZqYvz{Vv։Wמ9;tPּ8j2xA=\F: ?1᧖)۸|G2p<Џy7nɵRWs!E'}[44_e᧼1 w5C 'j|.G<Ђ=kE C}gp-pZῑڥ7{9wGftQS;gE$-$YPn|Bq?8yZ}x+F{(f̧$m/ƶu!?NYƫ9a@|M8;Sv qlPe/Y|pկ~խQG59CkNkŃ/o qS8xe'mVu#sYG p5je o=N HcX=i~HsG g,֎WԠ1['?{]J%UY8wS"pgZ3Ɗ֭~֦mS[ }8nxf۶mNK^nkt-6ڻᄏoF:='=A_ gxo?zh&΃Y&?f?S0x!'?9'fCwygm h*U IDAT+~x]7t+=mU[e^WeM cMx^Ğw?ɜ{E0LŸ^uU"PVo7MvENb_utZ )azYgMR[d)FԴvb4LO}S gygdάYؗbDOA>}0-F紜WUezyS??kaCWzbLQi1R*TՑ-F̴+z|(eq^`bOa7-VV iqŰ#iZiqVK1Z6-NUr~]i1^ziV^r3Θ#mZi1u}гŁu)lV ڧ(#D8]۳b{jN[i'cz{;^)YqЭ(ZŹ͕#8E-N8Bob:ƈoÓ%u}ئdr4TZYJR<?lѬ @38\)a}=]_]W^Y髏LO>zݬ 8W]_N8ap3O֫{ڇ' \\v2 8+勳^z@#s'u *MKpkemT't_ZХ8G|^";UXט>LǴ8WmY|BՀ"A"9gyjtY=g0@{b5 8#:p_ BYV/=/ Fx7-y<\E7"^aQokiwaSvvzg} wXLb lG1rb4X"9^ WȢ,Xk8G 709jC`mV[>'Bdd}@1?-)"(ZWT\oLl*Ne}]MvgG~'dolLAMOVv_I-d8e0JkK1>+n%pWi.CeLkV@/˵mOdm1ڐqtW8W^V .%R#CV%[^G?њɌ%#cNQx[pdW/x/t3֌]q'\UYWٺ̷M2gg7sxB l*c9 pA_ePyq@*7Yp5sDv9g[Yk -:39fͱs- ;KJm6FYQxV̜i[ȮeБ:^$]t}dկ~u)Bnyx\6H{5: c9c}|͞e[SG&{MfU^V8ddgy.i}X~~eHuk͐q䆵cvk Tzڍyg{(s{da`rOEkamy ;h[35bs0lQ6 h`{R?3 "kb,%h?vF['g'2A2|\hLŰMۖ*V_Б3= ǻ)cegr-!@r 8@A~pYeBk"0ͫ[ЇO攌f5o~<9jwan A-Ncq08E jΐek8LwyXf46n@wnG۪IGedlmhy`kDJlX-.m %Y 㷅Ӗ\v1p̅-R8n+ p|g6 eGR]^2|vKku;:OCW|)lo \Gc^+\q +6Ԙ/Akn b$%C Wۯ92y߀-XGPl`q7Jf:䆵si6U}N7ZY+o8̏2h',~!JcSN|-Xc{9WdR'%^iju3蔞Ag -?,|1gqY=i Ї%E. Pl_!ISz/]O戠S|AjГЇ6QomF6-^Xй!iS@x 7Ӗ{( +[_MYvya?ꢵꄷcLcڂІ9Wȟ5>etӵ:p d >7/kxtWzj[[h5Osm.d{1*휧l# zd d)!)˜}CŸu8*S0c |9o)friHs)?hn^gå]sʬ4zG'e^ 2sj8:2xiyY/ޓA;|8G+[΃>g7c䔒*4%MߜT'\̙uhޕ? 9jK0 c,t``i̼s}IN p4p?xl}}u.'g_e8VT2o֡ 2:{$$8Y7h!c=!38sU[1nF+kkOu9G6N] Loj$ v B(\Zl #(D,JA-NivF> l um%¸(B>OyFX3|m[A¸% p֯m x(W(!rh:aM .LF9PRƉhiYdM "u|jm ~70T6ƊЛ<(( +u+M2Nl'F<Sx5AP6#2ƭ=s!-:^6';M) 7GWoFz֑~gKyI4S`2 XS*hg VfQ/cPYЅ9HIVcʚ~g#u'x>}kwx0(`^eAl!5dy'uXd 7Zrz2~eij^ |=<Ș_k#"Aco6dy̢<]5Hw356KA,,G-k + %kZh\8^C[mӸd|3 /ͭv-lukk@> P+:C[|x2&N+8'')b@Hok@Z6̖JЌ̙#@[͜r"-;$lCLCe=\;xч|i϶@/dͫ+C+sg.jۉ#j 徵:l!Y{@w G˨-E-Q e>SeXp!Ka#P`[p)}X<BzDT2%x[Z NK۪AP0 kA1 'BZ1 I7|I(N69-oy[jtȕ%`ToJ`4t6@=yO>u>empހsBƠ] 7{@xW]mi@WB30ò$``A<Ю'Qlhxqo8)'А$`+pkG9}Rjϔ5V(b_\V-\LyNo'm^.{cYGC]vۀ&h;0cKfpҏ9Bkt\ἑ C@;g ]cNF]a#]B't+>N1/VyW_0m4~vNံ@xZP"B+Ji}{_u D,dJ!jiryNDH`~5gba˸qɀOXXeթ1ѧ,NǢKf ^d; !wF(CxΉB&N" NNy"V!%tȘ9oѷVfT19#[BR6ngl!.uMs̭SISnN4/ƁGYyt1p,(fv07% ڒ!Bm.}w Ƶ׿ V5v7G㶜1(alp)c2ɰ(YB}8s.k,kE{3~LN ;a9 @s0 Ħ̵cQ^C`oso͐}hQԗ09b6H:cfe)b1h 1p8# E]'4D,P]",I +C-j#ВŠԥ@1 S?߄;arPe(~[s8t 8}(". >d gB}tX$dY=.GB`#@۱-M} ' 69OB 2VaP pc:YW|IOs@P ܔ'h9,+8-7A,Y:whgSlz$B YK Iu.`sM=eSh[-3֭ A3uX[ iYA;K= d-/>Z`1'|b,eD~FvקsJn Ц+8> =:X}aX#'qo#;6[G{#2( 0d2k57gAЙZ`Ntֹ : S'K#}ghyVΧ lE]NI2p<QYwd8_=F_Ά1qj}VvǬomiN7>.Ǯ`ʠ>f }9՚VOfe]U%b-#^6^ 8˼pCp~emK/'p7' He`^a çpd'Z{Uƒ{Q;Z3V8:)@ShQCއmc1\![eA.%@_h"ՔH'C3kaRS"P!ய13{)08O)FRfiF[1ݬDoG􉠋ơozw]$ E}PPJ1&V - )Ֆ+"uμ S( [f `4g E4a[Jv)8Aj[oHuUxތo _9k?u"sǷ RF2gƐ~j? "4 3 XG7ˢFVI8Y֊g~yd@@Lg<%À L K2jFv-,0,ڌF\{x)"REcqዯ4IZ`^8#1OH1rܵF喷 YwKҮ10ъӧmIJ^RVP@neGnh.g&h-{8A8cp 6LnǏ( ;l 8@2&9wN.>ז{ 0WD樝;#|Dv;.(l |@B@6Q5.&X)`ЙN ~ ЎM> ̟#Lsǜ }۵o)L, IDAT*JwK' ̋`m1x.pq>շŦkTd~$y{9qOhqbF&F_wi0j1, ̟@]»%ʄ0ݖ(0 "R}ƧL68sF+|8e(zն3mM0 Q~T-}Q&mVBBg:Pζhv Zk(׎?r؇z۾=~9F曂frd#8a Q1 21_' "Gں-o|rX8 d㦨D)Hr֎c ':0#ɽ<4,1~7j#qNmvf6֌v[ۇ(Zws Cxf>@yoM=_}r^/ zhCGײbSO2ˀ6%!س5=̮l_PyNဦ2 ]vq<@2HG`GS8#0H(Q;8BBdbXDR襅$:(ZK8Z"%G1* D*#jtb$r{ٔgP 5ʝ2neBNA!4Oo ʆj^ih葙aE{=}YF%;a42`a Gq` ->h hga]z1A"zc+ge ?S8 /}Q#ef1eմg s6Sc5f /kDemc\r%њÃx-y8%Ag8KH7]c F-Ch])C3dg%g{8cemqn(2zҤ-78w=|(…מ9}kː7w4! 9Ay47>xk >@Y+ ο"^W~Vcx=k:#YcaR`9kpG{'9Eo{ED-+aAd%Y0}E-D[<*'@809fY1e8S2!̹9):lWc%-2l~f~ l:4E:bvhf c5_; ǡuʐD_1ؓ@)08cǝAw@]@p ԏu$bC7[ReA 2A9{cp0Mu|Z3e8XWS CNVe>DY۲x[7:[APD&JY~mdZd+Y1DIE<V#e5iW3e'W[VWp]5']^er-m3:9/C3xm{ia^[o95p ?AA ߶ḒgL);k7}]]xCNQd5ќ!qT_駟^ 5uD'˙uFciX],q:"ΙALÓuݗ$Fbdc2ƶ1sXCÏ3L^)զ 9<?%+mt ,I|%-h"+(u o Do'Y?i(9KvW(НL1)6LoA/SƀHĐe c(kÜ1PS>rm0t$<%"aouq B+%Or@MŐffƠerJc,$蓡  Ҏm|2z{%Rf+,gvV}p׷L>l='s$pphK}Q@{F(/ Zphe9t9)lEQw^۶ܡK - ӷ9swAhNq;4?{[9ko>a猁+=yxOG~vd6GN֐5Ў^em՞>Wbqލu8m:`|{|a,c~myslεiDۜ @s"0@tNx ozD8ǩ4f 'V~0&cT rsVkp͹ZX%<oZK9ˊ9t|߹S`ߤ@w G#=eQ|e29}`G@vQ8g," 3ؖU|#+N'h:e\w6x:6M|΃s MNF`Ͻzý12nk΁,U2s d/E1m=͋`娡2ێ8'x7V9 8G5oc1$9ErYwݶvoD2w غinמᄈ4Vn`n8_ 4̻yۅ8l_4hpZƗ^ڵ$0y l0Wp@Y01tҷlRʣ ,u>.Yg2xZuN^0_7[@Q6Nl`F-G8sl1 o(`3܃g+kg uw }-.Y^SSSS`Q i jCL/Fo#!%gK`-֫c-So1Y2\3/~Wv=1gi]mow;kܐC1rp96x!)#Α 5֦k$s1$ؾGC92w䝀'w.8ڛ'񊭥0=|8Vދ.hrq-pkMlYŏ:::::vsz%a'k<3#RzWK#M2.Vz5ΔjkõEFz;C׶=T?]so8{,OECG[e沽j-S+ԘC>9 ~Dzw?+cH^|w@@@@@@w u ;) ~:Y2s}^[ϴҟ"PsgC@@@@@@DO)(rn϶= BY8g ev_gp$m;߷䬨-1B zNNQ plm'~.[8gYpC`:l, ND[7h::::W6΢})4}``gަǫþO8YyDt70&Y]jFF]@œ{z+;ת=>)Qy O5))))g(oo#y= e WP쌗o6c &gkY?S)C蘄82?cΐ_m~Tq6 Pҟ»ԇ1Q_Ƴhk>괯~Q8+M}oȽ~EB#EW-׼$|Vl8?xՋ߶hS}m)g/'< u{-+R?ϘtI?>yQ~@QA8ۿ.|=a>>ֹd8U/x Cr/T䡇'~kr9L^WWC~wO>ON8wpܖ-[&8N[֚M|С_WU3B8:N 8?jrꩧN8rq<8$.c|q@!2avy&p7O?'_, >^/}Kky׿_^8q;'w\8{オ?_OxwZ+lΫotA#? ꘵c }c|sO:'OysFMN^ע?5hNNOAN>8Z d/O嗼%UzEND'petX; x2'>yϫLqZ  |y]s=:[6mY>:;ΎL~lHrx87o(fde]N'ߖBNl΄gNGQd8>2I83jqI;䓫56vNǗDZP,q^$&{ݴ}f9p8%x 5N~8n2'Cߓ:k>6J?+#) Ȗxӟ^*ک釓~"\sMu܌SQ6ge/{Yoo&[nV-iq!]c2pU???!9~SS`u 'N;}6)E >BsB! \Qī^SSSS` pレd O\dMn馚sw /,AJO [:e86g]"gϰ5GRFS4qOqC-]G}tr=̤}NmYp5ːݓrde.+W^yy p s+#<:?V&T`[/*'ϸ82N+Chnݜ8a&'p[T8#q߷ڷ?5lMÙprM-hOĿxO{I))s ì{A?yɧShkh^ZgYF>NNN@Y|+u##;td- w"[8ↆ*"Fn`0`5X@4HDL T 6]̂&lf`*(xS;q~]]U{:9=$-`@&ѣ}A>WDqnpYˬ\w]fe:V /H:  R-+wsŬ^U B W,3)n!vю %G}) U%vī/2om"*ίnU΁#yСFK :UVebن@|X_~gJ/EF@f T\sSB B G@ݻwAQV,s$`[&Jqbln­WRz_]KUe!c!37.cyev'TLͶ++׵րw]ls E ..o׃k*Ċa۷oZ$!_o{5@b f%DSo[@; ?'9KHyq4xfh2"( A^vI8Ӷ"}YQY"⌨#J(WoIxױź9si1DWniJ[cȺ'shY.WVVB2m7NsquÈ3bMW-տNkmՉN| #/"1؇Ie@⅕kڿbu[]-;_\ڏK3+al#V_ fF0k N9I&B`.],m%[oqaZ,bBϵwo޿II^2ci uERK/ &$(vf'6Xa:6^|I 5l(\:%o* */Ӓ۔0e压ɢ[ /߇@̏_ L2Ko-C]\@M,: IDAT:6[4u y`!edU!n8fC?aPo8@WڬJwFL
XJ .!ǍֱkǧL%Ym]XpYYÏUOt>vEvzDAa' ,-5w㸿ӧO7L0XUY!l3s?zhJ[&µbF\dG{?|]s%Z3;b?u]lp"1ʕ+MJxGPݛ5 RCK&B`Jߚ4`frɳl,x:W>ԆKB B`U:v}(!%!LZ`ԣ6 SK=-TUeAB8T3 ˾T*\48] G;(,Kl gg$I}+ XriIV-V8,k,j^cW Ac?1D2V=}'OmRVXl|WWf`DZgGW(&މ[~ד'O6|Swxxwf Ad@Q~x(~ST^Gf/A~\ߢb]_7WM/^hEY߯/WENҕi2dnܸ^k!jՂb`3`I BxY:WI:i-{Lb*N1%f_%?v[u&?E9YOKўݢ.xVi# &O/] y7Buَāԩ}?չ ?u&zƭqz*0꒬Ń83~fuq%V6B >O@<CSfG5rBcR An1K$uϤ}g@!61GDAf_ P- ]X$'Y#5!U~YYI[1fn+Ċal!!0k5r,(YR EV1.Ss38m Vf-ٴb̾!D!.Xf~ov?>w/+4m<}00:x!W#% I! Bk^# b -j5,@n^FJ@':;ICd9zjg,jO</H>#&]=8l+C B 61b|% KPP B1xQ% Y9%d\4C/CRB Ę \HY'oYR_+&LID&L1 ! u9#rE ={mbT,(`|NktEGo8he!Htz͖0DKt֎,ܹsM5V!vv&ĠK/,Pl$&:ҔЧb-󲼼$AڥWIZ)3PNjD ͬuk~z?hn LZ jx\NSB B`tjxqe2d\L+\iֲnKk2^2}TK)o@xr4VZk|.--5=~X޽@W)) Q:Bu[hΐL:|hqe~`]AֶÔLG5B`QP}~h2Yո_B d0, }={C MU? #`r}3(f,/2B(L-iĝ~u~DZdY}bw!!T9n }v<}楰(MBjlAǭC轘ʹF)rن@FnuD`ŗh\tzYK`4 J&ףC B(/[m=MnMQ72*3JLlC BZ}m}FLO/ 0RB B A U\HQ8 s,O> tZ4 D+@@@@@DES@D k@@@@@ @DZ4 D+@@@@@DES@D k@@@@@ @DZ4 D+@@@@@DES@D k@@@@@ w*m۶Q&}B B B B B B E`-7Q}v͛mJ@@@@@@ ~ƛ( G޽QJ@@@@@@ l߾}_E}v׮];v>|Pe!!!!!!cG_z5ze?N=>B B B B B B`~,Q,1 SF·@ P(IENDB`2gDd !5"   .IAO 6Section 5 of this chapter: "Your medical care: How to ask for a coverage decision or make an appeal" Section 6 of this chapter: "Your Part D prescription drugs: How to ask for a coverage decision or make an appeal" Section 7 of this chapter: "How to ask us to cover a longer hospital stay if you think the doctor is discharging you too soon" Section 8 of this chapter: "How to ask us to keep covering certain medical services if you think your coverage is ending too soon" (Applies to these services only: home health care, skilled nursing facility care, and Comprehensive Outpatient Rehabilitation Facility (CORF) Services) 3"`PK!%>[Content_Types].xmlN0 HC+jRv@݁# 4J6ZDq(ۓn쀄8&jF1cd穖x먯,U=dĵR ZpV> J)?cWey0dSǘfON\S2 lT/UT/xt+ S6ƕoQ3Y5qTmQuO8fg/Gʋݟߙ<ƒ |jPK!8! _rels/.relsj0 }qN/k؊c[F232zQLZ%R6zPT]( LJ[ۑ̱j,Z˫fLV:*f"N.]m@= 7LuP[i?T;GI4Ew=}3b9`5YCƵkρؖ9#ۄo~e?zrPK!H]drs/e2oDoc.xmlQoH߯tC]mѸWNH=ݭG}@f) |/7SUa2 !S燿ݮceidn9-’Q[|?{3H$1Oܺcw??lNW<YJ`$;̭UoN޾͂[|p5t6L ߺiIy Q~h/,ȿ.I<|{[$[y?߾,SYE`G4J`~9%i`W,@-`88GcIn.6R[JPh5/|,]k/VrS$7mOm8|6r=w2\z;q Xg>>1x_%XԱ$qtFG<&}/bam3vA&G0ZMv˯ّ;A&#' U7wē0H4JF cq$+Y) bpDH)q'MQv`q;L|su݆:t nCYzl:d鐥إC}`Mk-EUǁ?E%d%PjEC&}𤐳 p 0vc% ؒ*Fnee3%@5yA0mdvOpD-wOtDiwOzO /dጔv=Z|a7䜯irS ܺ4Z Xwk daИ4e' r,%d}d$dAI^+n6ƿ_a a+/e%A߳`}իPZ,@Vix2|TJ1`UN8ׯУ) ƀ q eu\oU Gu!KR,=F uR~mg P ,-3wE.qYevdC1d?VWyR)}Rcv/]ŨE`wo' {'Zȹ{'Z{3f,IdpÊzjâꑊ *>./"HW8R|e8g\R ]"Va{8] \qdž)S^ a23lgՂ !t66! :됥pCYz:dGpca%[KvB.b" fk60-355s[avOAodwOsDXwO`wD'~~>e9xQn0Y/^ wf9{=_|2/nBY/BPAnnu!K],=t#?ԷN-[_ܒu_EL!m|? {f {'Zй{'Z{Cyo|_GPgǑ Y׋; ]̣n ƍ1K߂\648e[Ȳfƕ!:A t7Ȁz:d됥CYC6}>;s(WL5v`kdmqg\NuQ± :h=`h=VOqƧGg劤pӓd _2l2E!L?.Sʯ7ıKxo1g\evTŲ05ryWPi0nvv}xi+&=DHAL./+ vP3Uǎ*f0yH/^NT& aJ } ۏsì:Y#k+E}H6Xŀun X"Ofhf=Ik0?B[zJOam^hʁwl;Om=th CA⑕XŽ;Q d= I Tr.xL{HCP 3u6! XQp=At!KM, ɛ?w1C2s ]hZh$WͻW4dHOZݹc"OT #/ t7 qF*T> :Ҷbh6'xs/83I[hSa HByix!9+)m- g*8_T[Qȴ&_ ֧{j' {'Zx{'ZX{Փxϱ)Ps:X dGn Tr4&ʃ]G1yo'V P|cɯS9@eAm'$L ;!9'4" Je)]2 pIx{Ms0@M+nLdf|svϛ=ZTTd5WT;]d9;*Zw_@H3ZfJE(7%ջMxݫLdehCUxak<[j"j" Eh l4D6V0%2TI2yYvKg*MI BtI~/uI3&/SX _k\{׀ Xjv+Jաw@uh1`w X7̀u XڃLI5V KUgTprQ7 3U']vUSzEtnJUHxui:`mCAX:+6Yz{:d鐥̦C}TcJ1-P EiW̽.uڕ~˪JQ P0SkoKV*3PyTQ>Z99%C:힪@:=xh=@hX:ꧯuPGd ]vWa+|&'2>MLM^n:¢Scu6Ѐun X"Ofhf劭Ǐ[~Z[Sj S^; =bE7r".A9!yt K%u'YmCA:ꐥC Yzm:dчeXgСc*|z?%uy4@]ץz){x#  ݏPP:Xr-ݷiz@(S=힪`:=zh=`h\D59yhs@7e[+bl#:`iNYX~m@7J 6cek†POIHq>$ְ?lrw(bX.Og5 &X34e!4Qa!I / 84 f+dіKrrVߡ5Y>|=?ch%&{jݱ7qY&#ǃd$B;LB W% ( .R*=Pin7,Epl{긅J} d'j<\v@'-"uLvg?%1nCK1!$^|?>!7p1 g"{MOL{v+H"w'ԥEaBDH76T5V2MYMA洉5Df"u Dԙ13=$->ّṽ$ ؓ)HKaNnŒ3<%7?:IXt$w3DE{ПNh#֔Hf3c@ʖ35 XPՀu+hY X7xr7`@4 D;_n0 _uBPiZE0iFKځ$O._^HQ.𡗼E*TV.Z p)8#k BԶ"l+;bۚ O / W|FLƋF?~/{I8*'sy&?PK-!%>[Content_Types].xmlPK-!8! 0_rels/.relsPK-!H]/drs/e2oDoc.xmlPK-!̇drs/downrev.xmlPKbFe7=)k6uߨFf!nFe7=)k6uߨPNG  IHDRV%iCCPICC ProfilexMHaї$T& R+SeL b}wg-E"u.VDNC:DuE^";cT03y|URcE4`λޘvztLUF\)s:k-iYj6|vP4*wd>,y vڴ=S԰79 ڸ@`ӋmvUl5`P=Gj)kP*}6~^/~.~a2 nײ0%f|U 9l7?j`l7"tiNf]?uhgM Zʲ4i[&LY_x {xO$̥߬S]%֧&7g̞>r=g8`候 8rʶ<dWT'<eL~.u"A=9뗚]>313X3-$e}u,gmg664$ыEzL*LZ_j_]Xy[?Xs N/ ]|msϚƫk_WfȸA2)oz-di2|m٣j|5ԥej8ɮeE7[Q|IM%ײxf)|6\ k`Ҳ䍐.8c.9YˤlӱU:LG Pa( t:G?9Yt| Kg#[wP1P1P1p+fov$H:r c;NKofm֬=qfemZj2׿/|_o.L6?HGqt:f%’-a|Cf뭷nG6+Ru KL#@8K.H=K>" ۤ &y7߼_~0љ'S?.,t|0'g;ӱսufwn6xfWN VQ100N7؜wyg$.t&7Tf;8ufw=lvm0P10 Ygռoo~ߚ> =w?6Ol*Ri">y 05_~yK/T!פ tfWc%r߾9sūΛn) ;Ixi"/O8fߟM8hzuirK***c ٱ׾ko9#/M/915tx@SN餴dT-RJiꫯ$òs}=c6`a;;SG?Q'nõ)bw]裏nw' C1TMn~=7 ~z{T_菁 v>t_}t{cϦx#4XꝊ 0pwfrz;nL5h[ұ#;y晍;ޑXb`H`#Mlo~Kk7HXO2kI;5s7{lnW]/;M4Iep /Ni fկzzn?NtQ+T )8s1,UgGZ\'6W\qR?Ot=nNu"G>]_kLTb`|`,\0oWJy_nHNC99CP100`6Cִi֣Rm1nbۥ뮻2gqFkZ|@7'78k$=K((`T 'TMJkK6[ns]:mƅZ0`_.8/tsdܶKL-8䓛4Sx'ꕊ1a mrlFͅ^TZÉB:~6KAc%P1P1P10 5_WWM}27~e܎M=?( eU GuTj~sT:0{xg'^k6*vqǼ RjSұ+'y;ŌZt@O |s{sK< >^{5jɭDI'c)hv WN ~&-CZV]ul6t,5v`]7WxӟޤFTM-b`}7Z;\"K>S?A4&$b'nKX"d`{̓U߯X|>^ul0JPY[&#^[lEs+T (~)r vKǸΩ]ѺP_yM6$o>Z:6S÷O[u V ƀ4@vH ltX߭k ӎn MD F21Sb k oBM S d[n42ǎY[䧎m}{gc|Lb+ƀl& V})fQc^ueyt IGq mw^b`.`S("+=,KB|fm֠GcԩBlO+T 6bݒEbf=AkL(BysWf:*&€ =;KߣZ8EnIgjЊ#nI!yHc c5XO`N%t }:K***ƉKǿP }h8ڞ#dX1eIo~n3sgEע*f0p1ԚEV L=aɽ}+q%B@1`Q N PksHve T>ˣS6 TVkXeUvJ+5wݛNGfp׿/9ƀ<鉚(| 7LX_10/0@K ~A2K/y+^HC}{_sdM ~?O#+T10['/|sG4뮻P{97*fh7:{3Y{UW]p*T T T 䋉O:%W_?h#fvCYgE]Loo/oFs)Č{GsWıMCӸ7\r%س^cWFϫE]ԳS߿y+_9Lp#|o}ݧ):(/eя~tN->0~p8wAzP|tM*g9oPjfm6Vc| "Mzի b-C=Yp"?6[siw?A3<3i̹2ž4o&DH?0¿4ַ=isG}L`mC9dV _B]gϝql\':g}-ל/}iֳqBe]X+ 6 %_כk(lv򗿼qs??=;h}|&Їb`[?7"+wɋJ9GQ4`<3~,Оr-#a.~<3ml;'u{] mr$N(7Կ| Y!3[?r)LKی㽽qɗ G7g҈s8\ChBLg<'?l?3o~qRʁ>/lno;uG>8e3VnԎ /9M/{ro7KIKm~>N?Co}s&VϹlJ`@75sL U~pdѥC,@{7~xJ;tPlXNL O>9ѯ}kgZϭ3RD OxBs6L*ݑ2攉va8;{JQ2\[Z3ٴŘ@zvmwƔB7 d7Hl0 Uhb4)TF Cg?3Er&|gCuFt ,HI10@RKJpbzr<?ጏA!+Ru/4w9'uѬѓ̸4 qdkihզ | `?>a }+}n =!>`wq8XcfmM0v-g3);Ωm~HpE3l m~@;hR¹pK>.jWfK׼5W=ycYR@8<,>Czu].liSišg^p^Nux+"ԧvP9Ÿ獃Q=췉m|*ޞG8%tf'v<+Uvک# pN1_kͩg`P8kO~h8^DC{ZӨj^*5g?Yn1iRvw^Kрh_?}v&Q5Z/ t>ys&-‰ -}_P#x ЌhjXT0DȘX6#csZʙg=Y0vF؜Y/Jc?ꨣژh-կq/`g p6wd-o</6x1p!7h} ڷ1=Qd.:ʋ{gwq+ǏTlK[Fp脸$\a{Xs7G3l"t9TQ:CiPzDFͰ)Avy眱}΋`Ʊ?Ld Nƺt /0QiLq#Gg_K.iNODd0QΘ6@@T"5lA68h묳Nέ-V\td[cqƘ  }ccJF35)eI>ZoN۔ } 6];+3Ş3h_]] )`$[)Y|?8 tGk[og&z(צ/yVoà]3DP'ɘߜp<gxi*:`'GIڍ~cV!OG̘!Mm~x׻Փ^AU 0 (hYGD`{CTH׋ S^d+n?=@%oZv>q;Ӿm^se ߏwɡn5L(;w=ƞA~8z:&(c&ϷʦRc| 0j-%zw 0 %irE%moT0JB(0-'>o$05C SAXKWP'!@}1sıv9gARecp0^B ്`,HF|#O68/\hg6`056*"]Ɲ4fc_~z;ޑ! YF >58+{A{52+V{Lz}Bc`+aY(#2mE_Յ4 xvЙf!,.z{3pds9 1.Βr 9 G>HBd!@OCShXr\?gKn سFvgݗ6YIer)'!I z=y7tƯt#Ge_B(>1^f> N@^[R!? ?Ȏ#&`oYu:#4/(3UҋA2y?P?z`c=?ʕYG s=_\Cj}@ E@u{?OYENd "pұ!nj1sV3%x(mk~C&ȉaw~& +].: 7cAT}R{lȯcF"*M0cX]ubf?Czh/Ό}N0Lc:EĥT'F!+ NebHL#h lJA6="xÄ0k=Ea_ 4m8餓AoCa/.ÆJD3C DdEF)<2BzxSFD>eHQ|4(!@/l8cSE1fWh{xxZk;CMP !Lx0^zj6/Dq_?<q#p^gΤ1±4 l@97>gmƪ! W=57k`w0;&@hLm9d}f! !5#0 xB ;1&  ~4^:y*t8P W6W<ъҳ'#2&$:Ȓɀ͐7ޅW2 (zF*blq.u4_s9=QΚ6?iA3y޷hΰ-aCg08 #~xeX(S2zhM;eG i9KRCJ7A?+y:[`?pvJ~P]q,RMx IDATfGj`y#Wt&cGǮ(5S-fud)l}gol%y~Q~g/ /#tMf.YNBPGBn'huux~U'9K4(vF{e' n剈;i.!)N$ɨJ3bz$G{o}k' N"N2R:B](>GbNɉ $^OY$,71Hn'^`$v^q:IxtIjvNthT' ~t'$I{$:Jp/IX.r}S' Na> LI,2nm-)E$?IiwN1L {/F{/ |;)Z۽JHJu%%޽ ;IxwAN$/Or'~ t}/IQi'ERKJ{]oy 1:I! L'GdtQeJ sPQ^v l[)rG mHNP'uȇdDfٖ ~GdwRpjIV')N ~uǻ'SC)r1KJs *R0^ |tbtIFJ'o4 e# q嚺Icz(mG2=KFD:yYqE3Im\2-%de>[?x44Ӌvet@?n!c^_ud9h+ڑv/93VzQ\)xtLJad/ro?sYg͞LFAeN e~.yk/^[2JR*. < srVyINrb:tk wm f=.3}d[rRےSuJ?#I3xDv/49:V&wb7s_r.tir:aR::9yiAYN\KW^T| eۅN DtRa>]0g}NN uq0Hs/ts-5{O_s lov43 %rDd9Er5-{i3k^# TRw/ _^jhOX)k"I(C4 Q$0s8e<= eDoT#%FL$'fcD(轩MˋШH%0c@>0^SAI|DVB`<"A 1 VT!fU~@;:4QT3'eD3˽nJ>= )> A4 / ٝÑmcv|f4[XҼhl!xC̈M~kg"h1iƙlG3H:]`AM'0 ̒$1jK]9k aά12(\>ׂv+6mf>-d ~/f&&̢)LMSDKs8 1`VHj/:4+ы ٚ4nfpAdt'C;df NdH)fM% 9; ;`fg},):eð郉M%eS]YX7,CxiBmUGj;]֣;KGoNCKm<ζ<2dYYF囥4 hzk7{Ld-{9v; vfܗrL2뽏ig/BfS63b1,4ع "}4p1y9ٮ\ 41:"C/@@ P_ ('A漚Vt<$/+tT)AZ8!@OEÀx&_\ZWx.[~? JA J E')MF/҆ږ) cCqx6=)Rq0 =BX;q|Nxk%k(\`IqHco,iO__ !sx~KaW )iB F[ pE xE+@л1[#9`Arh\YրY2OD;eRyh3ׇڌ`a$]J.F1cq+LaM8~@t5a2|d0`ɟ^Zmȼx?ΑO uvPC8{_Biᇉt}rBɀSPnL}tlioe~&F:LJi>r؇a= lD89z>g rZwHA"X7ܲY@R  z42/'H %[e=` m~쎲nj>9N '41'8)`N b0H ]Z a0oIGD gesVt#KTV )nۀqOc10 b.3uT|8@ )fQ[,-4>!LwυtVFF7挆>~/zk?7uJ|) 9JD἖g<;ݶGnK3 "h?d>L ~S%~#:svz]k?gӏWFN)/zS^p{h3>뙲V aY}g)eɿRemiuc™3(eٵ^<7m[F9&(@cܴQqmHVH!Fp RZDڃ4Q(]8r,BV AF7Q0ɢq1\Dũ)geCD/9=e` 1 sDB``}aHxgtEDhU:%c R{tEp2!"1v]!,GU(3N9f8,nG+3ztSfҴ?uuW}kW "k{(# k?q | ̩ʏ(kq>}iWs-3Oq7!f,5fČ z(gi)h]([qb(٠-EE hDb6oS];2Le-צ,xPtZS&(t@8{t7?2@dnf:=?3U&t8hTҨ$,a*nҥkQ6@79@fҟ ~Dٹ taJ9%#.KE6@O%4A }dMlJz67#Ʃx/%&zmSMsijٚuvqtC؁f k Ml`n9ɺ!®1bOƲT0oR>:+i \C@|`[2Wyso(k3c8 Ԣ/a}3 NƣTr(].KcfWzHl}+(p$zsG7#`1 M3vŊ}REJm hu뤔oTY2a}< 523$9tS1Ă3@Sa ޅTb^PVwX=A3ݴNn7A?H=mC?+ںF5 f8oܚ6?-B7ep^ q B9FD.L02Ɠ3!PW~]pDCjcaI ØyA8 #NP 6k|ѝ2!K ~xEƴƑ?ˠ.v451g5'(3 oZ?6=SdN ~Df'[Jb1<@qdZfl$dŴ3_joslf6:@o2TUid̢7𩙚^m񯵐 ch$ORsZ53&ɂɂ>%K\>yз j Ʋ}޿&~ /W $s~`_k6J9 !~`wm EWRKa,zmp P:jl _{rէ/;e-8 gl X[A%7LF6B9FIrnCP6鳀֖zε5 \FyPԒ[5'Fz愰~" |R7yOED[㜌NwOq+AǦA~!Em^R`餈YDC"܌8;8z/ n9H=-=?IDyDH-2!@OBI (! NTLFiyD[C'}vC"70@r3@bΌ )H)o$:IuҌlnoR,{Ӆ[|¸_B]Z.i%h. Nv"ä:hIٔF-/~\rS(.<6V퍃𩖲 C 8O@,r-{,fم >'LЗs` ٌf>y nw>kz+$!'.J[Cr22{6 Mt?IAN0E[CxߙN·+ޥGPei(!:%!9<?бpþMYgs7i8҆u_t?>~cѕ2ݠ{srcV~>=,M>dJ7VLYY;:dD#Ysо)hС9Mvq1OϺ`94גs?Gsh=;lT#88›όR CsltuT!93IWj~ bj*5u". <'ɻFIQE%u&*'G((苈KH # fɑ4yJ$ițȗBRVyج݊DhCbySى`rjW"<C*E}"!믱Vj6x0 'b% bb]EDEГ 338N#vz4Ae3M":f{,L_J-Qzbb̜Vp:ӎ@;r T_^2^pXdYt-zߢs3Fmb;=fђAAf]| <ʷ\ XbV-5,97H+G4ydJђtf2J?睅 +fLԙ.:AzrC |m fS:!i3%?áOhCmxUVvgG1'J :\PO Tg;-KЁe=qUy`]\SMflklb5Pyþ3G.+l1ft A~K5Jj,O6vg}2~qKGJ=!͗qgL8ڷ6?l!OfFahۉ=tGz?A;)B~<)!$r>,(([;8~@}d[:=x ^@ߵ۳s w_poLv V-d)|c -kR>hwТqax?tl=,S> isy|h h>>Oѯa~;fM{bB1`G/Pd^ m] FT} a h8Mv QF0`&w6ahC[_8`":BY@A  fлK= Wb}93;a\ _28mr4~Se^+߃ʍg=gF/x10t=D3~o9VX IDATC~2);&2dz5~ C8Ga3YzK*;a2ezMsaP[8(q/&l~dqLw!󥡵b`jֳ8Z t_³ӟ4M֔-7߇B7t8 #zk+Ն ;yGÿoGj/**2,e87/B ?qO~o7 C|a5/zыa0K|H[4^xayfQ`/|yk_<H߿yի^5cя~|c|>T[C0+N:}ݛ.c|u]/˷7 zW7Ї=cFWjɹ Ā >l[[ιK/tC^z?a3:K٫f౦ܾ  8rGd~x4E c5xQh^-ehJ"wrf:mo{[#7 \qͷ檫j6la^3ڧ!i9Kr:e-!숕VZ3]=_R_1P10B ~4d ۏ ̋B`Ċ S{gW"?sフSO=Yc5 C9dU Uh×v; 9m !6paĵkO>y>zݭy_goX/S/0?"{3}gt>f7|993]veZo&կ~un:mȸ8sUYS?f p fww^.\NwkL"fڞggdRM̎ZyedZw0@(3>!'}rf6d G=QgTyv\m3D^㪢;B wq[.g= [cAbjm<|o>5x3QW&6x;??g.m3^{m^2vF*d%Np7eE+8 MXv#ꪫs)~w;+12B<yq=_O<ӾuUkWr2Av[\9*3/2sկc=6Mꐲ=WB6j[+(qVUp,SNi^3>/h+j3 gc_ϴASQO?=mUN/DG}Lx.ʉg>PN6 )|;Zʋ6)#Tn2>ϕ|ЮKYk^n8G 167t>:)A=e*|]L~4Z ճڣ]v=hy]Ѻ> VkC1q6/k?# Rpo[vU@G}t*&vU ) >[쇲GZ~{;q6ZsMlk1 u?A晒~fIٴ^ʔM9<['?j'{+vn3]w]^pѶG>Yj(Qk+/RC[vIԞ>9R uI#4[$VZe~s[_y_ߜ}FCiڍ&6ő|5d3C:ᐮxw|Smr-odʅ,ђrGҜ,nl's`慹ڮYMz=q5B d >aГFZ:O9}v#eO|k80Mo #Svif"1| +w 'oZE3$8fb ;BD L#k#P*/e3POzғrEP W2 wAze#G: eD7J{1[cJ  VbY(ZF,>Иe2&E 8@ IQ1E F\z~QG<G.IPBrf#z3eZgu2N%6MvdxO(|[ߚș6ƌ:(Q;I^yQ 5ZKcI{ӟޕ #K_6'nfnv)p 9h~xh_*ڥc艉B[yO*)m Vɨs$_zHCʹLW9v|W8@֓/}K3ȘD=|ڊ歉o瞛W/<;y{èLd/%ێ9,S tȻƴ^{P3R Pƀ8D' 4 mִ00÷-͛g-Ƹ{@\ve1fYٸw})s&`&4: ԍtoy |0\W9ǂaE1+`TI{ŠigƵ60f,&9È3m-ʮcJ*gl@Q5܆r ,;19`9B)% c;7@]3PB0JɻfvȆ>fSȠ Mưvα@ah9_ap #8Ќ?#Yzf1Qk0G߬ c>9] f:X[皲cUv@~F_fk M2<ȶ_/">ǨFx%NeiO)Sg! pKf>1?|#73\x}c֌=p9r ͬ9U͸19l nAhϺ_=C]m1d;6F#?6dw+9N)$l|"(¹tpL9mK608ۢ(@)H/ {R&g­@py'e}A44r"d@m5@v[ޡ~'9IχD}JS8  s8kq^8!@ гFt'PJ0EshL )%%Q¥!MQ `0B8cDě |2hG!ew fD%122x:3)3.i`1zo01ᰠ5e,Ke 0('S2$EA]Sbvz3ˠ*!eaHV3=x\@_Q{xsmlc2蔯Μm|GT~7 Zi֞;_iӲOs$vK |zrW)Fe7TnP=~A=8AB4-1h&Aק*KPQP6|^Խ 6 r38dd?Xcc.e ѧ:0zd4 Doe}rttzb`qOW_?dɸ[y?aYMIIK2 Hϙ)$@8JQ3% <[KlY+,HJsfcnY>TQ߉"og˒M  kKycklbmWPaÚ?C@Z?ؾI(`2'#0PݽeݔCDYd]u3҂"@CJufF!l щn{{SMEmmdaCh PLTZub#"@n"DsyoE}SU&JJF0'FЌgv3=x=~D<1,r 0+h=9[&f%>;6ֳG[ 5QRS1a VAgE= ִ/0 c=ja eʺUSʏÓa"}'k࡭zOS HOS6J^oNQljRzbQz1@@BX ̡Mk]1 1lkOf1BkuK;ׇnj ~{)d RH/#UJĠ٫~u^#nf3@d3K k{%e\83";Jfp03<lzN%P]iƤ|F|/ ̨Y!'9mі{|@f\ !w/(Ǫ*f1 8 X`ڡ#3VVA,Z/^`*W9z&Oޱ̤{/gs5d<>wU~b݇l4-Rc-iߏK5q̔:JXcu?ډ^>,7D>zL5uke3L^v`b=!Kc*CBa$އPav0`̍1jlmM^ߙ蠝6j=0iަ٩W1P10 ~4Ō;TbRR7OhS8Q:EG^w(<(Wek -)pYtL`ӫ:iѶJ T򤄣ʏ`t=Y;mI|8+ʵy"dJ]݌s A9 t _ W6XY0q}2;fV>,'>tAff~&)AGSΚU4\Tc)v úWl'xmm"U ;mAY( l)2[W5wAd).vR$."]B 8۝Ίuy 3DGl)ƕvTbNvb; ڎנ2꽊c v~Q]b6茩mxcXY_7J&HJ#q k3`5&\z0(~3 A2B)Te+Rx);iƷsN2J,%iL"̈(wM QP8Nqkr'>Uܥ8Q TllJVl"ˆGd۫ѦI/δsÐꇧټ'(>ÆOxcXQptsuSiF+Ibwc Tp Y1/2X9T R:]Q^|ԧl6y/b84C@椡G1۷2q`{]wc3;kRŶq/pDs; h:gw_}_G|v|y L8qɂqC?@d'n~@Oh,EςeؙVO&D*ç"|aKyNW4zQ&5)IQ}sKᏜ#ќQ\c &2S@V#GRD;$@ aNrnlh ߂N\CN'ގ?C#{/{&6t1Ǧb`.c t35! puH3J DD))ʜQiPqc&K\,B9{Gc(Sj  o$e:Т)XJTy:g)(6Q;13ڪoKyڥ}&p3Fe2REyǰun:)|m47@aXz IDAThG>K5WA_D.tb8)e܀ШP8cRҵKks}ep pb>"P.O9 :ƷqMYm.Vy//c9&Rx~֠Z%\ 2]I 2եfFڨ= t:**N oDHT LϑB@DQъy>R:ڟ?:^>)$@پN]m4Iq˃TU >S8c0pMkNYObC-:)DUMS}ۚXkP18c:׾yق=4ʢɏzɿ9$3#+AZG]i]6{aؾ+)֍HOQ< Pڨ [W[3)h0~ X.C$PZ1PV =Bn}bzc2;ny 3%ҙ09 ݌ɽج89f)dd]a5&Q^uq}⼱ Ϯv@F/ah;H"gўourRCCzHBuOT?m0O Rd8 t:j j*Ψ۳g gI+QMWB70:_at:*L "tަVx31d'D@_NvtAM7v{6g/wكdB\H[}UFjL|!WgF5D`Fʳ N݊qc,0G]}H1x|z w &GfOQi{ p k}I?t_/f@k7txvs\̺; 8 M;'Y8$c qMP10@>lpCMSG>򑼖OT (|cD7jcLFoj?|o^ T[ߩ ;k5"=f\=яs\gO6yscuղ*&|%g5/Z7LԆqܧ J)R8QfE1K/n5G}tΤas iO]fvzh._Zk]W 9 H:32S~ qЊ#EaAvUw憹4M SN9%58nRfы[7[8T7za0`yFof>箽3x=3X},e/k.Iڗ|9fIDl,ݞ{ic?1>!0RHZ.l[qdX>?q^җ6' p }(={HBBSrIcϨAnA`ay^,~Ũ{8p8g8Ad|_P AɴI`E4lTD@h>OLf\d-U{e4ExĆoc#<22KF mOQ3p0zA[mU]W1Of^tE.8RfW[myj =?sv|jS(;^Ό>D6H/)s,y34?su:,YTniٮq9RTmM{~Q%:1V+b%|[if䵏X#nJ鉋jI_cԁ0ʵ,u{]m<} Pdd&̠_t5NTx2R);_h_y( i>>M~82 sW<siu\a` Rkَn)ߓn2as UtfB/ Y Ru^f3V 9FqYK3fk#Q8a ^H!  {Ɏ?O-w7 ݯP1P1? elYL 5Υe5l4;ڐb5ū`t&c\t /rn'uv s Uj;`)`x; Fmm ( )1ݸ ݲgh ٗwy|]v\tt _})rO}f`ΩTyθtʏ}cYVR>bf[p:~ow6|b}AQ|bFN1neOL9昑eT_[=qɎn sC)b8ڏ^ }2Jp(ˆŽE`smeU e ՛(vd|{\^b/`9:MK*,~v΃ cv}|ec_$/>lp54Fqͤ2=7NmDgG? :~z6 bf ௙p []DՍ\ <0^ +NmV/+̪ ZʹAk݀_̀H< 9|"=5hMf X]<C~]eU烷>Xo.z- ~ѧ?(dcheH& !lffvA60w@;UM6*T T Lv(DžF16zhPkg)P|~9v XV]uռH/g/ !I82H eJʵi fsJ~hexyh*cIg9#>k8ff-瀁qD8KC"En{p ,g28~ӞHyoFNZ)Uoߟh^ qxV'!gf|":/m4mn_h(M%CWvx9'iO>9ftfGСrY_.sz(Z,`t}-,<2S3_ok sjD(I\2QM`Aϲ\ _:F~l SY.{o~swug%f) 42-%iVY\$2Z>1)#<}R TTҗXm;sz)ep!UC]5K 8S".+_]D'qexs^)y -gR>]r⚉b2p30xm&d"e3=;5]=tnAoy74dZަkg^D32Oz=۫\ûf][1h{쑃.=[ߊ Ј>XdgUnmg΂--_&T.R)JʎKhH $Ę(S@: A@! <63i!؈Q!Jl h@'*1!UE\*yt/>{8Ua=ϓ \yL(?Rդ@r< E'ZթtѦW+&e.A4vx%aF`)aބN@,&КhbE#xxPdE1{A)zD4,mZ뺬~ 0V'_Mַ,Ч}WVq%评IBB4 F{l$k|'tYV2B B'|ѝg5C:OP @5VXX)OwT1ۀ0lOWYx6R} Rcu)RO`* bVFbeBܼ;dt5YP{n3Mp=sxdeOJ$%K(ߔ )(+-u,U dqi1' \TCM._E6L,.u Lmuz lit|~?*_ucMBGi>l(jW>yA/ fqBJ,b^+c$Rsz'ƈ$ hT=׿GW?pU&wL[Im5IBuǵB;E6k=,7|sQͪpV|ʓi,>(A߶~#H#,TH۝ U]uQj8L_iH-3ƉqG)yo8}FP.\oۋP@r`}p+Vvp`]%0\Pa"¨.}Fk:;]趮\3\^Ktq@Un(p~o@a&ψ(}qZ(sehK?%4} ~뾠6mc)})ÁXK^g;yoq8 J(2* TRr 98U[,,u]e =F)uyy/ۂlqS3>Q&O0Xʝ !l8 _]/NJ;"= LD}s>³T$}>^:PYzE9my8߲͹8o' J(3"LB\^_< ,,nDžQr 9mTvtG}KH0REiKaT 5sA^9{- ahq (\N8p)PP $Ts\qy+:CGNV26-5$E\uHg]b,0pUo~?Gw>cNmPer#kHv> ~ĭ~/(4FzaFx=sSr֡w%D q>餓^..S}?'VB%+UV|YÑ~G +>Op]{g=2Tyמ;90-PNXj5k\NoК(69lyXɘf[g!rGIɁ@rַJWq̚p%ƇOn~H49Y8-´Л.xm̗trmpW y-~7˙bnR8SO=Ug|FAyǮȃ%3L;|g>Xk]q.qb~'_1N7w׼B-?~೫uo}!x~1Ϛ9^0;cm^J$&e+gD2r9j A,_V _PlaÆ'2q鋐 >Ϗ" P.t =:C 3*tϵ p-JKT,\k[|Ij_Gc__}*/ByY%VW)0q2o*K췭@c s:凹ç&}(e%Yjx>ogˑ[oy[wV&ks^^G?/6j߾!;Z!%A UW]+:jެjr 9M[l<쳃۷Z뫾=W0}>ADao]' жZh=(n܅XOlDpcA"!tx6!Bjcfۣgaw/-}a-+߮S<ׁksY>ݞˑnkCEm~T]9PQ6R;ϕ IDAT]:@a뫮BKN1N2[O5ߛ)~W,][V.>f3GY3X^Nm Z# 駟Y@r`683~{1r a}pn@׿>9tWBa!YD ۈ0K#+(-#"LAB/a?xՏ6QmB7>I'^?7.߁Bwg8sYWG)A(GX2o-zFv@XB|ol<.pm 0͛7stڞ6A׸Uޤsρ|>(XPg}T<7vۭx|Mo* @ }rqbaї5E3M^.,_~y\:S೤n˚ x۶ݵ(6\? AKߡܤ[J.ʺH$8pq }O~r@D4(iO,4&=p]@9A,M&Y>0G[m۶-֯_%ZhDn m4QA0(%;>@w@FXZ sOvw)-/}6Po~E1|2!GQxg\ uܑ*Ze,y'v{ k~1֖lPe/,(<o=XBg}\orC9GkҬyx#<HѶc Wi|55i~[sXh׬ 8}?Ӄ~F#8bwyTJ)LBs,IɁ@r`xK-ܱc/Gk$)Tof/s%ydʢDphE|!\EM!997Ֆ! ?sٔ|CZ}B"߳Po:e B0=,& G"7mm-`낽'28R w}b'-Xca2fAd9\QjQD'Xs'g, .&%Ɂ8@8묳ʁSe}sEYc̠&Jn _ 'pBѦX'%p;sLay2e˿xGŻ9 <>r x'_`~9>$24 n\XY ^ګNCuxӠig?[xhYp w7Zs-s|h|;$qo?brVQGU?s7k/zkQ0xe^$'5*Ɖ>NQ[= '"NC!bnbOSh8d^b͚WɁܴiS x>2)jQ9ۺu iV: Zc9f/},e1QF€ x@_rYQ`1d9p5Yvz[w%ZJ|jnv#}QBpE]d-}VG#{o٫~#rxxpdIfi^ 6C53"ON.Hy 6Jـ1Kqc H-pm}Pu 5mΒ(sS"SvpyMJ$r@#=`ޥ7,?m?" ԧm7Ak_+*4* Ge߀wQeaQ. h!p<$f Ek3-`M5񑥃S0.b]rͳ\D?яs`͟f~۷:`cȣ$@mI-̙^[)k#~Vc@D(G]r*sO$dGqc4(B'%:P ?WQ.OE_{B,(uLE YmE!ƬR=\(zϓkg ͍[AI0קo^ ?'!^Zc$ǔ<,౗6\YAhY * W_}N0uN&-prb/H2YbhB)*q%i8ETd(cd;&(@( B ˶i*6-o-g;9H%//9xe@ɑn^Z8cg2Y׌B/˴±`8a(9m6++ kq@4 `hZ뎱`JZ;8aq̋}h憱ZƭgVJf l)2Uy9k輔"ƀJ:m~bI KnIɁ@r`%XbTz0 9ejiϟZh8kh.& *s j{?,Җ܈ɢvm !Jݴ)`JQJC}-[Yj.!!V+${qv{~PߏqKh?$5k2NXc|2~Ya_, )㴕a}:tM7̬MRr 9X)(K669gc( ,SꝵA86'jj+RGXXkMq i~9h믿^{m!7b/r{helPtg.Ϥ eaDqYՒq,Cf_ Ɖ5ɢl+A 2Yǹj.xHL ʇIZ3|,Ur`-qdJ֗^zibJB3Lc"JJ5Լke__+˞yh7} _B|.;sesF ncb"~xp7}N}ۀ=`ވu2Sd<:%imp)E>Gi8TY N7uƍ@r 9T^@I@E$.nYq^y7& B% +Z#"w~/|.,B28ͭU8=VMl۶mz{I]Sc E~M8L9S㾟͞qtD(EI|J9ib%Z4zfɁt9 (t6敉DF}`AApOH.B v0~\v>ϗAlLUPBnojy#[)l]^{Iʬ\?J,J.R=%(}efJUu w\v?EX..%ҷii{üy%8^gy+2Eyv$EB&N{W uމˇr `IZ[ pr 'i^⌾eH<vX3.IiÊn3mgNe?+5\SƆ GGXP0 2D8N:iދM^3tlKxIt1?9/1)9H*GOX!A!g->;sZ!H Ɂ M(: MK%p# +9nZ,W`= ˴'m&QhMEuskLiy4ЇETRr 9cs?(4O9hR2q8\ӤL pݱc`w/Vy" ENs¾8ch@\4G]Yy?1&2c=⢝PdYk"+;BX{5cX>X\M5&hASb*b$"}eKOj8p~3f=1b01:OAV|wmqQ /b=cbɵ,mr 9+ AsS@ 6XE i3s_ ,D]Ф\L'xT; NɁp b`.O}vGP3'Oh!#QOHv@r 9'sID  _җJ %%fg"xEz!24Qg=pDTo|0IlXWL1ˉsɃ{hLbhooZ u__\q9y-*Ll9 lmI#wZd$VsC67n}=zp睥?SX3ATLBք`O^xa?׾"i5! %8߳// kLTX#c_&E!|;I9?sK/ ^5! 6Eng!J0p|趟'Jл}~Gy~/kFQz f][ D3oGsd) ^וP >&XAV`L~5@`\&1F,`@!ƍ'Y>.K7O~*-m`K#~& pA,SWXmTBvx8|J$}wZ.s~Y]?y,WGDHs)m~n<ܔ G*HZ=ݔ?0x M0X>9lTFzq>PP4Xf͘`,hX.G|'1A[XtOt3h?xp\{ORr`8x\dXgk/$@tm`0DoG"q뮻Z3jlGYG6 !w㻾wMzv馛[+ g|.KJT,/cEO<24C<~gx/] O=`֭yy;jx uQֶEW|t/m.ht~~S{񊑶gU꼿w߽Hs|iܾs"e8NJE$M_|,_1a%%\y䑢$/u6L@Kn!6'%dQHC9/X H~>+ ڤQ=Ǭts@DoGvaeϢr؏fo"7t¹|ҹ_W gNo'Ozꩯ`QNǜ}_/ e~ Ho/$τ믿ȢGC _[n,Vm۶] `+ Tx )vFB@O{xS+y6=%@v>ZH!m֮H۷M>Vc @$`E;SJWL|~L g-t?R͸U'm#8(Zxz)cxciUgnԂ)Al`?so/ʷ=tIjq번 1"'؟4OLBXy>Nr`8۳3J@'c@pLJ  ms-E&VBR$ʧXk@Ey{0 8;3 X =\ci$}tj|/`"J=SM^kFvg =f) DfK lU6Iڝ;wks`˖-"%AO` *O\Y#<ȳAn8Yv-\\`@#ۘSyW@KJ$[ @XZ /(/jCu9/.mɊ +^Q(!%{|{W]uU9ށuO9˞BIYu&ARr`8`';$mfIRr`r`Ո%'YB (ׅ>iO(-VZx( >OdD]m\6:B3ku ;㊕[!KRr`^8`m2>/u*\uKM\%_dc$d^޻zXgt/%+`PY WB h p7\)k~LW_}u: k >X \&0(n#\osm/unxV5rEaX c^<;7&wdV55έS_Zډ(BH\38)l {,ڀAYL[|q=]c Ő)4$(^XL6|MD]>+H6_IL4ބ@r`19@xo OnԱrB38Yll`IP>Ye~C@)`R߬;,Y \\}x@pyp{ؚ,,N|͛_h#S[nr$+U`K$+ػ\ b!}0 %8.ǝ $Aqw }R6_9ur˓(/}5]K " &c!O+pOmEy_Y2eopu=H>xM /E5?}QL) b'UBRW ڇƍK;9^H#%}e[*@mbslzpx79H,q`CXR ) !"x6~h ioOG_gjq-,@p:}{vAu Ylbj'%E{y۴iS'Yb QD?L `*,>qw*+$hq z?6FJS g(r\ʣn'MU.y ¢6577L+(ڧmV-uE~+tb6:2ܛIa@ d? b#s- W` zQhI?@9/Wr 9Hz _?.hEBA&  V!{hŒX`y|<5'%M葬& 8ԛL,5FcaE;yu pp) g[00y,XbObl\5rkXA`(%t8α3J'|YsH"j:Dޙ7q7䢋.* kl2Ur\ 1m|CV>OO?XdU/9g"s$_k;RG@՟X97i+_ &K2/H.Ys9է&\v~YYTY~΁?EJ$Ɂ5g 00G&sYf Hhi! #B({,"s帷Mm|DG&qn^Wޮ!2 +rt\=$ ecQ:G~5RҺG"^Ɂ\Ue1|45;7u_IɁyzXQeU9S4ѵ&~ǎeVB =B 2^#v>0*o a}+OۓC DX>5*XYh I`=g) E&;",K_ F\7L3WƮ=m X&o<txudrߍ4F}kCa _Ul9m~ih{(}λfi#>R<ϨLco1c?PH튽 4C!ihxGc\ LF&kSd}={h"Գ]׷/-Ww%Cfp9&|/Mq֤^zƣ1NgP_ec=32+xe-…MЊӔ#(u/k[6$3HY`ە8AZqVOng(ֺQόXWWq1ͨs`)Pb^Ҏq4}oZ"r1ӽQZXf}tz|;nm\ ӈx`fJ&7lxCxK,d0S4W.ä,9@g: z{;"T13Ak*XFYھ)Owhuэ_㘖qR (b䎨oAyk_[,4x^Q#^|(YmV>" E5*%YQcd "kEwoB`}T_~yQRX||.~iO \FB,[=&&yp;wr 95|E6D<1J$da ! MҢh;,!rJ0t:S qi8^xl-,0^|E B/;iCcތˤy;}Bʭv.e]V {xr.mBjC8Ȝb~+EB=9~4s}TIŁrUDxn] NA R4J}ooqio `Sŷ1f %Y> HjPjJe:clSx@%O^#eJPRP pţ. qU>kK*ބ()uBc5/'u=f{s_rW\ʙדɁRp$ <s`BmeT\mIpFh0ʜޢgD} I5Chc?]E5a͙=kl""V)Zx yH^ziIƐ˄AccaJ&$xfokCxKFH QyWB .`e˖"(~>|;ι@@ ^Y+okGX(FƟuRRCw0| !@0B/rH*$__\im#-FL諵ldeqs7jZ2,ʄ†u9?;/Gi*0M0 0c@0Zz xc^: cɊ2]cҚEuTڀ?sXh4EJc9o6/( ƃH$n3^2ΘI bcu^Hza[4&arInwE8ZZ;#(ZDiX9$h YØiw,p"r"" Ϥ%~>hQ^?}P0[LPӇks2aԕ?3;D38Da8]~ e^_VJ,_c?2#|#{19gIr2NQ}Y:A#eUuy2{ۮE#7$X/% ,5%Iu8xߐ>l2}1HƭL"ژBKEg=Z=iQP֠R]ƒ=Ƽ  da1d1BkY-s #maYkWOr)b&Q&P%E{-.&'s2ߔ;A㌕f@ΡU|$Oc]7HL آP q )SYF[:^ede^aULJ$Ɂ\Y E7"=<4= wPL0c}Q@ EB{?hGY\X#/C{qquGv`aNB!+ָvwr@OiX![2ڈE}{_FT&ݻPpﹹQtn4\Q }#/2 p k{\ϲXmfm I3DMȪ,l(X=Fy rXWQQ_ge&r@P ȸh\'}`ԗ1 GJG1"Ł{qTuum?披AM^(1EJ|H ik!:'%Ɂ|r`,+eˈMtwlV be! " gOt59 :J fzr`9`EQ_ԷI+y $Rs,1YS?E "|,X:xvԷL ;ȞH/Pa=++ܾ>4X?uUދHgJ@n2qr ~e ? )&G ~:[ XXw#q]~*3E;gxػ X7d`O .Ց%nFMn'Ɂ9my#+Bd +LM"Z,Ā`MN{&D]|\8tr#JJL >™^M$>Bv \Qx&7)Pn(+!@J}~H[`T'ˢAE=e EO}wHoR\m $}c\ e>%CqSf%㑢_PFnkDyҿYϱM4mu|奾1^ESGSҷό=fU),xLym}p@bZWK]T2O NM*_Q5yIl[k֮=]ШsqAkR8U?g}-'e*yPd=L{ev&,Ege"}0:ODPgM\jy*z* `@?@DbaTI-}nơK?xX?56^zȉg([&*q]@&Ջi\\s]2U:QM~xL}"X=듬|'bZn\G; Gn(2l#sRh@Pws9{Ece?^9Fnǔt1U6N%2++MgTg>Q;,s O `V/r"bLtz#0 tQi@a5 VCkW h=c *(اaaFVyɭ0#L.ò@@w,(~s`G#|[xBc}m㭋u.{76BFQn7)HY=|t%B\`ှ (V㴗=qәY)Oﰸ5A!40eSF.֮q @)zqc'\MV6OIɁB"]_7x[9<x45ϋ5~UD%0_=o)&WǼ0ТEmN 6g;w,gilddAXi lP(9!m$-¢=DqM9p}r@ E m?F~Q:W£s<#¢qHx^: Y>F]VΘsRDYh{5uV(oC@mƏ?AٓS_0nk?kEeiY`u, HY<Pwgs%%EƏϸԥg¸y>+!Ұ6 ? 2XLgH&k 93xݼyr^YsZuOIŚrbia@!8Gm=AhuX1a5H`hi,tLd&rb. 0alFh%$JK.,\;|~@Yg Ӈp:x}K7M5w_,q b0&9/Sx,2G=PBH-d1 2j!2 rs2VO:+ I9"4R'r=}V*I(B͍N]۲eK٧~m]4,X8IɁ@r`Xq@O(s9>QF4btN__4}fڞq{օ(om%o=hyONjZ'{oyȂ!/yNQfu'{,&,-aX"Go-nn˦bu{]y75K1m.M e2&BQ/n|4{B嶯V )눅H@Wt_zʹam"H7<(#,TC,L[Zy-9Hso !^6I5^ߙBϜg47%[\Xby`UA!Kۻb4(tU1@4G[?",9zoB| (gYUlO?5uQWe-d1<]$]X z )|5QVQ rҶW `PYX"yZ|ɁM٠TdPWY)26u>{ Y@r 9H$s:kb5mdjGPgɩJXxuXYܷpamC`Q#̳ 9@UIm!;&CVBxޫI`W@9@Ҥ52HE@ ]%SОdk+e_/uaYy> P3+rjH}2/z"Ng)$*k4?w=KYG}+wXWm;a(uJy걀R]+P?$;L\?ku@mS!xҕ} .a\L^ F:q;z5N'ޫ>P~jr+I?§hVF߄@V>=eP:C!QQϸ@kcJ x"dfi8vu_;Aᢷp/9H$Ɂ5+a^@pTUE2BtXSKeXn|q #(AE( A0[Y\, ?>o\nBIH>MzGi7/Xƻ|Wa%d9}|ʣ[K}M^'`eyu(ekqﭧ멵Ɂ@r 9HIݴZ&$75@S \6=ްeaQAg`Ia=| ,@W^y`p/ަMJY+ Ez~*wx pϳs@Rݸ7=\2cʆӥ:n9xRf4|E_=K6,-}TbJl# H?z,z~Ɂ@r 9H$XX7$Fѹ+H}qXXX8 5[?z 5$%W tGf}SO{ [tn@hioRTo<7G[Akm8NLYv3l_ٰFQqVʭjҟU(rwݰGO"NPuJ$Ɂ@r`8@LV- K#PVX t5-@35(Ő;]y"?``)W`%}C0wW'++K@%8*[?L/(,7Q|eM!oCŕx^]V@ aem# W$mm^D"}>˒+*?ঽM|>=~˪Q_IoOǚc*a; EZ-뷶#m[H>uJ$Ɂ@r`8@`ɕEP G YE\BV?ő `#8s6a+6fJIT֪~5@bXX1v@&|X"u7@6"dHo"ɨb\Yl?Gr"!Zc5vY9N>ʪ|gSkw]GeN)(siWM|SFy|=:8-g&avA3x|yN#R4YuY\!Yv=p;B_?Tp!{,ė(E^uZD%2U=YzOuW\cE,[?Wu100!~\@Q!fꎳIɁips̚dQ>61rKHp}i$Zv%i9Xi9Cرj(_Rr`8@Pj`Mf)#i0"%gCEc2F`Ff#Ȳ@!a.t<% O$EIna~;[Mv< b{ @+ƕO]w^4`h +0_κatMKD\ECXx.pl"^xB'*0.swS )}Yo ?" e>Gmw=:=q#c.0~5ªW~V,!>KK<Ӿ>W\+2=QmSuWYL>|x{\YH~xNWS)CtGE_VqmߤYD]Grʻ\2x#ݺJ-&Ɂ@r`8@h!%%fJNPP t,\0aH.b Xwsbed`@:\;,ᝠ]wuEB8LNLh/eH}Y 7*#jSX)-2lڥ @7 p_ X_iKK>"`N+Vy0dz]s{@to =_Yuhh+6GwQ 7[kgg`siw;8 cu4_OpWRr`8]|qy#`"TyE'X4 cikOM`P 盵صr(Y|ZxB >mm,EmuR6b5A5{dEI(_?YԹY[ųq_oW9.u?(8FQN~^>5EqME<(h%qE1kO3s TXe3,{C&QOӃN8a{$4>E(.Mt A^r|q9^;O~s۟Ug@8*{M@$sK5>YL?BV}@_zb)"Ki~\֟V/.ԣ:jWj3Iw>Т5qhTޙnrO\l `])>I+n"BYiXW_7 bL! }a? W4^?6O3wuWq2y rfFM\5xeRV6'<Їےұx&"%p -("EObq0='܈vAnfӦ`9< /mK6ysYB~ ꀸqkr# L>.-{em XԱp\8#RV:?γ .[b<2qAt{`xɏ4?쳋' r!%JSYQGyHr-{r}ktwlؗ'6'Wo@37pmA>XGHP86blN<oVhOM`Y}Br`zoᆲ ߼6eNA~4BHw{JBPN? pF`=z$ړ=T A,X!xw8Ku G0x5 8&V|,`s 塐\rI Jb1 :'YZgt}),.?G ( ĀpQB* tȆ\V=vym}qŇrHxg_V69́J"C+jqҚZqUs UWV^<'MBQ?ɏX^B Z8 )YOxGQ.VMu]-_!x},n-a1Uf}9^u.Dx[6سLᖅw6{i !HC.N/yC ڏu;S{Bkjcƍ%қЧ/rAS*A'Oms!A4.)ye#hJGY7!Z_0^&H/ rrW#|7cK۫|-[worny< >igo ,h B{߳@-yS_nL4Ƅ}WdP^'$:U}ӫ} 8o<3YjQ%QCc]Y O"1fhz!) ?7&gcطnrVpƲaQ^ xh<N"3u&HK,)lI ){Eԯ3B-% +uԿQY8>O<|*<MtЏkqe>֞+ƆK Ě.}P9b#F'.EfSUrA"V|/{nñ9EY%8SZ l2O=u}KXĥlۣ(ȯH$\B k@Pga 910DP$h, I6Z $2|kJD'+9jPXP &V_-ڄM7KБp2âL7FV|pw 56,9 ŞЏ4ܮ 2'lhoxbB(~:۶m+m78b7/~Ţ@!H\𧎞Pg.(FCQCQZgpI~Q֘~}W}2wogL<s%|SgsO9 `'^=s0v_^[cڂi37mdlP yrS6 [̳Q:CAu|Mq34hŧ&/P|P1탴I}żk=h*/橖39ƶoa+Q ;/״3}W w) S9N30{6u#\nZ&D駗Ņ7&X\f%#]4 %˞E.X@g5ӍCkh.8=Cm-u IDATC%k,;+!C8Y:*A>\Lw Qc3ⴃ.^8El3R%an+ h/cSX.Ƭ eb-d 7=uai4{}>*Àa$(o uqM1&!Aח86)h BIÁf{*Eڮm)Nѕ5Zդk7'H7cX /@5-և8R#MP5}s ?7wd3SDԭX/; |=5bӭSƝqiPNQqԚ7;4_+K!4Rj! d,'z-l:;Bص`-a EIڀcx (%OnZהW9w@1;v(nx5ơB ބeFX ob0A5)nBsSĚ>7ޫ$s%&Qfxџ}Ih-g)(Ph_nwm+1#hwAǥ(z@W|WP~+.BIgE4fc+A1nE zh#J }*v }d,рϚE1oG#0EX,cZ_Xg!6@JPbqn[Z\ZUqDDR(%>ܜl@DS]doؓkp)*5M~RN<FZo_cϸH'?:׼; P<\Ul/'%uߌ3 V.E @w|^m59"+(p(2Nw-F~sr `g0&֬EV{P$ų\oB(OW_k9 tGg mWZ@G/>>RzM@G(G,lfӻA_ex;<IH])E  C:BB!QLp%څK2Eʓ˸7a)$LS4o<(_xE;/ o;x9`/1mhN!0j8A"мHM.4O G,H}T5Rmr̼X̍yil^6?s灱Ro,,ơWHRn,xEN?ۇleuryPN 6>o鷍:}C ysɚC8WǶZ.y@&s+QPzWSe a<[laBأ7n7|'~{,Mf[ m͢8K?5(\)Bp;$ -m^q7,hgPiIhXgL:6PږN5iSuXUX  p!8[a8&>-|h4ie; BŶ&$>jr Hʒ*gQ_`M5Y`>~rmu'I{4ѤؾP>NE ebaeUv-nBXYAaa@1%8Xb1 X[8 V4{{X3.͞ ?wWF&ض=^n,,K(U,>@v\SW @<Ƨ܄ԤB &J۔%Z$y%Hϼgnd-g )_}vs`wIǁ3_VU" EҢFSIL;7`6Kh-r$oM4&qd^oUi:\uj͏߮sCnJIQQl+Etj"qIU G<^(IX GJ5*ͼznNs\CYXM/1LxiOD*~̰.4݄ICÜj.t `_@R}} ʮl2FP5{|ܰ@m|S4ܛL`#ܳ10 ? RYY,Z}˖-͛7~XTzߜf._j^ts9K}og^)w=oekLkܲ6>%!O}Ә\J,8'37vݺ]%B!eNYrjx5:}}5+_>2޽gX[ٟ(oH~&φc7X_ڌGWڞ"m̼$>9x[.\Oʦw2g~=UQeum n5a,q:a4>q?nzܠyКkW}Q߯' o؋ym?P['@>Hϻ+}ϑܗV 3Vhkix=(_ 2|Dvi;6QeA<[wkgEo}PX'"H_VxVzqB䡎~oms->d*וk y=J ygԙu炬o$22zG:sܒW[~#7I9CyQ}?D=\ݕ2x%OmuϫM'5+Pw7=$GgY!ta,d/` #۞1c3 Ʋ/# $,#@,XbnOIW9t9s*+_"#3&kāфI &:F7 ͑BxXr)y⼒AZ^`вZ 0d1F&ԏBN鸸_5P>u"D@-L)Sgm'+9aAN,+_'P1h\}+87M,8c|Wd];i,!iG48}BB_ǘZ:r}=gpX_Q׼k{o|d.63rݖq냵\o‰͛•-MO.{:/+aA6ߋ"}e'E[֠(vDW1ϊhRL=T!MS/{ZmNǦ'pj1cMPvVnO&9 ®<:ks28x޺l ;nm0/yAٶ\_;Yس`Do묺1ƫ/~)O]a )/nLO&'u,Ex!o:b ]WxOɄ~KPJQ 9Ј*ɗ}48׵E%|iԑNb}oc@0z5Y1//,Ao{k9h΍82cDބݠ4QQ~/&=g̠s-Dx 6(hlr6m5Jnrc>Fd6ח%!`d_ɛ߀p%V&5`\@&" !>Zd# ,'oHR4Mv5>#,/1N2LupyV}<{%uhwu3ɂ|yI{-HU1i E[,>Ro2-)ڊw v]1w P K$G'U'i!dT4o}M??]TEƼHo[9vHmpڧn:[`~'}кcNy"}e5z4/3>ȏ\0nxD7|{3D̘m ѧ6z~`g{o>KDLNrʰM~K< G_ Ƞɍ`_^쨧:[;@ B0Iz*ݒU[< t¥ }ceP:5U]QhrO@܃ tӳKGVVŸK 8aE!9r^U?o+y'9;N7*g’U` c00|!dH/O"QЁ( E 08 @)jA0I~yu{8չ aAE4&€$!6 &%$:P J8 Q0e%3iU;!Fze&+W:2Azڪ>/t((`xTD+9"GB4HMF> #6ɼ!/>B) /-&1t=/Mjhq|B#mY_F XK}ebbѷOfcʫm3+4O h:M՗:a5c&ߌz 1f2)s""ik\>0?vtԫo}H9;_Ȥ3/ #:׵!OW!>>T`>zz9h9<}+:-J@@g$AF:LglAnCan)cryW\Ů7 % [ǀpvM7;go,o-}n$" G& .2, IVZ}Agh *5Q&AZ"rDD@q`O:ڔ-2-[C8$j_v¡ڽ,]'K/=wDҽ3Xj61L6>Y&dM֮.K0@s9pAŻx~yqwFdTLe`֛(KmNnDTL4αON Hh:GRz+O'^! S"介`oF~thiG[dȵ1 |<@h @W"0[2|lW 7 y"+].qi72HT=RӮGsq@8I"Κg!idn/2L 065́2D/g N2ʄi&T4EZ.]s>! Z&O9PJ5L^Sֲ(zSYi!  ܥu 6MB`H;*;P 1Ԁz7oZ}֮*lh=BBmP|C/yCx 7i?;)<-l@0N&,pYζa;*j}/ hSs9hs"Ch B@E{"iG'&lUؑBAVU_W-=>a?+}&E},U'ӈKT$r$n{SsPRth[;@p!s<"Nac™~۫&TA`aԱS\C8x)c9 >C{n<2u~5AynSoKt艨:ć}h}򒆷XrX \=V!gL'KT^!x{3G|ğ<308`7[ {^]lҌ 5R F^@aLjH]!x=Jsݠz{g8`Q)o,kp9ThSEq= E_ Ḿ,BTD_5t ]ky)ND[H^q/|nm,ޙћYPy3k2-{y `8޿ 0+BN?éiI!%@aޞ-ROh$_y!]J"U>8j ݼp6QD`a2`oӴU5" pM4U[HuC'=|O>?^J'GN'|P?gǡ8s/{Wf%t^ګ6r#LQK9 QšM$Nh '"<x61Ttʿrtݚ́@s{8@*d_s_{2 ́3@DtȌ)B|:D{ bJv?%b'JK`ڿŘTmj` xSWð7λO+%Ro`4u vx2嬑y<S?ȓ/0PH^+_/8"é nSNZJY| _ H}S,?fmkԀP+\'o^DC+?П7*K} 'EO#NG0ϥNU?kz06.#z`ui=k͇Y Z <+/)}A3]@s9 (A9af IDAT/; @EREJ(0hp($<|2" ;p𘀒7KbG訟Pjd+;uEx7퍔^H媷DBN~<?&mnUOa=`!i^y>.zx~.3ps*k:"~Дo Zxz_m@Y :P?!=S|sR_1L0fkdG; "<ꖀg}l&3'2G+` Y,1rВ%{,W hs 枝`rb>D ! /ƽ8Okz1^ 8?cӟ^ Gu2')4ht vE%ɂ\A b4;i>c?X][28,8ˤqllsBXhɧtݻƳnsX&<ڿw_Ɲ{\H華 $zJ3sKIU'<}&5(;A3g@Hw9Gp_.}(4oh.YH8pR %)!YLz0Nc_a??'`q~t{``!-w1 J&Ʋqʚ%_#(K40X=)UIKV0duѡ4> i)Kegf՘yGzi}j1|oᣦúr!¾8PJ'I/x#a?f9])_x96Zc%>RV,)bKhOh.'ZQNnQ\wMUs[#'!mAW24ğ&} >N.@:{( < s_d3CʹOā ߌ{A,|Wo~N<!<)8w މ[zu``d0hZs}ncs8`^/5" S;OtTz?sd8b2;ܧ8)Pq[\dѥ4ft˃(f?)յtmxN>cPDi]DG(w:o]X+=e7\]ǎl(55t)mߵioWYHɃߑc\V(NVZL9O޵\>J/iZlWOr_77Ea]@կگ͠SsyM NDto5@dO}Ss: j&AA@D 8/O2!/;"KօӁ1c8I&2sy3.xyuSVU GmvؓhD$H#A x^zy\JX0l}04֕^ő߼P9$ۿ_cS+ G___Byȸ^(aO,o}]/'dJ>WGi-z?_?́@s9 $( ,u R@i;W(ʯ"G˿٪+b @O9lJ!y!|rNeq@!%f%^(SPPփE򵩙a3E}Y?3?k, w$i 1 "c*[m/2EiN_ 0xo~ ,N1TsF Dt}&[IƁ! c=@Hdqr C k򠽔}SqM`(4[B]d,yWfeK\7|e7tN@@!0J͡N*tuWB@Ws73Z(^v㩒wo:}wGcbXHz2Ɠq-mZ! ]Ss9h4' 9,%(Bհ cA߄%,9+hQw ;פփ0a{/APTW~۰Fg>YP'+ o8j+rx90^ k6@+* Za fE2EtJNdw'<ۋ$t !+5C:`&/u8" a/.mGɟ:9$W7giˇфR=a}k S]k7xN XO#$I|9h476*[bArKj QRs0ʷKy-x4Oݣ^^(`5%QZCYp mR|;sx0HDR&)(LI.@!%㉍< (x$O=x K@ ׁ0 gr˫χd`>BQշ#. 0o~s6 (K9^32 Jf!UR9ƹ}Y*xkP1*+BrضoxyeQUSc PdZk1㮞zk4W*>攦q@G}(:sprw /CB r8X罋ɗ,c~g߮Ih4́ *+>Q){c]+0x Qvu5Sxau @aw[* f)pHȸv{`㡤>`ҡ$7/-КOGMqy0#2V&w2_#4OJ-k#+(32b-6J+=12 Wk;]sA~n4nO(:F!:Cn=={mչ{=8-+E{$-.\q= GE@wRl/EQt<|d%UQ:GS,yNĊcsP3|SyP)TБ짬yp' ߁&-:6\Q;Lj#F㄂kaa8yW}W?>X6 ;#N8ygoD $VB8uPCP9̷y8H{b_Ȁg4E^}raB@(*?[H7>-=< W&+0x#Ņ7iPnx}7T&<Bx[HI'd>CĀ= (xeobG_N@q4@-zȃu)=b;3/mC|9V |/l@+9^9@qz0KkT?s]>C2$2::ehC0E0Pofun}n怱,DZn"K=zmp{TXyXYt)xBȒ8R=qP ad]^ʯɁ"lo_ߜʧQ>ԕbc~Bԏ{BP$J{ JeI#qBJ5xyXܫҋ-J^Δצr3@#֟KR?@2>jmR O|$O'$bma|8|F1Ř>WzJ+9ibLi :588`L5^N}{37s0RFJ:'!hƑ0\1Cyc3wF=k2RB U(Tƙ݇18I:u J [Wb̑aF!2ZNMh'Q1u^\$7^@ƫJ2N5לBx.N'9prUX Ŗ [, c˃aqT…X[Ys->=+w<$r D)`FFܗ( ʵ1 r~@wQ՛,E $s.)%@*9rx ~ !ڬQM6Q(sP2Yh(d@61A!!W}{L}Eɋ<򀘌+dʃ\Xx0@7htdx,|do $_c)k9[zFҰ8k_MYRy()No5>cS$pohq\ߴqyl+?s0kgMso-26|% eK/}*~Wg%JEҺd WƴHr1]X@ː-amWK WGnb鏚V%k[/v{zoYbn:$Kqx0 ̢t/P$JK@J8 ^UtH,p.ʵMwzվ.=^4BJ©7Fyȼwp2 8;6pׄ cM7ߜ) j %`iʏR?t?{7C^ `d{f԰h #WB:{MQ@wLXD, dE]X5dh(=z ˦kk'k+#Q5tMU'Y"pB㚌⏓vl@v$m^S\Ơ] Gx11*@!3/ms{t Ygy0J EAY+Vvvs#:C0ACd2m32hHkg ^CG|̃پB:zH5.g qs3e?iy\֏v|KE}Uc5SI ,gk_Ek>P5P9O[ڧ3] e斬/ި$|h'iblE־q=TvH]+_;4i9!S!2D?96 {/M(TS@X &2" [iP !À"/g&Q@a]ҳ,?4`2d2q ]'>Yޕ7'SءI" ƒU/x0^do`BC>L-Rq˃ D1 ;2-rڟro{>_ @UxB6?41J5@[vv\E314%yP@>=hBAАE5DHSs:9 rDؾ91gEiEK2jXۜ յ칏NA__'s (.ɔ9JkDomD%Ҵ' /ED]tQ2cz ̄ZBBX&>Kdb1ٙ_g)o%LEÀ7hM|rDt(L&] l鐋-OdLE,~w|XH,|)3Pp'D1uF2Q;6{m"silו,H}P`2E|dI?N@rǃS,b1Zյ97PEw7P0Q)ڢ;uj<Dtcmqc fCG1(2<g< g ;KYr8O ;_DzWog AӚfDgQ/F@RM[Bk O9B׿9#PIbB0a7f.]-6 c8s6YC!uOxD1j3.o g:@~Tw|U/dxZfB>^u܊r2@~Ka IDAT_ۦOr Z9aoԺ^ V XWs/"S tdl\r,ϙ߳?˦;V}WU7ߡ:t(=0ͥ@Z}]eծAp<&}(WZ tZ_-^ڽ Tʆ#~m0~Om pH>VJ7NR3J0{i@bĘ .I%0$2vB/{;*N-5|IP``x V3lSZ#DZ! MNW|s[+pl U_/e=үu Wܢ_;2ڲ97Gi:b]NOmq2&Bz dX_!No`캎MCnȿ#`|:~KD^nW6ͦNP~B%siwh3>T*O^ZGahS7`@unH} 0 !j ռ́?u}v+hgUv~=plNEye5ER~@9w x0!.aLŴBF.G[ )3F^R+V$oX1@4py 8znJT6-<%᜼ek4s-!׳ב=}@>r.Z}xe R6$q @.7y0vsAnu@s9h4qohNxWxx)R1^5Rz(\P:Ӗ +D~ >~x>%`F Q To^^GQ&cW%ImvPi$9g'ͷ$ ^m^IC;(%}Q\3ɃzϤS{])tԩGA6y7/^9qW>;šy%`Ìx5 5́pPcԛ%oޛ@̾?@W_|>6Wx[E(v^{!׿G`?~h3^6 ;y惴o^I,y.\Ϻ YmxƋ??s(0# v(GE^'X<<@nJ/_2%F=y)́@sD8@a,R(NOt()E_(kBK,|TQNq: 1JɓGv)xOx9hSڽ/(o{ }F!#YԐ~Dx:%@FS1y*+?'ҳ|@.^8H@ɫ0*@s<ÓCsv^[!zw7ߜVBnG3yc< Q6l `g>19FHN|̓ycuQyL?3} ץQ/ͫkl?]>~ً@ z;|odAjy_wxTXVו<eH> l!Ğ%cޓ/ꫯm(d0 !ehj4&zX1a%Ơ75nd[xۿۿ͠pK:Z(Q'GB^!vc)Ms0OY'B^"`ŇУ(λt(}h1 )9^B@գcF`XpɁ( /|OU);7qu((o$zq3;`>PI"ke,~5n1|D胼LHh|v` ţmWzϜKyl jpʓmNzwȄl'䧦@s 7n(W4{JL8[r>27́@UДCyAPhbzt5 tC9u/j< bHwXy VxeWYcޭoy_j/YgQydxI^\t}BԦS;<|9n+D'cظwv%̳}=)4'|?̯ƶp[eiyqdAb+= Ay Zz9@QY\M˖j/gHٵ9p2.dZ#YQQVuzf]W.hb ma}@K>HQԏ'B94_| ^.K{gV0 }@P)nꥎʷCl{ٴI:ꭝc~P/J}7S%a @DM% Xus *ƁV`JOX2ldq9uu޻3;[@'2s|:ʷٻִ^u0/+ߡ.p,빾|XgQ|>Mw' Y,=ĢwXXd\kS!pUynaTݐ;v)kg)@$k&\e QG@!^&?mA8ho4*YtA(,B.J<YױÀZXgo PPvЫBbuV<2(Q?/}!|e׿xdSHxLC+yJ&R4VyOȆ= } 1P}?9@]#9($|8 a=n|ɳFsuƜ,6JGM//bXԁJ1!cǚ~-9˒<0&4Q᡼*Ygz2$;μ5aln4ˁ] A6rY /eRijZMf! vncE\,XC)| I8@WbyD-wVk8'')ה޷~{f[JR".'ɇCYSjUeAvRM,†(/%Lл]>Rhbw 9˜88UGW®( v]=+k9ТU%eܵo W,}?Q(hODʝPkD^+ %~ X"G %50*xdJfՁ|Px;,d <6nq%shFmug %w];d~qA\a`l`BWئ1E6+'͘3W:H"wd8-aAlKf/иkFQ2(c2|^X/]}~ _ g9h4N' -*ؼ ",VCJRx} Eӛo9{DZ|(bVb xfn:{PUBa" ͷu{B|ٜ+ȱb Q~ŅR 3 h\H;yAX]&^QMB(8H /eH]ԁG8ʔGNz,ݼWO_ le,ʤ<8R  $Px c C` #<N^){yd Cb&/M#7)_yx3Fxy`c?cL~[ߚeL!z ِOF%|)xD$D.7IK̉qrlYc̿ysnB2cn/ODwW%;csϜ2G^>UlXJng26_&:Ovc١{Np%XoZN)&pJeÛ tɁ°(p]7L( ʰ K%Vz8)ڔWW 2!p%׏"P$O)H:˳cRYP)&^ʊdMByx0=㺰P^)[ʱ[MwLJ>E'SZ>^8BrMqDXX*i7K C RBD bQ=@鏕F]19" D?kloz-L"8xu f!%t$E D`" K - `yy\x| AXGF @!Nޖsȥ HA&]6S&x24J\@C^) D?NMbItPՇr>? TEGgEۜCa>0x\TLi~4;=_ؗiA蒍cKkdvi)uqq< OM^Mc/ nrg 1G(z2rR[EEqL[g&'km¥A!Ftm1 1[ǪG-Ŝhc8 *!2$ 0YDq0<(p =Oq : ,}'i,EP!M健7?y@Օ5XHpA;?Kc IDAT1@hSxx0+/(Bz-w7IDȃR" }qr7\>x_^\ ,o3Cb<VakdG$GIK~( W:?%(y3 ђQ76'U[;Fٝ9ppy,K1Zxe`u=qRXXi3EeE%+VeQ,!1:Y z E)PE؂]DHY#K/PP*Q,Q 1鱒3>L L䬁ʿ#ړ]m ! $}b?Yi#?I+/nŋF9#6Pg*Jߓ)DOIZ<Թ=5 $1gzX),# x?*RG=,ȇrᒇ[(3& 42EUa&ˢ+oM[FLexPߐIRdlBmkMyLh)0گ^Ň,֔yKC7L_?fbTy #]&¢A3rd7PtyCXY)f"iR҇E^oT`>_i/2K,,C+/yKyCUxmz4?w<0{&/e285sI Ezx;a,= BX2w(@<¼LnƙyӜkr`e0ǜ͋z``6Nmk<szWqQRfƿzu:%5 0WMW9l;uUoو2DXrOߑNQQҘq`C[]$ubdg/[b>L[sUWkYc5uSҹ|+9yx`cg<#B=ehݗc6mp$l)#i|Ks5}~; 28T7Y(*>y-@7!Y E؂b219j^(&HVV YЂd2m ـ^bWxX _$Y%:g61 3Ii05dM6P X37It?=gQ?M{LxwoaGxFl7,a&r,^B'dH]:!  JE_y1YAJ>gr7ʸddAf` س91aJ~g}GC&~ av+xɕ\MI,|ɿ/|,el+#dZ-0xrHʪ,aL CEy0,=j C!xxAQ"9>[syKkE1`0c=m[l}k[BQTjd{8X}m<I+_24[_7o{*#;!c`gADT5_Z=e$xe1r/YlKD }gkϩ#%kU I:W:``;3ĹOXŕ[3:]Ytl r}jiX>?岲zp^}Y=K Xea58LWh@|ƙ)KMʉOȄOj2YB EM|<zk%/\!H@5iYG7. (reߢgĎ6Ebc5ǻnݠ<6&1C7׾yE7هC^IdQs¸EZfܤd55$(DGmFWQ2!/j li\71_L&%3m0Xb( +a<iMd1kd<0-J:"zFN,&E cf TW%/HG>a?FOf՛lWpY2[D"k dyx,$K޼3rmd4k懵\b} 5]B@9sȠ5jmAY _җfej0v\r눶Y(tƺ&zF# cӧst3k>3t `lS"P@:i+PG1t$!벼 s2@h]3>2_ "Ҋ>U C$gFWsC2`^zN\/Ywz'89`y@=3Y #oJ-@BIDn25XL`&LU.9h\94sEB 2\Qݧk->!dRј5@3iGSu tPv |Vzj'U$,P'!LBjR(6`)啭ߢ S@ԇ|9⁓g'x!HkxAh_eɏ-K &s>cE L\,B,;EU>]V6́@ssjC3Lf` ڋF| "ZA `A$"W]MYyj]SکO eO%4<1ˏLu'T_ o~$eԉ́@P¶~( o]$ʔ6ƛF E,͋g}7˶DMfrJ@PG` csyf1Cqw1^l y*r}ikFFI~wy_!!(&I9o!<q xrN +v ,.j`L"Y?{vOBlRRJm'mp:=$r]Yx]ϔ~} iH`nut /W'oa:Y-6s{ x*<xY*^KW^R6́@s9pn$yqo\ {OowP΍X}╠GcQ=Cٴ;2z.)Q W6C3))OdHpt fm%D93̬  KF-^3>k.{Wf>y v $S?:*@S[JͰL@S' YZ-S 8if#s18/y,% ^0l^>g E5SeZ}sl@ǂcwYF7_,JB ZC&6K4/'=Ds9hq(5-!J儕Rƫ»pndm6%OXh6C819@@Ll'P峋g-_,\ dv@!4km\/íYD|F2nEkdNJFD~?~gH^ewz<(}'PD泵9M/YKewr,qI:و:I^g?>7́8@A>Ds(w=zbR"Ƽv,V("Ǯ iJQ'.O4N|v<3}0Skוo-@*ûJ}ca*>cݪ8|Ye]:7 Pq u GK!0։C=Nh4+r tɾ9~X{seɂ/@yR0LʛQNꔷXí< y-%^y G8}0hWxּ^ʪuNbN>x<ʯ q@ڦ D66?́Kp,%UgԀB#atj4J" I>87D;ws8pТt&VG;\3Īlmbo^1B]Ý@sh@ľ r(>]XCk\?lIp꠰2krާ7e+28rrʫvk=p*+fT')p_~%RwG}B_i70/{wSK}$ IDAT:;}X ><7 tOݝB tV@o89pK@bO`>yM$1Fw?Voׁ: 'N~ḾʁEefΓf|>מ`F]3׏QVx j ?0Ty.ٔDK8^;+e:Q|'\uzPCP#zΩJuNCٰH+ׂnRC2-U&DQ0Aִc9@\'ފJ|ICɇ_ȶpyZ]@=C}y+7rH/OIGWο뿶Ry8ݘw8Y1P.zzSq"uZ| \7%( qb$ŷVb>9^Q-Z(,j,BaI[t{ Go}I(dL]~d Qh=Ga˗+}MH:P2d݋hQf i(ǙC5 40 g (dͷɨ)喜JﰢW%>81o)yFd̯>.<;k1|ah!Ȅ>%'sA>Y޾/7Y!!o|Q\<LuH6Ձ,S"^'i\㖑ʼnַ^n|zQ1NV7n27pj[P%˳̹ޮGo{[ 4e 缒!c1*18%"!~W^qH3G^csE'3~+_ic^TɠɁF-p9FK9؅6 ^ !Au؛a/](YYYV=sWX-Z$yq,ZIJR pY`4-(ʄx4),f57MM8F e(6k+O& `0XD{G:s 2Vv쬭;)RdPţ5e^uoMݖ'ڮ7)C YLg8U;F>y {`S+Qy ڳqP V>O0M)ـXsǃiŀb Ztѡš*Q g s7Y8( W eepPg)+y+]<#ۼ0`km,~QJ^s%8`UeHrwoUͯd!J"JKxQW2/lwG9{Ɵ:1p&aP?u46ϾoWLS'l/[luQ s_ȿ1c{,bgSJoU(R&`*.d y TC{]Ahomgo&ƳW77/(@APGmW'3)}H=)(*٤>vG ~X3X'xvL>WJV(‘1aSvd&v IE9J,'*ڻŀ#TU=(ފfc/(QSԧʯ{6 @2.734m?5yYDtr˰د2K_j(Fɯ{sڡÀa B{wבAéP*/FS@1au+ץﺃj\O4Kc\fL5gd7ufM}Wƌc 5XGX'996ѝw]}g7+EqhЗIxOEUG*2Ǻ rQy 17Yp__o!4(%QǸ(G qOX"uQC6or yQnN!QÚN,’v%8pXtO,ڽB>7~~AMDš1#5I0V<PU!ҒOy M6,lQ U zM<*@>KO&Q{%"xd|ֺI``Da3YN%̾shW oBF'<3 %ed{!sx0  DF6ǵp2&NVzR,@}٢`a q͜oNwk4me\(yL[sxY[xg۞M>qrr#G:uQx0vcݵ _sf$61FoE֑9ں1]:*Ph3f06 0S^Б.$DG3.Pwk+A p@Y}7e]ɂ$zzzKkRB;k2[X]EaOx20A9te9,T= %2iOY!x 샥Rzl:H/&A)"ș<y> #(Js@w}oËE(׽f| lc80&q^j,>CMScx9B%7j޵X0q: roy frq +=48\!V8 dOV(%${rY CVa:%*x,"cݘ0[c5n%i| cݤ~XD,E8v]H! !j$ΑS}#$RnxޘȞ%9tD ҷ b3~H-]g8#F=GBҍkWw{|݈>7>:m>ECi{ǏM6 S P׾bN]tziyG 5 .wdc`N!jI |Sz)_ %`xN(,İj}W F17HA'[%% X-”wQf)\ `mNMeJ=*JѦTȃB.D cM:5Y,͎W&ᥔ |)S~~˛=hE^»+8/YϢ֏){gi̸8kx@yȎk !dgH޼,&~kGk` eNo$6jh,˗QCX;Fc7v-Źk8`3ߛYx}:2N1sU@r \50;1j^mFV$y岁mxbc_djC:~(6u\dq(& -0@@dmUR):r@Cd Pcbp /!^.S)<#*bJe cyVXNpwZq2L6uer^Tԟ.51Wtȱ7i3HUԽz I߻々?%4K:< (J"ϕLΑ!F`8D<<09`U&Q '>B 56%Ȫtd'V&n  go<  1vɯgؠ;Zm_ &;{<78//:1)zb3t#ͩ9:y#J$?iݢH+ww*K=}i}ڔRU=ԕнS~W!Mk#o}M)C^x^@kTz4DZ|Ϗ N @=?"ItOe`iL:$ȼ$l%Uxؒg1%/DY877 evQjGƁ6 K)#ZAG1\(2)>̒H`ƿwO9"WEȿ0˹CԪS2ePǚFY -<&@WYmG}) 9m'[&ee-2Ox荝ۓBݩXhk94lz~84"?]*%a亵BJͳ#0QA> t~Ew"4 t)@X0kl nN z#kRI'}_)A}\GٞS yXs.9̴;:^3Z8+d2[%{靽t5~"  CiSS ݞImgdsKh&2.s15mdfDxlRȧ{-zf G ={}u/MoK{ltL$'d#ɫγEH|k~WA;,/oV C[|hnsis3oUU$ώpU>눌L ϦD,5^<߫2iQ_/ƍm3^gM@%`%6Q}nX&DtX7o7}k g(y;@.3;h ٷMv¢kW!qֻ5Efr4P)-"I4GeR^,@"MwQ+[m<Ȫ"lX @?R'nw}5`2ں o|&[~_5`[ـKz`$/K1[(2M2S+N* .eM0ȵoːi1pep`pJqbb4Q&%X,>9J5~4(9@[:<(+<*u94B96RJ31`W[s@$D`Py#ʳBf7g@@{w϶E`1QԛgEy(Zm +WQ(:#@PÛ4LbGyDx |G1G@2WWrK}m5B?5i^ x16HdF<[xSO5WiX̠ |) x5B K&zcepp"LɰX$Y,*&NIv+9@qp0D1S|yS)@P@ 3@ EȤX;x(gӖ'\* 9 (pgPy "Hyjߞyfޭ)5PLCbtH3Ge?@;^ =oD5 @bдA}ZPx>kBA(/ﶉXPjxyChe tb5zS9Ҝ=d[zT%t-|@@zKgc6vŀ,clXy3bQ|V=rp_GsDnl s"Y(əP98/䱂{<5Nyy=Sxg UѢf1V׭3   \q;y#ڏ!ʸ}}(nJ}c\E8hU`F 4 lzh&Cю!Dxb GOHVK hkʴmɺB+ݸ?T Гz:w) /lK`Px%#(TqO1+g ph7`Q|̩ M `[^#[r  y{nMxj7@ GmB8*SItr j+O,@%*b<^=!ecO Y}wce>ڍ"N,<2<=^oeui`~)@(1D>/Ue݋/ck.e6@eQ9AٽH8AU'mW:;H  Nd@E<ᝮ-BJ!lBG5-e;/t!a Ƀ}d+_xhCFBpM8PC9>޹Zoy7@pHrBxʫ @n p0W].=KJ@!p{:߳zbx31TO{&Tt^2C6xe56 xM'i}ν<0Q\~ iB*Rߦn)[EF*^Cnߪ:d 1L d I$CSo䗺Sx$118080808p>[Խ؂CŞbTDVi.*߱S Uu( q @\:a*%I"uHXM ^.{({bV՜iBQ*$}%4:e4{) pQ+N|8Q D9u6xx8SG^cK{of]#NA*0 <)G NWYp7>#/j4HVp@]: V}%^"a4~W70Mrj'y!!^s[aCڭk C{J=;r?dCnܸ@<7^rZeKz2ie b Q>ҟ2Bc,/;&߼;}+s"oۛ3"iޓ\LD(e9@1]*K&$\W|Wȥz 9_)/(gX ׎+-%IYs)GZh-qOѠ4[ME ꜞzPnd,$;Q^eC 9Q`! Pՙ IO zhl_yE_#mWtw=({H\~cE2+@j_٫Y5: uV_yN\n"gWO:y'(Q2WȔz'Wy@Wv|]2AfEɷd%~7%,#>3yx_[%K1<[§}*r]QBNZE>|E+23*'?Ib;8pxi‚xX>ukF,V>`]|ɂgo?ެk<3 nBB (Q* 8;!c@ *Ar+諸9A;QxQwMyޫr&)K<$(5=8p8@QB+E '/{R[G[P7B6v48p  ޜl)Z0#¹i_@mB 69+&>%{?l)oB߀GH1=@B6 c4O(3i Q6 ={XY@tBUGF>P+xIy)1G:z!'L}rC(cU#dPe68W7]ˁk -REx:L3%˄F|nۆJ6]W[G \8٧ JVL6; $ V|a{ ت 'o;N Ur; jAOl/%y"P pI 9&򕯴\(|@/LyxF{s8C&;8BGQvj+ gRN)BE _=` 0LW9F#Ph JvjтB OE^Af]/4,6si^yxUy+gܿ\п>dR{/5d:qRdM^sFx 5Gd?˷EO]V<\yNu,-t~+ӳu*'mӎ`%s!C>W]sǻFieg:ށ5@K2 '9酼 zg.4u0y/&{!-vqQ79߱Dɓ/y#d5't)WeS(̑q(̔:\2AJt%KAʲ1(vfg1o̒mNƯ2Wg3ey:XYd0Hrށe<@Uh%Hqr#gǀqu_O3Q"^Ԭ~ &kޝ'/8{>OA>~m\(Ut5ϠrxBoۀ+iQ_im8}ɘ\3U^[ϫπk?W{śtTg"x[HoE % KYYoO̺Nq΄yY-X< SIiu!KcB_A/c)DXU-zQW̳R4ԋ^GY[d-™>Q)Y\X\YS/5(TP1/QpkYd% Z)-D6)E_ʢ BxgVGL#3ƅTQH)}- yyʳBOWސcuc7/h G*H{ |=y6u*S[Ch8 w#eqMO!2Kɗ1;d! :1's:C5"PZcN4F%2㉗f!]DA]q=r;~h;2tᏏuw%^SLIfW>7~   \  ZY)@X<-",^{P&-,o wt콰yEQ 'Ŵ.{̞C 4phѳЪŚiHR].@o~{PxW% +ӢmoZ),K  UOq ?#God8ɭ-#_d>FNuWk~~5 r !W!guyqq@!eEFY?oe͢#tM YL->7scԑk=1ZZC#[&gMgD Fۂo@7yƘAÁW+/^S@-S4k&&ED *EբgLSx.hJk.)J7uֻ RJ)QʪpY mNae<Bݬ@HJ;XԲC՚ TN,U;dlwk"?B%~|m ɏWh2>(8DY)_}{by(2vs>PFAvݸ7#*fY瑷Ocf΅ռ@\jVpf}a<ū$ktƓGY{j~NdZԗ%] 5ƌyZ[=W޶:G'd 4Gd ,b|bȴüc 7QmeȉubSvIxzu6CǷmuS/sR.dĽ%Eه<YCbͤ&{~Sj E:,lg. Mt7Ϣ03W͹RBʷ*/w)ʭm| P6%krM)!͵ߗR(=*B/)x=#ͧ>&wnHK)dD`^98 ɴwaXb\Ƨ7_[ǩ!;OE ޽>@8` u{[Z6kDak뢿x"oucX6&f oX׬EcQ"jrhE|éBal3$ؚr\"WV'=ieqUI/K:VP C4,zg=+ojKC1 RDV-)s]:%i`Wͣ^Ol-`Xت7{/JޗH ^Y_1iz׻ZXbE쇭Bd~-_j x8BvQdu8pˤׇ1:8^ihL6"{#b2O.(ƮT(  `:ss{:%'EyuQt)\c\.#pŖrh%MI0[oM%a*ƠA'x"g@ET K-2&lpx ϛ=Dț5$c'Qzjo8OSS,Yk;oKfõo, FFQ1J0'b2'P#vNa<Ƅ(BFY[ٙV?]_!IM,EN^ʡSI)(ȟ2i?i/uHSr)Bxz9Є9%UNMxr(p Jy2[ӗ'Vy>rh2hejɯo x}k;8 9\۟j_b4qkA!EZx9YS_nӌ;d0ؐAc|Pp" IDATҪ*u4.bRM 1L<6P(oum3P%Rok=x>IoweL\?[[[޾5*cw?:yʨwfNE ^lݨD=#mԝCZX,"((LK(&R`CF֡9pS,KZ?B+:)&[8oOJ+(RY|MfݵRh)INx<Ÿra8@A~B@M^Y$|Xy =Vy C ),$ɇ7ʄ)?~cG"yzzoFƫI6|gqPz#O}~d9c>c<86fKs?YƶqdeZ^ɛ>rr@(O\M#%8R@ͭ( RzgC`χ *kUyLcósIg̤~Ƶr ،)ϮV /Śƈ:ȀZ}u9`ZZm]by{Y'?W͡lyd> ͻgJdA"*\g VZ;׏ Z48N r蟒0,¬~ʝB(=mXNY4 c3,ʀKH|{?sP-$(TXUu* ʱhRTY=κJ @RhYT_^G/1 بjP#Uc4,HY(]P,WQA |쁍B(495`gR繓΄&˘ƘgM@ 3vJ1٫YVOD+)¨דqg#m&zΕ2@^ڬ7힛'+ú)7}O0+xi`g^2&oG? Yռ.,D_Xʕ7 #0y[C՛'7䫏z=8@[;!Cgu?ݓy^o.{Q_uU&r%uП/qD7YI>Uɗ{G ,aJ@գ>ژiC>ϵp_[k%wA@=@pI @'O .:7@a%LMhlk6x/ hRcI!| g*!{キO_2r8kMXM ̐A4px"O&8J:鷌d΢JxɺI9Eeg'FN'ԍymZ upM%<'j+/7'mk.&Z/S3f2Ř480808pY800#!:`N#0|mRJA6ƞ[Sw{`Vqc|HO1FDh+NA/Bc|I'DR'Z8N}ZtT#XCl0(|BNft< E:`M"&Pxm@'sk {.nSj ~7&B=w}]rlkCMR&i4БJ-<'o +U)z#ja&+ϚC!zu#l1t‘[u./yxnse^Z(FmTf5쨗4@ahv|  \(@/e3j|i#OϣO7:I}SC8`:QB KuBUb=K`}BYҹn lK[Q3//zy=ed賎L:YQ>}(!K2s?绿W}+pΓR9` +$̓ɀ@q~@5l '(,/, :/ <@S)⽰=A6% 9 ;帧Vidc0}SO5пJOSoy27oY.{ wݷ:<9C_V飠}Ʃߺ}|ن=/(O> c,2R0Pȳm4{y'GpPC=HP}SbwLB*+9yQsk(GVWW?a;dN?;;{㔲|ByQx6}D˕V<ꤹ䡝r^w;N A GqUy&})>˰f_}@2*s|ּ~#IR6O'ԗ\3VY"4smHaz2/ěrk/+QqgI٣[ J}ZHoBt{!LT>6<=E%I>s $N! )8yؓ~M}]~PPm?2Sf/g~LDg-IyGd2}T;ȲWV}^;yЧǬx{k/lC=G9{E>(J]=*՛V}Y2(\ C@g ?|䱔oO'H:%mS'TJmO@EySy,yۻj7R/iU+Sz;ZoҧE=/DW<`1r>Gx!m/|^G_ݔ#_/>ܴBN/%!2G*M6ԑ+#Wd,w}ͰlcU4@!=E A48pQ0M҃.ܱȲ}x)yad,0W+Y{X)Aw@Ś2K)@lRyHI$׹u29>P+Бa%1kZ"9BJ6Y]((@rku_{( "ƞMնG7S!ISgCx.o'^ >cs ዾ!? ǟW\it?H]N#R}CMyo7_GNelH]}p})oz'd &N&OMr{y9@,n/L\Aˁ~0Gd+17wW3ixR̙QzjR0-Xd)#xc'Pc2TR2 5 /ϢE)%2^!DI`{ӓg㝬yu9[:J+3u]Jx֑zϵssXs7'ihW$hYmm-+U ԅnU7DpњН#2&vԶrn\j{)\X(<ǹX;*W+ 119,r61*܃Fab'~ 㷲<|Oi^1g=YRd.^.nOVvLqr5.xVdrs``nw^{sڛ*|asB/q=ߋaj'CJSR^kT7Qr8*F9YXMB ݷӹW|4ɂf9O4qqsϵFdb)P,(Vw(^<3 ~t7>2w|lsWZH_ :3vV (8`FY,@~yz;&T tm^^iٟb/zDDž wlɃ}dNTgX{vx=k)m!"Sﷃxc )E7Z-ᗺ& P@ڛ(B d\8Π(4gbbb-qȼ*ǞʼpO.uԠ°[=_zF(si\R:֐3yX˜.BMQbgB%q˜AKrHL9sϯ&oƇ:{^Uzzu}z;,=߀{e;g4SUvLi u"YP:\B>կ6 4 p!nNNc"?syԒyQ9|@AOVb  Lj[>@#w:[?5^!`N&zK- &K•x}moa-Ks9ܘ'KוМ{c(Gb2rKXXdDcaXZ+)*SEBƚ4!ZYt-죈`Kpi[zEj1e'>sB^(C(K ݱ0 P7׼ b(0Fabg(@c0>i,'&hކ*g,(l'g3wP`܁g*?m0!%̧9Cb IDATo7whK%})ߞSy#vJ;r|y07.ȳH -*\;s>V+F^<|ɆgUXe Gk'g\^; dGJ-r["/^Ook^Ʈv:ž7ɩCu7C !J\v=l2f_'X9Lh::PH1b UiQQ,Y0*iY Y[,B~@,Д λF2zpqkbЄw |{۔bG9a-[)BwSULN.eQ ,ވb:E"n9xy.+עe)g?,>e <(W= /B%B͚z:Ѱ5J_" aL&hjJ p,eQb<n*qrqy( ,~rIR ӟp1d@J\(*?-eT(PfJ`<o~ՉK^թ[P{c@P =O1gĦtcR^m_&O}tƩX󀮹'%Y{!.,i:xB*g[o5LuD?)oP/@V̻ҙB;U&*s7sȟ}.0$B$ȵqİ@*w.Pjj\{^OF(_9Ɣ=yW?)2d0xKsꏔ?vρ,ϗ#lqx$(NX,R@F'3LڰIPZhY~-쬩syŠ(bwIPS\)AViP{P(H]-<;66#uɢUJ]8zxaiȃF'BHxC2gJ"`y`kșkXa ?o{x&OQG㑷MUz^ )u @1x=.:BxUd0䣌x}zfވ 5w(Njb/ )W2\c^1I_#o)G/ Nn3@(pdXeO^Js}td!/>&< 0OV\P`15_u{^y_jdޚI$Pꗼ֥}Иax#|ఛ=I?.ևM֥ZDuwב"cN8dFU{]]By8}VyDʉhO( bPe!x,{0(wx@-B(= S(ʕAo?EĀ7

hEɤC^2eWQ;oU[\oyC| {1+3~< PC:wju/缽=@c9xArY;.x뭹A㠰ZKz&_4 j^΍.H`͹^́{z09Jb/w2;$@1D.d W@=o$Y>uƍJ:nt,,Y$e=ͫnA69xL3ϴކ2UJDҲTCm2T|Sk f/A9۩oC6@ov~j,)H^QPXw+ϸu\ y?S CR< KNEd <]pm^~m Sj`BJy?`g%گz¥xP[*ԅ"'K^ s}/ٷ2]TIa)xC>^}R2R }ƕ:sÏJ !&ND\ctḿ"OEiYlQ,JUI r_>@SYT p/+AAj<& VdS gF>f8`~yW>Hg#7mPGKa`4Uu.ҹ[XjXH9#Pj}VoZN9̕2A Nv̙ύ7jgI'xI{d>om<*|aqUs!9OXԺcΦ%Ph jᵵĶd|#ET҇ўG;~s)yoxg ΓN.̯亹|P>kN"GɣXk̇)sorbQ.K5@b 5:#5l_FF7z6HTVBC{Y_fշ,kGs Tk10'ZQ߇͞}-6}l029x`v'"Ps3/2Z*WyC~!Ygpb4J'@_wNzINѺ/U=#>#2u>BT1o{eIܒ[c\+C9?U726&DSY,[`g pr\)D7ET9!IVRMSJVYҪg+qsk SDXd_0!:Ia _"r@+%nUypuDead|"`2L %dZhLJh3ZL`1>k'5F>Md"Ɗ|o DjEBƇ>0]eh:N:E?Lx2MsqefOʥ6d1ǐyc~d1'sjN:90^aoަԺHq2ͻZs: \c`|:!WȘȺE/chض@Fό9@]ykos5|-6kgk>mvF%R7婇zD2n}M:|omRHT3xykZ  rV nrh(|ڣN}k^h}BX@%QOi<nO:r0c띵ܚJ]{xOu>{if#Gd(P~vlxL! ԛkƇ#h~-{}Ƭ:lK@ =}䶋Ge3H 3ic:'1է^AX9 a<8 @ʳ>UBIh{w%kQSD?CD@},.OلDCPP6E%*-bbO(j(_tt{NO|KխWuuoǘ£Cŵ)#9yH勀#ųվ=g>ڿgcTr.혤ɳŋD0bЧ&"?ԇ~FמQп (aF0c\ڢC{""7o7GQÊq0Yfʄ"$\m!u3V ÛمThX;Ca:lB^x>V^]fe&!5Qm(#[[ENLvGo<-ȑ00`7_ ךT$~ۄ11[T3-P;$8Wo2yϛh_+ ѓ~o=(2b;Tμ\z{e&Q>1Dyg/#-$`<~ĥo2 TFϐ1&?7}.-ywտIOlu$nAe5O[#^D6De^D{NІ` +ePWl9&) G4ZpD|I<,>,?nWM-tVmG~qi贄DOll?q߷22Nkg>m_ta8߮ gw'CʾbycB!Ϩ{[Q #qHa(1[pESFI8yNsևf,3ݫз3ib07rH$vl q u=}idM_Bg8(=|^-oeECPr@jbeD kHuc4=-~F|BabAS]eF9/^ԉઍD"_ԍoun`W|[VAwt:"џ&l!1&mRXȓNZ>]1٢D[)>WyW$!O]C_ȬɄgu[ӠyOGBG?Uk=}J",_Au B~$%4ia-nމCc1^z5<v@5a\umde6̤BJO Ɯ& L%r̄irD 0xg1<$GRvhCc](Y&‘&!|hƲ5 /Dš4}{_LZ%M^GKPqȀgcZX/F_=ΈEuHIW1ob#I;N7ĈA^aDwmsLs^ogKi\rz˸k$$7,xxAC eVxB$Q6GZȕrJ+,ea +C-qȾ:A6+vhiurɓ~3B%3$\'Ȫx ;~0 ]:]m؆z6\Ц5dž]}Mog嵜fJR1vOJ",ofw<7ٴ'Ans3S3(m#2{lٍ=$l^<kժU%'EwDwӚ4Ǝ>g #}39qN9-K#OE[)<եm6jc6R+ "$DҠ#hֈh{zv+/~)ߤMy - hB}+kpaEJVs.H3ܕ׺a7E>TIZO<4#5gS6|_^?D`LGExOh!cy 2mzHLc笅b23ǘg3|FsdD(AH#dֻV:R|w `#=RhkYEF @hIF{Duȋzy!3{i39\BV, C\9Cx d!T"o]xԑTrI' AVmEMyk}#_*ҫnHV.uB2iAO8n=XA{FXnqBΕnzMGσ-QnuC$T=k_< jrN?KuL lyJ4& )vY~Te:@"$b"p `1SfF[=͜һB;BxCa]c##C#cMy!QF7i}$OR?a$2"Ċ̷uߌyޣ= IeΌwoeBVpK= †#3 xkNʏlH+vaBd^t@y'yB`] NJ6^iupMCWvHd(vb l҃R,tEOG,%R}ҖttWu Ⱥ6B/m>D^GT(뤧đ4jNPr\{pmKGK7i_]u}!ή|oSA^?HD 0b3FN0"y|k{ׇA<3#-e}j}1Jʃ$}g 3֮E! pQ>]' zi׺jGva oX{Ǖ+p& $R!5m/%kC,DYD]\//Ȓ~ބ.!TpQ&M^8_!0|K01eO #z'BX_쮱J5;Lh/ Rdi|G<7|XrP$sE.KD Xp X/()Dh5 ߾B$//*RdM(a A-6fqc l.ȯ>!<&G<ɱb>i lٹqh+d-dli#Ι pe[rG9/j 1E酼p ]fЇDY$i}a;sϻʬD&˃(4mEor[eMSr2LBڵPj(,0N ~W,9.d mRG 1FLJ"00}HI. "efm둠O?lsϓ0=IZ|>,ZtD/M)_Mvה.礓Njo^oGA[۫#4[zo&-m.~GyB-atv*o#8 6v.+$׵굽uvt?2o[ۢ^]dACxz? 2yKB1!fr裏nVv7R1=K tFD`ZÈ`O0>m, C<74@^җ6|;..A7v티I)v#y]ᝡYQD EȔII_/> F^:; OC`}/{iH :ꨲʕ+K~1{QIh>)@"pw7&oRQ 02Oa x1< 2D`>D[92p>&%Vxxcc`{nS[j/sA`3Z'21꾹{ekg׵y,HHHN>f5/ r^o4+zsv0LIklF7udeUoc `ȳdÄe욹J6)'-̅@D]@:Х-t Q>yc9m'׷9 x;ڡКDL^~f%{BIxD}}n{C7M 0l-ND`)vb0DX|Nݬ00TF Cf 8!U]ۨtq"`N^"9{z`\al`{ 5l! x݂Z(J7)YExחTyޑ iַB8!s}s*^Q!"_=&ayL+(k|+_Y6lS#"vȪ#=ʫx^Y}RiI!mr'V\yp]t l6sZG;%HD@bЌ$%XL6cxR8ҵM=)! yQ u;FjxyDKg{-Iygi17EK^ƱxTh?k{}ȑaޡD#m#O^{ |7-v3 w_=}1ИM SBS(YXԨg3&Bl a+wF&k|H AxLF~嵳 F-mo f|#893;KX?nw=$ئ^IʂX Ψ(dgOdϽϫ&N>O,+@Vb~]PH!jf|9xY^G{4]=􂑰RX0} B@.Ҳ9I.#e/{Y!>S[Cfa ~HvNy3v<ċ|5Im_;#&l4 /ICMzgRȺW+ZݳP#:/yԃ π!m[s]"]dЎP;__1&`!pW6|H Ƞ~^sDc-oBo *vN'A\yg s&}L&w޹8QW9~CZ.LkCСVGe:V{v}sפ[scÈվGr>S YF2C*3<H;W42·h_&7›m2E{yzz,BI=أxBO:ⱒ݀W^`SwO> A8\Ľ4mC-,?##0|e@wHb匀Y.bx`̍cVː3g׺D`@FxQHèk9xdx1f 3ֳn Cd N $855DAh#nLA! RD # ^z>]R>flŁ;xh?$s)b$ YQ w<~mn."<;.MksI=&$QB ^([L}Pvx(AڑWUL&MJYDzDj&O_y7Ak\Ihկ~GRfF{\@0q8w偩C5,›̰u efSIG5\xEg<{ .lrf w&cIi֣",HEFy<ӈ .b(MTz=l4"xt5ukǍAƿzBgB,Yy9N2녇#$Q_I`*z͚5e2KZ5fq]) ?Bk"B'0rtYvM & ݅KS$@~UOqM[/]aI+mMXaM+FeH5~0yz>첶M$/EqcY]- vE7[w:lR6NB #ȆɫwܱDxL9g"Iы=“'T97aLi3)dkyXzzYыL(_}PҩhyMr*vciB@hpBFW_],]k)HHuQꢳ0Zӡ)8g V"0 < : ?.0N'ϵ-ՓޑGYA+*C;0HBhxx?b &]EHS#ҼpBN;B-j+7ĬEX!S$3u|;R_>I6#QWȤ{ȓSʃSZb/Z򆤚@,m%}ރCǴ9xmbK 8-# U`Ȏf*Uc6,:nY[̄!a{9Hut)$"` +Ô7q ^6 fo&ʠ]{#?Y^0jbl5 0ă dz^-F6^O`S.Gַ! 'pB"?Ou=%SxaG_#q1!m By=u]qo*Tm;Edž &8$ )/dLF\GGu@G߈[S:YqN{կzNq^ܫ^SnqvWR:1`6VA2ako,N៑BJ5"Fy5Rb L] %:dMYD`R` 2n&ȃQ(\}yg3V^ _R]y棬Xs/ C?zlAah#D v+ƶ5iu?wMgC.Hv]BRĽA8"DB,tI[kcB"6" V_[_J);ᵪG0Ղ谷C0+D^jݡPJ0&Iv^>,$<=]ʛ;ceis,8.ZgWn煲j;&DG^-~m'ҝ(,KƜ=B6+[,,TlƋtuxIvvBPW :yd&F`mCgA})lp*^}kTk1 0ҬZaÚ̐Dʳ{?%rK9BCDHS)L>+}78 Bγo \zu eEv&L1m匴O DXǃww8dRcfq0߳do %Rs[_I~uǖD* giϏS2uD␭#YH$:Ʈm=O#a! alnW3)Rft;5fw0ʼ -&NzfZyo |,tM,!Q~z C-Co 5ݫxw!axnaxGKl4ɳh~xцMum(/SǴMl^:50O [%>ű6M?B(c-MP$ ONQ~÷~DO Ubcqa:i*6hOvlz2jZa$]}Omb]"aT !3)t!~ڍ1uv>5!$K&Π2"}6NQ8@ PQ؎A3v,Cà/[Hvr:#11;j'o>{DD |c zk3x҅Ġкŀmq>bhyۍ{~5kڕ]-_WrY,m2x^H4؁%"eك=2d\LjZ$snHZ@KKqv"_@`wcQ(kL"կW<Q4bM|=TȳED՟2?֓:v"lyɃIZCN:t!Qm}-8#+ktĀCxDz{8^\"ҏz)z<Zig-uۑ^DٺM˱_ 7z J3QWZ @yLt futhˉ}?:J.B6ΰ ?cf>:5b>sXl jy ^זQ-_ ұqpqa.{ި晱s"4vFtXhMq)BFY# HQ0Ğ}v޻C A&>Lv.ثQ^mBb3oȐt!'0Q^ ~zIk+6 o%] A++3|\"92+]q!U>ڇrpݵ)!ju&Mt'DoA] @d1X"҅-]PD*ai:4+}Gg.ljߜQzbWJmqekJvXo~Hq1NRx_*?D*[xm.o1fpbw=d;YԬYtUM+t~IޠgfK:RDVN,%|ƍtgB+D@6Q5( 7c!b|5)M MO1!a ҅ v9!8^6[w㙡ke emBdN0fؔ$R˰ٶQXi| &`alF@>Q3xܛm6Wj# ψp,kA^A(|<3cw,sk LQD +z;Y30a'?YƆ\g82 ں1A*귶ml09hL0QlbX}/v?M5Ya܊I(c4,%HE%#f "Bd"3TΙ-D*R&.Rc?1C7#1.L_ikQܛoyi`ĐGH8>&:ei"P?#ؚk~1<#3i.5C (pI?BsǬ92tǦ@Q#1Iq!c\@=qK  ZX Jdpz85OE`bHa@!a0 f q]ܛӁuDZ]QcZBlKE xR'ڭ~ AA}>0jO>uۏrk_ca",%&(bӍ@]]h߅G`;mD[i-|6F䤗DprքG^7ohZֽ8>o/EL,](51E"r? "bYa^KI`meHZrXĉ52ѤpZAMD HD %֔ۀAffqq ^5.fW.Pk y[oo믿YfM!^]/f=hn8߈>..) IG Gkqѕv>nevзY B^mAgYFԧQqukm(/$U#%dclڥfiKE;_W2-VԿ]7pn(I RD HD XV0~!_1@.xL΋x'23g |n.^DB7>.Ahq ?O>|S*y 2/f]@{^w7R}/;Vy*o6ιo wIw;gOFl/r.eV.w^9~"7XOvmˮ4ۈOf#LxIi7HD H4Ĺ>vz%D3z 'Rr)LEy?Dgo{'u]^sn #By:rν6r=ݤi'fDkBo5BnDtIg|»#N=ԂbyC¹"%@"$@"@ _pB$F(bQ 2[ $d{ ϫ*xɡo{Mt94~B 38x; 1 +K[mU>+qZxF9Bxmy k${K/ݱ[A|kbSG<J?u>PۃA$~l-oiN?u99xݮ8<3BWM_ f[lkD HD HC"@XSX ū[:B}Dpiz DA7 +6&Dyu=œ+ۊ'M&UV>O^x`aȋ($v6!<7˿,!qwxZc0[Zh󞶸.nLHoOLB␊2WR 1H#:D[ne1?RX|ѝϨiᡣ7|)KZ'&|z/7Ht}W %7pC!xpq\Hg?#i(/0^92L7j ΄"u8mZk78*;a`;xe=rx'dN푗.<ڛOub[=ц\U}!tҮ[k]"qژ=z(:Yi3DwpM7-[ۓ;=TK"$@"$C 3,pmw;xb'K!1k{;Ym!yC=|$ IDATgc`u]7ܜuYe VZz! Ȑ ZV^|_.K,Ȏ te9ÛO>:]}pλ?Xh9C/򒶵5i E2!ғ5H!"e$:Xg Ń$pt /e.DZ'>Kvf6I裏n﬿ 4IG=x`su"x#,!F{1E]t;!ڕl[ny\F|Ƶz9] ŵ.Sڷ5\Sm@aꐧ؎mAՙ S8)5z$@"$@"0u\pAZj ze}x0w]}@&Ʉ  txN: u6zkpEFC荼ٰtIzW3Yl6MHgڵeWh7k'$TK"$@"$3 1g_mAFx-A9&tRHgo ;ŨAaKφ*~#3 ~q4>ɻ(/B) dolk늄^V}{?J" ^[1D%H=H&OoW[qS`3 !ȜRfU>Ž m1J=oi:x5l.҅܆w[y=Z˧?.+Iݐ:^cݺJa:k7S?vD HD Hҗ HGxX0'*qvXۅdk??)/1LB iK {_]^vSimtVyҫAj*OװC䈍q1<]ѯ]y#7F>Dz {5P덀*oúAzߤE/zQnF;<=A<~om$@"$@"P<a؃Me&yiD  c0O3l|d^M֘Z(T&=ԗK=ЁT:COW^*}mYoE6ٚIR8 :&@"$"b+(gm0^Q n2;$BjHׯ\r(U r;yN<<~g'A R ~Ǯwi&AJ쨉!Cg#HTl߇ um?Q.Ԛ8 7bA>.B[o6 H*boc;BDջ 5(gUJ[Mk)mae2 E 33ߞЙa').HD H>0Ԑ^q rCQXEFJ7GOK y ~z ׌tˌ:}|Gz~q5$ f:xfˆBjY>-C# "M{Cb#&Ck X:HgvlӐVc'D6JLh«®!6bD.l!ֻz5-]`m}\WA54\SHw"$@"$sDhe:Ǥ:oc`"tzFd )DP]"Ø1k9s;k$rdEZ3I'qKM%CH0'wNμ:za@/(i(=aȂcÈA{ۡʾ{2i爐Ӌ!6XGM`N:uB'EF ϱ[< {m%%D Q{ _X4b]-}x#фiLтM$ǵH*BB38wqų譛T&&lO үMuޥ4_WM/6 %=hO< "n^ Ym6c2< l ϨtkbbT ѨҕN016D HD X0Hݚ7(EXO b(]Z!m#1,nb"&^̼~'9D/Q &"7>d X8c3it&\jU #Ej(1F8j D~ғb#:tcNdA@VMSv]]~>f fi5ΫCՑH A(f% rе aNWԾb:i"m + T .1"6^^;Yp>*xV<%Лnmaڕ6뮅'9vۭLr xl߿>ZÑD HD  ?b.LY2سqcD3>G<Ō_ O ]t XK_R!;]^Nd.‹%$׆13 %A`m$;hCNk.`FN]d.ڕtDuL~ )uҥ7 Q>U{ky1/a{FLH[ZL/HD H<= 5LYx&lpd'o_7kZƠf͚ʫ4[MAxg+],1ky)wWq bl]#K]:&CihC }jOcG}t'F~hü`fvphfZ@"$@"@ <p#`q09.0 ֒Yfl& S^@X (QH-O\{m\k?xjˮyy7#=p@"$@"T0x9B%Y 6۔uTB`#ֿYe_dst>yM"l[{-$;m:96vqlK(%HQ `w%xB E&ZL/HD HLlڵ#pفNg?~??(BGLfcKD HD`tMˆ3W_}XfGf&$Sw"[nOP$) $;HD Hy n&ͣ_js뭷#5HK_RYOf%)F$@"$$#`=Aeꪫ&Y-H|3ݧתcQ0p C$@"$Ӂo;PWve5?яC2H&K_~ysw4X1p?JD HiE,$_zc?%H o}?_MO3W@"D HD '>;\f*7'y{"\>WBG_4yC.׆ND HC1b-V-:LF__J6lXUJOXD HD`!oF󲗽a}Cj JID`L&]{ean5I _ޜ$@"$=0ov~[yQIDyWμ/(k>Ia ߉@"$@"G?^{|{k='?ɈRdD`"Kx6Xx$5;HD H >9ir`/|a)g@"ۚw坄/mqKq#'@"$D@#ȲOl~.K,Љ@"03)|nvq t!$IBy$@"$C~vg=i9眳 `,p"K/hUV5HRP!HD H&3|}٧y޼]jT6JECk_ZکhG4 6NRHw"$@"$c@a=s=~_^H=2D Bz4Kr^ׂ$I%@"$rC@}bڵkc=;YD h!ӟYfM#tn ~W.I o&$@"$@Sy^f7o.袲<0%H'%NSaycB?IlYD HD X`FbŊ栃jǖH;s5D`Ap54ozӛ(pM6Y4.q"$@",75yM!Wn.E ,7쳼$!Gyds7{W }h}AIjK"$@",ix~[mU~_ꫯ^%#/~9ꨣ[ol@e__Y4BH$_?+HD H#nnV n?3lNI?n{<^Cv~'x"$@"$xAzPxO< [r!9SM@3|<|WC}a')LOD HD`0~aJ'ܜvi=!ct",v w͏~+#B~PyB'%@"$@"0FC${<hN?B 9#'> 17Nw 6ukD x'ENJM@"$@",|77N:Ko|k_YzV>pYbNg͗µkזsO!}~ zwyS CND HD`#`Wmԧ6_|o)k:YD`) }97WOz?,Db~J3SX?D HD X,'?ŀtMK.~(/n0s)@"0i=psW6g*nCkcvmW6Ydu3D %/kwy} <ۋ!΄POD HD`ˬ7hxDeB[+_ifvjg<)@"pxN;yjwNwF+IaFND HD`B`H"{ۿݬ\yx_|o/ck[5!̈́T^d"zwgQ藾~?Dc4Bz&)BJ"$@"$@5p a6kB oqz y|Ww$ߚo~#})Ɨgp-, '9T $]D HD H&00`tMW_x5k.`jG>e H8AL4?/|;׾yϦ4-߷zknݺ=>χ}eaJ"@ '}Xk2O|b!&UG'!)i'QI ND HD``2nyx}xԧcWF8Ok(0 1R Dgg |\>-ϐy< | C(d$Hd byA}[Content_Types].xmlN0 HC+jRv@݁# 4J6ZDq(ۓn쀄8&jF1cd穖x먯,U=dĵR ZpV> J)?cWey0dSǘfON\S2 lT/UT/xt+ S6ƕoQ3Y5qTmQuO8fg/Gʋݟߙ<ƒ |jPK!8! _rels/.relsj0 }qN/k؊c[F232zQLZ%R6zPT]( LJ[ۑ̱j,Z˫fLV:*f"N.]m@= 7LuP[i?T;GI4Ew=}3b9`5YCƵkρؖ9#ۄo~e?zrPK!v I lHdrs/e2oDoc.xml]mo8ŸboSK_R;h;٠`iȒ!Nr=I9h%LԱ$<(g;^L{ED /ͤ E杰U/DHL{$ټ{6vWbp#l\њ'3~-Z_o~6(tE_{r)?e,O{ǒi9~':⛕ Ys/y~ gȫД7b;I}WFwz]mfz|zwu2ZSCrd+.a.9Kb`ϲµl{0``=_i]S]BGבP + $c#c}ZcI}>"-璶A((xB w}$'=$VȰ ^C+1}jvs(?1Q:ScJc6Q|чi/E໯qHw!=ߗDO~vkǯ#[/Svi-.mZIR$J{ﭧ=Qx tKπ䅌mK>{{)UM"5?yx$pq/J- gq=cww3_Qc N,ne$sX)ME`ɉVݽS ~#m!8w=kˢm#>/sjlCLT7}$'=c,Ŋ B,XNgK8j9T膚{}% Q̎ݗпn:C=QϢ$r~}R*VjA=HueC3 $h|{4^D2C$!Ԁ[bu \'^K ([K hWGJ^?&0U=w]JR_ew6)Y)P0em=U#iۊ]P!:8;B֣֕S=)dm(`$͠v dnUoYڑᗲ`Rv6fK>w2Nd(#l3*u"/PN–2Yc` &(z.? & ˾I=*k2 9Vې@a8Q8W;Apk'o`m9nh-ĺyv7<"6Y  @ab2%.RĥT 4ѕ.KZi2rPc4c.mxAdG0Lv 'd4ϳ.@GQ-3Q|xCbAX }k+_ZX]#hO+$bCr`Wpy0H3 =FBM Fc;,pN2Y))aDŌ|&;YMvy+8or05.p !a1 ,0{מKσͲbmAR,mc1|Cl)dG|xx `هa;7[HtVm'fL:˲P|: 1Vso魚j RPnFeP8#/F8bD 9.?`5juhj=ɍÏcQH{$C}Tr a6n@zHuI;]/g!'H(8G&?$Y o^Ɵ.XjhwPyv7XZ ~@k{8=*iPFHgQҤ\6 4**M^SWq;IquANu Z 2K d:`iP\,-؛*IDŜ#%FJ-qt=G[YhP $ 7©{_9eE]U זq/bZFWoBu:fiJ" g\CCu>X~Za![hbҵ,SXN z)Re>V>brG(d<K'Rm yv6Nr=AڦeK24ExpӜErTbS70jRE)fuP- Lޗt]+jH)즷oPg&uo7ϧR8qS=ž6)>Пkvۡ2 ʝ. n+ɧ{:BcPf9UNETdLPK!$!'drs/downrev.xmlLAK@a(v1RDDm6;&lnw{Ml'F|| iF(7'yXGΌ;3PX>M}&\O77Xji}嶓I-DžFtP[c9Wj{w,^7ɴh aPD۳CT¥JRE.PK-!%>[Content_Types].xmlPK-!8! 0_rels/.relsPK-!v I lH/drs/e2oDoc.xmlPK-!$!'edrs/downrev.xmlPKqbaK3[>-ƓQianaaK3[>-ƓQPNG  IHDRa%iCCPICC ProfilexMHaї$T& R+SeL b}wg-E"u.VDNC:DuE^";cT03y|URcE4`λޘvztLUF\)s:k-iYj6|vP4*wd>,y vڴ=S԰79 ڸ@`ӋmvUl5`P=Gj)kP*}6~^/~.~a2 nײ0%f|U 9l7?j`l7"tiNf]?uhgM Zʲ4i[&LY_x {xO$̥߬S]%֧&7g̞>r=g8`候 8rʶ<dWT'<eL~.u"A=9뗚]>313X3-$e}u,gmg664$ыEzL*LZ_j_]Xy[?Xs N/ ]|msϚƫk_WfȸA2)oz-di2|m٣j|5ԥej8ɮeE7[Q|IM%ײxf)|6\ k`Ҳ䍐.GAu[|DټD HD HD H9xăz&KD HD HD`& 09ZkU.lq=ID HD HD <.O 7ܰh_sdD HD HD H'yC;nlJ ,P-PFNND HD HD :]bOaz$@"$@"$@"0Hptr61HD HD HnR $@"$@"$ @ D HD HD H!Ja7dz"$@"$@"$3T g@'gD HD HD @*ݐ@"$@"$@"R)MLD HD HDvC&'@"$@"$@"0Hptr61HD HD HnR $@"$@"$ @ D HD HD H!Ja7dz"$@"$@"$3T g@'gD HD HD @*ݐ@"$@"$@"R)MLD HD HDvC&'@"$@"$@"0Hptr61HD HD HnR $@"$@"$ @ D HD HD H!Ja7dz"$@"$@"$3T g@'gD HD HD n =AՂ .X Uw>yX`ʷ|;K]Qvg=.uhD˼1FɄMNJAXdҤi*L9żA#Z͝L3~x>3Q9s{'[$@"inƢ-"CйWƭZ(]tѹɿsAq{\)禛nT}c2sOz]-£e>/KG>sgpA׿lWO|_|XITg$8F a3 coG<=cxkd|_@X1ÿ}?4fS'Hx-Ѽ0~]wu?xS+L@"$@"0LvmSO-u:e]V.[lQ՝w9'E]TEx{WYGK/3wpOO"}fS{SD>aov o6l/JuP(~Wg}}s[o]'?o&Jt}o}j DÉ"}bTqmw'xbãwm݊d,_4fSg} /e%\R&Toq5QG5bD HD k@}tE.7կ{~zu饗U}s MQg;>.&)ڂ8tJL`(SxЯ|(B3EH4ųoDmsz Wc ĸ,Ef>X(;׃&IՁVϨƼ 6Smi:nu sshezNԡZlC)d?z˥Ƈ Bzmxk/Rw{ʐ]4(_{~6*Y!p-h')Ƅ?uj2ꆻkBQx,.%a~/O$ŽQRy'ŋ:CJ*,3P'/$=w?~UWӞ"=9V,cD#Q=">Qn`_!e \9jVC$Iah-v[`~^Knk }F{fއ>O=d| @$DG{f۵^[hS/z%Fڣ+Z G?*c! SkY׷h56ԅW^ТU^^Xvm 'P-k]CseœB퐄[K/FQEmկ~U+^bA0ks<1y#<SuHLjż+7wuWs\8d,3iyƋ޳gg}g>|tKڭ]Cm'dMc~}_s9eP7ۇY؈{m:3eocL[^mpAwWeG_7Ƅ-mR F~Δ$@"$SP 1V["27/rC%yGH9s ҄DIS8%Py'?aQf^]wݵrP"4յw{B{8׾VԄ~aY-5(_ mQx;ʇ:)/, /}q-ꦈorˢ0 +C~袔6%(A{a$9H+kh'xg?uiu֩>ϔj'>;N{<>Pa EQP]}\C{W}t(ɔ& 6ؠz^dˍ ڀ&+_uR$WZ})TЇK?07>?*5(>aZS% qϩp> #+_J'O:Z)a~c ʢ+ø~/J=Lnc> f8CC(;䐑=أ(AJЏ;s9G#%kzS o{8dmv^vV2?)E˾[(Ic@T(%C%Z8 50˃>Эτ\RNi5(ް2VԡaC?k;jᷲ(hןh+S-R^y|E,cQmAk1(ȗ߉@"$@"0yL b={"P;h<J}rguV G !8 BH!X}-ŋ_"dMk7OR }aŜ׼5E! PQ"(}N#^RB a0*TGꔴb'R8Zk"S?яM`B?RG(3Bt3E/zQQ(<WCm!߮`G0'diEȘ77߼J o v୬߿G6*2Nmp^u+DHv8AƉq{l(y ͋C E쵯}m)h[o2C kXKi;XHP$(e,IWqL^Fc`F>_=~+_SX)"p#%"КWt[07(WO4& eYSx\7ta#FF+LPcR&6>_%}/(K`߾gkemECbL\^Wj?,]sy<|Sa|uxF{e7vK1ڿicX4 [ –A ^̛D HD`J!8%§(A(yłD%ȳKaASdQhP:~vhlIB1^N44^ wQY]xi>DK;)_#GyeW(C8ye|6q^0EV,[e ݤkRA#|RJ|%0jzBǷ)u_~1`Ǜn;S~;=횲m0Q(6-i?uE>0Bshvm0g<>}mS6v0:|o\P;XwJPNFZ[(bPN*2GCW朤>d|k0vyb{1>a7ԧ ゃc0^@41~~wsO0v׍^` 5c>5';%c,O9~HiL@"$@"0tfj'"yx7apa!Ix)$G"k IUS@!%\k'R.FLB+a7P3J5r}NHe'@Re)@Nq!Hӵ^&E؝Ëw*(yo u(/JDuNk=O ~L$nMЪ)(U!& X}٤R$(Q,Rw_ CB(MF!R{%me%tS'!E26 9%v<smE=Wh/.\P>6lj뭷.ƚv}?ƃ1"1FrFmAnxX*=6''X)>Ϣ=z޽1naө^8F2v3 q^aM\eCEy5S( uJʅi$^ر{jz!GQV|{x#^MAǣ$J)ZobKs"ofh5Ihygo86w"$@"L=N)$D%$5#ȆJp" co#[/$]HЙ5kVQPDrB" ANfE")LaoDx%Xc{AxP? ^d;ep%-P?ۻH vT>e@8J~ʌ ݒg(><ҔX$H]Dk&e=R[1v퉓H4J5GY>B JkI72O4%۔PLҎ7E{)ƭ]2(!Nv5Dž l+f51ES'R)?V=R`TG 7bHiSN$J#so4w; WDa~4!)k@)] k*Lj !b^J"O)'M!p^hP%V z}@R/qvNXi@: NBhe'z"HFlj<^C1p?FyA)VVԡGa?=LEテo|=u^'1RROS])3$PM7<>`o>EW&c}UgtH0U<ȧ an0m>?n?gѩN7pi7hmL->pU6BͥT&o1]:Rr(`l]Bq@  N,ƃ{=\vjg:yH #3MuPkxfJD HAd88E wG ODh"ڻCH mBSJwyT );M c%I1q$"n!<F3{yM1zlP87{R#QX͉h| %8UW0N/a; yV(jJQ:p`WuPn;!&D::%yk=*3hfMhex)NϾ=JzÜ=vU~ 48ϐPA1^Ɖ+wdX7(7)X?qj<o;V=">'㒒d[ƃyu :[_ y޺V3w~*:D H&CF"T4xJDmeG> y' T[aSY{Ʒk!$$۔@ &W B>/!5_RX`[ߡ.nφG0ޟhz $4 J(A9>ڢ>l*(0'^ a/ 6J![=+A?.3»2#l}C?:N I:EBЏp H |]q(|^Aɤ W\&@^{-B@Wʇ0Yd3CDi`HPRV[mU)1Npr)'h9Z$Ӽ~/mQ 4nc& ~xr=))k+(YdmWZadxLYb NIa׼WK7J` {Y=32ƍSJ ":(1խQP"b P;pqd*h2"F{uʉpND HD b$xgGS({SMh!xY(<>X }lk{9,6a F# n lkUŚ]hJ7Q͠hQh~)0^u4RxrAPhkо3J%(Sem%44RrJ'0]m0>0m0-iK.<.?<P[eRxMFc"_#W+_~tjvmWx7eABo3N` }@8oz>)뱢, 0&M@쭄uIS(Fy_)iCYC:N} gJB< ݷ9l\G|M£oeh>[c"]x6lSNZ'l]b ;-)|i^u 2.qy#7|ck&y塐{VH|>'@"$@ skmQ:0V.xXbYg&A(JX;t (E@a!A+" ա.J4ܓl4G0~bB3aMSoB'ԫ--x냦N4ˍhTz9hE=t(@~Cp a]~uwGz)FXE?:%t*O9hч!*O}D{uO^y PT$}'r8ExR^&/t+5_9K:y),턝rX/<ѬÃRtQNo~h2௝V)?z۸W@egr1^yP5+>Bov5㭻}tw"$@"?R8e$H !qh9Fj*oYIN"$@"0Hpw~6=HsNGuxpT{$@"$C ᕹD 3?"qr0PۤB8f2c"$@"LNYM"L(Xg&D HD TsRt%@"$@"$@"T o$@"$@"$`#J`OR$@"$@"$@_Hf@"$@"$@" 6v$u@"$@"$@"T o$@"$@"$`#J`OR$@"$@"$@_Hf@"$@"$@" 6v$u@"$@"$@"T o$@"$@"$`#J`OR$@"$@"$@_Hf@"$@"$@" 6v$u@"$@"$@"T o$@"$@"$`#ࠑ?zЃ44D CCCU|x_ۚw}wuwV?N2&Y]" CYxᅫG=Qe_"0: xv}U| @6.,>x#+w{x_(Yݜ&#dEƃYb5nXB&=GߔS2zՙgY]p5\Sr-s(}N)iIXC).bլYVZZeU'=IE̤Dh ?: //s))ͤёm=,iO{Z}ys5 t{7x7W{nu%T_~y9”zz1XC)d >q^zj喫V^y)OyJ1stM>J!}XN;?A"(vm_<>u&Ǭ~c[㳟j 6fϞ=l=o{ou)T?2wusD`z @{q.+/?a+~ы^TE(${;EkN:EuWwQ 'fɔLG9+W\qE}A"?՛ju)F b~}CI>󪣏>x|GA^uU75fҌr饗VguV_EpM7^ss œH|;[f])3oګ袋?E|ͫWūФ*'F/ /k+Vy{FpΉٳ ~3)aQ7 :)Hf0M` "|R)K/f?m#|E@Ry3%32OZ]ňXz _X &[90tWW_W/}K",R//3L@"0#p'VzhW-onV8#D>PgVzիWx߱D QvX '馛6aЃ-Ho}s9O?v<mQf19C[BE=ϯU/yK@4J!n}xys>Fg=@"08xŊRKUG'R8BD׿o.;j-Δ$@ +>V-آz]-=ۦӬ_)AAF>^vء̔$#wqz^U'PM)\?~{4e֫VXa j© ׿^e"*3S"L("R8Fl|a: }:쳫׾% bM6){fffD`$k}u]p \:Co{rr!% oϔ$cC?Xs5Gđ'z"4TK Rq5? KO˔$3^6e'R<=_^c1)x.RN~/I)Hn–_~ '?I9?$$bHs /pQi|>O>~D lsCi[I* S1P%'pBySL@"@ #ևb bax׻U _aZL@"riQ }K.䄢ZD9(o[;Yfo|cFFL|&h! Q|׮ƫR bNi{{8t!-&@A)\B"l,昧NŴ@N `:?ILk^WZy1MD3$a䶣,r*d*dzChdD HFB}{8yPC›r$Cg?[?)HyAP&to.C:k+hs:{QNL0΃Ɗ`KƏ+^ hQd'=I56/}U K?OxFD  UVYnw54 T Fޅq82>?rj`D Hzى" C^VtS=N^A!t@XD /d.g[:r K/(nJ<&̉ 2%@"0V~/^9SzN0۫}ݷ(^)H^"3~)J{YXsO@9 q7. NJ`K ;⩷p})8eBӭZdi{;"YB"(n%Ի $lC-Ywuש"%M _BWtGT^z?uBF!\kƲL@"0{kl;r pyNBXm%k2A˺D`A`W8z©WHK oc-SFq-I, c{𽣏>; Zhq$M3zw?;ÄBnXhND oL|*6!h>hdJD0;hEugLBx 7o?dL@"008)|_uU}յ&b"]tQu᳞E.kOiگj%D)t؃CoCH8ng֗$#}o9 SCl~4vqrࡓ%3a ?fC&b"߫3< yflu"K(e1a_jkӍ kSP#BL@"Lbo~~GKމf/ٳ4MVog=`,zK^Rwqc^?҄B+g>~3~4>LC@8ixzr 3rTࡓ%aIT?-<֏u]g;л{QW$G|*_Wװф8 e34Ң.:擉@"4V\q;s>U?9Sr-% c3%@"0<9ϩVZi-_WC6kT/'Y_"׽uե^Z"-RȂ%ʆB -4&eD HFG"׿4P ÿկ 6:#Hf*N\uUaϮ@A;C l*{3%`"3.=w˻{xJ!//})H^" 5F'vYg}/{˺e@"^SN9/Ÿ '_)+H!~m&M\?H^{ lV6.g2x^Mo=آ/.QM:tBB'ƒ)H^"'< ,xe'@3)Yn'Yv"Zrʞ@_r /\m6c!iyԣoj-آF~^q`7޸ZkJhM74zC`ʇZ 8޶MUDR|{+-hB8t @y_aD HzH{(/s'*gJD`Xve%իDկ~UNi6 !Yf%o۫}}s\eo#2 N:09xy;Qd<,Hy +0%O[^E'ORHUoh 9!`Uwa"3#_-7boE ]ʙԬTvکE7e8[o--Qx/O!`S=8?߉,9 φP׼5e_Wqؠ8z_,SO{G:צ6 4_wuh= 2dPFJJHL3G`l#3; u[MR}_N>rYWkꫯ^~9ֹכ0C h9Jߧ_P{dkvq~P3boXFhT~SL̥AH ;Mc'[٬Է~{";'?IQXBFJ?-؟煇EPswfQ+tPZچn8S|ng(Dfg?[B5ǻ41,g .(JE~\Sv}BH ֟^&*U^?RYx+)oxz8ǚo-<^m s4xj9sTҊΨΚԮzu6N l<2<Ӥm>eY3zT$4KdkgR^Q~y0,s M5r}+NN::d&2;V2{%|p`z}kO;>%x#X-p!ːD%8<⋗Ym;C2V<ꨣ*yHޓj9{ϣ#0gQG 7~BA|3xp'6ֵU>Jl. Қ~EU [n8NT.϶A+Ɔ~5ƴW5c9=c*O(x=»FYYY(ɡZ,~>X DN;0fBUW]5Mf u?+*<%އƸ4҅IwcLg<18/)aP7 ԫcDɠ'B/Y.x@%k4cXE\JGQ.(#/^rG»4]k;Ch1^l dh:)d~x%̕ҠNx_r'  CȢ/H8QbAu&CYS~E=أ(rɀ0I1aQK=Я~Ֆ[nYJٵn[:L;%Xqdɏ^m"%)F SHrEۜzyFUsU$lˡSrW\q^#Fg([xB %̪5"zRAidr, tJ&~{Vgr]of^#w}˃V44k\èIC; wg>r;tvõ?FȚ>Y"iEQZR?'O~|5̈́|-Es}w~͂?B H#)Ÿ1_לgoxS=5?r]'u*۽fI{N)R{Qg)kh։ݞk_ZGjgwY7ӘKڭ>he O5?GyN%(zSr}Dcho??b@UI$%YK%#H18[of)8/"*rPᣏ>(#*l뮻nٵt[EbA~H{ɒu:4z~ 0Dȯ[/Ҵ ocY" PYLL20DkdGnyλ 3MdIȀeRSɬN5fݳ ӷrLP`tZHELEZ9IcQ/Zk2kICL08XBꪫu''=WHڪn 3SO@cW\+Z(|1L7kfGd0(S\'v!ځaGlcMQnۃl/ZDё,ƧQ9;FgLX0@1Ks+9x^/|vmgGs*FK76QA5V^|%[X u Q> O_ش]7W^CƑ >'`* 4LHNpѐ`/+_Yw}5ʱ.XtL[X#|>j|bf}̈́QPyަ)]Ə-\x@ii&[6d41nSF܋0n8zQFj=ۣ~SFTw\曗~%s\x䛢sh7Gmi,zL1d 껯}kѠ4!䞾`5ܥ;,ye ߭Jm\crIX,XAvEtګL*d`(#mo{[qiW}:ۖpD/K:N8I\| gU`"Y(%2D1 %`2I;"<[Κ:I9?b)sXhgQB X`Ia9|V=DD% J"hcI{xX@q+aL?qyߑr=?R"4_AO}\_b<_"j\7fKWX)̈́h)qo$&^:G"ήdK}O$f X`$}H$ LE@?H! :lKygl!(yʼ _16̉ђe ixԑGYdCnJdqODh!^Ea%X?OT266sZJe̢M7hSթnt nu:@{a T'nhɼ'x[YW}1<"TLYO 1hG+LϵG_Kx&?D 'f3Sx7^m{֍W] #d]w-uXv膍5㙈?ܺw6ÄnZ.rb-BD~dd?hf00=ǐE)1jOa( e ED)9S䰨;wtމN59k.!?Gd'6C J.lBVNP Gvyam6T&d>mԤz\ʺaYOP<>kf_ՅS3cԋP=jP-XJP=f'/ޡڲQ謕 n⒯ |DHVO:zXCWCZu Պ[)fs'P-\EܫӡZxƔ:kRͬja~fC5*Ak :kjzhOY+ePlk!Q/R͈jaf ˥Z=EC4Ls-y^Q3ΡW)V‡Xzj+P-D5延BΡZzR~-<̑V^ }x;"icQ^ }<ǃ L`fwkF:R7֍+c8}T[@jPbVʮCwaZp/L Bp_^ 8T C"6T+̥ڻY)Q/C%l6 Ջ\ȵژ0T/CQ@][}X!C_ƉJWr=e<kjEbVy0Z£ע pVcJ#2UQQ-RR|k:~Gos>EFVVZ,rc? fŪ͒<ƕ]^ᕬB/x0Q7Ƣ,x^9{P+s#ĺd671;So0'YHyyJv2#I>3mo|<9,ɼ71lgM)W'3X7J{-mjGx O[= o3' &y`MmT!%M(P.;!f#%L#\j:E`¹ԇ_җRڠ<9 nIP[#4cc'7>kKF|]K̈dۅfYxfr2>K. %㙇L_>2ш4Ӓ2]~7an!d/c&~N}"ܓwv]|aޒ>1O!H9prLsGީ֟3`СQo$z-xwX1%*JHnu`TKYxb]d[׬=D@P0P[@/D-c67x(Tĵ` "H02o&TxG:׵XHet>AR`M>nX\)-~B [P.y%-RfGgBGŒ$a:-WUѤutNcBr-ff:X[L< k-§\_3i{NȽn=077ve9>/a|hn< &S^, I8#@ƗT)hw9?ig<3懱G6+]#Z>o h AĚ70@%pHVf^1#lPB)a:$̣(:,7GH$؄ G!!aԖcm< & ϵA)'O'd -@їhDO>h Y6o ['v{EqҐi006x-Pç4[`,sfKp:MƧ,/q394/<-بWY!#%*8 p|.kC+3<7w#3L<DkuxhBn{dA=Q&ϞrKѫl{$otŒ5^DSb 6QRģ=R^~d%43mQxpG?)Bhog"i,m"H /mÙ9LR'Ë7كb~KU(2'ɚOs$61Ff'd^Q>Ȩkxq7# =6!ØvQd{#c"\GzVde2gы'P2](T'yNI x.Y|7 x6џQл.}s~B"Ȳ F]! (U_PZ]f`0{2>ūyzT_u5~cPD2MmYIaQL~Nh4,lcl dڃπuo< óH _ `‹:fg5o!H34cԦf 5/6? !G䍉H.y ,aEu]$F~Gv-#+X2C(3bNWA-yVx#Bߏd?!5 2)|` pJ$ڃ%cgx啇Y/$ Dzkgm4e6}o:% {A!daۤ'ܫ.ɠ_;n `,]6k 7v_T<+xLNH1a] -7h<nq 1D8$MR)<\'0ٗR eAPXXBE2ZgsEcIj7XjYK+tGfLC(Yu,wD5(\@vl$O &&Ѵ5I,ܘH4tcɩ,̀Љv++H~48h)?Mb d}{;ˍQ(5g0b L-,Ɖ/NY< ןq>=7!GʲpF23>ݪ}Qc ǧ1s~;" nJ!h ˜z3BofA|Eo4h15ޤ O+P9t A1挹7G=ݾ!Sxԧc4kG_[gB@<(ouncFQ.c$O< IDATmaxvء`4ag#gk2_yGcDlONO<Ns= Gq /'xƝE?h#(Zq"H29K(i̺+d7v;?9\'X/srfv9' Q?"ϣ|n&ϼ v:Awi?.ijJ/W®E[XiX4,{<+cXr H.ar NF4YPXt0 L[^vxX9lwvG?ѯGTuJ][9W=u=TVk>K0NO _ZW(a'sg?zЁW_1cM;mE>17\n <܇'A63E߸ϢCF෰`T7%1׍L </ XeB$uZ{Ǣ*XB9˳IG>B!l^PH FȐZ|d¦BLგbg."űg{Q.-ptByۃL/P|6tEX݂`rk!~)n[a4,5D"lkǨډUDh)8e«sV1@$v # ˺k& mrHiØ0^N8auxʓ<BuB E3I1'-n3UmgUG@ R!P#Bd H{PH1t NmW6ACS"gp__,RΕ'qJA~s5.M7ƩX}J=˩^Vl/ءPAvB~ ҍnT۴L^Sډ}&jڪڋD4Gc p>`K|M !-a/N1J{ yPe59wjqmR$a,PD:؟ִXӧV`_3(l|?yœdAt#_Hy_2Q09A4/s|@7Z ao7xƂ9abཝ(zM!؛0Տp5E4J5ԭ 1GeAv-|ɚcC}N!v=" x^"_h{4*XXfd 5)Ӻ'Y;%Y#AXh8JE'IRǛ;c:Aĸc|6yS80Ymzd*s\ D`0Yoc)R'Ít` q?~YX)]  „Y184,?Vn HD`:#pZ4N@ݮ58^ԩ x`w閦f?6yn4e@n^DyTއ28/se^g{w@)O#o:7KDav;Ek=Xs!IM"0xpN8AOD HyC@}f9|(?m~jɧNjo Ϡ}9:V+sfD H@`|ARAPڳb_Sߜr˔vKV$%:xǾ2&b$!ٳ/mw/axSGQ֜$@"KS8N41y٩ωk*'@"0`trͶn[BG)#w/!)*;REs훺ȚD NUȖ)HDwP\iжL@"$>:i(HD HDoϔR8?n-HD HD`BP~ygJg2|t~l["$@"$+:?PAP"0 HptR$@"$@"08ꢋ.:ꨁxϥO/9Hfm>j{נd#{P. c׎8vv?k^g@wgk=_o^^4=駟^}_N8 w޹ͨ."򗿬YdiN;7Yu]պ[=a⊢(qe|% / r-Փil`!GƻJJ Efe RwgVG}tZi!N:Zo!7|sя~ַUq{1ioAP1m0ߍry^`'a'#>'EsOUa)۷4Ye24/B7Cofv+GQus /pn>k]ЭBaV{0WGVFx#梥[=A#SYO <753;:ԫmbtj6G7nj݃5:}yXui,S2fR7xj\s;to_~Rk]͚5lP62O|lP­歴z/!kFЇ> +To&TW]u0^^{~e!+ [m؋z F[oZj7?~~tZk&=b@$DZb%RCFAIa$062%cEOu嗗97kUVV]uբH"axjW.q饗mVꫯ^hK.:SwܱP~k-]tѹHxF&j-gAQ:S苇;)+Ϋ>,p%weU"|<'|rã[x>SwP]u&b*: QХ<!I(HBUQ) .T\.gw23w;;o9WݳgO Au*"Hwܠ&dh/}{GW;t5B|7rGԤ`^rO@v^&!x??<9Owް֘4zZ6}RW*=݋̇Eok ^ ~Wܚ^DGcwri%ts.;H( B0`ΏSLg=;9v(pvQ%<31 (W /21_qwWGb}>;]򒗬h| ^ t]ó'?vAicPs=*anJ;ݩ{^S 8yW$o<_'pBg?W(Ac=ۻwoַ?Y*mOܧ[pcxjpf=y5vw';SN9V )W14'5|`o\1zQzT RI=8Mh&v"5MF.wܾ\ܭukrlN( ՠ_?֯)OyJO?{ӟ^ tu׽wq 4%$>.܌)>X`Gds^s!ܶ`2}iOː'*_Yɵ~w<ȼs޹|O;ZҦk? msu4h[y~2s-9|۹&ħ;׳64#ׇMc;mdD9U duߐVvf?n8CkYx3^1sq"_g;N{O1!:8dPǼkݖv}]OMi;t\pʵyisto{wFKs u޽.W[B y䑫%I~7;@/r_uӛ޴uSU]J] X^vI=#$P9'Xꖷe p;T9TE nK8Ai@*4*E.PttT%3!@_/AG4&{h- MTz/^l<%.q} _X7G$5 HuhWN*{H0>{ʮ),z#Q=;SUfA9@կ^.s2?ƠZ p!lC!󃣮iO༌e }b:8_VB> 7]~/| W~$ymiG:1yLUF^t%~%7et}]NxOOkvC,4[NV+kl~A%j4F^m%Xp@\swJ[wmku2_E6X2bX]#ËbK/4].gwpv29~+؎vLd[ٝ6X t/k/6 !k@䌽rQxNY3@_iBFX?;nxmoٙ>Pw%l&^G\[c%l, ћj.;,~7HdO# 2ϼѯnK@fb ַzg;𡗆/4#+zM2Z༧`JE;2uz)!|PJJ3pbwѹD.UG ukރГL5ҟ!$ex_ Cmw˹B(c928F=C(ȤȮ(EyLoҞ!"Le3fAqs`N!NZd[GØ2 ӟzn0 ףP0-~ ^Ӏ⑹!1w^p en6Y4 E^#xzgbIP kg}edi$k-Kh]8-~Je/{YUJ*8^rܦffgMg$d 9̗p,= "͑l@DMOIHV<\MN8x3/ wdi #FV'Hi@0(@veF@t1=C_ed=Bec;2EWOY#0dCY"kOzғVe|[Y8/3o~c=,0IGZ2w# Ms)&w]+}dٗ )yy6n9snu5vN<:^h[&h' wzG/RSO=u^g>:4c(p' d=Bf/^(KHX  ,hy7Z9 #Фl ~g1]f̀`'Qtx-zkq@KGEfZ j/&AhR6 2"#:I%Qf7P4oc|3t$[OJ+{V !ٱmˋ>incBO62 ǂde0@`Nɫ_Y9;[2 6/.sJ8m!6)Ct'V[ Eq_AD@Vi|Sp#Hr(] Yd_{4WEPؘJf (>gnY&I吠vFZ\Dq(5̬Nhen4SApd9'X?={\i fd=(Q;5SFyʒ2|3rܧ1T{ê"C. jPr-|#)!e%I%83~|ʎ!y"I!(tȶ%1$ȵT HP['X1Ѡ :ꨪ+ ˟Țl9vGn&QI"y ggi-Ar.`=w:k+I)6^4]dv ~p^NWDJzw('N]tcwI'K_\Z^Żow~̑Mp]uO@2D IDATh$f;Ip‡C/_}qpoxmSJX/~z`GL i2E/HV, D?_K5G: ŋ[݃&W5>l{=9} C"ٿ 5k, ӱv}+gxj{" 8!yh $m2%p8&].0d@M@0^( N%i> 8.!ay΂(%XY[I`2p>8t᜖!Я,Ȑrʃ(+8m|9h }q<НˉZ[Ӧ2Rz2G ^qnR"J 1Θ#&Lؽ r9g;- qы v< XF Ov*Zk(έtED'0 d]F׎~i]oz|JcjC^I< e5; /}:5e=F/NM:UBK;k=l@+z[N/;MuAp͸n6m GSm+ESľm1P?sں/dxixhCqU&|$ҬvKY ,睲&տ>l- y*蕘ebv aQCA >7rs~G:?_ J.Q_ԇg0u5I&B6-E.7xdX7I"\e.0pgSxX+s*n?lc$1vڌk}cc,V` *U[Pˆ>S4!XXB WNc.0pK̥9Cp+01>>ߕ䠫 3G`|bD'q^3X8QCi첝 g/k;

1I r<:I:z]/'.>yv]CwɾG2+{eY4{)ZC||X_ÇڢkY|{k=߇V - _y|:m"$wۖ~%ȱ -]i%*۔Ed|- Y$Ag.+@ ;O|\#=m}?o2k>swTP 'CBf( 0,Ej-lc8yEU2/媞0EKϹ:SVH˖3e1Ǣ`^yV[C9~悦qzrmc+@p[WpiM(vr=*U+3N!h pL)=ǣ}`YKm2 G `T:- d Op0rʁȷ4, 'LPUkǘ(ȚMj7S6XXk^of7se)b7]zVu~и-8@  d{Ȼ$m:om>Kel6CfMG_;+X_9h跕 AVbp\d%H~ ).89?O/zDgkϾIpi^UR7kjݟ#C39gLe%)![>??һ/ ƀR$Bx||i{.׎ceo#}'A$|3>p>nvf>P`J%Z[jv d -%19ռ+$<׎[/Ul P ;CW% ! \H喂FYfR#p>D0gl3YkШE[ '6[?ES3 N(WUvNf'XYGm?eFBb<$'ֻv9ͧ޵9f1g9`3a bҎ ',0  |!K#`BX6 `|?E%HR>dqSjx8olp:Ơeݫx/$qLݷJ{I 왒I (Ƞ/d'M0@*rɧ d.j!7$Sm?JNe Y͓5v-صb hdgo3iO9*;QZdΡ$!^~z@0~I:X 5o7{CWUpA;|d9sٝ;@`#0pI{P^M|Ϟ⃀`38%;4] ƺ_xt*߆'0Y1f'A=3 ;m.:Zy |AoGKgKˋG %:G˟ o}>䂿g3d^3AH|QС3y=]֑j+ WB+3Gʊ>v%زSo*蔜O ,'g#qp>^";zX U:9q̃~F6SN?cZ 8*SC1qb Vu^0èy$9uBfڠ91vTh7|D7D&(?q ~榝@m|7c ,SsE:JD3kuM_Je /%lfĦr.iw8F/ gaxb]y|9ʒYqpqvyJZMt>C‘ k̻mޗk+%Yd6liKɻnb}_J2N~*z3 DUU(FvG<;>lD ' v;B#$`N](`{xS0f3kf-W Fg ֚>xS@Cp S]IVA^4tm=~lIMi%C}։ӹmR{m}{hox# so% hLz܆v_]sa3mڧ1w3IΩyAlsJI&B9 Ҁ 22A iɑ1>9O(M}2bn("N}6{K"_N Zz} ?T[,i 'ʡ38Pp[LR"ʳY c.9wGOp(|N:;=ZrFQDKJv˂wπA1''h`˽y6صG *u7[aݔlN UsHјU/Ni :`K!-,M7{gJ8-{J 1RVeei1;Cq2~]Ξ L*a@Ǹ;;G{L9 :9opѿZƵV'6AW`@mɫ&fxpJ/l0#)f42he(( z;/\8~JXs9)O^dQ{68i5K#vvȒ,y#^t)]k˙F#t<wK@χZ!}Z#뀾h:?} =W2I:IoiJx1l|w;aB$4893y}x3*8dWe={C+x(7zB L?t!s<5}YK>:n@NE 2+Q?sΣ?)jy<58 P4ʕb#WdÀ u^:tЌcd9>Clx'bOi]W6;|C:e|;c, %'ߛf`WgHgΣ Iwҹ Lv|=6Sڌ~8PZ6ҴXJpr8a߀zQPa!ö=Yt0Y}Z e]8"jY %J [m8VqH8^Gݓ)z΂lEZEnypI\^vv9'h;lj" .EGc2y->;AM6D2_Yl`͔*љvgv |;} ]:!4 2Lrspt<:@`Yo^$xؼ"VYk$tZ*^YttnAViЀ:X+ms"ѥhTr0fH7ͭnӏudWfVyNMg NvCCrH9rc ]@".{cvͬW#{h}dk ɁS0LI~e %b<3GU6 =7JR,!?.K|:?_0H?J^K_-.iv𥇒g%SؑA!B i盉+Gl o3d q(uon q2ka{c/6vg7 NR8L"d V>NnF3M5+(1NO 6w5=>`qZ ;Grl󬶮澓b ڮKS*^2x0dHK#&hZ飺K>/_|B!_v%GjoAi7D˜lV@" Ɖ1͜l  Zmc˧VFik '^<j9mFem&otxyi4̻^<Ǝyڏym4Y.u'o|}e'ۤ^r4ۯd-w]ex=T\.>ͱvE!-3ySJq)t-[6k <{Β7ybmG  -7ͦ2ך,|Ơpw붟^B=Ec_(Ǖ)ɑs t36)0c7H#F Ơp#dԘ{GJRfǛG l2x[>e4>#)0R`H##Ơp;AS^RE#حݺF Xyx񽰄߱ij*}z#cl-t@hYcc]~'n8#F )0R`H-'%TMl%(ޮw 0.<_9\|S~ ^߁=c}T[#H#,cPG?z׻p/__|;ߛ< Ah%= ~Ԗ |1o> YʳsgFru&6wϐB˭҅asN r;qկ^wVVV6-HE?{ _X ۭd/}i}׽]^Wv׹ugfӯ) ~L^n_'<￴2>vu~+7NpKzdi/v89]r&t[21gsҗTk>]W/ښ1$pEK\kdl=R`@ Z@7?aIϤdKaÏ8筍6_W\ܴgypw}߯88'c\2w;K]"<7,/t ՟JD7uź;^*F8PyP~3$6fsP?egO9g=*v|~K.Icw]SO=5~<=:#)6 ׏qW?5왜ed׆ko}{ғַ0ˀ ifN/|c7<;8<)܅>d%Hkuh7m|@;|;௽ .yKviwOۯ~޹y}AtnL1s/z&@l>ifXZӌ1ϛ"x~KfxNၢqeelc~ 3iN;2sk] C "ڥ.ucz_<~+{QG~sb<򑏬h]';薵״od[""!8|{߫IE 7̚+YcsnV/5j)6g48scPl.?񲗽֫, K&׾v(h?!"Peb+˦˹uG귿pXXc#v+^WT'38U L r}B##+GYp ^;#=iNfF76lnl/i,@}{s=7t{vvhi[W?VJɦi\$TI.ہJjT2:~; 6UKo{j O {_ ,| p ݉'X%n|3k)3_gI@O}{SR?|j{?YϪo $ 7v}*aCMAg=I'>Q+CKG|mSp@khw^*GGs7ob;񎕖y@l)*nxַ&1)\M7 /L2_}jPח-VKzaG ,>v޶yq_Zn)?裻k^(ɞ={*p%BS޷vnT%o^,o^EBF%+94?p[޲*UzUw+]ByvFvhOBح{Xw Y-fN"t "Ёg^J@ 駟nwt}{Nu OJ?-GStq׵BeЇj歱>Q4h|~ @SxKR~bk_ںlq[ſt]Gk"UD gw5r[xuvZ8l\"eZ8 OZ~ 8L d0I]ׯkC#jgc<[ڲտR<5tG3x櫼@I?t޼Ѓ@8} &~k>k?ʜ<lLv-d}a) (cS1D8'=㠍9k~iCI,@wsu5־g!{| ,?^l&< Zi2}([><y;$CV/:GK.t o 0==AHVZ<~Sp|O/}!s#2.z/&=4:\_"E{;W?Lx/:q?}[ S?k}__i }<۱N8㙶 f6:ѭ)ŏ@W99OFNZxZû>xmĺAS8J%pE;Cڑo]^$Wd&`+MLYk6}ЗVwע0ԧ{wv4;YA%gN4ŽvCaW.8IzZĔ =Yz۩|_=S_b~w VBp^NxZ$SljS "jķAg?! |l_v޴#Gh# 7`7δ|Swm~_x N cުhI %bVU5_ZB W?A=f}"$# @f[dlZO~ur+W3֌|0͍ lraZo0cmqݻ !A@@ml3$yL%/yIU6I ( 1o"xCvDeJLRsVF|3 J1fъ3 Fs%=\oq$c E83tTq:ʳ(yE+*ƕB ǃTwOɜ08(r,t/F@:Sv2.z}>Q-!42x~wӮ Z#)lY)>V ',ƶx X;jE |e,֚"3t$yW rۊ*amdw[GKx/B7V{O7cdIw|>:IsBA$0!Kg#H_p>7e2&Zm{[0V|?dM(Elu|)yR8>|q&%#>o(IQuXN NJ~RRJ=?aݥyj[Ťd&~3WiVI٢J&hRI18ej?hV _=_Iը8j?/T.I1Wqj!`y+_ t-狣Rۖz(?>}} 'EM 'x8%u֥8kUIQhsSNJ,ˎĤ(Iq,kSZ*9_Ӥ(IyĜgRƤ(zǶh] 0'%Xs)ݨ ?ZCPϤ(:S1SbΠzΑKkQI1KLqB&kvLLPzYu.I F(<}^ դI &ŐO3&GQߠ >"wy2S*dJ6)I xrTw~zd׍K`uűK6-,NLXLQ*٪%s.@L?$qPյ%dͪҙdf̵-ܮRZIIUIۤήֹ8OKm.֚dէe'&cd Xy͡$VJ8)ji_й$n't<_t) IyǤ$/VmUI6VH7hs&/8{kK:MJ1)N~^YcKd= k@eX-\mGswK@Yuy7 '_͟擭E!rm]{dbxκߺ|%}=BJP]qaW*Ex|RqQr}cM ߖ|LJ[pSF% ĪKr-W }^IIf%Um|ٙ{/dz%_i nhT*/n**ײ_'k bVu^9(eG~t^ {~D$uf䙿RݕV־T~|Y~3}LG : p`ضRPu2z1PUoZ=bx[=~ѧFwX]@а˴C9ݡi[8,`DfAVʸg]6-Yi2M@Rf>&ˢ՝Y+F]$YY3vl۽ *UKd db]|GѸK/K;:GU85n7bG 7 nS|LlzG22.hU *22ղ#C֪)a(Я,l 2Y,CtrU~);otnp#_v5}дR5-c# dLX\gm",] YHFc[ٮ~8T  > QcuV)Cǭ*9˞kOGqv?@_9{;'--YM)kOǒdc~^/R3tQ41d^"[J89"'C@+E;ogAƥ#Cf-ȠH6/\cW!vo7Z?s*Z׀g'N RRL5пk0?yo|B_KvoZ_hwPt;bd=.v t_H7VٳgOۚ쾒;>/Y?|9Q TofSVJ6hy^֍OH5nAT9iPѿg)PۻE65%90N 083#JД(ʖk>;Hȱoϡ arL-s ܆9Ǵm`E{<\S S#e M3 AhqnϙιRy^D` x"㤷/)8BJX93@5-[M]:[\Z+{P9~w%N"GY'(UǾH蓣|%ięx}WjH*3ɸzqQ\v A?%$3,E<ݕH`\O]C[e>t!`KctdQʃ9OaI^iхyA!=^y-xl@`)'Hi)pw:ܕ{Ú;>uyRPm)(ڡmd+JkR{-X2-k=y+K~xKo~I4Fc  si3AXlm1-&hdge{+ &{D`t4F!Ch?.S2CF2xFAzu*d(FcdKNeN>杣ܬU2gG%lZ\JyetVs1a "!(dp6 wƎ`1ζg|/"I,HXHzyvՎLoEw%(JkcNgivx7˳vD{|Bw}CWzq8Y-ˇ4(~s>?},ݳoɚsy[?r?~ho< >Bi4 ǻ?^F/AuwhHC/m ;v &[R͋chp^d $=Ƴv8>S?| ŻgP!9*fL:XbD`BIalc59y 8>҉䓜Ťя^xY+@/l ~ۘ֙lGZ?zc$g8m;'~1ӹiyC+cK}M=7-f`F;>hcLtF[x<]o->m/V;b+G^Xˎ FBŀ| x2%mF22[pᢘ0D( t]̑`iVU ܍A@ЙxA׬kZ_E B`_ R6vK@R(Da/:P;s6)KG;1ıYe)4P5Dc ώ`@CFynE/b[J)hna~ qD|L]$pgy@g#sR;<9J.x:o ̙1hZ_6'G$ %Ĭ^$|QPB&F8|=<"6 +v ^(s a+oY$FQH&.PR22Pud~A8` Fr3J}k5  $q4梀!>AȒf Jf;Hp)EƳ2=?Ed) ӳyEpZws  ?-k_7,hK "{Cwch<O'hk!| ?gJ*K>1g/UG:a_uXk^tk H;ot h˗3>)Q~>w`m^Ã݂6q - w~0PoB,rc-t>W ]>å/83/Q _MƙǨsZoB, 1 c|A _R Ns$`+ P!]ݫm EVXV?ƎqEja&PW`>IBp1tW@#aJ_Q <|Əп0WBL˨[G& #:zPw1 Ѡhbrx`ҳ>{M4orF[N3ρt$hg,c[ƪT!e$>c^z0~) ?' tSd;Yx 237dYa >{F(`v|v2.'O/!<7Y>gN+IOM/2N>9R2E}$h`MgϞN@!=~u};%It3tL{>utt-/8W{K$cy;$9@FYD%= Yp69>J$/$$>#_%+:wz?XMpgM3>/\(#t<4һUsb9YSD`ȹkCYyf.8TD'X3]o/ fwmX3\!`}i~]pCvt Y q(x$nN|l EK$fȡ?kls_{oY朹>Y+e?U54 >HFFyl" &eh{[gh\sT p3& m>`Z'N .kAbFb< 6 }\dRp' ɾ2V  'T>fbC}SJ`C1!,F vʤ(JڠišD{ S\z baW{ˬF^ee-TR)~`1vNGθ kʸePƴ#ML@Wyl5Kle8`LA1oe *A9+Gh=XVʎ RbadC%*0rH֔~b\gY@9tiD(H%+ȉq"ә)$r8ʖ!޶]NIu`[Cf9fgJ><1΢X{@//vtYkhN&wl3R ;㕍٬~׋Ր>Yo_y,َKVޓq#lVv*{=13.0@sn@0i[{?Gqa9K [ #(sg6ɡ!ʑFA Qe$&` TN/zԏu2 Řr8$p{h_ i `G=y闒@2#0x1Sr8 uh3f2q2 ?X:C%0"06TԼs4,b9Osncg0 J9%2Ӏ3an(}?\$c889ڡ/Gue]9-b۝nkѝSX~4%xGE \Z2vm7Kf ;LE.Or  9U7IG^̗E۸Ƥvւq*Xf\rmn=F+SydGpB檭$蚬klT=Y}UJ`s3o)~4OA"3 8x@bԽx X!@o+\/4ӍNpt)Pal3l~bK/g3vDN%[>Kb]te߆jq\;9˺lTɺ(AaHG~!}hcyKrҫ Lr1ʞ>0T?Jud8ʳ)sÈ!289-Zlg`iYݭݚk/#0롱ys  F7f9iȑcǣ}dm=oV#H@qfY\rO+I 0e^8B<-cNo`s9Ŝ~)O]:u7گ|`|^e=oH#6;6(L})0R`PN]e;/|K%e91R`H#F 8 Aၣ8H#6D%93HJ/R>k`πyQ?{sJF)0R`H#v'Ơpw8# x{[O/kzFJ*ҫhc#F )0R`R` wڎ3)0R`SOM&9Ue~g#F )0R`S`}7tg8R`H#F )0R`HcPxP,8ɑ#F )0R`H#F S` 2)0R`H#F )! x+7A|7l16}cP$)0R`H#F 8( y_\w{M)M޴=P` 7c#F )0R`H1>=yO7co|݃}lO|bq]k "i䇪gV#&ḳagPZY붕p9nX(cAg'#V;>{Ӟ]Wݱ8PMt{SN7n.}>:#\X}k۟owx+d_׻WU7-wY>){^}3YH)^t>ilY)p3/p t1Y1Nw{?]Wyk.KNd߭WNwS<_A~{ӟԐ0x_]˕[YY?Mw |ы^}rvްN׈l HXc=]מ}xuCӃk֝sqt !$^cKk~{l`̌^U^ʹs ^XɼZ\W{tO>w-8 /jky}݆G{ѣAr^[距[=CAZl`oFFAu+_Ou9yOxj>F)T;:׹Φ//!R~_ַ,oڠ;c_^T\ԧ>UϷ2j\us{w.Ƈ?1>`yaV%[ ᢝ́쫁|/~:`Cۧ?c_C׭~YRU=pFvΒmDIh-$E/4Ѕ. \ oo_O.uKA X|8hy衇Vu1G:ytNYRe#Ovխ;kN8|;݇>}}yJWXyc*gk^#A8[ s<xK_`E[sV%0|я~xkGZx0/]ڴ3`iMc-NEG_[[,2YV'iq;ew892{]ͨɰr/l^ڏEa3l 5;ZmҮ?of9]zW"sYctuq2p; ݾsb3E׼y8>Yw`&gkii{mq9ϧzjMSAT~~:ӳvUr 򖷬>Vsܦ:y>G?*v=q:^WgLP>ܧcϞ= n~ם fgn}:7$]?sjz]%]&;Zg=Y]k /(c/r裏 V37L 2|]/?B`*U_ E.rg(N[)e?'|rݡ=c:.&#HMiTg<wb7_/siVA-Hk>v(JcsuY[tE'Aă]rF׺ֵjB!};ώ)c~(#B!r]FB}ˆ>ŠImH?jy~Z9;ȼ ~`l"pC>ڣƲUg{O=\uGA=;H_u.g^s93cKw_η=krl휴1Ã/q>;$pw~Nx9Vvs-&EK+tS;~Ctch&s}"N gE{cfx7y:hП' а!kp ~p0圣s>A?sގy9%1 8p[??GN#pw"\7)r/]P?rF-aCVT2E(fk0ಷ0/qVDi@<ϭ1~Q' {GP|@dXov׵$3#-iAe:=cn+?"v:]d,' bWsӁ9'W?̗~1CΡl LŘdP`M%HenI[S ke(۱~@-0w}(7YIٓݑ>))iJ6u|Bx̂ wIcЃt\/O5_Fm[cisxKVoz Xxr/6-Ӂ?{J ˏ)'x _>(+8E lNPC0P[紧'Zď#6>t:z6}n,1>ol1[t-Ǽ$fzޚX[Gt^):pÙw, cƠ0G u f!D"g1QӀ`ۙnP x `A09clKIspM9 &N0HOS:i3(8 f>LP H3>w A#l%أČT2O22֔(%]ߜ J]XOQ9Oe<8 փ1NŚR NA+Zs88m(G 8+d2#]̗3ŰQԀkB|1'Q^JS$^vxO6q10@cl/@EWi9`K?s+s`L9RgNL?SΑ1j+IAδ' fr‰a%GdwRyU%jF@@ %o*yxA@P%oA.T@QA THRLTͧͺ3眙9̜W^ḱC"4?8Ӕr㵙Nm)W~3kHK-R=+]] mB+`Ki8eՑ#;z^;|mP>ݘn;dJ'CY#9ȅm0܇kDXO}\I{Q*@lZr`X9e -cV_{!c=}vWPtw4 |ʱذbDyK<쏺50܍&9E r_t]DXc뷵,@h)zOD[Ti+HGUh#~h1|#fxwk񎯪s,BtJָjMc 5!X9Ӌ9l}3&dΧ332 z%06[?5f`7L GgYh(}gqL*<_$R ^^d 0:mqV``Dr #c5xZ1/Ś7ӄZ `bPZ|Lj|c> ZIATNjowƢE Ea4'Kϸ?!$IĘD[7Cڨ,e3,KO^ii>ONt$ P1&D͑I=\Y'}t{8ZYGY2qB{iSf06=OU"K/5*#6[pPfIƳ1j.p4cbp2Л1;/g 'P"sN.gًoLkSlQ󋃅CrHl:!Q%sм LD;tݤ=DzW?.Əc 1'I[zҵP(#@vG`0*k+ dªixT 7^%fPQZHo XT2)B 0\:UJsegy|xZXo^x46),=AROi {0`1Ad^{V7>(6?C9IAta+20O<͜.r3>OExD._`@ߑHn3c2#G:S|}?rHIUן FqOLN1=,cA|0FX ǣrJ[?/3w0h 9ƱB"kH{+=׷\/+3>%0-&'25 Z{bN܉nM榵ה8m1҅~sMY儢WAҞt lBȒs4 !uW}r=l"$|ɶ'N|V.1cY雪>Їl^6,̀BW)pF`#">,Q4ƊjQf%edxA$PdngXdcRTg(Ӣ(R PPQ5!LM![ ,iBp7}h}M43 lL:u }W%DfM Ge.NL?tv`H!D6._s=gא30~WS\H1VU{ʯaq,ґdlr ΜKq+}AZ9cc(vS<=``bR7lKO2h9眓mPD:g^&u"gU^x AdhYG'|5IOnHyHTUFIgIw/ zk~+Qk*cK S{>A5  #Ō5'mjҬ.MKY@~'6ɻ`LQ\[[|ǁ$};R0_3T_O2wOY12cw/Y`\0:#Dmk}"'.ャ.#ЫJ1`Bіϰܶp{i0g"AHѣt>9m`׶oWNTq{oWuò":al=cږz 0b#Q6^p x7d&Ӝ*"J.uH:(8 P>]畓1npbidޢ8.nd}Et>?ƌOoէꠃAr@YkPF[d՗um[)G>;M (4Py<0Ij"$L^JD٫x. /gAltpHR04ITT/dt(boʰʷIm&%ޝ'eTEj "1xU(*W0 3FɕEorG>ϯjBEkHI| `&KZ҇g!+u̷msc^-cNG @`8aX3F'?GC猄^dqxa^7)b_1wDmى>0zzPdeg,|X;ȵMlM">W:T1.9D?cLo?oMVF{z_9q8N_R!N׸f[wC u-v=5@`+qJ@*{½c/~7 ы~Y@GSPy=I<mb㛝~'k^["2H\SRc?<0vw~?88٭^#gr.ptIG:[e0h+ ?{#m_+*kD*9|6weccJ2Zv gE8aM< N3 M 6 u "0XsYd T=[ If x2#gq`r PlB6՘Ɲ9C/kVJ2*sƱ)'@a{ʧa^i#n\zzsӽJ3DBb @qE<1OmV? v$Vꡛpr]oEdH5HxP':)'d7lk`8b?Z+V";"+[>uo5~Q@w$̩Δnb#1{ (4С|_gWX'P d&J,115,Qho3i!ͅ` '@b3<1>4@."$ 3Qy<"<m1M'ex>ߌ |`f\&@)WU&#@.yMVO#<>b>(kA|.8pBySQu4D ڏ{%S1R<) 7<1FSB5*{UCg|<]h$o@O8068W=s[Z"X\V] ̙?ƽkU] MH9U.ƳyA^uZjq$#~57C[yy,Ę_d`GP/w 襽s5ǡo6p'T^{}\MkYkqIo*rtb#~țah| /" "3үNr6kq" AQzoe c^,F!F![%E+'w ;"[KȲZVD{7z+' ϯ?x3r_˞acձm\em: e̐t,3^59kSJ"#:3JB>ǾdOgL 9Y\J&aZ0Ar8Wk:}F5+% c0>Dtڧ6c1o1't&0f'1͋]ơ1zQz yFqL&u)wL9Ƀws7,m.Mך3$%% |jNH)1knQ] ,tkWro=-u %{7Oɖ =/bZBLwt~)%Ԧ0N]tӣfGYo 2ڀL B>HjvixP {diܛ7ƭ +F"}kR5(_[94[?Ȏ}:0ޜuiИmNl׵Emմ&׹f(`m!e=ք/?ܤifdt_S2GY:8G BB[x,?O-C/jQ1BD[,R% '2H`,(b#p~r 1'"kUe)ʼn_GvMBd.a !i㑒wYk[@,e3,mg1$xE]x#Rwg9C#\M EZr⳾0DBÀg?O/asʕP4~R?F<:#ߓ 0~MnƤr'dymY"5G X2\6R#35 c:o;ƾ/euz R/='3ryq;)# }S|ӳCAywc8|k>Х_O;uu.hJNPd#pO!0MəV_(KƗək^)უLJf'pFУgKrgkdCHdkV2iBƴ>Mqq$T\ @'sh2 a$F))8ҥ!s$2Y^뷶V[*Zoͤ7H IDAT]=g0f fmTXP-$i]ׄo Ó1E @)y"wMkSޕ}hs::61Ày~`h2 -̇&z7 =02Z8E(%ŦuAQQ54 r:ղa֏  ,dC2Fၔ󿘠pivt-{VH` V#dϥW^R|'=?іaMI-EEBECB Ht.yk  쉲)a0 7x$`ߥȱBK[=t'm5K`ZiktA^vEY=""""ِРPByһ* EIn  +!(қR:ϡ<f8fHC:X^ΛJ{ڗРfc(Ń[rY,Q #  #@ҐBE$$x\"xK/4 )Ć+{vdX.  ̳}N'P@@@JJ_~yOk/Tz4BJg?Yz @"bQ!OHm3/$yT;֒|#wy!YX2u)d1ضfteϒ3Eg[zRt&ZNxTd?l;>As^V<I @89Ә:);cz-19R˖It3(Ď 6;"\G*((G! =أ(>´0___K*H'SZNʝG3OK#DƮ{W6iukC1vdT~} 8LIf5!:7O%/a_38cQSxM6)0׭%>$ώ|;=/H@ցTY)T/79Iσ' _B%[>s9`l)(X;;]vYJ^d=Si\p )nuk?O'_xᅴ5Ş~i|qhs=tz:P-2ZQ oYTŽ?7ƛZe+ٴy˨~t>So[e ֥vO[#uv}_|E0kB o=y:蠎ckfIeq{P뮻Pa2׿N/~Ov4Y$͡1p1bo3_|Ŵoɼ>|;{ Mk&)=FOd$^tW q$Ec^e, RE㬩/pzrSwQo/mh|]k|S[~_=o#ի-Ʃh[r$\qwsQ/t8Ed-饗:/ͯy;mUUߔe U:>L9eȑBUR6ēN:tP(X7 {̲҃pmժU}Cx,~;n3oOxbc~䀐N;-e\QFySN9%{wⳟlGy1?w9N_u9d:30 ':\TOtJ4o|c뮻UA!P7tM,P\ϳ>NDkg}IRґt9,"a1s|[J)$ik)~ƺg8+G}t!-NZq??z)]GMΑk&hڮ=\əgkėK+G / 'd̆w'(ܓO>7?~FQu,2q׿M7ݔ>`H/wma6`8afeg|uQ=3U,óW[-I`,P3 $jR\y啝˗wNkJIE.C xYn!m_mt:,~2@ qމ7 04O6x5,4e0}fhK+""9)l@mo{[s<D" B߱!= Y]U@x衇ҽ_ҘП /edvg'qǦ{ngW\MMē+6,Edf'9(}oZk4k^X~wx p#B"'Ȝ(UW]! ~O}*=O#H@7-F?9|'a?x'{<<}\ "Rw84s_Ț6xi>{ 6OK{'+V$y^. ,l?\;~J뎹B)WDS>NNdK/4e"B"Cdn進Ӽtr*IcE F &#E yI    /L OEŢY1tǧENt@E1x] ]Sֆ%G]9PYy9u1AdX%_>FEG1(D\j3a(5$ mgD4 /3N`/t1v%/rȕqP~s H""ov0`t+ ׅq3ϤJ amvm/Fz1 28àbXxyk^xW-l(sP <Ɉah{T$A3.zթhdMf 1̌Ϝ'2/ƃ>oBNJfn "%dpvzo@[z{Lq"lu#Cnդ׆2H4׀~~P$hxC!o?d('sFq?P'uKADҦX#o223Ad?( y!]UD!'eRHNӟ&&E|Ims׀dFSEw㇑i? aTA)\4ƚ)X4B@ﴋmA$XguVI}rS ܀mB\f8ysKоm e!Əq|pj<г1 >4ޫ:!|3]% }<@ ^ʯdM++ܗU6 qH#tPrΉAױMC=49 B=ݔMp(Y2au4^m kDhqOqmtm1]_37#MigI} :Aoo$mmLK^h&I7e!FMR"6%@\2B cu1-H6IylqXIec8D*xgRf^&K X"6(E/6C ,0 ;R=A mɽDfO(9xFxyEES O;;/-ɸ6HT6R! qYH0 `fD!=HWkx@6G)Gi {ᇯ1V#Ʋ )xZMEb5gc7Nc.uWDDk9en+"j^ [+#:N>9E@:Di>FP̃<3| 6Do9g6y{&r<\ƽ77xN NtO^4ʜ黜ӋncN=SqImuk tCu ֡*,+K@rH%ˣ0?9iUgӱʈnuAGy< )Ćҹ!/$ÄDgKa&(ͱ00r0Jv`R1Pږ״3xsEjF!XhiBĸ- 0<ꖶ9ʼnlbeB-EP1v-ͽ u t}Dk(23D62^ ށЁ22X tߴED p# La I%/8!oyۏ*@WN  &}ݻzSq{_Y/g0RWCq|lfoS#gA zcJ"9}QՈ(y'_<-f?dH'۾gy Q.s(St-ɒ,dz/z3E 4# s}^UbJ_ KGkߜ("Ks`#⿬ d$*(ĢNa+e3g ɨSCJLLQ˚LNMK]}x- i^PRҴol[,=ohcH6tS/S=2U83zm*`A"U}Y=]ͽM.@[0([W1F|EDrG00 1A%#'iGp>:ِ1 ЊRD9ySFTy}gF1Oy|1a #4/o:cAI@/NIR27tT7%ΰVVo|W?3c3fݘCҌ&qkLt9YƖkGZG_$i% pZ#97HV0hX'@c)ǽ`^/l5zE,7h6M^yqPV+r#dSX)O)㈓ 4VDV*F_4>w;}ΪnsIT_uYӵe ,P VĶ"޲_{9W 'Aaf(10qȿ0 TqwF 6/мEU@|'_<A42+ !OU Z~4:rT[tXrvV s}^Jq 2\GcmہJ0h1P:0TY mbZr|Hw ^yǏ$*˺qr5`%.=g-CR;R7nڢbT ܪybl<L㬑- CH"-rcPB22-UO9Yڦ(Yk|EV;S4Xp6IvxH@k]'~&YR[Ri>Z*Ʃ+jwP9tu(((/䤓NJM@T878\"E|#=HAwӱ8fO"c򓚞;*ȩO)z[%F `ˢY >,Ff:WYA cM:0=ΐs9┃BXVuN)w )aۀF dhKwC!b0w2cA<#ޔ2 9c&0䟺8S2Wtgս!c}QN/uw#.1v:]Fj/{bXbi&H1|f7@z4ߜ;Id8P[!t7s4yqIrbO1',5KyLŷ0H&[|1ƣN)v؂^>闲(fѫ82)j;K cx i9<r^[~y;n6d(W#џ@w6OKGzok =/` ֩< qt0G޶5H  eBqylך58ȻE">DyYc%#a c]`k"IH EsaH_ߴG|8-qdj;`9e:=ؔ bHC-bً@<<ʊt!u[)BXU~m#RơH u(+PG'3`ux{-쀥H~Mj Lmxքˀ ooabDM-mZKK':ҚX?2:EYQN믿> rGqiCxԭ*I">vr4qgLCV!_@ "mR!(J>E9™9 H?vH"G@gH3wXO3 ڛe<OM m0y'ўЉm]- iƬLhS^ɪ)U뾜/zd%`P3(5ƣE;bA# j3"Ă^'W'% Uue,w1m@&GO P$`1.Ri'X(y'cr-~ѦeHE/Wd~' /=P]NX&k0 "MF878AE+ hiDZ&Fq"K<9#% -~q/M(YEnZB~b3Xx战sfHO3O]X?IUןc^UrL37 ʖpԐe> h1p@]G٠ʓ L({E-w/30o#Ë7o #cu(FY``XG!Q~+ i {@]\swz< v:P`\0^f#1Â=x9U~>eo py[Mr&AXBxֈ :Zb׵ .ƒhz̓'29&rg@Kosӯ5;993ZoA#Yū?R~^Az(λY-23J{iX0EܟחױPbP,BÑ/Q~y/Ş[㴑$ŎruCN [2[b^E5G['#[k+RZ]ѼLUat XA-2 CƘm" uoὮ ߉uUj_ber.`s\W>L{c,O~A^z_Xyixd> OE±WH`V%8`|Ȣ{%=94lYͼ9 dI!ፇTaT-X -IUH`$\fI^ʫG/drϲmZe_Gjےj)g$0SB'MIWnkt:#p !Q&JT+Ha@@s 09H1,Xs+O8lg}(4{Џla/^k EE$ YщSF{ ^H >L^BEDCK!u[<x* ̺8ix9TިBE,kG]\{)Ժ~x.@<a=R\^qyHHH5 ,QZ`QK0jynX mtϿg6oT_u.X aHTaV-,s>+'K:@Ni3rE@;,_<u8̡pRJW!rkOӶBEEE !BHiLwx] i{w_^8:G10mH Sj0ekhgH\[$Lt c0PJk$M/3b|_Oim]zK woڕL4Aګsg>BGO:9sE/H<;@I"*G8}欳J=9ݜ 9.Avw ~=~~k7"_+WL b>hZTH`0rˤ/A{キLP" _ܹꪫf6 P3 (X rYp HZl`%:zMQHhе;=Q@Js<@nkj;Ex‹`W^S}Y=_Duʒ%J~ Axhųdnei~_>\|uK2l}w '"u\+MH`Aa('} Ee(88?(B(0n~8ׁ5QwNP?1}O(L)BE$ ǘHM ex&w=yHtKU=ԯ^^W&~~S` P@$kW\ED]rww'?>KW:Tzگ>lJtZqtoo裏^аtmGW~'l.<@+qu%[?QYtEv(wScö2w} 4]}kѕ &5.u/OwIodg0':茻z(T(wwޙRwu`5Ld뭷NϾfPP4q v/w뢛x>ӽbmY7KGY]ax^Emld$lO~IPI^HF@ȼrò-Àikk/~UFV[mS|iA[,77rzx (-Ul7I7ڛ9<BrN9kӜemb'xbҧlpē=jM6$ miQ.:K.Ia- vG~qod˅R6;}?cJtvH pwS;=:'A vwv'y1 4d7IlQ㢊89б]R[o5G!oo~"w k^ (DM4S$Ѹ<ZIar0^0Pu&I4s=s&k1xgNd2!{ݓ.?Ȧz  L/n0K (ZDJ;Ţ)h.ܛ6@Rx ~DVYdI2729xG9<J$%`~K.b@p(14>y`SOúK+`epΣ9drѷM3GNH=GCO9A$a-wqG/ϣ}ސs*,>2ٝ*k:-Z)ZDEܪjժd"vhc{jOr)P):ڻEtH^=!o xjrYgtoG`&+@|I`A!CCϦ^zo}+M{>"EOZ#wit}82|<%w9lfOh*5^WU1kLΝ#8b&yJPFGҠ(L!iQ6%=?8-xB^#{G&XS@(BE"4g`Ư>Jy$k#,~Ka:Ƹ? 79!o@H*Xj0'>"jɫ/J Ouey =!ƪq} cq>&+ 9MdCxc1m6CKf/b"\H`V$$ SMeu9<'[=YdLdO(\ư%KW@$Yk8<-3ҁH򨦔- M_o놑;g ޥ\qisԷES `Ƥ@yx4-6dm ZR)IH"xBDeC =O;ZS3]*$$iϥQ2;]aޞu?# -TBr]wݕ&㇥p2&UmGҤ9!T(3JCI%Hfjyt=}+VH`b$>>ȓؐa`*CAGs,bЋcTJ QmR^H`$`AO^Ʊa$j h$dpjƓ^W>B6&)RX"T0p:h`&\5H@1}/JMʩޓOJ[ߟ)HmEgeLF2vڲj)a$U_~yxB ;㒧 .H)a~\z饝XPj, HW23p%8Cai=3Eyիl }rʴgq=y"\R/"ƃg8e;IݮF( t?#/i=U711D\"#;,eD]NF6RH?%o}q$uf<Q〝%{I!Iߴ\| 4LµrϠiZnH`I7]m>y֑&t+VF/ (ĸQ(E >@Ã1Md\.8 E1jԢ70P$8kA!8q/0OD1<30, "|axC@u"mb p SGHH` sc:4WH=bKiFtN#`rg IDATuKQIJ|` h.8 Ng$p4}sҿ?=l{ R@vkHkmtgh(sY^0sҷ"6էKޝ8s"ңS w}"ZDD*p*Y 8c裦 fI/Eaipw8od[ 0A3?ZMuҴ%RNROgRJm^?묳nQGy,3eDϐ.d߯^q pAx@a:"B(Yt0+ / C=4.SǤ.r @űcc?T=CA\Cj~lڍt) mUt9W,k3]>Spz%`=-G 5 =pw$@ݳ¹Vƅ#o @}BmCeQ> ,9 ǐR= H~Hr-4a21@J.mf9jړCE+ AU@ζtLɺmd @}em{L lW/ĹÑOԶq @X U"E#*C{ua!W~d!ɮ <)b*#:^G7uS!@PF~EH`Z$x_7`s R&tjSKy^ۥKÁSE-]((# Ad7ߜNzse oяu'޳RJNjKd?T'+-usm+gT)P@tJΠowi%\I Cc)[i^fIr_x駟;mF')d0RഫO|RG^&/{E -J'"!`  E(WJ%ɡ5b"B.l( ѐby/n &{BEE-k_N};ߙ8((dtx~ Fѿ?HHHHp'g'9 Xwh([K|)܊15IEĢ$<',,T$P$00=_WWhAH`I?aP$IЎVAuYMKYEEs*ipA7t\gzCѿY{GеX5U*.hH+K}"xDі>-r}9s i,GVXt=J*T$P$0ΊqzVbn)~s=h{챫 /  ̧0{};=5Ѩ0((P贋Zk,9@g! =iF=z"Iތ3w_r:gUx.7 7;nig=h=JHf7_jUBSHHHFx{,+M%(e3{;K 8]JwJ`ܯ]lI:t}]}Z _G IG#Ʈ>6MEoºwE.䙗Z"Nhy<ԙvvA%'CgBEE#=w^ZEm8ur"qz clO%2a8LYq-ƨO$Od_dzh goGo0D-x2t<OBj@ QQG׿ oHiȉbh%R<^ )!4[&kfUxs#C=ҹSQ_?l>9FzI{#Z-tTf E,>0/7IjR.?:?|g7NF$P.(_ ' ,{キ;;r (R4ͳY*xb-:)cSN9%꒒*F뤥:T&{{UDlʽ"ZV5t}ΝwynR98ԾMDGFmRIikH` Xe /vi&ljR vN:-G(""-5U4Gy}NRA ~Gy'hOT7h%g1h !Rz܇L   /{ ̥*}':_G`If'8d {=1qbNsU/:+[Dl!vm'%M*-HYO y BEEEJ@[n#5գFgMƔT3Ѻ曧Zۀ0xC{4bܭ(T$P$0;xP@d%`9MI8N?x8dUPCCl6NxK$|MB%W_\l헢qq*:`]zע'gѾ0:s}x{RiR?9Dt 'Ӕ95%Q*Ӌ.Y|yHFʹ>Yj}Y[$0i {N߶IPzkti 7\m!Ha z%UZ/aIa`9k_Zz-@[v9n_VuYh$ 0_,)]TT#w9HOOU3S\ȓ&lZE\H`B mݖq9ϧu.<.KC왜aB]-Ilp$w~Ӿ}ZN{g]N?ƾY;Sz9BK_RR p pN{[:do/Vgsq"Z4*'St'U 3 oLs9')m)3j)*_)lGڈ.4Em֔i۬w󞧺:' zh+ѤHXBEE#sQYKDp49j0TYUvk6E;: ":=5:'A $q*襕;Iq1.;oY,]Z(<6)rAPvƪ;'cH֑NWwݸ^y={)~^^;ԠwRӷy/FJ_.ځgj.|UIV]=X)LRF$qQ$P$0RT).J](6TW^b?sv$THsC=ҲEEsp1ZPCD6I /$O}*5lfJK:)[N&)%'`ɛ΋ IS1}'{8 3 cWJ%J}YRڦ4:QjsVNxRz`*e|zj 2z=z< s2ŋl]d^/9W^y%ȡ :G?Mh`c@>Dumv ?X@@`̋㰓Hl */8i9TH ec >~ꩧRjy=iJEE)W\U9 J&Z5dcC|3I8JgHЕjJG6Փ#kXJ\յhN[$`3^l\d+0/ yL ߤ+1&PNrx7WFxpV`ϞC)c`fa5u<<Hs||ыCY:yJKe/N(& Tp>`S3#Yza ܁,N^B<1y60_Hv0^9lEI=^ϐ=pOO lIQ'DxRP _kً^}t ?P nii~$dqfܛ׼[:Rllc!waj!M]{g׼5]2h9paJlu2c_4")խB 9##fil6@g{I R0tb]vIDwyt0sPA62=+ `>$믿> Q0F&0B"/NԾ%lv \wq)*|XPzksDe5mȴgGt8jWtqpG/vG: | P+;뮻n<0ăEP~|;~OV"h@Vi;!mEd;ʵ=gQh}@?cD,\H>ſp0^oOBHNG1/'ɪqvw|(T$P$P$Жd9q2;o{ZקSX dwp|rɤN)NLc8[ q[ror`Dv@ȶcCT&u* }ܤ K嚘uzً{p~21I^B29Ō hPixxg5'xH=dGNlK)^:/GDL.&%6RBpAW} 0)rg!e^CP 0#_~^S?H5 BHk C~$K/DVRT}9@bD"vmST.PGj-F)( hGM, ?(emdjAՆ&dl]/|)pFٮ# !g]s5irtYVG.]3I2EgS̡I[.(Xz>)s )p1emZdh'|2r);~R-dpZm&_Ȇ FaZfcGY®rHN0N}fs' ( }:VA!@(&-QG, SE9k h0ȯkٻ`ۊ~~JLh*KQcEMpzF'P'P,N (ԈCԨ8J*~}6xUu9w=^km`ĺL{ CVȚe.\^)S/R),n@Vk `<2Бo-+8`ռR`0cmB0 `O#8h6h8Vp Q{Xz54uu|$(xFky`l<*G4 vX706O@GѶ:ZIBO+%k#m2y.}EO >tvF5OVm՚h@ ?GM`xZډkY=8-S0$XY 5?!edf/ãU-E^khQ'Ϣ'.ׁ6:gWH:Njh綠<_ٽ{wL/<RO>?c\V7ps¸2.765b IDAT΁΁-}km+aN4`h} `!릭|FRaѝx;0p|x.'xmr`AIjr&#(Zac=BcN4rb6=d  :7BG ؔ 8ltxz V#׽UIJ=N=hVIPu=Ӌ1:u/RH g!tS}nrNBܩ@PyBIonS q;ܡxD fהmLht,w.W=#'ٷ\p ]bBepIl|ipX4@[ӽ&c`д]5iXc@k؝j~[S}6r ҭnC:H݇H؎}^[zjٿE1^Ʉ֫/zLk̓,zGiSV=x&!83I A7}E x66 (eó]SPdMJ:;gOx6ۅe5<:9mD ,ޝ &<0q6(ʼn6< '?aᛎE/o=w@^'GgAtJa 3O8va<Ё>MzPzޡXH`T7Tqb|ut2>Gx؁ǬQr{_Mxr諦:E0p Wssss`q2NYf[um61&$''znx%oZS51l XrU^90c^Ԡ87Q»GCn %Ħ(L{ PMbG,6]9 T`}zC*ʛ0!hVo`g{A!$op>@FVFxgSy]@k UH̿PJ^f"emkS=|mdO^WYyzH> H>~}>MȠT#8|Rƈ2G*9j#~'~ZB}U'(4΄%N=Щsss`9`cd$ vC䐑59C1C; ?RzCy25ѤL;a^./zvEym.@abTΚ<(\m5 qV& dV=(3sV{O9E3N#N~  ׊UZ+7p=M+i[^+OgÇpSO=Xj})*w{tߟX#m!'t XZ4eIG'u2)#54 ݈n.2h-aM7Nq:fMKdKѬ^Fp3蠥SX5d?"D0J0tښ޵q]@(BFB孤]x2n: cb|ay;uttlD?,1*veݘO)2yC_/akIa5!@Y) ьq-XkXP֌ut,/X  ]kr׼ss`38'KIm݌lTlxg38crgVy]{[xm?Y䓶[7=@[_z::6@ScyRԩsss`39 ϖ )Ç?rҞB ߾alu`hO!c0Enl4GэK^#Xc}8o4n͵%UX^5&-/#PɡԛkR^g,۪}5sXpFص80ӿ;:v$fe^<@-׊!^5=~+^ݻwSFdw_=y;[^۰]~7va;&ĝzO>MV x3|OɁ']aU#ÄYڋ}r=@Z{4l tK_qWޗO q?Iuږ yr$>%_݄O؊P1b 20X$77 4gIAfr99Z׊e}LO 0EqIu(guV'sGU`uB)s4M2v(w,Y}YBR۬YHYA)CH}Rg=kI3Lz&NS&<7㐶S*7yEM.`cwlrfrܠеO~'=y3Yo&zk_jc(0_:yRcX9AOѢq4d%z p'hvEz^fͳY?#, +C/**l՜5dQc O]\Rr")_ޜyr,_.{אP]uey:׹NisB7y 7,~⋼􃶩5yY-Oy;_sSR ɓ"-? !J?_{x]@=puAƛpB#<1NxfKwM{eQ)Pd\\/7ٻxK±BKc6O?6owD77- PȦ=\z{IdĄ 9k.!/EiyXp >GB_|Azw&7~Fɀ߬+h2%Y((A[Mx-ۺR Ryl990́N8PL(]@wv!(o0=MPy?ϔpP 2ЂO<o_sN)o߾2'd|ok_tAO>5K/\xᅓ~%܊W!OvIAK /2UM{/~ԣU֢:zyN7>U|>WpW|ejy>wKgAy{ 1/ʋÒ00( eySZ)eczo((/Hd y#`]+/,#HfٳWdKo|'WNo}G=mo[@Ve1iM\Cr xmNaКdM|[R³>±ɍ ,`%(wZ=Q߷e~s9tP)^@G(0xdz|Q q.`P(䱔$mu)|{ X5Y/{"#(_./ ^t E?^ګ^ D/.r+3>,\rI'''f}`~\CE7@]r ?YL$x5xK .{==HHT}w`fMQsHQGUB+ tOfLʉ7d>꼢]zWP;6N~#Oy߾!pyIv^pl[PHA z f,e`Hϊ}S@9@_C,kJxM^QP:(`B GjAIMrYo7ʣ((#,VMJw 8ȋ/Eyxna#7(YP(kcWs(dԧ=iEcbc9VPxF[/]YS<p@`d~ JE?^N`c(sumu{߻(@<Ї>T<(ǍLBexmP$xCxu}!еGqojտpyA7{wZLJœdL15,2EJ:i>~1fkXqCTik` VFƅ1ư({:ulN#3r0ԐMi]u߄0:P!S l*t, xQFcC^ZD!|jOt91k"ZS b'o>!iN=r@H}yq<2RS<ʳ+6|erQyxnjvP7ԾoU%ųW{dp ^:4gPWa{+'ut1a1J?euc|KY2Bj-4~Q6K:! -/< KƊ?Os^ڄjìϫN/W̼0?Khc>3py=Z΁cޚ rǚ"^m)ABHaIY׋{xӷ !R{巋г Y,zi e,\faGJƷ>Ti<+?Bzsɿ+]"cjL+_3ꙶʻSf!׿C g6ɵu^bP1yBYKC4Zo 11DƱ1N0L{kCy5sljWoZ{1ٜk=P24PŤLknQ󛇒U@V}v-x)O@a1m6/:?!~gS2T}sվixMyf[?ف@$ x!$^FeC=t;4asKF;;%ֺK wJ +  w`QݐEC8Fw4"g\΁y eIh .L.O-,>BYF&eV[e7op#2z˓E_-_ lA?)7BwSzQf¬]ӆ,x/DK{YyHz?D^Z_ 8gPC1QX)q4|#aPGx2(x~0{N'~46O< --x^{<8/mH]ɻZe͙OIM>C"tZx2nrX|\#fOLIʘWNFBq{޳h6惹"tvj+TmLX1o9A1o! CzYs׾Yr~C_Ȥy"ӵUdqnMqzL$g\ַd|Ձ5~':Ux=ʞ6};;}:y΁e]I,*rwڱ4"nwdRx-$Iw:V tE~PqF : 0˂<;6]AWsq^,6,8PXt)xW@` Sl6t<A'tA4Y ~V& ?EPGi`Sz.Gz;@[)A=M֖^F Ь{nDt考&f-: "!B±NGyGx==Gk(DQ(9 83 ,*  rxFp>hY;(|>ÂЎ/)ɇDftJ <}}3Q|; !`q@r84X*B?oN~N h@k`!J4džbP4(dqc1k}2A6Vcum'c€qO:uon9Bx` 5//"AczpCz0,E'CFucF>+uy"??Ԓ|= Dh +@v dALx)z: ]}>SXՅIP%|JT Y-*%/Iy,@(!@!000bږoF_9\Y>Y,9XXk(@q+I'=rLA 8.6'HI8]p7f(48eGy߀q.k #casq>yim9e% p$?E82'EsO1NȸyiK T2Y%&6eƎ9#yUBTwcEsC2>d<~K̛\/?#3I[ȷ'eU~k;ROrW:Q:Zoe_}6oF>s^*uR IDATy rW cDkj~z}=[{gky3Tt R/ owz`,[yV4nr_|,v<'9B̫ !(cųزz" cq Q,'@d#L'΢hA֩j1x(D K#P!iei*U5Т7EI=x(@%][{2%>D1Sy%yZ)#wGAʛ7{ L#us<ωj,/":&_@^j\9*0\\,-rvY%<1\4 :L[CD]'2]x"u 9ޑp?|~>| 1d S7[e-o4ՏL)Y A_Y#܀PRvM䖾?\WYD ExƾEs9DX|TZkϬ5!ڕbp{Ѽ`D1΀i|NcZcGxܫ۽~k~տx>90g"+ȬsdZRx 53, I#0ʊ,CRI/ [ 3Ɣ_QF2SN 2 ;{w)c%JG[PXw$2Bf P(mQPط8P 6dϜŜ䎁Bϩ@q]RC䐓1bU4 |y|[^>ߩ9D" |%P;D$`(/0^ɭ<{C@kXYOVsxf}j3D__XJ]YsyЩss`s4`3w֛EEZpa!5@h(MQJ/y}Z-cٵƄ %Jc7CiS % RZ, kmeC֛!OB (GN}E"@E|XB_BD9i"$L2+Z$z< 9kɽq[ ^>%)0`!g*V~'~%@_8/>}xhk [roצ?PZ%W 13}M9Wt 4˵ׁԩ}&2jgbD-Bd/FX؈r7 |.ۿکss`98@cLetMd /ҚGR9d1Q\)׼^۳е(ǔg0f>Vr:񂵝.#|oV{֪>Td1`-G,(Ԝ =˓ /\[B7Yy`%_cmT^M<(t@&4f6{A mI.O45#,$=p u\ZwbXpB>( x5@^k[Vss`s %O߳HϒsqqAʠWY^Z;:#:8ah@!ƻтk^:ԭ]0ϞeEKY09ϏYisVxV'rv#?M\YP=ǮyC yx͔G o,H>(3UUnp(4EM]I4mOPBvꙅў6 ^;V7V<ʻЎQ],,O}?L~"וozqOL򶱟N /Ϛ' }#De@^>Fڂǎ(W'ES(Po XAՁG4O' pշx̾;nÐ:U;@Q sxơk0xD{ƗP7bJMuNGqd')@ҧ}zXx$@ P) l8|4@ƢW /$@x f-J o" ͺZ |gwDx#hߤ=!} i$NאO!}(I`ၾ1g?,Ɠr/%/@,8٫M̃|߅;i%+tV_iPDZ ;uo3sj =Ӄ0:utd4yQ8do1m`tKZ54#Zl,wOkA>t 2S@rq.Hc8ZEkf$3),_IaLMޜEs{ǎ{hR{E na2ϫ#y)r-Hh-{1E;  |ow~|ݣp1 /!/{{!Oy-BF (suL{ @B5C.0py|b`Qr] s7hƚ1`#mwkO35o55'AOBTy$-N^[b 孴/d;/>јq67V˓|@@Nn?> d=jefگK)Pry2v>ۑ W#^~`!BN* iV7a.(ЦIϷs`%0x呱<w^s)L<򚇕vttlg,A3۹3z::v /|z׻^1v|Pqwl&:#;qR>ƉNbGTh"pV*^E8lE0B:d18)^΁΁ŁŁ٭] O&ÁgEey'X]vYy/w>-Cx_ǼWUE2흢Y tlc (< U4{OũG_FN[ 0պ%jZBOm m܈9Pa[YUZ97@va٬fӍo|4]hı[3b"!-Y*ǎY ][N˵ysw[^[ΒYmn󜗾}~gV߼mҫj`֚&́}giJ_L^Z*nҶ/z(:l)/2/~}ޑxk\cs~}_?O /7+(xw8ԧ&sċ;][\3޹ê??jn`Z!7 oy["=kef¬t˿_O^OyƹC/ykNx3Gk)pSHS&@RSX{LV/^D1")Wyw2A^@=]hcVٔY2I]XJK?,p\r#HZvW{=vgQܢY }m{-Z3q_rQp6~+jZ׭98`}ӟ.')7J(+Q -ta_,;9 O'[+9昉Ӯ  m!7g'ZJ _|3׾K0p9| zh(<)0R9 ?g)Vư0ӰCx#GW:Yih~[*@@w$W^9PB|;7~{cS}CeG] 'K@f.$b0+\)1.җtE2q'uj%#Fۍntbxpճ2NX`mEx'ZًCZ`<[( |3K:7bsJV΁΁စuG ZK 7/x &{-ʴ("gl(i! 6'R/Q܁z{ޢ3J}y79JX6w}[n# Hs?C96!hR>+}gz׻2WW#kto|')W( ڊWRWdoi. _>яECl^SO=zHRpC}_#D{X_>7èx䝦~K:@B.r§k{&Μr (\1f(YRC_x}{## TXxӟ^@~Rgk6P%#)hWUuD|goy[8akN;5^EOs|?N6FG/*cCGK 4SmpPC^A(Y@bēK)q-#ox<:+@wʳBE ߁%+_Ji9E,P袋'`T.P ƏrA˞} Dz)1Ҿ(=cOmƌ3tZ_,{6'sȺͮyス|*zxoBG(lq멾JhaMq/m BsCMО3Fhl?i̹zL9(?s5[y$_LZҥn,<}%xVڂYKy#-+iBS[tI'\Wol Sm3N[Z4!<׷rӞGm IDAT^v;^jPS} yN; F&No0^_oϢzpoJ#gSױ?f}P(pJkD̳+ρ%e--yDؽ{~@>W[{ ?sE3ϽF<6m/!?gĠn^jO-W>OيOjw$j˘cԱ֤q>Y4$go`@Z" Ab&C5 'rdTV( ʮI9dL>$y_䟺*$Qj#\] Hʑ:Y]' Geȿ{څ'w)]N|GooϪ;>kr_iO)#rw'xƐ}A|)!Be)˜1BK%Wb?(!3) kّgb^Pd :3} "S B Ȋ(Ad" PG٠/SWv $@L QZkt޶\EƷiڙg}TaAϒɖ7JwK5}'rR{~h?$/f ӎ0g_(0c0O{-i~X q ʝ7N2N j6XKC[~x0AHq|5g~S#<넧'/2-c=IMGy-4<x]Ӟb$ eȰMOΔY2.uZ͌[u:Eo`bnd2hY L*E7Ey (H) p0 < IR/ ,` cOF$ʗk u)!$-Fii Q"M1x\Te0*ᳺ)j6<1q,Ba6  鴑Ex͚l'"Dm|A? SW;ƫ~s`8тd!*bye4y(edQ]z_xd+w<2 +r5J"N!jʧx3foMJJ$y'4yyQ)HU62aM?ceialg˳qEu(lsFFrk{ʺIn(2>bՙVk3{iCyO-CJ`m;'>e"o.d޽ 5 p`ϫ\O/bOvbB:9HGtMed(8VDSl20cxZd @h, s&u[~W0IlylO!FZ. 1wU٥ tADROGsJubѣmO%'ÚlqT;4'>뀲7=ơ]^RNH0(G}!@Psxz]F'D^*O7 1[Rlg0Q,,O<30'X0!ԉj%P(@KgqX dk;%f#ogv^L.KOp aKM (v"ʴ9o "/kEk W@hPkym)8Y@nDAj]r‡@d1:?#)PTPr!%Ӷ(+,m~BUk+liעbf]#[bY}POJ)ޒ<T#_)"U=0 m})t3NLuieTkyNFD737xr5tM`ѣjԓ19d 'ܕA+:ϒq WA3!N=1y :g[]H ,Fpc\dxt d]$:֙Q0JmǪ8 iޙ )9dv2^\J١.'f<M*EIz?m=O" (Nʢ 0@Y6ʉ!-WD}0-ߚ@K}1Dl}~#?tu񈑅cOmdܢclH5z{aI8<.h˒n@?xd{ x#]J IEe2aB\q r;>{<(LDHNا( i''XXuLf-j &vN#p_M9E^׉8N5Q)(l&D>u/{p1k/Ѕ(exM݄N@{6UKL7 4_9`Y6wɇ̽_2* wh9XZkNvdו/u$ q+yE [Ϸ|gTd F rK u߭ǢbDXMʔ=SHV@ 'TkKePl0釞^Di$ cgN pD1"lvqYE-Fd)Xe{՝(-r nH Пhl9@9Y4^ Y2NC}SF铿_ڨ~Ƈbs3#/>܈1>/uA>-;3#rcȂ/9‹Mnպbҭŷl~W1_xŕ,݌Mf?Y#}yQ3lk#iޑ^=6.| /9>2wUV[[2B[4Q&ɑpˡ:`(,^Y&`,(CM"Ě!dȾ?A<;|,]C@LuM>A9wy`,vh>&C\ﱬJ:7,nA5e/R[B:M9p7=d d޴u9(Pf !JB=+CQ_upn 2!!Z/,.!=Ìqh**u`au$LSkAcM[8\ ,>h`%Nm>k SƇqEb #)ce#;BPaF ~RZn|+?eG 9|bM@Qn?F*!(@ *3 զ&9DmrkQ{x[hn@O}HB992Dj@BR#!t u|DS82 <-9d>5'@ FIk%g *kNoPQ81){z1b27y ?m:`,91ўFK" In05j&38(ߑ{ע˓  pO=Cuc@X=7P\ mʺm^{Y|7mM@*xQqL! O(CYk2 lw<h33`քD܁wǬt'z^ H%/o` M1 7]]Do:o2nA>LiG 1& Bߕ6c-QCH#O=Q¼9%=ɞN>rVG,ˇt6u$2 rV ޮ2*B SEIc=&횁28I DuD5X3LL?$LşD&I0(,q <7&R螺O纅MAN>bDrH]Ҧ]QV!}#.=N>U~pW>+X Ș MĴp0~h>Bcj$J<`hȻi}rCZ-w {uiBqy lIZYV"dNOGǨ^[hltߌ H3@]A00BtQo:o0 H_&ʋQF+c@)ڂ!Șx`m@^S&Ty3tO |g{Ov.ut`G }@ _ms xm QxN轳~F&rڼp'2d$3t_En'猁ys =+= A ۘN}~c5qiKَ4ײZ[& *gO b@l (HDg BE" 7ōNpm`0pm\9+!K11):'1&4HX}"<pd0 z 8bSAXǏ )vab@Pi,pW7Q&0km){[ܸ@>'=A+4`$hÃ-RGy 7 nګy*e YD:u' ,|r<'O2 JYޖ:g9X(Uy)w[LJt)zu~3z@@Fo<=k8$ܑ>KFw5gLj(9 WPwH=QE;7NTzߞ3N:]|k#1PI.}~>@xC=u>QR:86m6UeKKHW''#>@kʣ>,@=<4?8rh `?~pـ,W[=x y64)O + +C@A2ce`\8@GIc5tLnX"yX_x hNt47Pk%DODz$-jJh$t|P!Rw^=c}t*ɕ6vН۶$4NT9jcr=7lvQL4[; xEvJT9$a^srX 1桒37F0,@¢+&'qL]YN6GXj4 6[?G>~.&8/om;CiV@e7o0TPHr[{ s΁΁΁)| \ YLP^۟xcuh-xBEVtRy _rzuʐ'ٖ]ף-ggC~򗿼ZʕF!K)1OrK>~ 'C; }]OɳO[*uJ^y*O-|:GQW/bPȼ1q/L{rRM_5*c~ͼRUW'EH| Rgu/~Qd30Tf]W[K֞ѵiϱsss*ɕW^9\­nuN er! G Y_uew䵮urLc~wwe]6o^J]z&su'Pݻw.^q/|rhO೺\, 7it8m袋&~<~o ͟p47{^'𖷼7y=_e/??]U~_םw]>U:6~r7ɳ̝] >&7 @ 'ǗN,]r%O|5q䵹Ln ?"w~O֘{"[wO}j9qq{ܼk~ZC~~C*2ګxw7&Yic9A999@9WR\w-@җ(<= 7-3LQOf8R^3wwr㝠+N?zы^Trp,@]?@}PIaq[ܢBwO.xx<̒^[y/x׽+mO>'=IԽ/(@[z` RP:+^}}>yyM^O:╠5)@M.!ye/+@Y}7&MO{)@ z9>yLկ~AzPICq[EM~Cxo(Wb΁aEd<_s\1y T{lh4J M''EO)Js1 od'81i #2fm"< d" .wZX= H>e;\p;boC@?|QZHp@Eb .=i>Oy,ڳgON_WUmʎ/nV<<,:#aQ2 0P ;޾o}{* J{(kO ȪOUkyI'S:> N*|`0H5Q)<* x!Z! oSB^Nm<٩Z`ՙ'?W}払/mwq__o_u "D.0x(bhWr eȼD@9,/udS3񌒿?I<1)SQdWDvhh<9E.m Bͷ h}lE.i8sXZPЅ DY|x؀/&xd\k5%<stM;/yKF-@C9(A"=l7X7E,xiE9b Tʟ* Ewq'!d^yC JP43J1g| 9_җGNvUC<$*uMH6_Jgr R<:Qx0vLOB Cy˸͋4_닔4 J|x≹\3䐽LMUymcVE_LAooS8im8A9990cphB;-z%-|-h$oWK+/0H;, &SxF#yӟ>9ʞBdk_uns$/\"Wz  A=U:i7<_M ~ RWBT+\O0빡 ޵ \mzigQȫ:-Y2?T;O+ߕAy< [ *-[>mxFZl(}V'iz^Wo0-]I;zoA3Tw?>~;ٯ{eoP蛧({Eru B\) {oxRz#U!jPh3LUPCԶA'dSB푾馛B/Dw>pu]WC]y(r'uhBE" V |3 }/_s{)u׋xP VkjS\h&|FvظaY '@]Kw!"DekH^.K_ȥmxo)G4ϴhhGF+GDn m53uR6O.<ƒ90@4_r"PFA nDncMX:ӢgR2E;y;|{ d)f?,Δ0QHڃVKixuUk=)r8˺PPga/a)ϲP-Vbxȳ],}[umt8@1a 1(#1m3Vo~אָq2OW2T|d$3y׼H.*.{{4^Y#x+^dӑӖjDꪫ*8Ƶ=LMo g逰%+PTh)վ?/Dg4du[F<'k4t?@ 'E{i^KU.ʾ-Ѿq2C (>,[RAip!J%>C&j,A!P8ą* pJ J KUY CKtPe8]X|N ef6xQ@ɫ%ZH=Ƃ~m3ע,Fֺg\Pgׯ^Iro?a›vP}e%}pBJI3Ƅr 9N6XzD 5iSW#s(Bj!h:3 !jY)MN\4REѰב@)oY|)1xYF@t{9$_7Hk/pD) yJ,9F^@^s5bLjSN # 2GR6+Tk>1Gz.dfD~i0 4RSuC˜5eA;^a")o:Pb2@{*;'fR?8kC"Oy@M캎)H^B!cyu7W\qE_&xHF)li34C0)4O5N:މE'xRȽi]xZ98D.˧ <'lqNpet Sc "CtMT;%=D$@!pd^92U6V["R?1Yw<@?Vh-d|4P'ulɺЇsS9p1ǞzM½j ,&sOJiD,t" bV%AF$VS^'`=*VewѽeR(l8-Y_1[V*}uRؐ,uDyr;T(ƿ,}- *KGpKq6g^O 8^zSY)dp9`ƾrD2d,d@#_~K^g$6[gaCC>#5(4 DkoQ2(_k7{o SmXv֩H38ppboJKOKz(&$(Z)"),UZԁbL9Iygօb3̀L+ A{/||  MyG| {23P~atCߎ>.905yFuAa 0֩O>/PU -(vjG8Ɨ<ˣgϚH 7u\n_ȯer|Ta\Q=j\C`!-B5yD8M\B)m rQb[PFQM&i?kR`Pb-!J¬9{f)`9ԃ@daϬρ}3ŋ^ֿA'uट_ʅPL\u߹o {2<(>8@t($6{. lZhIڝ0\Y~iӚo4KH]ԗQVk@yIxN|2_@}@ό<ꄴgP 0y:%^tqNw׾URhah!T c2^r>?:NpM/JD4|ؼ[œAqVմ7t^+D&eIuy#'.P*>_*cѠLYy )l)=; e? h L 71gV :]FfG>~ w玎8Gt{]Nn"E? @OO=֯)0C&6=`x Oym\s$z?\M} tluI[lp֖eam'LBD"$eoaؗ&|K=C,*ÄޱP_Z yХ CAt)PL^omPp; =X oy3 9ԕg"R+y oO#pc,q;oY[6k )h@:k_7@\QTNC[MuVy#|+`ęt9^"F2zOӢ͑}xT p϶Sx/nlQ|j3D '"y7^[_*b>]Әfz:j/1N99{I|{K}}yu[kϹ!N}[q=Z IDAT{Ƌ0 K ~DǢ{ k;N30Gzba=딩c~:L]S&!\VG.8`gNj]2>1 W׹sn-0E"|҉t k4(i8}2 ӵ9SzG@2 ,HT̴KdJW/-ѕV-#^Ѽ^}y3zv.# ^EjD@S<<"zvMϗJ3λwꕾ!9uMKǂZVV ?vrUwU(gp J|rrq6~Xg)'\JZ=+ `>=kjNMO<|BtW=ŧx|D DojCʗ?`GV/l"ZRԡ[5/'DyˢKrܯ()`/Dm;Ԥr o: d sB:"1`.[r~Moߊ*@%/^&msA:}#)ͳ>9<+ T$*B@ʋ@ys.9^q>?_Nb-n}A aVĺĠ \qHZ/5A=hp`p`p`p`p`pp &:TyN8uTǩzõ|@SYpXDȄ.$)@` H~{xqʤ5@pg? XHrO YB@ [.ڱŢKKQ}-NpvN@w=S. ⫶$L@b*(0Z)J\:`I|q{FySbt<^W+]}~Bpufs}:{ 5#>I!hpu+㵱4hp`p`p`p`p`p`p`S셤1=l:ؽdZMP('h*l=޿|+[ ;sdi/T'`9ȉHS.;l|bk_ >xfZA׌h}Zsܲk{WCly^.!~_{o$=*Zq.`?hp`Ph$O"/wqG f @a{z pTCpAo@x)pËf4lInm8 K`fi(\U!vڢ@h^ n? o9^)/ 87> 1d/͓؞t{p`p`p`p`p`p`p``N׶ހB+ab/x`x .yZ^xɣMz)n7 _ \h*7 xȴ%eG%䏀=$.OִU|Xl$۹x L`JYǗd8 '{2=6āi{b9{xz2ՌXnx2=ū$t(NDS L׶IڣNt-MɽM!|K hT SV愶*2Zk/\>TF>sZ@:w^p`@!O)x`S)qr2eSu:W)SuI]z9`-%‡qOvAW9 ,Xmɹ^Uf㴺F$:kb~Uhuת˟nSq`oG5'k S7O}﫯0w vJؓTOn'`a*I9N2 WQ^2|yM\Gu!H < E&X?#?RO<R=O=Sqp2raGO]O|kؗ.^ƹ|GU_d@0d dlO-!1[};kqt ëD_@tZTZs++$s\9{axL80ׁsW]uU=/0gVs`@Gx࣏>zo{ HœS__!2usU-ܲuQoW,Cb-0U B{/,Wg|:lg+A('tO}GB_^סs?T@܉W`^Qb̸p1 e`vMk)s:=c{o]w/cM\tu׆H#:#B^^ 3G0ymQ';7NNԧ>2y9];Ps ~:?gLB)[/ ]z z')Z^,#KޣO{'8"1=UW`$,ù0o>p#HywW*@c ~_LBe#0ou@uY" ؾZBi*Lǟ^z1?Ϭ5/#+y4J="= g爵 N$t`vѧu$z-^xW5]KGu=]We_9u yb}뭷VTȭ}'{| 4!xzx `܀e3 ~/YSyyE;㓉}϶֦\o {]wʨ t@O_QYv/̢+ PZci:`H5$޸X/6oB}Yq-c7Y"</tQD$B?3/֋9]Q>$^~kH >.՟\hXs-#&gt*:u:ZVܽw|#R\]NuE?Wя"v[! =}hRğ& Ës2Y3O&E:L,-9 O"w*eXzh̩<+dk=Jǃ  , 7Pp O0+*Ⱥ?eD9 6Kvb< 0EruS&G ^g=YJQ|P@֡6lT> :H3F $:ϖ(yE/+;}m{ ǖQ8 LXCx >wjЂ GQx<FxxyV3g7\Oe]&_/P(do@֖W@#Ek)u(N$Y%"ŹH f kuVC BC) ~<p˹9]]>%o}Omڳ*O[cڦ98Y_Η?Q;ߎUxjp`p`p`p`p`p`p`p` xW` ƛc$Bj@LZ'^5б,.9A~%kxnۏCe<+<DP<{@&O[ sPʋǹ? xvB(M^A{AR{rȟ=cV "R݀<!:4UGe;1x ROpj~<-xNr#){ȁ:8$Si'.๊3^9oAgϞ|7umH2ˠr`x ߑe}sTo{N40ôM!NiIa4X=OClxPNw)0]<΅vB$Է?C?߄C><Syڲ< l9<-^7y\-7HpZTm[#lWxco) Q{80@x=J,8@Ų_ 0x|y2Pȣooz.??(=i'i!ǫ%i}({ bb@,RݒM#̳ÄJ*߾̞x g1*LjjyPSHX12ac@as`|8808080808p(<>BEU.zË/zJ *Pnap+ s;ۼg|x=~@+|򓟼PC(O}|t_xnA'.=}wiyH:- *(T'9">ϹF^84Hm]t<|7MFVv1۝?N!qoX>ĩ87bߤ~lb1ee]FY/5JSP_ - % 2 5"_5s{XBGN I u9P?ϨVy}y"ӧ)'}(^)M:'d/ק"h~:1>4qT}^ %o攐Aa [Kx%G,{ DP8ЏyFB'},sM>kk4^>@}9=/}K1fODZ ko|rO &Bi,#'ھN|'{#d9?arVdȐNt} RNS}$z3D9Ы.a:}jxU=ֹO( UpIJN` (+ ZXś"D>]k%<@=³(H3 9ʼ/{nȓ~bC jdd}9wZ ԋD!{ _XOsq72!$##`I#lWSP}%Ss:_@ëEGзwВ}66-c EƋCP17w!I|fܞ=$ϖ[D]'})t0޻[P8 p~r0 ^:93Ƃh⏺E/u#:lQ@68vk~?tx1.Wra)!w;Ok7ݩRȧe8 6B1ȧ+ ε= Px޲DpN1 3%qM`T8IJЄ8 pV) ]8x # V`X; ޏ2NUMP{<iMd^E.4( d$ BȃU}[Pԋ#|6 WԘp IJӟ¾+ .F 4^)мB ߻ߺe1Ģ)yڲ;f-y=#OwgΜYesߘ* Hcwk0~x#Po{ɠ*9S^o>^ǚ,^aPdp tMkT0Dq90@ 4y NU:X #{7oLH!@^T!4d^HX]@z*9npI7/.)e/9˫q@ַU^И{# 8\&[&6Q򢘨#וS2?Q>KE^e3`"+7@koiӔ9a9kGY:$bUY5%>-쏊RZ/?I{UWoB1][ZGz@ E_:(=AkO/姼_}J1Z@uaF)@aaUx#闵[PzCIihI 1CO-}1#tm^2k;co>]^qio=)7c2㵟}y|34~\*Mo~oyҦo%R hM{ h8=dAZyFnHb `*z| S{G=Z^/3,vP@yyzIY!BՋR|*2BE_⥶OT=Yxg=&QW}f|-?5|e^2\AP{s*@2Pal^!_edމQ: 3GaȜCN!9Rǘ:}5]&6B3x8ZOfK5Gs1E$D&5)k 5Kb%n i t gabH|Ѓ;SXh#,L&*GȈ|b˻]8IKȗ64lZp_V~)SyʵGR/ 4pOlpbb͠#!( xʱH6e-a!>_[<{SX+YHmzc""ϜgᕴC kUeS4E@Z2ԙWESj7B㗴sOqgQR6/?P3l- ?,B׌mx!OaƐc1\Nm~k9BF'SH2F'GrY:c gh~3ŢCnPFsg/vD7i]7!rp6ez? 1NwCd}\)nqE|/>腱M$ZZθIB^S>YuBqC}>d*_Jz׎٤sX9 E_XY}3f<36S$e5.i9WЂgguPr[p`CYB 1,ͬB",8P r;K("ޜ%8ePX -06ĂN4!ĺa&|(b@+iop)(kAtxM2ʕ:Yp-б%_%,R;tM7kEݢ@~ܑv(?Gx$=Bv"tC-5wsDbi7FA=/T 4x9}ol14ƂMݬ“, wuWUHu)T1J)b)[3"קDJJ>TW6N {)ƵGAMǵȘ$[Xx__cUyd ׾ bx0OXpBzێ\OHcdq*d@aLN$_Vxr2;l/`Y.K(rH['|1\[Fdm&1N^s #H!xȅȴrOLvɏ!Sx4[ޒ듶idz2ƄpadqH`ˡ2亏>_dzGkפv}2d'Z;|c-2d4_ d;e@ɓ֧D^2.ƁqB [H780808+8cZ,`KE),"e!(橄,J,؋(/±((}`(zX%eZ{Qښ^B׋Ҿ(VE"HP_(Efke|)EY\jEYX`Qz(*nE_,85P(آ(C.( (6Eib(,ދbejQEQ .Y΢X( U}, e\xQLNŃX2?^-'*Zba/ ҢEˋ@61U>kQo/~q_<+E 3ZYGGK+omc}xRZ. _EQ0EPLQ^.r(krSؚ1Rb+oSH.AH- Mm~+ER{)~sE*,2(x[i X\enQ,ڏbXPy[i,+goxQM}YEQ([j%s1FW_}o,w9mLR9Jf^*|)@cQ cUeaB1E?qWE1-Թժr .1dQB,!iQUҰ( z-Jע}WJgOʕD,bJy:_Gٳ(^_x3 Z@y|$ե#d-ga_Edƺ`,tbkq_֜P[UA:_y>`P:K_b09IYJD] VǪg;}/iYO]i1wCV)˺cܥ[]5)yBN^y@S͑6,[*b$XI_+F \^뺪qh3vy?dS2O߸6a~r.k=,ku.Ok yYj(,.BÚZpm)^a/ [TTsNb Xj_,X5?V{@ʊZjO4I/]Zz+!-,Z@P6k|y}[Z=L,˨,3źb2'V`岠Wo!O`aD>ik_tp-$ ˺MBr̲+!-82x yqW2*٩;Y)όx𱥢T")eLQK}!}owtWxwW琧Wu/coSȫ񋧼<< ҼS'}oS6o5oȹbt29{d 6+^3b^}^vNV 3?xt ?%Yb C^BɸsxteBF ;1Ϗv%/>!"r:< 'u, Me𜩟o{<~x0d^+OZs\Ǔ9 Iehy-s<ӯK"A}dh8Qw]D Q,>ֺxxF#Ϟ(<y!xxEy)"p\Cn!~?/2J II$r#!mU2?GQqZ$o)y;SZ?_!^AƁ=5blQN엠[Bab:Њ$d|g%$e[E^ɰ'B"x&/ >:nB"->}},^(E@(e2)))QA`y n!V99mK8+ oaABۼHUd(<\mKU_@R*C`8X%F -d $Ш#+{) imA)uDrLHPdL m;5h,EO7bn!cx /M ?oBsW<2<3Xgx#?\37Ӵ f3"` DG!e['m򴟗t&s<.r<&7,'@ M ^&0|^Η5\Cd_Qd ~L$ܺmHe\c\ #JD0}cD6/y.樐g6aC䲾O{p`p`p$qh[B}a!`S8`!*QUnx-Lm:* b.M) <) -u4P: R o@HdN2 I=ۺKvwWhOq vF]jO:F{un{˼qԶͷm뼜Hc6ތ6}RAɥ4QS~Eic1G&]}8( 2yxϥH55uw@=0@ɰ7=80808p8p4P>B8ISj(^6jOf^ÒٓE*[o D$2F W^j?af AaZkl92&bRը D2l{ݘNze!ey}4/0eOe=FSCg(S >kS - q<|"+9Ph[PA=Z7SX*z|yu55X{H }?_@3צoaMP/u52F[3I rI>6K[' (( q:g$B;@- k EkπBn[EeqH+z9SHP_sKp!B8X*m^u_ ؇֗i~eHOSY4-V"C,}^ϵG,t1#i(n ŖR\K\=*ŒXt"~gO^&S>(KxIAP^!SN!>㴽7~xndopR#`wGW\uU5|njS^Q ۄI/# |`P]]+቞mԸ$?11Nj8@Jڄo.H uni냞f' yy7yC<#|<Ch trX,I(n檐[Y=g!FR, <(w9 Bk EʇBDYP0$Xz ++/JdPiL2ma[{23-MѠu\|C9WJtue~;[n' T ?-%dզP4X= Pu(u&, 1p{0uS#bw aSa|Hg d |X@ƨqTSZ3V@ 1_ I2Ԙ^]1{&p*#ډO@cDWٌo;\ ɠN {sTGGEY!d=j;Gwrɇ<7k#gOx<#dqP 9O3i66ҩ"xþؔCN/O]|\ k<PC@g8 Q,S_Kc<8z\{5JS^:w Ei]Ed9P,Oyia@480808o$JoLY0 un֋Y-=o4Q@xZ/œ.tZ,c=Vy6BKIPt|x-2Eb@DP,06[еAqhVEB>+DY̅Pt ?HRH RP >S? H>/ʳ!J^D,mQ"kYL, J+HPC: +e2N,ډg=0ϊ .#y RXV]FQxdRՕBC x)oDIR"(|Jr1OڌOE!@ʛbkPf)_ƷRM`"ٷ~3uMWUKe<=i=3EuoG%N_28gϞ=jSh|sx`d(g8ԍk,GsqE9KT0{c%lb ynx1Nrøs5rNiSz r\c!__myA^d fiܛ#<h YB}ު/oXڣ 8UgǠhmYFxMnHO_ٷf3Z㒼C zL54!o g'.`O9e~%X'eh VuH IDATA|>/۟-'F]X+!epLcLֆa彲ÜK`.?3"<0X>eG!}eF:{V:|iD'1vH(yC̡pn' $!.uɢ~ʾB@}~t(A2 _% 5/= O$-劂aσž~eSX)#G})M)uDQv(A@`rB[\Hhu L:J5ZNɛrQefGZJ$ZfMai?XQ-lbR,]m?RVU&%`m7>L"ʡtmUW 5GP^GŖr(˓ )KN}B;i)@H;`SOxKA_ 0uUh`=#)`Q7 <Ɛy0os28Q0?|,1|(5n-~2o/v`>_ 昺syyr)_Sa#|T+M6G7slprDLZi߮8U x8s5#@"ueT͛>hp9@1䑗&=v]28B(lk'XV1"*mo@hn(D]q[aE-$9̳m>Px D5z% yjzbD˔K}َIr %{{@! ۪)kU]r_=yx\J2vYF&ZLWBHW?lϩ({HFQ?I-/6@)Y[݅uJBr̴8!9%Oq(V,j^Noet0{}]9G):ԣ&D=tڼ~xSoi}K)ezOsV>w)_Ukۦp5sUy y"sD$dM"&D: 4t-G~'mDFHw]ueZ]]uGHfƨ)%g6d1u2My.K?U6oF8uZ=3FSg21w_FiV{9ᣗvU ߯ںw(aQ8@r03l% pRG˝2kód/Pȡ9sj       pP"+Vy(&9]s3ygyxx^ToS{'óȻ"i * U?*G/ a6R])䶎37 {$^/Or6B!@ 7pHʊӇBKC= /AWV<<jrck[(ܯ10j;8080808080808p(8pM<:<ŵ+G y Y i`BlM}e__vm]@z??Jy5_~NtM^Uk!Pi!Vy(qa_r"0/|`)T5Hci:eOtѾ 1?y}uR߿C MvlV8ɦ^6: l|5~\sN$(TSBOŹL-wj<~v?W= $ Y757̒-1SO>;`(bp`c0%ҩV4zlC'p_җj78+?~??/T t+}W[ϑ9H7Okh-?_uV)!*\/W;1y>lk b@hoa&>ބp{/3秼K*ŲCmyb6`-rja#5k2xlm>J[I怹r&'9Do|c5(կ~*Nk)[N?gW#H6r{a`SFX-7Q MۜG:ʶ3LeoSk7Z| "/x7:eޜ''+8g6:9Ewʟv)]CO"};-%@WPQ0(u}w_=0 ">^=ђZًǖmdpNv+P[ԬC&u)=6 Ӭ|Ye$8 #W=<,Uz\)|;Ebǵ[o>3-O,z׻껫^.M? ]F{My[kQ˝< gf xq8 =v&R||~S|wУ=Oӫz~DzW7n=Փ{=me*O} Sd=Uo~Uaȋ: rFExu5/f&?Aus7uoQ;BiȻSf08G GtcfWge+z-1Dhx?\/qSlL B6Lb#'ri;0 crz&ʂI._o"eL9St !4yv*}ڣ si UʧK&B=O=)^i{W{D/ sy2^e{{/xK_z믯pr(EWԏ2t3c hϖqr vhxЂB(algD'/)/ל $[Q> g;x=\ xc*oj3ʡAgk:瀹U#zJ8l-7 B`aSoF! &6@HZdQLV VLB3g!ߐ|:![:0IpN\`Rs=&A]hFiUD 4@J:D=s裏,d DRw\~_x.4+ʆ,oyfF^&S}rDa "bx943_+[̷ fK]S hڙuR^ywape|; Y}__/[f<r=w`IdrG!u:W3kH&4z)OHI8*iԁ^$s0S~[)@ng]id0-я@'=g`r@ڧ7C#K$ҵ~2M\Ч[5gvmƓ&*1 0qΔO}SuBQoW,$f9a؆tR:@(,wYCG?z(XM\e}A??:k'?F1Xw"jY29H-#ױNx2->hp`y,I->25'C ;k->=!>Pr'2#)3{9juϪ|}ZyۧOK.u#(5-IomvIЦ6ڕ1)GgkX;.oT&P*pmyEoeO!όmrxCПN[kI>=1tMu͞!\Kd~FB's'$m-SD?%Zy<ѕW^Yu%za/}1:c囮C#vt\)L |g\.)kHqry!2\`Y{ƐA[y="ļv_8 ;8(9, Dyk.%$M@;>nA!#r(cϕE>5gp`0g(NS$'9dGyvꙶnSk ڄqm~@CW.XiSl6 & Jo0 ,^ @ 0xyh%jLZ| P!n| ^^\] /.@ʊNCB@9S)TQQV +lՊ' C)xxAy^? 2+JGxT0.7p}^A8`yoĘe3cyh[]d {8! >‘zr$DzuSɂOQ#He"/c*GzPE>BY0#Wm cJ0>hg ɰgHmN.Ȓ4}k_:@ߞu@pufMe;^K~M:8`&-K)2{)\7s]D1ϿM7OA HЃ.rZCD ֢M@!CEHQ'a=P C JE⑳AmiMLn MsI뮻žHu4FG^"=x[gu/n`-sL~ W}WR8~|tM.rNQkY?W;/Q ٠U`@ -YPQ*9yN9o?fLyk&9t0#sL =8Q]yzt@~KZ>'ۑQٯHv gN>]7E h1tYo!|#k7-tUWzjog&*$G"* s0u &s9|D>[ ~[{\yxTkF9`13xЧ(Ţ/9!$wF/]=*]u݃oP vPXYhyXb"zg (EAb)O4TJSV!SteA8 &UQV,5ϭfLnK)= ( H Ye0~jx\4/D y&<O,Kֶ,0^m]՝Lw< Ct!Oԍ9_B7N #ߴ s PYӂ;GΣY> K^`{_.={vGses^uF's*rΗѝqJY: Fl3F/y$_6 1PHcp &r'{p<9WΉ:!kG='3QB4oD,O mqϖ-g&?'h4Ibhׂ?,F29e|*ezYBr*͜ ~m,xFZmYv)ʳ' qRJz<=#dE.o>38pg&sZ(+)F[A-[BofmMnެ{R/ f3Bd85P` X8:Y#Ԅd;iyYKy`2tE? 0Og фQΜ9SþRy冒zNE{YvARr6vx8L=(^NC F1#'ȡ0-{)O ./.U?<A+ntצ_ח<I&Bf#;eYh3}HA3YaoNYe<#s5i#-k|ӏI?ʁx搱{D׶X;ǵq}p`{Z+E嘋<9'7 2jcDDp@wp e\!0)!>qX@$%@֝EgDY^ ,aI5CH w3J:Ye}45@݄Wf@*p"*Kv3Rtb<<oᬑ>x |"k^¸,L.oPZX{2f8 ȆyPz=gWI%GX2Trcxx̑Y7fd}+ƈ|Z2:]vum`Xγ#ͥT)jsZ :mo{[5Ǡp6hM& Ժ\ˆ}`%: @#{X(V0fj/9Tx)) (iB(ir @?@̀cFDi`mf {wrq6f()Sy,LȔdJ8)?R2GcBΑd82ϑ)Z_=y{?{j{Z{k]׵u- B΄}[̚5ԇ!Ē'"L٪hri+c}_ c36#OB 3lv؞20W$[|gp1،.3 J nQ5E12 or5aNkSײn9a=l 3DIRuN ]Kki~]o"Ȁ 6ؠ(d?-pd5n*\\FGT'u;׭Y)dU;y*N/mrj!`& [ampczoct<UaF>&'7;}M"ELǬr粹 DJ@ CMqsa!4!f vh6'w؊!(\!ڔ 4FU{ePjdcYٌҬWCG:!rwS([ CZE2^5%)Tַh(5{x:z$ٳ琲SCOS^ϵ}l= = N>3fi;ܵU};ֳW3~sMDT!)~ Gq'$\Z{:Q&9aƄf٭ex)H,2N0m)f u-QYd0u8L'ok95BEB,eOԄ `O@c6c'99tQG:~c##<Հjp1cFZ!K} W98(` va({)<?u5b7st y>z ԩ#3/!v$m=QئוG#AN^Nay8_&s~J0ۜUt 'zUB‘ǃZs(7`ØC_b uo KA\dTsr;Q[Gt:+Y}`(oMh#܌zpq`ϒ爰okV.f/`GJ-tHӧN\&5r髲msƵv($@ k5j+;e@̕8mڴ"Oy0P(ٝ,)dlX3FV\lQ2,x{} a59eAQpc&-_|6Ev"5VCg!98n)!ͥ*2۲ EofszmsSv.5(2Qhݢb;nlK 4a;mΓF@" kdҕx۲ڟ@L C?eA$bb! Cץ^H|!WrfVR,)!!K&~g/k@ 7묳'a?ݤ%@ >k xV!\믿6,_!cӼ$/\wu r-.9Û_~¤8$YK4,ro\B_#J@O X'9x뭷GԩSl!;SB B(l0#[M P2z衲uuIBu1v62ńp(_~;S'qe[w8l+v{ \wu^: Ӆ0 '| .hxf]v)E$0%?c Ha^ziꫯP^x{oa2Zk5kf##F.E9bd~כ{kpw,}vfՑ3hW_':蠲d9W^yewqV[mU6Ķ!!@n%W7hkZA#5B`( #%r-(ʖ+>f i_qzF$ӳτMd$0#J¸Z#믿n2;D%`fi3eʔX<,ܱYn3f%,aT)!YA^wuWY s駗VX!{!w(F0d'5#(S|g0|^q`zPΌaJ`x![;S J Ya21K~J̪?xsZC!1:&履~*يVkw߽G_H+C`Q&eou)a Dʙ  E32Ѩ I]C0;!6gaf=j&:ot}(~=E >?vaYk(qcJpvmEp >_2.WpRHB @m@%*BF7db@q)!#6jگ"NB(曛ᄏ$ŒhSN9y睛LP#%1 ퟒ#2σcZV$'=ms1ǔ5ɺ,LtΜ9%ff/<1 .!C$H6#w}WffϞ]cQ$gΜYH#̌AhAxi թf(eqf>b($[C~ӼbN۟Ƈ@t@MEI43f,(b}%?/zV(I%Ԭ[w% y'`֞Fȷmnncd3~m/#C B(죛@ 됄Q) fF}} >}X3WY8%B @A@_]cD2JL  s䤄@0Q8Lw3m 8U!!!CCCӜ4$B B B B B B`<bV !#pnh!!!!!!p96B B B B B B? eiT?odj!!!!!Czߎig}c:B B B B B B`@ , [ot(_|ˊ} /p駟 F#|!!!!!!063iXQ)!!!!!!O$ٲIENDB`$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$Ifl!vh55B#v#vB:V l  t ,55Balp $$If !vh55#v#v:V l t0655a p$$If !vh55r#v#vr:V l t055r/ / /  a $$If !vh55r#v#vr:V l t055r/ / /  a $$If !vh55r#v#vr:V l t055ra $$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p$$If!vh550#v#v0:V l t0550a$$If!vh550#v#v0:V l t0550a$$If!vh55#v#v:V l t055a$$If!vh550#v#v0:V l t0550a$$If!vh550#v#v0:V l t0550a$$If!vh55#v#v:V l t055a$$Ifl!vh55#v#v:V l  t ,55alp 3|Dd ")7  J rMA Object 1This graphic provides a summary on some possible reasons for complaints. If you have any of these kinds of problems, you can make a complaint, including: Quality of your medical care: Are you unhappy with the quality of care you've received (including care in the hospital)? Respecting your privacy: Do you believe that someone did not respect your right to privacy or shared information about you that you feel should be confidential? Disrespect, poor customer service, or other negative behaviors: Has someone been rude or disrespectful to you? Are you unhappy with how our Member Services has dealt with you? Do you feel you are being encourage to leave our plan? Waiting times: Are you having trouble getting an appointment, or waiting too long to get it? Have you been kept waiting too long by doctors, pharmacists, or other health professional? Or by Member Services or other staff at our plan? Examples include waiting too long on the phone, in the wating room, in the exam room, or when getting a prescription. Cleanliness: Are you unhappy with the cleanliness or condition of a doctor's office, clinic, or hospital? Information you get from our plan: do you believe we have not given a notice that we're required to give? Do you think written information we have given you is hard to understand? The next page has more examples of possible reaons for making a complaint.3"`PK!^[Content_Types].xmlAN0EH] tA*ٓj2<&i˂E,-ZQy*@2:k}*da< us}UmYdCJAk6N8Af=UYi)!"-^@t+ S6ƕoQ9JBLVM\sUysnJ7U|Il2\PU&<.~[m'E;Vx PK!8! _rels/.relsj0 }qN/k؊c[F232zQLZ%R6zPT]( LJ[ۑ̱j,Z˫fLV:*f"N.]m@= 7LuP[i?T;GI4Ew=}3b9`5YCƵkρؖ9#ۄo~e?zrPK!gGdrs/e2oDoc.xmlr۸;wk(J9cgיI}$6*I}Wy'9HhQl1&3% Hw6 ȚGSgGc,G8bSe?&0+^ƁRDdLe']f? gnhM3(2p'od$ZL*ŚR{\YB8!X\ UvXP<-/Tms—{. 9}.09/e@DR-~jisF ƫ͆>AdB%K*d[쁐t|x44ji#\))Ӡ7sx7qMUo\Kl!T4 o9~"I{o 1U1\#F~ f+Lf k;e KԺN4?8$x05`FV1E:ޚNlp7~,.f)<2/,'^IQE -^4B#wS!P7]0WGא:-N~WUIu` xIsTQ~οь&%$UϞ{ɳzY9xY.]@66.<F'A.aqQq'L`[BB~8 kݢP,[_66M[n(mt3#-Ւ +9hՒJ8r`Uq𼾥O..^~.7mcr/q\x^ueX5{"SK1Ѡ!X~@S(/vfɨa !0#W2)PV  P(-%xU )NA ,а@xh y"ŕ1/é9RK1)l(ς-|[ yScwIS0z*˩qd c7J*N5ZbY {x;G+: E }W.&i۞OZr9B%,wȰue8s+^nɵ'X+T-'211g b?qG5X3@==7~#%}GP+4OPj4/W,=hޥF.4w)Ԏ{. Q4 U3pDmjefR~p{uX,݇|n:=/:ٷM|h-=qjq>-V`XFRcYQ)4 _Pp 5vM5v)K!] i|mx_?%bOmr]:X<|ZA;TЮV2m!]F0< V}ʆ*?qZ{7{6mIw=W Z&-`l?Y-0sơŵ#aeiD5hztɑ!5 G5ɫ*}I4w)IK7Mjs`'C-`"pʰgْf40, K \lb_RGjI` pJѤwg5դץ&.4u)Nz<>l40VE~ʐ_.^ACt%\OD1_I-(}*AdŶ4"_*6`sO]b?HzU꣗>:e0R;NtTNSAk֝!ULF"+SnQ=UNq4Ԭ[{.6:S;D!%ymY_|:cFSPSw55إ.45v)N*~@~g`l<5N,g{A!sb0wa U#4g܆ VV_㑹>v Vlb.!.aG-iѲ|N"=b^/ALpx!;%M;% ȿ(ʠ2k?D H3/ PIW_JJƂBYcg;I5uj]T_vCۈgXn6u5RA b)LQ#0E$S~|IPޛchxȖ4gfΜW$\5ݳ N8<,N֪dyϵ<)ޛ#3r&ꌝcYAU!rs@ǯ_|P' _ K"C!I -&zz!&aj4}jq#pJn7<0_|{?ÓKw*.SdvjzȮmd.&p&43H8wJޑZ _i4{otYF2 ףkĪA}@ZV GqFЮ !V$R mazN,(G PZSYA$7.u1./kIȔ]wB+B^_suTlշF?#zc~PK!m#drs/downrev.xmlLJ@0͝QaYc& zQ^&623zKCQEWvqi g +uϭT5''9f?+elpBik0Z]Oxr7+caÑ:erR_VSj>w_fkϖ[P|AB>q`A+Z^Bfc "oPK-!^[Content_Types].xmlPK-!8! ,_rels/.relsPK-!gG+drs/e2oDoc.xmlPK-!m#drs/downrev.xmlPKb]ި@4M]!n|]ި@4MPNG  IHDRYM[sRGBgAMA a cHRMz&u0`:pQ< pHYs&?yIDATx^%E7sf`\ŌQ氘((Ȋ**E$9(р"Iw~횯欄ٝ;sysCwWW+SU+ODB` +nិĥo;z[[D HD`*%Ɠb7xY'b|X"$@" ַ6۬wݯ]B~rL?BNi>}OI d:u`uTwCvYo/yLJo1!HD H1.Bxo|'05)䖐^{Jbu @ցe!Ɨc"&<{' sm$@"$A"?e?z;c?a/^XF{nm_o$Yd:0:`0c1gvmdYCc3Ӊ@"$\A[S NyϾ"AAkw޹{{>/~o~~d:u /XB-k]xq";"zE>1.=lD HD` `M  ԏ yɺI,nկ~;#{'|r3s9.wWb# @ցY&\%\K>?~v}>4H#_[ϛ;3$@" ;1?1q -i@w:ޅ^ػ+znw7 @"$0S-W^ye/x≽_}K(bωa3@"$@ LJsq_f:o<3z]wԵ|2HD uLS"$@"0UW]'e)vsmu9KD HpOCcpu=z[RID Hf=]vYSPvuȗcc; МIMD HA6odi10861vvxz]+$@" `?^d3G@"$ o|cdYȧvء?9D HD`(0Cvn |~'>4$s&3HD {4V_}A!ݿV @"$0"`wC9?%w1o䙣D HD`Hy5/9餓zΐ$@" #?ٷ~r5o60;& ]wP+D HDoc9>1g.D H!AࠃMX>-v;3{dHD HǮp~76ƻC>0$Cu&3HD 83c0>ӌ0o~laV2@"$}n6J{̍<$Cu&3HD ɧ=СXi믿~Dv*I(!u3%xmb1'4ehG&1'aΣW%:K"HD`Vh~6"p7IkGlػkY=묳zGx?.C"0Nm&l;#zD©׿5:H{wD{I!sȕL~"$@`X'k^^ˆ |^tE_W~~_s%LJy 7{KN;ͅef^;z}ov+]ۜ/#G?~GO.=F]az $$:K"HD`f7i2wkDK{x+z+b[V{>?=J| |a{nm{|!;A?]w]z~oݻ׽oG/zыz{G+e]z/~{wzGFH}{'-8I>\Y'@" |t֖O֙lTfG>rgHp,]r<v=s Zk--ܲ>O<ã^sa.\8~~,D`H97tE"$#0'>.ZkQtVpR| D"/Vxis^W׿w}G)6m}C~Lޏ~nrp饗S⍝{'tҘJ[|"^XZR%_W {,d%>Ł\uUKM9.sxxNz\<&XY+]ʈ%ꫯ^q.?O^S~>;`%J=QW>#wNPRr\w/q%3w?^{i-^K.iF&ģ׿~{#cq37,5I>\Y'@" ">w\+Ͼo:x@. GV>>A~=ISޗ徒EG=Q8 eD'Dž;V"^җqܦOj䦋XW#,5,XlAo]w+%IOzR?xz_:PY{7BJG)E$ꍭL&XYKkԧe}hGRp됕O 01a-fd?ɠuV,X{[/#D.oKv;z>phL[A~nj|"ңJlMӯ>O{ClOtD ~_uZ'ۂIv]-ث@me:Z/}O,5&@Ϲd.D HD>7x>)J wR,)zЃʧPX^#|爒kg>o\;-88Qx8ih :H|o~sRKZ:vŮ[ǏZW@Cb돼GwaWziT&=i^S9ԩ?zƮ7lK};ifX I ivyzeܣ^pk H52>*OW\qE :Eyy㚎h/Z_"< kr銇W}[Q+B5i.*6ڸk,9me 7ċST|+[G??yеi`ܲܳJ+/7yfΰH9J&?HD`n 0'KVxO|}КAJ3 nh"θ_| _Z-!U/!-ȺLO~Z>i@bXmB B(,JY,ŰGj3(IC>/*t5K/y ^׽u5:}G^emsLmý>q8|+0g?~&Hꫯ?>]k0"c&,a\ /A),JwYj=?2Ivownw[-oyKh"AYüݒwR<=LN_WųD=Wʨ:3@Z./dcF\ x=WwN<xTY AcICî B\mfBkiiA@I񘈩C|f[~GY-ؙ)*+hʒVۜɔ :jYH͍ fTəgٟx(%I} 8X.a_r -M97tE"$#0'B jb^[9HR),&&u~,NvnHu_:uf]-R q(v=lupzR;K%bSB p\zC&.ְRm~eXey(.,0',Le7MV=~{" zdN5'aE>Ӵm9GB d5FhʚUBhKޤy?뛉nmƒD0NlTBm9Lj?&Sk[6ToK7&V]x3n(UsF'LK}keL4t'7Ҟ}zKGϽ+d7ĚhH9J&?HD`n [Qi_Qf)EYY6-!BYk6ġRR5dk-2H:b\!F6HW:(9h'*4wf(9k23x92Ʋ&]#>Y dKiްmtt#;M*[dƒkmy,א7 9FC* 3j_veȧB^UЖJ:] 6#aƫ&ʑ.c\PoTОH.ȲIU> uwn]2ʰH97tE"$#[\RnЦ4\Z 2Ŷ>bb`Ġ,R)\HIk븹ջvO^_psxYw*$OIɧ"<˓! k+N=#.nϬ^,Ԉ5Oka<г5Ai~\6,}]ߔw" Dɧ.nAg|&ǥp/..,De}#|"[zqw.i++)k) TmYbe5I`#e-5y*m;βd׻"-6 h<)mu"Ku"&;tVIi,cyb9'Blb4S]-քͬaB:aR^E>ݏrkeDoG u-bѳ;T92C0GXZ[dz|N|Zi3#J=q=퍃 A e>vŏ e% d>0}m lebl' 6`d yT\(K|xZH9J&?HD`n slq,>V:?"6)k(mMawEʺQ6=`;jֺ9'RT4iGv@Y '?q1z[޽.+B-XW79vE& 2&6=-햅rzbeް\}PgĽKi[O$սgx.鈞vS[@XMŮj>ֲ-XE.&n,vyWnMʴbA~WDw ֕H97tE"$#sl@%OyANSԨsp7E2|9ה]X|FeE>[a}>#koqE6\o2|RG$řH{{]#H3@G[y#)%ϊBPi8a",ȧ4|^Ā|r%W\˒U"daZQN*zjbϚJz]nS!C,[j(VL4L䈺$Ĉ2f;srYVelEek j9,}sV~6*+A ++D H@ϱ "[JiM>(6q S%ubDRWC݁K4trӳה렶^(PMĬ^=ϥ>bG۵ΒHD r|R.k:UKa} y R >jUc׎zWے&du!-{R)_&LXGFbGC :m>Cz.E䧎cIԆ4zba6D(loS5\s |䇕JlHC/Rbܲڲ8 U{K3)xu i.+I'u:;w:jFhpd &[ꃺ$*Z-g=6:"X"q GGLҸk}z[vo9糤Eć2kX {Im灕N>⊨&^&II&xۼv!n9g򖷌RXjulJ ~ԻrU{s)vu]Ī|p؅+mW*6a9X6'b EeL+r쨓5~ Xm l-v8YY}Y 0ixFcq,w] Gỷؚ*S"&>q!+Hɢ%H*5tL(")Hb; 5BR wl^V;(f˪kwW.]H툅WO$,ΖwL=r!.k%%=-/$Z۪eK-o~AkQV>kvoӹ6{Bܝ} jΈ-g}6"]02Y:| %s$@"0 +D*X"(Zk(}\ˆ4R!RDil[;*V58ΒHD r|v+/&!ozӛ:7w&JbYXܐ9kal<5ˉu"Q+CdD H I>TX:GmNd ؤs`歉@I>ZU'@"|.ؔoWB:a$!Kv?Ӯh#Twi4f|0#sh-D HF wαZhWRGVdHfcvhu˱߱5ݻgs>"sUL|"$\A |T2ω@"/|%$@"0$_ X6H@ϡVU2@"$s$Q <'@"0H9WG"$P#0ӱO_Y9pWvqQ[<}v-yqE]<2w:E޿=Xsn߁8lO~D` sUL|"$\A`X_{8hwމ=O<ZU'@"|moп}0k{|pD9䓧,S?zmF'=c)c?x;|tP rF"oԧ>5*WUi4@"0u|%$@"0u=ɴ>ԧEk,"S {GSO_b;3{GuT﷿m PMdޅ^_?CY׹;L|zwr!v ')ke,p(=8u z{w)Oy(2eG gqƨy` S8{W^yeg4_|q<̒߿[Z?+9':\zuYw\+E>7l~'wqφu2SYZ3~uUY*;yWK=m{`=γU73V?Twʿuي@ϡVU2@"$sL>m٦ǒ/}&AvD[V}oW= O}!c7zmZ> ?=~O|3{kꫯ.o{_>WmV4t.O~Og}{]wޖ[n']%&6cXoUWc;˷+M7tozӛyU_^ӧ.^Ǻ>"s!~ԣջ_CN;N?%0WHnX/]AkXw}~}Zݼ/,I>֒HD jD^J`!Do$X7}wl}kG+Xc5X<~t]vY•Yۘo?… {q,[d&7ysz]@}쓟Ll""Zv\}+^ѳƴ~b-lq׾Q۬Hvݨk!$u`9$+TbB?at":NMv>C|ы^39q=8Dȧ|"^Vgw}hT:~ZU~w=Ȥb.syApVRX'KD`H9ԪJ&>HD` 0ȧubŊIa$S2޺O YӐB$ q*J7#X6q7O5 )KJ&d)O.Il"-WH\186PrMW +Z묳N?.YdN]Yeu;X6}SnКlDKhO T;X$S\rI:"*]ꫯw-eE>WwqFUq gY# /2Yp=e2^*/+BlXY5†nlpP!3ZW.5|Hr9hY&6 Fϳ\ru)!H?kYM>k屔6 {"S5_#6DȾկ.֐i-.ˡ:ZD -\X[ uLZZc*hXlpU҉uv/n"6*;/R]5EÒ얳f=as*fn s֮N; R""!ɰٙD HD`KcE,V,kl&K>!ڵOFODDDw"rQK,XC",K6=b+Ȕ>DFGX:[4"KY6ɺ[po7R/Eq;v>q/FY*.x!m-deQ]?&,ə\?/"OJjk& Ƌ[:ͯBKq͂uflQ.)V lF&&Oʞ/_[GīR~^ E[zqzOO~ZȓccľwϬcY݆Zq'!0gM|Р;'K>meMlo*V,H^&dO߂XDP&䇂/w wC}|kYկ~Z|LÃ>0$L>WYehepȧ h lj.! 5Bz$rΏ 07ӱ,1Rkځ嵐Oqr1]S.eDɧ,yE,wu2& q!֘' Dȧ#w&J:}ŽuX>:a֢Z\!]iY.\:\MM>9[B!|sJbu`u CKBΉkgYyfȩ!EZ,>7W㿏)]?ߟc}fJ#0'}}`;{+V@M|ڔk [YO|^p{EZ'v>v{kHo[iNjbEe"֜Y YC|r mfE>v`cm.yU'j! r&_җxB&;l"Ú[ɋA_;ж|L8kfMy׻ճrT]Gܭ3w m䡋|:WAxv$Y^#^HC/{X1Y6wC/ <,> ?ϯ0,S~D XnlƷ ږtW$)8QΎ5.[)rVEPg|\ֻ~#ĒlG."mY uoy. "Gs&KM"Q˩ wځ53DPHN[`ۛxWB*ςD'nr +/ _iֻ%;Er>"\m4A,r{F8Kn$Šv81.A>M0bzS,Q7v}Hi~!E>} }Jbu`f@ig]A&K_H,=q54mBnQF?YϽ?/e! yd|_|i)D yp?j.bid8[2QٜIYvj^ !u@ŲXk[b}E~XQBmv(ֻ׶g5^kF𹺺KDzU.etƩ k __WF77B,I,\.&W]^׀W,xBUȟ]oۖOq ox;E>٥k9 wi:R%mAЎY[kvc_t(s,H93"Z⺴uD@$&x+i߽7XKC k\l+!m67~fiyW",:Ralp[>MX4kQ26 Lϲ 4+\;8DpY*Q୵DxMLA߹w8GYYs4ݳX :"KtOe]5%OxM|+ _ɀ-{] :jnfbK.{Ҋ֑.|os>Y@ #nWڝyܺrϠl8>@ޯ{ +|)/-Ny" ,Kn:eID]$I$˯(]@yEiyD70RR/I% `?ߢh_ rs,davEJ#eO$JpY i.W 6NMfgqD~ip,k+uHZ2|:NewZiB@X/cFOL|Zoǚ' lKv܄/~q2jy.i+^>YCp:ڲ'gGYO"N,͘r5\h  z]Ϸ-vE/^'u-veM:HA\Y4QBLYo׮=UB>Y:Ҧ .X}]W)JonݖLjBe@|M|d?%1:0~N.5ıך.2/*CA:rsI?D lic^bC2xrFNdUksdܮ_ŭNX[[_\u@|0G :Ka7ԧ>uK ;7mO: G"05lvSGz;1~.tYkcߍ}!?G/DudrٷTki!å zZѓ"v{_ !sLD!ԣ!$ՇshX*O#7,;D:4nem!zj'S( (Ǯ4!BY,Hj}l&)7I~.eLo^(UH瞽6l~ ?WѩlEKqs=[c~mLXpj:r.,ڬ_ҷDg lӎFWzƝk8"qC{vNeh^M%nt ώ7ad~?7:dp GQv5:F.qRܮ VNjnqz"0]SRNЛ$V˜Pg%S'o$.:ќٹVFD/ƬX-k3CC 91䬸Ƃz #~aBL2︱?}]4ނ@3ThvZ)66p+bgiL>)$esBm'D+v<)\xq8'd]lg>6h&tu*qM1rx`2uP 5ȡޗAM>y[^NegD`X!bn_z{!? uȟBggYKC[d)NRZ[i#-(;㿧Gz57K]\B fV1Sh0G:%&N>Fgmi Iau&`jk3yLq@ /%}  +& 1F#_Cw}6=7ݏnuoZYc)|LuYG]@cS_+%>7w?# ֮L 1ijB>oh,xliL5$-kgZu),Yl">.e||C 紨I"\(AzZ6 3~;> 轖8R3cd\t[.]ZI5!k/M*|4dž-rFqg{V鹲Ȼ9.av)Ns%FLt|ˇ5֥l!X$\ZK3Ybm}B}N1 5://s+BM23iٕA';sCؐžfrB ,yf4F1 X3zcb Q+Cyw.=v쵛mGsq1\=G>"f696H|m"0Wm E֏~q|'(ҥ OXS֕ƽ׳0ܭm3Ō>XvQmFcQoyeMєk݋;B4[BNBcxa 1pSG6k"ȹe"I>oJ7Qc<- '?,Rz498]q-;"C?C|n^;D`De_Tg{m4sʂ 5]hx'G\G!hDO~D`rI>gJxD HI>䃉@&F:eЭC K3dr˕7. kP#^QWMw9Qe~&._w wk:?$Ƨp/E<+{H^pCs%+gȞ񟳕k9LCA W-ׄn#\BnRZ]'-ε%x4D`!!_DɚUi$B9P4zknȉ!rٍ8׎O`C>J9jOƝ$@"<Hԛ|q"0+` /;sCCXB'rrDwB^c= 5?`ytQTܷFeuyOpZt(\}a}X>|.Oh3v<_ڻ F{ngݻ[s9N;%fU{P=9\}K}mZ^$nk긵 ^{m?ϨauN8ᄑ$}ѣY16J9?u"0Qr? ;tsxG"jO<9MKޗL;Hg( ߌ}ZTқ̰rUrLF" b|-`q{ܨ/NKu$E'^W\袋zkƨ4|ws5Dvy$D`~#`mh׏ K''4!ۇ#F7s`y$W ]q-qT cJׯ٫C~KcDd"ffKR}1*Qi/B83٫+?B~~zD\trɧ~n_yczO{zĿFf?O(ZOZWG=/\Ǣd2L]wuq>}Hx}n'wsL[VoO|b ?jV!Eya璯g<M7ݴOu\GxwUm*xy=JK_Ҿַ2`l.WwݯrwLz?{??QibYQf'?>&bU{s{^!=ykF0lw"N:ًu;7%B$XMb~_}{gA8ޮ# \sQO=.3^~]|ݏO`d2gyaIu{1%mQMF)_ug[ˆVp}c'?OQ} ;:-yVk:w퉐O}ٌ#Ȩ'\gE,^Hvɿz链䷐h}~QNwSx?yGW"q^HL(.57^]v;]ZCƓo:蠻`'InE1K!]kB+nyѵikµ7tR#n l#fʮWܨّgDR'0O Ff.\']FѼoݿf0nmP"_[}_igou[5dL Ќ 2~G O!\Ez(~{>׷ß>]0e|+\`2d/y߽}{c57"hs,Gi~?*O#I;1%k4!E(k M=A#.XOj%ݎo|~_mz^׿@eGQJKxX$(鵫#es{J6)OyJp]BDV8ɠĒg>}Rq:z[QאX\(/yKRY8{5V=@vYRXdb7xVMPEM>|*(pp {Yԝv`d .Ո^{UW7QxԁE|!_SYc"<X:n¬oնk*w IDA{Бg}d ,y$M~y-u1_]&VYqxs)OL:Z&[mmeLv-uդXݚQŶaq;}H0wfy)=lT*D< SmA.VmL"[3;Q'r'pE1ѷOT7z!{MyF!GuTe+V۽6!;21La$ .H @sìW/ؗ?XX(BE)e{.ь=ũX,z" (pw]R]cOI^a=yOl{?ӎFDFDr9pS.=UІ8R<d:3V^ DaBlTb^$X ",% XJW lk'rYAlF*KAؿ@| afbBdL((;W_ɧqyDZJ<}ťXٵ@e%`cBRsCKon5inE@ȐƳx 1Y&l |@۹Xݒ^F>e[o &9L$!nȴY`_#>UġNu'\9q-ޥs=G; (q \S,= P?xwH'R}LFWcm8$O ^u$+-a c{Y`rG;eU_m5LW(@G:72>Ct}lafWI>~OfЬ ]/c(>o;niN>}8ɨhG\,PJ|*漠lnɇ|Yx +_H "P)BlVJVJeӺڝ8"常D%V >R.)m_( r-o,B&AynO@܋'U]m4;׳ "Kt ͂U+̬5A]܆ՅP\AY >5nqgm+ɧ&?Y{S=y;Xl S79Roħ"mwH.5Pc!gQoS#&nVYϹYwY13ɡ>d˴{XMPMsM>Y YSK@Ҭc@i]kg8 p'䭶Lb^꿇*OgzBK9mrXDu2SuZr`(Əż^ë,SySoBc`% I>Xʤ'C@x1^62'Kg< /N7!*eTI%G%:HvF%өO *=J>&$DqkD$5 SXuL~;P({Y"o;hvDX3(v0peaE^'[6,6D $WڲۖO5&:3Jafuqkt}M`4SU%o{ݮI6DXjɺPYL*@`Dd[w7рռ^y0`L3VUue՚hy]a#6E&yUOc(M>\C/CWX\sch!m_QP$fɉ?dά [O_;d'ψ͟lTLK0T_DDl/.}F E/1OA<6MS!9Zx587:QG⪱v-[,#LW#Cvɧv$(J\ ˮe.P#]2J1f)+^QkeXsk/kLrK7 Aˮu(H'rHaG`2dle'z-|̓[lOބRMXG+*tiRBvXZZ!g]+ֲ6tw~:(? |R{mW@aJ_YnR1*E "۵nZVŮ2ln/hɧ zg\ퟫxy^zZJ5[\SckbqUnVL=|"`/q$cqo"b*%Vozӛ|.8ߙ$soF{_xUn|q,Wܲ$11|.z4` OG8ڡf2r-;[5/vg p0OV(*\;)ĔX ! ,Ge+BMDXXkZ²'Z6)i`M4pdV*Ŭ5&ID>m X3#iAe]7py5a2h +vE KٰE>di/H~kb۸k{L 4/Ov.hlj|.Dy-GԤn'6,Ů&x|r|h(]v0SoJ[,OG֒[d}UǬ76Qo;#da.!-sDw'\D 8C\-/xdьglh:< eB?3*VA:O3+ޜY lL\lw ATa&%;4npƍz0+k34Iif*&J>)p}ɲ7`e afqΟ =,܌G>'bZ^+E>ۖϱ'wn} w~ԕ\Ľ_{\NJIAZ@?7۫YH}*~?l66QGc+_[zQenzQځݲ";-k\d7>.خ,)](Ԋ:Ex eeI-rXpbe=哕:ZY&G&KLAjYGlD]]?k&c&C>YS=SvcLoZ:H%Oz'ZVv~b X(V?.I)h6pc&gT㗬ˬ'%-?sωN}_MG%޽?\a _4d#{0~=<7#( Q<"(scUbc a'ȗՊ k]"S|2Dk։XveA4[^~[8|EճE_skG6ñHJ1zC{&wcegdF:e-,fۮF٬ |QYYّ,|NEƒH$AhJ1w2dmρZ[ŏx@Ig29U?of8v-^ZP뉡eM>M zr q(m8dlF:;5I_1?uݰ~?R'g3I>gI7t0J=9ƓMb|g9qfDj{s[?̍9r1bq h VT:&ʠ=e"\nKQ.<mƁ{ۢjWTȧ6URE^J,1)&OX9˙O2#˚|jv7_V6T֞wԊ,uaW #6&Tn9uQ+@$$iy=H!i/< ?gsH{sQS|^Rh7cB>acHڴE9'ɫ-'H .+,@ɒJ+J0ID>ҁBl֣Eͱ/#PEE`s+OR⢉!I!e,Hl$@c9<+MH k \["-H;,T$fVP;ház'] zS\|CIUZ;\s&gpR^uo׀d{3.* qQ:apUXLҔ)$%QS5ò&IBҢri&.x87ȧ JMꀲg(F峤_fߒ> KIz}T|&紩 Q"L3LvϾ*7ou$q֯s4'+[ BTE%7>`f*Q~0T@>)MX{CnqCn&HGBmB!fDиr\֍X/psuD&(16+ +WbJ8e.m;ͧj˓g<ɳ$_`bEpYzoS>7t%luՖDmlO\uY{)..\sx %VH=qû>CԦEHZɃDLN.VgʜTUSo|"mZU}`)+'5".实s%u&ZiͳH',ŭn!-7_l[S80EIɧeKWWZU/5![]fb̵ tԊvVڱ<8ܵ}X:L*G=ۨwp/ڮ{6ڵL۵h}GM,-p-V'LS7֢}@"0B'Sl Zٱ<-rc?+}u֎R;{Y|:޼J\&L']qA@m`%l,vyVWMbL#ye7Q+1`YZ S±cwԛ+Y-ӎZc+3jnDLض(^5>.Y?__W& |A-a4v>q%EJV&%H"\%MtA@qכrO>!C2/fBWADÔAsX4@܎( ieQf òu4Fv\lNd9:uZS^'7 qs`.,7ܮFŅpCAȒRҴ[1@*)H;ekLG?="P{:p,Pgʗ5QY=H7QqY?KQ!K&Jɷf;]6Y4rЋS=6aLy,\m(Y[(ͬ|Hﰓ3hP.bɻ|KIc\a"LҀH=h_кYj+z\7.U}5%~#ml 6c%yUv~u< hNgYY!>.GBa`rVJλ ؤ@}x5-^'zM:e6h2ot+\õإ(8?e,eK<#?ł,-Y&HA.ھo<(%%][s_;ݰCCYu,>Φ3,ޱvh ]s38VV6ҋPKعV;#jS]y,R7V~䥮uMTiqxoi{#wX#cjP _4 jtoOڨVhqã۠5 GK?1]6?J;*iD`!`:x鬠3a=3fAB[#Ȇ/QXPqŢ9Ϻ?;dq<:_V-c@Y3O A Eaq0rM+.g\%>I)ӓ}gޟ$s .i9#| Ąk|X)˛㸝iN7 q@M&DUQ ^mԐ4 u _P*-dGYvG%!_ y)imklR?Xbs#KgC>fZN;ҞiIى@Y.ӑ*b\-9ƼMyδ'@ tXh [F58ya.}hEiFa:<6f6:l[5Pg|lT ϴ\E`i>hrvzť}O>$vsݍkFs+\[>WǸa3@"0?4xǚAv=L_׬cuA@eoN2[M=i!$ZUMV:"ٖ9ƼXH@,\͚.a-a"oxqR$VbࢱQh!WD,H:slm' nωAx 7Y }A;%Y %3$@"0r{QG5cuA>DED5d$@"0)QM y # uqB^ ^ʛm=s(FlӲ3: nex\#ʰ+/=fuJ2C@"$scŬcA> RD X.DBpO8>uZ8 !?1n$|4TmsBPPրw-qqwgu?~r=6d0C<]o紶KD n՝wfC}Gt?o`7cOY07'Z{T\xs4~&ڮ`oفrg\?'H6QXt͖ƀ|H 7t 1,?i3D HD`Y#bvz'x2f:D XE! y3}ֈO;1+ ͛r53s|)^%oĠ|~2{󟗵KD HDž|M$1]ClTD +w ApBnu&D[:W058co)1 If[kG|&\m:k2 nw%ñ6B>J|.$@"$+w"}il3d# |E"$ h=,o '$tಌ6Ky9_< E!xSgQݔ\Ǧ+A:%6XN;gϐ$@" z>Gz« 21>$s=w qAk@)֌W35Av y ,fRzIԖqC5!CY&赂Luب%5ܛoG׋`ǧiNFbMbȦCo[#ܘ.ydD Hf#W]uUko=Oyqc5s&<HI" a\;Wj92v}m{Ij1!?/RuJu5qߏgtA-mfwYX@Xy䑽 .wuF#Ӕ$@"0z]tQ?O1KHL0m*:@"0n0}8ƫ.ot=ׅ .؈x≽38ODo٤dZD H_~ywSC9yvi7V ۇ!6 (w&@"08coЗ7Hueg_:4~8'E83rxVhO6 ?.}y1<>y;_gSe)QlV kiFVڵb-$Yd i'?v}uB33`ƚ$p#wzu𡃂]8pܩEׯkO\OcY/wH畅wZcC( V "P $Yd:0:Pƒ[^c byJ|V[mR$*|ʹmCBu_7܏P39k:ft`-Lw\gD HD HD '='xկXwemCw܆S9~e}i!%w̿59.M,]Ǫ8(5?;@B!b&5HD HD HEj6 :.xՠ W]/=DͶȃx4-cY |s@g[>2=@"$@"$@",O0]:=8؇8;.4/w#ёP^olLq-@/Lk%\&œ/ID HD H!DA{W\pCu0OrFF6+opO`ޙs杉@"$@"$@"0? o9EAޥ)":OqJ G75_bG&<ٔh~Vu"$@"$@"$G+mp '1co;Hƕ];1vba8@:!^&5HD HD H@,YgO_NjGk7,x3$#s 9l/71=/cUf$2D HD HD Zy9>Yjօ^+a<G[@-0'=_LfFD HD HD`6!𯵂WW{y6ai әD HD HD H3su]\1Ǿ; s6 kw". ?C>to̧D HD HD H=[3xAni~G!`ߝE=/ }zdMo4+?*΄'@"$@"$,C OW bipsmsU/ Qa\=OCnZ*vdqےxβID HD HG Soѯ:u Nf)dcm>dâʴ͂]_0a7C˰T2@"$@"$@"0gg葊a-}h[ N6 2AMCCLd"$@"$@"$C^{Hg6{NseܷPd3v}X$K6<>7Pg(2LD HD HD`8蠃9cӡ"ٟ׹'{f$CDSD HD HD H w υS!ׯ{?wYŬc k1kæy̼#P&.HD HD H9@x>6xN,6 .wsϟ[J9w32ssc(&wUddˡ#ՈgD HD HD NP)a8}&Rlu_q0]2,A*(mɏ9?濍:0yD HD HD H@ *ɶ tu ކb ې'ovUvawu&L$6 {dՕgU21@"$@"$@"yˎ yK{[pxFYw,f$"zvbQksxdop3*_f1HD HD HṺRmpX7d!7oq`ηD=7O <2yYLH"$@"$@"$ k9p8RxxIܳaRrYQd8uQ0Kh_9/c]>óLD"$@"$@"$GZp-oe1P_>*}s\vK^|2"љD HD HD H9A,795];6]\ tv=G/ɼv |SdHl3@"$@"$@"=.\js~- e<>rI|0ۄ%se c_ p$4_$@"$@"$@"Q ~ȿȧ%1'IHlTr1X|n|A;6,Vƒ :D HD HD Hf?|mpη~{}X? 2ۅ%s G:ípoOBl{d ;)-D HD HD H&@g)[']ޒ$@"$@"$@" q7vm>X?o xh`nzϚx ߈{W'@"$@"$@"Lpo.w^Z|6~מ D;[ |;ILm"ozn;uD HD HD HqQO kpڨhF;!sm^޷~"ּEϙd@"$@"$@"$ӆ@X0ׂϨX/6>mNti{qWDh7zq{$.v,3<HD HD HD`By{/ NwSM}|Gvv^^GԸ>׋+!phGqg$!i"$@"$@"$ |!!{˛ۜ6$$"JyQ{DH5փ[~Ќ$"#MD HD HD 1!)yF/Y/7u~ܳY|iF&@"$@"$@"ͮ;fݧ5O +=!k녜κvP$N$vӞ0HD HD HD`~ۆ,q&.h0N^nx K% ryuׁ^.q}`+yʌW|A"$@"$@"$ӏAt ̮]g~9d O#6§7"kk9b%0^i}1&@"$@"$@"@B , h䰀*He'^,8!>diyiF$@"$@"$@"jm`^\<]덇, >NӒ woD| $^pZ^:"}$n!+5d6iMz'i^rHNjA=*Eܷk앁trXg4yz*ʱ ѝ;=3s2D HD H1ͮ Gj]oqCgmp/"DŽB^vugΓ{﵃.kryTȢB >-!̆>6ұC!):Mzu-rp)G\5y^|:Ko>:<%߭^e'4u|fD&->פIz2~.HD HD #C`eOy|t;}e|YrK{çY"U9!JE!^Ω_+&mO']ҼmC~Ac\έB+;ϑzUU^?e8ye|]"$@"$C@̻7Uk ~; %Y!K5saW_%@"$@"0{w .=GߟKD HD`(mp Y/DH֑+',wYD E7}|rtųB|'Ɛ_XF^YrC! ŲFQ6Yy!!/ Ps3B6,XA#'C$ēs&B>`wmP$}҅@|w2uc,t0O_ I'&/Ϯ3d׈7ykwAί$Ě:BUv yfH!{=_r9Gc-WbAϳܞ4q-ʤ!&ox!yECUrkvzRB`v!YiǮY1?4DNi; CmTPY7þThi'|[߻M} LyOw뱵UeT'wq~{rRA<ӢǴں=&@"$@"tp gMDfDyAܷ~2H7;fCk=kw#.jmY[-ߧ'z:uHBX?PG;PRT6Y1=eO7ų&mY&>X=yWv~y\Ur]p:&ΎX KM :Ai<$q␓CEPC.AK/ H/};ar. 2e7 $!TWjY%lU&la ue!6NOiw iT!icHr^ӼF%@(JKheeXQdH(P>gׄKҐF63`y7ȈD HD '(:6kW\|Ní9b}6;ʿ׋7*K@EB(c 䓲^V~# =ڧ5x?҂V\G7^U>ߑBTB#2۶J"sBXI'TJye;Y g|vU.? { ADBbL8FMB_a5."NAT e7ўRޥ\:~gŻ d!-|(X7׼3g,-$ҵ߆hce% sSxhȞ{Uvu~lN~kȷ`GfdK]4)uǐ(uԽmW Y%ώG+Xgj~{ %@(EpB.n"F||nRMV#Td .g?~hoXm6 a5BXYNv81-,ȕNDF.hsW \7=u Lad{#<|"!%B\5C C KZkkb< \\sU䈨8v ;& 9 D@6pd?1gbmeZ,~!&pA*J\ɧ+mN,K)yVn!%{Bildxȳ"mj!\Ml bbߵl. iG)%ɝ&`$rR^ȿrR^/A3$@"$@"0\5m xI0io|Szq<,M yiȖqSz|R "6Zў,|JBhPL* :2ZS%"mudkːlK䲾!-Y==#>k k:RD[oQlY@*G{)҇"@կC w!V5'!d 7&R>哰 S!& ^ԡbF`俇 \O^j҅?HCpZ޵F|A\ lϙͳQd9/qg"$@"$F&!owv{?rJpƛmb&CRtrYD -%*8kB()3V4v Du-&Ho;L|nܠj,jNSuF>,mbF@Mt rȠOjYJYhRI&&gC3CD_;9I:ɧC[fM7aDuت_rFX|"M4('K zf;^%@"$@"Ѕ 䍕mi&~>΄s 5)r(E!ut9V4 +(K&!,dF{q|Ww 9Q[,y5$~y7BzGFBƂ7UI16di&r])xf_ώ 6CbV6F"'K>5ɽ߇ⓛn-aQ: 7^l@;jCf17~bN{$ yCؾR7s?YVRM\Sq שׂX§zqznHST\=!uߐ.b2ӄ!WB2Kp 6i̐zr-&@"$@"ta?\]<qoOd?4.[D-FxV Y?<8;dɵK\YjCtrDCCʺ8$OVQYX<ɐ]CXIYW kL|5~j,!%H0:S׼~Ą5Bn4bK)Y6U q.G>?JTy]-b/9S9!~cHqFe%ssOi/$73O 7Oc"yn(B][ԓ \אMBPo D'k,&+Ѥxv )dCYyA\rivuT݂2Q5C"$@"$G+m܏m!SW>,p0 •var_n$a:<&~ !@rc)[7PUHD;ceumaF=Z^Ș۴BQ,u &L%#ynP7ճL( >X|HWy+] dD@ ~SK# )}s#`X,CLhtЦ܋T?zX_c'3]i5yFB,76H8NQT{ yRhi@9JoD HD Hf  .+N>M瞼A0WqgDxK.FY<{]qǏqh@ &!^ .cN.Gd a*PSY('6q|R!- dw!{VDJ1DX? )A(f񽄅5Lב$V#%H]wf(խ~Fn+3e>! #MPdt2,M (d{Y_8&O̢.εep?kaʗ:Y_E^'[ʅpaaX& $Ąx$y \y'+aL(HN!L"/ AځtQrY&IX7 f^,\K^J`S ~H0U?^Rmi!ȻzT4Iz r,g`A.*y5]<5ܽp]{p|7G*D8yځsCԷ21cd*C]D HD {۠[5VQ|056|A B7a!]0zg]wJJj!"e5cD&PAj(լ>(?C r([J:@i-+IFr ˄ن^Jk }&)YAee5D&ȳ4" )dM^'>d!\]kKр\t!UZ=!GҠeLNtZȔ:ydG!!k8 dk4\b;Y/^uBzX.< +ۻ^VUVHr>(wix[j!cYx yIHN/l*m +퍫dZ!jk">]uWeaG[2"]!g?db< Y&j!<?vy'.ߟ$@"$@""~ho wqkڇ6G G,I>JV̅V,_gX# r3/jiMܙ!\6Z8%!HD HD HNxTMuhӎ_ A:8iƳ8Qjegs)Kmv>SnM.u{][5^ZֱÉ!g{3呶|g"$@"$@"0'>'>_9FD\rcfE!_/hXHd+7u,I>Dig۪ Q~.eٞawl( @"$@"$@"0M|Rv 0|6{ MD?.oT oQnӔf9#`ǽ,X,.zm>#6ڥu9ӓ$@"$@" Ân`Y9vtȫ#kLtPuAkg~P3)M"0Pw 9kF| Y4x_6䵓xf2.T6^< u!oo)kN|l#?~'uΦФCv AfKo֞b>-!ob|K"CЙ w Y%~bb34!m x"q퐰vikDGYv, ӔffX~0-!ia6#OrQȳ6|~\sZ B~k!w-B^݊rS5!H|'o l@f7 yy뚙τ<})h]+"*dq|->)B aouO/Y ! *y|fKNrnHN>.=Sa;d6x ؽ7!7fC?OGCˮ7Ʋ }O!3x}#䒐c|Bк̫8?` w"a<2l%6l<," ;W _$)#煜.*Y!l2iP60"oX sVE 2dv=Z,,G73M4m}xfYݺy謐^i~vXRO>Q>7n4>|Y'3sR'.aOa=l1#3CLLO4qclAvOR8S-/9six Ͽ"qx뮣]ϸfܰol,=[19NX:rT 7;('ГCaϰRf [ pkLl׊&p 3Stq׍~&e hϳMwP@kݶ tٳ-C2JBfXӆ|1g֩#9\# xZN 1L8&$nn|dHȸџ2"%ZXĔ"an"Cf3WE`Q'vIs].}LgL<1d8"A3w4ߊr{1ntAw{ 󌐍k@>ެ#QX^e!Y+AHwV#k \g\ʌ](X0.: nhʡKUth:]nu<${G Yt(aV$CZE+|9<1DYgU,Y&k+Q#]t zN( Gm„ :!pkE+Ǯь}5::ny)m=/)mWl(dn W5Iww.˕J0ɃLq{BAXOB ~Dـ\gNr A;:s g׫B6 J8~Bi,z7J>KDQj5Bk8hV"[9z_T(/ZqN]YR~bB!B& ucQ:Gx)DnLnw^\ ⪃!?,_BJy o 3CnyJ>@ڡ{-u~7 \JLN <ۊ(Ku\m;>MRʵAW}9y%~}H٥\"# " i6jC?SfQw7WQG7ig!!R!qeuVʥi@ာ.&)8~B^A=)DUm[K >z~OvJ'Jn$ڧgn_㭿׵ødܯ H"1u^V꨺0]=0ўjLJW}X'>Ko}xcQum\k76V긿Ҋ[]v߾!T,B|<9?n'$=Otg.xvNз;=3VPoa j D;\?eQ!ډwx3I'Ro ,mo&v!_6BWh\H!i4jE>OtbcP:?_߃[#VЯѿF9d]BI/)mYOEWXȐB8JC`m `V5(q;&B ^َG2/7>tT, "͹Ĵ=L^+P i D7R:*tQA|3J[! 4}g *E(%,B7p^=S, YrVmP<yD6ET9J?R}!}CrA @ :h 8ׄCSzhC `::P8 10P (pCnܯ(g)4I"_ Aݺ6֘xk^_WޛܱQMƗCz*^m_;vZJ_cxOH)}zOo}l!MP~SUx}6T]ȣ[/+ u0Fb\^98 KMXPK[=x̐2W6ke6^RY}Xƭ<' Q.SPt3guSI G/.ϩFB> z3C~B-aA|yIAZGIwO׼۸1`f&]VyM1d&&vP6N% ޤq] ;6 )ukQ|Wύۥ}bv|攝}8¬MC>sٝ͆A>/MlH4ZWa6 VA3_cKM'ġQ<)(U2u qi0N 7HmR4]B/Jɀ6<5|@|pTtuP6rR@N3: 1A{TH!Sw!(BV8Jα`uPK00@jpR)FP cǿC(uIto( "CL|džeE :J{Q=0?cx=^_Q8(c8!v|jڙWg( D!.i]0GѼxa|ꏍE?[~-~AmEzG ȑݢ~V~uspHAug p?.DZce5 o waQ(ۼ.ݥm됶|K2C!_ tR?cnv%ء~g\G|E t|F1C#k65]I>S\0@,׼'v 1ήغ\J=W}m[o7so_\rzH4c%>. rF:x3b  ĆbqEX_H<:Re !CG5hu:* t;(+MȂڀgY]_yxn8]CC(Mz$f;hGPkr`7z@K7C mFVN֖ۊvC锷R?"ohmGuҺ?*xV[V6cQ?_ʧk2ĉi}nTP ?9?6ɪoÿ(&(߂P].m"}!/A]*:jM|5uoc_o_Q7LA~a88I&Uo]SҮ׎TMXH_;PލbB QRo%<#hY w]FEI5"OQ ٭_ C iۢO 8+kp$fm?GW!r yyGܻskWȺ8u҇:vi:t6vkZ-x?Iu.mY={]{&B>fm[mv];9Pۓc[OIs{gܠtOc1!5!TBu]i74D?ҞܕWc2}VQ8ommY_J'БgcC뵱v~d"cJxp|7^rM?ltpƐ՚KvM'u?>& +_~'c=)=Yl6""kDe]έPB(SeVEATBTX]Y0 n3U:dLBtftE.*;+  RN"5Y-~ptXʠ$tODАǽ:.i0u .4 K4|ek@9ʐ=BNyn;t A6riα!7uzEqP&)R ;^?m6EUݠjG> AA|"xu^Ml K֐vfGo4jQ2RB;(P$. !vG+_/: ny|\Hg)oݖ8e+G}"s[lj;SߐtzgW-)BWknFxȇ~T]qkSt: ɧ& _"F'S;Lwi}}!yI\laP_n@GS.OmM>Fuc!mM> 62ԶK7+]ו맔:FmR*V֏I>_X/0SBm]^|<;0Xp(AySp{o绱>w3>2^DZ,MHχPfsP٤g9D&JjNN'(!:b!E)PKGPh(q2ܰIz˛|Rt(]VA䓂oPRTtJNMYVB +&h}Cq 4)v0š|u (5;vGV!:IS}6(O]2(VX"Ik"8D.A䀼LvAfH<ՙ%%nPyx|WHWE>)cϒ} _:l`HذtODt"{)s֖AK69&՞WǑ}^}Q[/PGrۮJu]J/,`7im(tϯ7qw)ȧt_;58DcQ6.HB; ٮC&2V>V.ʵ "uD~}I( v>a@;*u6'8ikqiGyԭ7g_}sP| Z!A>kY\:ل3;҉\T<H7S#=WO!g=k &|ȧ3!Xzpf7iXN|ԙZ-hKQ~f|`L8D_vv&b":L7O|ҧ[(,&к,`" +57:,cO27(0D@ Tm G^b iem̐B"&.|"a*saD M@ շ(v@JI媍 9o߫ݨCc6?tICWZq#ʨ=ؕcosgA0I!I-i]o&J~Xצ|~IXYL|[&%0i]aА.ct^etMFY{c |v=HĽau}pH=i2 v{!i)|'և*q7\^E>E1XNk3A`k0tj1|TT3ju0~h] ( 3"Ջ!f)k9e Ru]@B),v]Ҍɏұ†q:xns6t)~3m앙gw$Ƭg:x/ X(Yo ܃V+.B6 AbX@t}x:aFl{e( wMǯu%O;Ik[ +6r%ҤprpYީҭ}3ݎLbv]JOi\(QJ9mR+fzmB[oxw =^zK.vfRATϚ 0ӥ(S{I1Kꓴ\wywygI48^ pD-}wR9emeX)ʪwڃ1RmnPvj}o}z"xA_NTF?1?`뷏Op{u<\2Ҿ]mWr*_ܵN1+%>o,fߚ4L ;{Jt'J 3.1uD=S?mҞ|6"G<#m&m7DC7&| 9'ԭ2ćr=H(^X4P']oݹ^Ϛ"G6ٴx(Y!)qq?XEPOi1] 1S5b]4mCX5ڳ]N2;^0zE>4%kL'@Y)ĬR(,l^?IK Y$DZJX(䥭(\bР\hNYSr [˔:.P Jn|H|":P6(3vf$)d ʠ HRщԍ.Dsz:!/|7K!0ţ.v  f y.J,.BVk}JzH 1Ŧ4Vg`ǀZB;^?6Q }qN!5/(:PMT\rv`aszrc֧(vX+Pv@D(*mOѢ mq:(꛲ h=@V QuP DQLAFa*>wAM".mK?Bs1(p/W7)CE:N yxпmr>-|A(Q?iuuC~:h{ꎶ b?nk lݖ?_(vf]zsxTʻH\ߩVs&L(D[{Ϸ[NJwWuqCc1iƎE!϶@W/BYuPŭ=ġ5qhg-B )ط $]m_-J?,$y! cBWYM1Q]AK ʲ=#[yA:Oc>u 12dV?+_ڧ$mjn>D".}B:Eu! 6i}8JR])z: 2]oHi E;&ԓ,{q0P(HqА:o;bh&iPYu+C>Jt,Gɾ6!"u!$ހAԩwrau:g/B>^S#60˃N&ii7I5tD:jy! #]Z!_BIXeHwjo݉_S o@fS`( H<`'curSAc*D9젠Zrfy/o:}C6 YÕ"ZO H 58S >]ABh70}xwo ]ݖ T?)eE! 堙anF.o !0Tƅ(uF9m%"z9NﮉIi<>oJZ33 |݇t{M)8\zeiH[ӣ7~ʷzNR UԭAۤBY/mȈm|e!7%+ڌDϔi̺U.|lީQ]*}XcaG>ob,MQuۇk >NF>-'9^+tG>jg%g\}5hL6yP $D>5D2w)*H">d{)Cf9}CWG_?#/w`ڍ dV @f 1 yt X\/DF(BhkѠSZ*P(>%i)a"m1PB yC.o-y1P2ʌRyR;%haH!rUF}ǓC(dgJv0A/R R4x˛5R<WxUw&OJ6eW9@0ɏ3BaUwh˯ Sm)+L [SAQ!ubA.-g CJCJb`>[=%ŗMHOɃ=3)򭌤 e~$R'n7b16 #u[ T\SC(d> a+;[ Z]^i<,9e~^'?PĐm}HzK v" C(4+y]JoSQt_uVEC|\eS/αzBNuKn/QS+> 7B]Ƃϔ)ߤM4L=YQp%ghJVƏR,x.:2./ߺ(PG 䫝}ևq?%~OhxA5H]mMȵ7is?B Qgӱ ~&8MA?D8=g,hH̘U7u!w!ڨBRz?IR=K2 t5Cn)K9*}[DuRMn}Z!J8Ghm1!mVߢ.NZgqDs.B>CI>O&Ӹ%hռ4(1AZED(48 ߽E«~^h H)iOꝈNoPШCLLq!:5B qP ts ʿf|Q(iTB>HG{||s%Gyv=D^?C!HpA!O#g '^sX3spx Y D3pUFϫK]\S^Πzk,%Co_ʇ+,ye{ԅU_R&M{),|g`_#WU8ݵw&ɺjB`Ǘ)~k架R"]O PVVFTj (Uגn< o SjGy-I%ou_]JZd4ϫ3uPsDVV㍉~D;)gJPʸW_WY:S |?(]Ak\-mm"~=55{)/ӁDLM#e^+`< ]~q'is..Ѿ|92kH}[-Z?R.l&WqWIZR7Uy}ppc5b4+U_:mT4ߒj[7n_+[Pց\-iW+, QfecnTdQ" ͥ&v2: 8"s3[FM J_C̪N4d!S C5eʬ>!c)p,A"1Όjx@JA,ӐmCLdF!&&B:3I]6s0RN?Ho3.D25 3Ifď lJNYIOV-OdbF.E@Yqs&qJ)[O,lBB s;_`Jːkl  ' ylHL!L#/ ,apymriޑώFFDeqaxVe-Ezp^7SJ٧)\L|JCC"{~OUw(3N:gVɸ 'C!%-\e0($]~s1yqpVȕ.bVbC,Bh}5'f-2bwnZ 8d7g[Y1OEfǕU!6,`^8fC֡䲐C(.){lƘSCKk~}k7 ɉ!ւ[i7A~:idĘsD&c FHwM?^-B[x ir$3U2ީ"`.nv[ِ˦T0_j!xsSc.m;n%ʗ!newl7[;aQ2̛ɩBM& t%@{җJS>Wl@"$@"$@"$3@8_$@"$@"$@"3@"$@"$@"$#s!$@"$@"$@"$uVoyȲ +eR q08~p`ﰹL FaD HD HD`$2tCZB6\Ցwjōy>$3Y[rYWf(4]7/w.W"^zqfr kV|)dwE!_ -dF~Ԥ՛U4C"$@"$%ST%9{Lm;-wϽCN Y:}C|NS!e4@"$@" #I>Ԗ>6PY>yTwY*;k#CvGE>rh ' :~5q<#}\@K~AOdU|X=[#i)C.R~Jߊ\^rP>TNCly+M?6/-%ΉOg+_iR!u & 7$gL~MD HD`!sg^bGbdDh?!"!gCAAh a,2BD_;־?Bjk$RmxFM< kC. AξPw"7GNFyYA< ٰIW|C6ÚH^pm-naޘgMJ0zf&.U.Nzk&m_H}$5HyM2I>;ϿD HD /$/%!H"!d?k]k9rv~E-!DX Y<&,\}w"(ݺAzeώC@+ɐB!HX3{5׬Oo.ۅX7[Z4r^Sq+*DֻXcFODȧgLIGgėBKn+/%@"$@"0H9K;6˟Y1?2dvh3! )##-"5ҁ@,2iͧegׯqg_\W揗n!H!].H 굛%NWd/B. Y--$m,Ŭ]%6b1oNY_3$@"$@"s| ?,0stN,]3,5iC$`rFZdvU q3Ÿ ɲ"1!e(HqeAm"v`tve-XGid'L0VZl҆Xs~sG|7!6fKq?$ :;wqwXܹk`q vwX<$\_)4ٙ;R<vuu}ygOµ@!P@!PlR|nҎѬIv_^]M&Od賡~Hd9D8N/ȧ݃( B}P2?VQZ?;챝KqߏXG[27m3Jl C0BPձB( B( E>`G'rȧ]X:Į:yǨˎ*6Ip~.4.+C?|7tDhK>z`[?ׇ-2q^Ba$x!P@!PBlwRo_[Ϟ :O;bȧEMuI>s-A^|z<%ȋݸ _E'ɞI3=Rr -Ի9GHk+ȧ_E$j=Zߟ,ve&D9v{ a"m=_"hB>zvo>szAБmP!P@!P["[*[BH9K?w{}?{'Cv!~Տ4YBLw}HVPԪ\c"eoP=Alw_߆ ];;N[9"j |#uځ0`"˽WM~og.cKdhwRù_;y_e=4H'`S}E_ ~vvgcS:N@!P@!(zm=U1=^yP?cwvG򼧙^IXz=f(ۯn +(Yrlvp=J#-q^TYFom[TD^K8FTfl_&Un/^(Ne(7oC=ޚx.w5uyǵ=ߗhoIGaǞPF YVoGmD7W# B( B( B8/U{!P@!P@!P["[@!P@!P@!P^|^B( B( B(E>D7W# B( B( B8W?bbթn˖%яՊB( B("PsQ-B1.9CNoԶw1?f6oV}U:@a~i=:L( B( BXe|F{C7~;yq}BYI(qN EDZb{ʻJX\g :%@!P@!P "+п"^$ϿϿ_ı{ГMWµECu>AM & B( B(67E>W޿KB|$לw{ɕWJр<ٵb ={h=9ьK z[n~V@!P@!G\CQqC^N.z+j qcW CO#y;rt^'lvh'xPA9B?Q˳p#oe? ;_h37ױh;CU}t*X]%; \-*@lϮ#bp8bIc;ޏMԥ߲OzvcF tB;ojQ`߼php~?@mIㆽBg%ƒ\~s)CӿO1פws\:1YI!P@!P["+|J b }JhK$̈ҏz ܫIC~9_ }^B%˭<:w识r=$޵GzAN*CGc=BP腍HЃBQZ <>ܿCﳃޝw%ڣ]lA7ɡ~P^_(^g̦~1JEnAcC?C=v kLPc{-) B( B`K#PsߓOdj 9 xB mwNJ&TBݒ/dHB|~ЏeHz?jnN ›}+>{c$x{`|L(ѓ;;p imfNgO:;dΎcMPu?H2Ӗ]/ ֶ GYރ #^o+P}tݯ $Y7zƒV (3g)_W_ńˎs yYs%"ms/b:p@4e{ݘ@@9]6;|a}Hh/bޟ3W-K}FtW;y TB,IosJRS!  ijmDt3THvCwʄ@|~]Q EHDcD$@9+0&" Uch7L=kI}ޏu-#|$毊I>-C'vz] h3k71t;)\$gL<:P;Wm(v\Cw uj];w޶|\.'>^n1gRv7X#!;IE(#pzS#vIs[:IJ{O(g1%}p1cQ!|ԓv;q?n>{Pr +;{^[`Rɟo =HEr=^Sxx(R@!P@!5(~og"XCf7ˮP/='nڀ xL)E&YBLhl;~>N)Kv b?4Ǫsgl4 }C[U,-LgBA#чglڥgƄ'O 윧oXo,ĕ)|'. C-D ȷbWW%@!P@!Ply|C>%H喟IDATGVz$@c8v&B~4Ԯ]"ZE^|"^H%@rFYB}QU8k,"vzg6sD= ݣVYNW!Q.Ses[W3| cLC}Zx@;I>ZLy}'ԎwSټ|cvVvL_#LmD^~ҒćO0@P[A_jyQe.A`ӷG,f; l\I~iqaG]ٮZ@!PB%2%vh$/ 3t>>:iݱA*$e<{Ӯ8Jf-; BP#K3RN}KOb8GMhw{n†YsH=ȉGW c;_y{<AK{OmW]LDE쮵o!P~Oݫ<&~0|=-lַI>=ғQu' W۩5V.]/έ6}֎GWH/ gOsm!fY B( B\yӎS]-4oD <=^< sPӽ:f+?"Ԯda&P E-Lv\me#PIC$٦ݭS>|>hlrvz@ %#ک|"cE껅cȗc mvw*˘/ cY<.ҒO;cY"yvIO>4y¸؀]j;~ =n>w[o6v7%C=zˇ[;P#%@!P@!P@ϕAO>bmGw"zcO*H$=9P<2=ԮG@%`JK>b+N[޳PPڅv]z:֤yw>vkQ#N$1wiOi'i䓏XjQ8y_Px]aȩ]Hz118~+/kMKl NBmw}+@!P@!(oɧG/7Rcz Tk'1iF;KEĽvi^}LL;h{-%`kzHl!V .G) 'Dh>6yl`[49#;v=[۞|{x`c' HN+yv>g7 YL]b$Ϊ=ؕon>Gzsc w"Z^meeX ڔ;0^ o# OjhǠ[nbb>`q.q 峭h3Z\P;7n@!P@!Pl-|!jAJMA)OD\|5)XGc=]9 G`%v}4tP7{;?vFIwv#vly?GLyL}=kc bp"_uήw!9k8D>XΗG#;BK>%?l^TdĮ5L0uZhIGCZCvCpHjO}LdPuS;k9AWB>'fv(=nlY;{-}X4#cgVH`w% TS 4R HS2;Ic ɒr^z0Ms괻Q=wIr=O#MPX”} Efte?gi˛eW; RaЖHu.w}mwz\(g#j=>#ccq.P_i~PR@!P@! Ps<&@_iJvJ||HT^D2lUIh|J~Oيw%+_PqhbO?v̼ݳ3uu*ٷr>#˗ 8#B쮶d.4$&*h1x| "yG{8l"iNIqlwPkB[ؖmBs0mxYkg%>#|G*.GpS\y3\ "ʃCٗu,>Kη[O;ˮGޔcr|" ?+j'.G-X0&6pQ ,n1Sp!P@!P[ "+oBvHx6MN6\1] G7zYBL'pBihq䆖|zS|DCjw]cu6{ѱi.wPvSΎ:r x$o5"19W&"C{^#q=D|euȶho(P}<Lَ,C_?tZ_P=RPw8]X:y&iqN}?[/HE lKgl(h&Աɍ֦Ci+?Ws{Dף%@!P@!P#znѾqĭ,<]=B=۾g۾X;\#=nq/MGb4yb3ORW/) B( BAs ڡWzmrsW<{бi #7^Q!ުҾzus^lmס-+ B( B`K PsKt5ҏuW`J~Y=Ery̶?"0?}~i%Kn<_~+[m( B( B`\1U@!P@!P@!P,|B@!P@!P@!P"+ ( B( B( B@YB( B( B( #PsV@!P@!P@!P(9 :_OmR4tߙY8~M/µ~}y-jm<Vm\,gS V_[gh~_um_]b'6K潿]]oiE>/UBaCϴf/fĸŁWwm86tT^جp\dX~8{,U BB`3#phkBoFZyrCC_KMlز;[/$xzC{M#E>7MWl{>!}ݱ^%z%GFs~-tF" TFLg\#֪؋G=uSzУCzUnH_QU"pD HUjXbCrGsñp{Ћ um*.9ĖSnFr[z+ a܌=3Vxv^eY5\aKͰMn q.VX^n/zsz[ lC%;9AnqyסbF0tܘ"7sg=}BTmٶxʱHn[#@б5z͋}x`׸%*] l0vB7ӻk׺,ֽ֮B-~,EZ_ ,z1-)y^΍ZU!.m1"B=ҠqC=rbգ8,ٸ gd*5lQe=w>z` hw qtޝOO|0T=  UI!\.7or867XYZUsKHb׾׶z5^Iۣ(+)c&&WpʫGR4Jw: (=^\*+N{MzѮm[bW_:<֊_iJ4j_S5B2Hv[[}}VM}[\ ͨS_#MW m-2ri;~qW\M>q~]V[ ]țg; ;vݴ_VO;\^tF$oG~u{& m77 zaiE4y=|PHbyks|G>q'yn~}D'>3& ]{vobߦnDc؜z\_+ b>sEgfZlHӧMccIA'}>KGY47cYnqo1o!>i}M{k+xoηYvpХy'^ם7o|}>oy3o&$}=TiƒA9 Gp`h%eYd"A <*P&1MIwn6+TǓB@(x {Cg'5U݆z&}?&/+-V^Oc]}w( L9]=s^fbPdi4f{MY &vC'p+CO6Tp㡼_g%}&Bm_{K㡿YwO&I&kp'B0Aj?\:MkL >qo| GsKcO2n-~l vlЄ#CiuL' m&E)K ;E_}Hw.žeyD#'p-y3HIq?>i,rW}# *{,Ч|)bPZdOP >ixAksKߊƂ2=Cnhm|#}q'Šgw}rI;ӵ-j|*4п ĺׅ.I?4sgZog{hs 9Ck%1uBCGjXyBE 8iᦟˍ1;;bg܋ }ah ۴\EW~..? C Q9g֗vY>vyR,!*˸d;>&.ʼnɡ 1{ 7;.FBu䧭ws9mm;z; =l1P'J{3徃'}f\۴vޚOŁLl@>\/)<lq'\(TL?>/q}|c2~ZVyP{,Nlϕw% <&tqůI Ϭ\P+)dž痆URI PdB9 Զ~dDH*BL)ALY<4Tb(JԫlDP|v3{]ncSPand@[LߑXH7.Z % ;ԋI&|Uֱ+>?':#o et.!96e2bvmu N^O?K\[ХI@[[KZ1AWޠ qB;T;>K&n_> G+g/}X쐀.v)/pLK1V~f1q&4|-#CՇsl5$vgd#C%? 83Iڲu}DL5M:x#VclI9s-1oqGz`;`}iH}cc|N<|zIzv$ul6[֎+spۂB^^v_;fܻp+2⧡C+uHdX3d9`+>#I2\{P})EcvH1&U0+$̩o=1 X~*곫~rNel.ȹ>}M8,䜲PD%tWBݼ[{_~xosO7Z_3k,."r>s(K([Z_MD1iWxPub1w:n5k K32eVbf\=KQlBA%v9(ֱU<X &WuY;o[br;>'Iϛw6缵k{Ŧޟ'>e>[|wƗ:v[~37ˍ[ccJǮ kϕ 3r +euK0a[M9G Dpzd֡ cWIBl\ K[LbHmgP+fR 8PՋe0 BP^0BN `%G4L#&&A2q&0I%E$(A[AB>ړ+XE q@DEiC{? T,r$HL-s _ m`yD")qzw {$9U$ۊb1_>T2 b&VIwWw=JP|@"s+;$D"L;.]975&~*VV,d `+01V`,N +e $̞Ə1)0ZY/6<瞏 M#m,1{ghP'JS#?|,G}h X x򓟄"_>4K`jCMtfq=J CO\25Ef+=i>`U{|*f\W xS<> Cncx֕;u1}18$A'.47)xy5CO:^>i| Ҹj, Z 2=9~_c03ve+E0_ɻcMs켲Bы4gԢ Ҵ\L dH\|@dfL4W;s{eE Omq1֋y|= q没9V%>8r?o9^I8Gڎcyw(" c"io^Vwq9c p[1מ 6'O+/0 Q(?\S^z-74}K>g]l.m={ #BV:v,km+D"PvH'M&[1D>3&mMJЖtMfqBI`g}s8ޗJ4MPDb"1m5h%+] 5a!3)h?]hISO.6\k!%IYcO0gIXobIZ ~Er`gOğV2!h+Vy4U|IBі? [Z`?%E˱z DW~zI6, mN$;pNPXc,\>k?yUBVC%z]c_s\\8p pm}<áqxPq/b~f'\k^h\sPcd<P}ceVvcXoI2v,W]j6&fyl b|Hh':3諸 ؒ{OqyR=7qDv9ܣ쌉wJ!VKj"{ r1l^ eH1lO }Yh{iǞP؉[vC1놡\;M]euI@e,m|T 6' vp~f /AaK?ž}s{Ctھ/ruX{Ww^H$䘜O_)T$V2kA$ !C~@ {W~0I|L"ύs,&AVrԋ .~wBPAL{.3|%HRsO/ѡz+d^Fu#@<X`R`ߗMe m[ڛz괢ڊ`1Ԥ=%7J:69u*[ W.؆ [Cϋ d׋IF9gӮ7LX|$hg &CŠ A{1J՝0$T% %dc ;X/56V>cGkeُNL6y7BI h3ܦ,Q"^$1?1+iнIN?6^6 Y[> K8(yn@ߋA$v-lkυCs~ݽ/ $'DLMR6Sqoɧre+R>s7h3{C+Хh7ɾkAi>&~)&+P{/b?OI_Gk>*ŸO^.pXLlC❅V_#|]?c ry1w`P}kŴdڱ-TqyW׎{wV}41WjP-Tr4ADy~[J.v!y@"IVgf-)\ o?" qV ]lE>IDH`e2#șLmYRdD"452a#:\;%}&BkS4)-GD>ć"◒v!a3˖t)DnkdwOratAd=K1;.,āƄ~$'d#Óȧ Ŝަ1~dkuS9[KIcme%L*IsߺW 2%z =^ƀD3BoJ~۹1~snߝ8Tm | c #sh93fq|6rja=ɀ8~k̐C!+|yL{Bf1C )l͹`(G. <ȧ|b\ά{Q&D9Njɧ4)&ՙ Vz.-x8*.aZ 睰L(2 D&Z $m&Im}w'! & c" ̹8|ڽ"?koCPW+ "lRl?iٷxϪQZS Mw릵/cr?F ayI&Pɧ>&.P0b1ҜuKM^IW|ܽ痍L?/B%HPLɟUh|1? A/= C1Sڌ}CV|n2$##y:v v$9Ʀ%Cݲ,1+v4_5H],{(QȾP>n~;G*@vO2 #:D>JO BVI{'Oo}s6_FM[ lCcbH_i2|,nx(=5w+.onf6?gO|F3~q({lshso[y=>6>P0C% 3mYAPȧM }< S9Ǜ?js6eʯz[i#CE>wuۣ`O$Vd7Za"BY9a4It|'%H(&U{"XXqG2fA$=rusϏ&(;OKБam"wz4grzkBsBC$cԊ1E*I[BvT|$;/>?ٱ緙Ȟ8gRI Gm^22z`X Q^!AZ"6DNc&Klؖ; adϊ|/;ei|<&aDrv{|ضɒV,g̷N[i2lw m![Ib!@GO[6v,H2.g$D/׍SwX8{g%H6Au2}7acsy.F[mdUl^b.xxgij_˧B_Twm^Flzg1CltqKG꼒SzO 㭽N57LF.B>jq% ֤cܘ3i4'X[D ^ْdl b|rȧA<',أr"6ąI8$AN)S|q;$w2rke ̏.^) 1v&}/<=ԋ?H9ʍuղ҃3OKɭr:뗴UOdNpIDݡ&`@4])<2rIVf2kL_ TC{ ފpI`ח-Aٺ{o׋@dBS$A_y/д yzԠk1ՍL.H$yho.*\kRmqLe"Ai >DaU3Ev8Y5)sgz6I3DMcX7ÁbvKz1يoٵ%w eZ}nvs?%PE!=u|H?I"X`Hַ$Ԯsu5"OO$8{nޔ? d/L0jR.75I+0PoͿW.7N]|'m[n;lA>;ĘPWweⳄ9dOz #b՜g[ v~ӊ6; $&f$3M_wLN_2Ƌ1}_X ї;Csn9i|F$*g^g.Wv)--HOtqĀc 11Ɯo)*?܆!,)ĕ+Ůkw}וk|C9^bb[6Ie!Eƃ-}B 1f=żl1cȊGqqwErȑ\Cw/:3cm s>Z8p~qZ\揭o9~dBO|:T|⽸/佋a| Is8(w=nSHMэs5.4! ?|S襡-ai+ (_ 7({R:Hd$x 0>-d[݋͍$qI^/YzST5YL#P&ׇޢ)a{Mп`u{kIB'@$CjoN7BM&IH$Z(,^$?3U>b @!JOj}Kjh6"PGa0/"#T/ 9bZ߲~C?n\/3vUL\Rt0Ty$)УC%ymj\id&th/4+BSLr%CuWԶ/  KIBC}&I4&%ω> dlۄ]ouM&\ڸ׆J`{ {qV2oKC;\]W}I9x CZ_> 3soDvBx$&PQB?X=qf$e[|7m[w0 61 yB''iC;#o!FrHuKj gSI=WLbۇ{!,B |]BRg($EiOƧı>W|Oc=b|eΟ&P5~(1'd9ƺklP F*'CX\Byl̴}jmy9s;'aLP|no;spM?%e7 @Qwm@>`G%LIb,>ym3,M0'n4Ba'Q[P[?ɱ-=H]w ddɇ!Ѯey6I`I>pR6Iĭk"m? YixLJ~MU n}5zį+ Yd8FĎN_ڤ< {$2}"ێ񹾭Շ6!8 Y؄|v(oC@ڲC)|=4cϗ X([#C-sΛKs6B}.g_MhLؒ'>s9ahu^ 1d|klCgŨ)SE>W5/1=Ɯ|(bT+\oֱڦn^D*۪M|Ok$m/MiB2]78aLr&6=fm1&7}B7cvM[DKطG=_Ll+; ;COvs7`u1]WzRF“qB?i4?ܓ6 v=C4L3l0m}UL>iZa8cP}H =~OK/ҵո#.!Ǜ2-ib̷c#tʾ^|qK~P b}.p8;uΘV&{"ǴAs._D?l5cQ¢7Z~'e\~B]c11ct{rXnN^g Mmkv*Ϝf91L]#ɶ$W`^>v6u~\}|u`__\>Vv&%gX*QyCەm][s E{mX2Mos.W6k$#c#lV3 Bx4M>6z,U{\)s[>Wa`{vYR)E>*| gPܗ@!P?z6GgNAjK.sCPWnjOF*)|+0W%#H6~ z]?sQ_l /NC){_ŜkK ܏$~ʿG[cm;x  mDc/YgSO*oɶNkHF_k.g+M:aӎ&ވN_%\ Q7?O/Y0Կ,1e# *T~ڼ*E}EsT " }Wc)/_FsT/ݡ~P=8 -!h</38焮rG~e}1KȰM݌$?"PsM]om,I ]JbF<6TB9IR$F#ӏ[7]+v8l<>"'yU@;ۅ;kԌcoU1aU7_C c\\; PWZ7 P~)^57b5ZFkuU; _o$YB/je'q:? 巧=[=3W'|: BT(V"bqc0}LR|^oou3ϤП"#M}/ͰU?9G2|J-|o-#vzq-_2=}!C2<3kh\zeX YzD^P;Ny“"? :驒Ĺ,{ _EdLtD+׌/W_N ]zT|^-}'c]KQ.&Χo/&1Y%@!|H8$&V8]*Q}W 4+M<%P 8v|n5cQ؅0`_C$HZǦ=;B%ƨ[O7ACy3P!(H_ waCynKB?ڿ 1_-+k`m=]QozF!:_@gj G"<1.~89[uVU._ l6A?:#2j7c-QCnFPp~{U#]kE7i|@X_:\;_<붘XV:}cqЇtu#7oE|'=|,\U" ~x$GPNz=z9+i/V_eϓV%kq5ZpSlmo>ݛs@HLm&AIy+~ÏxõHh?iUS?1I+AJ<1y, myݴSlBZwk[q㑦]#VTƅv{<_O룱y;yR;YD>^U><&|Ż)u+ m$ٍ{ZcojfUݲL•o%ޮ:[4.i{}_8DA73kw _W*ƞzM=^Gjǫ|ܣD|&;bQGmiJz#[ƭ3lGk'.$P7bc=g7MN'gD_6?TIHyLѻrȧ]ˌtR7t\ʶ3'>eĸy#-@x= /cGm]={:*}c2oL4ތi|#4wcb!&?s;;wtF-MH+ G_V=kc#m=ۻ{ۯ/ p}+#ཌྷωc9:Ucz~I3TB$͒Z?4`9Y $~-C* R"CLuIVO\h8jOUC_Pv|Mn5u=†J>ܜh {`)>KeX,DKn 7m5A֏)&m,2m&^$Ǘ5u).F;ћ^DmK2 {; y>#jm l#nA=.XPSRGZ"ٯcd )m=Vdc$!o Iwz"{A(_U?DQʡ#uz?9K1$C~ =Hwȋm}N[VK p萏Ix+xV P MAl.29Ctq?[ַrb ?_O8)? E@ݿe m }^gQ4VIF-Yic{%8]:$0`'ޱxiǵJ۸]vZxev~<;, fxꀑv"tZ=2#gaA$ LHvhHؔlw^uJLyPFb~\a]w 51G&iX=ʮ~L]W e]_ ${B*3°YE=A$i)T$yrhb޳[{CNĂvJ#$ T߿+}G)㈱H% E|-PHs__"H;VYo\gqDB6B/zt3uuW켃=lN qv_><ڄÜϷ`sIR>tP ġlk _[&zP Pds@*n /IS,q6%bZhǑ򔋰?y " ~> aX›C+[]+fZ<9Vc_>)s)>#X~$O!l1]|]ܒC[yW\0' 9 b!r8 VKeE1]]|s,,LGe숿y,NDKkSv#]OcI(a E>[_H|qFső Eރ+_hmNYbK)vjcasypiZ(n۴3Dy܉Ⱥ^l,á 5N!cQ5-]bb}塞;o>W?nOI!P"+o޺=| ]H}dڧBw|nW% & OŽL w jb2q5+ǡ&A @+BH[AB[ ZB}}868p)K[%6-)&ZݕsZ9P7x,ds5}~v&s$*EҤ/)SnkG "*w|'./%D>t'$l|߉)Cȁ>ɑ$G{SSYFZ8TC%-sOvGl$uc9+v6'45yp: Ym=w\6-&&S+\{mdf%r8&4//A1b!FL9*ncxhy]pgƩXnR|@~NXIza7{{2ۡB&Q6ˆ>pm%Z_̒ ^Dr%B;*HʾZs #;8'qd{ƫqۋc_ Cv1}-`j>lIi;ߎIv:~P H{S}̧6ַ<4Q$B_$bEiT Tq yb_ym8K>lYP8Tr8 fhi~@G[7~%ɾj8<Ĭ׆}u qx3I;}CGrHϘ=c q7ʰ;/~sجȞpS1o5Oo} n׋uI-hrMrZ1=&b,-|I1hqAa#_CVC>/7 P;>:\(5d0F>ǭ:^l8P;gO 7BsDlG!$;I:#DElpH|%&l$alhW癰v}c$hz%)&Y:!Ysah[}/ER|ڥ׎ K%$'&L"$'&lP$)ϯ \I8H2$-&m, V`ԆyS:s[[9X'!#V>O6JS!(݌s)E>`w|F ,F$6||LZ&O:/ȧ~#s߄_b;%6U ćzcg"ܼ~L2LIz/ε5}EhK*4}Hyy۹@p<|Z9y'a6mLSew涏ߕiGNZr߉sI>\f;i~TǷ'?1[mg#>Ⱦr[E^diLcv5F=kyǽ6:ixu(&!PskƤ 1YPɧ"99,Vy)&>  ȸk*tI$'dRB=τg|6QimGܗj.s^V-b if($=Rٯ-n$v>I 5L;n~&iZSRP ulϝaθe1Ep!❲\>cTbҦPD>Goc|>=*z8znY )k>[@3Z OʆkL[D>, M>e[LЯ pkBwUi}׍r q}v--R39u]쑦աB@Ym&4њ^5kǹJȱM>E&O;# 9ky&1򉤘񖸵H<"VW|Ȑ!mƖ,LK~hw`$mkracډC ZYn^dgO({P<;CXIG<6(%JNdZ2 2iW%m\y(\R"9gbsPȧE%3L!|§6ַ$~G\dA%v>%|Ie"9mW*'v=fĆI2FIb'/F>'& {=A4vΧg(=Md|oB;JK,1ix-#dfLybL9ɧzeLqvT[GYZŶc|"y'n6yr1ȸqmI!PE>W VJ@NKLNx-ԏ9H:=Ջ_`5Dg&ۄpN$$a{q:kX t]UGk:ey朰IPK଺AXUq(bUIJJ;$ѱƦ0p]}8H2-4ig= ȣ:R\;v87`; _opO1-]ӎ[;c*9$ 7>/*/bŢnБL,O1ƑGlkggĎЃBS:)թC]mQ,%цǤx+-"`.Fm @=lŘR ?oNJ1a< o<ݎRxɗE4g.nSza mc"ҮW=Ѡ.>mfvuocڅK׫KyBPN/ƶ1n2oSڶg9,qp_sM/Ov_yZǜsM+Uc~i8,;-n}$sC?b@evOņ _ B(ym$_ EZP)KbM7i9gBvL\ 'Q鉒.)aPJdWe=ńIʖ]Y]&J&}? ʥɱ%M ;(b23&Ι\+ 2r"}h$HhSX^/&P2"G@e7]#9h(a_wKB]&i+,ۡɂI~"ŶLI~7V^wPۆy8! OHy+ 4Tbt:z p16z TH O2ݢBa`=t/B v[Q_¥O`{[B'| UP(KZ$vQqc%I Τx۹mAo⃶fmbRE+ơ1&z I,7{,c]|6Fa15[RWG ~?e[2 -FXŊg. 41{1BLx"<&a)wjagH:_sNDXƛmy|kw܄؞1hOk8m0nʸc]<5&2fڱ00}s5;*Ӈ mw._ݧ;r Nycq\彩0sݴ^3(\Rd+ 0_>t! Iס{Bs B1aGR&h$C!d k\';f"$m2#yGJRLg{žv N_'ل$TM|, HmdȤ %Ċ 6pPɔQb?DۏI8$=J$,{"`T%d2:M#Mxp(LZ6au8>WYݮX??"TcƯBkh){C{egODi,kgvP$Ymdž?kY+!R'%Yƀa?~fE8xW($\|_)wX!sIMtdLrPɊnBqjWss& K[d PH]Cm2fE!Q~c*ŵ:e_ [{$&||P1D]u`"Jr4!Gv(%&]um$qW&/HIg&Y ;g7>-pk䏭 UPI&{eȵHb`-vraYyv&%YF2m t N*9im}jBV^3g MbvwƗC񛢏Z_ׯiߍsγImO_PRiqb?fc'{ y|KI\-)/T-:81^ 5mHCy{C[-0<  pm4[m-9'J3ne[ 7uHMCc!X ch?_HǸmE7'/"x9[k XM[RCk_ftLڲBUud59g?t޷{ B䔡P ;# l7ڶmGw6S~m̧-昹p_-9k|P^6YBB#3S̉ bX8 ~w\* CD!o;KnX G L qI s H;Jr%d*)Ӣ<Хr)DNA&lveKJ%@F43Y FĤ08,8y|o&B, sNl`֩GKpe?*/М?*3NI$^`9П=0ỳD[7dk&$Ǐ/.$%֗YF$/}o*Ob؎e~IDo9QP'K#H!Yoiq> 5 UEOQc8v-ݣ~!HۤE:_WfoxG2\p8I|+س0b1KpU`b".}۸e%pJS yDҷGֶL1m2K6IW[ٺ r1ա~뷽oǵ9SO0ߵqoձX#?dw\}LJ3aOKjWa7ƚ16 cc@/p!P̋@y B`" amWduxv>^ZB( BX( XGֳB=*=²( B( c(YP dq/ BEn]\6̕Yw@!PVBVjk!5GA2_~|dez++. B( @ϭB`k W =b&_uw=WYkp'mz5T @!P@!(򹩻W@!P@!P@臲( B( B( M@MݽոB( B( B(E>G?@!P@!P@!Plj|n@!P@!P@!>(>( B( B( B`S#PsSwo5( B( B( @eE!P@!P@!P"{q@!P@!P@!P|~(+ B( B( B[+ B( B( B`} Ps}CYQ@!P@!PFj\!P@!P@!P"ʊB( B( B(65E>7uV B( B( BX\PV@!P@!P@!(򹩻W@!P@!P@臲( B( B( M@MݽոB( B( B(E>G?@!P@!P@!Plj|n@!P@!P@!>(>( B( B( B`S#PsSwo5( B( B( @eE!P@!P@!P"{q@!P@!P@!P|~(+ B( B( B[+ B( B( B`} Ps}CYQ@!P@!PFj\!P@!P@!P"ʊB( B( B(65E>W޽E\7aSq2'R%/re pL{qôdX͉I㺝Cl<2eGøֿ'_rݱR2 8s詺N3_U܃]r+bcE(P߭׷<~q[@]_l&|7Mԯ }Go(:@ YWnV0@p9K7&ۄ>ammY7 ?b')fP痍؂AR{р.nX)'nu]aBŢiZ)3?Gt>UU75x\eB`"Ps;/YT%zWuF& 4]WnV0V_o RsJ~J66/Q씈.'^PY|.ևRڵo1mWWRs.yV'ėx7.FW@ʻIPyT~x' :{B߯1h=~0}ejeա%Y 8*DZ>?G;c>@1FナI1У=f 7M옾U?ƜG3-i￵}b-D I1XY`sΊʽƜ{]sLܿ==?#xqB1#|P8, bL[,+}9p3(Oڥ |]9뫴Gy} wue|i{ Tԫk]?գ C[3 5{\fc/hD'yPbޡ?ߒχGO;@,|mԒ}q]QRƐ>a>(ۘp a;߁pu ?OAc/h}:ܫ}5ojzZIތ\ysiJqDbE "N[޺9.hIN%CPɀ-$PzP.&P+rC'EC E.DClH}7QnXRmY }T过~'GC8zA]gC=l}$wϿm7?מMģ֧jByPŘݰߎУ;ؾ'd$ǖ6xV|ʏ$C}֗^#owhOJ/I껇>;ImH_5/,# =Od N$Џφ>u+S$(lL~5Ʒb2%5_|S'c쳪=B-9;k|xy|PN'0CP1%'I 0O›"X1=C06v$>}R+O\[B C=BԖZdi#`@$ч ͤҹ\@. RB66=~{C٪>Of.>)b=\E 'BaPqnW[G$LjCc&;r>ϸE$Ƣ'/|#Akc_@`E/ș紟*6ŭ>}ԘC -s&'a0R_%C7w"cx7j.ᡜ%o6Px+;DsyK˘?õ,.c }JLC A:Cs%lY%]v`Njv0m._r9D*Cǖ|?M1\,'c<—1!NbpAY&YD Zm\'c}0n|Y{_xɮ"=b? rP:WuXe|Ж| 4\\'p!^)9HS"Gy:3iDMy(w/w{PN#/&#CۉFaLDD :ɮ$yS=ys&h B&a-B/AQ0 moϷ͛ثM؍;/abjm7{.t8f(I{MO xh;Q# u8~2+]}XI>dαnp%0_kOw כ?Oo2׆"|lmId9k?%_[_R[1]K߶cBDŽJR|F\\M"P 9k͸8:8lm;;|L_>iG/`+5/8/kP>Dz$dX3v}#K]2؏3ɰ~BVCmCb}^6%5p`X¶ h"Cm ;o]^oQ58$>o>w>iE".of۾P(r>O1@wֵWĈ?ӞzTh$~kO}]S bx7$n[>5KBmaYʚUNݟ +Y.d褹\"g嘿[O>C%x59ksa+!fѡ'c3A>')s[条|g4׊|>o!X0`scqylq1>@ϕ\)18jbT/Ϡ`5g9AE)Dńz9 R`~ C%ˏ XRd}{Cl&Dbb3C%c JXCL{$S"C ED$K4W L,ɃG-ef׵,`zzNq.A.$az0ԤPm|(T[$a&IHDhW(\%`Xn%jP$(۬[ Tbl>(D:)c/bW;%i+ҖPIp!C^$?7>g2zD|$7$S ,.ǑEXWW=dh7w %/|E#@)WWc-I<2-}Οm4u7[+JZB3e1,Ӵ$]%|q 1w 8~>8_;C]{(K=Y{YSBhGb XI ?C}E67M Qɛ6~_)QK+E9:?if\K(b;|QHo2/_#˞$5=$0ajyP6)wp!-WB!w>ho?cE̾[h'r8}9F;uOLE'%}C8y`q`mC)^3L?n8<<>pP͘f,OzAa9_/q#ԼlO+;B5,.p04~#fl&mx{C8 Zi|S?Z/ E".]iXn'F>%<8?jsU3Qac?G}q~mNjQ_v 5Ů6/yP23mp+NGO?hP~*n Z!Ps.|^m$:e| hkMTㅚHI`I"8I܃/b.R}[a)aIw^B8܇, ak%D}(a'pP>L u=(XaCs6vo C7 Et2>/2IAߞ1-9Cf5ҡH^%ⳤY?>Lw6Ss6{ŷM}8!ɜ$H^%lqms]>63fܑXk)Q^ PɾmݒTq$|7c=mbL_ٛC]Dv$l/*ᬼwk~6~#dڡb@(\'!^7}<+. AZAe_?T_w! k', ߢ{ԧEdD8>>ď]c,(hXO=㳾Kj(GY{Co8M~@5~m9ml-> k-;Pc੡'ƃ" |+>ӘSp5_lӸCThb\/U9V*}]6[Cc[h븹#7~;m'䜸)PxFظ=tP9I!/00GQeK p^,5;bcFܷ&q {*22,TߋE1"x>5#MiɧwdtCK3>j 8"kʭ#Ps/|"?7;UD HMf "e:p +ɧI &>M|Od"*3!< tail'oA^457bIe\k;|8+o9JI$"Tӿ%ƭ>{Qd🣇WtH#Ba8!*W-!lˡXp]>JzHds!MB ejkɶЖ|f2w8.>G@&\?T\ 6ќǀE|F0r^/F>xPxa~H᫒l6U>x5H<8jz,H[,3}1$T~΃Om6fGqAx(,{QObPWr~rB͟ږ㺭ϸȾg}P  e"\?4[1# bra.pL`~=/B=⢴ۼ~TA`tЯXI; }ZxB?^ܴLah~y=8/8ZLpVy Q,zdK>ov==TGsg VT] \,| Db&-P(@Z6VS4D25z!$"ĂCw"B}C>M,Fv3H|w%s1([r;i''#EsYi@?K$ȧ \yN%>ЃȚ]&$8 w&j1܊q~u- ,$pg{}G4|8=3TZ.zHռ"S~0T,'/ ǞP^Cr{˽ŠOK eHm$67nl{|_Ʉ3+yq*uc:#X|uOM=W 6/-Bb6i} >WSeL[ELy-{%μҒO1oqF/@S7F]{^8\1R׶8.H[A𵕯8sj.`!>g\nnIƖ|\/j!" ӆI}&v4C7 2,ϵ?p;_jn7 '"sH}hʳX ?7 ǂ6R;4X̦yb-lcA6~"f͉$wXdCś ]x)@CnRP܌"wyJMk'O&tg/g'ѐ IN#|TEzZ9jlJ: {.tBMl*gUV"SK>Ljq Yf5+8L;$ r>NkZi5֪<"2Q;P~33I 9GvC8~;TRb֡m"‡vJ=i#H %S$vړmqM|.;jN,1?b]I&Ţcb$-ak8h'BҒyhFzc"2Nܣȧڋ$[)WLι%|o1MLZ0+-Tc[vK>߼l #gļghi#DD*p!Vs9g<":g|Z ƙjgQ[EG6`'Bs|Ƈ^FW1_IN?㭹|pHlaSoIz imx-;}"N$&-T "tIRD=0T$xmE3|1ɧ$Hp:SgUHL )yفлf C>s2}fs|0݅=ﻛ6sNRcrlP%ڀ|Mizpk\;H2`#)k/T[Ij'Fs& V[IӾ$ 7f'} MB>#QKPoKK>[eIhʱC &Q%r8o}E>ggGO }xmMy>>F>oOM$=$$דџQe1d_2>g$p?yrCVn:\ԇZRb,1ȧq2F>Ƥ->'H'Jgr$Ee|mF@qlwC"f<2;=ȧVÈz%E/M 5߫Gn<1?<ْqߴxkȹO~fұ_v"[aL|$9 xT@[ԐOmd'&b+eg!_ 5iZZ|$:1TU;9&\EuLLJ & "gbYW\_{r 9BhJP ʪSN+ PXe 뗡|'턘``I>OR;Bp%Mj|1'%Pׁwh2OLę_$ѪbϤ@<9.mœB%"FL$CI%ȧ1 L;+"+4w>w7?Dzyi_G$/ ŗ6Ͱ"G\?lRve|aۇJP }x[kgƪq xx&Br_I")ʽڷo^ʧ_W=HO>{rИ;q10 N~8ITMV}d׺|f|P\pK>sh˫E>۹2TETd.i!gkLa!V?5>ڶGRIqDCMeU^ cH1|Bcbr$dP]ˏZ17[5`Pl_P'NȧފyM|47gy90qR*[o%N=}WB?jáƞ"m ɧ905/OS)-XTQ|D~D/t_h&)gZ 2P ajM d?dO^򥏐{e#^18!$g n}D$lHmǝoᒉ$Ϥy)qP<ï3%㸕m%p -`%N_'IB|_ EPf7ado<&QS\"yQ)Cz }^g\>ȍ>E\+A7H _+))/C 3>B1p/򙘴¯:'@2`lanyT쵠j,&}EsOi.rU{ _5K_qc1kcqicCCƩ2ksq\(.iWoT{CK>s9*] El ̯,Ɓ ר۵s@y$iN>o {y@H?R,yڸK_-|>z?iY("+WPy0s/jB`PI. AI11YH 5++HIN놲$8D 5R"+ǵlPkIN XgZSPE&g&&vHB\C*@JƓO(*W3U${)Xe#I`UB%T)yP41>/T4 Xԇ W%y&lG65kIB?آ Bj븍&LFn&3x5!ꓶ_gELlF> A9Îߥ#>KR;+`8I$՟ҷM~qNR|!>$Q?qvIZ`fG bkc ǏqI_ 7*e{趮i_]+Q2ϰ1A8R`eF|qO>_Iz;Rx&qXM?4.?rW}w(R;:xw]C۱v.2{`z[e;G; 㤤{l\'m6k(2QSDz{ uea8n \ 1א^Wkvn;_|GH}Lw=Jz2op18r爐 7 Ũ,zG|w>{N\JRT/uYe,B4lD9 G{2`&%2Iƨu27X+i9P3=o?k.GcQ%9¬.Gwo)K67_>:(<m }ql Cۘ6O#S vv-xl9`N3s6y9͆BXCʡK3LkU$.HēihW-Խ9C #Ƞ$}(D'b$QLzidiN@+@|mQD پ,d]#0< ͤ}EĮ'00!% Yd ML&f+iF\94l`]ں%"rPr>~K%ޏ c$b)TBoL>V_nKLGLC~'H;%hKFu}rS.9-"TR MN)S_LI$ oǫg m'3wɼk#Ay8ۤ5l:n磄I"(9ko LpdؘWQG#62@~"}~A+IR/&|oJ약+%y$l5CM$-\hP Xb?>E}ҊMXqP Uvq`!BnGõ gU2r^_o s] =Wh&pG:lL kʹHH}Ik|H2߭ya^9G\x`Wو[/#m)N̥BG^\c{˘aʘkYg6o,<9Y8b%%CXš1R]?H6#cAY 5ژn3"H;#cÖq{H@[;~֎9q1\k{iDs0E"jOnfn_ g49Rrx>G[!_8V(r;J'Ӈ 1`{sτBB,0G.vM@:޳hdc2{n Cr=irX JX(K@|&!.. m!I &y8av~6MlȜD¡-1tPI0J$I&8G>.$>9TgMB%&KTѤP$lɼ6/?b߮cdxǐx:%:ZrߖBz '5sAk'weHx_ O$3c)0KZ]fWP{OvM%M;sĦVLٗK#ew{Lo\+YYHzI #wC{l3v$yN0R> 6L!z+a(1T+6}1H>`4fWdd|6zPMXg%|{xB[ŹŦyu o'{كB_PqJl߱Erpُ!}d\ {B9!9^6Xw3笲s@ʃYk@d~=COCDƃyb6?4ಁ/[/IyR}sX?,_\pK(?盓$iƽ)KqFզ'f!&Mus~Ƨve{V酆2s?&'`>9mlyW9kmcvξ^O{i($ƣ1jNSS PsupXLTPܥAU$KL*i릑nIuH &(׳=cYK>M8ĽنYdڐwy($=uJ?*PO|JkiH Hpg{݌M<⦾ 9}e>;pk}z gαf7zm&z Qyb熪.<_ ĮGV3SSRa_ׇB+/) B`@gZ"Ѫ$d{<;kirʶJ"49iGJ B`#]ӣcnV Mb[B4?;lzpGG޺( @ ߅ޗtB3ȧl.z9u{^) B`^xzvEmk\O˅ ݿ]_@ZY|{%V|zY?,vJMXy)) wPʼmW EJό~ȯ:WR@!!P\( B( B( B`(W@!P@!P@!PE> B( B( B("kqUP@!P@!P@!P|( B( B( B`(WD9MbCZ~@wqǎ?~eă֕?Tº( BEgC!P!p8S<+B6qCOR7Ӟ`r8Хkњ7=Jŕqkn*1@!P"cr[5 ݩ0+ټ-P4]Z|Aϸ"-Я\9<#%߸ =S˅>45{}U}d{^{̸q|ސ,w5Rcِ]YFZ#Ps^?9Lys(BП~g{T+}{O+&%kEׅ4yz8CП~(tqE;Nֽ"ǡ =ۈm%+ʝqC6׆=T3j't!TH};*Rl~ >IC-4_鿆S6zB(V"-{g&ë>:'{";{PRBrl^$}kB-Z,[7ác.sRyP ݶ~Lt;Z^kB;CW5/z(O/Vg jMS\zϿPnzi Vdjzt;NzLuiz)bG{aв( @뉿 ,Gq:kEIb'4Ɗ]TMlj5Ze/t1G*KMQekFLvcFǞ++wn\9''3.;=C6훇=+pXtG1Ib\^jk+'/?Ԗ=ӯvH6yDg$J=oضvwoS'vӗѷlWEΗدڳBR];k D>e<'n m>-iٖ0>nB,ǃ-˜7 Ӥ;{菝48|(?pC$>oUE܋<Ĵw>Ӥg\$ r\kȲ>1TX~u{TrPXwЎ|$c:Gh_. B`!PsJQ$ Ǥֳx0r'4P_?2In'좶416&?ցDXRg7塈ͻ{ L /N0&[Miu^XFo8]}MωH?<Ʒ-O;%vuwMs;N%)0)DJLZiTƎнXc@|ɯyJb="km}K~E"W_  EelH:Ӽ qӆ Tz|lnQ_ v^oZp-b̳o P7l>E,nj=dMx(RLcD4<\:s{I ?,}C7=|G0%./X9^c 3?1=Ks/ D?w|FX}, B| I<BaWB%lךs{v\$OX$yS)+C+$ m'{K ݘ]yv/JK4"=Jb^7V%Xv#I2?i|ԱIߊe"M=$|)TRڊ$ӎ>i&eWV9Vb4-J$⹋YLI6.Lm@ēIV_$]r˞J[ve=/IEXsр^{$ګomYI,Sr\$ kA]l_u"~ni?Z@[j KS$[ HƳcݡo =b9'[[w\OVD!Jv!ShPq;{- ňJ+A>w[1Ƒӆ e[;7mAeK+#F8s8?5`RE[C+tuWro(^m^~yȧ"@ {q']`\ݜdMW } u||;o;C;A{[ˆ!Q2f/"W+) Bh(rw0J2{ԴIkZ$r&k1B3I%vw R ;lTb? k+A R&$YDJ~bZNR$:v[V^+7/=Bs{&ɕvK%?_DVt!=l{ hPɘ+IԷrq@V$ۅ.v6!H_>е -†wۑf}}P8 |N"N!+A^->#/zu("a+Oc6v#,Bo=Z pNN|`ö$@qn~vA1UPe!nʶ]'1Ң<- 6l)v3lJ~kXiEܣݮ'H5FDad1B]ʅ;@[cL>'-ȉq} R!bʾj0E'E}/e,O淮kbC9ܤ,__1DLBK{{kX7m~:^FʻWsg&8\%Tbad]҆XNҧ9$%l˙2L"+nI)xTucN䈝J.qdQ4&] ̈́a4UdoN&HƵ`(;%? EoNNBYާ;o(2hנIٿ E&_B"nhkOB]2$ Y !iKFXpBxH!rOc>uI|ȧokndUbl̤ VڢvmWO2k$˦SrP r)U"$uƵqdw~q쮡9V;&-qo/ȥvǟ1,P sa1M ŢXc!dxCfg Biwu @N +81rCn}9~E^ cbkHc$ȹ0)-r+X#+i1Q~vnߺY fXq0bOhǢuFC@!Plm|^[yi+W㡗daF>~PDQə$(v"\T h,A:܇!UnH'|IRj>#[9^'$Or!BBlcCYpIN̏C&I Oib\(?u6=.tqbC_ u)ϏGl|E.b@JLb8Rb7̘\0"/$혰cxɔ[B7Pqlwi~˷j0/t:J61dD½CJ(= ;&HB&lS!;bk&db7`0FC!vBcO6|N#v¿j!EbiG;Qg qmy~  PڈtIz O AKl#;#yB1cG*mlv`Zin=EwΧ?,OҞӡ=s4ujEZ kE>=i5m^I. v,"b4iw]ъh5ސ&vG֒|! &㛟O6OPh$iJO⢅m)EL淮jbE>=`!ilg #V@!PL@tlIERG dRR5irK%5I4#d1 r-y`"Ij]oi|uOn^0iE>byfG>O_%}i;'|팓KΧ6>>U LZX_?TLiwf|4Cӈ͈Y8$qvή]Lm DKw?6KfcK{$6[qF*~^b/wa,iZ|-Mc1EY 7,UυBK;z#ʟJ B(& Psk{޻Y#IC= /MR}ZO $B4I$7MyPRɡO նV$z{^(;JP C/앐m9w8PA EO$xԒxd/Rbb7B=ރHxQ<J<Yx|MM! |='a=ڭL|"->@Xr I$%F*dyL,nCdg wC k=vdcB}o5;Db6!n?|N} OLÝocYl<>Xl^G ȶ#Gs,=SH:v S xnv` :=|hf Q8ӏ)mw(bA>s!h!> eъEv"ǥ6Xc=vk۾sv~vn9&n\eLt~xPL[BМOfTw"Xxwv~/ZiPю*1=3@7wvBb(qi/) B@ϭB`Ҕ Y̤#v&eb!D K$W }G$5gHP%Ȏr#qjwd1KwP DI2&v^Zӝv<J֣$)A"_ 觜4>H=I!_dLb&?qI=Y|fkIBh= mw]}!qI%J)U7Z\N}v`ދо.Tf`L$|i봻1$ml}y=P#V,Y FIZ\ā"=v=:~$N{6 ]g'=Ȍd=֬yQ(lQ~8vܱcƼ.QZ(C%Fs}GhJ٦!,3NX0V ɹC-L';@}kсoL"Ëqn/Ʊn%m٣w0]7cL;m С_\s"ϵz.:ة\>-)b}bGc瞡|15Jag[P|lQi.߳ǡc;}fbk`P7+Dz]q'vkC+ B`K#PstdNЯowbr @"&ޟJ8h w_Z BzHOK%FO5Tx-> jy ; EV%Ȝ!4G6S o"Q)W$enZ+IՏtIrs%˒(SuCɌ]R$=]@"aH ΂6 I"yk"oeiC_ .t>ps-CpMd HoP/H$`I9_V $? 7\LTL`8 bB&2^k|x?(9!BZƷOqRt/x!c^n djڃH[|p3`/@|q3^ĖB1`D@o1>rk?b8\I+zoqKa>1n,}XA =,1¢EI!P|nא,#.C%G&G .+DR*1w҂ Yiav O3v@J-&P+G' Vi'enRod%L{%Rԓ\ײ!%S;(޷fyZ]&dܭ[$-$ac ;Ba_hp,צ=wzPg!=g*s?f]3 /*ևDK #Bik,D\/1j,ctir8WgsƭkEY(kGoIqB-}->"DXw_Yfs**f #WclWzcª( B`*E>A B( C#_ X{A+=~.K B("@!PxBsB]=~`{w(@!PlP|nЎ+ B(VqUF_nzhk׫ZY6~/h뇠YI!PE2( B`UWP[?6_7"%;/*{{E᳴j. B "sT@!P@!P@!P"+A- B( B( B "sT@!P@!P@!P"+A- B( B( B "sT?qX7mCzg= !8CQo N0o2塧ZKPVlv?<ױ%azc3\ }]E !n6(kW=r Y[ZB/ ee[}P|G, 'YK쿉{n6Udž~?3Yvvy1υX{=z٦^qB cɞFsbS_[)ݡăSqiz&A&6Cb7}GO FItҵhk+5c? !EM y݀C@Ri EP f_gZ,+r͞UϼO"ЈC{|;/g fϷgC=>X|)s3H< 7 qG*;b(j}@u[ (pP=zПzj& #@^ckqXB =J ~ZAf,Zi8GǢRcr?'[U 3fmVjWϭmSCP/Y7̲K>tVy<9K%3vsU~<(Y;k>9\{l%ʳL6knUz;៵eQ8zyD_ > V_+Aw[s:*Coz+vK΁ϳv")cnieea<ΕQ߲)uϴ]~'KF /`Z'޽}15. 18lmT\jqmw\yA.="P;t|6Ǽױyvػ?cHr>o֊_=ԦǘbW01InCϔ>CӞ~K]OGڸV2mzCCP|p-cdsNwqx`g my=2~8]? rݵ lbF|j^mg^'czQ|H'2>5;;_{S3Q0I' ;['ijwiX0__L7i^owJ`ҖbHח旣B4N#ۛ:'=1ֶ3MiweMGj-O(|;B?Z|a&cJfǔ;qojn?#,գ)=UA-M05o\) T;{Ģ/gK68E>WށBПI$]&Ib="P>(B huDR%KCn"9Ä9I'~+De=ǃ  ~h1D\/' =Zb ٤#uOZaInP]I&o`繃=8g+HAzA"g? D IФJл%4Q M w M@AE1TPAy{sod5ޫΚ53Y0yka-I}צA2 t`t+Ꮕ@6\ۆ($w5])C7mh,%@rlؗ602 [2hXa#[ASYek<+C.jÖ=2}|7vz&)׏Ͳ@@>PЏX&k@v?zo@bgZ{p>a[k,"6ߍB=Ĺ>Ϻ8ټsxG^'pdOռW֗M|ei}0@t0]umʹm ecյ_%K͵Ս' ]|!ٖ3'{m]DazC/glu*|G5xm%dLS}6R? 3ʯ~dy{b %>5d_|K#S[|FCo}2ړ dŎ!b,d?Ba_ Űx m}R>VS.kzk_oE+eAjWGDw6muymX Ғxfs @P1_ƭ{=FO~`OÌ}O Ag?f8 8 Qr-#7 sPP8ΘfU;qiC +,qKW+@>W[\>3@C,&09C5^@s-18K,ٗς2ro ɤfgCAfLFNY\{^V$wDK  T"bG9o< s9km _4Lo/~vSTMctIy"2TǼqk 3zsƸ`oK\m0^ $8Y}MvBoyshLR `Wen> 4͹=ϊ=S:i[#a{ʗsMWϻ`"QFeo-":<%jzWfogtnbkvUYzgX#kɼn:M2~7{ګyf!~o>}~̬ /j69}T y.id/oEў\ ín؇_r|ki[e6y|K 6"'q!W-OUV@ds<$/}'xi_1Sګc>'f %;?]eLJ+AvrMq }- T y@~.̎1>b,(^ ~L0@.O$5s횗nj]J G4&eP0ppq_oWjG_@dj=ZW=2Z|iI.>76S~%{m] C'c*prfbTYeg +@w9@CӒ>0?[ٿ>gFN  {gߕ@B0<*>{b PUg]c >p2e~ UpɊX䬿i+x4.ˊ:!rdx9q=vКssI\>ˈ?63ˍ㴇ɵƼ=G\Kl:Nfpkd/HUF[?}:5L&Ts} ZptĢHB<#Lguvg|g=L\d =f Z;v AEM}6Ql 7~큇3dce~oګ_0j^ڔ4]*`ij=az!%To 鱽G@GɄl);aO4~Zpkt-l]g{ۢ:7 m]ѾECVt7a%, ~]/Dc71 -_ג9W3cA't@. /Hoh:#o:-WYa}0-!}2>{ 챹CGL:ha@h-b/:ے-ra"\ z& v+k^셿jy@vE='6ho䯾Hޙ+ཌ?9^1$0u|*\Sq3qkZp8l `=ӳp0 XZ,{αima˅;L` ̑QVSFXvƧ]Op*ԏ A88$\Wh3m]!(("{L4SG&[ v`s:ܸё0g3 eX)ۉMD&^?{) }:MhkN<{4Eۧ{y0 >]]L4iAGOIk.c[P)Xb|8,PX=,H"0"]|9]$D=N&d?A1__ۋ)k\W 䂜"ʲޮ;s}OO zA?C_glý}{N 1 K1[ @Kõ?}ꗚq-oS=ٰ}t `f-q[ׇ6U:&k<j'[˶;=A>-Hjoz2MmӁ1Y#:RɌ"k k:SΉ[p;3ԯb_zbpD6^'g}Ԗg.q-I^osXlMv䯵&K¯/e<=,).t H`/"#b1l>mN iNdx P5$9orzpX_‚h2L:G2dgEj|8 <,"ϔ5|.3f >U3uFHg<-El⡰@@r݃OzL^_7QY"sCÞFO{ ͫߚۿs;It =ճ[[ x~"\m' mLb%'x_lo1 ߥZ )zm 9Ҟٷllsk_$UF^{'}H ȿ  k,; l>}OOz̍R$O|'>=,^)]3Jvk=́O{0UF{d=3L~D|n?k| hNd1tz/g§ s33T]pX̰e6H" 5{`|i|2i ͹9/x%0֭ӂKl]ǤiuY%oLP3#<`t@s Ax bv @spxfN=803E8,\Or G’-!\8ׅĊl13=q;܂*'KM 4%{NP){9xeeS/G۶^ %M=h})O&m"@8.AjD?\Dt DF S,SEA9֙O% =̩p/0߱vo~jawf;sdzYϔ!w c2ɓB`Ud3o Pc%gN+҆} %ē|}m.ZfڑtyoX ߒ},=*|\9u2ӧ|cgq*'Q ۭ޶z9 |.2'ў,yUY{iVj hzMnad( cx_U;WO Di#+hn7K=KA7*o|J]bA<sSa`:S6)}ϲEX>eUc*+' d{eV|3`Ose'Ju /# n֌kͽe@MSh,σ| ʴ0 A5!D r2/6܎mh'<SH^D)73&h"@e֓>^u̮2]G9)@~WN=݀ǎU$65YG-A~; |]^YpTs6 ;N⪿|zB I6S-"(4wcX@<]2RNOڂN%/_\ HkO$lzH_v!~=mtZM&1H?&'6}aɓEt4n%_Cq䓄DٲO 6X>#DO*)Jb^{d:bs*6 kD6rWZf4{}]{YWߵ4}iCz劃yC{qtvͽB`)[‰"C h-Y1xcb{$kv|fھz `̻%06w.# :dHK@@iKtM6X`p>=_LÉ{Ët̏ˤ@&/Ϲ02um:ӞZCc0y;q@Cܽ+~Ls}87gIs0$k\yFlޏL Ͻtwk W@6"uy(V쨾z k.$+저|_Փ xc$Khiʖ}6ӫҹil(%0v_jA\OGYK2Ռ \>:G v~3X 3h후l=q@ہ+21=h_hS nTҢ! 'MruXr$˵f%ֈWΙ:'rfxe[qn 8vдGk@nK԰xkardO9G,4W] 9pLvK#$.smYA;66?/ [@L|K~[r+afA%Y) `|v a[m=ϔ)ѿt g𲹦lFtKg{]qb-ٯָt 聠 =[v`8?Ypo= }7;/L'z+Ys\Gogr-{_6Y!3HSllbK~aE[svҟE6n-'@C=e$0dc-6۟f_ ۋ Ğ ;-lDkt|OK~6OHAgC|G%wtmK uk{?ًjДk}>HU Sfm9ڬ E{?ͣ8ׄKW-r/Gܹg۰db?.m/zSm{zI$~L WCXВ' ,o=uvBZSήf>f(Db50 ʾ3lł/lˌKa" Ζ ]FtC'ch8dž9v| 9?ZҢ]}][\}<̙3@ G ykx NX@ a= :@I0gk^ct0)21ʙn>mCv泌ᗬ(amK5ekAwr p0 rdtz@"Ap-H=#0aA@ݩPjGm 8[D@ 'q((\t-iGރa*=pg-]$0\r ĒW~Evi5=ב0[vw/Y`W?޳m֗n D+\Iվa BZm%7 o֌[`.Ju샱c~Wm,$$s׍ͶY6x"Ga 6ʺS=ӽeQ27־҇gooav0Ut\EDkUݗhYa6*_r-1p٭S<]}? kSy?n/V3C<}>6}7߯`kg5dc#sG>[}/5$ I߲;?k6f-ҭ'9ms_>&/g{<aqW;#YɤS81l'eڳX͡}gl=~ 1g6h1PΛ_-,DsMylrG3l1֜ܚ]8eU;wNr͐Onݧ߂% -":[2֛S LZGH\d͏LϬYe,! U@}[`-*W]3?G2rzGsG]qg- Z>g5@G z XCr$o"p%`TFv,P5~" dsЯq#=im\:͏Nڕ֢\ ^Uk:۷O01v_۶zwnXsͺ7`.-|SGFuZbK,#{ %MۮkEpfɸ%-!W@hI(TV -lTd=? גf&e"6~'n-j.#Xj\oD?se6z=Z{ҷr# z˗ž!^-6[;%S#֒[?͵k]Lr۶ѡsOى˭L؞"ݲagu/&x }ZgPe\\62fsێ$]Ş\ۻȚ鷹6ols= 2ʜ<YugN { b دJGCov4G!!!!!!t9GU{T8 yBU8 ʡ{ ھ;y$ss#T۲ {)٠!!!!!!c/o85}}ǾÐH`ϡ Y7|Oke;@ON>9yM6P׬Qt3 4 ÷kC@C\|s6(hw6( ȀA ۅW}wiP~tȏ,] q LcY>h^!!-[.&%Gʣ7>7*6ݨHw/ ?=GTNUǯ 5e$j}~(X!!!!!!K`W c5 7haH`*$/5J3<mܧx~ ON!{VtW_ uSAcCCCCCQk~)7qcL<sLeH`H`H`H`H`H`H`H`H`H`H`J`2c\CCCCCCCCCCC<sLeH`H`H`H`H`H`H`H`H`H`H`J`2c\CCCCCCCCCCC<sLJܦ_>N_\W 8w:w+ l]'AC[!㡷篦/i#F.2 RZΥyfx/ٽ͆fJа1+5X,Ȱk"tl$` /~C@xկnf~nQwH`=[ >V;Ӷ_0|,8CVtkAD b9$0$se][d ޘ ~,8|%aqQk5  |c$4'd :~Fma|co`.\6 ،6ߝ~@X˧ᯅ>V w32u%୞V'HHb6.4$0$pK`ϓ|70| [&"?%o>r_'Ͽd#ERaN8 X?4Kylf0Z=%6 v| )6f%?OrycmlN4$0$pK`ϓxb^{H_3/^z+8GN{|e}'_r,15iFC[+[ɓeDߞ $|+`ۭ]cٚZ;ˎfھ@\?8gt7$0$sz4k'u%=Gyuᛞ$:txt6ǽwOn}PxeOyzv\K"?3|+)v#N>ttϖ$?kH`H`%0tGɔlg~ԯa۞Βwk^h(1@ǖ| $?ΫKֻڹpG%tIWwPFk|E^,;X̑9G7>0z1.'OzNB5ԏOK;\%\eSU?l)o-1{V'[IkuI*':Emg7~=f7}xP=߳m®٦Kw$%׌%c?[+zi_mF[*N3^>D2ha]EvZ{j:dkN>w9;R}6?֮:ђd?LlӞ{^aߵjK4uq.v0q0g_ j +@o]fTc"euuO6.Aﭛ*iwjf=*0P:N>,x4$p2H`ͯWB8++`?<#{*@|Gzg.y[X@ͯ0ׂU@E/jVz^N&yr}&8h[? zUʶ?>7;2D>/҃$r2W6c>0b}Pvƥ]WKHTO6!s잙íL賄ϕsO/Y#qJ rYχN`Zp(8} Hwj&tO84:dn- vKPY:z6^@_^D^}4~{2FD` H@f_YC_l|4v,kA*(C'XD;/ {N0P{sOtN L؋KϪy>ؔ?4.06 E 9@o}Q~gCk'9٩#6n~THBn[+'3jg%3s& { {p%ڍǾ7n,L]Y>k{p ̕}CSn4|sͳϾuoM\ ؽ]U|Vàt],R :h: EG_n;;@aZC=,!|[9HCqCaNg. \32j כP9aN8)psR l<OXENoe_kRЄ/~N]eD a-%;}* ܴ3_ ̌3 P8ik*@> ? FKDiG!,\y6wy0 D:@nH%4% 9u0: l5+DNg>Cȣy&`'Ar|;Y@_z+hcGx ,PVMm35`\@:i\{H#{quxM:,92@,|< ]j/+a'#Z>XG28<d=_>LO4sOKlm@/(*9jy  W}Sۥ;q(,mW"d6/h/s5OAخlv-飚Z>8M=ݠgEk^W6 _#6}6Q?kxvdu'E>u0Lrr>G#w~(L7EbϚIG oGgl,{p=/v$w" `&'m9 qk[1kzU;_(INb H lOǂHcp+NApՔxzuw07AstPF)L( %O ,|3sNC:3(l}O@tpek} ]'ZZ>z _df=AS"Am%a[s#X|N A~-2 eDf,$с5h&CkO/ 'trK#`k@iKPA9jXx}y`ɠ$IJ4X'$=%=-#G;b4okvOߜo lX~[[:[ɴZՔF@A4W@ .ED,4L{MdO#& %΅:-)\bw-qVk`XKɬET5'o6?|_҃ou,{G%2`wGk@N&"ɞt0曁"dpO$ߢ8}8z"?5$0$]%0W` 2ϛ[4? R?!p%N@N^ rT^`y6GV~CNxOß >0XI-`N_ $,QXp}NZt4yd@}t/ iXW%";r 1S"Q Ι$l?V[%WSҍn}0]-\jiݻ=>|ɳ (D$2"km}= m_>ku̽':I>5~I({gܗVAesQɖƼq-,A"Sa MN{!Nn?j:(i[$ ݘ=9sŰxcj0'EsW k= Y2#Qo+ l?{DOWFN37^¢,_~рOkNǦ;1ܛ'&il/]#o&׬;9'l*ia|4$0$p H`ϭ[ĵ4Xng49O fO}]/p=qXN;^v%  P8! !rtBe{2? oS5l[|s벪m/h>،i+g5'J5 ֣[R`FDzu'Hs€&Y$ڻ߯ϵmR8M;.͝-۩{=ʶ  4Z0ĴES0[/p2wXU/鄎|&ڏ"2;a!JǞ Ed^tɬ6)Auɞm[LB޲#N"i$~NQ%~UnT;d$[>;q-?ֶ͗X02~s~=^?oW$XYuyОDAkei1j|"LWNO{^zlGYa%鞞_ Я{=0bs4a'6S{˨so؋2G֖" 9EK}Snk^_$F ސ{|vВz)оT"zMeJٝluƶ|vXOt LG"vOmdNz<s;α0 p.Fp֩r8MK2  L TiNpU'uPE[ vME $t@.k3}炲LM1Y k 5g4yk/6V{ ڴ?4kwLW=ɂdۦ>V嵷"od[0Nsn lm@;ųM_"7'j{xN2%2==kw0 хj۽x;|LW ʤ5q ӳY;y\xNG̗=9q{C+t[||&JtvɩW_l iX-}?g &on]4@iY#fi>fzةܳZh/}?S9^q5d>,l].ܿwUO$Gt—Mg.&׹d;İDSc%%,͇3sIH.N@4[.\ نZUK{N[FvM|'["cK$Gl;gsִfHd-ٛčFlLW֐vi5XYLphϻ^#j9aAτ99G$RPXCI "֯봣r28Xpr"%bX 3}P{ ̿%3/ 6ZD VߗςY x$pupmyr']8t{G_ dt̩ЋJ'3n]b-@A`H`$ߒxT:3$+r' dH05‚ٞO.P%P3'*g-Av{kkԟy. 7]@1ZC/O7ыفR98yϮmgc5,ԡ+WDchOo a[y?v09ܔ#=]6-5ݷt@ؘJ&Nkfc ko%G~`b:ptKP49n dX a0{= j8o_=P+8oFim76:׎œZۿ Ǹ`q[9 5,XO@N\}$d%j--#x`x.[=?4.#^D5v *aɀEpiC{Ip,,x}7 '.+eϒx$Yغ:CtF/L? dN=}Ԉ|`aIۆK'oz,d0Ý G\x L· N V7 #u_^ςr%̺Y*o<ַG=`-S#|{W Sez.9$@kH"a>օMl[|>0=WKP21JI<8\ຫzKej@9rmbogI$$ج{K{[A^0/6콹>7l]֏z)d'%D`[dɣ%~s.?H}{^7W{oX5/}2\zk^4/,U{x󑤀8jZ$C$ a{`5wr{0iGnHb}5$0$pH`ϓe6? '6@_OY~=1u9Y&Pd+]֎ m`My@K4 = Q<<"ᰶC` ^zr}t>;#D:`u e$l4\ 9yiX /!\sx:k4҆,A*YВSo0Gp;֨3AZF:,9HX9kCl: \W(gOcOi=39ݦ}'M J@)\;}\Dٺ7-Dk-q&R]b.ҏ@]K8JFT?T;7/9# aI**cޓ6vpǩeD9sm_ezvUm_>z煹K]+/vl *lJg/fG~8\:$w/~է 힐+!.[|d|T嚯@ z*=0Czd0 l# Ҿ@ljΰ,9u@jsYgu}@=A^q (/ԔcS;>/ ,_c$.oF;:}a9W5@«g'k!`ώ@Vv$@U@Ǻ[#=j\κ*G72d=+ƥZ+S2(6Ze`[D kwuQ/AөśqF'N0S'*7-*,JGgeunmu"/n X69gO>jqOqn% _poZ=wWrɤʩOOEC"۠V;l0= D[_|/cs-055ϵ>ID;&~m[*[ױ[?#o#vZ1NΦ9{ Kk=o?95@Aպո5kmj lHഒroɶz֫U/QڭWz22: x_ nА@v+c-J RDf%0f%8 +E4 lV|nVJ RDf%0f%8 +E4 lV|nVJ RDf%0f%8 +E4 lV|nVJ RDf%0f%8 +E4 lV|nVJ RDf%0f%8 +E4 lV|nVJ RDf%0f%8 +E4 lV|nVJ RDf%0f%8 +E4 lV|nVJ RDf%0f%8 +E4 lV|nNߙ_5 4ӹΔ;%78oJSWw>@59\)Ͼ>wI..g=ރ O|ONJx<0)x$g}[>?83?a !a`iLi[sGS^v}7 _?tiߟ?^ lL|nL^}ˍۇ?~OÀ`~C{ >?SM7; |Tpejx_Թ<^ɓ|wLsjgH`H`H`H`H`H`H`H`H`H`cscK;x*넿)~ׄ)8zP M@F gmUSnc]vG:82MkNE99Xf?$0$0$0$0$0$0$0$0$0$pt:W>8#lzv @r40u_wi;kY}w޿_~jCo ni[G[u׾=cVef hԆ>V+qۧ9`> - \}VY}ᒿ9'xqY@މed\^V^&)VTN~ 54q<&`;o;<.#~QkYj <_L$uW)/Z:Yp0֎fM?>B;~0=~ p6+O6]ڬۓةo;Ű9x6NriO ~A?7W@=;ߥÏya? Gz259~en ǿ~@SkACCCCCCCCC2~/0pY<<Wr ;֦r@PoJ'.~g>ׯ3r~<pkN[ H)Nk#IҔu?} V}a@\?" (V;Nb]FY2]Nel|Ȏ(/Pa`ma`+^0D+ 0*󱰓@fQtɩN/$qS@[T\\`S]m`j\78iU_X |ϪV,o609xP|u}gdmNPF3};1mgeQ /=WpL=,`֏loc>2&4$0$0$0$0$0$0$0$0$9 9Ums =1 x^V^*SCɣ;?vcj)WqjRĜXLw"里 H<hS: k@~Z3{7c}S Xs}y]>\ Hץ9x4X)<>MT8#a2 N졩=`G@~\-E"'Ⱦkl~֑<%$zy: zskw}'҉W8}}렾Hfq 9}<H}߳ r0\c pݢ!?{;lM(s|`ujtf [W-cJupTPolm_m%S#E^:|dHƞ;.@tTISM@+`^CGhG^ Lv© 2|Tu8$0֭)`Nv+ymaXrR:+" 6 {M՞:"^ UmA0['u{Y_'|=`jS~< hWO@ $"'/'>=_U>f+QP$ǖd"+=ҚcE:N>v"~8 :M•lh0.NM uLD h<~t]ebT>"$a?~S.WnFATkVO@^-mX>DD"ԞU|z]uO`_"d+EO'WxWbNþwt_T9D!!!!!!!!!SK|nz~O'"N(EI&sn^c?9!}RHH /zY~' |:}Tϔ+uz'`ﻡE?Eӫ<֦ͭT:R܏=2Бu?84,֐%>n=p}iHDsoM@w( SvCJo;Es:{T޸v .^'{U"w7OΧYs |^ioa?.ԾW׫ZwopRUKk]))>vYpe[? Tn|b}F\xS ;s:3 (]w>Me%g B@SgQ |y؉_oLJjc_ϯݒ`W?8eX>E u!+}a~jGN~ǔ|;~.Y[ԫ=ѩ3$0$0$0$0$0$0$0$0$pI`ϭ]S?lZ@wMxjOߌ7Lmx5a%eԢna`A'^1=#KƯ_mO>" aS;N+})n;  ;wE#n n3O>2=36)DX7h(Yyxk?./}eV}p\85%0֮+/)w M}\nΟ n+m{a.=Д'V]?Jo^>jd;\uL?{|x~SS }G[s ip+a0iN6lz/ L_֨uw7eo6"fpvr{^Enג$|tP#q9$0$0$0$0$0$0$0$pjJ`ϭ]W w2ymˉ— r=a 3^u{_iF'p;@:^婎}ukOܩy 7  ׆UTrp}q/ʒ_uqg~M}e[;̩_).8=~g.y'~$ȿ}q4W¡=]md׏Iqn)>~AY@:,-9]<_iz58>G~HN$}TW_~Fٵm+NKu6^}o?~MsGn@5t4W'˵_u*fCw a`5 =/꾲N-1.\?\2)c7zvȖsVgmoQqH`H`H`H`H`H`H`H`Hr&#K^+w;P?ג}P4$0$0$0$0$0$0$0$0$0$pH``2^/d8=U?E'qȣ!!!!!!!!!!!>O> T~þXԏmþ!!!!!!!!!!D|& }y~$Gy|_w= 28DH`H`H`H`H`H`H`H`H`H`H4") h yW`?$0$0$0$0$0$0$0$0$0$0$pH``N<+0?U$mȏcN3sqj eZ\] k?uЭSs80hH`%A' =ᷟ|Cܼ G C$;𥶡81i|plqHW`2:pvrƄNΞ~hx )0:3? <y -|w&[ae{k 7±/b_Ǿ=8%Yr'xyp_ _w}Z?O@]3[zf _| guxϦ nZ* zd?0IAXn?0_盇de*hzKG 8:_|V~3|FwԹ_-xVEo^?C[*' yR-1wN݆2?%]vXd?~; ff  &,`^/]%.[iۛ1|(dN6)#ɞ|rOΥ8~dz/Q/~}}NF ׅd@,s_ܿf5-bۄ؍&>OU?UƖF@% woiU™Oئv2#,s$| ,t ؞We |pWNvzJ&WQ(6걫Vg/ >;iˀhm;t`hܛ!o {|+NbZWB=ů{V0 П4ILt S:=8\jx%9|g;׀dlΖ‚[z3D9U4$p4T)GGSyyL#߱KwUOHAo}}Ҟ IJkþU9ϝb^CU]:uıngϭM^&,۱und$vOk:E^S #ʊEDv^c%[6^ O2PUWZWW U |Wt|Q yd/_ܝk?C ֤'qV%L7d15nY%#)c/2jp|>45gz6Gkn3Utż1ّoKvDs=z @pcvSm5:m i3DS~?x3wu=@u_BF_/Wۃ>ZJ܅R 2:]ۻ:[&؇ܫ`+\{0[ntC^?u6Zg."Um,Ruv} K6hYNu4|풡}#j]w9;Zkǜ6zwq.;%gzQzVUEa9kɞ׳KS m ץףz QIo%9^}?r~|/qQ{/!UZoj=DK2ZRBg:0Gt $>Ov8mE =z ^L9|K7V^hp%GcT2-ToOZ~(\[  Wa1>HԦ'熹g=#|TωuEEغߧ0.i]kֻ #a2"Özgf=5^>[{6Z?~=zV_5ɴ]W[?:WrO>=={Gt)6ٟHjDfއs-nuٱfXGx[Â6'ev o5ꖄPDя9 _~@X0rpcK,Q뵉Ҏ}lz[Ƹ?f>p|^G q<-iZgQ`{~=>ڲuMfO:b"2]/[\|!XjA?`&/CҨa޺ys &clL}>}!0_Oc(Qh~m Ek`_0m -m[uwSoǩݽg; a\~kL]}}E|g|uڋ^կ>iBa=nf̿61#NIymjBpŰwQ0\}$#r€֟8R`4p/00wO]fEaZD#z~' /pNB2ys\'Q$h,!ax?/,0fA<(M{uy\0@꒯6`5-1TXXe6cm9 { FӘuԟu1[o뾧)+{ͻp#뷇7}<5ׂ^US0mwn$;}=6EVs$ѳb9+ZgnCeO fG 4<O`ij˦` HJ_J03=!cz+ /N@x4Os UMal,5{Iv~ߖ.JXWs{@hɃDS{߄wL*?>5t Pثk- ~b[ʎ< (}Ϗ _t_͵m֟n9փ쭁q=WvXͷWvCYQMVsW-]B=vSD^wmk.0n͝~;la@{{v]Mj}ŞK67C¯ ZGs*cO6l=ز+?یE2^N~IWȍ.):bnd2mP1;@>'` soknf7XLE6_!wS~_>-[=&]љ%p+g6Y/Įhm"#lA=jZٱ$8nӽSe7;ba1@Oj'_lRd[ǵEns+]i04dY?}{_-blk`=v},y$ y2g p[|0Xؚ N  4zpFg̻%ƚ2gK[ah=[2"z=ë/C]y9.rdZg-hEӸ&]||,^.fserg T@I>~eTS'Zj|d$(ogsЕHb>l;X]yCWٚ(μ% JZHpgi%-r-8Dfm9_lK}l`Marhɸ颶y0Y 6VVثH„ 'c\0`@"hnuv׺T=kɞ΁{B >ɛ_̩}Zbۮ67vZ@ESEz`m@@hK-lή?ESB{I:eo8m&C>NJ#,pUdF'9Y(0@=4nqp/m?˼av.e7 [Ԇ8sTNeKUzhmgw,'Ŷ__}=mm [ -ڑW8\E 8 X=|we0#msŜMAzRx-\1kC_'KRГuDW>cZ|6>L_d7hn&w<ߣkG,3t9ȱhڶD6xa7<`*9i?Nwu]pN_~1? ` ~}u3Zz @\z0|ܳW1r"i#Â/ P8&Et<_I{AAɱٿ|T_TI =qӝfn rDV 5#OZZ"u8 ^j/[@pahʾ t~`\}d/]8 |2ZFHdFljoܒ Prl}T@qG_`? Z"Syc)Q$P=Pݯ{{$|ͩ0ۢao=dw5eϾm{BlGK@$%6EgO-9 6VNxr0t^=> ac1-4`pA{L1jl-=$Z6˯0J>8׽ߑ{֣n4@dg|30Nо0+霵Cr0.[kq0۩Y>ZڋbO跧~~3˶}d-QǾIљELIr5L4:c_.#ɢ_r{6vi>2|CEԏ|}+B/xS7 g2pf?P)]ɸ)8Ce}LYqM#N3@@#Q|FYpei 1D" ԯ5c|4FOW AҎ|I3TCϙ=kC`}f[w@*3O}.Td<'t6qs$3{Z{]/9Ims^Wľ&o2i\ 4.B_{c7tLȽo?= uE=p5|zZm9AЭ` `>x?Pjf.Nۢ੭˂d.PhhmEcȞ(ڈMZ*EE7AdFEqsv6t8<Jo>U:^k}5 0Em/D3ggv/)%4ZK`eK\9x0VJm[[w9[)C5.6dC[bcZ!VmR INm,ta:sÞ_2V:'EsçMa~]5G! OzߜX5b[$b'D|ul=:GRʐe4:ts${jD[-r_ajcWv$Gŷu/2Eqta [Óܺ:w95{LZɱyGAqb  sm Q;-Qb9lS>cx$ljs=)s8 |ƽ{s3AC[r\3֩lbx9ߢD[ M캧@Y 49GeepE]`CΌnG>UN3_ cM^ Dž/dN3AacDpĚ@rOQf8-8ѺՊcf߀Mg2-|><]o|V?n\ NZ mq% d;P0pԍ>b@{ %|lPup, z|`/kX[el˵gY|&Sٽ,66nf _vIW3vɖU͜Kt|=Vfg{o-Uz-6.*#n$׻|V%̀kt]?g^m+K^avk7 |/&e򁽐P3w .mmy=*\VvhSCE-.Ii~' y-ٖ al0HM]*RnAme`U1T\wwLAdwlswi`gn-@ל/kM(p@dc(۶coD:qhg7 [FXme |1 |J>XCkAdܙr[NeSLӸ ^^+2%,6˻VV'n|V{sq4U`rX#mbc+V:$(zr.*ЍeSShYl;p^hot%I`LߎA'CavHamI]4"#eecM Hg2l51UԂG'!`o6V  Wb\[5͂σpMls<s,qȯ7]29sQALPKN-ebUollF$eod *Crȸ9Uk 2ŹSMsAC)M{q 9p 8Pd_ZJ鑓luIx΁:v;#Zf9bORU |H} ש\_C~{g-O VPz|TPϜ $2= X>=*p>oN|9LȩyVAS z^) ^=6"?ѺUg.#0E;[贺% =*QɳݷNv-hz|=9(<9+?X`Z&>ZKI+~](Mg͍wnw4+^fgZ5usz{['lU4Edm}F.)6ة:[a"+yf*Y 0vh`\wذIސ"V dmzgI3@dSg1f*Ql68zӟ]Јq5ri-f6S=M"zƉm{b9,?T$9Oںt%|U܎܎rl$#;T`rVݐ q> Ua9> t9p-5GlC^tP0m>= #\<܃OC  *o3cGK L7O} d@浖OړQ?g$crc\lw 8CDΤ{q.F|Y7ggKۺ[mL\kxOW0G$YPniw>80krCiM4dYDB1738}m=jIGݚ\ >+ˇVoɿnf?n RȈ,>v-oq.Oց΢g pJO^~Z}`O= 0[q46\lQmA3{| vBB la.JR.-}-%IzV=aT ~+#`^l^՞~?-:{ _E=ǦI:}:섨Xg/<}~يv䚮_nj,+ Fgs E|)V:b~k{9b0=h kYk,'@֠%@XR#hO1b%$-2&;=}`%=/7{f o p?=EGٶ]]CN+-$DoXŨsDO=1'Z&J M ?A֯lFȤ3k znyd{mOe (x\ mJ"r0.6r[a|Vxm Ԁ36j Ne逤ꓑa۹rRn|*9ČAONEUq gc‚}kdnAN?6"Gf )`Q{ka ƻ̀աа@|òPTxaB#<Y?h=kֿ%a{ : l}Zr2%׺ZiUpcT%slndNyp5kNj7]?# (' 8,: ^< %o8I֭ Lo d ɵ0pX W?_,0ѯo,tަ#H@֤և Sؓ`/CՏxm& 7雅X0[:$2"+23WsD;‡^{1,0@yN9MZӗow\/۾m֖Wn yIᏅK43e_oZK{-3mG{} K;aw>_$Gf#PRHp?Lv|gdiCv3W$%n0~puV)g/kseDzK쿵F[/ҫvͻ-rlW7 ]>7modo36}?' \^{==OyW Է}{2 *UI,ka~]|)zq[!Zqή&%ɵGJY>͟}X`3a6}G_|F7ʵxMJJ<l#P9̘0* i|H@1ş3>6"<`/#0erB6 p!2< {N0 7 ͑9L{4D-rߓ3 2yu`t3ʀ>V)#g1;0l~^xU_ȩ 3֎,"h=k:D%8v?v` y?,8l[hwnS/A靏 ˚Y+W׳Egj+Y>7a[_;]aQe8MZQl|[/5ypH 0.&e wȵy H\}sO"&A~?=hCy/U[Zkݣ-0k戀 3;#Gdl׼k4C~Oگ}|CtGG*1 ۤk$ڱ5k+%3\4+ͧ 6Ōrp osbp{ӶsFӦl-plwc c[͈Έ32]=*9vۭؠ?׍O\2\vQdg~% J &~9t1~" r4= 漗\&\u\st@N:k n=1Z/2!+kuup ֞1xn91J2g]mѯuc4ZA202Gz;KA=GW]%6&G%e.@~b؞U^P\Z=$Ʈ/4kˑ#8Aj>Ek.7= Cc?ajvԱG%takie : >:SG@(DkP~3{bQ[ Yg5 &u`wd_.m<՟]nX[WÂ?n/6J8 EWk*k+2o|p%dVtcK! C˰ ?!< @ҽOhOò*7>)[_|1 :8ytq`4}GʨUq=LNoz"Uc9!KRׁ^M>n9QzSX)z +NGĮ˿ s;y 7t$0qbCߏbFxFxw-6(i ny"5*Ge˄nӸ)ᧇ7(E|]4UJ^m}¿ Ο'QbLӏ :{tkѾ+7%;wix75\cp:N8 ztn p^N|i:AE?^=FrB&/:)kک{d[WȢx']U?6&zxݏ >zHm` {釾[+2&C?$<+ϛk7ՎW2\e{T5<*JPˇi #WkdϾ}xJď&v}Slny/H?WD}~ USL t6- ^ChlZ_o2f߶}ʵyEu\F!!!!!!!!!!!!G+QoH`H`H`H`H`H`H`H`H`H`H`H`sݢV|F!!!!!!!!!!!!uK`uj8f3ǬӰ_c86&l)-zα.O~/_̿KG.ޱ Wy߳Ȏ|$Uf9|ve@]ly7' yR-צ맦)ڴc_[, rgyM-7T kۺfOhKz<`鮟?O~_smi_~k,Ky_ >B]ї_51\r?jOF%mm]8&Wz}v'_('Vӳ/Er*ho.~Ma*W|kC/?A'(>W' ~|H)_ϚOڙIГ/9>s*$~?;VgΗy"9Oo6B;t D6@o 1y`^*ǹ՝ a+acj h 퇣!*Qa.t dNOO&C|ilg"?k'@vzDto 6,2à2S2-nLJy8$IE|T˵ 8r:b }UkGy?tyiS^geANOG2N=%6κ&7c`JhLt#V&8{=s[@Ͼuf]96uՏ.?4t!Ѕ.>a?-/CO׊ޕgO>oĊ.x mq=S6/9΍beoDmP>F'[+ ~,{}:9㽖@t;>.lǰ6}I'+??t;fWlrtpl7˘>qۥӟvZ E;ϔ9}t^?^'V6's ߥ|ɹ'o9A_k9hϭ[.̻EcҒMNj/;m{/(  'a?yޙy8-l)MVA>s{+Noo蚭4knڳ\r_D|y;b-akW؋fQ6`|!oİM4מȍrk[>ݩ";Yg}z013zkl`Fֻ'G~6Lv?|o21-ѵgCSY {caMq5?jU{p`cy d76|uG>,[E||[ *Mg:4Kڱ ec(#q>EI;OHu9CJN/1isy1g9){/',cWŸ AxL&ڦ'@{;d6\۶+ 8 Z8/?~QXҎ}Լ|oCm*@S:SP𓧹m%+K08zRh0toʪׂ̠֕ (ڱ?0]$\Kc6n7nO 00g^e~M9 [Lr=*MխG39sjj35{‚6 $ d:WX1|o: \N>C0*[Q> NLae9&k茱"~~ђy ݍY34]/*I7m+Ò~2ذ}#y$XnN?k$8:꯵]Jf 9æZ kEW?nHT?-ڼ~٫fÎ苟=S׭RVҢ|H[X\2VgVa{I2̖doٗ=obP{V1_<`76xKx`:ӻ#ỆݟDkk^q c|e P"<-XpnCa~Zo͍ӧj\KX_og:V?kڠ[7s2Y77uZ{gl{اyz!|’_^_]omuFx= jך[ޒzKb:8Lwk<,ɩr2_ZI /̫}o{5gal\?y}AYō:%WXԮ򙿨x_?WIYUS[O+=#gmiȵ=/',|0v4旄C9t ?>˶nͷQret<Q{UX 2Nߗk}cXI`C1:C, d|gR}ӳ^Mi %Zp8kmׇeXxn 3`_w=8Oܺxg/6׽Wnʔ|]NM~\ jU_We&?(۷ݏ(84fmҝ>-q2 1g0 O`[G؋wOfgJl;p'İ1\$sOmG|n~I+MPv$HX`-HX}7 HKfnEPl  {1"2α'aA 68~ЇlK@z.d?5!!΍'A~_lFg].;TT.>흖ŮEC glް8úLⒷkY K|po?^lPkijH'٨⍍XǼ識Tl! vpVoiԾ~;Ϭ^:oMΔ:te|X~bʼ|9O3}ܰ uٳ>b/{g-lj֟kzg=ߛ +`֓X= mG|n~I(>? {ۚG#`1'0gݒMi~;?0@08E0Cߒ@EwOY.@d Ps$6>!. è٬=0HSS32_ƹ*r=n1Όm\d@&h]+4NNd/Ppz3떀\t0 9<8ms$'Au;Ny C?cAÑ0XEtKǡ[Ks{OoJ`c~9((2'KAtSֹrIo? O |wiҗ^+]{pxhq҂W`IO͕|e[ˉ=q$oO ms/ȇ6h,לLv>;AZKL\=c T`i{CDD>"(S &k~ ٴqm v'I$((~oN@chwL=PO2y҂6we6{ t՞سzK&d]eXk׈da?b @zO"d`~$u.}$KIajM-6][ߛlRkoIO?TnL}VYN`ZɅn><`Ho%txzd SXRb˃#t z2vnY?_c. pߘ>KOLBܷ^sIOڤv%P/nx9RFTg$W򭶧.SvfZBg$ %/8ɹr=n |X! !(] sԜlPG!氞KN`c~.  n>#,_dmv')H|{=pݝ{^-|^>e7>_{ q‚8#(!˾4V22 .*sNX*ɩpgLi@j’`$Yh3zu QAi\ j/ s"  \r1/{_25'`6I>5c+JzZ V ])lOO>8nw >E6HN@ٿ9,Ys{Y!Şd{wXJF[33Q> =׿ez֛gɕ-B=iO ʖϥbx|x`dl4maؓ&Zj'}8*vZP_DHV=g*oߕ ~Ϙ8@}R~WO{sc[3l<6>|E%{8*ɰ5xm$W}J`T3T=: #Gf;է0-i-ɜѾ|F2\;+e_Xn07sa E@jF rR wfv2oO6~[4]`s8WLHdι'fk9 @:!?#O 5Ưe  N53[ǩ#se{Zhm|Vt@d@Lvkmx\Γ0p>?'L7 >9 2n syDpJ-|ҙ6ɴh;`qThISz$N q.[ ,Z;ZŽ| h$D tI S;=KlѳaAQ$ нu4 3,5G 6ؠG;io/smM&7;s&u8a'57%{UzX}E ן}IDR[m!W{>ʯ+'V[/!I9oа92Y̹l6/GC='ڶH:S+zsȋ/|E*O~+,sܛv?.6%8Z%}ԑ:t4־>g2nX , Q- ϕ{N= ?$XxTE=,hIS@(h";}(#{u%@UYe<)Ǹey.CN _/Üza͂OAGd֩[ )#`wp=JeSpFz GD.0s da3퉮}W Lu*_`miAbM9<ɘZmʤ^>,f*UASN-, j aeΖN h (l+s䃄]t0ݞ,2) 7e\R |֘&EhЙGw&!̗/yY;~Q>< 'ziv~$ Kv,b Y͍SzJ73z{рO29i^DT`?@F's$ܟ/&)y0?\:-9&JRt4ɧ>_}/}^}-_uAK.6 2ڕ2\NZRO @ƆT$WuޝgNa"!]Fs<29 Pʩ Nz`$ֵg=' 0"s-y'`Z(s*>Rqv4Nrm}t+]kiUng~ ѹZ/6 ړg9ވ[s'NNOz榵YLAs_&蔁ub@V=uȀZvڢggonk:qqr[{rM&ǣrٶRGb%: p]`QnѩL_)oQZ=-L샲%Us彦I/ȤCm Ti`;Ƌ惌On? . hon#=-bMdavZ doWؚ:%LVl4] \/=$@3l͎ɱ @_/z[Ď>,~ُ_p)bOs@)Ԟ`e1sԯ2n |*U-MTfWxΗ:D@{d حE$nr`AD@Qo6]c'ldFH魶k/ka}Oe3ўYvWD So~/r*[uD9jv>+^'˵ķl9c}O}f;ʇae8k=m9;jH_>|'3ŏv `,zԏsq[dod#eȵ: ;Ő uUc^8:@e7&d(hf|.Uig, f2NHd[p_ 4h@- q2-9iir~!k8[g<",f{0] iǹsa'ked 9=1n_ $AɱUry m0ԗhүe@Ko9qw-A bBl)Fsak7GzO=.oz75kv҇dp][tdwso 3͵ya@taȚ }i?<4L=PL[|۱A}Ig`nݳЅڗĦa=-֋MfvO,ҷm}>=cc9+<t.o&=RXm]vB°%AH;paIJdGzFaRZdu0h}px.v/e:!Ͼ/v^mz|uxxΗS.p{"ݏܓ [枠[b|6&<v.a@R_߭h> fwvU{n-= mgĞUKo8v[ zI,qxigedgS#66Dvɛ(~|}Wt 3ly3Gcu&#FniO_%81 ;&)i&Yhm$l@60g+@'wtϜ-_sc9$Sf&?{TC R/m3~Ӽ'CgΌ:dDZ@9 AUpq PKUwtO apXQ2fᏄv kɰ̟ dLa%Gs'*'w4ueeĉ1$j vƿ9;cW8ۄ )|FX@aϠaNF`ʄ4aQ-pvXlMs9G nwSI8dEfB@kj[D0 R㶾7`ty N7Ӹ`sR[Gu`i@= |hqՇuةCa6>jK[{ l=Csd4 ;|=_F)`}@lrM [`ִQ;ɇ? YmW poaI996kPmg'T&공k}\j_:oI2LѵaI=2W "lE֗{&[l9~&|$ȩ~yp.kkk#lj&mZq|߅٢^陵sKn@>a/N-;ZiLʱ셹@mc>cXmT 6ۊg}ǭ5;DfTFd{uؔ=k~+Eϖ$$u[|N>rvnI,No]p*l%Lȏwo ӭgCa>žF@+=hnA2L$Vح|\LT9|_y8fUNip?\6Y; \gA{sWN٬v2_b)`ձ9ͿO;FM@ڒ3FVbhUUmsTO.C {c>Q֐n02‚tpj_!YQ%taN[9289<SzH[N>7w\# +UF?T-=dq>8a2>4A_5WӸ0-iL=aG p_=%ݩ1THP*Xg M3g& r;nɮv-Wlג%=?tu.ӎ xnuȵ@UԎ /VMJW.>{q`x8_z;NA*[0-Y'v}\ r At;n`|VMJFl/,nG.)+!hɻ a&=Ge7{S4̾D3>ڣ0ML&EMrzrh-us]~Om?ֶӳsV|xE\ve5.:X}rc;NVps֭Z]lt~X`)9M Ò%\%Nvg?vkNVAv8my 釼~}d ~ē6ZWsM= 8D!5WJZz7z$+x.;r'{ U6H\-}AaemZg{O³3t]zuxgrn yD;feN25@᳿l_(T9GHsFQ@1 '*ֳuEvň/ιzde/z.xڭw^ rZU]b>ٷ)cJX^z`}e:Ё]S9eS18't.ҍBsk[zUz0μHoֶ͋%KqrhGx[ZVШS#Ny_׸"Is_ \Z[7As8KhOm?d̡3gwڰطu6l{>ȳ%rp+GI"2m+Ou'`@o[!}rCmI 5 mg;,>qj뜳~[o = i>;r|Z87e[j|}Bþa/GmbjcBɦ M}t-oZ'P}1Y~UpM&W5o-+l}'D[ļȤ|<7k-X?ߠEָ ]3Ǚi}֜ޮuI-YlH'{m̵am|,m5k0޽ᇆs|w)~5mËkЩ/dG-8g=fxJ`vOː 2aЩ#= ySgJj&N;It2 (F}r  $s.ò[MN /kJ ^$s-:2VqplNiY |qI+mW2m/ {eaTi<:rWgOcqԽzȞ*E}̲WӨ3#aVƒ*dk fS {=^elr \w;_q.k'̾X'_5]H'A*ѐJ`-hj[H3gosذ&p{Oka% ݰ(V0j?|csQڭ]fds@WJb-_0w5w}qߛ;o!o6{1$p$0 IU6tB#Ǩq/{U a&ưӡ>^N=WwNgd{~hf+/~~flHkcع{51$0$p*I`Si5\H`-cbYEHU x 99)6'~'TA['.2cAJk%FXH۴FхFG/QsH`H`I`m c8CCCCCCCCCCC<WuiH`H`H`H`H`H`H`H`H`H`H`I`m c8CCCCCCCCCCC<WuiH`H`H`H`H`H`H`H`H`H`H`I`m pΞy=i_CAہvewo<8?+Ooq{I䠭&K[hi~9?BRk72;mľjp"%YؿOO4'/_DdeGm3Ws'=@{᦭jsCU߇w|[~(! _dj H֣hgUњ?% KhBfWٹA7uu(gsݜߙ^{c'oO׎?ʨY{Λ[)=Xh>>6s;U'Bm$>bCL>,|0N_+,XO4{l.ǥp%}N'62\iOӷOL 4I{IߍKD6eN-g T#ه' "IHn$7vf$<>0Vt\H}1|8F tOoyY᫄_́|ެ=Aڐ صE9!돇 [Get;$pp"% oΉIطSDŽ?~f,SӇ@`H[NڪOd%ԏ'$0{$|UkX‚'d7\xߝ(N>/oA[o8{q-r4M% 7ך1Ɲ9o Tث[AI54 oDX%`6c$5l;g-|,N Q7썛AC'D|N I6/4ta g#$`qL8U^)s;K:|uOAM0a' ~TGpsUH2 _羏z:!zЩ+4̾HJ􇓞$[A@0ై$y}eXj[Rt&@^rYV2%͎xFwC_2|oqʪ(uB<.^6^(_1W΁n[N\9}Ͻ:i^~gɷO/ԩ6Q_v;si*muapQ38^3yׇ|.8uvul?[Sv ¢WϜ+%G/{\:499 ׭9я՘V ;I ;ʑ|}FZ1W*]*X}kh]s^vͺ}Z#w$׽/>}k~ KfskvsۮvzX7͋~km/jBv}th?{^9 ]m^aNF|Ͻj|YcjcҭUzr?e\>am|u菄3>? yd]zK~,>~z\K WXGh >qjWm@cO~KX9rWΉ׎WL.ݕ3'-]*}E {EaN]KzSsߟ-(/8;nׯvs6j=,8'(ŹapU{Ͻd>y}<^N8^Oܩ^|ג}G+WkJ==;~2%Pa'N~,4Ed|_a01kߛk':}P> ܽ^lGnݪGV S^瓑d}/'lsĞSؚf>umE7 ioف=s֒#}pjc[+UL?[eٮ)l*GUB#)T}$v!g%6BwlΩ_wOE ^F m|'{_adbl~[]l_?2:H-ѡv|ρ+?6:Mt 827浌Um8؍;G۶~mFɮܓ>xj$cˇGq-<+*]>!\~5ow_!.43އOʇg?x>$pTvRVbhNi֣k ܿ ]X&fpTkEJkjA}F3| 4զ2`JP܇Vˈ_2 pddAis# s@m[q ?lA[g>jxm1`vkT_ku/v,hۯ@a}?N`@өE j[Gk="9jzIA?-6{zwh3z~r6O/rXDgN9dEy[=r#@Nay`g/lc &v\D},&s :c@x>X7 8YAS$0o H= ^r$tO諺ϗ v N3;e4]Ho2dK@[Әӹ3C:[wU߉#3E;sA?#l]/+HZF?{’= +lѿNƩ<)?̏<=2:}|0a//?^~ U |\oB6`0]zp a`Q9{ KnmkY¤~tCOSDa T4G9hʫC]IHl'uշ{Qցm9gזkar{GkuKۣES Ė//.aCgl9m m&wbА 'D'Sat"ΒS2pf\_ eN9;! xxX$h և`B0'svq]kX0Î8>AS8u|@‚jO9rOāQ}U0@:c/Lnvs #L 6:dp$ ({Z>䥎6gfm/}g[/ s]<" 8$kWrTN%,,hm*eK{ZÒ&tLT$|ea뙀^NCm V*\ ԱO|kHk ͵3?`gicz9ϨCf ]!!ryKH L㵆AۅÿnH Cs kܬ9{3+qAm<=IձWԾuJ&G,|0LZrldN-7W:<׸Οkɾ26_t}Bc?f'fv\[; s}M9Ud_DXRY:7V:a[/`QLJJEzi,5A- 9⾹GO$Cɋ. ["+tϬס>C( *@"hcSK{ȓ/ 2G@]pid~*grI\ @H];lS8x-=@]blnA_ >ւp'*;QɒG +ȺKf +vazkɯ3mdw0;ɎcKjx#~M1Ud]}I,}=_akiVO/1[ sZzJ@µm;6>o}ɞs"nǒbg>f3%KZddQz߰#k -F|aF'S+ $#U;ıA]y /XXr ~!9Zw YP @R@-}>V&KڂǑp UZ~[u>7‚}^m3e= 'YKKxN՞5X0Ђ=-4-Z/" I ӒtS@az,`:P)><)tZ~s> ։zkl։n53Vi< >*}Փ}F'-mJft+] A;gd@ (qt0LVlA/G'Np@59ӋS"E 46f}`"A1&Sz*>k[7o< Oh467B  *CS_=qn5'B#w%`>ީ\-l/VbPx.]٢9ѓ=S[l._[wЕȔ^Ela$*ϳ66 ?6doJ=- &5<6t<'GU-"Hsr\>|s>lsЧ>ԱFsd$XlА 'T'LFl.qD4@sN挮22+v͵ |_ 8#,#1)c`U9Af/׋@`P |&C{SOƑ3೪ (=^1fiOy7Su)`&@P@Lw_%'G 6%U`B]3HN-L}2O9rsc)$ T@IՂO}>10zdgjCR; NREIUOsءsONF݃}lz67VSf_uKFW[]X 29Z; >Iю|_@իѩϋֵ֬˯OmHXacz` lӛV/1TP='_rt ͢b k$2{U>׋Çs6Q[=' 9yi|*c4FЦN aN |V9rXr*gf; |Vl]x#a;$ğ9vn3| +3gt"k؃s~k԰=n>t%yZOlrYzjVw<8fv6,K(دcXVD#Ad)҇ .,; 0, 0 \apr$U眞xxNUofUg@pxgg ҍ t߈} 9ryl+ٔ$=Z)jNţLƱ yq~|8^*x$<jXtn1csjli|"vT9[TؖL{8 X  EPga\DZi2#Zնk3fp5F>#7~[Cx~pK'\"ׁ4޵ 1su~kd\4Pr4F4\|AHF/cm@dkυXj+lDz;l]E u9g!FtW|;B:TO+9f\n14t_{C#),?o/'^(K6`Mm,B>/EyxB(y gOAw: plʁ!3mLګlDcJL{BMV["vM*[_mW*O )|(Y #msBkwYDQ \SO;( ihwM>y/tlG*T0cђ$YAlE;V4v"VZ=hh%vv7b_>)8"[ځi(%Sy[<So|njBN -9Pi?W`-w_|.ѾOd46$|/;L#^'n'ޡ킎*>qb5ɧ~N8h^DCOC>a7Xq/90|K-,iﻡz"CB,_"fAOܜ[)4ON" ּvLGv ʮ;P%c" q/410yp&_Iv8~WqΤ /"G [ۡB+Ȑ ;EPd#0hE;BRS^S'P8}s o" "oe(2:-#e:-.3 c AV[q^E;AVHh^Z )v8?Blȓm;_ >/#vcUC/k6HN~-9;$쁍"6Mu~v,ƌ-vlrώBO? R9GaX#v}N#$2^Ӯ#+ӭI&kEp/7Dpn:#C&if/i({ʩ>m#1"{&18Io E2Oib6|cAUMoisI[%8O[uI>>4Czco]G;H=vLٽxO #D+m݂%μ٦1w#,.=/ʐ^>V6󵅧9m)8R?8~ceLdg¡_Bqg"xz(*]nޜ4mX" ]<'369q&6o+ڄ"fӬK Zh;.v#hrϡg^ L++~*G 8]^_^TڵPmmN(y!&nBNǵB[ѾSNHt'{< 5YkC+ 30Mݧś }iF&ix r'"JW_[e81a<5T| ״}i[IƣzW [ XkbB`\A\e[J+$'~k u!5F/9/bl'EqjHPcQ{b E>Rxۡn@^lCW HsB467R.0>2-;&-Ț A|ޏ znZ e>9sOr6Y!}^( } E~u/3?[ Y6eh.vO. \ٯCc녨}!Ԝ_l[u3-yBZ_;%o HN[=ƥ6o?{;߆޸3rdy" Lg d;_R̫6$o~^[CnOR@_zCZni(m"bgԾPO("n|[C3oWydy1Pk-a2*_ #r㷅4B_`G/7lxCC^r!^ 5E½. }?Tp:/j0סVs{1E tdi trv4k{?m B_vq&OQYPuLUTd{ԥmbZp\[c ]z(D (05^ L<l xSM) YъV>6F4;SWhDEY}yy ?ѶI{Tno=%aK!p$wwuRC/܌c(+Arq3_Ln5s~aOȁ:.aP %L,&zZp;jM[`GҘ!/QIy[a&Ƭ] KCq<1_"o"EfqQ6_ ?3Ks~[\=icP>+K}җg{خM9j[?[ ,ꞸQBO uJ~yF~ؑjǔ>@2&׏/>ʖ<!uBӇص!Yo6ndLt?m-"k:*9DLd&a9, AYq }IV[.喔d97it߮d懨9߇d L~{ qL8ln:s8. G H-p}LwhA)o+KٯHIJ1QL+mݳ1"{̾V(/ ,"i'NCYQm/Hc*_hhZ[ ~k䞛5yÇ]k_(r= j۲c3Ԙzg8bM)bl;룯 kB˿"m9SABN4?RWbȔy\0`cq,7{*"ž}qe /̜|HmKoFbϏ^* MHG2݋]'Z(cƙ:1$IF|ҷ-?lSiD8֦<5y A3}joU;o]$~m~o-}C9=m5-8eLݐ@2=q `E{Z[-v˞Jͽ gƔC]Zo*] yn3ߦjg7$WE<7!;mA$l;}9~8#%!G!5 P;Vs\1m+dXH&YA7g*W ry}\[v~|ɪ6&LH_[#a8`AMdIEd!O}帮l:UĽ 'ii֖x̆>6i6.GWŞI*i^:,$i-Ͻ9=1ɶ/Yir-o \Z;qb%lqL -ײiYyn1qoSIǑa  196D]>EL?i]tLG;[? ~' csɜ{Yۺ^zc65[PL/M[ԗ~7Y~۾>ZY9Fr\MߴoYn-=&һgV6C$&l/ɼ!ϭ/WYv-0$"}c>q9^)Ofַ7>kښqcsFYoקb2˒ţ^Dž"PsM^=;jauubUB!(+jV@!POw Ul!1(1q9xjUn`Hx4׊C2a@!Pt%fB ?hB fZ@!0';}GC;uۅ3 ͌@> JЧ4ZZss&) B(FA_;/yB("ᘲ}q=fx8byJ_Gb5D]E@!P@!P@!Y(Y{]@!P@!P"Ps B( B( Bجܬ=_BOq(i:u?[Yr֠)ڌײ\؛td>fvm[Ƙzn&7OR|c_ZhlF5]2g ph]C5~Їa)ʼor? ^;ze+ԏ2mOɋoƯA/e<0ԿZrBv=Wr拫 *hvg3<&8\VQ:۾~hBFfI|"+<7ʼR CzP1F`"O CQ($i-Q3{A,O,^QsC/z-'*==T0}E_4ԿYorΨSCzVä>|9Bio jyi{NiB =T uO A, +حEɃؼJaҗDN[awKGa_RхCv[8$E>lOuz]CЯ qmr0$}oB_Ojqh=K_$t,ꋵrj"~OC c딾cέX0 1Y>Zn szE-f݊śnF5i`E>7CfLvu`Tv>oWN@l/O3C-V_m}f=?n8c8sB賻 nR~Q)9ŢٟӔxĻ'dYQSnFCwTUރ)T}f! 'Fz(]n.~׻H"._{r`yϲ{F_?kLy#_w{gSƾ(xZqϧL.1:#NOпm̽z{-ty][31%[Bo|4*[:jԣ|13kԯor^]cV`/Z;]os' -{ک/x UVњ-zP_(z{z=(9])r-py_z|}Jzd-q8}ƵCϻcmk5iȶgƋHVg pD,awL9QY cqO 4[\vN۶6igk WM%I<*tNFZ .V/5Ի~ӽlmdg, c:%W / poV,bm+H[8!sw4u1#oڗu <1{vH+#!W)xy\'y_6$8E>-Q{lCM}{p@t6ՏyEgkgLL- m?i}`sߤ_߶86fwb e?2_܌Rı9~a]םS&c{mf/o_ܔ"*|Cepm~㣳m/c=O};G2\. ,/̶P>3a@h[g٭}r_׆]G/SdqHҖLOj'ޗ˳r7bU.y0ϺrF.6g*Vb;hkoS&2˷dO{q[ԽM#آ1O}W]cA?خͿA׳l"bnSݦ-g-c|ڰ㰕"+:5C3GCYA_y `%(k$iuPq3Y)ti \O(ˡ&&AcCB'Gk~kI|](s|n;XŹ뇶VCq9QLž/2-ԯaڵzfq/O6ydYD~Uwv_5eWs Uj5Y<'mpω/L` _)8P=pҤeeXIrVvU~B &_&~CVȧQ 9P*,D s%idWc=4*0yK"eUSA֜{W艛ygN$rm|:Lf^H`^ފպK"y& M6(bJLz"MA$rVvwom?SmPcb]^& Aԋφ1Hg  O98PV&;$ERYpș c6(2g/+-o5~? r3F"e)'@ j1>F lïB-< 1,~| |٥k*B+\*_DhXr8onVsЊy|yﳑ->mzLsBN+b u0G7 o7BړvoJ_ގkc*}|`%st+B+,$N`ħɖ8i#\lcB  bk?2VH[W y>v_b ̶|KC0.W"BsX׷|@+s_Pu7ĜS~kO\CvuiP- mRs]bb|YhO>ǹ~b\yiPN508cR00$cPT2&B]4T8AYY9zoh}0TpW r?ԄƉ z~JhK29A%C4Xr^d/4ɧ ҷ0 $0-ނ*dm/Z )"q'͂`Fa3]94Y"'s+zD8>g,&Wdo5grK\U(jW7%ccDZ/TV&c (LU׭qN_ v6տ75?+T0pkWGً1,`}yI@C_>.&NPm=mrv4eg:c d?~m<;T8/MCz8FapХ 8va_C~k|,,B8$e”/7˗[|anOI+9-ȸ n~Vз-T8b‡KL e)l#iufك@1v a\{ş6H?.Om&! smoPʎa}IܢД ]mr m}XB!w"~ |hSwynjwK>q>Ed9|oN ˗K/ʦ&}3`cO|~'kK}C*! } j,q`H-opſ{e%{Q>c@';Ɯ/2 e#wPZ'ħD e[, zok^c6E~Kncyu\7׋|+ |+dV&$&E`9p C97*H.<#KNROڤAdN>IEXPcbBwXt8ρ_tHhwH|<)e|rrǁ=gh>Ct"`w8D3=ߡqT]&#z1ɨ}"9{Y/pub28>&zۓ82i؃`JߵraU-`\c)v>*j% Α2c+bݚ0vI.hhEIcV.? H/ĆV߄"Gpg/ #y/$}Ɵז)@[ +[zPHVyH,a}MƲ1dq,W)b:OU`1 ̓}z]!7CڎW8%/ D@8ȅ'k@@9ԜKȏ ֡cX߼i oc<϶)_)P\';җ? _D/G&rV2zsZ|a|+;yc le̶H};|{~>F\Pn7f ?2>rjOθP 'Ę_č }5psͻG+Hf+# X#G%\^ ZމJ l֘H#O1pW~lx%]/z lpzsPrq| ~*W4m22+`I+fHB_bבb ù'ǜL?JguJcNn|*QlvP eK\uvM,j -MCO6s'S䓳Ph?W|*2Ba13䯕ŏ z͕˩vX lL| B؅l]Ћ3T?~3Q#,ʒ_NYySsT`k)]&'o)C,iA_Z[e i11^-.L~=Lf xDBc-a H{"E,L}3K kM܄ AMlk,_M؂D~ܥO̿✅mEZȶOJYsG#G٨~aD/"nbjG\㯗+J_|jO~ػHŧ'q/M\ -ܢ/L(Lapy֗⦶7#|n߭G75Z2v {,2;f E^_$NȹC3_D3`!G/;c>E^F R"' 1Ӣٔ[ E޿ZzP҂vn+zaJ5$@sBLHb$?LRǩ1Dդ'3&?qϱ$)'v疸fyH>SӊGC" uI?P*@e_O`=LO`O &h+kȀ]HL e9R<مG&sdnMDH@k =Hq@'ےgO>Wꇬ2E>ւ+!GI[,yi,L D9#kҌ+"T1*߶}|aeaL̾PnO>4Ƒ=߃-N3O &c 2Kc'`O/Sqq#d~o+ҷ7<"^v Ky4cm1̂ͅ fVT C s,?ҤcOc3# ƹ&^z"Mju̗X۷I!\(_ClHb Q [|dB>1i_oG,z#Ꞿ'qf$-m/'C2hQaD1~~?SYI>6V|.E9I>dKPk ?i<$BgMXm8]NNIѦ_m`(6)AZFKGza|n{81q1B*:|2$P,*S@;ZZm`H+ŏA, [4lrFH0%}d(–ePʼ$Y@P5H,)Nh#М?4v#lc|>6|XeL.|o y<mIR^.d[lM /l;.YL#`2u&|-|+F(_rHȗ+_<#7 YHQۚJ<0܍햮U}[ܼG>9ˡg?of)(lsQi1Oo8)tqV 9)X2aU{(rhU $Y+ϷB;Px_h!0#J]^ \!7L;Įucs cF]9oEZS;?v׭[mwc١HC?aGnh|r!_Hڡv[1;]c 'BbV|B^{:ˍCwi,܋X/oDzXw^ߴb^b[Xdc߉? ~ej5v9>rew$0oM-q˜>>[7̞Pc5n1>:ԗ^7~/c-3N)챼U|b_/ Di[n^Xn߰_ &9||K &wA)BoP15 =g|gP^MPB2ܛ$L9`fѡ&QA*M9*T%zso*)ᙔ|qT@{?Et=B5|('7~?i~*_jҜ>&,v/tpMFΩ Bo&lY`GOj̲vqB~hWCn}`g?qMl ÄHW4dM)4I>&w03^_j[ocT:lO( a  PAr 9TQn eD0:fOMǖئ: Y߫PmYa[Mfs=U>@)rzd()B`‡s[(?#M^![oeZcC* L{V_cW9OGx}l/blUc1`[cion E 9%#{Cٯ.sϱ?A>zPXh4oK|yk+CmHc\h2yyi?+}G :or6Fٙ/7G [oZ_nd[S[`Ͼ?x_|ȓMgvC~G˧[Ĝ/7ﭡ/$.f[χ[rj:'[>}ef9G \|4K zz.7_$?ib(y(Sꐱ4ꨮıأ iҋ`ϧMq6{3 fy=*kjQa\u"IDoBc\s (+wjjkpg .&2C9N {}诇_9Z"P38wekţBn&AYMm8i_ 0 |/4 >Nz;4IFpP3TH;{ԅƎyoBzp+2Q~@ J8OO 5Xij1m&V`#t_ ^P\0=+ko6)k"ڸ Yhvj<v(D*1AvΈl20 ƕPx^MgðJv|jH w [6aL&)ap}ho7=cq$̻AܻbN=x/.YDՒAve5L \͍Vm+CڼMy!e -~yssͷQoi/7 =z˼Sq˜{cr83Ԙ;7T+6N;~I ˗X7:sG1v=d).qEC{xBİꨮc>q<1{::bC-B? [qnoo/~[!?WwU@@#h4A&1ǔDm[NdIVUkUgkBrjP8 Ƥ*F^&3"sUUuЋ yrm6(CY$m>/ I>yk?m9X*x|wF?G2R@2h8 "FSnҝ+;CSrHv%Vf^kF6Vnl=ݲ,G [-Lna+{(o0O_;"[PW8gMm_!l\ГcqmO2^AŞ&ovE[Ѣ"Kkk\ ɲ,`Wi+,akcʳ 0 D8e1wB[o[l2vr|V6֐[5 w-&|f9s@o_)63u矩>Jf 6ͱo'aKg*Ni X>ꣾsLO/LmN:fl#\cG{Jf6kzцsɌ6 y]Rs孿d3/7}| ~%}nhK/ErC!{߂i"j}0aĘ-9&syvۧoǷ l5ŀl}cƸ7R 5ϱym:mͼ!I6sPe7NQx+>V]?o[lo^>6E2.jڻD7}}:fY8rlf98f/9 ds౨}jB+}Evlg_̳ych> ylCEɔ_-2FVE|<,"%MI!YB4#JVﭺKCg͂ryH0; c;' 8^|\ =2TpchH<>tuOa7FFCf<:g>QB` phǐ.?`yCazTk`u <-5{d17/#gT V/({/s˽Z.YyT㭻.],yx[zxP<]JI!@:_}#+HP8~ 7:}_% jle#_w7DÛFxgےBEذx/uqǍAVsBupCG7 f |pkKշX7 }o!{\t9el{;FΞG(7ށ؄SztC?]$>~Hfj{u6|i Y=no3?bLj#aqUIWzPDj}2͉y߹U_?9YYmenޏgnWow6]WFbWՂ֍"WN@!P@!P@!Pl0|n@!P@!P@!({T@!P@!PCjN!P@!P@!P"WNE]56/r_Wʤ(V š_6k67 =f`{gegZ](xed_R@!P E>Wʤ(VDzieWuIOvNR~P+d phBvkDFBOB( B`U(*0V&@!B<o~#+pO|%q3FVNj1%@!P PsM`B B`i f롷\qVj#Oo ]G( B`C!PsCug58@>zþ%+k"ds8JhkC_1@!P|Q[.>ھv8P!hC$BӵkVT9sW67:ntq4yhqn[GE7i]W'n4Wh(:dsM}="oneډfe)NXh2'ىu*?mqCw E>BdMn{9G8YyUWbD|4iv*/l;k\{lG>n WWC_5\Z=yWWc"?VcluXN'v9x])SOqĆMIg^i>V(wkTC;[F5OWO;mK=_(_Ҋ̺2b>ƦEzzp^f_Z`=&`mCЦq( B` PsttLCPP>8ۅ~9߇_Įyi_*`"H1#y#^{B_*`RF[{oARlמ?7d?ꀴCPd%EC)q,8IkҼ'GJC޾@6i E<X Tmyq|DP>yKKBC6kWN |x8_ nZNq|n^S_KXr.͞=lBGg({ysڡm]}gi~U/DdH|ܷ+uwȖ`"aûBC|wCҧw!¶gHcl -qk}z6 )ή/.z!,~,auE*t6Ӥ?{[Lܯ?ִC G [ ~>I;a5t.+l~][h06 ӯ#~[ @Cšnl&EX R[6C8k뗟W-m[譺4X\(N@!Pl|n^\~{B?0>*ԗ6O =& `G"ΐN`;t3Vc$D˦ާK#Bz[z>1tl7L{; [z3Dpܳ)/ ߭IIs1\r=ۢ^O R k@+v9o˅}"6RuE ν1"ʽXD$"pDT,V{f(;a(}s$GG}IAнKd>շh1;ʾqW'mV/|c[{y6gې8W9ſ-v( B`#PswH,uA <&RN/@z&ii[ZɯIhнC] ^ji\(MvRU*JyrVMv/Rr  bwyGa r*]Vvn{ߥCa!F^ZA>&f ~9 W"!S; VƏV XmE[H~+g^][C&Xg' }]9d5IaЂy%n@쑯ʔG\6t#VVoNK;S/]6dIK8|"HѡȢVzVF](4' j{Cϔ SZ^5GdFZnP UH46lN R4FR">h,DA*.6 ܑd?/poe3؄7wy7Mj;i<~1>Ӑll|(>eOeC[_ـDŽEEceh+>=DڧzOh?F!.) B<< N`tPW*bM:dH'ʴcdg$Q zᄠRCz5?Bedn6^I͆ԇ {L*ν&t_Γk b#A925yX@{alj/"'BfE(yBO&ϧ"NGK#BvosqO1֑/6e\WD/ i-4Q|E$8PmhI:YOXzu(P>xz>E>m_*C>=4M0Ԣʾ-"ocL꼅)#-CǞ3Ec\]}lƘRbLCn"%@!P"G'M mTA:i';N WASG zyDhhuA%Bwu렍KY9S"hd׍\4롈WJGE", Au\7̟1#!Rf"v E#Nv-S<+֡F N;B_<+D`4%o/#. 2b lHT4ƑE {A%Cv~&?H-Fhͻ͢bWcGȧ]ED.qxg(ҒNGٞ:E؃ "bǛemacC=cGkOD>I7a}4YCےG|F=][O m|{[p)Pdc OIi`vF{al}lMTN@!P<\{-^t* ghá4 v扝U6hjʴ#-s(ɶ?&ꝻJAgA|xU?' i'VB> hL];U_guI[ulGmH =29.qȵ)*mZ 5c'ϳF e;2|Đ=ZhVKFiwjgh•ϴK6B , +d##BՏXgFNX_MĞWBY'$[ȍBckQ+/~NZa"baЖV߭MOcX4&[?kCsgt̶2ME,) B` Pst2!`nFT6/dOp {c![=3#r'Rx s [:k!qO>x'b+y˸n'![CWB>6e'; 39a 줗! ޳lTqjOue{C>;e%SoĘxs" @VfAfkݗpMhG1C<>!g RBꑾqJ;1H#Q e/ ⤀#'G[vqApöHQ;;ClI?& K4IXfG< i"(;/'u |j벡9 N^^y/c;}v>&J^ =:qᷡv޴ĸ IOEϓc/z6FsǾ-CjǛ=&95:*N1d;z<I>o;r9 ͭ\7~v@|bi_e/}6"G-ȴ|b|N٭a>"MT4ތVW(DY#G_( BFR{AcB$vتw܋H 5vV*V[o+gY!ڮ!֋rcg:\ XFs'.xTn4iEp/PS.Ґ ^/ }=`zmO'َ;Ƶs^-IDATp;6}DBGkQK$qEk#HTn*v,d~ |wH" /ָ8cmyY1Ԋz M2 dWGv&l/8m=ƴ#H/`k,27q-;poa _ }U"x&7 `Okɶ۶7'[s!ιbw-,"vaB=+K[/-lVTcY%|W4 ,G+AEc+wd{قV.V&կϫ˺~@!Pl|n^\~vk[NEJ}QD0~P;9 bz fW [POC6!BvACPnyV*xˠ5bŸ[2- ѻI8!4BX>eL`~4t$@? t DYݤ}HTePzwp)YwONTׇ"HYWÝ^] Aآw"y-o_ EzQذ=NB^6{umOYzK;XOmmZ_%o kNtȗ+g=D,XaХC'lcm=N}}Be'K>K{k̲9v%Aa3:j@07ԇˬ<2CNب6"eP{HCti}cT4شYyihk Ѯ#a}| $ #c.ߎ~}p?4ƎwBرqÔOt͢Qo }]hH";4'c2ތIO?!=r/W$|m,;q‡cNjI!PAe6.`TS@d=>4F/CJAuqH#_$"vr n1 rP&5o]ΉF,oABSYGЩ1D"F`/kw~v|;T7CEP n!~ E @qk(AN k ķ%I. >̢-P!-y=CVJ"Gl Fٝđ="-uim!@zBP;9l¢Fk=:Y%H;DkG {QCXHxos?'NNt'} N}bC7 4Q,Qc26ix{`S<,Nm"Soʽqo HST!P@éVv/hj/ȲrPW k7E`&!pYCMy b-[G*((8wr; hR͂Yv^"T"PS]egwNЮLKV[ q!dː\ZgQC]s 5N6̲[$i_ >Kb .}BOet^nE\'8B,>:(nۺJ18"H1!v.[1l1F &Mh+Dzy SH"mIlz GFmmF,^?xK|^)h8S ]}~Ę]4jn2ooy㲕lˢ`G|FІ~1:u( BAaUUB؍h"% -vv$룿.` B( @;UBIzUG䋨{ֿ85UyH; x(T}C/NV]}$m.84VٕO!P@!l|.JP KY>~pcþڷs=ЃV^$×}`ci= B}( BX\R* B( B( B`c!Pscg( B( B( u@u-UB( B( B(6E>7VVk B( B( BX\R* B( B( B`c!Pscg( B( B( u@u-UB( B( B(6E>7VVk B( B( BX\R* B( B( B`c!Pscg( B( B( u@u-UB( B( B(6E>7VVk B( B( BX\R* B( B( B`c!Pscg( B( B( u@u-UB( B( B(6E>7VVk B( B( BX\R* B( B( B`c!Pscg( B( B( u@u-UB( B( B(6E>7VVk B( B( BX\R* B( B( B`c!Pscg( B( B( u@u-UB( B( B(6E>7VVk B( B( BX\R* B( B( B`c!Pscg( B( B( u@u-UB( B( B(6E>7VVk B( B( BX\R* B( B( B`c!Pscg( B( B( u@u-UB( B( B(6E>NId'=q C)gýSk[o)KMꠔ\@!P@!Pa@,OzЗ9ա Z过H׊so*_՛z;N#9Zq!P@!P@!P\n:ydw~&F }RC+ͽ\jq "AAe^@!P@!P"EY7롿 j(AztBp&YUtצގSZT@!P@!P@!(:@Đ=tkYC/z8#kǐTkMrKSo)'3.}tM*U@!P@!PBā3^'oF8gw =ss4%vs(Bαt vM}qԥB( B( B@MAJ NC}vJ8~v>7vG?^<:9ͣm=HF ]!ToQܽI{t?,Lp|ͧ%" Eسvé0G!ͷC­YB=P*G_\D% | }{4?{Cg}Q? B( B( BmC?P;҉ 2E>gwE>~7=gч |?ݯC?;ǏG9לХ,|"YX!9dO Bӡ^G"o ez(_xvSO ~zyW2~ lW( B( B(D@͸N"v>jLO;sOϳB EH=CȰk>|4xQ`%wB?+%v _7܏'Hk5ukH|prN^HΣ)z<6"߯  dcH+0+0n-UN-LeL3y MuX@!P@!PE>Wn>󊁔ؑf9E> C/&ݥ3"QY M@{)1%O4זK>PcÈbGnMv7H<#gXxS}R>?GR=~D >;)$r <)C}8釡lgz"k}9է EUnԉB( B( Bc|*=Xj{Kv@]=1o }iZz ]lw>4^m| C~Á>!TWմC#DHB{ mEޥAjVaI!P@!P@!P,@q5%>:WZ39¹=G9wΧw>mEz;Ph'vCtzrK)}y]Bd)^rȧOK-qB}(?$kyޱڞ5ԇG?zދCz.-Y`P;*) B( B( ( Psn! EB= S|nI&__Z_yEH*ْ$zf(q!i9>dyxrGhvQ P^9M4>TR@!P@!P "PsAq@D1DLw=MOU!`<e·?ЎR˵vRzUܻؐ_N&{m玡>z!ھc8M׎!>Ҥ\e,0EN_4Ea!P@!P@!y(z}mdž}%t#A>zPhlETsW͎]+ŇH}~k."x;'B/-ýG`WeSQ} rIdۻ{#ýpRHmW}DҰw9y#GоsQߒB( B( BX" m!n|E]$;Gű-/qY"_|xB_d>SQ"=E6z/7Q$V]}v=mv? HApp@w<8kۙq(iKУˉDZvB( B( B`E>!t`בE$Կ^xa>g;[G?(Uy"X7 ER} B( B( B(:E>:U@!P@!P@!P@ϲB( B( B( @σqP@!P@!P@!Pl( B( B( B#PC\#;rUs<$ˀC_gi{#Bj FY;C/ehQ oz zhǝhCJQ[^\,U]y{\O뤲z1#`{hj3E^ˬQo5*`߲sG YHr|ÍvkBd#4hA;_5W^9B@?ܣCzT"YCw?~?JNuWB"F! Z  }bq֢BU!E@_,ݡ=Hm,T4M88}CH,,kzw 8͡;?xbRyDB;RqnojEF vgA.`g3 xqؖl/VXBzTh?0J\mDj q(yYöVȝUٞd.ν5Mˌ~7w=a]vT^.ŅB|οzLݖCpU̯ uE2{A*N J66H՛B45 )*6w*cqBͫB_KzCh"sCг'.jy\4> =w>/p`¶ [.:H-$fT^+D  /LJ'BK]LjgkOj?"Y\1N|.t%e`Gx{m5z%lz4E;]I!g't2xQD22VCi]Q7#IؖE|꫽myd5)½R(zcoQ<}|'#H:u摦YǛN8&jƭV+o k׳g,na{%֖3~?/#]]O|amY6ޥoY[3Or.po4!-&|X%yq+B?0採:h[ι9C1i"kvVvďʹ댺>v1%AnBuvQY>R7%N[o]mC>f;B-~#me,igl u80O4ߋY iL[-W)7_G"͌lKE>W޿3 ~+P~[I1*Ev 9 Cޥ :TPB #_ õ#yX 5{YsVs[9W=1F~NL(LVLlpQΝ 3A)ʁ9 [WCM*&6`dP~@I/ɕD]&DX!-UjW 234Z&ek C)W  m6PvrPƟjqE{瑏5CVD}O$$HR=b%tlq$Dhѡ_hjA>)"ln{w62E9i&?=-~HIB;mFyIgWϼۅ BIbvy2fܴGRN/ɻ ʙ"l E| t;C3{ص2-8v151c|{2;1:$=znơzl﯄;D|J,׶/ՙIl~ʶDC|:D T؅~L ص׹[j"·0Om1XcZЖ\hH [zhYu5? |qq@+cS_\.ub ky4֗|N[ӆ{[+L^7 MoX\󴑷Ev>W7v8 Vab9E[6qϕwN9V^`b LnAi}*AńB9`B96#VN*@yM('n"UJ/hO@pPdӅ3Xt('ފױ@G t>7%Cȑ 2hC~[ V}aKѯ&kS[猅oW6P͔3 LmIbDh7 hqq#B[ Gdүc"d_7x2ıqgux|g(䷢KCS&v<X dC-.|^`PO+E+\HaL ? OٔeHï9[f1|K" z&*R_.e| 9f飧uVw,eB#na,n?-|·1m?7~)7- `V @D~Hr?G7RBPkD;w&?i}"Ҋ%6 U_srηwkj }WNS#3&ͳA6c[[ᮮl +sl%r8o_x~-naG69q|NC8W>7'߶;o^7-kK[a(aQμ>걀+C?&՟5%?)NdĦb/枣Bj>!m۶УC?1:^(o칯-ȏ{k_Jȧz$u9?3>TzУBc? KiK|P2Q|_Uz+__կ>&cc8wŵ־8qs'|k^s[V#ld18|rz\ q&"8G@LD plH@aAx[(GP TiEȄ>.r>cV4CMdOXa,%k/2r> lz)݅C 99mWW8;'&oZA*=DJʵ4ҊD,b@U ǹ7Kql21c@MlSF^;w AS+G mn)&VLBl\8KEm=r83ԭ- LbDdL{2&>* i#/7rOG ,Z?c;F4 "cmas&NOX 6P vՁiDŽdXj!8gK(q:sxUkXDoAlnGcGH)H>P&-| ·ęGW>%1qUk[_'i?_i#A5?u cA~q0>~M~Ж ^BQcMn 5t]6~=n;v,[tzb6oA"ޤr(g 񇨱V?~2F>=xt(}!j~jL's[Ml,lzz{^u8vW{U-b{q-gql/UVƬ9V(!ݷ-4)=C[)FSпOT} E/X&B5pP¡`[)&TKP}q&F@5/->el e&V 5bү&vc15OߘI #x_Il;@ fdLKAHۗSxUس.cBsAFr-{?= 6fS35 {E 1GX (ζ?+P|(?oHYNi,aFA1DcB_,*Y~K)(#^AyDe9~$T1yF{Gࣷ5*)?D{?zlO޸PcҦ#-zKjϔl-GnSyGƏg}"H#m^RD(2F>:GVeczg{qk;c}9a9bD5rn-v8F-4L L`kcV*q38nO:rq|xD\`C/|o`fb+e%xC\gJ.7D"U2( zѸxw^%' nBHMB/<`ix*đ&PN? pLR*I9U&8F514)"Ij5xRm)igV5{"y N>k^8}[S'$Gpih 8nTv:#AyGP*X4MlM#ĭ"HTTDh%6YDwcc$~ pv6؟zQqeO9 _ޥO䚅^|}0u 4(PBHOZaEK/[{v:՟bqXؙA<1hL 238v鋡Vc/D[0N[,ocylc|"|?720A3S!-ra[!NJ. r#[|^bȃ?̛-;S』[4m×S"A cY2|c \h;O3\+SdqB*rϘ 荺;Lb!JLʿŏwUn}/Ö#0>IHz'wWB>soo ]B" JD@-pIΜ>zsF8" T0`7"@F3&&,AR Zݓ>/dmc2o/&5<)E'ǟNe^=eքe3}mD;m6tȧW}b !CB_ڒODXZH( ;'ic *{J@ _&_SBC_l"|D/I>1)~{X}܎=Ƴ{pjO;_ eT=$%&C6m޿Xނ( ԛ/D{ɟ `a[sa}`qpn)<yv֬/.B>x|ɾv͟oQ-NX8FgOAX|^ros'"y|/ m'i S|GȂ7 8X=rm"4icYs11F>5$gOq.luB>ў|Og{B@lysykc"́O1ʇZ1d |7G-:(9M*1A$w Z5LTJ7|cAlzCPB9^8/"Vďhqc/vo8Ŭ +t b]y gb,ɹ!@Z?|.Ž3~BL lo^eONI/`19 ^!_ńv3,_OÁ2@;{Ң<3g/=v wy7Cg0{BKPnԊ=/fn:gg6uv'3 М%ОqZV sqN4_zP#8]u2؊ѡȉ AJhO>תU`lCv)u2Z7iB}^CsiP@|cC uynU~IqNylj@@[[s+uB_ju +GH׉ezvL2?;C^Eq#>H!8; m Q?!#ږ"vM5w/l\;P"cK{{CNPؓ: 7 "#UA^ۗlM~B}kz%8p^mbL EVvޏ7~+nLׅes v RP+߭!~`m$1_u_c7-a',e!'mLf#)ysl..K%23 B_бs;j`\}^&sL B)[>2|,(`?ȱ5'ڽ4&j~mE\7v7[DZ~|k(f̍[ |%Il׸/G`Y|dw\;.|aL·]ۜuoLc٘6{ƂM/[\`s.^V,"XY#E;C1yF|ghKQs1~3#)C,0E?$4:۶Pdnb%мbos,[V/6p~sE >4?l^*ؗ񬟯:`[@[J@eu*X4`w M#m  ] 5imBt&yPA08kgD)2I]I/P])~szEPA,AZAڼ߅0 !9}WC`S;_ d^&A4&Ɩt8 4Q&;IhoKRh!Ԃ}طiDҰ]&R(Ԅjkm7W[ZpפޙՑMm8?MW]١|v>-Tü' WK-LXͱliI#fw&6.c7q e٧ƢWi+[dlm+:AAR4l E<$y/Rl@_^-t@BUu`>D$9^8T6ɾR@&N2MǶㄡڠluGmL?űͷ?fȁ9\O)ٜ'%~iۆK~}p~+/81!_Tccg E*2lyjPPW~u1{'m&ƹ1mV/gwHkmv~C;socc4_:OH36f96yc~c'DkP#y?'~V~5ickinurC1!+ǹ}昶xåa-h\/oxTYBsL؎ym~-)ݵs]33 @춝벏>Gʀ}e#a1k|ݿ 5k~G"KLS>uͱ/2NvoDY}#~T i䇧i4< zjIPP(?2s)(p&67l'yC/rDlu2VPW[?wrߎO<20 +He|r&A9~}e1@SvƁPn '`I;M2&XAB&0™b"XG&ؽpꫮm )%{@@wBtl&$9cya pΠn=7"0o|kߎ:z?+VNX$0ĸ2 K6;oڹ-tޢG5qc/}:zx8|^|x")| o`ln2p<вVvL<+~=Է|e߄"Ch5IPħ3\76&U3v ;?KnVzsb[1%2&1 incr8i,;/=h.POc=W 5&Z{0>ͅg[hAP5kI_C|Pve|k4v"6! 5 /C֛/YнC4y䡱_<>y sE<.۳.odž^WbԸ!Ȟ6-6{oGi#(oO>٩4ƧkƷ4Cbz8Cs DEs #;p~|ojxV=(&i((HSM&{MX&RU@Ź7UNSPqm6a>&9|ʚ(LND:%w-8ME䵫KMxW(#|ɧ=+}! r-I,M4{@GsCg=4}&H$&6MKg$?ˇ< 豼L>t-\/<lX$$&u&g&s?r`HV]ƥlB(١g2p ˱h2kAN'}2QcOg4l06Ş|JrS6Y_ֻB~8EhwcѬ[Ҧt;’ư{B UF#86"-C~. Ir6v;Fݫye`"([2c+vL~9S^~r,$-im5ԼǸP[~fp%Gas9& Ea1gjAw߯#E{j{SGyŒ9%OcOj.4Ll07m [ca%yW$1Ma[lH9 (}/r㜻w"~YmEzs0IH|~#uMݶ濶̏) Jj}Ou5/<9 E1blom"Z" " nD8JP96 ҹ7o]o)Lmz{QpX)uh묭S<m8$Թok:oyuO\p>1OӒ4i fg[.lqlu#o1&OMb)`d(Mj࣎ݠϲ&Q/O٭?UmZ^ow_>i),8Roz?cܶՊ4 }ޗ}H܏̫O+e$~ѱ:xJ3eg==ҵ~cxc},ҧI{~,pJyUwi?ښv>W{mlXtHh6}9Xvr.m+EC_>RYsb}WyNl͗_ [GSZ?'9(1@?q}yQ/11Hʱ9o[LIoQs)M`pGn ڭ@>\ E>XQ") B(vۿOD|wQ<_pFsύ֣=GVv^nc5mݶQz$mQ&%"`-S@!P*tO|͹؝|PáYG;^ԇS7j]|nԞ=|sD;CPr8a]&txg ;##قkJ{C]R@!Pldw]FO-{ލ\C;1C],;r_;Y/mp(ov4 =[ux4_ Mm%>Ȱ?^礹п͡Dvxdղ( B`="`AׇM{G*'>dqp򡦒u@uU#Q[_O(P_?gMq{#>,0K|,!y~xJղ( B( B`E\|.>)tkՠEu/TEDŽ>8 {x{ն( B( @ ݽ 7afCzS΍lzn\%Dn(5y5BFdu:jCB( B( M@Mn]?}Le=bܡ$=fT=]/rȷCVd?륢UB( B( C@Cz(;vyC?:kCIh4'lc_}pȥ|y$8VO[?qTiG~g{ ıFIO*{gC=w8ɟ"ua!?y8:~ɻ6݊|_[o%@!P@!P"6s i~9G8qCL齃}Ҽ4/ozkX$HҾ&/HB|). l(rܫB=.=@hʴCEvNMZm1![ W|8^vq)>cIာ"Oڭ{hd8>HͶn)E  _ -9n. B( B`3!Ps3ծЧz/oW(RP$͎b/gS4= %{Ahּ_e!v@/@;-]f ̙Æs퇊琩cB}v"m\>^yt퇺#[Y/ʻ{,N쪶mUZxkAޡ1d4#ǽIhٳBzDaÛz?}v!!Gaֶq{Wh^7@+H/BԻ( B( B`!Ps 3wvaH|>-2('>( 7-A턽"Nd+ %E1ymw LJS8N/B= zPy؅{Ko^+>k:QT@!P@!p(y?tzlB׾/iGYS<^l)#d5E4HB펵h;$W E~L}Lh/"_v,=P9pin؎`_{=h"nn߳}/J-ɓ!dWuDm~+8ɉ$bnw\ iQЖ|Gf۶v>=ު^lr8T9@!P@!PG3G?o#MWI7]㚙GcS3,`>.4%?4wV|*ӣԇ<~|Щ]`kl[w{]+']D<lAak6kďo\( B( B` Psu{xGbz|_ K}}s!QU;pI>};_ ]ձ<|֣amql3A*w1#cf~v չ}-;ȼǙ[@,{;&r}&_wбdzg|/@!P@!PG3Ejw(_ehw|4a8ZzddHyӿM!7v-];;!uKܫww /rPw-ݹw9?zĶOC8#K5<Ӷ>uޥ_#}'?ES{K}w>-2rq=7#PDl_䲷&T?iFS@!P@!P "}C(dwn[qOcB}4EIE쌶D6"0v@iKΧ!:|:2qU%vtzABȖ+v }I:gPm͜ T;Hyo_EYs4爿,-ǽ=ChjGY{ޗm{$؎+^8jׅ>kÃ㷾:*( B( B`#Pswyܡș]4;B3_v0$UT;|vZҒI_<654E_ vxG9uͼ|8 ;yS[űK;i.Jפ?b|,Ӈw|U׿'%vMZy0t[h/X|wSo?&KO :=hE0EB[-B=FmrܩC۝ev][{/dQ B( B(6"E>7b.ަ+ƭGc doGҌ,fJmץG%xPףc9ײlI?;s_.ѣżr/ڑ21=ǒ[<:&sn-gnFTm6cvinPZbpOM ܶ!?{?#T@!P@! ( ;\@!P@!PZ#Ps B( B( B؄܄^M. B( B( B`(ֈWy@!P@!P@!PlB|nN&@!P@!P@!\kīB( B( B(6!E>7aW B( B( BXk|5U^!P@!P@!P"ӫɅ@!P@!P@!P5E>*( B( B( M@MB( B( B("kxW@!P@!P&D&jr!P@!P@!Pk@ϵF+ B( B( B`"Psvz5( B( B( FZ#^@!P@!P@! ( ;\@!P@!PZ#Ps B( B( B؄܄^M. B( B( B`(ֈWy@!P@!P@!PlB|nN&@!P@!P@!\kīB( B( B(6!E>7aW B( B( BXk|5U^!P@!P@!P"ӫɅ@!P@!P@!P5E>*( B( B( M@MB( B( B("kxW@!P@!P&D&jr!P@!P@!Pk@ϵF+ B( B( B`"Psvz5( B( B( FZ#^@!P@!P@! ( ;\@!P@!PZ#Ps B( B( B؄܄^M. B( B( B`(ֈWy@!P@!P@!PlB|nN&@!P@!P@!\9Yu?}蟯< rl_YiT0߄¾F@hkƞqy-Zfݷ4Wwn-+B( BX|ƿ,ngiY4~~uV!?FzgOSE@K_2~гG_č' j{xVp~|CŤ {C[*( B(6E>WWYyi#7}UV!ũr }^(2 lwznHm&Ǐ7gA씞9u|CE6<}@!P@!p0(rt=!QʳyTCO ,UoCx<)"%'gjv8ZT<!{hhaG@+ծZ@!P"P@tf zg?@+hMh( щk"{`#=W([Rj=?@4+#{ރV4MpKh_0n}ˇ]0=n "Ǎۇv*S ƻH/B>Oi/2TV'QE}$zJB*.z$NC+{zHeC{#<.~ ,|woi<^[R tmG'LJ>w^' M=]Gy֗T׿Pdd@Y|xKOB==ƣi?2َǭVDG a7䲩O!}}'> ;y(lS m9)X9z( .m;e/je~5㝡p iDsC_+xٖ"o eS7>Zpζ[pWء{ pbMϸTR@!P "+Gv| ; ľQYn R K(-}?(Lzmů"K^Ko3}- \CdH"~*#rgV 3#&szW")]B.mA *7fG: StnwE H%B3G0,$ m=ZCZyxs/˖8 O;y_NfW`z@ _k>8BE>a0|Hw6fyM(ҕׯ4B 2~7%vm zv.1(1&o|.q;>=!xP'bG/v"N](wc᭡uƞ47I}tqӬR&c(oŭmZ-MYuX@!Pk@ϕ=k3= EVvV 61Gߎ C<.{Hb94]ǹwt h ݇| I)o!P}"vzjWR(AO Pˣxv] *s,c]$gfW&Ҿ3&z! Hm=xfhq;0ȍW wAvفŇl-4#كwbz9Y{s'r`E=Bay'γ:o(XˊDгN^ΫEjCBvq!ݎk f{B=Ԏo7\vy(bȗBlcn)4]$Aw_?v >=Ix"z0="T_ Ƣ: B-bՐE 3꩏^,t$}n'ÐNZv vg>UՉ=K){#ے+S>^v@o/ڕ5|q'tWho-.`HW B( B` (rg$.ven*8N9N3 ΐ]OC R_pfYY.)΀Yˠ3 >GKV_)q;bȎ wȕB1'LRuͦc+G sgwK衬s4,'z-Q9Jq_KYbgѮ>AJA&n*Wֵ _!6vK0``[&v@,tMe66;|ZI(m;BMzP#k:mg B8dF:j[SЉHGT,T 5K=C qrKsMr m?_e?O `Q N-c  -6A=9qKʆ4F1"_xZ(ߕbGʒ_f#(-|IB( BXc|Y$ Z 3`ySEGf=&GO|f`uCq]0;=Ym+vK#~-F"' ONPdFMv!IJCOŵ|&aqntw ,LjGdžtv w 8ӓ' puuƮuѡ Dڭh0$bgsjO@ <$BmG5 .oB5R$ikB>s!&]'pwsK>E/Kq @~}z[×Bw4ErNeWԧbGtyƸblN /QyGf_{5ȧ]Eo'0W9bwj.spɶ% vs8#Hߋbߢ B( B`\!|qDT/;`%Z <[!+΂(Ľ|̜kA0q ҒO̵";zwOc5y't 9>w(dT`hO^ڧ My-!׶Ж|fn]mc;)/E2PG|"I,E ,Bh?nqg&`e!!ۡƂk iw>=r+) B( 5F_ hXdObH7F>I>-ďIqOK>ڭ\&~N3q;g>y uh*Bnd5ȧ dA^z|"lG>% ⢝[C9TzWKDOO" -A/M>ۅ|"i{CvwQY*a|ڵk#vdВOcjssQyHc"Ni%Z?ηg}!wnTK>=a>ivm1L|9ndf"e"U"ີ( BX-|EJO Q?p*>/4lEbQ';1=-q^F;W q玡mmcudVdž]^D&eL>v~e.DdvG6ȧL b^<#uM)tGs>LYdN: Yc+ZiaCj.%jw˾$9XDi׬1g"Xav|,J>!gBsio9x֝G{V{S]vwy;O#Ƈ1v1]lwxPwOL|"GSԱ*"RDž@!P#Ps倯5D&6riA&D0>v{02ܽARI$=& ζ5i?${#mmŮkw|vcA>{P;~vWhGӮ]D$⪡v”ﲺO?=)TM<{cL7xz\3=Gy"*6NAt E)~"҃|}ko&ͬÕO`i-nv-`)'i-'y硎짷4%!N6f[|G z'G>)Z3팏nh;-<+]='tkS|&)xof>õ"]B( B`= Ps彰Sy"+v١  *33wiIx"~Tϗ [1H;6Lj*xF<>hw$bcP#0("`O1KrюX =vwтigݡBX\LޣίǰGڅD\G`OP剡vCwP C~fOm`kY[GPO?4흡%+%v›]>`ZAx<\P$v၄]#h y  }h'5;M|ZGCnZSC~vٰZ-~)v0}1F>P;bmj^/9Us@!P"+dЎ@nBCˀL=/Lb*o`]-qxkQƳ/ Fr&uzlNr8&o+. zqD {B_)?zԎw5s'U0UYv?: W"/"&2?Od'aZTōȰO{ T~PDaEֲ_12$s+l 9M2!ݯB-Lc'09bHuݴc@f'V]^ew64 j51vk狆4xc6<&l=ڑa7܊1y+;Hz+G3b4Q'؟E.qsoC0|rSf֙h;[>PK 񁈦q6}cW=M]Kuk2_{C?ʮ(+;'˘}+CCN@ ]([$%v?owNs8FZ  e860'D2-AT)|_j8x.MS&  I=VdTB/!A|E_TeqCZض[i;{^$OakuMp6;"xp1i)gl@!P#pPGw7oMxUCw-4I 9/i̊ \kj{漀Jhv yn?qOv;϶Pc棫n;A(47,`$qCG)8yB3O"&6 *P5oKEda>%هAvvg5,I GHiػpm{D7">QW" o =HܶPخD)|a6-iv']lS(5z9y[,|d;uLڼZXdCOٸؓ9<#M\yGmҟ!. ҰEkhs/ɧ1mhՏE ƕj3T ?P_l]Aj,^mv[(R5ԮB"ȂB%d@>K B( B#;8W|-o`_c%f@@Pzǡ}{aBԐzGX'Cios4my$DI!P@!P^ٻw_Άez.١D>^/YuM!t{,5+b?,c뵭c,ޯ]l87Gxk^E]GlWʱ( B(;dmo>浯}3X|rϧgd~^;…xG`|ŗTo]Y.ӄz{{C}9ޏ.z ޻}`'>4T ) B( @ب#;&׿A<}涩-Tl6틝O>%f@qNb~pj:{M{w>vp'7B]`'KbFP@!P6 o#!Gnq=Moz2Ћí1h!P@!P@!P@v4ːm ꫷q+%)/<>L}W9@!P@!P@!p _5E>9_W¿m?y_|Hxϻe}q}KD@!P@!P@!P@yxrS3;glc$S\|ۏ^//z+B( B( B(  jhîσw|t?ϝA.?1E>#Ey?A*ZL#Y7=QƵC3RKĹ;=pKF$' Ew=A,6Ė֫\5*v8zS+ES|y`-;;cw1Cےc9O3)qO#oz3$c[RW:>ycBO6RIաy`W t R<|8΢8$}3qXjuj"g_ aClPֿ~C?mXi}yZ攒͍//Z|5d輸e=ڭoZ7tV>nD"q/Їz3HuY<Ѫպ2:P#BMzG~- Ѧ4qADpү eCO2RA=uHy >zL6R֨-}>*`}DXcBרSb''v[:T*pm჌s|kF+bg$ C=fz[>,[]%hh/?!؁|/ ,HE/HxxS3CG/h+JG+Ԫ=oz0uJy0Z`y"B/PO4۳Gv<CZópiMmI! 'ti _Fy{K5~?)O =X>,Nh^N[Wc֡]䩱;C-f8W(w]w>_<';:.\ sA>K\fV1#\6}np S).z"A%}0`m9lҼ7Y+iහx%TB`x5 =X+#,"z3E|=TW1G!B%;wvnh }EOYr y "qs͠x/T^*.Ac? 9Z\x<{Cʵ-`M(VD_'mб^[Wx=Pi<2kx-oyeO[e"v~*_.Qeue",kp~EltS}ef?:L>Ou:uK᤺g;7+>aʘ1[z_M~Ҵv2emىsX_izϏ =?c~bV{n9v(&-b[Vv5gv؞1<IZ;9E}][yv+Y}pc6朾\d-6c΋ƭʞ7o[A>zؒ yD>qΧ6G)Oy_D Gcs ߊ矉N:hGqu.sN=Wxzt=,zaP̓M<9,;$Rg=K;T/ݺl:Ж֩{㗮[q?n|蔡f/#Mh$E}v>3_t;v\Q^ W+v}M쮡-W Dd?"튍R=e4TN=>z@Pԋ{ݗu72Q4X́gvy:ekD+NjNjol*z]9'ѷ&RJm=,1 ާKZ>^F談;b 7_nFmqMo`xг|еݽ_N ?/Nmooҩ1g7#Z$Qb~٣Z|f\gDKӖyyF0α=b:nݹKϣ[C=J_;ϯ!5%\^3$23~e'tȏh *#Jjqy뗶|˧mPr^.2-ǑvZ};O*~'-/W m=g'}/;4;#poq_qx?.3ږQ{kGnb,61!H>c׈`ӗO쟍j؂r>1c' %~,t|.n͟묏~6oy#뻆~^Â_yЫm㣜g:c#ҶW}$B[o}zXxA.?Гϸo?h$9|cSAN}3)qThO8YأxeGO(Ps&T6ڊ \a?%~# 9ס mmЏ :gY0!H5q)Lc9E㜕)iBv/c@ghyLXzȳ>i X5id 0!oAP/jýGߧn25axe -"&T3 |ts4Ҳ G k@^ }]X*ظr螮Z&1ԋ>GVO Lm4ޘF\MmAO40y}C}7ɳ?*b!i3?H<fGCؿBh.Zte#M `}qTC -Q$@w0 zk顋)B17cAl~Oqe{dIvsy"ozQYFXs[ύ)lemPvJtrc6Fy_s*6d(:M&/G . 6IńLcU0s '` Yil1囜ĸ0 }!8::L9}F[ bŸ'-5p0 3!4I114|2S05GC΀K#G#͖_"9k9AyQYl=lFtaLsG"qRWcUh[mʻao (ӁF 2~!ᅨqR'}=5v`Pwa(oK>{mmoa?_D:/zhޑvhi"l]o }yh#0}]v^w/:+ !bBtIDGl]~>(򐡐[o6y86i"* zdL 2nX= cUYp##lh7 N7[GHAm\C瓭J[&}i6ZqV)]Wnt_=o l3ac mekQPWMx0۰ 3}5LضSΝ"QgEB>Ciq)DG*Ұ$ll^*^>sAe+J9[]/7v)&X1n"mu=ۧUqw39SBVz}qgd(p fr"%!ykӺ;(LqzE>}slA9cg2Todl4.?|n ˏl`Vr@I?%< ; \8yy2g8΄dR n& oߜu{7'# <¢M GsL@9,-qiq%zQql1.pZ@WNp8%{|cC'p[RgXƄXїg? dI{g8KC̑"?o|?0x8>Os9_}zS~hxOI5ňyE[vy9H\KIG~rS#H6"L59ȱD֍N0/)Kc?#"i`ovԃ vEݸꓶɛ %~Sl(BB91xD"Q#M-YvHOJ97X2 L3>k}P?im^m:fmBd<Սm1&%[sH|U4"ՈkW#T3ގM~Ny| 6h7}ad/pE:='Gl;g?y/@Ӿݞ|!?`m^p?iA&|6SoU!d,NHǟDɁ p D%F4M%N8>" ,ɜ/1Zu_v>HOx'# DĤ#,g]É`exҨoIM VbuTc&IDs8TӤv F8I~3Ljғ?N9:bVS1!d[OrL21#&4Bd5vpM_sF80|:9d6>tӫrۑ~QY Q{ 'pl= Fam89r1:vcH}iS*9&-`]n<&1es8Hߋ nbgDj[$iŊGإ24qS9k)'pFGd;gfLG~`z‚AZٰg]r`,YJPV# }"9]"fF_6lN_LeY:h8nO1w:-^ϻ"b6O<5Śv_Yezlaq-'s-V6~<ø1zm#xҕIsâ7ֳgUf8n|=S}.k~[8)Ǒ=3u|6wyx`{N]/E,Jt@?\u-5ocXZ[~6e<狰tM!=P[ꓹꈈŖ>2?טs~H'┈3NklX X5qβ9o7|C# ᄏS.~rXiS A}' òh *mVLBMnS|IV␨D8S c b| Nk#Wq\AޟLZYpHI1I2F\*#m5̈́CG#bѓȧ6ɧwX1jt`*vˡܧSrxLꈏ lhe+sozo#,_?,kjam$eDG?װlfʦU3|iXfV 誹U?D֎%ӥna)fg, >=CDpC_w#$q45>BI%'~P⑯D6̓8 䯱S% lЬaLna{DfF uhw-.DbI禒qY-&3lFG-_e^挲>9y:.3ԜHp ћ"%ǧn' l<,Z!tǻ8[ķx5'p5/xuFSʫyM'(xG>mX~O ;'|~S<&Gx/҅bDi7zM2ƙl dTOF';2eJYst=AD$;Zysf9λqĤpB䓓z`djeO9?c36 }Մ"ٯ.D> '!01rc adǐDʑŽsMF@9,|_-}ġCL=@F~rM&S^#:N O-cGYپWD[yw0`+r|w'7ȱ5k*џD8S}0|"B&Vέ#tC[J>E?٣8@)2\1t)gN>?6r؉9a1l▒Oկ|c25ߊ\a8lԆȧc.Ř [bj".lg'5i1ϧ}?  y6Dxѣ #xz<+Z+KɧC"x^G̹s:1NځL!āP3#b^}8ԇs)?6_~ω:k|X֮q䫿PX}3p؅>[[J> -6o'bdL>rW]rpS䵑Vosj7<_Z|",|!mcƹl~\u/>YZ55a{"=ypm?c򙯔|=[F3\F 'C<_pNJt7&&1~m{ޅrb'e0rL &o#ά$(´aw=h8RWH810r&~WDfL u>8#HGk/[C>M'9Ȭ}GDne3%1sEċ_G>:9t1GsPk!$LJDLqH9q"[EfmCgOc 8Ψ>6b1i[ON 6њea¹X=Ġ\ Ph b֐OzRdJ{q٪U3*6|ZBbag?ڼ%Cf̕m! >x֐O9C͝?r7#}ufyalBiȻC>*M!WHBn7,M%z|cΩӂvZ0Ef٘" -ϧyXg%]nѱ̼E.fOu`N3}dqˢ¬dAx$ɛ{K;K 'mWvǎo <%V229>#6cΧՆJK+ B1+]<* 5gjC'( zj%nLiccɈplj]D;\קS?Òs8c! 2ioߊ:#'5cIª6-atm1XLaqzYrƘ\$>rimtZ䜍#H-O>!p̗L r`so1[4sv8oKh#B qvzŹ՚ᰪn i&':+R~ГG7 ,S&Ճ"}q[h:5ӝh_:L91beTVs]~pD%1.q*}WdLgX0!~LgvPd=O37a6&"ݭ6H[aGzH>`hCnZ,o\?ܼk BӈĖ,#ݒwKVf}D1\űU7%GUb퐗cL=vxSʑ9gjQژ׭;Lu+Hi 81oKrU7@8d!x=%8kdը #)xzQ1 &IU"E;9{@RLFK_=}#V}osc#'G;SY##@28 *2_6u8pF`Ƒ/rIᔷ:7`f㡑m"ڱ1ߚ|ysב"HXM$gGq?!:O &&:\7_4,ۤ6s>>7Q[ʤgtzd gUH[:=xGc7]I8_+XCTZ>ۘ0 tmb_.?8:ӗ7rXe=}pHo9nMS#f%WxK\/G6h*Xw Tv f c8hr=rӷnK,4[N׍Boc9:DdzQY0NeIXtI9H+zj֏WvoV612nIEi:ҷuFuYɢ=@^l6cbչƛ*%;F|=/BgJSE߈32k\5|[v{<24Diq^~!ocĘuLj>;8Kqlrt==7S>^v]Y[ss?GEN,b>7ͫvl5nJtFL sRO{;+bkGfvsYG}99!)1ad4eTyو0Ɔ08_1W~#$~D ˰s ^s #ПˀqB#PFtpD4uǡmhht#,L˙i>&;\Opi]8~I&=#`k˻#GDz8vvT%$jVa0>|D_9>F%f:]Iwj3Q3n#y4|zWoȉCLgR= [银dR<_b;1NwRdx[_Roc?#`GX>yM3$|>άni+J"17-B_z峸atͫl|P>3ID ķQ6jtgl&Eyƴ1+-Fo㾤'|ҕ'}qxX1'э6{rl_DWɸ6ɋIco1Jїl=R>'˅.9/P>pGX do)yḯL)"0׿<{galv>9jV7D3P-OƞSۗ?h̀S50 %gQUD_uDOF>>H#.u >De9 a_yug@؍] y*ODs; gL dQk'8>%e&ki֟t~5ʃE #vj{U[7BYI՛&/dhme"αʼy@870jcg%}n&n5aҾoEo,M:s3iOgQzr/E "Se:vBI?NjE1>ϗ~tc8S)O Fl`;84>_R愭wso8^nqvO]Gn|Nq֗Łew8ovy.9,uEQ'pcG8 Ǐ{#G " AV^]Ȫ>%$<$w߬<8͟(+X`aJ`qK7ϟrvkI?)>|iKuNtCۅ& C+ ">Pp> '&~\q63+z"q75Zs|X__D!~Ndh?e(_P?ZYlCW岓4D [Yz^ta#O _<.wzV4!ԿO&m{~s7a@(h/dgAYeC@eb˟0@meCj1΁]]LQ]baD![^S9s `}ߚ !Yr-|Z;3~ù!ӋV7׮<}N[[]"5}dVw[Q&]QoleN- i;n)guw sՑSVU,FOn 6Q=Zڠ=޶g}FkSvbW^/}7b;RƸ~X[l:Yvkl˧^:;l%ߎb#S?5s}]1ý>NET_ IO69AC󌭷s9 X7; 710|G߉\}T+a ~3bR!P,DD.Lkf4GG$g%&M(Jlo($Yss+!`y0/0'ESm{B<jCj "oHItaC6ngll{A_.Y3"`zYhngĨ\,7L'Fn6Qq+ھȪָˆBf "+՜BJlUUvjVfY \=GElJk{wm؆\.9 ȣ+ s=hPdD? +o&VvKNܧpn7jK-,&V yyPX7މ{7F3-BTAm[n]!+}KW!G6"׊,}%{G}G>WG.Ktۗ{+mݒ[evduY{rn_il/)>,zm'y 9#~9{*@!P@!P@!P`{Fpq19 \ss&\p7s5W0մB( B( B( )!o<~!3sv .?n$ c=]&||z+@!P@!P@!Plr?՛g1CW"4o)c}"[';϶:y `} |V6U * m|=n䕢'[hurjŒy7BsKֱr-0Y)F7&y-˹.<I _-IQ[rьsF6MOg Cko$_m ˯=Nxnw} ';c!`y=T-$쒋9aVX5IGW2-x ]# %~;6z0ԟYdUCr#GGʰ:{7zkUG9>rh_;N+"%L6Q+ڻwN6.m';|7W XsؙyMdq"Fij 'FΌX\T.A *8=Wmtd1o q"?|1n]#rȹq=Rvv2%Jd)'XVʶGDkSD])?h[eo{L3O|?[B8Earexlyw+5h}cc ܐY_#&+uTD.-3[UVExk<aANCbxXn߶%H8i"K)ZjmEY@'+9(ryւĪȶּɬ:zWo"s=4lO`ᾭ;y2rZDD%DK > ~-R0x>`_>EN"?l+bcM ?*09~<)#nU岗|p28*$,T57$U(oE&FwJBlq?ߔ"ZhrZ&jAA.d*{& y&+ɿt[e{y#w6W3W6Ilg5]>Yh!GRk6y؂W#,Ѣȧ#_,rurɟ#|87^}rWن}C '_<J%3ܾZt+ n=.04X;R&Nv-ߋpf%шFǸf'gVsa-HrVFmAĶle2inF#lqrn"n/l)V[E{+mI[vY],YD =l w~cd!6E%D{oV%/Dl9[woc!li$kkV#7 c`u)*$¹C}*nUm$!q=ӽ4s턣<穾霆_}.0TOt8>>iRn/2_{Ih#{Hd_տFD>YL~ORkw;oI8M־>רl햯ڞC_[8HjTW׶WuVgm_;k3F=|}B7k+66g/4'gkv#t6vǩEWX ^G̷K2; A/tVmYIrVs/:"/4~[Bvk\TKm%ПX4=Sw~5wc &1y6dyk7#/ SMaNϚԻݛuS,bĪp<|(l}gVHsWgPF-PO˃lhY^dN~ڏPNЛ#FF~u5yrT8{o+mzǜozϚHj1f\skPg[)fw NF|ˆjSWĄ.7D{7azqz8]h} ώHs&>=??`j8};b[" 69̏a7EvO' d}In. p#ԉ̵C{6ENbOoҴݘמqQF8~"5v ,9KaA+ Aw-z8?+dkOjϕGmpq4˙t\_oQ~6>,:b\k'Cfl3/Dv"؏?[=|k aFF-L% Ge-V:ȩc`JV(gU~T}g;uhR>'21{1]voVte|ŤG$sF' }}j򅮾7~#O'G|<>?)=3AR?OLacs"9`Cvh8\׼82E(yGƞUcLdk{ȷrz`#9tޘQkϗ8ok8[^|7>z#,Z;-{!5tfQgmkh~"O=c33K6Ww;Z6Fu4?A]Ĉrҷcr g}2=&Cb/}[ߦ $GGbgW19o]&dq:rl=*򫈺gM;GmLV%!pSlڽ)q'nr^ s1:q1FJ>+Y@3ɸpMz=N[9_H19Yz0#pʉr.}i5=1v:2N_6û9'ȡcJkUw"~( &GD-3g{yD`O3-Sl˔p$F6ic,zh“"}ߴki=hzb|8NgvgDpћ6N[!M}["]Kl ag1]cߌ#SCl~ؚ&2c|zM}mCu5ۦ'l"M8cbmYZp߭-!ʡ}2ǚkV͗k:ȦoNCQ~ yEAIWtyov/L!m{rW?`lw߈luC@ͣ-pȳvEac~a p0>o~qʏba1_lvoI"ti "- ڏ(O wqm6/;=e;l}Od_C,7X>6.9"኿^[0td~'?<#Ԫ@9>n+dq6EbteGXXȧ=NHάqOkx#cQcB$8NO,c1c$+! N/8ɃzîWw{V&WSܩ"ɀC"-d3Aki?8} pp SIï-q~O$A[qjzrtAF[/1%%~LIK?Fᨴ٧ʙA#KΓ~}Hft'a:;_2ſN6p|6?G?7lI~}wS|P5Nl o*q"#+:~H*D3LT0&m>l ة[gѩ-nOޙXkDqgRdf{)~)g[PaaЉ ƨ3_.ϝm퓱w Nȡ % ?sa7-138Zܔ7#Ɵfz'#-P?&ZOF{D[0͏ F|.xӇq{#}R+ N]m,Ñ]C6ڢy7sE ~#tF_SC[vN:3Nr^6'͎Ͷsk>^;"o*`.0`oae㋽/ ]$OB!o !&69sI&kF8v|7s&z=|52v+/lT_=L\cco8(F8 RNY:"&uLX#2a~8GL6DiO 8!%&~!cD~8Z&q2a>>0&;M8*ty Ⱦs9v;ّvi;]9E) k&ڢ9ƻI~uwc᜾,7|cʴ6!*Cc u Kd}%2[#}bG;etb#G׌60di~퓼ٖn8O>_Olpl5޾ak~rV{Ҧ#d-?=6qN~W٭5q~q9j[iQ1AQ;FU9'Rqy$8>% =";g{?_'tkؾoEG6H{}2W#l9L̋0`{^ieZ=:SvG;a獱S$v|ɎJpk[c{^J>ISs9L'$xRk`pG7Ef#GҭncQ# st%ljeb'7?Mfk9cf-*-T;/wWb8Њ/2\ql+A2I/0.KF1qWs &ƬO3Gj!#{V~kgH;{Va> [Dh4Q8&`FG2'vciA> (-|ZBM>.8taNS&c4v"X`֏s."EP:rOPb\e|s~''='=9OqGNpxAן8!.%g>rRY:S&fDfw"ԇC>Qj82CF"7>gGG8}j&AhdcYGyd8dQLt}HE8l~l\\sbmEU)Ň~"Am|ư:q U8a=t 9vqKe_zTdl9ԩOq_=9T4=M՟qA%liUsO oЗdhq3ڥ}p8F~iZ߳-/'/6@KH<F'sƉ͟9l&GPE~eYB槩7FHe;p=Y=~o= T]D)I%sږBvj.x@6Eԃhcn1OHOL%[0otQ#Gxz,T7gM4bU}>Y:m'X|X>ꉶSsֵ+T|3>~LFa =믺Fhd>'꬯:DV-2yE}|L0Sɤ Sa| 2q%dD|yM3ۛ|>fdJ#u&7z!GM`0||[a]s>2qkCY@DW q&UedoF3C>LlxNs8G*m-%뒗1el-lL9[K>z[11E[37)fw1lp@=Fy,D>O9qٻ#|cßl.lowyD{:Y/'Dn1Εٶ[ "\|ˑ#,RЎ{c\B>飹FږS?{DB|F2fyPdjhl`H bQȩǞ47v~? Df[8M%C^n lykbv>{;k._"6K~˞i1Ƌ,6/[ ϖ1W|1bܿk ?mog| S-oAn", 2yIx;y Ӗ[<\]Xٿ{7'ǏU #';ߡ=<ڶ%SXU]\42kEƤ3!wy G.0r&_sOy#T%M-²|sEZnVԖq|Z"wڰ%s\#`%0|Y҄41&gb }kdM0BaJᖒ϶aҚ-%o21pp8mo[Oz|rȵq>HsM֋%ןk#8MO::g#8[cįN^_ AMu|VD]")DӲ>rPM=ެ,4v|“-G(Ց--qg3YCaS;I2sc8Tq豾zr-$<"΁^-W)GkVzj0Fo=#'猍/,q^=֒O+D+an%Y`l+m"Dnp@@{ǯEEM[C>#NSN9첨Ȭseǹxn{tyd0JȞc[(q%T't*r4Zl#4T޷#mvG>kgFྐC5䓯EwnnhTOO, OSdޛos6iikBG, |ŤŒ>)Ę|gk.3 SYiߘ՞q⛈Y㈈쒧܆d>Q=?Ozye%f-Dn]SMrO3_K)[WJ]4׈hTVG+|z8Jb A^83!V(LʞpnI"HH8#x)H[SKȪԪUQq؏M}1,DD{PH~meB-Eɱ."b\seVl2*&OE]Iy}W!/uc˩\\}"S I쮜ޚHV'N߬7 H~sp1wϪ|qQq5 }00&g%qMZ\Y3\pJ$ޒ zsxY7o ޒvi0>^X/}|K쓺WAĭ;F)#ȡmmql89=6E=zҘϿKj8k*#VdK]*!,#Sb0^SNSA}mI2XMXƲYyp9޽cdY18 wc/6O 2!k#M ں.!R:!']AVG8kqz=7r~>iլ%;vruכ e$AS}tGV>1'di:%be8 Y|;WM!G⿷DԕNHF y" GN7a8 &#mw*qLdFVG9mпߌx%h+%N_SL`W'sԝ&Rְf{-k;3s]d_41%Drhe\rY{>JsܛMDdQ\yۺL Dg6k']ENo?h}E 7oX,fFbbkmyoOF{ά6{KGM쇱/rH9~|1y}UDmN|(?;Ȇi:H_54_v`_oP'?uK?? i+"Wl[ħ'>lmu(o^ݭ' 5"1O[Y91L%%s96s[_Yh) &^78 -Tza0AGőY;ƒ׷|cEr"WKmp껺; eCW R[}>]U7,YQqi|oX{e8_{BEj8)'s+o|o΅)9It]\ hUq.,&Uvmahe? "#ώ4_jq1UoH8 ʾFme)!GQ]:!iXAb-}؄e'-]9_`KWEGZΪ[d}uk5i(o.>"BKCg0ЕGoK-ُO%{`ô8!=0΍D,{\[89y {3ږ&X{tDHBo[6\}e0a3YڨOdK?':rt}b{?-Ȗ>rs|bۖ^O0oѹqb vAXivȂlR<-}̻='9^λ7aOeNb&yM*cs"`Rxd jDZ]Gy-GE{BЮ_FD*@!H}׮֩ݮ Dp-YR6so-/X!Xy ö[!Mf@!P,Q ߧiJ%kӶD]N+ B`#`zgQݮ5̓Ξ{^XziJkv%-pFc b-ɆT B(WGGlwJ#.wKhߓ"V* B`# x=u7|#< om?޾I!{nDu,|'۵}+V] w>ųnUv!PY~UgDT<h%퐱M'_#+@!.Wz|тMCH^&wHB< |+r3^%zλlZU @!P@!P@!P[{yNW|nsP.!yElaė @'OG:Jt|t5J* B( B( B`!@ٞ}W3r'o@ dyST*UO9?JCnHHT@!P@!P@!P,OM3S?2r!1T]nHߔ³90W'yUh!P@!P@!P!՘{G~fmzׯnse0D?f;.Oč|'=vݳUp!P@!P@!P]=\mo0|KɦO3'7ڎ!',T B( B( BX!ͿHppvN 4.7H{Ɯ\K J^4= srlaZ:( B( B( B`k8vpoxGs'Lx֔ï07bËLOMywᕬ B( B( BIHJ!{{Q p pݜwN=ﲁf=qHWT4Nyo]6@!P@!P@!L@q]GL=Vg )]HCT/LÇ5W' cv-X)9Yv @!P@!P@!t8[8>!7$W,ẆJ]6ZF6[TO|4rwoUB( B( B(cYz>'.뀠'*OOC j^#r ew^մ( B( B(v¿6Ǿ=N]uC3ܺB'.C;ղot5( B( B( D< < v ~+); mֈ4iA-;C'oy˟qo*B( B( B( zB>+9_!C!GŅ, Iԩ\KN/CVEϣ}*UB( B( B)k+H?!F"( ew?* uW)S^ ߮@!P@!PvFtfx~ÛE#-ɻ* {ՊM!P@!P@!PK1sOë᚝X{wI~ (4&@=%n\@!P@!PD/:.)9:ˎx">K@ ,!ڃZr@/wZ@!P@!P@!#M"G wz{a[$m Z㺝< hx|6>{s_@!P@!P;-:{ʗK>u'iw鰋3nyi0V23$ M=Ƀrޑ-ʳ/ B( B( B`!pDž3}_.qϮҐs!=zޕV'rU_9ɜu'bty.., B( B( B`!𲗽\L|?[mOMyC@p,fn&t|0 :RNg{YP@!P@!PY@oxWqnY'+-3-! iSw>kՠJ/ B( B( B`!{9u[mmt~>\y' MSe_WW΅@!P@!P@!P5lUέB4ϳYU- B( B( B`ApLōp&psί# ?Z`u" yjO5ftaX@!P@!PrG O=GHC&IԎlnKz=sߖ{wxC*7{;@1|1ޡ*( B( B(!g͵ms۬WJ s߾~]׵۰*;OV! }qI:yR{Fw@!P@!P@!ټr"Gpx %tBt}/W;=7&[d /QPDFo\OvڡT@!P@!P6@pF~̺Q.?t/~3__3{t{|x .:<鸀_d̖_@!P@!P@!#H$9nY}c}eطgopl{SpIaFn}Y@!P@!P<7ljj>*ópNy_-gl.*{t#8a !l-, B( B( 3@xU[^"SQ6r@/rD;@~qöPt[;E`- B( B( B` p37_9|s[>rsBX/TڱbFڐT~)>D9g4睚koV,0հB( B( BX6x2m Sg}jN^E<ܖO˦˽G$ sO ZV{_p_@!P@!Pۆcqڶ]q[,K./ڿHBPO!Y!eA!O2r!P@!P@!HoHc/'z΁x6ߘ}@<RyAE@yz+R@P~ju!P@!P@!P,G_&<^ }-,Ҷ߄6W\m^QuNgS"_󀡩'CY5@@ _D~]zEQ) B( B( %[@>+RD&"7K{GZP@!P@!PKO lx#whm'oS֥ҖtyɄߙ;Nt!D-=(s>y@ T( B( B(&{nKlDϧ9նGݹ-QylG.wLF8{%z#ϮycTօ@!P@!PN@$kC:"y1&ڊ$_5."EOrɼF:Eo:EA4rym˥@!P@!P@ pm[` rݘ*њŢ!O'>/ĨYu|EzѢ! B( B( \xC>pDLss9;^JAV(<լB( B( BXxE} >^qd{Bxcƿ,:e#j:~t"yNnER?%~]zP/ B( B( # NK>wOKW;[Or/rBZ(ŗZg.{{'tm:QD9{'( B@bj@!P@!P@!PDmo{y..^X;$f*my/b":QEimB,u/hyL;)B( B( B`E#_oh4\vٶ?>y}EU[(ӕC.m'gPF-+h.( B( B( {yμ>ώOO}Soʱ?moR OصvK. Y8b #Ϊpc9TJ~W@!P@!P|;e'~>^(҉tv\ TYDo{ۆ'?D> =v6DB?yV2rxM( @>o/R!8SOտ.]:gܓy·_7;Om|DLm W8"!<7֩IH|~(_^2+ڶ뎏<^nϿ^{N i5( B` 0lGviiۊ}T>;џG{6sU" 킀(g/L|GWHP@Sg"'暟CY|Uvte )~G^﷛g=ZQ۲sG^WVSɸ; UK B8Q-#o y8jM3@'te\_l|0>$Lndk|6^eQي{aud(O ]V\lncl \8@!Pk@$Y22K$a=y\ͯ(90Ȣw;w'oUG_ODʻNyov|<[6D9xn{N0}r_aX-90X!^2oOja(Q]ԗ@!PlGB .A$V1>๗esw]np]ןe]n|@ ntmz׻ܭnu'>G;oB>=`֞ղ.ş_}lˑYoE:rzBixvFVmWƅ(ޅ=H(obR"nVna \hG/Zh@!P En!m+q13o{ oxܝ|5k]*Wծ6wk\d`p_}3Wg<spo~D.ߍ<+rDϽt-'مqy#_3kE;|u6=HH'<۳w!0}ʶ G!Okz5K/*i!_ 3 - B( @5B2[L91=1Lyk ->7u3wk]kEC9dIgtħŶUD*b->ƟHo~eʧ>`s;NL+?Řف*ȵ䯈b~=[p+L/ieehӊzs䓑%ì:kTg@!P#qDŞ/omy(g>󙹧>sm7o%RmO>mqFЛ&K-u$Tijaxg5yܡnzAWwG;6RʦئxZm݊kR= h1}j݉G俯E-B۴+wxF/Ar MfXai60ƟkZ6ޜsr_D>wJo;U`!PE D!$ ?ߢPڌ?l-nqVܺth{ YsޱZt7OO4׼4Wʅl*pfֿz8r?i|['m[NK^Lm&kB+J1/"!77=m-=`jӮU b wzmxpd+F!P@!X5l<';+_ʹ;St)O~7?STyKRȧ~DҋՇ:OV W>?Kq>t;zn'_lE;_|Rs{wp"ੵ`76U" mjV$?n&#ߓ19} ߿ƞ(T@!PKKϷurpf"/zwC>;ߑ ߖOK"E7{Xt=;C…-^W 2c-+\.ё'VexJB;m[n{Rxi9~rCȱD.*KBF| V@!P6d!1[xf|QGͽ={8wӛ(h?%i|繗s?=v`m|I.ZqjXoW/|f>/Es^3|?{!>)_Tk 4mjjy]a/ʼXdp^0½@yfɾq[iy.vŧQ׉KC|DSsw\'rzRמ_!P>Ы,E3yN~9mS|@ғosmEnl*T-9+ca[po2eٖa'mUX6- m^7<[~01~/F5ᧉVw׃xonk^HO:C6;&3MJٟK^/"t _,V4!z`e=7݌G~€֖EE B-I{9o{n{Yid3QS.rLIaP:P:P:~t.Ѻ?^=womS[׮]-Bo~׾5O2rD1vp?yWY~ڔo^ds[J~/.#}0ʈuV`PHBO󖷼ܣw"[?9ɖ?մtcmxܖq v[UN)vs-m^YI腖/^u)v:6h[E+:CU6%rHE)^eji5<[ °tt`[p3MCVpvG<ɧױ*y_}wk^o}[[t)2_jsܭ3-*[:`~H{vH{2۲^UwE<.l. *Y gP< 翯wb<0#f;CAxLۖίɮttt`(-6GmPA7}<Ss{@. E`x_e;.EDGxv&Μs@>F?בD>rC??o[eYDST3or8mJ8Y|yyn\1rP:1zC%F;|z QA>d(Ӭ\+[iC@EE6_Ar;id9Q-IsܡB3[k\qpm 6."O}gEgD72\%=>gHB( Ƹ\,J]bPnkA14G1ᑧEבWR$:uԾ.n1hsĖsmذa!y܍nthR$"OO} _8E߹N;mPg>!Sf?5?-z)IOe<{zl9ur!Pg6K{w?{>K ҁҁҁL&! ndϐyĉ֎=qmO]jE;kv{ް)M#O\Ǵ-5՟u=Lzuy!P@!PC 9B5>#Y{s_җַ>!>K =0?|n;`οS0SUR!P@!P@!P+>0|?̐P|s{~oނk{Y:NO-nݒ M!oMOp}5( B( B(B"f!W{E~~f([v܍o|T};q/~"ɋIxlC<8/{tMY@!P@!PB $"){jַC;6\O}=牲^ł (hx*[9GZ, |(#@!P@!P@!p"0lýo>?'} _|ozn{A-ꉶ?򑏜k&6t)y5!7 ; . B( B( B`"0<~ŒY};ߙ{ի^5w{k3t/f{ӟ?~QM<1\pղB( B( B(/sq7JNlpUme}ы^ΓN:iQÖRϏ޹`Ub(bU( B( B(vB.Hȩbr3No;|d}'"-)ozӛϥދnuXU炿9zZY@!P@!PC !fMd𭞆(F7DS>n8n- um"~vaT{ߗUB( B( B(v>v BBgvCټ5+P-݆۶ٺ7ܺu6?aigRD~jq!P@!P@!PK0v}Pz^{5nm~B{A{()bz[j}׿9O]LJGoʹ6%lUB( B( Bعq;Om=qog>s-7˩@[t;wcy]LJyPf!P@!P@!PpCv 9m1Dp?sznwm&7 xc瓞O}SsU\utgͶ( B( B( e@yO9ۇ3E1'?|~"Vs/x կΉ.&>G2]@!P@!P@!#p'_3DCBN^ 9:稣|OhOÑz( B( B( B` OyHBN],Swmܸq@Їνo;#7>Dcox@!P@!P@!P=!]>7%zm~IyߊF.8gL!P@!P@!P G jT4nÈ:r|>4¡@!P@!P@!P4B2xw|~!-m$O!6ۿ( B( B( B ! 7$qqGY$M=N:餫wBxɅ@!P@!P@!P(5C_2EBbOH><2rB( B( B( B8ŋFx`>~"*x B( B( B( ?CpO&*x B( B( B( E#~< 6\O?K9ޑ;Ts։@!P@!P@!P=!}z9l}^;Ko B( B( B(!m |yH =1?\Le^@!P@!P@!P(%C<|)- B( B( B(v gO1YYIh䝑k/V B( BX$yD<<A.F>9fpηȲ괕 #lfj `-tT D, =lqB( B(5V7Eppt_GN ?ё"WtdղF`+o{D=╃.]wg!`m#_XY6ErlLչ( B( [DZGn;|r:ȧ"yGdg&ME'D+ B,B)mGޘJ2< .Su. B( B!=#/\t>9qX*3ϝkNR4[5'F.Q?`ڸYW./r#/?J@!P@!Pu%g#F+"!p"m2b5#Wڊkr|TduFD2l9~Ů:K~e?m&mKZ[=A[i}fE5&`mVҶ>/Rmiѫy5σ;sQeYlu^!P@!PKDi_otiimaYOpOyD9ctrp#rcg]Io8CDU~bG2Q&u2c#ޡ41΃8|7b+"iچkHcFy"Pm{wx01NρϏP>?2El5ȿ?qwچщEq͋> --S}_?#oq=K]``yhmK|ljCV)P1q|WG@lcIDyNϨ^0a^ehtGc9,Tp8WdpCkù0rodgpܓ^٨]a'oa#O'rVa ʵhyRf h 5#DooySʰ;cK}1n+BH[ı@Q_T,^ڏV] GqOSSzYu( B( HDA.E8u"'%dɑ9OT}fӈHp7D.0d"Q-!o *Ӽ;EA{#-8g!*ZIM®?,2o4bѢ̉ +șgHaKȬ}=+h r+Rd|=,D _H(LLDE L'%V[FdW$Ctg #}$HPAA7>SQR R|ȯ""A'h\ K%$zNߑΖ/pTiBG~㉮8эE܃("N-HʅW[}!ډY0Y=|{h F089}Ƌ^9G$WOO-qyQֺyQa!LvVVC4x:J@!P@!Px8# acQ[8pRΟ(Tֵ !|#HTQvp\}lmm-AxD8 3<yĤK7#"n"SD/98̊uWDuNGAZ("-7$}ɗ"AK ""BȼaB(PO}ϡ!!?GGD,$Hk4 }. !uH"X4 [ vĂGɧVȺQDYiz5}T>B1ivmVk"MpDZhҒ G"S=9m"tZht[a㢩Ɩ0[/Xt@dKD[DŽQ9-=$$‚z6]c5vbRQA"Ebk ø={OyBE??5tV* B( B`#pôqyndءspx鷠\qp[s};(Rh+!2%""ACvE|hf "Epܧ^l9D̎:ɉGXQFBx}C,&hwc/ lVTZ$Bx !?t%cdQt(UCQdHlI4 &߈X@hɷ(>3Bע70&BBߍ @$MBѷNB2uMf%Q7EԭɹU8"ߵE=E> !O>R(oU.3`1ˢ 2#q >Cul2 'zk-Xآ"Ϛ({!h#baajqʘOeBO,>J@!P@!P<2q!#sO J3q 8N͗8:<:Ξ<K?DDR29εNgVBv!簫b6E$\K}d~H"(DTQqk[(/d"Hd5Η\\ɣOGAm%cujz_#hKc' g].P72?- k#ڈ|$C#yEVf%iv2DMCوEN[E [ޢto.J!j v1a'u h4E>?mC Q@$BTpwIDsdo: B$ccmeފ:](}N`D:YRc}RnP!!P@!P+D8Էsh\9?m_F~9xOte$RqK䓃l/O9p˱=9"WA]?ߖU_P.=iOF)HjmBX%2Ęo!O^#F.mulȌ"q.R{3sf[$A.Aa/hDH# W(^EڶԾE6d%;1:8WhɂrDz8$*PȩõMuXH?2ID"HXa`||,!6y^tLx#ʎ8UҟHh=G}DFխ :AL$jQ೑ù1䓞p;ӓ묝}9( B( |p8Oc"%2!,C%"7_4f\'J" yBl7ES#YS FGv{cF}_6 g%;;#"SSv"2j"r9w5qVrޢđs$qolيwB$j R.p{{\~ut1T})2w'ӳ!© =ڠn3#Qg-/]<1cfD鐨)65_2-rymzn=]"p<# }љ>q)G]v[i#H"=e@4r|D=:? FZ`0%veGBa"PB pǤs)]/Ŧ7H럻Vbua+.Kwv5/> @yLr|H*ߜzsD.FWC\$d2' n tI^}dO8#0vVj'Y3:.o[tXA躺cҳ3)DDC3bk'aD8qȄF):F$u*qg.wH]ETA8("#º>±~CDCs!/z1%$ѕ/D>ٝϬ/PY _ABslYu OZWaC 4|& 27" ':Kz]^ 9GGl^ 95"Z뺱",G`2DڌTX3GCe v~@ w#9C#ƨH]"t zg[ԉa]f<"1`Q^Pۚ=GYKd,M.6ݹDU7'7 ~C=@\3( B( 僀mr"rZkDἵ|&2EE4sWGmxȷpqE+g%##-ҟ'sĺE9@2"ç:;!4-pX9$? pQ[9}}oDwB);RaAx8׌H~uO_h#Tã"'G~ەLʯ'T}"mtdsRѱ"}J _IQY t~G.6\StF]eFщF8K2׷MPN>/}`p' <$'oD)Aw Fv-@_EGWk"-i#؃D9=3#V>]CmG`W 皈r>is`}~#x;X2Xdlê]o''ȧ1ˤ> B( BXpy~D4ٓ|2ysShm SEܮZXNS[ѐ%N8Q2VO[v\9Ew8|BdHKO0Q,N_>q9͢86sWD8G ]@ALDpV!%h}Z{y&GeFx_?,{Qq%%6]`8W"4[=O`ʏF,",ۆ.6{mdl^Im]w-/#ƁEn/lnȗxToe4[<т%8Z4J`oXǘ]i0DŽwF1["2jA|@!P@!P "m>8"$;)r##bʡT,UlAɵеғ [nY +j_!P@!P6@@TjrxmTkrv#SETElmT,Ulc|Rnk~kw(|[zDui!P@!PJG.>b;bs[vޟF9ھJv- m"Em\iVhەC,yPKmT@!P@!Plc#qhB`)!~[y EDݫڈRC<=Ƨ{Pْ{|캮( B( B`"pK$҃~8Ӷ A6:qWE=lrKU[oՋRB`"^c3"wJ|zL?FoT;U@!P@!P@!P@!P@!P@!P@!P@!P@!P@!P@!P@!P@!P@!P@!P@!P,'<=#sbyw :rjN^W}w+]5rوc+5IںRpv7'\y+9|+r-ɮ$l,KT f9=ږ|mtnUGD>: @!P@!pfp#o~Ǎ+LuCC^2uv224<3^]#aWA; #jzB*_EvVU@!PKk*S}cG 2ɣ]s|"{u=86~X:g5J7k} m K z(qќry62+^Â4i]zldgǺ,y8Aϰ2}{ud(ұw׺'k#i|s7N~H[|@O4ғeSDAd}jw )5|u`JCʒ1k潃4r7+/owu1`njx[ύB+G蠾?Y0^iiŇrHaL<;evC~5`̐RszÇ>6lVo'v8-DF8u( B(  \)EPD08K>ǐq^AhDOE88I)r$rxKOɗwGDZ~ α diKz+!n/D8ui#B|W}" D\DkāFDԅvP1׋pJ9ܰRVƁ0UF850 νĹ3#|Nv}" 8HD ц!b{E828cJ;#}]o쵓&-l#doWl:#'⤍ЫnK/9wR>-X8@Ɣ"-muG"GZ2Af%]jC Ik`@ȗn!WAE.ƲqDZB _"]xZ=m .4Bἦ<ɳ#뮙jɢ!/DtNGy M,:~D ^7kk\!BNG[a~0h'ݱBSF-$_;5v f^ph qGFjE6]u"#>dIJ?lNWu+2鋄=bY;k>T@!Pp[eGp08V}B88TO1NӞAJ$O(+r?=G8"Hc\vj٦؁ݘcv ]t-ԧ1q9i{O$WD "mLM>=ɔ} '/.!H(p,&HAGL>5?8H#r G_*]>"]{Do׮ 1hxk'y:̗=q9}ZgVB/>9<:bțpEZk ]Ďm"ƀEmu R#+Z1̐>dwXp]G"C?o`\>SG$_2M Gmp$fqn 1D:\wz̆}|?1ňŎFM@آ>;X O}h~G֍f}I}n1>>2{rzd9u1)?X`@B }#_tO>lmjZnV-YAo\lCy^F3_ەQ_ B( B+эNpYt!'CeC \׸v|Us1…(pԜN"jpH89'~sRS7/#s?OD.$]#aC9(Ot5Ň?Rxp!R Ku?sE5Ѷm~FT9q|!qP9X@ԕs+Gvp0 f\h l˸> ʐwIA%G~wNt# ? #Nי޵k8_ H#{GZ)GD7AARG/D EDB:noX4PJ>-/}8}.Hd"]ExD$ xbu|/oSV>,~:_M?Cut]әEu ˶ OSOu_% ߊ c XgiDz|rYc~Hq66ƔE޲ߋ B( BX4@Q)FR2@pZAN8-Q DFRYIr8qvqlIsEpV0F4;GwKӻrDZ9E"H|L><cm O|;5I;"`]_(@􋃿?b[dOGˌs$?FٺHO#g6Rq!0*789f(wV)B0y/ح]#S9nYji|CKa%!p{׉zt9GljV?~O:q>Fgvx34]F#l#wU^oEEA+@!P@!h8WVE3ljc֢~VÑoFO%$gT8n/ 9-(GQs,ihq38+?8-}WKG##""ؖHDyF )nsIy$ $o+CDDF@;#آ^2E9'}؋"|&yLql4_;$5yh`#}B,]dy>/#=6UQnHV: tG% *ߔI~AFq}bɚCn'L^tSM_6'lnXXE09F- ! Og QxеO{"L utΜێڈ <`K5|-.(0yKXҾ>8UORόЋ~73^.9?=ȣ2EӵcWd"@סB( BG(Q8#6iq?AtVEiDIX!9 ŚFp0q9 !`#q|N]3 #Xi/GG&CEο\D9"_Wƣ&2Dqra-yG,C_ykD;ZH?[xD9iQ^'OY` 7L-\,E#'? a}NUO蓨pOsmlI=wdBiIӈEcO}j,#00ʛM89rDbh]H;b۝tP>E{k21{D$/}ғ^R4[?}u'ʵlFWGƭhg]H6Ds|94Q=[ctOهN4@!P@!qdH {0Dˑ@30!E-!"M#"4☭7ݪWuL⩗HOC"cG5 o*g1jD}y[|G^~sXg? 'NÚ)cD##--D`F~)Q9'23&ؽ 7,c>H+ZHS"OyXXP>KEOXXLr6|3$[)۹#MW6Fš޷yd.8|'[r}~u{Gk}rC7< lc5 % E,G8Os\oˆ{I!-yX@k=[LgKʺ{8p4&ȹp`'9_^<"!XXgW3N-hƌI-=xC#ȱ)GYB( BY|{pVzL'*"ҶC:(;Cdl;!]]tۧǩ|xzZdz8,!b's#"4u{-w2ı}W8x{y䒣">Ř y"HƞC4U _KH{ΥzBRڧqTd|OE},yU >6z\Dg 8:OWu'[ Ayc:Bߐ;H|Mq}C__p8*D4^5GD}DƂqނLE-7Wâ:q(~<<#\JOe.!?NES+k{aȓ pxPBW}qehWXc؊>*x5,7i1.룶pSllu XF5v/?%QLQJn6>5I씅v^9pzkbץ"w >[7 o_( B( I"\?pp8 ?'g)4k#pV9_;"o\u8c8U"UDIq/0p8`LdRYkg#3p [}'t5ǽj먊gq`䔡9Pr=©YdpŽS6׈D°']yEdcD CbtpdL7Glͳ0 3у6 3ڧ7NFyoCĈ/nO7К]g6?, }XQ?EĖ#b4BblvUȍÝK0A ~8b8΁Gy<&1MwD- B QW&Be8[ l̆rhSoW|YIO'-cY(>f[.c٨klnY`9$};Ni}~l*{A-Y(xsΣ%>ZXXPvQϛ"4Y:ylyۣ/ES5NqmmO.iva":T@!P;;TpD/8,Ċq5r9v>*||(?yJ&ߜ>7'}Ed#kGyی-"Y azz6G԰kpaȳvM[ X6>蟇?vɁݚ.?G.f%DI[ə$rџ!B8R YFA}OzĪ|>9ЈqI'9N`?6CH"xLˠ>E7F/wҬ['dL_^f8R(bihDΌ5}5F-挓Q S:)崼jSy_cu} ʛZR!P@!P"8mp* H(%ҎC?5\DE6D, |W%[h"Օ B( Bi1zɈ H-D)R'\"FWKGlUXDmgN"/ D( B( ch{Խ>P!pV#`{#/*>݇XQ;=)1bTr{*3'[fmGvok~gƤ^@!P;zp["ϊ<,j'âpO-D^yqOK+vTыj|+菍-=笫-ك{Ʋ\{[YP"-}ӀIENDB`Dd #$H  t A, Object 2These types of complaints are all related to the timeliness of our actions related to coverage decisions and appeals. The process of asking for a coverage decision and making appeals is explained in sections 4-9 of this chapter. If you are asking for a decision or making an appeal, you use that process, not the complaint process. However, if you have already asked for a coverage decision or made an appeal, and you think that our plan is not responding quickly enough, you can also make a complaint about our slowness. Here are examples: If you have asked our plan to give you a "fast response" for a coverage decision or appeal, and we have saiid we will not, you can make a complaint. If you believe our plan is not meeting the deadlines for giving you a coverage decision or an answer to an appeal you have made, you can make a complaint. When a coverage decision we made is reviewed an our plan is told that we must cover or reimburse you for certain medical services, there are deadlines that apply. If you think we are not meeting these deadlines, you can make a complaint. When our plan does not give you a decision on time, we are required to forward your case to the Independent Review Organization. If we do not do that within the required deadline, ou can make a complaint.3"`PK!^[Content_Types].xmlAN0EH] tA*ٓj2<&i˂E,-ZQy*@2:k}*da< us}UmYdCJAk6N8Af=UYi)!"-^@t+ S6ƕoQ9JBLVM\sUysnJ7U|Il2\PU&<.~[m'E;Vx PK!8! _rels/.relsj0 }qN/k؊c[F232zQLZ%R6zPT]( LJ[ۑ̱j,Z˫fLV:*f"N.]m@= 7LuP[i?T;GI4Ew=}3b9`5YCƵkρؖ9#ۄo~e?zrPK!- \drs/e2oDoc.xml\ksۺޙ ?5QعIngc$= $mVqĦ`8X{ e=ORd:Vr4O2TQ,'ie%8:ß~DKTAԣU:fƤ3ĜS ‰lze|hV*LBk|+ >X?'- Kt3gfϳht^ -nS8 ]sIZTeI'A*ދ7>~8q#I|;JIoDun)!x^c882?<2?<2?<2{W@C+`GF##TS3r3c)cd[ z!73=LMXi]W e4L0E--t=E-L9EKv䭤 _ov=T8S"tdx b{ VϞz%.*B:VD%J:R*i~τtߜ8yd\!VXLSr͹Ś8 H;'ChfΟOؽZܶ^@zg YھCuX9ӭ9[Qfoj%`>X|ƗgܓZZp`M-;IH *IQߋ8K"ә%ZyAt0~Ʈ:Q+ZOo k}I#6E ۗS\jLsX?V85&`/[_sAN(&hmEPwf7e3|\n0\gf0|fz>jj{6 _p+yvՓR/!nGr!nnҽGҌW>3WZnk)R:Y^G惻Q|?AW-yd۞`ڋN~W_ܨq,%ַUUםI%P^9`c "[S^k󍮹KԂ#_Y9& 𢺦!1̑D0fH" !Co43ӲNNg{ eHZzbeIWm O tY2dޞ1Ыٕ5W vN dܚ7 ՚+j]PO> K=|fܤ҈֩7#>NvWޥۻiw >0.\O^SQϦڋuvtaV.XQs:xWAzcF1.g5#/8PpnmNIw2ETKWdOyiMgRZ2.#oګe ,)9v΃jF{2e1ek,.(H)EawTETZ`Бq#.9iXGf bC%Lj,0?F[3 / /qw >y[BћAֵ}`L;Y!AHi4Y9,+CW&ۢ vJOT72 tyv plT]z(R4Sl@(hėJ;N!:bEZd/"g>".Z.}K6Q2]Ktޗ+1.aze )̈ mzdFwInA1O?Q{p PK![(drs/downrev.xmlLAK@aݴPc6EAŃFQMcm xÛ jG! g(۞[O'+P1![.A%1 :T´[Q H-sYNoPK-!^[Content_Types].xmlPK-!8! ,_rels/.relsPK-!- \+drs/e2oDoc.xmlPK-![(drs/downrev.xmlPKbw69V œbvƝ nv69V œbPNG  IHDRkOsRGBgAMA a cHRMz&u0`:pQ< pHYs&?yIDATx^ר(5a (.{ǂ]A *ؐb/b "[wn<9sΙkf/B  ^{"OsL6+@ ٲfq_gaL2~ԩ-BScy"ρ@ @ P.h֫jz+r>}ϫ%w)KyWNd^<+yX&}(.E9I@ v_ME^,yM2F}#A2I+" $0hw:ڱI{ټt>_~zo "@ @{C`ʐo콒Dt +p _AFpe%r饗z n Þd ػ}&Nn|JRXlz7@ \x!^F|>#}g%{M7n-R߿[o BBBBڍMps;D0d Kٳ,Q@ ]ɐ2txTK ;|8p`+˿pC8@ hh4zaDnGce~{ᩧJ^P+ڟ9@ @{_} A[)۞\΢Ley @ :wl>HFM7p}Yژ+[@ =zmaѣG}>2˞\e7?fUfo|_L @ AW929AeK{imG>@ >[fmy cƌYp@ <>Kث0ϫdOgD2@ hmDd+U~)>'B @ F`„ ;poĆ7tAn;G @ hu Z$‹[@ @Vwi"@ Z ~aH^aTJGu~3hBZ`ntꢋ.j1[ˊw߽c5K:i P An;G@ hujܲWxfz5\s<«Z`_|Qٳgaw[^U?N:n֪x .l:8S'h/f}{hzg o!C4yu+lMag,O*>B Zmu&2@ r;3930CBvge';+r_~o?2eʔ¤I@'O!L:Q{h{:ꫯc90~u[4BWnr-WY6b{(|L+#^|biVuw-bL0rx9 ?~:*֖In[^xB -TuY4ފ߷cPIV@ێQE@ ZZ$>r!ɬNVN>d!x.vam0nܸP&V Py;&.yuqϹ[K?SIo'ß_/Q2cfoMgn=X0`@^{#8"y?^sY %m7?{',%ĉ {l)|?8pm38#YZ*o,&-{w'H !T7?fСCs\Krߔ.º+6QL?P`zzwYg%f2q峀~N|F*߿p'X~#Gc ׻wꫯ^o0egO&qW=cOrQ>!h An[ݥ @ ttj.EA~ .0s&1$wV+@=ܳY_f{B>} K/4hLD.駟.@>+u]H&l2ktIfa!8~ k{f})Jn2 tP@^;wWF1#2S'zmIkcҀC9f̘mݖoʻV[%ro1K eC=.tC qZ7%~Ud-8wy'! ]曯n%X=3~+ z*W^1J|deUݮZKݵ6y5<`?z8-~sr3wqVJrۉ` +݆`Xq2vkǤ.I)oVgqr=( @#P'XTUNRv xAp_% f W?Aw;쐐ir=JrORJA,j-Ti ̤A>!7|s:TnY2b o~aEIJ*33L!!Yo=媤>ÓYM~uD9 ZkN;T_Z/> 'I}` St$/ 7ܰЭ[<⊅^zW[0bP Wey-ŵq ҥKk9Sټ%vevѾ.P(imu&2@ Er Yl y^|35bki̎2Ĭ/~%;Q!3L$11#,.]7޸Ivil'|2q!#$’7@&@xEw!Ŗ%3ꪫ&m1KYm)7ėxXbd/y#bک(,e)#'A_~1f%ys9']DB}`֗%$}H"0SNL[L2S;k,f):KafV;℘`/e?t (̼kG,fL7R63ne<Rn8hX@lMA!bOigQꌁH0KYT, 1π:B#"䶣{TQ@ VG-^  0 $gɵ8fgq![ j̺1ۃc'ν;'s/{1D2k6|Pc9d˜oܲ,e *3,e2lL0 2\܂)U4 eV,3d[9!{~Sf8 }~k`}~sri!H_:[`-qqp 1%V_2,#`t1$#9{}`ei{יF'8`vܿEi_,@h+H<7tS=b>h|2 :G^|`/<+hluZw\ܶK@ "fͬwKl0wqe"N37!~0gu~T 8~y&Ő$8{la"M3MvċYC'D%,/l`v 2g'3rY頃l '@ x5Hf~fYb|[XN _e`eYqm5@r232,좋.q`&_-%_~ɿvD<j-m d#^y/Y`0@'WOqoF mG@ @G"@Xk;8(6%/W )搟 5a0@R!ƐR+c@Vwi"@ Z$8⼚^8i~9)8 S!3ۼ%fJ=ihpА'xB( i:.M749ȓ=#!3\tNei(3QXb)/АBS[H?K}dԲdN ςKCusz?d(HnWmv)p9}8beٞ22m[GnYPnYr3 !W[,X>3uef şr7xli,furwAΖL3a-? r=( @#P䖙&6$@LqSi9qJ+9o)@fe'1s:_ Q,. S]l.<V{Z23ox=T][|UW%ԶR"8v5[^fgg^i;4gay1ˎmvkJeEG[kr@[v?+}im&]@ښ^rh+(@ZܶK@ *+3[fK.yO^|,=: ҇2;˒efRL >YQޟj'2cUͲdIxxGᇰګzʝ̌#;\͐VSgSOz^w ;^CZ&ľW{u ˜9(*o3V~"(6Z1Ur4:m3,;%k&dHU ;؏ˊ WA@p]PIqO#䶣{TQ@ VG-ﻬs㝫888}TÉsͬ0>^Jf5e%ѐFfR}(vR/:&# i<ϾU/iRh#]M6٤sfp!e9f,w9!жZ̲^^D`gRy 2=ؗB8e}ҐSȰ?r $"" ,Ӟ- En+/f=ڌ&Jla\jNK@,KAd6Nk&m]Ξvʃw >%6An[ݥ @ ttN@ s),_Tc˂b)4uGߵx% uq!6Ĭ-K@Is'`)!Pdf6eÐdkd@.Gno[v!!&,r=3}y(f~R~fo392`YH|'EE93#;q@l{KDnk[א7xŕ $ +URvڲcH?A(,[63g\9~aS}gO8ofi?䳷S^Vmw7xj ݣ@ :@n3H;L q $Ch ˁ3,bs!bB%b,apBfnj;fF$'A^fϓs aی(~2}Cr@ Y !B= eR57̠RTd"ŻcWye$h</yBڿzQ1;ܿo$A%3lĖB} F&"^ؗ+tl#DSU@D93,l}'/ͣӶ2! .h?t̔f2lboӎ^x,o'fS{A|A'^cP exO:!˻xY.v5P,%ak6{/r$Z 17@,eu=`,e60 q'mSX A3 dX!^C;fL`b/@G,n1tj.DٽK`de3^WR.4hP:YASo-#c1r.Md @#P 8„@\9ίrd)x4̦'`fgݴrR`g!yĖx},Xw%ƞ!Iyc|R'HN5zG5BA,?0"RgA|ߚܳg[m$@#PkNo~¢.Zͬ%lĉL^Xm2ÛoYXr%`hpY>z6lO<{fq:묓'@M#m>} ^{mANZEtモ够T{充:J{JB6*YA_ 4Dn\6۬o,1an+^;) 'Py ^xa᠃fx! /8;d+y睅.0L3 GuT/@ (' ADp' 4xC9逈"IvKCUr#KG Mj,ZG@ К ũxw 7d+tԩ9e*S݋2hfAy0aBa%I&ե3ƍ+'y!_#Ç/wu# dT'@xm&2//BJ½fÁO i[KaF~xx-ڔ,Iݻe)SO=UQ,t)u 6H-[`:O=غxÙC=Ts=׿Uxs 3zh2Ly8(:$_tW^,7AR (\z aKdܒzdv.{>@ [3$0hhiҎL0c%#Æ K~ePi|o%=ϑ>} r{v~QkJk{@k! ~Y.?d)& -phG]o >{Bb88;A|W Lzr[؇ d4/0A= ;sa9笋cg.lV seÍ7X/M҇xqCV^y=fm eHw5K!i(X% fp'yLpҶn[8餓̧~?^\ݼn>? |M.tҥ^:!W_}uRbK^x!)K90tպ;-AK.йs¬Zb-߫1no( G fn6#3[s,9 2$+yM<ܠ#7˚uY\Wct ,ت-dɄ@?z^ 3uBTrp Quڵ[.Ld2L뮻&ON!f&q2,oFPnµ'$zyBeFA!Xzj&dEo_؂{w^Gn'>y˞p#!}>y^袋?)Ybl-y>!`po,!3X=n1um f25}瓥>/>W?[B %7⦼Y6ˢS",>痁`~G2X nL,k/_/ϔ%Mf}!<Ϡ3Zw֣|@ P9AnN@vF~mv̬C=CF!}UۉvV9gx@ Qp<*W!j1?=[f f!w>p28s_gXRW\1!G~vR 10sAV>dRlr"_%̜BꗽK BwG$9r3>SܒpaٵDžDéMIn-^id4kɀfՓz{/{vLGn'p6Iӷ+w@ C Knà'3Chr|i :~ ,My-k&~ҷ} B>\MC̀[kVjlkPc(y"c_rJf-Koeټy晧пzyYk bFwfr@JXJ yek60s(d Bu;c~e]6!,#{hIȬ۲% xRNm1~Z[:NYR% JLٿiӑ.D@ "-6-f2Fg${ցcD/G2'ަ=C]ѽ=)gx+%yKy֖1T+t^%]n>ݎD@#@cQ-ԈLi4l5zH$=[fY=b06# -F(lh!NKf60CFpb2R_D+͏%w75xn(d P%3hDΡu/,;fVlV-vxҙ=}'YZNfT 1-GnnjSo斥lE[~ˆ֚[uө |rh{bݺ,LS_̜oi !r3V %ZΞO'Ȯ|%zSfQ y>!}Sɹ4}lVV?"?oawD{F뿡o[C[H5hEe1Cq"] CVةq~qǽ綒et0!Ny{nqV8xر)S] F]ӓm+3,%Xkrt=Ŗ"`Z; b .V$9S6^Y53r\#| 5@ PmVt"@ X)yK>'qU&2J0̮Jŧe@D3ϭ"qk >`ojdzBs %%EOm0綒['-ٌÄ rEžS^bqőt⣏>:y*}h[o"&{B1FАjN˝>3ܲt[86۬T+ Ru$,N]F'i@[NLJk" :eAnۧϞΚ, # WoG>]z3Ә-]frɟO}FϞ]m5y\A JGܲlBhT76Oҫ~сRSXR(׺[7S7'Q rj0'cyueѿ_uܸq,1Ko q%>=W`aZ(r!頧8Sxd({[e֟s5Es,Rއ"Y.-N(@ Vv:2̼>rљp. 2,q΋%0%/aƖ}z-|M7 e{s>(YV p zP53* H}~ Z]ZzB94m6%y睷k0Ėy^Dl?,qu~bO&y@ټܢW5/ROL\\9Ank jJv{ɷ[+t~%P-% %W9b@ۖ"@m!}Y߾H&R}7Gͭħ3uEXY8뷧GoZAW-p.,EDʲLfF{l&r#Y^ o>9|}.f>֞- /,ebK9 [y啓Y>Ne&~{BrWYeD ZH?Ō 3 >j>4\|<H!믿~Bx1f({--><:g 3),2}<,l?Ɍ5˅Uf9t0r? *Kg},&>f'pfI1Х3ʤ\>8Y̳̘SBze e;y@ !6@ 0ѕˊ%wI^wN[.Gt Nx_sɏ37Zx4SR/X~Q%kcI~%н6my5Y6Q\W_} !l{i1!Z'r#Kޡ@6yG=f9ٞ:o8,,ifo-j!>"l8l2B> C 5e?.rJi..E),THoB)vۉ^כlI>U'j ZE6frg$L0P~)mrS~& T_+<$G>M~ kO2c'AR[W0A3/ɱzv+8C+V-efWJ Pm\Qj`Cؗ>jf!@ (@J'pX|vAOs+~}sul7ૈ|8S%ѫ*"%oQ ,Q,mW}nZc;XϲI[}JǪGmjl0#lQf""2}#,U氬(Ÿ?XmQ* 5%&SNZRߧ#9E'teC5K۵zk4e) RaR%,)(;J#4쾥s76k< %r--F5cyWQF#,r 6Ǐx#@ mܶ,rxOdy+ޝ {jܖ;aNWv|_VjyFSoR#23tduFf*t?R\Uf%rS;?!9!İ3B P eo-lٓ!r1. "ˈ3-@$P[Sݺ\kokfjDRfjb%zkҁ\bkQR=3I_ٟMY[#F$0aBJ$m -=|mOU| MD\@D@>\"3R3It r.܇/8ư 3wLTԍF@tq6vKx,Af@z~;,ht2"pb0%s-# K/BwF@6;, xH2agpT%ާxa?[ŁSS^jmS)(*YWN">/%Lfox?Y'$ @  }#CW zt%#߰]Ӓ˽#" c#qz~WB"psF Kvt羟Qrd]OԳI째ѭu>)L25;@ cǎM[_yMf#@ A=T<o!]7oq|<@lEjP=X< 9`TEكڶ 9_ q2o$Y/~D@ 0k;z_Jv[}m & @ S5>o|I_mri')?/C|gu:. ]3WpKqjrt@ @ &MTx7ٻwdWȦ^$Wֿ;1z&@ h DN/N8 }A {?\!Zܖ 0Uْ5s;eThޚs{.&o]2RyF|NM @ A?O1k0IJ_k};/@ h4 U+s;3Hl1D ?QϬLDC`ȑ3" 1ҊVܭEzZdvYO~%ap(Ɛ!C }85@ @ Aw?-=Nuxm'Jnk[>r@q4 xn/.\Mޤ6b/o .͠JX7l.5:lXNXy]Idv ڗlIb̊@ @ @l_y啂f=a-$]eW nN$@6lLF+J.|Rɖ0'&8\WKgiPPP%(/Q%|tZ䨄ZJMٯU˕T @Uc}f#F nxt@ #:UNHzW"W5{5S'@ h=yW) (ou+8!?DãTQgԌ-Az>R%_=pv[<9FWaV#c91=#ys=W /B @ }ɁFlf@Xw]좋.ōx$@!_:A2Rhrs7qk9dJو.F#QSEngi$0q;Zt>ʲc[_#3Po.|8#\<89d.L:5Q@ i7zСC rK[ɲJWo&A@ zTq_!ټw6o5!xV.Ә22QW4#;~l=c9I'/SzA\o&p}5@ ZCo&}gM2ck~Vrlg@" Һ?yx$&K^C41k}ApC5d g%Syܣ;l/)n<8Eb #Hn_G ɫÇ^{G}TO }Y/LnAvjv_/<=e7]y Lhvɀr=9e엑Hvo]%gh t t t t] &Ǔ,%U&ĝ@ PXPts%o[%XȯA? ٚ5 MM..r{i)fluދ9mVE@ @ 5'!О(y]VŶr/u^!k+Gd^ $+sƦI@ @ @"AՌlgq3E\?"&ՁTk"|j&('#kug4He)!C9A'w&H>@ @ @!pw./.vחl M3 _oޣ
"=0 DZ'03*# qud}Q@ @ @ UŮ緥NPaK QQخ"pz o-(;)`Mwmm @ @ @u9rZEx-_ix?ۏUQ不*b;@9U#l."a)@ @ @C@|lq"?sTtϷ"5?RU 9Z<~vL"Á@ @ @ df"ôjvbW{z+Cٚ5"<*r;%ylmͷ{Cޅ5Sy @ @ QvyGUў6lذuPO#]u'm;@xw@\&;D@ @ @ZWi[5qt@VOIO%)r~Yr٤m$r@ @ @m"inb .RM`v&"9)~_V{S*=yw8p; HQ@ @ @ Zq4!jVvJ׵q{c-' 6(꿄Ԧ cu ܭXt @ @ M2%~vd,`[=Sݞ?۔N05L0@ @ 6[J#Vm)e IJb%{-bO@}qTA@ @ @hIj,.7IJ^ך%~n9M]3̪/y-v뵟x;q u(`d2@ @ E@ݔs?1YW&}\oݚD{fP$@ɩ"Q@ @ @ !kY yoAk{x݊%<." 䔭id8BZ,Yk Dy@ @ @ h-oe)ٱ]/Of߬ŬfZ:d#3+b;Tۍ9r Q@ @ @ -5nҽߊުޕe暙Yb,yƞ7UvX*ڗ;w,ld:@ @ Fqfo!lAD LÆ )} *$ e)j7VkvUl @ @ Md(w{,p)fx7dg-Bw-vKUȗ%{ƬmoQ@ @ @ hw<3n!fe'[zwݻ`8\jQU!RSY*OvW@ @ @ åbLx/WOs-2GN3K*IC(\vIrLy d+|"@ @ @ !гgtU*u&?!$7/.ۦdjYE}MӽZau纷mӅ@ @ @ Ds4yH:[׼vyK;보YXurŎt߀;c6[X @ @ @v$fX{ ?Ly"}_[Fel6fm%O6=Gw {F۷u- b@ @ @;Ep-,MlQ}IqfS+fmPN3XgB  @ @ @ h0МGݽ1;ߒ>a:aT:iu\ ޥ슷-tݧueC_w٧4?E^&H9Ad χujߜjH]%$GHtЦv\%QҔm!yg:`rm]oZ-,7<ƚ}[dM+U2:LlErd2{Kώ_ DHm:t 887 μt{]3 u+'8uSOvM߈2 @9as}>,Y>.6Q}$KDVaLjӇtں҄>X mA_Yj:f")fh-?6AygkL4a|6%JIn@-0xoZ< ӎ%9G;\״|Qki>EhM3ޠVٳg[܇ʈ:l,3r#oW=tȌXFDGq}Sp`MRmM r{ӝ>Q Ck?`aӖ%IGK[gFgUY^8ӫA0t~зcr\Ixؕ/LגG<V%LtN;ct*טdjg&*e6V|tֲ<9KnYH-Pz3eaNHN.ѝ }mjXqx8|KOf䖙3:{pppʑ|Fؿ,AQ%K0ZZ.-FPY>E$ -K3?a_ ’t:| $(m)Gc$_q%Q8IC`vzcC9X,#"aQCcX~@\tXH=7t2yyVo,Cis C0E K|0})Ǡk,=_IH~XǡY}2e}<0o;Іi(eRq?B\쬕<F9i/J &G|tt ̳}ӐOF:r6_wϡWf<3SOdW8`=ZY!gRL#ݖ}"!٥&^'xO@:\5'$ggmz* Gg5=K'Bp AKΎ{0|/NX3s[Af y1 F/ʽY7t4ԫ;C\>WݻNj^ҷB(CJ;U`nD,'34rGWp'pOEI a_o}YG^-mo[ p@]/XMpZZ >s>5> }3}Rbd5HP7?JjeƖf Ү/klrzBp><>2@`!'H藋 ^8/I5۵|PEe86`/,P_kIe6%%=^Q$ltC&ZYJІѩb!q]*Jrb6{;} )F^]v6}4uҠ~?cI>>,!9FIOO| pEb6{}.!m~-|"_7gvcOm]-K'A=?[nt>JԩsO:1*vJ_bS<(VV d&;9Yv&Qֽ-?]D _ۼeMS˯߿)C|lY:2`IbAyǚGϺƀI[%:N='ߠp?)!qL0~ eOO;{MIƟR0yr.LYGq0~hK g0$l@BPqD ُ$t6߹``|P}F;qsIc.: q4pI%s:bxS>HR])xz' SOH~g q Fnw(]c@tfBq<|YISQ{1]_&4P9rkz'p(XZ~p~p5K` 6@CKSz?PVgh$8oyEUzO1MD)NÒuKڳQ 4PSv |j|melplqH:麹-7}ctپkEӂ@'!z~}X?@C3qZ P%8܋]+Ͼ^pV#=7I$8Ӳ~? una' bjm'|@ '9_vmyI)b;ӂ' fopo&<!yDN_fE+:KEG?#('g4zH&їɤ/v/e'eP#ҠHЅb=d8}eħ>A+%[K@ky>%1}LiYm^+B!o ;[frҪi~wU5 N+? tʐ[>EW 14܎Vqj1HJAsCScD 84HjN#4JBg}DH8 "Y|8= iZ$NcA 680`8!5xYq=ƦSoe@pV1iu5F4pp:5GNJҭuF8/tP&#ZK;O'14c18(?`H#mƘR9Y\bus|〓F]1QҢ%1g ƈc<9TtEp Oȯ;q X{#^= ʼn1S2c-0 88%+Hh F>-l tYi܁8꺰z!k>/t- Ĉ5\mV_{4_-pF_hÔw`O&,{KC= >rˋ%֏EnI q pYCBpeb:OY,uewL0 D2Eh}F_9ʺ#m+aCH̶D[C⠜֧u׵p~,|O ?}\_A6 e$}td۾P v6NB;YBf;uƽEfsuTC`R%b#WJ nm :Yrhm{(?{$̢ˇ%5ڪ6-æy4>}Z^iGڦu=.C3ꢒ{4c;aɏӭeT?BMs>M'e49E2<(E$*/vO kM ( F8FrӱxZA.:YP BZ6}"Gg9syΊ(+!85Ji@BF'KBMK#CyxС,Y^KGGIHcq Gҥ:m$֐ދ3xL 1RB]bV^|S$8N6JBKB0Gt̜IѵKG0SEGJh/ȈƭN|Y]P@ώf~vrN_*QY$HH(Ϻ$/iGbW% NgkkݞG¿]wYr{.o!_`M  '[B;A;qo0jhY~HrtM!-OƤPH*dx Mh5y!8;i{!QYB|O*wCm%8?lƄ7'ũ4=B7Eqpwhߣ%~)}z76F[[Kk< h0`Sh];},ҝS-hSc%5,}}0}`H66h^r/eO3\YEKzH>H>+*i@;ʅ?.ڀK).}Şnc{~r4 K﷓3J3].?q#O6 ; .KHK<|>+wcskN{|;?{_NL@t}$x7li/{.vA/@~>Bt~_3>uI @/R_: %O~Q vs64Y=6v}4] } }9}xtI_2A<`c m!}S$`N|yK8-~>-}{`Ϥ UVm?`?G8)([˕>мᮻb eZ{Rh5l%4RmTz? uؓ=t< ;DTpq4 Kl n5$$i[4K|Ut6TM[6b꟧pҁnB~08H܂qC4q|~@Q|FBZȁ+ceAx ǜc:/% KS!8e^W|aPHp}ã7i0hW088 .il_BWe@_g2F1rKީ_sLpzM.-"YQ~BB{O#,d@X;C)/ vSG'OIM.ҷ#_ ֏ўp ?3-ӅQ8ZN@OMJH[!t!oC8Qf]⟚?#j`I zITJ(l%:H:D2IY_mݫk#.XҏP`s񶬱ߓO02loeU/[%Seu-LlYspq\UR^*~g# Iӭ<ֿ!Typ<B熂c(8fupy8WHcHa>+C7kX!RAN_|8qHìDgw #{=$F"pJㆼ~:*OP ]V̿?:TF/$BvdS _CHx̠\qvYO]o0n Fnq&uH }1<8H%yX8)ƘtM9.5Fl^;)i;6RZ:U >qCpJ̡"^O+%RVGw Ni|*y@nIgDn(* i8{O }yo4n_"%% kôqzNjbLD#5}'-6!O|ql }bUw-En-nz~~Q.-OfSnu'}ǚ>33'sbcl'm!y>ޒRG'm|}Ö%/xr @ [x 9(?E/3d& пdgH=q"ϱ@_Oݣ=b.O@j) JlK;+?:ζGH%mBl,(~'~Aw }賑r{OE^п$$$ Z, 7>Hn11,KŸ99'2&DZ@{:]逑=3zC?C>6'OP <?M>΍E$0M~%컅ܦ}M\%Jw®8v2oH!8~2-ηN#*EaXIa4? 3  8Fuc\%K'bS#}blgܒ<jwN< %`d!H&F#+FEόbHSY8@V9L2M:(bDg0D}ݝރNރacbQpOnS<0@y+> [~dvNC,TJn1|v,0roi9 ܇ %dA "\H?@;!)o$Wt%#f%xY_ (Dg=C{BgqI p}- [,Pw`Yg?XH u]k{PFz=K?iuI YDzZrb-ic l52/@L= yr[fxr{`w]ܗEVgA=F/f+}zKCoysJ?n}ECm+²aOĊ[Z%~ -Pf}+,2`%Xnc3k ׋HhC,dS/޶wp>N]k%4? [u{N%}џ(rwON=ZNuJe8E^Acڸ6J =jYݛ] t%ךT;\0+e.%cARdF˕=x욃1I' Y+<NJ#S8xq8b['t&SG̒RU)>F?1tR:M`X'l9>-aRY9<7B$qJ j;[HF3@nh rq+ =#gNͽ=`d8*z8JJ[3|rIp-_d)+H?qq.fl%V/8; 0п@gYɡf7ԃ$%J #9惶lhA*Ҥmq<ǭTp$}nk$' iC ZnP";\^5$c%Ė" @lJ /K/Z]TKnf a Q|̀vt/Pl|і܂4bDT0BS[O<Fa~Zg"#.xbJDJ򚄁%s:`:隶M]Ӈ`W yw$ޓ-:`3`*aU d7U =Ch%^lN'XW~=``8(|A XeW/>L js!􅔋LaD'i٦hg;)#/(UMǟAXr~^",H|62奍{ȓs=W-24Aow_ dK$?JMiD&b 9ϠAmLč%yV1rKgBE'F3SD:PG&ιvnH $sB5%4"<Ζs5@8{I([viR3baE1`CCc;09b1f>Pn=vu1KIPf|#IVKCANڀG.@zE:d]ݟ%Qf`1KH/ GlH #xGJVNo@!Y\)Q[bǨ;9|F R=،Bw]38f3mقi: ȭa *أ8?ćDLz3N8*݂M.s}2@԰/8d'uiڄ0  }Qm6Oz??VfCRڀ嫡J6)/d`cU2IsW$}0/#ɯ%/wyɶ.ƒ[:zć%'$>Bào#^o]Ro֙G8' ;^7˄x呺?Ϧ44%Fe N:Ĩ]/nňw%޸vw0A!YYCg N/#>@qCur2~ $ $Ebi,Ű2B}F3:H!'!8:DG!ALjD|,!1לF}0P;S$Wt nMJ۵A\yKtI5.?z)yF=~d%}73M8ϲy/YyGr m0NN>e Uh8S+V-NzG.8]K9jYz 'v;yB2ed=Q%0N~,D?-'8 mK~)>0Gp ~ {JI )0/HgBn +p#F^C-пӎ>Fmd?Hܷ3;=$}ڱwX&G灁9 `c#hfK)e?AEB~xҏ>3 {nuͳ]%$;LG@o|0LiK93*ڳ`@ {I!q~_CFX|G%gI|H >C>LI󎞃? }X/ Vc򎽢^hGH'H B,o*}ޓ,pď=B q ;1F mlꆾ^Jg-u^F?`&nI{h @>ЏrXS}7W9|&l٪Q~6;qvJzGB'](! HR^|AKn:H[͒>m?> <-좋$`D_=?QA f=2][b!ܚY+8f"xytw )kmˋxuWDx *FEw.S&:i|Ǒ fU: C 'bF dcJ`=K/KpzdbLǂ !g0x4g5y 6NqʉcE=KQ4^OnN4wp1#Vaa12?0'hcρ7uCDzdO_:&8eb е׍jn~BDnE7`DuЃJ'H^^udruqi[H~w0,N졿i?ĝy} `TJ=g(/ qCϲv2Is@KI ]0XQO=%k>x>Ч0NFpЖi'J:g";_AqL;}h32BnxA8ɕpD~Rq؎@<-O &\*a$rwuz Pg&q/"#u SiG洒ꕺ@_Iy7iK (X@Lq#H_L@aa}QB=[D|$<"}km4}Drdo uH{zqm"Me|UB;8,>щ}$HiVCSҧBw3aP|v֧3@,uA:mLԮ%xdb`jyT8&Sٳ"]H9=H F=tPr$w:?Fx*M: d{0`ٽMA6NhT"}sip6Љ 8yBjitِ@Iiǻ!8<'|%Ont^B'F=ܖ‰t)#ig8 aHz&AC!o8<>dwI5T6J@a^߼c}<5pD#M|I2Slvpȓ[3Dx[Y0J"+N^@hg_tS5Lrq21Q76K[N.,Pg-mqA@!{i<]: 3󵓄!'ʆNzC!t>v@J&}23 ]).s^'ʎCb]ߤ>eb5fЧ^Vwk3% |'5ylv+)]>ˀN!bUnB`#H(iRIy*S +~%i=\PM9+͏I^|~T0.(4b'?>t {Ck(b}y姡z]./]ݕz֓[FSqёj,;ā5V.Jrqdu jTɦ]IjWJn6F巹qDʵ2U#euqG5qUg< e*'[j^,}>2/=pX}TQs_LY̫ocj$k*}i뫪X]^ί&ݚWr;:xjgw~.y& b+^Ⱦ*Hw6xRy2w# 8|dGr;<x@ @ Gq%gOMkW[_뾳uԒU'@ @ @ txxx1C '&[SUdI8OﶅE]'#(_Uy@ @ @ fo)w|V:ɾw˦^DGn_a9/v&}kXCO*ts}6{Y@RUA?ih64x.hR튶O=ujL&E;̫ĨowGhZruӴ)Fl@ Ю` :WV{@cDnO}pzϊD/X~#55Ƒ[OZjB Wȵ7A&Gq>Ϧ胚 [qjNcqťf=t=?ӱf<~0:6J^+=ʋl [-߽ ǀ~(a丱XSꩥq6CMWvm@37HFJ4Y޽b.\zHsVxs\ (m_W'7MCxMi@ PxŬ̾G񶞧Y͒d=0¢ӄ^gӯg)f8uytU~o"Ǫ\kHoؿ.MPD*s&(z M>>$4zc6W7C ,or_d?IS8+38{F[kj-o/?M62sJ]mmk"h2:N;{>+ӓ[frM|. ,(}N!D[Ym. {(HU _=3e` q:[u`{,pkqpʥOYLM̦w_2G/RrP&yp/UWՐ[ҥ<)Yr_%440{=K~-n[|zorBn-%q'K'MJ'z}iSy(S u_sye7G)C1=7}$ye9t؞L2l|wr|?RDr[.+b6ێ*{VE-܋Mnq2C]Ju|r8+6Xm[-f~Zdm%{6sV4f|Kg5*H8KMrY}1ׯVJn ѷx&0,⺜n-ӿ5A+>1M"?_LuN+0F'~WFY6sI{nI^<4`@!ItkP,|Iev =Ob]re,ib 0d \$,[BX)OŹ&HpHhH>>p{cB'f}X ͖?KNӯ܂㞒G$8X* YHkќLKH{t'ؓ6uNJʭ1|3G粤aZ=^i<>$Ǽ@¾뼽 %_ &YLž>ʈCmyepK¾|7ٳƲq3|$/&_c]$GPC'K0 :)R,F:Gn3􂫵{h,~:댯F2цXֿ?@OlIV:8/,( NSA<88S{cVPV y~p7#&js_`oc?A0W 6g)RKږNiMAn`};ɟ׷UL;JBYi , 1϶^=%$[q/Ħ&yņ `IPoVNPvU%얓gK ~ܠ{_@ ߿\"Wiu 3{1~{Ae$:H>#EhS"}t_9lzmE I3rt}{ڹf +;dd $.^>?sZ1P]9aK\8-a-#sѶ߿EHlm1ot=@ҽH~rX/G e=kb+!{$=$yʑ[*aڥM#|l=N+|Y |1V3Rb~^Si8#@p88힅&iB^pOB#_wHdgI[A ?St" }}[$Kgq: KsiG#)22ɧo)(,i 6oJN@d f^.kQ\Ƀ "E{GEq;p/qNqtgTϞ=}}y櫙`3i3F~Sp2CŠt"8%:m%~4g#c,1T?K008Itj)sh/p`c 䎼;##Nt=HR2@!1c eVg$Mʋaę[R~4~pL-_I]@1 & %J {0'?|\L7CfHeI'(2=;N+Ĝ˷%n8JOt }aq8/R!_O<Ր[%^'щ. 8E=菵m< Xk"k|)1 grQ'g%Jk Qi9"߭#$ mx_ D0 1rKZKr~r_MԓM+yCO鞅?Q C @[Ul)um[ɖnII CҠ IWڙ2@AK/Ho9[xSϽC믿7h6lLGnmX\F1zI0r&K1Gp88 Iñ?Y!9!>JF1I|DLW98t;]$s8HbL-%8z$H:PY G09OsG88O$/KHp֩%C'#H{?*EWϧyxT L/6+qdc9;$=t 8{6S2N>CG2m4nw.,wX"m+Z{Y81Ң-s/_*.A<XKq`X2&zgΕ9}kL*`]*\!} yȒF.ѣe%eNS'Y,vOn+ #[_J9ii~zT;wu;ë= $^ 628\z\NCy:MG?`06~ $N.=ּHv@&'䧿H3Kt G±OBqzKIvz#ͦk<"[gkPhw8I[HqGKП?-O#8gHl,BD!gwCg]lZZ@[ʧow?۳$qk €3lNSKtBQ]1-&i amY=W:;}=Oo<(ȳ[ژ]7]ϣ?H v`Bެn;eLPc 6Ol:؏%*{NЧQ@H.uc~wDhv`D_3ؚle %2x&-7ٕM>#t%rdw$S)Ð$Õw8& CYY* B0t̜aXY8~S$Hp|}0:;iHṵ-EncTB]G4,xrO?⟔.}ψ1x|'В$NŊf+!+ٜK_RמB.//BJ0B(p^3u#JΚtDNSl|7 7޶ Cn!@}u@Еq7/z¹-1 r:.Һ>6܂ 'ۗ\ NT tޑP8tLSS88fܙh8JH DfO$,N}H?sY Ҥm$X=B(;N"ڈº6rǠ:О|el o CmrCci™O0V&)D ,1F_i5I ƴ#p=} .kp$ߴPBv9`@A7[Vbdݢi3>@tiI2qu# {]Fns% L+> <&GdOs(zGYBC^-6꒺6_Hno$LzR>L=(A*6rK_YT^EYw@?mΰZ%'oh;%Vwď.of9rX Dt]K?@a^BIr=$}g/p9~eMK`I"M-7fe).@!Wq55`{lm2;UO/z5/3K}Pv"]M$B*0 uB`F R^p->'v)raai:8_81vWJ7 "=)pةG^ ;mf]M.H>/Eù-U&h2y/6r A\RIGp Ø4MHy$"ĥE ď_]+Gnr::m6ާ{)z j 1Kq0}H V_{ n8JbO$[ TC6vo}x~{hm!Cz0  >]#>Hz6`WKǧ-6 6J>qs?ef&WBGI X\*,e`}_3-p X2x wu2[%M 2kK[KBs,ɋ9r$Ί.Ʀqɢ9 '<],~9 ?䢻88AT;M4q0Gy@nDzr[3#H=WM1p%,=W&$rS+ @@tڰT܂ ZMy:dP@'-*,@)rkQ̡H/ lF=7L./fntwuJzl6;x2  lh $!46@P=AVi+#G`X έfn! b߲{hrk4ŃOnvRcW-3yE"%60-Al펁 ֐i$_`_̖2a& 5uHxrI$Jɭ幓.,ɶ)0+Kl{ S3=A 2ئ{n=6=}iuҺ:}~ ︅ܦ/L;v _m:jfJ!8q䫴[:wY*D)b<J'qB\1Y0N0>.Onf-hB̟-)bT`1rARDPrh7IL NaFYĖ ~kOnwɮ9. Vg%o>8+&+c\> M2cza}UB81x#UuK#ޒ_e&xǒ|"-i|!Yx#tm(A7Yr70`e"Zk@yg`/0y;u;} DAIWrtƄNz]JtUOɀƏpцw u 4m |h/(EniJ.0yBC?覵rtO:mfm^]Cf/qv0Abe_+>De^[!0G{\!\;WBnҎf>•a+'PmXD`'OCwhKGKsK tʤ 1fЄHLcPM8I<Ht\&v$ A~MB'*}+! FF@s[qO䖽ۡCSֲACFd]\e[ מHL[bd[ niF?!'FI0(و]#wkÙ$ƶ%*P901Cg'5K!fňJ1ąs ^hF# 1&TJn18KIA  Ϛtd 1#H  qJBY O;'d} т}*7GYP^%N*4dLj)yo " u+PJh 8ԯawAa3˒ !N/K[IvZ'a醨'':mtp~ql/P.aHk&`|XA,!n)Gn!`kt4p2!6G!$}o?@Bũ!3Ň-Ѷ@Kn8!V_6m{;JbƐ[D`H7yD !;%`c}zt{]!$H߻J~Wҵ[0%^| g`+!K?ś$ |gy$6`h@S!z<`#um~䖁l)Ϙ^M1 BAO58ƼmMy(3P]b 9}Q ak)p@"0<88t"$#$T^'/#Pa)l/2JZȭRfGDH1DKY>18$"_zI)Đp I!H 1$(8 d GTM[p`͐ŁQ$8"FPqp8OHgA|)ek1 'Jow?@I?O'?8s]yͨg,OҧX?di]Z8Nn!8`=vI/)Ŝlť% Vy:MQLA/fmCSy^BH:AViXh5Pi/Jiw.MǩCg?dFOݧA=N v#%pCfhV+CA,H/l)e }:%lOQʵq!+A u$}$8'ed4g9-Y@w?ρ͇%T xI]$3OFgxBhqpW[~ IEf$(12hiTQ]$XTn[_ TIvsBU,Ў-A75kQY+/RJpN疓džzsN? m0*O^ޱdࢻ6FpXP"E-4e4, f<ntvϳOCpǽ~>A[Op!flF7YZJBbp&J43Op}\y6ctErm vE"MuF7ѷg$#$ ~ﱺ0'E#%s}G[p}ķ9jį:4Bv%>!18hf2E߭Ö/ͶM_ʏA@3'G;L3EK^A 2^Wyp o> %;#bN#y,SB~iOJKӫ+ eks eΆNB!8 3@YbQI=Wt7{ F q:yB=_2\2X3$:z:z8L㈃ eCAʏ.RgH[ #0 f6|gGc E/PmSb:J_lӭ%9䓲ty>K,&i+`6!}]%K<;Uџ?n NW(谑[ rw-">M 1] '.-.a ?&=a/χ8օ=% ZP~var6@hA]!/~N%@ !;/|iL7]D""{rklY}/A5](8 @bؓ::lcӅ,3&88,;`qdp@JE% :p?qv@܇P&?"kP=WH^ JJ|+y y!Oyy9Ҡ0y&>t|FD#K/uŽ 2qQ&~KE3dg!I|:i=@ȃ:W%y%C =VC;:ϫsts/ ~WrRG22UC.Ep'%]EЭbmNWiwJ+Os1] 0#ANCފ קDKW쇷e`GDkQThԍ 7Jd6.O/# YOct@Ӷim -}+e>Ӽ p"/O!m L`-%9_ iB100^UbIg#Bb6T@ h^it(#s+lEmv㮱eM{s@ 6_#a=ɹ$(CɯfH*>{r+' @M! 98#=\/GoR\,ȭfn_В m#3@ $KY^$ϧήQΞPfx;K*Y@ ~qiej5䖽lI/Ye@ м>s{(ndȭlW=\3[{  A=]$$'H8TNw7x&h^aVWWG\qnơ鳬`n@ =⤳iRuK}#L$yD7=IigϞ3n?Su==~yv":HD@ @ @ -+K[)$;OGnsb rZ݂@ @ @ hoFkWbWdzֲdfnw /En߃i曋om@ @ @ h{.ǫ~}т|cƖU$vz=%I&5ͬm-ܩksދ-p@ @ @ H%SOuGZ{ng҃WDnfmaÆv9 @ @ @ %;|[8B\ܐUqMɴV= 3\%@ @ @ 'I[l3)gR3LGnuӡVȫN#'@ @ @ .y-m* >w+{_HgniںlϭZ@@ @ @ -8ID{l:r e>'W/\sڔ{Mi[Gny+V#7@ @ @ &`'G\tjU[H/3>y:r?z ȭ|/~k (K @ @ @B =W?6%u[&eQO܊_5{۩m;r@ @ @ PK@n?O%-Eně=KIIɵ5Q@ @ @ ,KGL$wC=;s[tYr%V6VN @ @ @!󟲧%s[ e_na @ @ @ hc{P6VY@ @ @ |܆f@ @ @ {ܶ*@ @ @  @ @ @ hmU@ @ @ r:@ @ @ r0 @ @ @ 6t @ @ @#Wa @ @ @ m@ @ @ @G m(@ @ @ @Ё@ @ @ v@v_Q@ @ @  @ @ @  @ @ @ AnC@ @ @ =An}F@ @ @ ܆@ @ @ {ܶ*@ @ @  @ @ @ hmU@ @ @ r:@ @ @ rzUse!Rnl<]];L^S$5ٖzd%txmZ*H'p%mk**%62ɒ=%342Z||# {Nm9V_d*3:^-gE`wEM ~/IK)M\r۰V)}%<XU?ɛuxcWu'꺛s w&<ɗ&}<,DZ}SiF,)9+mkǷ$;)݇${42}]r8L>};"4J>N߸}IɬU&I,s̓|Wv>o'Sr>-B &r۰jT "߷,%(Io B\~x`a2QEwЭ*,M;3 韯8Xj=P#>8ډ \rq[[.J}6 ?C%KX!y6Y"6 ξrcǒfi dvU,?5o4/Pug"B 쐶Z;#~"pbYSi|l'y^r?sJm% s@K؇eY?7zs[AŒI]\DC܎(laXG,Ae\AA|q".{CYf]l%GוZ?S&FA;b霠yb8|>T‰8^+8p^C&9`g(Keb`9&o&JlҀρ/x\*Y&bv.|\` :G& ˿H;zBDiS Ǒ0ⰞJңT`;Ŕ:CA:,#}aG^#}UzzDx5`A%R K(""b(Hi(Hh"E MTV0*4A5ZsoN2Zs9昣ε>Y"?W:8;g٫_rZ:?hh ~9[As^ ?#bY;z|~9}sU\% _徥17-=;Zv^mV\mÇK["߹Ao~{V!'QnOBRqM۞^NqC8DA퉯Ws*s?3H58louskz/ y@`$??$_B(?/Pqtd;6rs;Nؓ9ȱ`G2ھߗϾ;}!2ܼiiǧqN& ;5ޫs, IW䜧3{<_H *,s|f r7%ǟcg7KފޜS6b$O $@G,%x{/ 7^w{>XO8v-/_'峢)gS 9dǫb_/:<UEir!Gw=3%}B/fߒv|OQڰڰ}~l['9ҟdxDx7]w$NO؆ vD$&Mt^J2kæeNFo.CDdxkH%?ݎIg~(xtGb3c$SLhׇݳPT($w[)2]~ǯ9?](֊\8s@ec$N=1^(/Q+3DEd!}[QUG/gޘ \='| t"\p ]ot,iWm#&b_'+Q$Grl*# WtuD'{6gF{:×D}/GzMsY@[?s1Y?S(=t\v頢tkm[kasy%/SQ.o?v@K͕'zHe-~oucp+ҐJ`'W#VH`@(Z+n ~ R@r`Ww峢C}qo֟ $\$q%շIPչ'RDRB{4qޠdQaSU; &`ڽ7j@b@XEj o_dT$=׿{݃O{KLCwU2W; /Hq/mݣU_%lUܶ d z+[XC"Pps^aӶ]g`ٓF}+ص%d]& e[|&8~ :0)>7N1yG`n6($3}KL˚k!cV⿢^2B|m,91 ?xh۳osmm>`C%;,u`s$l}N Uz{%c$ 6^~D}1=A/9:dSAt SkTwŅu>0gYpرu`/'+|>Ï+ zP)H:߁ZRl%_W֢yvѓb_AlUD3I'꾽9f3lMӡwcǾlH $y=p@uv߾3!^'X)*\-U0vAWwsqc@_+_<c0ksL>(tsG;{AP:mU{% 8W+zOj1S>lzoU;7ZRFal]*fk?KÂƭ`Xw9G|$=3,_Q`}+'K_| } /{y{}mV=. Fq{Bv2v|qslA@2Bv8vNP}}B#v8i3o@`v_tH:SAN?\r})=J[—'V$,ߙdu@m~*-;D36hj/0o{N$&\]$b'tZ[M'}LxTUŭħHU0Y`sAH-P ܖ}ќ#r#"K*?Vˡ@(=ENH[=.bNF/ۦ1%W t _-ɚ+>欭MMgQ_t{MӓdVXs[{37 vg^EKd/\9i-[An=6 w>%={lJ(H/5s='ĭgv/*^. |{}y2TWxc0w+O\.23躁btKcs-yk?&}N `P-KZA#.C-)~"^c>C@__6lzbWE ﵞZg덾&b\*f w 65$CMOͱͰ=99hOK- e' 3k渵{kӭrB he187$m vۢq#8 %I5g)HB$<69?ps(v%H& ~Iε%s[hN%@S;m Mm\ pz'I / $%N}9 BI?՘IjSֹu KCH۞)I #~K6TAjYp1>MCAtYsQ7^$K qqo3}"%؞ @r%3=IfɼǦLd򲀜~溵飀#dN7 #kem⋭+%8|(F_<#WϞ<Ǘ6zKew]A٬d(sCA$SE*iɼyɚ>ݫh{Q@EUɖkU7o[)z_#h.ַq?́+2cE+=`w P:xr04nEO!iP" S9>$h3:(B[}K,$]O Kt\xw`')D$ ZD"ےL7'>H( Ze }C=K}J4UoN}wϤmUmIm_cGoIH1+Ͽ>nfl:^ LH(([>]:Q %A;8'{9?X9ONZg'{֠R}*om:=>qs} .FOKŭ )r`u6fuׂ7nݐJ`'*Ͻ+ŭ]JVRq+ ]@ k!pN]3$AmqٶL 4v|[}_ *뜶" X!_RI^^vy6v߭W3 ):՟_z3vdtm2KK[-n^2 HCd.9HVU9dJ ֳvJ9?aS/ Ej`@ =# W$E`c~Iҟ6jLz|ڦbC1,S(S+@VK2'i8w $6"D k2{RF$@S9{S+>F ?/:p)d;gͫ-$|½KRbY<-K?niN^I~6v}Bgjl7WTWe^mq+y9sŢ{Q6f^TqK5a9ho9|ٌ֞f)zZZm!@*ߥj[EGK <~y<0U(V6\|wi3b6lQ%̩6xVI[wlY]Xrp,3*ޟl;6p6A6do0ɿYqljȮ .6*7cbXn]jMuYq]e7[͊[}W!>sR63qjH`kYk*7sNUObJkfYq{,T5Vw7YF"@( :4RpIKW$]%☯(*O!IF圝_Ar=#)W H%igUT\٤99,0奄dbgkIV- s:]m~1os:oRzvM/Wq;Mؗi)K>^(Wȋ6<%|5r$8[*\A׳&# %P8L%K䉆~:T,A*a*1' O=P@$\B'ԋLŒ5K[DUS}IӒ$e6*VhV IDAT(n r|V*ڄ=o )_6}鋘hl_YE5u/@ǯb3Bm~nŖIT/~"p0gl\J<{u W@6=BPL𥮵EfS&~cwx["S=[*Q!|M6Vݫixo Z}Y-α+zAkwtS Ct%X_O*Xtm.t%,ʣLyȪMcb6&: Fq{"{~;-g{4v%DFKvUΚ,ZrC@[ dZVp~pK$xJAIg &v7 ?H%M`-ap ʂO(SlI@QZ$gc9@!Dc4ƒ`Owv+o/)ٖwxhi#'=):mX=EM,ڄς]?690k=0IOl I$!E{.QK(mIfFtם$4|FI`'xijڔXov #Vz]I2{Gy^?+ɮ N]`:f%y ]9+oη<6دu2g.YI)ʭH[_lh ]:c\O.ňIM~e<UKoT :X Xђ'l'ٝZ"%i~KbMG7vo亸>/(v-\ӗ́}G`[RPڼzv09w?liw>U`bQۏuStӋ9 sUmQq\_㲉"L% ?ʋ+v/;]"ET_ʹڝks1Cyç&\F|$m\Տ d Tm6jjdr.X}faCƦǜn 6z򔹜O%6ؒڴɯ8KGt]Cۗ(n/S0 $/N>;WJ$Yv8 qڒ%OKzI  =ܸ?TT v{*.oviNHSL t_G[))k EiJdLk/~㋃t^@3$Hr$H5dDK5X$d~I;Jbe%—$JI!S uܓ[b|, k9?RuΟ W /5^j;Rρ&> $gLW`=Ywcm.Sr&&ߋd`37 2RH Ȯx)bGhS:Hp%`rvO.*~ #]u4ۂ $>./E^xDW;%f :RD&UûzԽ oռ]7ll)$l&qx *P1ѓ_X MY > 'oN/XkLcAtw7ڳiW{vCO}vX>eL-6zAv^ŗ_yWeS|?/~_ڐ? V:5֗}{^֝<%Qt: Rޯs:fRqu$aPHK4^֞=ЕUs/*+O+ ̋߯ʦ\#_(^es%f\?86v瘭>3 `xgг6Ѿyo0ז/q_[1N|o] a5ݩbcm|6k{E6y ;g^_N{_46?.WW"FOyǽKV,>vd/ѡ? yH`E9Á-09N9J&Fq3H%dEGd[5icSɃ1Hݫ s?8TA[c dEiI *.d{VD=r IG m/+$Tm3>)9^뻶=A8ZXr!]($lH +p]sn~Z_[}I釄I$=tR+n"z@1AH$cl \putM1庱PARο1^G@~n"EDN?(0+n缤IȮ^y0,Kob,Jb! S_dvR]'b֪#-]H@ۂp?][I]|~9mOԇ!kGzU_NE.|n 8'#s@ XUNb-䣍=' hK|BO߮ϣ#nqמ mpG^PeGt&;nU ڤzݟcO{]l_ Eds>@hmڠASalil *"ٗ9{ O ; +[*6>'pOOtN{H׎Mh{Gl*pD1?crzaS/O=^.<9z,CŌC9H{,-VTnOcӅo9dIȑa_״/nJŌ孎<Y$VV N`}6m$s3vϰ?r0NujK3VBޫx+$9ÕKxHAuϡWp{8 ƶo6^kжUxoM˹MF7#A19I肹 I#S Sd?rSǘզIw[i'[[E}:M?ax$Jv]KnJrvMK{ٗ$'% jǺSHb'8;ݾH`m%#vkhw]{~|un|m~en ]oq/-_A4=i}P/ ā/c_dR%8V&Ey@7[U۸X†_W\/"}_{m3!f}6ɥ|uWȥ)Fzimߩ ؆S۫|f^&<"/Y6$ NJcXgDtF{WŌ]j|nO}}AfE .NA"/6_jlQ:^U9_|c)Z5θ6$e v"l,W! PUsmL9pjW%u?£xs+>1}g8YA\l0iII[ˏ{!X׺*BjՇɤ'J4tq []+,1=Bnܘ~t"Xi}?x54̗V Hilv5vi7LVt[TaOn[?o_|mͨxmvo;_ hNKg zW^"@ΙArˮ79-zskc{ںyz_7zw3lo)?V&ڗ~/958nuƟƯ*yYsv rVqK{5v˖*Nڷ~z%Ucӝ}*(*FV}WLYhWWzz׹=97< &[tmmֿߜI_ηy͜Nu} bbovh&b'QnOn;a^q{oC$p?я˼5ACKtYO瞨lז6T.  _ d\=k2*A9#/o]3_՛Ob{??CU]7/*` ?mg p: jT g2m5:ٲt_8h^Ħ=(nw؂m]W~7xFp-ܻTrC/9 .._1pu6ddCbզ''NGqm6,{ SM@ i|ޟWl`:5۸Do)}:b:O)ve[:aK}^ݣ7z9N5f~Q*f[HeoM&}?6fm[7}d"t,6D:홻|$OTO[ 60]=5X98xYN7-*ЙfVg(>\ kn0xl&my[u>C04R?5a?r@o?;u^n4yvr68߁^zԓ'v፯9USh~kx';'tu[Nw=ʝ_F[Q?WoͫOb.X%R˖ǶjF})"L[sǓjzZ֎uz6{-޷FX P> @aQoy%Sĭ{n;G[ G&;KJ] M!k)s}GOTד;t5y)=~{Jk co~~xծ}Ry7`{{Uɭ7qa;!ۺg;^xiힼ=]hlk;z}gc`N|xsP\q7z}޺=uչ_k57_]Cem߻Lv m cTJJ^ׯ? [@з#chLr^7fЅzc׉=V67UF9V }2 wOze76Z6Wm^Ȝz{P%O~ml=,Vqtf[\|N=9z!7DWA©iq l'jcr6K|q*6W?|fil~?+]ɏ>۸xY֓͞~w\5`s\61ۯO,~/ ŕE~|y +#գH|ƭ1kLf'ySI,.QMmɽv%ƕЗO:qߩ];U "T4ֽDw798"7v]; j@bm\H=Ɏ F~<39eۂc}rCБLXO㏫=s`Ħ ߫/{[SUǂOM>PYgeclt_rN?>86 27-wNaVU-;aGN㔜sdcP| Vra%^Id`i}PV~ʘJ$Oݒ%~Eٽ^qmMtIBo(|n;Α9`_[}?MJ |Rk+{h} >왆xVq[2R̸\#hdaɉo`Wع6fLY)ѯܿ᥽WЉw|yng܃#کUr51=>Ou|ZEjy]16;8񯐬Pӣ9UT99-].sujol6`b8?I?:w1m.>l9?T|NY v3$I`Nh8ސ%* %`7 8D(}zpɗ$FyJ"~Finp;׏)q<^J$$Wg_):9 jd uNߘKO#q;+$ߒQɗ4xl:娾3f;kF>Cuu3oLK*%Drl`>/t}1$4kܠᦧ -5wR|"}(v&AfMͽL:\~ ٫H|f7)dRJ9}g6 Y2`W<Х"twīWUD9`m6Hmuj3*jK ^O_Om0V9|ፁ"%ſb]Kb{$/}dށ`6rR{I`]zr]̴&l/c=wO>ښg=̧ߑ./֮sZ?Phy<%P~ҸrP9@C99Q وȓdAw~o>6Nmٗ8l6.xcjnt޶G>Ї5tw](>8v3$I`$G8yNIF3/–b m6H"e6p?9y dۮtD ÉJ%k J2Rhs dI0hzM>cɓ"T04 O\I<+(D ōI5^=w9za;W2В`(jޮ}cR]R(I$\d +Tِ$~* =Y'ŚN=1$}boְA m {ɐ$RYH92ٯOA @ښV'dDv׻ [2<9Vl$xǂ;ڷNKQ66lTV_~I’a6I1t|taa:ŭWЭC⚄MB9G[2,:&ѹy횎=Gֺ)6H~lISm =bxl\ &|b}Oo{.~7S<^82voNt[)ƝۼanYC̀l76fX D/;[RtK֋n6Zlڲ qQOr ~K%bG-_@ נƗ `ȼt>ojIGb:D)k>},Xh-YTqH Z49pKb~*X k% -YtRf ֘ ꏝ+:[/ ^lVnҝ95O*m;ffZa 8lp$ǟ t]( 0LL mn4$s$9FN3P| 8$i.qpص}J4XM[L{~Eοmr<>U c+C3ĄD9IIi</1nN]RgƀV)1RsTxK>p,I"sx#I+X;l$JƑ`W ^"= =Sꯃ>]ْu.!\C<80T8(ĖbZwi_5T>"6l .Y^Uhpmtj<#֡l^=GH6E=)^ c %#$e/,J~1{Ix _ ά-YeyGZUt#?g,^рlOSjæ,$lmP>H1tXiI/i l"$:(({r5m6+nř҆8(Jzx."N 7 N}p UDz׉#PX+]MT ?S0*nlW=?=3ؗ'xV|{JvMc Gm{f:@DFM"1Knϭ &+؈ @n;ymr'i#w4v/^GȈ^ӿ.Ɣ3XKT\">GܒS:Wx{fݸ>/kֈ i/o~NFq}+\y +|L-# ?z`ng+J8XIcO1|k9w8jj?ɾ.zKꉗ鄠fG.T*fr"ۼ+90uƼ{0W,ͰtR ^-$s9Z{%.5?YaВ@XD-BQ ^X#͊[z/*H؄K$h /㣁Bpn[/%`n|IS&Jm΀UPl[*8e Xup?sd(" r %2Wv3do2hUqnȞ˧U DunX~U+?1]jkmjY/gkۛ{F*3vMLK|L9t*Kjn``i`]"~Z+NVq[yŷXG .R`7K+//uE܆ɜ ȍxc'6Gl0ť/VEª%o]$/]*f( z-?Z=[6f0= "+PZ~7+n[a#~X; pڈ;o˱<: A6G!}ʷ?9ȦVd8i#';:͙uh#Ѕ%bӀ.mnKT1R&Up҉J`ۗ d{Ok ;R2\dW["|? V%)nd8{R ζݕvHcnK޴s P 9qOjYSqsŭy.9v8~;㗘 8^"I$H}ۯx+nW[ 8Tp4XzjuO2Sk|O)(m"6%pJLJ:۵$y l|j{csvgIc؊dmgnכ+΍Ѫ֓PBsކW88칧͊[>Y`O`=ߖas[)nm~ ;h6#'NeqksJ~Vlyv-5u[Eɺŭ=,m2k&$jOaRg%tl.!b[_~ (߹M5~ _ܵX`f>t[{{ŌeO]*n )>* ps-_'諸SNw\"Aȱw&I1+lwMA[$KjnsU$o*9>ӕpiTO=6#ESOw46o(n66 7 6)c9[Y6/R$\=l{,֋}RTŮsssIm٣NwN<>LSY"gGIO6 H!Р_Kd'>x7Lj'3߾V*O2{ t Ut lb;~n~f-+%_t"҉.Z!+):Y-;$+ٌ):Zwڌv*~N 1jJ@Jz$t î]JNqk}gWUB𔠜aֽ`a˂%'U/Ry Ip{Ž_\Dv%=Gs•YҧwO w4}=/(W>i]NkGP.AZ/ l:zͱ]u<=O%_y+Ȩ_IĜ$Z;xz>9 ^sNMɇ's"&]pA%EU5!UOJe'=.s dU׫{6?+ʟnL|I5'-IР}H6Oc;G_ Vky"_IqBbz ލI ̴6B=dʗ( I;>xnv{)R@dTm6*l=vog tBvtWA1OC{}u]LCMLlyi~AkK=IPOr/QUt|$KdD>޶q=b[XчKtIeG6 7W*53)wS^rj<6~S]:dCl5>_{2œj]Gss*}`|~@K[lٴ*go77~ңv,rN$3<6sL2Hxg}[27Zvns¿%E,b-#WI>UDK?qU~(6 NOtaϴ1`L7ԉH`ۗJ 9=|8`_Ik'1$d({(*FQ9 .$@&| N7 &46 FUYzJ Gmk?usκ n-)^}[u'/qXcr{rVI6Mv.A\͈)Iu3|SJ@N*~| hnvlzW7_ \ז$*=c^t:o6Z𡀟dO7Hg'zGyh~6CA_9^Á<뾱ѱy%d_,Qq٬b͓ sunb_"Xb䵃{ri]*NT7%\xwP\2/#{{w͇OǿU[_amd*l_-[i$%m7h5h;  ck%A{|~u>#>u9`nbO+,6kc2|d_v~Grǻ=HϣLPV p9/G|X`}n7> 3>X"kO@K}ɛ[nρɶueȺq[jQ`tG|mm7YqǩU$ 3CpA)N{A3 c!ђfa !;E ><. K1ɡCBIO4}-$ $M @$]_%%`sS\ M[ʐ5J6'^9ݽxqn/ƩBΞYlN|s|[kKȿ ~U F~<mk'wza}$u$T3Gl 0POZuZH`ۤniMħ>K>tPDqn,lwNghiz\DEfs&uy|l"61Uvj`{$}w ȫlI"a^+_ m56۳5&FW]>kkŸ3?8%Ml/6G4]DSx~I~'2za`.t]ͅ9[?d۫H|(XB_q++l~ 6`#wT[֮ XFuO1M}Q^V߁A(|>ˉ&}_(ЎL%gsP[fqȂ^2U8 K=_kʾ cTb/m7Ӱ͜+)ZKχCR~Sc|%#jcƁ|n}M[6b.;cc:Q{yRT~9F!t?;v?|MUݍ5qU*Ou n{5M*QnUbpQCM&D!I`@%#%ٓk?N`Xy Vəg`wyԴߗc@8wI %%_Ol9>,Hj9^?uj/ c$|US<|g *(\$,yGH`=dVvW1,|_SW6 瞬ĥKM6| 4^Hj8~nGŜfXSzAEDBkjdoA<:y*xfBriRbMgWk@/ *$-Et\;vrNBY'zB$6Z0Z{V.6l0Ⱥ|2x{zϺHZVoۀJ7>FbGTqD|"k޷Nt8Kvb\];|>{qB|fStOkV/I+[iKd\E@%h3i7˅50{tZrto?]6:!nQ3=br)WXm}wLz)mⰵ7N`7Ĵ9~{Z"9Vwܭ_횳/[_⏮%uNDfKhRa3S˨mU1CNwFF+kk=~NǗMv%lO35s.}yur _,v\W;6]5M"QnEZ~W.K  u B *hr6U N_ m(bK' q]M{xQ]Ĺ[s V6dw3&V._7"d[ѰzOG>psfݳ6班מzF׉6X/zC}ֿȚ潤vCG|/cGwV=i>|x etXC>y9rϜ_Exd2?czTO筧lmWYo%֯CȖnj9d_%ѩVN>شy>#d56a† ȺW,k}Ra}7=spMf9˥^$OyYx;yye=%"޾Z?%UtZ6h0Xۗ'vVGvu%ߜkm\ljp;~7QWd5 鿰vv>uACCCCIOWm.O,݅y i싧6ހ:34$0$Fq&^-RV^9 QPܾ)zޠ%Q1e7e8$<~aҾﻟU V=_)I4$|7w}Gҥ뉮ih3$0$pH`Bjo F?|0hH`H`H`Hܑ: [_ |oS<^!ACHiS{/=.ȹ(G!W=;ž_H = yzs?Lν_wi%O /7hH`+[Jڿ [k8$0۳ltD L\1!!!!!!!!!!!L=|LwH`H`H`H`H`H`H`H`H`H`HL(nUs8$0۝_2+~k/"ܟd |y`Oʓ,s;}4fHTHTt>_)&}#8_p`/ړ Ő:Z @=dv+ 6ţlǠ'Ky>+`p!sM|q0͵{ $7X[][TUC"Haς"=`ŝO/GBrZ=Mo`\>xR?IAW vAF;F]9Pl_O _1?_1عzZK.ncIθH (nw_'l%t`Gp3Trw}OroQ,f3?Zw.^`֣љ.Gu&>'xj"{z࿂[; AmNO' O/~7 ,J`;S9;l{矃i O# x=+ ? 4m$(BwoS\ۘy|yriz˭ќNԹ򲋍I] 5^ѓz43S6Ɖu+}s 여+ǘe{m}+n˜?.ɡdfc^kc7 bf|1cIz="+A/޾9/\8O%0,~6xVb\Nv~eԶssr^ҁnJ29u Q9r/'sX6Ӹxw}yk݃ 8c?޷j\׏?pʯ:^`կC & )ӓ k|nb=@[n=>xJx6c~#;m;p.^_TO5?}kՓ|zuJh7-0`O^_|ͽU^}?WO6#߅s׎8Mo ֌s8^]^"6u;N)d>xZ_,}w_kU7%p4#zB_Ja yq|^QE{҆>=:[Ӷ?b[+k__eW||z]?m^|8xkO=/Z{W$A.~o3*P⳪_">;-8"]o ]f`]cV_j?/֑mF^r%ts {sfg/k3rSxe3|{=_Qr7cnF}Lnjfa+nK}5vFqS"@a[+H8kw 8rJhW[ӑATip9 >[%ي]P%!JRpJOOn; \ $((bO0,pHf<}pd-((MbdH! oI&2f^(2G>AX1AXPU}hɅP cAT#I$Z]$%mJ%sIމxxS@ <%7IPeK[6(?DC`'_pkvֺ-0ُuTh-?ųmڻ HoodO:Q怎87- PH?=0I6 $YQIBg#%XsG_X /#cҫ92"w{ˏGW#!W~s^!vI,hej>XAڻOV?nCj#rl(&W ;^+z_ӯl]آU{3}+p`鳘SŊ8~ r'sذ90a>ֽ-tagZ۾Xз­]G>pD6D∸ϛqwtbLZ#>k a6DlT[xsK7 ? ؎\%X7E{M='/eG(s,y(!ߪqC{fT1W|= ӛ3 >\]6o$"ϛ6.vFqS >Hz%7S98?6`H.* `]!5W<ԇ@`ɲ1IhJ#x*yt ,X|+(Qm TABм7G}D_I7N$+0ǽۮeYƯ``o/xH>x됄U8_psc{$/hJX$3 jCB9|Kh}6 Pr^dH&E: JN\$+=hqk]%SOd`tLjSbBq4n2Pe%\@@Xؔn |U>+\1#]gԙ$ߺJ٬5kPe EaJلDxUDCk̪v^`CiA^$m]3UdOaU =U`J>%ӍxJ/ɧg싽H0%"휀 vÜK=O~#ݴ|EtR퀟(91]Pc*lpr> ?#2Pd[)n%6dހ~51O.m^Z9o]V.7+Ljؽd^1Q6꞊K4?GAjdcVs~O 7?Ū9d-YAkG٦1ٗC< 誂 !}LOE˃?=wl?&Ɵ8|ƒ;3qٞ|x;ev'6/7<5~,ʎ6r,8_/Ze33ǀ-G8(^Э?0*d #Q_[\{1#T#xx~J 8\cS{k#W2incjˎ_F/!+Qno8O#OVRI+gg- (-j7U~$U 8r:"T@oiW>)$DV!q@o+ |H4Arӓ-([p% hɚ" %$$m>2}[@E @hmnԜsS{kQu@P3,A#_+w P&"U,p -P@yN%?|]97'HL%/E%N=u羸uݦAb.sHdY}@+PE3s=Eؼd.A7&}ū':-!X@[[>(2{-&{3~%}Kɐ.WtMJލ]>`l@@?~.?'zEj@nn<ȥuKs/VpK{~eu"cI񺴑| s~}%PסN#Ř3wN{.BD]7o/|ϗso `_E{rQes:.D2o/:gW|/ cB%`t=ѫb5d! L`|t_7KrM1k6ūkF4'6(oɚ9mi|s3'Ob 6fI b~E'ShӒmm>ׅW?>M_:di Ȯ'y{~K1^+^*VG;kzۮx%O2hH`J`_: M2Vz $˜lOBtюs!%ϓGH|_&K{aH_u}I!xY$C Y#+-&И?Imd`P$H0nTs5#ɕ̧% wQXV? HMAad#ŚLwjc\w2[ N"HKb}k Y}$fJMx%z>Hr%˞fD$/ MEI-]9AFbBXkm]`Nڳ9Z*nob#n}gvFqZSd).8bc'nC#٘ Lۇ2\) xk[_tri_Nv9$d)O}`wVq+Q 0[-I($}4~s~$B[Od W$?*^oZYF{$w+:ŭ9ȰX&JZ1̀'[hSkaW u[Rq؛+nOf bh=$ Ğؓ?/ m9,ӏ*nkOUOS@A_n}mZ18=R8};U.%mw*nܞ?sQZug~5:4K_Z/r~V~S@@lTl+'ғ ŭ鴍#>H1GK-`t{~qk+kO hvbc]NɢGH 艼KK4=>8sOڝ?~d1 kWs,|v\cɱ]6S 2w<}H^-|G (?fױ݅)CFqB@)Iii6C]aډpqbYA\3]8'Ku7x%){RT ~(OKX9I rۤpw>Kn/wmu398 z''ܼZjSRpWQO%iK+1W @bГ|LIJ=TH$X+:ŒWV󺸭yHJ5a?&iDBhgŨmWv%.Ֆ}8`ţ=lijKIUOJ ]K'[&Wm(.M|z8C|_'kHn|D/N%l}k|͡COB%RqkCوD'j aUq+n/`5bsox|/YSL;žq*f":>q]9 *n[V13ߏ圍"9-Ֆ3ۨU/ b{蚹,^~m Y[q3N{ vKt[;$5]^1l:XJL~8@2r(^igz9@as@Ӝ66r]$)\GbNUܝ'%gI ſawO{荺VbO$mB {F zJ#I"Cb,nΟح$Ӽd_N^%R is`j A]>I.zr ܟhIV:@BQOIס9}cW9bH8۷a[<]+md)bE9%,=Ѷ^AݜK)JU^=#/bzWr,nNs!O35f[+#sOlH`QģB:nf|l3c9u@vZ\Gl!ަb_;OV ml& Je!j5[*n@rlI v=%iAgsv夘t.1w#_F&QjxMwiMN; vK"J^dQ (<#I$Œ]:ȓDc[ȮNUb)oDZ`xj`9oy4^ I¸OG v[:$ؼ7Lٹ$s>Y-tkӜVEVѵr @}8hf $_A][9TqS}ρF@Kw'&W<ɭMm#h2I$Wo ΞJ䯜S tvI֚VUۓdAIcI񳫻@ zZ/LB]۲<\'+CvM;ۂu 9kyV\$xNPIBk]%gۛG&IorXP*  {=Nr|uIWX_ۼl EwJ?IO^/3OE$uKsZ;UZ;M?۵6U'a%>Ӂ!ol35ŊU4X lԯ7Lw:7R\eBs@& V<[I{!9GlQ%N\a6%1N/i|_\;56 ^ԇ \W)zF ȄN_i⛽fMf-2>md(.kK>ufeWm^ڈ""=t[cMr? hɺ %ه||9>" z(a@ e40X9Ͼjs_|0_=邸g^kH#?85$pJ`[Κ, 펦d9''/'`qTŔdO R Tp6 Yg#ࠌilHVNK6&I&iAv%iV t>@v8Z;E~uM~4B}G@}!$3~%) m~E_IPK%SedF"$[/FOidzڜߒ82s @qI,'*# pxZ( @@bDNM5Jc{3OrAcyYG\79J [/i)bSw8(]wJ"X\tW0J:Z*$lfїOv$] aZKZ jǡ 6<+ }H%r+v'?PØ?Hxȏ=9?A[)mcoCkh=$j|mBC-s  _t,8^< #DGۣ$_%,(C& ɽ䮃vFqe\9ُަ9x3(hI)8sOǂ $ ^țNJ??$xi; xPlԿ?#0籁$q$"*K$I$/P*A_(?.|\]"LP6OA#RDJtQt/#F n݁`*H֫I' |_ @hL峠gbZu] 0ғݽ/g)S[m,wK:Jz ,Er@/m됾wxsO'~~|?]kIБ#M{<*N$C+?!I<8lџ$_(WПGq%>'$잽QVi;{PknvTStW^| t^^$׻l\ဿcy+%g%d̋N[%􄾴Czݩ>+[̷v)v߮+&8UD*Tϙ=`P6I$Ⱥ鑂)/I94Eϩ׆ εd%m9Aů9xSx_' c~%+~-A?#̓|Qm_%1Nd޾#1H76 k:b/'vdd#@(Pر=KFb]?_47oxj .ѻ[瀼鑾ox6Џ/ OxᏭ9dck279>jl[=)3[R6 WG'<_Z9ϊG?ήE}dt #415S D| rZ,|K[UH_}䮃vFqe%7&/J! V 낞u'Ԏ]=9e ێi|K{I%ɪN Z H  ^|9Scձ'hn;f냹WN!{k;[ ytUn:ɯBSAg<A'.:zwގص'rxTYqܛb'aŐ*Qܞ+򪘧/]`kJ "ߑZl{[\*>W}v ^x+fK*5Ag+Ƽ8hk^74$P軜8EvߙJY.1!G={TT ֮Yy݂5̾SĹw}?P/,xDɵ؏|0!{>oy(]=<%@uIɱ h3IL_Y 6Lm]ތyVzJ9W0g#<3$0$H`CNI_}Tg>x9ڵ}j~ϭͩ}y[|q[ zJw>$PɢM>}l=eqq v((nw v(nw v(nw v(nw v(nw v(nw v(nw v(nw v(nw v(nw v(nw v(nw v(nw v(nw v(nw v(nw v(nw v&ō \Tp_w 2D1kN/ɸF3 G-14˶[j}ƅxh>$p?;~&q{'aoKܞom |CZy_$QܞKÜ6v8y~+8]638y\?]=;nwl~"0W .t{~6r nq* \fZidYk-mp[N7sRxh!/ XkX4@p8tiLo9^}lk;O)O|cyA6-4&h}*~o5Ƙgl,xr{fKx̮$`p8$06x)Mx$u9b{,NB A~08]~QX^>y;/sw=y][;n9{_:1EݯCΒOv=wx J nꕂ#+`АSC30hHഒ(nO|9~:]cp5zWAǮ:ʸ zsesp3}[oͯ9_="O KzuHz'AC_l%c+uwgFq{+ߤ+OV~/xmVsSh໠-u52O8F`:/yBl`5Sy5R{xi Q񰑃~_z6'ŭBMVw9YZ#o,ɈnnWxA\}֠a5~/r ڗ` -_q^Uvgf-=[OC}}jJڱ/ș]X32&u}zΚ.~]|cKS kJyW۾|͢5u%KoK%I鉌qVFZzm[G6!^*nW9ɋ LR1KO}`KK֋_fV|+?-6kCrzT}K?edT>mo?8ח6xsku}P+z3\+W$[Qs1~׏kt^Gr'8DR{;K\޴\U;@{gƥt< '@w9OQoξg~ ijRpKY`@C\!?1heʢ/ ^ߑV^uoGEMڑS&^u N[*(싏瘬t/%O*}a//u X izx>o3ɴqw//'qsŭN\!`Snl̑7@Qs|Nwo2?s+^-P ŭtZ]S@gJ7#AG?񏮸Iܦ@%/%kxrοi _\{/|MH>u#x|ٙmx3 $c=uvD"ۣq~%66e?bK] nc5 =*`X^9_{.Чg戤5^lPaf+f,mx\O;bNHy1pUA/r|7&ʦfs1t/0x1+q\}\U$u%#1;suZ{51 %ڝ 6+~.roz_O.6d O`Wm"Z2$&5?b{sMS|164ɫhN3g*{XS%0_}-ui+qIP9zYb%{I"$ Ι GOVEB! $ mkl9WNL{ILJ%B;=qH$5oS`.d 9ǃ/_6+bmoW=lU>f ǿ 5=٤X^/  s!vrkC ěֹ ^X"yV4Z<=[lα 9 {ld\3~-͹bحրnFB3XwFq{++p _,}Q ATq hprU8~A WHOS)R8($ X1B )}^ oiw>Vזs +%7c;BphI@a .As{@z/q_<$|oKdǮ5"Nzr5 gOߖ4!i3"PX?sWAP29oc᷺ ߸a} N<;{=6Z[i"I"dj_|5;ͣ@>#|%یQ\$%Pw>N}qGrdsH%EQ[vWE;m2T>)w_4t+,*HjξId~ߦ\7\SZ=n܎7N9v5IsOG%UpUqK~U2==T>OQOJ5KΗJcN_9g{>[Hl hm+8­u~o:e $k#㭁A;ɫ>hP|O?:l&uoڻι%"8t!X[gK?vD~I+%|VvbieǹFU_d`=֋\A{wKʧ\ |5@ %1曊*_''bs^;d7Ԟo_])](buH*'7ٜćB߰~/d /~:6(zS`ck3k]y♯5ri_|'+GΗ[='xVpf,cjsBハ+lP"h} \-~~^|0xcdtp`}Td_׍W+fЧP@W,◞|8\ZK!AgFq{|tm19H%ůVpVH0J&Nq/mw$yPiLA\u8PN3['E=}ENH6$JdVA)$#s=r/̮Nt]T3wdNX$m#VW,$2]I9 &KA؎͋u[Y(&vw<$GIEk[Yݒ$JZo>С=;3=Rdm菂kmdvgW|}v 49i gO}qkl<* W^iW` $X=?:]2X QK `h.8F$&DD@GM-I$ nlS{rMlkZ3⥍$z~k׮|[˿ Z*OK SU%K{Gߊ纏?įfi`m^Yq^k ߆Ϡ;(F!'*},6Gk'WqK>-]+zr 1~٬3y8o@1)msMEN$&v[W̐3*?G7r"#(KT3M=t!h*8%H^D*|{() P@0G8GQʀA!i:NUr@u`>]kZE ,iQFNp@ | G_`g)%97ϞI=$7ĸH~(EcbUsu!Lz(۾`w:[H_I~%l/z[Bg{$I XA޶OOfn?~J*aZoߙ}t_㲵.ɕ [m$`oe\O EO'U-K,ɦթM*$-ItUZx>I9v/~9xn&-x~C۾1$d\K}WHzd^*,5ꋕR{4PCeGְZ/E+:{v*Z%tAw * r[`6}E6G"u(h𐠏[x@Iln|UsQ@Q漵V,+el!X?•=i:W%ՓRsA!hCdn 65ڍ:[y%o6W\j+f :"\@/w |PgεK- ,;]=$ud &x ص$Jl;Og6]!t,D !>0ޖ8I@@3V;&Yh.%Y&m.yK?8gvWQ0ܫG0.v[Ẕj:T ~U`YP wϋN/l]dA&=-Վ.НZsr|4$BE!Ό59'*Z?/Kd6#Ivϟ  RqkGژ% $7_u`{E0wR$閤Iڼ-Ip<\tȶ^؄OMw}~>~mu+\ m%z{/z|>(`]HzĒr^㦱MxzA,%smC沔X.oU\ˉl"-"XP˾|1+/=dD:s-nSZ(ldarlgiy]sm#Xboi;?6z+~$l任+LG]X3(nO|u+ 7#OvZzx>pRXƓNU@%i%\8i~sŵ> µr0hՅY) ƽ''O& 8{sιHw`?3S9`@- sɁ%| ? ^|fס,Ȥ͊[; Tp)N~LM>K~?@KZt|̀,$J$鞖[Fw$K$eO)Ξ(u䞭ؤOkW,Mʵv)jy$IE@Q3Jq빟oȸHn?緿u}%цݚB-n|I._Ls"RP*n-ـ7rK"6vDlv.?(n$|/b A<|73K;K$}59&Ζ3*8a'P>`sO@vmA X+XWbAߑR~RJl Hfl$H ;fdJvId$֥͊[˥v+-}@%kwAPی# $[%yK]9B>]  i)1$xn}ቯRt\<' [2_' VKRס}iė.y1sV(YY-n@~6H~>|uf;О4IJ%u4gN)mIE?>qj|xn`#mM:ŭ$$ԭnl GlP /2O_$#KsE=1'v/fd3۬>6֥͊۶vq0`bHQTeVwՇ'hq#)<趹`l#Weq1!76ڍ+3#iɺ/9Gֈ ڴiSY9|vfّM"#w7GqJgQܞsrdz m t|k ƓN]+{i/^ KB/ 8ZvVJxcũ >0KvG^pK+A{-x KI`2 'd'|9ɑIz-fS֋,$ u[|A qUS8;dwaA.ɓJ=qTzRyX K&=ŵ9 yZGlnTJ $/  \y3]" Z"ɤ"Y[D6k$[t~i 6smfHJɐ,jhbm(I5W 4-W<)tJ5ߞBA͏[#W;o_÷@{<*0gm<Pi63 M?K{s̗JȨ_扉M9ia J^6z[7O=zFTI6W9HiAFtQۧ͋=|QV<v ^m/x/2c|ļvֻ1 v^Ŀ-=> twO|g`Ns~.W_6*Pn "O7fs}*V׉6Hs`Ώ:[A3 ֢ߠ`#\s?8~Ov;W7kڌ$~v~Zs_Q\'6hlT.ǂ>?d+dv0Z򙝊?kKF/e󽏨7r E";~O];\Κ˥1gnvFq{ǁ1pf;i am = ہD_"j] $h?&x| Q ł}7>@Ƒ;M<ϑ{%@g O$E !:zAZ}n# #B68ڒk_l@H@Ғ$8yrWѭrVnZ/ ԺH$C $Y= rɲM UW'@6uʹNr&?KI\#m[7Ŋ1ʸxc7}R`]Ȫ6цE[hcͣaE:E'c%S}HNg飵1ȇEJ[l]~:Z"|+:RtHkh@O&dFtd&ٜ֍o_d OsB!ڮEz@N>em~ E )N7d =j~CQv_5U_ XGћ"z|s?gNGO6veWks{`]JF}.&J|웟D~} h GxkF^}/MįZ¾-YP[  Zc}3?>_o:suWEu?^*"f,Ւ7gma"266 1tZq Go+Č օO 6AH_s2譍0GxMP AK'>*r[1yY"QnobT:x[*8ZR-r)gϑpO 8Ar#YJ쌡px]ɴCbǡK"` U\p֎ 7ڤ;ߎÁK69EYRi>u9S$P+Bs]\ gP|$w`݀GɠW]: $a*ygI~[WuO-Zr>Om$G dbڼ9[@JN(A Ɨ*:[6\hzs2>dm}hO.HFK@P e\u#%(??V!27>n$ Z=!_%1ST;ƣ )XC}ׇ 2:`ɤ%w lHZ57B~m'6$|/ +(}q= 90 l.;Ik}Cf/I{Y9^[E %$|h\z)jZϚI~$V|y~2o9?EkE+wC=Wkٖȋ شwdMc%7cj.Ckclܚ [}[63cI cUT/@^}MWkH2_-&ތ/9p]'bCχ1ExūM'Q m3IK{:a 4k6Ks_Ğ6G-p:ngOp(`3=o4͏nhr)\yݻkG}>Ӂߛo[4_gdj1^~$x^+ks8!"lIlcO}&_k򁬵kuR\my|ǒжҟB w 9},>@,:6C˛閍Zi't??N?*:|3lXW,v ϒt7b"YT1B;i.ƿ8b<E1}ݠ):O p3=2*Fr֦ _+⧃6WQ(Tfc>_oXFi>u#(-nFb@>kN"zAzeV|I~dTca.9/l,kns"/iK1lM6_z!+}a'zcdNT_tn/,^kzw:')/Om DdȎyH\V=tcWK9$G$vNw،~1B|3SMvxzbp{[eJf{yUf͍\e˺1C_䣘mɜC7[/~\}5mcy5ښuHFw#?\萜i34aNEל5Y UT> 7G2z˾ {U Jwpk_1$yr?{_*WM[=6aw\>%0qUO[]v^b3hHt0i v 6~;Xۓ˧  XƳrH&B5dke l8%POIӠ!!I`on*+ztS%1!b5$0$0$0$U vO xu͎SyȘׅIךK^C1w:)  xW9;wq0>8%03yuNߣG]< t/c!% w8A!!!KŠA;lwl}9w |VʰS%/?G] @v _h4$p:I~IH?Р!!K~}`/[{ (1%<^_KN xrgS꩒WB\C'K~}moG, ~ QnAX)Qܞ2؂FqaCCCCCCCCCCCCFq{zjH`H`H`H`H`H`H`H`H`H`H`H` 5J(y./[at׏. :w%p:کsWcZ| ݞaAI|6''NGtřiksFgg+LF9ȝLe5v$NKNxm}!Mq-xs[JkO8ϕW`F_#a"9V(vT6n<03| lNWy/7, Zss6_:??wn~l7s{ľO{鴧?^vLiqo{}$&^n}}uT%-}E>=qVn;_,A?iƴ$;f|m/ 6'8ިϋ5Ղ =Ogkq[wIvU ۧmaOwM 7Ӛ'QܞqKzM2#Ok#܁L3'Ӧ MQ+RvoOqH(?4{w|b޾'{튋 '^v_>rNF7lsxf֠S/||"x]`c'k7Or{Cd NNwMO{b@7fO1):~|nudy3][Fů՝ylcDgz\;9rZOn|_.ʼn^s>,o6f>7:1vm%0f9Ev\zm:znă^ֵtyG\/ӷ |\|[4e{?PH—H"(xӨ ɾvь*KncM;y5+7\foi_h'{mϏ|\wE[s@@~Zc{ ֹ~/B}zrڒAf!/sxcZ%B.c6:nc?rwZ}Y@c+iOqKNK=om^Bu98}#] };6_kO!{ 9SK֡_| Ӓqй}W6\G~%4 )VZ1) /Ժ>؍)~[_d~zmƠl'͒ O{TJv(/N?Rqy =eA㻺شyx ̑KyU[E ]VWdKbi=gn [g:Gţx 쒭񱭾*U;u~Xlc$~Il?R8Qi|?B|_|`n(GO}<=(b[;kþ_+}xDFb|^tDboxՅFr =#K K\lk.-_֞l_A.rgR޺4Okޒ ӹV/9⳷|݋㧷}&\/N*'٢@b灧Gsc}!idHD|t_/]*jfߕ Kkӽ)x0zE9$Thq+sz 9cc+ TNcf5k`ndQ̀$zt'_Z%"KE9GBSR@i_ _#'9-L"(6+%|ēq+H0 -}&mG@''E3XgWQ]}+ dҒ5׀,>* /r14| Hu4@ٯi3Tܮリ0o|w˦Zc3{ $-?_L,bdƾSEVw\|/j7; TvznAG蓤K+р Z2{-䳫6տmAv>Y)HtdjHXɈ:9Zsn|V`,gbm[ϾhlMa_m^1Q#6/w ] :-|x@Pc L”N}2Z;%sAo‹ᇽ(śG}q+>87^h Al?'O['k̗1=`)m8=66`+{ 6+Ѝ\Fpw;dXwSJ-#z/ħ zFOc$'o阎Cf[<%XZ]fc_>'W7sy/?VdN/ Uv&v;#NK*8:A=AVR8z@G"@3Erl3 >ƺv}Mn8x,@h j9@H9Fť` }B)%o)$tJ@B0 F7g?x? j )9r$!AS2Y|ppɩc]PH@&o~kO<㷃~*$dJcΚX+&A !s8X+ΨgsN*$* ȿ%px/]o?:H2,dL+ {r>?%]rG_%˸dY{~Z[$ ${+KɧGX9"[c@`v86+1pdͱ)mN$Šw)C"-;V YU+[⋬%$0`zFbtVP+X0@S%>Kywu,b cH!;IZA{9S}"ްsrtQޒ%}"Sby_Nj\/]Ez^`OM |ᕏ<Ԍ_H?K#RG76#Mb\K<\C)D_ ET#DEt9A |ؠzo@/Լ(r%]Acg?Z3 Yv?u࿂cGkJv_l}슏{Fl楁|an5iMKKk)ߑdd#q`[ڸk_eCƄ^ߔkO+5|?]jt%x;O'7|3'99wAb*o 3qF(nȭ?z2J,@))#d 1VPIr$m"PR.6kÃc8|3'AD[IᑀB Ow;r-9 Ŵ@SD9"s3@)(cрsoi#$NKn}UP]!9VY g:Gdc ijk@\$K$#H璽*ƪ t`mϛy#4M4wa:dp ap].Y6sGgzT9w윪Nbdҵh  PGK-Ym^rB/=Hg{ZZg z}ϦpXITiGQt|ɭD5; ^SL{[sV0ΏT$6ݺ.2Xjf/ϳArl(% q̓ vtx-e|W|8 >:XqÑD@db9ZS6NAs'd7 <ѵ.ʃ%e6O蚞xiAk Ѕ{ae6v?ˆN!>e #~uW0b0}(t0qvKT&7h ٍ޾K"2uR`;$'F[6,LY_G҇v] kIc嵍q$6t8%`=l}vGo]_mrk$I5)Ğ~5X0Fߋ}[{\d#kz8f}ln%-Y}ù~`%h.0_3vhW(8'^I7Iۯb5N+'ca~-xjcfmdkS] ōv:/g+In#IX ȘI\ޗk|̗ l϶}5ۼ+]Q:\ V9Ss {8fcpTkIg7 (dVno @@&bUIcV`&&y @' /4Ȕ/dok %,i8~>XeloE|dȑQ0Fn|:J Ljl fNJf@%?6Hs 500fK`zI{ck!q8яXh` 1o?#z^(8 &A>&*Hz ΀W@w ;~Tס$FljHPD_\#KDWi- [>Fa_ḰIgvm1^Bo :הCn* }~.K/ Le@ ,$=ɇNňJzѝI%=ۻ?<^?;C>>$qP$}7j$/=]w}祉iv#ױ#t:Ho~ 6ɯFN>J?a?%Y4k/{@b%Ӊ.\a٠o{Nom"yspBf?~Y{MGpE6'[K K2 IF.CtxSŖMM6Yt{Qٓӯi'T)=O!ca lܮ}82KJ+G`TI6ͤRکxIJH 1 qƜb݅Җye,AYorkNDFu=~ '1<\fYn kώBcd98&)&`Ƚ7[ŕE۩@%EqB7@z:^NLjA6pT4ĜÂ9Ր60#}#'㘀u侷p/R{I #AUUYTr'_yJٞzJn %󥛭C>-BjvE)q__m+x5rAP.[A+)5#/5c}id>c-XߍW NL b@ٚ+l#b!vTbĆ+sk QDjIR`M>qSj}=b1bϷ.JV_220`6$$S-{ή%I?u)h9f$SbAkwӷy4?pQ$gN16EDB"Iώ7혟SdpK>S{ 쵩6שqNR̓%쁤'1[[/mql%6Έ\yC{ؚYqZQo@1ĩN?+]VboѳqTPq+ $MnSfѻ3))xMKdlp*:qƌ5Z.B@LbԾ|X&K'`)~opx0[AT"0/24ܪ ~,]-KnUOo^ckA }/j$t.)kEcNVCKbzP2-j8{{ewX  i)A"TYɭq@e퍣kʦOі8!(`(J[#ښ^[ jj'g$Ftoo=M $= Js5r^q?ps#㞦[>O n 8sgI%݊ +EH_l-Yy6 3^?\dnHp&PSJ4JF%cň7ɥZ[E [F(L cE8z)|%1o:y?[R>j(8%&`?ԛ,vn~%cT[Wտի^E?ljx+_׾k^o~w,b ch9ۚ91mt^rvn5ɭNJ@ђ tbU(F9p`λ& &#-mEYཥt-ɭ1x,Y( UU#N,XyP0g;fHǂ)Umyw3 rgXݹ(ɭʷ VX Kn9& %$bIkInn1Ywm; m%Yзt [<@{ ,Wkvr$Jך%|+ drk A1Jt޹c4JnWI,}Nȝ{*1Zkr~u(^)J[/n~GOyn)[ٓQ\\[rcǬ8H@)0l/,GJʎ|`KNJxby`-ɭD}XFY-Y% 7MaϒVrۯ"wn%t+ґ[8 d)n6Y7k^Sב>M.7S[*T=4شl%֨g|c-5Vp^[!E)U! Urk=IF: ZH¬0s #-1  Tsg֩HnTN^wHI]c@h,圧[w$tgInńt*W*}R׫~2w*}ܾ,N%*ֱ#HV8`c\2.`ђ`iOߕ]WSwG?6`? 6c8hͷtv`kJAضDaɭB(l #I(tMwe K7W#cStJG7{b_ς ђӚ҉'":Å\bYq8OHvc[ YO>^ iG].RzKT?,K^2|OӅG% mgK^ʱ| ¯ȍÁg>p Iv3}r5)X҇loJ3#;:< L\G9sA$?{F1-xG0#')2Hb6@VJ/c8T˂6i5x ,}&7yY]2߷H0PY,v.X^0&"2$Yr` 궉8;Eԗyǫ}J9cK7Vq 0nx0j DΞ0 zv?IdL)g;Inw Z2q9nv0ou4a3OI=pr)^Su^xw75xoFƙuqRk-qX%5kG$I1~d-87$B:؎v,/f"#A}`ADG̯HHSi3ƬPBDFc!3ВD{H2];{c7d\𶮭bFIgP;>Ic'%=Fpnlalzײ =)lIxy\ޅ?o+^±1wg0}!`ko6u|)|*{`8~|0}}=QPJ2wz[tȚ>nh.mc6mt}>jtZ1Y_: c{-{r}&9~ V,fZq= ld_k\kf, "}ɏ >> om /ޯbí9^QrÅ艞ex"d>m~i0LcR^&~t0Oƞ/[a^uׁ|}{c?L4ۼ+]qobs1{A WŖP-$9fJzq8DOuAe P#,ZȮm VI-Qd&XEH'ٜ&: vm)+J0`kjkLB"qߥB 8 %? dNO γє|k?\֒` a30bhKoiR{;%W2A7׋i/P1OY$Gڗ j,C0ᢿ3 6' tJE>ׁ^8pεI$Ibx"~%:347/C8`k*L+r- 6.Ji>vK.Fl/''?@ٗ޹W"Dh~kOw ӗ %lč= ~_B\&I07?CR&sbW^ld%ę038xGdL)u>nn_Ճ{@IQk$;ƗԴs;s|`mZbYt7dO5&w ;.H#>gQr3E|V r ,doc֔]c2I7~R'.x_g>I'77 f\/ n8\Fԝ1"'Kf{ߢ[ޮ#_38G5F2g.\C%l*  _@.>o9v>훹<[=v~ M͞ %fڦ1Ҙ K`pX-?B,3;I}3;$xfv=}="o1O[㠼͟[Cܤ~I5uv):nxj#>xiQ"z#v(Ey/ CbI\s[c_ 3ع>c)@| bK6p gLĘW haam;=uuvKX2¿ DA-fE@qCG``f2z?Xsͻ=WL8a<= md$\6Md@$J`t mgۂ j9$K^N8I`_=g(e:c LlE$T0۴-5M`>_$ ^k6_(adbܮ]Z=s|5+^e9&{kd?7%3dH")F> fS,V`>1I( Jrbxk . (1k,paw0@:$d1vIܶnYgcد }6sk3Θ ZNI {{b#m"V/_FRDಭ>4kɾf7ڎ#α{goK3=VH穚_0_o o=M?7?]m}sI2/;?Yb9`2q3OZײ=|`8^d=3%aksl#hX(nۋ{_)8}s}"kI' cהx%k_" 4/= Ay0(á}ef'x_0'a\N8켖zQ'v%zZmnlC?=X%a٘ :U2ƶa a$8C̐&]<0 ڜ9߾uySq`ڜWCdfDcm[+A'I,Z Kyxo}%{ ۇ'!+[}P%(; s 1sC8`Lk)=p.1kԣmMsK]德֝h+H,p]8XkkF&6a874ۻV D?̹]G6%`@kˬt$<DFI^0}0q8>ã%mu;bS6.yRNZ{7{n}+qDzY^eG,Psf& /G౽s8ζ5ދIb\`3_o~@S ur$ l14V8Ꮾ8|x=c7|C#I7ӧ\,v6>7㠼F@z71};+9$`OK}6ڲƹ#}!gdzھ~Wv EF eF۟5:Mŭ}f+*2&oZ벨]%[" !`SĂ<^ D^fq8`F^]yc.>r1չt.)zO yǔMoٶFuSVۜg .UUWs};~;cP]vދk^f uԦǴ:So,cMt?jDZ~=s^>5=ծ"S{$p,[) bdozc¢s^ Uέ|\:γW+Zgrcmh7/oaE0'Ҏ~mj_1 kv]s Wl`nӝa^oW/* ])=8c=oOlP#DA_c}g2;S>G+Eyw?ӷ͇} ֭/c{qݸ^@w5ikﻜ㩡Ecy>~L91򽮵 Y%o(#鑂>oʯ䶯o@Q$ғPT)=&k)ypU(1 w%,#w,=ajI.]۟7\mk+As=4zuryz+YZ:Ur{pW٣>*̻=!Gyq lNѝ?9c,*$" Ƒ2Gctj IīaqtEkv_raaޑ8U%'m]YVq:uۯzQl#!PY iϫei-wls#1Đ}y֮n7_k>׹zӛ&q% ( B( B( B@!PB- B( B( B8hTr{Р B( B( B((dB( B( B( @% ? 3.|".E#4EW _tB\/Q o?h> gQ!Pcb'ҏB0Aۃ~R ܡ7h~ӯ90Pҕ0So >~_-ˉKtK~nz;ޯ3>xw;ctiJf=?d9}ӥ;G~߅O qdOi㸿r׼@#xijl5d*t B@ۃNG#$ ,C{AyLv߹ V8OwoVBp+FiDHWjg_?_>|vl{pu%+s Fݫv vG8(2x, @%sΜ!7H[n8 K1<%v{htO=]4|SW3w^ {#\7BA2Hn+$ñk&zuk}m8Hno솃b(>\̗b!w 55%_ > 0s)iP ˛{O ~#uF;F$hh뽂,-:x(^zؓ ~&G<>'xcEB`):V3}~ B"Ph vG  7%B8Tr~݁zz\ѝ% ݔ!ug,N3#ѓ;jv;Q Us "KqרOt?ӧYHC?`Q)=sכ~l6|TF^W]BI?~ 6ck7" }%L0 sMTH8\?C54'܏<%x%nizMfl[\w3_߹s78-ЧG>P6sHc?_>#a kNvcÚ^gG|FIg D%}Z-qσ2N@1Nw~ Q8G{$$%a˯=k`|}Ҽ8EV6W_̅MboLo8n`1gs7 f?-{Ad{'[ⳂB) VhǤ3)z7K6g^N2oe #|T^ھTx~8.S}<>xi(ly0{b=z~՜` #:`+0C} /[aʯfW1g~O wv ,qcGb(i*e,Oӟo8^,9 FX0/7¹&`ў{P|6OVépۖcɭ$)W#xhi)><4Xʝr MyΓN0\O֍7⤀,H?MzO?Jlx/=I8G4׸8OI \Z#V_oxL?Jno)lЛv'Kd[t|zCT9|ُ_7\)y2/wKL e{M$֩#];k-ٓ Ɓ쳐05“5&;I`1ɪz$M}`H%X+c\,:a|d[=^O<* OМEB`tPa.Xpw cMp8F[mp༥y-`^H^ }OIEO.X GSjg+!Cc7[ 0o9}}㘄~.䋤@bDy$ٗ*zQ[ԥ}V2itEq!Oa@etGڂbSAɃD^yv ^ڳi!}B'w#_t;:;r`7s{@bيlXct~HQ@эYGGү~XZK,6ʼncquc;,=&8? $W !j* EvS1LOKLzJnvp.;cT tjD`&F۞T;6 :e(Zb9 Gjs`cpV9(xߖuK d{Ya50@㘠SR:ĉcO K>$+ȱesSE_Pt`w9HtKOKB㗃؊cohl|DtgVrk=$ƗJv}}&=|$ĵ%Ah$"dro[w rdEH.!9iGt_J[Y|K~"_hD%NoWI$Q#0]#ݻ $wi%H AiB#2h3k{ lkޱl􎞶/}*+P}~`L@ܒfĂM[ :dpʮE?eDa Ѱ`xH\7klDd'Р@?>ymg~̾k(eq Vw ~ M+a+ 2q2>$}K s:cIX0;H?eq͎`'>Nod=`bZ+d8ܒN%l=  rw-;YC5e[qKz[3"N* "PdutFIDTr1K9ɪ$iT'C}hs)rb7wW'/Hr`8LnSQM"qm|&;ƜdEp` 鑃5JS-g-xƵlc9aM$H; ,JEX.l8z fo*Rđ|#~U0E12sc-8}iX9ma.I%~LqB'?`IbWrs¸od۞h;HzCt`#zq B#P %a+3eD1C:2|ʽ$#c$hpSZmo+ms8]O 8^ȑ>sGDkIJK8;^'Sxaq, s(c]!Cv)Jl%Z[$:=qWkq /S$ygҿiF.<}"؝1,S8~ O=iVr%[S}Slyc \ c1k#.t)lQ]⏂?7rJ,*zv3ǃwΐqno ԩ?eb,t l){vCКž쇿ǘ_6u€u)Do$wD#Qk0dw1w[L-M8/qاǵ}K f{RS? Xy5s 썄]! ns2 o fc~.(ܮTDIP,yN%)'q:q<8`o;5H<ܕGLOƊt78iDVSA3Gm\8k3~srkHVॿ,͢ ;`}Qhȼm )kc; 3BB'$O[[|'w71Ws8{tgow5{q\{ IvŹM,j,?u=&|tLn_tXc#{wbѐ=`K`훖P:i ,* @%zkt!1TAݿyɭߙ̼9mC¸mmS4eԳ}&&KI֝4)"˝N`!RYVAm}gțoa?;K9Nk`kw` 'EF1Ʈa1愳MPޕݘvnKܪgr{ 2ҳ%YA0ugD2;Icɭ)۱{' u0] N̥->ܝiI0Yɭq0^\8+v\#q@0E\ۛRr%ldn0p-"6n'~O%.MbzI%rA-;A=۷,}Cߎ #=t*͓SLAq^t]?xIum=ґi{h$m_;޳!'A ǫ^SlIfF-)K_b|Y~53z_kq|=+vpq׊sp' QM?D̘d,kדj :I06L$*'cc85xq"|UUܡ RU!9%E,{<Нwo[#C=āK,HQA ;D;\c+*HL[%ʷ}M#mJFP1`"4VӒ cw`K{$_Vۻ #}⢘EkwNfz 8:/o$[WHC* <1ئ 37FxUOQ~pR vO\{Zݜ px9^gޒDo;ͫ'O<)?z~\IJZ`t`s&K;H.='_%I%tKў6B~m\qtw̖g-DyP1^+h6S5jO?aƀr+D0>(GHTvۇ"޳7lBik1˯ 6[k㘂JSS &QU.lm ~~n-=^tJ1M~ ?ۣ-MAF,`OӉF' oy|){/~zzNA+.whw֙Cu1;}5@!^*]; +Mǰ% z'XPw[bp]ONHA:'hEj2dkikp劃,VȌώU~W,xr^r+`3xpzfdtl9v|w$7oP% Z8/5o.rcKvl z]x|$*朲pd'  /5+AdH I} ska!i{: k$}]0s|KkKsvcɻKn@]R`A;uӃ $$dn9/z HW4 σE,LJg}s ɸ1_|>[_{&ͼ^Pv`ASҽ="ζ^6I7KI= 3Ǒ^i\k Rۃ}9/8f ~쮛;[0Uݡcz)J$#5aw$ѰKү"< 2ݼ8[ҒH涡d'x+;Hurd_gn}c;喐Xs u[+mo+!k}aMSfDLVf?F?)&DZv-?ɕ휷^[/   suUO($"(B+ޞQ})!OfvristO|o$dd/B:X&`zخw֗@؀4흛\_ *mu-eT0aϱ;)]k'/ wK^|0뛾Z JvZ oy\Wcc!P!Pa4hId&?_B,}`U٬ v,15g~raIF޻f-.9,(LF>F`w$M%n?)3~$; `wHs8n NFonW^,xE0rn:I"dN\*֩(q^r`C rD' |oI ?7Wzr@kct8h7X`AJSqȣ'>!bD,nϒ p|s3176}9+YyI$$=5 =$Y򎑵>*^}ڎyz^S)XJϿ,RF?|N 7EEl֖t`=F.^IO>L%)Vv{sOvi.֯Jn1?bͮ8ƾtMK?Ctw[GtA|[Ma`؀-U368-{3|tgH7[]s8H%c>6X7lCxM_1aFGk`g 1H1"~* )*]nH8?s-aSg{^qW@D_ɜgy8'I{p]ʨs,*{dծ!8*㽤I|vX6HEΜ3ؤ&ZɊズՐne̙qhdWٽRXEk!IuiYG֮Ⳁfw{4Eb[Y5}h=YX<.J [= (Ut&ebkIp̭ rMB f! ;vDžoi1>vo!$RBܶW =0Xbk[n11Ա}oƂA{3|y޽svSh8aNoNml/ (4/o}OG^&_d?$c1δrI8$H!-ݔ,̻s}|_p`$3{~qlx5_cݥ;~%_}m;3ٯҍӯoشJkD$Dythp5D7q>.T_.%Fp-k|xɀuD 0[ Ftqz]N{E_n8N-o`π{5}+Xgn 8d=wu}ߣktδ'׋I"}^p&DÅ@!*] Z#,(Peqʤ7 V J8e?YwTT%@{%S:vե&E]2x]M:( BA1oM(f PmG!p!)߯*u@!P߁b$(p*=!;C +* B(6{Tw$4(ր@%k.)61 컷) B(L_qϼ*IG>Ԭ c8 [M/<ׄ,tj@!Pם/$De2(։@%./ B( B( B8Tr{נ$( B( B( BX'ܮ( B( B( B#P_( B( B( B`TrNB( B( B( C@%~ JB( B( B( u"P: B( B( B(=5( B( B( B(։@%./ B( B( B8Tr{נ$( B( B( BX'ܮ( B( B( B#P_( B( B( B`TrNB( B( B( C@%~ JB( B( B( u"P: B( B( B(=5( B( B( B(։@%./ B( B( B8Tr{נ$( B( B( BX'ܮ( B( B( B#P_( B( B( B`TrNB( B( B( C@%~ JB( B( B( u"P: B( B( B(=5( B( B( B(։@%./ B( B( B8Tr{נ$( B( B( BX'ܮ( B( B( B#P_( B( B( B`TrNB( B( B( C@%~ JB( B( B( u"P: B( B( B(=5( B( B( B(։@%./ B( B( B8Tr{נ$( B( B( BX'ܮ( B( B( B#P_( B( B( B`TrNB( B( B( C@%~ JB( B( B( u"P: B( B( B(=5( B( B( B(։@%./ B( B( B8Tr{נ$( B( B( BX'ܮ#Sa6|Nټt19Mp8 c:`gÄj"` B"ѹ8Uׅ@!PܖBC@"7|ym>0CD-3Bic?7VPa3$^|`h# x\g 96:x1PY9z!XBD5N>2^Oq|]g 73K%Fǃ}.Z w,<ؔ:w8bG_t즧Tr{џ\ӄ.S5SdOnV|jBнUNJ6MHr8.  GMOub1V}5- B`1*] áqb|> ^&+s\ᛃ/ɁX >&_A>g=cN+>6@Ex4T@y¢v'`z<Qk{>GSp.Q-=@S0uwY~ڹO\=kdXj:g/Lk6^Gfْ r>־^Qxyyws:{VaC&evƗ?.pZd^/å]ߥ?hy>v~ƠΘ!}i ק]K\=8(I;K}Ў3I9pBCk.x}fe?遃d{\#]26z>ݾ'CoOw87=^8{t`Isgoow`X"#4F;s"cx[׸ 0wxp'. &gZ` >#ȝv=2\9gsYcx'ûqgۇ *_ ܒNNw| kYt;<&b˞9DE{5ǤS$~b۷Sw%[cst!.OSX_yr(2\vgOgNs{͝ߜOgg7S@uG3}J>~>:g0{=m"_ y`yCYb2ESlcө$8lCkz`v~ct\O_a{r̹֎ї]dvw|{n lҖ`y^ L o| ;`C`h4C cXq9\];>!`{ mv7r \7aߟ{tb pa>|}G; xPX=cŭ|j ػz5طwt_d*]ۀ z/iZyɭ18wRO w/prȒo QA n= 6^{=nˎom?>Aw؍Aa;.Qyk}Wr)dא> m+ۻ N )M Rs=[ `%qc?6(T,M_;=}v E8]PWBX1 }Ѧcؙ9IfKpa07:oa }{ƗH@Y~eɖ$) >h5ώlM%L 2K]dl6]w2} v_":¾+°lbk͛^?8Qo[{ycBr+gA|F]Fi'VC|K' ϚDf"Qpޥx/c;1_C.~I$][ϔ@k"ķ-|{+/{^<=ڶY'p#:fЭq{cgbHOb1[2b+{6bՂͭ}*Jy[OF I.ۃ{cqfsy-f#P5aTfddFk\9/p0?|;cwFw3ČV똝g49Os +I ɻ;pha6MYZoZ8UvmBGU!]t&\%6GNS;6mZsݓAq 0Li[׼pV2&aWu yǓ84\D +P ZvN!n1 BGo`B7)J~z4\kw5/IRMNES ZSsǧH`5XG@g: D%َ 0ucc&^=+U*$ѿ  ݳ+|c'O2'=Cp3}s4o3Hf<\nl:ka#D*q@Z zIV>DE`̢qҾs yL Y5"`Ѽ2[G#c]̟|' 5M+ZO ~w0l0حCֿ x_|`8 Xc 6s[ǰ l` UlH8y0AKyT :c]:`[tWۼod`[\X JטPp<>-zI $lJ0?k. 8Wa[Sq dtT|̓_WwyͶR;X֐_<oɜ`h;>s:2q1[ N^o>\K 6kq׵Y#6Y7 nug܍S U!PƌdMl]Ar^rB0 /(%@DWq*,'8YN)rTX3cӭKn9Ύ,wKXoϜ[{9o}'1+{ǜӦ' '4Es-quqq!Vr`I7q4N'I T`m~[#@t[􎑱Ct3^Ԝ\}i%YȘA/DN. %d<̵tӞTlHR~`I%YHYSI:]'xkŃ[kŏ oߝH߬]At';YkKoN'6lWVb6}:̞ Z<ҡ5DJzݥ c m~YkY(G2#4&zBF>*^mLߒMylӉI- OΞ}np$_M_Z&qy,IL(:Cl!)JZ7ڠkf OL`r‘%`#ْ‹o9%<ғ Wzj~>xe!["v %dK`ka0{#y2{wEk.A+ $,WZ d ?8zU|1+{ڸ0Rlb&.t2$Fd0no{a΢B`Trf莭h6X2c*MiTr03΀0n8 Ax?\k yqcɭ%pHu\ήrsȜCl:U|HI;6=m, 0IvdȵyjFŕ#$Ho]+b0̵ Ky7DUZ4K׷ s,$\ Gౠ~?y4K%.;x(kZMYń1O H04+tݙEtZ2*`'`kܒ`N+X$^ֵ| zW? ۂɝlS)pEPUB#Sg.bt/:6E+ xioyG.:'ўܲdy7gزj>'kw`;mϓ1E=m\ ذ N"H#vm`#`~̖_I@b(n׍hGgS$d|w{[0=MKl)C_EW :% ϰ$KO31}fi~Jp7[a/JtJqG,ƐXc[a/gLj_UH;N PN`/Q<ۧg[1[!La,i#" 5[ȿq>u^^,w:kN,e[o<3dS\* d?3* qkyW0T_w.{%6qd hg] 91<ܚDr8#AӃ$VR q\kw9mz2_} ,!zG;S$Q$ TJ5 %9t#ٺ1 9uJp9I<;$(G%s@PBKǂ11%s3= n1gʸĪ͒ ~(A]? ɭ= I?+IVtyq}Гqm >Z$9)(daa9 $)W+׬$rkݶ` ݁VZJn/(e+Ba }A\{ 5y>t_d+ƥ/k/JnWcg|?:{fȽS[`~VrХFz~QJ^ $_t?3XS #:)I_wx`z1|͕3$d}Xg_ c!**]\1FHz`{8P-qI%E)'8I-UOSmo$* Q#UN*ɒbsN8NϜ`fiqI g2Hȧu{Q*`8I3X ,"w9mc[O6\txUh3 h?*ͱ8 J7+meܒ2hw7yO#|` Twt_GJ R`]+I ~oXBщvGK $)$7FƄ&;쎂MfLw$`O&>tySd%(ɦ 7xOX^uں#jm$}ɭ}`wvƈm$'Jz}:*]'X!%6ʞ]z)2-IQf6b$#i-v>\Ϙ1?95/0E)jmP7Ѽg?upו ƁOKn)bM|ܧ4􋞽'8 sl4{*y+*\K%b~oǮ|`>=^^xVph[sFqW ΢9؞P_OkB5/:ɭDD0R> F{R]g0:2~1&iԟ>+8c@$Uݞ$Xҟ 80UڵBy{$Ѽ;c^I;JU cP!9\N  zx?̼fV`yaERPy|%h'D3'Y$? ; “͵6 2lJh^d`w`j 슀N [F:P81,MY-l,I +ȷO$Jn].5^㫀{S@iyHr`/p⼄>3?1$%mqѻ?WD"{JB$8 ;|F/ 1˩y-g=bh|LZKrv`EECZ{9hW~)Wl~2__Vf ,U>"EE[{qkpo)#k v%{_լXܮ "V јYOM]x DTz:I%܂T;r8`l_er* Yvwd%m-;`>qGcNhxq6*2Y~1'ӎSn9fUXI^;>K"ǒ,6 uw]WGi+]Aӧr\ӝVѿKUre;? t;酊n0ltW|-X`r?ߝ1yNY#^'dqv7]k-x,{ȱƦ)c^@@c97IA%ّuaXq ez$t %|wNC#O `߭GtYқd/;pd2uZY6dkm0tQ{},o{0=Rkik|0χ/u|$$n,oV~u Zd0&3F3"aړ j}Ҏx Eg RUi)LX zL/{uz9; vC>[o n}]`K𣇱gg6=ثV$|߬b(~}Z0[B k|WoO`o.w}G2ىuS*=rBe9G\-AX%oo0(v'S`IྥBɸ`$!C=#;#? "N%Z.74"8 jOo?e/5O{ǦUqk(>E9-M  PK Z-ۓ t%! r$jʳѧ\c@Ef'D=-N|=xK@R!`ɴ $ wTz>msɿ r%; nhXD%p]ʱO>Q:J%Ge=hd.J}/ү>ƒLZ$dfg?ClhߦKOCG[Gz V(\ +Y`ġ%{ &" No1/] M>ynwudĖ!$ORA;/HF۽/8N"1ؙk ؾnrKq<\*&9$KL| Q E$WR1s?7XOQ%/0E$EkXZy{{_V^!>}5Sbľ]*̱uS6OO2g#XSc>>g;3QT8OxRLrL' -c%g>FW $vٖυXAnJ:^ 9JƸ$XN%*tI9{Y'iPE\CNÐ "43yGb{`UKgI3Ch>^p/K֑d?? FX2%ȱ^ ڿ/S{Z/BwFp\Z|$Mю8!\VBȁJa$A_AX[ &Lw.*3ѷ$H@G0nY5% bS.msr-w׵Nsyʲ?{]3Z`z[xfrOf )޻۠uI `akIJ?*I'Szw.Ǿy|YŝOdA`,4ڗl{3>;!9~|pi/xݣiOnU";++ ۂO@o*=ߚ>>W~ZC:y5 9}odOG6ÖMAbW+Nյi?_cg.I|Ik5'`"gˌ;d3A nƆW^Ʋ3[&IgzSgiID{6r͡twl#?~k$}Qzeuhcelb5G=:aQYzV_SPXhۋW$t`\O$c>CgHpg,SYѴ'v߀% H`I,]FnLW~-37~F(чdh^qCIRV_k_ U!Pԍ';9ID@r+p!ʤWUi#-B}OK+e4{( @$xzg9j/ =1^tl"gu;6>ƹdvW3['9Ȳ7xVߣ;ӋӵǛ,s(֓{B[Y$7Ikq`q_]4-5ɵ#>gg%+l0ɟvR"md.8:%ydW Pl!KBd52t]P;yrv} ]]{6WƆqТ43}%G>۳=]"|*ֆѥɦ!c3{zL8gA`J]{#֡B`Jn2J] '\T҉{6wA6g%yrx!sxz檼lK`8I/'>Epe0,ӝ-1uI968B)G1xA7(r<<T 9*pAZcS O;f  \R{U$r98t]xhOp/RׯIюI[sܝ4M $ӉWb?FNw,``f]&wOkj h 3e;LJ#\- !A]uֵP6IR^`P~Uhӏ= 㸻(~*XBll^6`o[zxOa']-y6nݸkQȜ6lFc]3x,Q_ߒB=xc{_1Y2~EN+73t::*G|/}i}JN_%>c<{w{>$;l8SƊB__ݜaO)w=F(*֍@%놰:@cq0g]T' 1/ѳ;- O# ܉yբXDw,XRTT!po>e]F'}bU!*]hu\ZCwe|ీݝ;ɭS}$]HN͡X/;+]/u'|O=I _tT=4Tr{hp?GP<4V;_+%* y꿷L.R{<6裗rNۓ}7Jn =Vc:5B!;o=; _WY$jJn5=3r` ҡ,p|~Ɠeo&#eq)FWɷ1~ wnY+Zm^x'?Z_mǙW`7 s 4 GRY~$׍;2+Qlotܞ`/K;)Cj~57bR.K?$~\]?lqAsxzb;K~-_eI|#Q6CgcpP`ki$}ްpokK/bk>=nl?"uXxdZvl}?/~cebbvm:1'qȶ`rMr{{(]9^+X0op\_076/Xio _k5'sWOt鶟ASÅ#P푫ٶ`3L@ڸ7`F/ `_=O_5~7 $ q`^.g3_i⠀}Mz z8lk?/",y4l<>x/#]`\` pq<0Ը6qb_aE'8]5-@iJy ;t\K$,~1etA#MSvOQRFNIlh&% rzZ/kykTH]1XUu _!xݖyo$ڽ,G _#~<' J9zd.0l}_/\DE/JL}gOI}OW6]`A0̞,@LgtNjlj֋%۰z٧ W6M;8X+ X!jiS&Cbd[6kt;-:Ockpv}l?Ϣ;ߍW+u8x}f0=d r=H@g;yՑgr/>g翂[2{kjmN{?ysI7rg<2y`6-a2&;lOy/Z uuHcl8=b# Y~mJa{.]N_->*{tAN2gԮ)]_%SD)slb'4eimr>Z[|qK<t~~U2m2>솮l*=r5D(1 vWBID8%`\i8Kq0ggP#%S+w`[⽤{Y-`σͫ'A`2r]63/N n2 C}[IȰ8:+ʾ$\d1osHoY F% 斸Y\/X XACKhMTwdrL:u7W:%)"/RFm`:&[HeדZ `2cB~A^ 4^_ 6V_n麤7Vn bDum% X.,`,9a=QH1@22#yQtkN'2Jk$%⽀~nif ^0,,Kh#^%;cA%f uJ+LI>ɱ̕-$N_ۓ@zj-?| XL?,xL0{"Spr[˜P,Dn|χgZ(I.:y`6ǚYSr K!~,$6Au9;.ٳl#)ilmdɾ)yUci?hOgo:?Gbe`> x ?K_hI\}Y? n"zC5yD} `]c?je}<\Xc~Kp* zd`x`]Sq)`xk0_J& ;n?~[avoycN-  "cңwac_. 1Vg|^W Tr;î@6 `73 Vc[bv dΞT`3~ 'xf0+80Jw'M<}x#(\Gi8+u=\uūDYE :h#&NY{A'ǂ%^]CI7[c'-Ys@z xs-%#(>o ztWQZc浏7_8`~,}`^+Ey`oK%&~%IPu%bl_Ol셖U@>Vv%=zq6?hɾ-7a>plyAf>t}r {%痂-S|0_ǷA`! l{{i~tjGI%*LncHN$֎M?^'CD:qSsN/1~ <];Z3 ]B\# [s'7l Y4ve7}|/;H2zu0ؒdW}!6uTcqO63cR&p5WT`Ɗ^m Wo{`fWw1{Ɯ U#P!H"%\@Hf[0V}e+H2a28 `NC{[$hOM1%Sd_ `%reH >QqJI9 a|Aq d `**h8%Z,Fc{c`bOL ]&XP",B=3pSȑ=Rd]蘊q,YJhɭDP p2dD@LD͗->,n:k|JHNtvL9Kv+H|% 5U Ξ0Kb [IAFӺ=Xb>tUXD{ 9a2UpI'[ۺ fL-c8^rNEVʞYwsp]_@HL%43|/ i)BOldK#C~źJl,~ ؚJG݅ Wv_.BMt\w\[ŞI*h,'%5=ֺ]"߰t4[b nO8,e;$1lzi9:xa0v| }ckL>~ٜ||gO`֓B%[E9N!Ct#-_ N|kc2V0سMb)ҏ/9|{mtGr˦h9 b v}%5N+|Ӱ#!xi+0[QN]eW0w1v+3ĩS"P푧7Ea`-^$tCUK㽀p92Z8*--RBfW9F L[r\+AB ǃH0>/~U5% ?0 9\{R3{NIo+Y$81|Nrڒ7M bS_sdGjh{`7 bVD,+>|0x#8H۠єNms))H*ۂ%Ԃ 7lu `A`8ބyX"gǒKJn'npd>о`IzKd_V%='<+C߂m^0xȵyH^yNren= `M9%eu.92B {4C~+Ɏ=6J`locI` f_37r0VNBbg}SbmgE3y~/O^>{$ l~Kz96t5 Râ:<~6Em\c{=egKzBJn?o^r{h>x퉽{);q0zD@""`{ZMr+0Xҟ %kpN 1cO (Tة~'[j.V}CۃǜF=d ,8BrL')tt kfm#Q50t/7*pOX1d*;\OS:=CW dZTﭝ>q6`K 2\+I ~OA'Ayڠ K 2W/;v53sqlLƒ(zn;'4gz.vGcI`MK`ʺ+F(MEv:FSɭB$S6/;q"dޡ'$D&#kkg;; Wr+؍R4Ǥ}W<z~K7׸$iIiOګt+־enjn=؞5ǒBE |ƫӬ͖,^csBݷ'!vP[ 8F['&.{XF>}s8w%ljk`,)lZ9=Ic$)<ܞ[MsS؝Ef0(w >e6=InL\䖝cvMn >^Ҵѡ_d/s$mQq%ߑ,2~OQim[v|:xʯ`>XБ>+yws-lmg=1p8oJ罊=}CΏ"P푧 `͂H"Xn+g "G zg_of GU Zvouc6 ;;4cC;6@8{>yt9ұ\Cfy0'+J:}1s{y8(nM49>弭`IMp#3X=hZm^p[0ߵ9?[$[ Ix褂@ΝglX@D'FOt.Y)x$oܜśkKf` OgA$'ٯ~ao08hJ"uPhP%(HX"n,prȫ@W;F?=&66=1o <|{2//Dߤih/HA=F[ܛpNq Nٳ {{~$Mt>pG~Kpw7%z)htX)ʔp4۔rAO I`'k*xP5rvo0#Xҍ^o5sU{r9mZIsZoI`Wzccv6оRn,?wt-\:}`AªHi}g Y>^b?K sC]bޯ9xUtd,4cE/E~C!imEѤx޳9$}X)kӯvg[vv~޲)omN_8)FUC/Prd| 3.l3{\Qo  DGpWM`twwyAqv-'&%?Rue4t$&/%*qeNwk{cK*b0' ud|?1p弾! yQ@`P, K3k%eK:;q2X{:k~w|NڒZk' W,P"s-QnxJ![%H[$Qw <%֍ZCc'dmO?XWvJ}dpQkzn2ZHŗ_j^GGONaKBߴl;٤: ʦpe}vfxo/ /kfNoA{b$'xl*l-!>K>ן|y+|"bdBK|`kl\cI|k//vRC:U/{U  "P푫2Br qD-q 1Ü}ri:9GiZ<ɒ ipKM?~ g[F_?# \'%3Zs̀I8^w[ʎw4sڂ68&K6q8i3ƣ⽪zO"Ys${I,A$Zb)!P0$6.֍lS׈?5k8.9 :.9a0>|F R$1:q4 <- ÜHz֋!mϖض`-,: ֒˚ ,f5lg{۹~gW YgJH r jyp05& ͥǶ} Ȟ>h%T,Ie1u\ %x7_6J 6Kubtx 6[./aw"$'=|;Ւ6 )xU;ėܣi,!ߊ(~MIbo SD觱$N,dMYdm%};\K{` ր5 4>KL|j5elz{^{X݃a)ڢĔ(7>:Wb]3& lk_w%42_e[~. }g>f;" -Yzovlr|M9yX ~l>l. fZ-Kߥh4Ol~%DNHܲ~^Ӗc]ñ~\tDH{20Krn3SۻY\:'5b)2k:nVw6v"#XX0fWB`l nc r_Xb}75\_9YI+F>s^88&}Lv:n|2KVۓ9Kpm"{*#BUuX6f`_`,5cc{@sjGK<h 4~JW:u%矲c5rL">q"[Oڒ+xqcf@w1j)~:ndz߯6v/LcS N_,1p1uXyczܮsg]v1n[4v|j}?F3-[J{m-o,aگV>㔟Ũ9{:){; k-:Gܫ=h ZdXvxlck|gx״w<_DÛt? >p3v5,.տv/?췃 CQ!P@!P@!P,@% u6[9-؟kx{SKCsՃ0rW >:w ~ms;% Om~؏?R%, 6GnO^x$>_7OF=6|w%bHK> {ۚ~ݝK?6q?xB( B( BXJn0jqW ~c ?3 0gJ1ֵp\1[>1 >wsO z׮Owc%ۃO`?? ЦdU%STO%׈k>)XKv_Anw;/ >fQHnbv%Y\$ jE@!P@!P@! .avs[pς/?#gA&2{U5=SIIrGuWO`wm%-I,IvF .9Nr'|3cO%.xG7y7?i|E?mT2z斖/#Jw%r B( B( B` Tr6%!Zcbs6X2:E{ 7+->Xٓ;G|?&%wu_w\?X8^*ڻz`?>,Xr{cAr仲rOJ~ݽ=QswkӦ( B( B(ր@%km_"y8Tr뻶;t;S䎦DLnH_(v'frׂ{dӝۤGɭ{{ ꫛ6Sɭ_~&9{$X)!"fh K y׻vy_"&grMQ!P@!P@!PJn&*!}ouد~ jow$e#LnJ,{d$k w{wE C_/mod߱;g;cv18.yv:\@!P@!PJn׃aݙ-BFfz,٣Uh_;nb5ۓ_+dMrTB\KSE~IR94b->_7npw%wN#9OK[O|+kgI͏_#Se]@!P@!PTrHiƼ|` b_J~YjIBv%zF^zhm= >=//;ܵwxO tx/I?> ,?v[y}Uد(KtMBXܮ#)76|ac> >AEb_zd,rG΃$Aa9]u:}DY;?%_ARo"Ⴣ;|ౢgKN )QEm|ttV+xl*9Z; #Jnwg7 ^'ۆcWwpehx}[ÌO8oGEWBrd,ɭ'?TkCqBȗ/k\%P<>x+1A$p%%.SOH ,Hɭ Dp3o;g Y0`w69~/e"Jj}1q0/>`gf sm|-i놌 ~`>(V@%k7dB/^g(`0q&?sBW\x(IM#޷Iw3~}n?=3OF)FLY$-NL]98xi ]!P?*=r4Aqw l;8N g# h;ۂOs'ܞݙ+s8\u}tv)9.=؝G@3w<4P ͗x+:8w|vߐDnB``znbGO9`Il>CFkYMpE%kq_EōG(*=ru@Su8AW`4ţeGC@nbSHNSWpS*ty$ XmOg|47RR}P;k/ {D=}WYs\ ^TvہGQ8R ^dVwzyz` V< ۾/e \AhL=fCc%kߓk\y+uX vg5yrOOR;+5j/up_9|f9sZ#W=.]/kM^^Ov/+׼VH ưoq#SOi{>VKk=vm/ϳڷ}xVEyyV+5^$c>nJV֋Qb`OYS#|oз1zV_2y%q0.$;>[۔n}CU_"kDy'd;]Smvgbba1:&kvS{}lOCY>y_oKt.d;x>͘?%OAy:91َΧ/~XJW׍>=Qvl,3n#},jhl_Ա @%_ SѣNn>T,G~G9O ^}P@xQ݂Ӱ's\ 󗝀XþwU㳄tWjwAY|q0Mzt8Esx`'#dwvpDǪ>錁{ gMv[=xcY7'k{vyH#a|7s5$UGyWe`Ӌ4w<ܦ(}I|qlP;1mOEu7z>>۲{b X~)yhC_s:2{6/.BK(=4'_4?,8u b:Ƥs5q0}v?;=;a<%߽<^gpy,#!=p>0dOq덏c59ِtBґ!6=L*]Bڰz̿*x_$Xr^r+cTOKp @_ׇg{Yo yo?,8kJHpgj3.xWp[>w ݰV9'f.s䖜wSɭü<ҧߞ0zU40n0H 9Jk"v|_9`h}8v-8kӏy$пC0"p~wK@bxDL0p@t^L:AB};X@y`n|[BIx/@D[K\gVg`"1ww2p\;~=?+i {ۜoQA傧O_Ƴ%WG`A1x~kȸ#,., 16<Ⱦ εkgngk/VV\1=r_K~[T#`oRu*Ma;=5#_ Ω62BMM韱D7و6m-;OCdX}tk#t^$=зΟdǰ;Ⱦ x~~0A16xps<7gE~/K ŶkBϦqkGpɨ_>mlZ/Zۣ,.icz'ci9dMN7Di_<5u/iJl"}W @%k_ *)8ѱdKbwõw{Pd%AX oss&x`E9pp6|k<8ǥf)XbjdwH8M\TO0Gʤ/F,"Nˀ r0KIɂ)STr F~5\'h0hǂŞG[[ 9hO9PT`*r%0k=q N`A7v=֓#5\ ZR|7! &_ &`ΗNǛ}*D4WkN'*dX`b A#A` xeXd 7.dM,0E{%0O\#X~J`rIqX/ |E?DM ƶ,XH?5Kp.N`h L:x9XП\3ް+@doNFzeDrf)@=$#P걤ccrH$N񙾚ZzII"@~Oσ+\!]:LwHr>֙ ֽ-^<\Cga~%ցHz`""]Н+{P}7\r˟IƖ,!酄yVD\`17'wr87Asvpb\Kw5{/=Evcөu`:&HRrYOi*m}ƞ(Nn {ǖ{ZK|? IO).lbv&v~/S6腤 ^i]$ e;R &3,$_dzj=?Ŷo}u')t=0]G-~`cnQbA>[qI_ҭ75ܮ-{ǛKņ(VqWv~_09Zm=*J5s$ۃOY&Nw9me{78ms=Ȯ-^_Wt~EJn׾6Ll{ۃrDG07ܦ*i-B)w ^ȁ >2^P+xG0c8&*X-P| sA$~DF`A'x`s}[p[KSɭM˞`' qrRn9e/|:X֏ڹ;@|]Az_p`2E9[ 8Zskq'("XrX&~L.^-x 0Fh U%/7'%R@0j"%1مT0\{oNNp tgFsB W:dSvk8 !i)oH`{$dlQ4ҿ88%}oW0nɵ [?IV%IB,3E))LJ J 5dO7.l%n=)ư] SDnk$l]){b }+d" e%,Xn>cY'NJ8Sm3$-u{0HK>S&ͽadf:]=mGv+q;GpJ NWi[~aG9k$)Hp%v^gPf ld':Hw; zd]+,u}5}8F\$ 3?=EU_cd|];)Kc&9IbUKt{bEەA6~'>]OW69ܮ}9@A odZ4}LLBu' @Tw Y]2XP%lG'Ii~ȝqAMc8ILGy8$5ڰ*uSɭf X/8xǭW&7^;=A1IJ Z ƒHNtZ.h~,X-qBu" kSG$MKpٓJ!9)({~03>TNW{ $[A~+|gk=gbK$9+o 'C#!KŠ= t%NXK8sK$PQT2OBۃ_#ב~m9#zD'3}Oؿ~> 2Vr=]juklƷ^ӧ1Oɒġ[K-d7`6Mh<]5',rbd$%3HIf*v[fGg {VzbSB$kulv)HA@$!:\K .Y4gWO9ݩV?t?3߱$#W d?Jp}פ__ vm[sq֡ X1*҇)ؚL[`=%zG4qxt-Y;qyk$l5n_lxkX{8HftA$!m?^v,)*ti>tjK~ȭP%8G`=F_FDCJn׾ @W@&Xڻ=(W.Jf$ 1nA`K >::+h2t;&cA&)(+*ߌ!gAvAd7YUcHr+Pi[Zrb́rxX?I@@r^uת($ZNӑn6I>h'ғwN[Xr+J(n:I3+U^Mr _roz;OA%A+ U'%;5]L<,s:D{PZ[ N2*d`me:{gHlNfr{xOKv/|o8)~Bo؝#$-M%;q$)=oł}o^NiGεLn?v䖾ɭ`A?Ȗ[;"=7*%NĆI%coMxib˓I,_/gƱGfmEkVrkV܊7[vKTv ]{?0=䖴q86>26TEqBɘ $cnN̸oIuZ0lJd˪ hKۥh;Ond_p,xz`"[sHUrzoG՚IZ;6Jn1s׫+~kБ&PA " E:@@TJJhJ ( K{x˽>yRI\\gW5kfS‚%m_ee%`|s d?7,Y{>Hn|ɏ:ҡЭ>PRfV+XiW.<߾rsjzTe-BD?d Vt"In5ehρ[GDu\hX`}c蟑ca*N7cKֵ=l-[I8 /<$vw7^>]s]gw\GvV%@iDu8yݜ燁z87wtM8z-x`ֺ>} =tz@wOrᗇKa*a3W- Э.>;ɩu3bj S-m]eKz?}†X[lDN\ E (ͱ0+1svOc%sv8>tOU~8WY6xH7(%06SصS n9CaްMònO R@"D^uV !˾~A*p`Mp [dR*d ;e? ]@8p'B9yuA[0,,[JH$bzZ~}V  lPNNm%wX܉[HKT"+y[+q~ #M<%X@n`d__A7RVę]lЇ"d%zb;ݍ= YYdM{p9\]J1MPF…,5u+{tD' nC9F$iKVq1]7O >{\N6ݕKQnVz5֫:aKZdgăK2%g;ݫvndܔpzvFvz+Beݞr{e!?!,-]37 TT&v^S!( yr}S^@-׮9#W_4Gb%ͩXߠdVDg51ɩ9bo9I 46jB,?hw}Lfoytͽ~V$ے;-!>CEv=~J6{659Nw)3ui7(Xx;NFV?GsU00 ݖIl+"xWi*$׹A`AsxE3v@;PPVp>0t?ƛSB^56 0'# pk$,Hn @cU}Mn&Ln 2C}r>8=^^h (ۍ뉾 AKcXdsx0=zI?/$UYMȼ/ Ӈ" 2}tu+s(\i@@<ɵ}EOԵkkt [@+8PN}H}/;}#.TȰ`DwQHTJܐžA-Z%@¹ 1ח=9N*ۥݒm,~[tNUvK;NZwy-]~@4EߞC*/븒Pu&.}^cJv|XQy4,@ot;#z.6to =#н+T3s| /%u0l-εCWƴmok+m{s5bm" 9 ` zG?%idT+8DCq<,${qfNUCmWD֎2VɃuDL=3\Q?+] a2s@H_2(`oU T @WO_ (G:/@w%?W;>S:w0[_\ĉ  Ǫ# o NKwG Ud{CIA?3S i׋ȑ<ɕ|%ybn7QCۺ `Z?.0j=h>65 2WG|#a%Wc}76t>#uk: [G9v@9k]lm~t,,Y'vu6LQ0X;w׬}'v0L_Kۄ=2M/PXxI|]?~^K2\ճf2ʚ0{}4Lo[1nu ?0ݹN3s>XFulN_4ftz6K%;vY?x7yenO}ji3:^х*GG-Ȁ ` j}Y;5VMvج*'VXjL{m?(G; Lȯ7}Q ~_t]eN@]_"A׸.ϧEw Doíly+~ Y _}*/Dr=8"Or%v}Y  [ʿ({_3#6͍廦ؕ5QfmVTPZ$yAVv4{Xw]yzm d BRĕ~[_fkGNӝfzpHpVਏmc0]Ưe}` sЩ_?p ,xX߁B9o}1'Yd%$J {=~rjRt@۹~b+վ5UvGYy_?uL؞7t<]Zν%Q#.6N!{j[RN0n~9py τ$kp$BK=t={HЕYCvnnBY_>.]Die'ud.rg96U_/>ȴ+Uw۱z|a[v}g6 [صAKW|WysAwcI̊9T]X f9vŮs a<Xz ۇ +Vs`51LFLp!x߄8v市us76 hu D2}FP-$BvL?.4|"IMN|= t[=&M1 lW{cl^asG涮Sc̿gUoP# ~xrH&,MS9&9Y\5Lw]kNr~N9Q3 ku`_$-}2.}7`m?6œvIQ%su{+d N?VQoZ9:u01>Z#98~o^Wxg(K>\(]i7onardorn_c7/~RKt۞tNYoK{qvz[ Fv ٚFؓMtnX'K. g5wW‡@֗%Oj}IKd:ac=:ﵦgѧM}6{ #w*$g]?c~&ڄ)`Yˈ'Ss6icvLYL3#j@^k|ts1$o 0|prHgHl38O }gvZǠ!sQ3~{zn}7lػ 췫؀YR{bxSًgxx 5%0Nw?|]Gz|w+;G'R>⫞ dS~А.";#}>^xv~wfoH$:}1W}4όW\|ܛ ~w;hH`[I`m5;3Q^g/krts>6K‚!sEvg#u^E4$0$_Ҧ_}|/{cSgݠy׆2hH`[I`m5;3>DK}aGntg@6@k6x 73hF տ Z7>>]'qI`3&ɒ'K!S+3.VA?ԩר}H`H`HKo /5m |Tkg^7 nɠ!!$nO G5CH>u3}eOQ; UNЁ<' gΐ$z&ЬHW'/ 8M9iكN$K|58I$ rT3$p$?;)SΪj{|Sꐭ>ۂ30-3 Gb)ʰ^U? D`~7;{Ϧ퀱|k(ïACC'Iܞ$AjN>w7Όÿ4ޚ9A}vvN՞~q.!!$nO G5CP^"l'wАٿ3Ӄ鐀]sU|sÏ mxLϮ {C`|xK`۳xr* egը`vLY= ր 'NxٳOʘYgĎ!Y p{f[a;~ْl· T:]ߛJ.'}U _24ȮOF'j%u[Mp~ֺr?:oٻ3m/:Q W[,:~#+`3O9YWϽX-0ɡ gEVDK} {vBy"se+oN/%Lձ|(Y>bt]Pw|YKmK*3_suSKf{[/EszDh]41~OU?7 rk}1"~KSmGz7v]kܭ;cCSs:nldζ| o^J5@۫vA\n :#G=r,m@]G眡`B~8? 1@>^2=!<4tmɠ3h (YcQq\ȰL;VhmJF~9@qֿa@H= vTsm2|o'6w[kʴ3^gQ-Ь`]WE6'rt@>tP#XS>>WN`xj $W%P>)ND.Ij E@O69pMw1ਟ/hJE'9CstD 5vȬmje֗ :JW[}ݱ.4j[ Pa:ۦ_6Ao @ؗl^Hrdua$_~yGV.:ˮI,o;Es:B-'_w]M@#ru%ictkR+%K=&6il]}vke񐜋J w.A;e{bXC^s>~p/<3,޻_7\FmS pM'4tK8_Ė3myb"`O | Oc.  b%XPaN>M8E} t. ڜsEJ_/#X8u$PRM8? zڝ h@EBAwƼ@X͙()4 59?/̉"@^/zM=u9 +A K_+\| ڌ'L狾 hH0vsoRדrZjxtq{ݮ/raS;  8  D afazՒ`Уv|W6Ԯ9:aӟO|kqYS )rERܶgjtչ2'|m5rVG+G]k S= \Įdݷ-L7lg}|=mnZ?|˷KђjXNP`z"~~+W`֬]ڴ6\%`j cަyZxD/[*j_w6bsC-cWߴҞHƉo@b qLK@+ʾ^d]D>? 1T?v0?nz?7Kw"IdL[ƱJGwekL]vzYG+ &k\ōlm*nĜnYGӬ է>9Q`+}(qL/TA%,0鉱2,`bY p68 dp]a-PՉ8Mu2w H% :O aX'(n A@,7q 95oTKK0!8J6B k]S; :̯Z6 'GK[Ҵ~끸O0/P>+c 6GSkuS樗gׂOs$Җ` ^1\ctoW޶/% 7]3,̖IrskйLlmq͗DJK_$G˵\Z_} kltȼmLȷXpeL?&L>[aLMϝr=[ p̳$5u9]ṹۓ7!&:*]#vGɔUDG|5k/KP(5ʹ.%;~vL-#@M7̿yũ>k4 QM\Qؚh6u:]tX3_k|CA5GTmYҚ8JwJ@?0ݡ9EF[ǻg<ؽ/=,эýO6VG;e=G~<Ђ5 O:@MIq4|$.U'sLv@'}5mDyew{MWNϗﷅcKlc?;W#KqfL(xJO'l}]:l]1#?bwɱ%(~Kjg6b_Vt[\bXz>ѩ+Mp> / {׫r  ڦvN)`Zr|3G-C Đ.tˀ IKw97c3Gvvaپg9oϑ`LbmW7/)}`\3ǜ`%+D, +c Es3/^Qg⨬="P1ǂ" s_p@Bv zеG'UWQ/Ԯ(YZZ_d_ Qsa@J =](]c6@+I;A^vP9aKOtN{93cKzn+eNq4|Y|#^Ʈw=:}A6'@uQ;-]&'ӣfuIycA$\Ş\j^/AM}෈\+ @~OOgP3o*{0vO]*Ʌ_Z.9i _}ݩd. %#~\~cN "YI+)nKkd- D{tj_H%&PIF@hP.#0Vcg}]#썹*6W7$x_3[{:b?^뉬­w2U~uw=n٣U:Z}W #7)"&_%ŞnOz&kZۯ~;7.zˁɸ2tEV RN#t!#! 0ҪQSy3~D+  "åN?{p q3@>ACY4}v z. ?'L|D<ݷ[< S;}yEwܖꜘݘUC/jEGYc@)9n97%Ծ ͭ uӷT3&gdٮ\Hoݞ6s֟tFpK]KmX # b=ׂ5S0о/ pkpl"U:Kn>=Zp-ξ8=΅Mm=ktk [/-=sbߨ{@έi2鋧v>]$ `w\4Fϙ+Kj}TK6!@P8?(VWސN&=WK%1g4_p8̆L%9~lW%*UV U;ߛ_ m_w3*1@A'[dp%oIU }jd[bˁOt-+sM–Kpܞ!f70lBA ';GELחM84ӳgpF;Sko `e7E[@Sd` ~+@2x@Qu![zʶHd{ٶ S N`n'[g_xy}jf3,]Zn='1f^sX2/>+c dۃxx. vjӅ{et<DJ@t~0]o邀[N }>kpI\9MvE;e##6<% ȳ]`] ,uVx&+*uc ud~$&|,pKN4,^%l.bс\[HRBRMY;Rީ_\go{jvZذ7?I]W;5v9ztN<`D_%~_l/V8Mؚ+ʎ@DŚF7քum<ֹgCV=_}zn1NįlpK5HG8ߢrnbdy*:8hF|_;C%hxO"ٳ Ȳ6Jsd)-3yhX+y݊[;ƪ} p}T!r0$%2̩1E,px4"8G*F7M-Pa;W-(Է'6ALC-3W52O'Yoٲ;:A0-˾ {7ޤTfp[-ii ,ת/}V)\.Ruo\WBp0PDk-ح đ O]Sn:2<j邂۪]`"v}bG|\̵`s `lB[鶾uXG$}zt5 |,p+!_?@-[zX v_y@v.[I"O{eVMO> _<^r/EY(D-uthx{F2={M/̓O=4NzG~-QUvDdJHRۚNh%}reaNT>[eg*vë:%%ܖ/}AK"wM+T\'!ڑn76/36S=QI^!mIaʐNak}SL+PWCǸ?@( \yΡ`:a;L߽]yʌʴTNkצ]r`u9Hߑ׾\4n:dl Ed.{}Ha??_T0I؁6%3v->}'ؐdMs]`qߟʅJNPΚ~0zV|qT~M|u-%e+4:}(o s7]fB!i ]9$t v db/sĆU$}>V\)>JZZ;=ĊAQ鑹z[&>beK$WŎk_>'߶kT .9b֩Zۯ~@ `̮4*SRYoD[cq>/VJamK_e8HC 'ʰuȉ@M ~YCaYX]wƋV dl ȸJF ko\ɮW{̠^$0`|?;mx8?klն9 j'_cË5U1$e銠SWd܂? ڵK9/ח>> +_/NH@%~iO}a sp#zfXBcw>gQ?5L e]"lۯz=$+2+MGg0`B!.A}KqdB^dBG$6~(訤 %~Y#95(9JF SL<-Xl0_cSC5S9֗UdatvC_x?jM.Gp;_ÇK0."=WkbQMa`-wt Dٔ~kf/z6>޳%9կY6ǺO3C9~gc9lmʰ/u jz>f86Gs$FIׇDw+?k|u戎:b 8# |,>9# Grq}Wava}!+qp&S~]38WAOe%[o,B3%_u9Tc/!G ?-Tqz50` &CTxx'ZO#M6Ӧev|$Lo|&iKeI r q8_d{c\/ƈ1]}sG YogW}a'%oc3GlZyZbM1 ߨSsvaLHFHi" ۅ ͍1`DM#$Dm[Eɑ?gT8Xٿep5,x(L&>}aqld=dWf{쿝 V%1k˹ JK [pdfn;s*Mc)ap}4 ,(i 4V͗ƯN}4nɁ 4,*e$({@d Hn4[86Xtj NΚ`V@/ *9\œS 55,0N`鲲Sm;{t]0N/}S`8N%t c>#HhQԓ ?!8!# Na m׹ayN`GpVȐzt(jkK`[~.~ޮ z^ ?nkց`]g [Fؓ׆ |IXKDϭss>Ot'JGlN? mØћm6UM>CK;v4G/ $  W">Ea6aA0H=}0@&?=~ }s |mCO|"\[tdkutɎWN$@&3u}GlV2}oPGs?\ӾCz >#a@ۚ}W8U<u>H$`yЖz?ܕצXT0=ӾK}{۾yMHR %1e1}mv0}Sv8}gP۠9%bl9۶ ^ͻͯ*`P2tY ρk:;CȈ \x (Ho-.@Q+GՖB ^S_V:΁ 8U3Ȑ*KVuP;fAK hdA_>p:|@{ۜF7`×t*LorM26")m)P(` #5MD}/Pۧ:\'hc *<;%GkT@DG%Z@W:V6 dK:~`no=oȧXOr独Vxk? N鿹3]ll= ;flЭS0kg%. JMa=:UReVnܗ䄽xD/K\coSIu9jZ_ zD."]1nzndE6wshg:Nd.>nmS) tgF/EluEt5'#:Pܲlבvr2DR rD}d]-GI\[*acjeY@]5 ԷL6+pm}}Kb&\W9GͳnַI1f(tƽ,nOYs';4m؂_Eo0&Ɗ\Ww_ֶE$Ȼ.Pp 4,)>+p/W_uPza^Awpڱ K_ p۲2T8n1>9`E]XyI"sDm=zK[/}R%lTm sO}i/\MUk~S(;~ W~ _+GƧ~)c,1:6oKdGeuuέȷ] ΋./~󛬯Um4_Vk4'գ>;;Vvܱ*({!!5Ɉ:$}KV:Yw\X3rLZɆ~Y~o$J%\Dz!Ukٽ2sj/tLh@v}8#>g=kɋ[iY{;~*2>/5})^]5_ѩUVϜiZ`jxS_brmeV'|87'{[_{sꣲ2m}MުQK` .Q'ee猗 2|ø}:0F4$0$۩ k۾uckS  N$^VVih$]ΐI'MH7X>˜.O{MgP6<2򭐟v7C۸WF{gumѵ*)V^'9hH`GK`=}Hvks zUEV9׽*|8ߨz%U?iUzo77}n 0p+i\/;GwJW$uO\[a?Eoy=]C5v*Tgt%О!!s]7^{ \ElφbUXZ֓;¾0hHtI`o}x'۾\)'>%i !Bܞ8q$YzFCCC;M}/ˬ>9 D~+x&e H/?a39+uf 4I]wCN;eF?τr|u&:3؆uXd;eʺ: i//0mKMH8"رvN@I`ۡ [>`'<>7%oۑ٤1/^7k8_E8 ߳ڝb_<9 J!%; \` p{E8*P̓JxcύbgVvk@MN҅ROo Zx~H`H`H`H`H`H`H`H`J`۝;w;^gWmNùkdоfvO~ȹ8AcCCCCCCCC%n&. &`K᷇t5<ڹ@(wSn8}z_Ȏ亮 ۍC84$0$0$0$0$0$0$0$pJ`so?+C3xWO/l].?-ܛh*?|=WWjY՛rϱqmB^n۸j&.nLWiq}M.nV~ ےg*4'5/ ¯_j^{[={-/kwkǮ-nS4$0$0$0$0$0$0$0$pI`sh M×?)oۈ{ۖ}P羄l euM=?0=?>nTQMho m}UmBݸsf|wsB~TׅoӵĜys`w>߿^^Uî[Q;~pɔdž3Q_[c^.hQx6t͘!!!!!!!!Lܞeb8v~0G+ w,kz'p=GfȎχ_]W4ng}E=M=^anGSp7r>vp=mlCa;›w}) /XՇ:wHÀ~zÀ9$v\p l?~TǗw]$ h ׶mtGrnsOc:;mu.vS:}^XS~|988%0>w|v .~GЖ*_3~k kv~avy[ra#@1|4lw: ̰ݺvåW|=0P߾ ٕtݿل*n0ykWhwK]sϫ^-0/a;=:߆gv=3=1@09H0%Mp )gG%'~[]]}?sz/@u鑄]OW{_Ӌ K 8G%03@QZ_+7=|_nlo5 +P7*Uέy ([M@+?1/+ Q#`qjG^s=\]d+-9*]7s>5A&7pBفzv-*wWG^p:0@栧U(uthjtxs:C&cׄBOvmLǥ!!!!!!!!sDܞ# sor `nG=%\5~l}]4I~G d"lnҮ~vFkΤv>@/PeԎMϪG=Pip*mO@jW%$ |Lk{~'~;qu;^ݝ#ָ[dG%arW沧%p P8|׾֜?v%4dcz#y22.W[; :. K\+P\Y;=~[iwlGk ra"\K{YS{]8WGMlk_5vWb=9>?>t[ddpCL@m[u\-a.{ʴMN74G=^K_׽"Vv}LszW{pW/ {۫= p0,p[;7u"ŻS'd;v}{-sVLV.N0psntӺksCd.kv~O'V_KaPVH}oOܮPqkH`H`H`H`H`H`H`H$0vnOLn;)@'1G+dOv6@@+^m_? 4t-=v}}YׇB/ў.o9vn}^?V)CHٹs I4֞mslw.Ϻ2k*js,Aph^;7.it=9#Ns^;ךS交^ {@?{Rn >5wo K/'t}˧~LҐY(nI]3M-4[I_Kl nk d+vY??hugp}W E^* *U]g鯏AmB@~KF\%`_꽪p`ǮEdB (r<Z4/Pz^)^ ZWd~\}]\^KL}P:k.(nu.ɱ )c.*8=<ӝqiH`H`H`H`H`H`H`Hlg,n6_oYþz ,.(Pf UbM/?&0 h~"X@=푰ߵ2/qn=[KrmMSޜ)ujGtn魧djދ<#;vpZ_N!hup%Ue5.^o6vɳ'q0а/ ~TU;\7 tsͫ> ̗MtgG Xr]ڞܳןkĻrzWuPISN7|,yT}vB~_[חW̼~\8v%;홮2o 7˄ ZmվrCOR_ԫ7% i*ȳ@t<`60]*N`KkwӦy6/_b֐;|G6P7,? ( pktvH%;OW;hH`H`H`H`H`H`H`H`H଒gt ,Jk~; zwАY%nϪ*>SCY* p{VM̐%_(~w]a7OClCCCCCCCCC;^)X+&ȿD,%CCCCCCCCC;AY}X)n x pp `H`H`H`H`H`H`H`H`H`H`H`H`ۡCCCCCCCCCCCC;^)v;~ :0$0$0$0$0$0$0$0$0$0$0$0$%0펟1!!!!!!!!!!!!n x pp `H`H`H`H`H`H`H`H`H`H`H`H`ۡCCCCCCCCCCCC;^)v;~ :p*$pTzgGC'YJ} 'M)t7&,\|*ϻGϜ۞ם.5gl>|d?>}* OE;Nv:VEy⹝D_^6[@,pA֯ot$0js ѷǺzU3m`Ж`ÿf lW ci_ PҮ<rrڮϱOq'8I&PёvIe?:N\Ю/p0'~u=Ӻm&k? ekUw _}~Kqÿ U\|xfXygHgYf}Xau|tA+Wւ 2=%8GCJ;SH¿>VWp9<0`e `2y{uUOq;ۡzg€Y_a,}¯?~mb۱M.~s\dM/w XW>u%wlX/ $elCK}o-|*[o>Q0xvfnw漝H h*GŸ CG -Yy/wm0Xok#>Ϝ. ,>$gG;C*M!! $7e^4wnY;[I-`Le{ yww8͕Mwn/e_Jr>(ho-#;<~Mԃ: p{W&.;e 7b̗Wה;M;.`wMÜع=wk'~<7aߪY<;,aW;hH`v$wn }b+>:m^m:X0޻'z{ɲ-0 zn۹nSWmʝ[WcӢܞ1oFTszru]3#*ċ2e-yaw|նԐx;AƖs4$p$wo {mА`,ߝ@M']i't4/KNG.,|ɓ=ݔ=c3 VQ͗W:lT/5^K\ )r[N V=Lo5DR}Qsax~Ya125MF浰-W"tYuҞ]i'tM{TyϪ%I}5@;b+^Wu.zy d#r97_벟/*{+~ѫy·Jt/_(]EՖg#H]\Ɉܫ.zIChԵj _f+t}}ISȿ2ܭzծVֱ!2IDATyoח:jujeB*l:틱8]0-U3WdkIDWg#6o{VoeNzC~ k<(b}<ZmROoc_N0%}+́W栋\уJH̉N]s@ݵ'[_^[夵aWݦcxskDy5L%cs5釥0ns^I4:UinVs};Flk;i}QN|c9gW6 .}B7D U6d[#1/ (,=Խ4ɿzr`\5?1Dw'ᗅ7d=Kr#CLz1gc-bw% ^$B/|KU/_Y^l6'W-_'bn۾?3b%"3/ɱ5 WZ]Jh5+#/lN٫L 9 3XBA 'bKEг> 8b 4d{FxbqطsFvB;uǜm[QY98uQSwu dw%#0C' ̾9L1DvpӖ6d@F \~TWf]]/29'VgȈ [9(oE^E0X26_rӗ9o@P>W\A t/& [(>4 ؘZe?d ˸Ur0iͭ/B>K_?UkVd^{@`17%s|f:t\4PZA@ݣWDo~{C6aTݲsa#l&h0 |Ŝm]%)zv]9-ai-P7/{K_~ݧظ8/Ҿ`]en C8u{\XZϟ ]9v@ֈ`a6Yg=I0`x{n_k^#J^Yl}27vٸ$-9mk^Ze;:qy.1ON-]*'K|RαḥDs|?>t= +1#Z[Kn/ k? ӫ:AXxK9V9?Gִƚ$Z-y}Xn?3H4G7:U~޳ҟ s}Ӷ~ݺڟ&~ӣ[ޗXw7 !t(0 18Y{>OQgNI'->h\HeW7 ^k=3s,ZRg#VYɷ0$°mg䁰U+79$¥&İ|TߡO)+ +Ġ1p5My:M x8LW뛱+O.;o @,wto )G/Pd9<̓9RNْq;C2)*ldĘ ۺ+@^^(IĨS`ϱMυ9nzGdw0U$pq $6=6Ph{\&LnຈF L:1 [:J r>8\/"'akkt;}9;eđ$OK͋֋@OK+ne7IJBR?VDdܟ溵+0[M# DhqȎ ʫ`l nW" ,pKasےyc:פ7)#=#r.`HM-GѰĀTdN76 jp.lNokW$gF{00ݒďU?ɜN|9R5#!ok^qE}͑h||P^os^;>)Wk5_{rlZtaka2e=fO5NM/BV Vn }Z߿ |rN쑵]AzG|fKZY3Z휺omq(L?>rnKK5`ŭ5G|hmvWaXxnɼDcw]G9ݣ_w|L/[E$PK Kt('O!hmǨ 1~@ӓ F~d\3u<|_AӞ}%A_-vPHX@C攎˖k9=g=o%{kӚo`uY$'dh $M Ȟ[ظ[/~Q:d+z_Re[@St^@$]Cl4aLSCʖ&zlщ r+a}­e$4JwlVJpk+C,϶ 6৻F6fOY ^.}@2CZ@SK]_/[/XdWg OM}gz7(Ⱦ?8~X sOK)HQK7/l|,A?_:0Ӈ]$^\%P=)/**7nS'%$֝DCKw$!^f[<7kAQ/\8f}SYq] jmEV[2es]vrnO|-08X9f6C'ydϋ{a)bgs,,?Z4 Ʒq wsHWm1=?޻P!p36XPUs_0O{G7ɛ6H@V^tps63C&3}]\sҀf0f.JsZ$(ήd- ^{@vElck)d}UN?2sajt!X\f\`MװT`!9T>p%e  1Gr-d#@Pdm#QAof<@]1k]}Lғ9hnc6tu r]& 6ܤnsd /ak~Ԟ6 2;IZvN ]"A# #8fGuNmWtؗ_]z+`,s^9N]5nWi}ٲA2d$BgZ(9WU _i޺>- 5k*ėׁCZ}! i]G%le z_a/~#~_:Ғ1쯲[!>b\"k_^=}^.qt_vir`/3Ξ\6>̋D9졄˳­,=LٸA`*!pA t}' ?-6YׇN 3$vF@FOPpA~M41Ŗ(+aP-s sP6 0Xv/c4#zƏɅ.K.rL€y3~Q0>At/_,ï#a n Vq9~kyခ4QuJM:&P䄍#mQ =i} 4ޜ:G:[@7稟e^-uO L\>:jgWdV[d ! _"85 قz~Sp[I$!8p`Ua;+{Ezzl(.;_0H:v$ uPL @ ymx^jr`Zs]2E&TA\`I_Ti^62s sf<5IH&=K 4V%N$VC:zb:)jZkDrORHymo-d1)1&0_cs𿦶%P 'I#aڄx_iT4Kͭ%p{J6c0;XEY9@`yVq4LK_N܊^ʚ~fiɹ9K:4_*#4_duVmE-[J<ȗ t15nU|vƘ'ǫh|Z8=9p[;{/DtdټnLkmFD( Lvaa281,ps$X rߒc#0gȷ nS ;c nBK!M pK K.DnL7PdJk8'`;*`:TF{XXDXAs9WmAdv @mH"f3m׫b̳ AV2<U.Z~O;X9sCfm*'pM[ka;%%+kuCKuA@s݃[ VaO۵(h] v悵n-Kt6U1f\tݟsm-mYQ)sf\2\h k3OV+pnO0{4guՒ$ @KF|$9 0_ ϙv6Ael~Oe}f/> Wll]$ r.ֻn< g:bUT?VBci opNKv_@ Ui?< PBG'nZ;_r.yclVm5̯ W|/ߦ u{U|Y--٠),=Iڬ˛[>MiO.syE߭ v$ pF@mXX@+y;- *>~W39Qp{pk4͍n?+(òE~r mBRagbAեNup,%$$8MHc`$o;|Ģ9(d!~8as.c/ (΃\FS;;]9 gMim@K<-[e6KܠgO6e+ $ ]lxOXPpxljN]I2|]}k$S"}kO@d喾?'n\ ":pV"0smn$ͪ>%~3Lߪg J;@g+Y'-KQ~ ٳaX@pksU#$S!`âqݫv唕$Xhwk1ZsgǢS nɔ)s6x ,|o;_2;z?_ܶs"yɇ’K zf KwbKK6)Ď=lDցǥV1$$pC3^vΑ2*D6Ydk `sFe$fOe~aWN]bޝ]y!Y= 6x[j) qv7!Az9l\Oe[:4,07fuKn P $P 8UFL3>;v@jW]&C) y޵k*ױ\}艾=vzosVYuCV]`P`}~tӘUGv Bc.s:,Y(go1 #ǖ'Sۯ!zNվxq%O9:֗`yb+ v:{z p)U ɖ|+tantriIIʔNKAvj=Y7;sm;1JN}a#8@Â9=j-m=dS?w@*R<(dwE'#`k槵Q H:-mm\4PPl6 Y0s~>VŽ-37 yuH$Z!T:~cmoqW~?1,J0}NXD9ln&lX KNl YSK 0PW9QE{d5I~ےӽW#8 [Ƹ@Nap 'ówaqdgzp+X 0XhAv(ƀ莹x /[c.\{E7!n~vKWv놁kzuCgyd1CG q@t9 c jG@ 4r'H,~WW` wm I ?6)I$8/,!pl9'sn+/P$]n9J:_i]Ǒߑ_} ZC\^kukb VprK0a 9eGK]CrN?dϑm+*kNn߫M'6F0Wd= l>fZФˆk]EŸ 3,p>W ͕%`:~u'ASK;7J dFj*_}5ރ[N\و =6Gm.؅~o~N=sO.56@_ظj?ճaoj.';0;'g벝*nKF^ҺVLrX"'oU!'\kMpn29 i}֊.~V[%K<~n= R\pWH[dֺ%IՒ0s27ζ,lͿxiݒ)U>gC閲|G7- 1߷ Ұ50 T/pVR$Ϟ9:ݣ+ElpX {r|$l}V[{|+?is^3,\"NӐQ#=#-KM%FH?û\qE@Np}TE}%ck׃Aa@ԯ=FMuL6 9{MELWAZ vd@q?iK{"5Ü@ GYc_-,< ,8svwdt\`+ra* _ؑuOW ri<@WGbR})!?'Y$Qq<|^ `nG|p뗹/kH »MX / lBl~W9Z>[#%Z_tH̋{t\VrSa`hX ѝۄtdآca6tW?Q~ik/027[wF խ9$cV^6wgM^۶$/$ɈsM:k[l:Bl?M}?:%-o⩠|iijtH/p?_=7_?f]Jv~$\I zo kԫzۿ1T5P]TVrΏ-mb0QΛDGVS@|`20=p43gίurOD.8>9H2aTK 9 p{nh"Khƈ-/'Œ+$ʀ#xs<氾kD275,dUS Feu`D9PVGymz^pP>KuS07Mdy> SSZE0ù Vι``}![76]g{] b [$Z,@heDhgsnSV/8u 1 #'2:0`C+-=кnȉCoyj3~ ~I"#cתLUȆߖ:&̻5Rcý9@:Vqk: )iar~u8p8|hzK0ک2]uW C}/ۘE2wPL?_ (P^ӧ1~~f mspin0~몁NVZ_xݘvDַM?̗S;* R~YÜdQ^Ï t9➩oǛo c-ul*< hyj<@L@_ߪ/z~S}Tc_6,(Igխ9~( mZo'myrοnjxOǛ::|ҹ>[gZ /$X)G3MU~X`i= 9j_i*ױK5Zߛ$'GwmKdݱ㲍˘5u|'{UVkٜ9s:07~:gy#sޅrr}SĎԺ,^>Ęe'o](Yz$Pǭ_eɼl em4I`ۡ CCS -Ï dѭsv lg xKϠ!!3,n1 xaY9N)4$0$0$0$0$%p .ѷ!NܞuS:4$%wO~䕤!lA ܏oC p 'etiH,CwY,1!!!! ?1O}x7PΔ;sFv|p‡|WZ~unݝ:!!!!C>w\o(11!m,n䌮 Uu|RY,1!!!!& ֗q_߽UsݳKܞ]9F3$0$0$0$0$0$0$0$0$0$0$pNJ`srǠ.^mGN%y^;Rʧn;_xe'UF/Q6|6'v_OS֙}7#Nl]z=VSg=x pH`HH;RoO~Ўp]aTyz$3i 4{Nrٌa?u827<@y g΃ ijlkr lWޣCߜa\;gp(N@~3{a:dF0|SȨJS=>}LMS'W yCŸcf.w,\e6C[Ns9c}Da}ŷ?=J tvĐ%p<5x,W.>UzuE煁8Kv. ./]w÷>ь}E?Y5F«y z_?']P|UOp? 2%Os9 km."?,oC+.g{xbH`# ͂?Sv/3@v6a";@G1 -?-Dt]2/{x;beY.:z|1t$K`ۓ,Q9!f^9113)NNOHv><^)Or Rه?N^'&&у$g>o ѐDz;Yn-_}ϗ^>se뺲^\a} %x+?yX_z{c< k.6jʓM˒O;ue =Wͣkؘy˛m^^}W}ˈ2i V/}R5dgN\Z9{]G= Nk>~T\:V^Kڱպ[k˯rG&:ݯ/q~V_Եò5oq1,}xZ̭^hFۥSaȪ֌%3r>8ݟGڠv@ڝo+^~ Z5_jZ}-]x ܚu[U㚳G%z7 Y/K~N١&֚ncU|8H9i; .&j8\[g:6Kk}+_.=8\17wZmYzn^buk}%0] p{AeR6} ?)aU$]*#KalSy m=~OkHw~Aʽ}8ëmPx1d-몾}rf5L&ڷ*#[ %X#,F-=})k=pW or1*z]bsGҕߝ󻇯{V@qoBTwCڞ"n6Nz 1Sv8e`vҹ諘>yk~gYkE;sl o7I6YN9nqd׿VŹ&pz;rZ"io 2_$Օٞ쑾ғMzNkwN߮iqmhG:<|p'v%St9bkͺWs"q;qs־k6w)k-ϭurQW[خ=+2`ş">u͖ "oGT~UeafWk/-B 9ekUdMt%0<c؇'0c& -sk Ƅ`h\HÂ疾fzS|EÌEq0),<<=緘8;o Vu]?,T xaϹˈ `OᏇv*lHFamhpL7.n?'N T2WsQpirl{€+~ ۄO9oZ.kQwKև"`OC@,x8Gb>84zNg6ܴ#q!!b悞T`JPaL[O;-y{0y SKnYV0P M>09? lNəܔ}c{YlMyϐ'iIs8L7&2[tnNi :5_;E.mh޴txmavb <[yjOZl w}|Fm K,NGoscR ~5՜nmЁ?넭vd6.X9ҕ烯R鴄qXl-lK|>W6`G:U vPgZ9:wnY5`L ='rasŦ >]cya1;olVyfȽ'e'~,i׺gɍ<:ZنzSW[xɍ#K s@/߇v1aZIªd[o;_eݑnm[<6P j7L#b{==XbNIV枬[Ը|%0b(9BBL|qDqP2@xcL+P(~ːs01'À'" Y8\0: u1f1O@+8!ap0ah>0h*Q^썳-/2n<`da6ˇԖ/_b̜2c<G5G/mpW׸cA\*ׄ9-́r87 ; P k0T/t2]+=3 V!L` qd梃9[ &`zS?S`3GtxL wk%sLɦu32tO;iߜag5s'"0bW33zg<䂀)aFm+waF_Z&zBFVz4lΕ-t 0mI_$ *dC kA}rbS-um9&#mGBNDm=`k*(u}?dʮZÞ_rW jO`Of.y˘\ izq~=4 :]=@_Pێ5K>;/=8~:]~hd[ng>f;ɱ%kԵgo Wbt-N/^[}DQ?V1[gT3W ?-o@  5.Jz_^$la?A9=Ilu6_swR,v"S},R^eZؗs6Myn;5/懯WݦO{J0O߫o^ЏJrlv6{dίٍO6 ;z/&01c։yhIYz%O[I>Cz׼ KWKۧS 9Z FKaNE_9MPgpK$xe^rqK ",X9k@ p~NKg/uD1Sa%E_ԛҗ pp8aniN8FH˱?; [FW"'@ `lW8{c=0sʀ&at @m.T؜G@#19GKyg<{` s˜csSy$ltsN\S9vm߆E==LvE~zt8,~@'_['lN#l.,D~UX65֓`x()̷{=a/ܡەsjX +|u9+Oe6'u_ vp:]rǟ maAy#:vm[AQv-aǭȕm0{@QcVSu9pX>DtH@l^jNCِ%.0X-5}}WEi2awرU'_lXwOلha p{' 4/L,ffKP97`ut fyH- S=s8#g稂qųsV&8g[^9 3 +D~ ƛ,\$%/ L[Ly\{œ@@QrpY"Q)n9`[dpH0)]us gga{íιi#>y7I%'+=(Ԏ9iW.6GׅD{/A1ˬ1k*m͋ւ[4_?}х1IPW|G擼(3嘌%b^K}js4 T[Euq\LAwTҧ$O>_w|N*/9ÞIDXmo1/uAOKѡeW_\k *j( R6GxN_.;-iGsFqI($+e"F%Ꮕ[ XPA}:<3 hkTn=c ~]W[dܒ,e 2|9/)Q< (ɵ  k\Zp+*#ʶ7!9p{\1WXX_sIӅQ^n%˱+,8: @@GÂ9=}&6ndd 3_LyTuu [ :53S֤k:/%p_t{-Dl f ܾ0ׁ9pW%c=4aSpˮ5mZ})pkV%l$Zp{Ŝ!" =vT ߻i9KDŎRO慯H;Bef$hJ4{Z*/ sg5vu7J]ikM' n_mͿέ~ʺOn?'wƣngsI2`R .$U1k8#9QyI챻{ܸ1w\b-]\VqKɪ k.5| (,(v $V]*0ү_b'zGA`:K]*7j X%I&ן#=xElQYӂhI* d[ nN/qwnl0sEj5˹diJm=@ vf|oǦqMd*TI_:!D iN׎ՓlM[~-ɺr4/ίp[YtP; i^z2/b d,;ʶ?*SaE\6Bf&?-N:~l|uwp۪SZyG߾uZKd= S_vUtqDV-]KXy#1~9?%yƊbulǭ)nO4wN]|v1G * a3I晳պ t-\pZ)yfwSD:0h` d r$ wǶr"e뫬[`XK!>S n90;M [n鈀@ku:7>1pJ:"nVۖ r] \ i#Ag EnTt vnF " Dlг&&OVtWDׁU[?߬iL K4p{i^&NI5URxx.6/ 9 8-.XO'n:mb.nB۪G2_),">%p+ J~5_O KX 'B^PusSmӏaRt*ң;u>MųyQKk&ߧ-»Od3'Wܞ\yM-+k'8A`nΨ f^S߉R3SIed`.ref\pYϾ]=LE"uowsp 3Gm0D.K9sEYE#Qqf|EusQȨoɞs K$c/G)= _~bsy 6P$#Z'`wMV3[p,ll-!O$cP.yeTu@N7ڹ* #`-K9&r cOdD݋-s˱pܲtzVm$(fKmxAP'nz\.㋦{JNvAs΁7}an4U6H8Gv񱰤&Ndi-[ړj{pkn*ֵl픭җv;yƬ/bsqnw.]@ov*ڝ|=/ED*~pd` eL|e%]_}NFly̑Wn2?'}ia2\-GOׅ+C1͑$HfwC-ّ".ڝAظ_=p҂#vNr!,E0M.=9=L)8ٓA_Vvm K$~0~CWPp=57Ot@{#}9psO߰+O葤P @1_p&AӒs煭XaDsҫr]X@ۚlͧE[(Rʍ  ۇdM P#eYsmh_ܪ>p .Yeԙ{ɂۄkw88^}?T٠r^e. IE%$((o==ank+`e$ pU6ho[|`G+m{'!/4TḊ5gdM[۽@Y?ʯYwQ$vaE9mZ|DSKl?,l :~Nπ=BFMr ,*ZG ca *fmŹp3Ĝ[ψ'0g#x:] O s ՟kG̣> ܵ5p}aCd`G~1Lʋ1%G%CEN-_^/@6:V=`9 $p)cGѦ2ls ̏@ιM:F%G P#}5~J@L/$"A`~ @tVa`J}oTuN HȫXv}i=Gk;)%J٥* >лZִS]XSeK+JLx0v|j_bdǦm]Wo 4,[[}+Oe95I$G>}MK =x@k2׺'k]ye׊1VGެ"ܙoizQ~BZBeNmDž+>ck2WՁjS`xݴFg7&;zN7V#{0[C ee2ic9])|ᦎqx%0)6A Z˒ޠf  9{|v8A[Nw#ז &0k%NaYj#!h$`J"̷BXuѦ'@UUat^ JwDV+gKR@TF_!KV WA4Maz ~n9]MuH.lG%sr| ]&Dt\] kMճv =a2݄$̽(^G{ӶkiqKv@W_^0&9{EL`09W{ym/@Ҷ yoK]<6|sk c?95uO˼? p;&!ƨ_o&ks윤e׾2ߒ9 _>]&hHO9ka09}0|zP8i#9=˰ϒmmo/phZ;⇚~ul{;M/G9fBe}UXgȯ/&{C=c[=o&G;؇"Ǽi׼7k¯'nf!ژ~}5ƶnki+ k^4HSlR/;B֯Z_t\2(yb?>X:Fxw@7e\$poӻӓ%nO$G=CCCCR;Ne#!!!!sFa~lx.yy\VOVOLܞSCCCCW2ۛڐN7D{J*1ʺn*,? n<6$0$0$0$pZ$9i+^Sٰ`aАX ۝#&۟ClҮLx{E|NBnOGCCCC'U~w~C#axbxdOGeCCCgG~]Dh:4 {45$0$0$0$| Ɨ42a{ACCCCC'K>>gGw&-}l]|̇}44J`(ԐF%?~|ؿ795U_ݨQhH`H`H`H`Ht7-ZA;L 8$zٿo=&~ qH`H`H HoZ?9q2dHq1$0$0$0$0$0$0$0$0$0$0$0$pF%0l?ޖ=K;s˧~}B?e}?Po; $ض|*v픷t |vM^ _īqO~Yz||-/]u6h wtxH`A;$~E, y)|*[}ΏsPw\?nOG/_; ؗovy]IO|xc(X_wN~iS]:{%®}]+i-}iN~^~Hg\[mrݺaaavDi :zsS_nuDgW?3=.WɆ>:7;ퟻܛ{·.N>o7Υþ{m1N ~ԯwTΟ42s;λr;{;ٹzN5_?|{^\nw K uCTSן! /}y T{Ròsd=~+c0|o2_?‚BטttiĎ媏ٝ=Fh+ }fW{0u{~_)t&M>gvt^zMvbg >mCKMm'\ܫ^e{T0:R_[ j7~ U>$d# 6͕'?(bKׅ-_޵6*zOؖҩ? ;l˜Ž\_+2OY{̵~GuoJF?UωoH\6LLM2S-'뺟# PT#vJ_;Lstg 9^fn;Jֱ kk8ص63,N9k;m5/<|4ߘʓ{{6Hjn\)L/>̭gtTz~TNE/[oz;mv<|/*&nMj.+r\o_}9ikXvʯU{7(s$0Ι Sd59S=2^ʽ8VCYnK*h ,‚?f9kEq.XhXдS= $\A nf_̱kEUWVɨy|YW=/S-<%#c IcWeFCfyg8rGoK_6VFœ#~d } {+9Y[sNնIcwTP[eҵq׮/U?P.pZ>=(tN" v%m^"ϫG}mϚmUtJ][vQͅs {@-Y_^jݱ0 J^ܓ’dlJyw(jc]o; KӘ,zaA_ Б&fȴ%e% ~G;_ҖAFuU e:~|j!o&8Nvbݳdg0^cҡ9dv9n7?nځz?l֔k >9b''}P3dNd-~Lul4V릭19.tcw^6_ϸg];/vwsNeKvzWѣtc٨'? [lݻGw.YQ6>.dZ/Jn2~}w; Pd^d?/kʉkt]{gTQiav]XyC-ɠnm[5NFG/Zc DI.0# e j3qW݌~1Ke|y<%IG‚9 9V¯+0_eKw]us/7e-'  +;."#AuӮ)d 7;ۜ‚A6m ݧڑ0k[// 2NI}]sVr,TsMK1ρxdt N2*R|D+ZS:"/vMjO$kXPgյׄɪhϠOKTUv);}8Ɍ\w6ce%T zZAfcS=_}+|_hחv֢{X6O0[aʚagG}EߘK>n5&i+9'SI>3@3ńc[o0K[&J UWhlq[{$w1ju3t_tݮr~ĸٖns֮nK;Mv6sd4 ݬ+ @cp6e$8YFKr"`80r\3*/ G%ƕa%A%^$, czɈs Ν/h<O_1H]v,,\~^3L^ 9T)/#ߒ@1;2{r,C, -*9[\$>*snkeI+NZS̫'+z@'o l# Kh> j g/l2<vZsdKG Ӓ9 W<ϖáYtY'XY'kH`O諿^tHa.2n=/zK̑n/a }:p[gPۡΑ榀n~-(QLbF[ak˦g/%Ix~U9@\SlVZo+גqԺOn99X 8t}^iL"ϲý=>Dbo3f*oSh9>uX{ ;0 jL/g3ʆ-Q;_tN߭Ά8o%aPPhak]6|,L-A_%C[vE [{(1K$] ƿ7LgT A:[>(iKR=~VZomLW?}asɏ=D/kqav {om"i_@dM s.Y`u`?Zwj>_rmgWm拝udـMckkKl#Zl_ s6Hm  [ǭu_R:i$\,9H #-PRɂL6!X~I9ak`eMtۭrM)uS@0&i >p(-Ӄ$P0g?.o nKّM pX)j6Er`^UmzEYOk` ?7Ys$4ew2쨠gn/ Y;,l/= =2Ȟ1@ 7a u:3vlڿ3ephUg{6ǂqwXQ7pO%|ӒsVviUs8m ?!ӸMHK6hWTU 3Gs>b ]l/aIZbpWɽ9ưlSdߒ/=~XxMe w~I oiw.3M]t>qϦ+Xb0~B3mZW!]WV9x w݁v,XnW*KVh2\@ˌGw;).b<=A8Cy0T>Wp B#bzp+J9(c]"$/ճs`rsm9ؽu]uٽ/=w 6=ρ[HJ{L@{y¢ρ>8O?_7ӏU :Kmi,vK'ۓn@P@? "vrO,-@@OrHX3m|(\s\ 6tX .Lw @ٍx\X[In%NhNA@S"%pkO_r6]e;g@ˇYoSsknSqI};nm.ж7'tqϘ{|g6i ' ,`mɴAںCLQovHX6@#:a¿w]lM|qV:p~:n;-0,ܯ#k_k_?%-;l +fȲk?n pfT[ˎ!8cpbIW`>68}aS lg> 1"a5E[@H8+tns"AK+AK$Ȧ5rH09ҝ]t[AMD˂-ч*wNs5G Z1Jv`,$ _-muح;Ns\IuwO~G`5_rF`.92wnKКWޘ#ɘWW ArթuGպnlvJziyV} kVt-;4@% 5ý?pOݦvGbMyGM-0u>}_OJԒZo4e48k%=6$o[?b%P[S Q@tN6 .b51=6+nT[6H@>q.Է9o |uĐ73*޴Q!kܻ}ܤ;;F:i]nr}K; &[D߉ܤ edJ dsB}/KmڑC,/(I@i MLeJ5 3i5"Iamn7sq/"7|MP[~,%Jցۛzkvέd׫SX`-0liX=0@[z}dW:pk\0*p =;̦|Su<8~[3vft*-]4[B5=A_G;~#v;W:p+ѦoE's Zk}ث@0Uo89b1;=8:[Ͼ6CԳ (%S;f^KbTљOHG[ ٙ0 p[3|4:ЁMhέ+vDR%Ll不z0wW9ccg\qd,#aXqv[o/kw*ھb™qdGy>*)HB%$ KA%Nh=T jl,z17Q*zSmO!as$^isw{gv5 QG$a7ar}>2pL26h藢'EKpYH@|GlQ׺/âHIu5!PήQ .ms+QA߅_ } ^ }j@LE^M~/;:P.}@F,udS&e"E?jl(~ ^k rct,hi=*EPeT}[ WHʠ0XGxC*>E5>k?0 6(`?u_9X?)sñ>^8\O(XwM#(Lձ.|O3ԋ e)Olo/e/ q/(lߎ)?2)/g9c m9nϛ3.6zQccKokl_l+q4"w?G1>:SϷ=<:O̗̿!߉$z8,ϸ+Rc8[tjxT1BV|YdW< pGu=O 6ԥayj)m6m Vwͧ"Wa4ψj+nӿ|`Sƣ9<$X|EE6/:ԯ7m. %0JP[Gk?ß+=c19cs2+́E/E8g?'2m,j9ֺ tr{t2Ik4)n"&S=5 \vDKȍƎÉ˻(" LlNN8%k8.Q <Z@ֵ[JR9>;eon&h 2[%@3%Dzm:$odJдdbrD39#KꯒNݞ59~oCk =* wzmn4j3ngW+K˗w ϧI5H섍@ug6* DM}Pv_5$FOv!+%_7 e<'CwQ_P g;zi>;1eV2-@~r&AZ٘? tZ_!H%²n-CQiX`9,`= 0M`'eK^(hZ)AKq2&ׂ1aSH 1s}Y$8o6Dlwa{L]ѩŲr Gr"P6a_gG<'~QDLc'{4g sSߏ|h3W~X3{~X>vcdʳ,(ѝq6~'sAED>}1(4'#cyV'l%0Gy:.w~qIgcJ)QGT9Wӟ9cMՂ1?m~7δեgHSH 1ATQҎ䚧G@hK;oycQ-!b0|37;uܼbQ$:'lv/#{Эõg a.?cSyb!,Gɟ._%6gI kp&oZoIS9z&}v w .}~*'tp:&LNٴʉ֎IPs&θ TIpɻڪ"1)rH! 7P~'"$%rDAFMI-rZ_bࠧD ՘lj  Tҙ̵^ѷ m r:ߴK_4!/&"b;Ҙ\a(_!?oFp4 Mt57u]T ^쾤_%G wu4dN .ؚl|m^9ߍHA'DGJ?CǕ Gߊ F@@N`[1EW /g$C!EV2,$ ~ nј->H8iok86FCnXW{nC} oR޺F(t"`o jEP$O}$fĸ㾞3z_Yq/-Aq%Z{~AwDNV F?Ivdi~cw-Yʏ?Rf9 (o]m!+;f؜D͓$A+>__W}sIyS>b)X|T1%Z) yud.l5gF5|y/cN|пTaw|ӹBZw/ 9p;]#&#p[E ?7E<|a)"1/"cE1Ucnm.)1-Lyc`tr{ullr`TGL9HέҕѶXlg=t7U9K [[0O]HϜ7gL{v\ƫXh-㞍_v)ݺ E )|5~K-kwfe|k:p\=Ujn?U\T]mֶI|| hsq1?-zqX!kȎx\ߴC/]5)E/pѯ}cUv_c!oԱ2n=qP:ܮut:+%X#݊v\v&#kI"*`t'x5'*r?!Y^vG`OvOw:$ҭjn\>[/Zw2]dwjiC@rVgt*Fo7EsMZF۵{@G` 4M͋a^uܼVDҚ[s[DByN+XwLz9/~#-<+ukt|EE]䑬UOG`#^gt^em+oxu[ ޭuϭ#2ش7kaieYN_&\&F"j^@G#+trW`<2ٚ K^^mm/oK:=m GGlRM,pkj6#t:Nn.]V1>=:/Eu[,r>sε^zrXE_ 3Gȭ.S;k?6e{7Ҟ74.OK,PW/zZuC&6' ezy9r$~ryxۮ7?^5^,cѠ5[=裣.ULƪ.|z썪t{h1_΢s{k|6U{mK9OMM>1-Yw#ع-l N* uêة</2fj쮽ȅi!U~~iO_ǘ(]"7hd+1v^>aSvno֔iNy> ec+As_>Hy't:G}j-A(8z{iD Ǣ1MA*:*]t]#(ANZoBtNH99"tSA""qᗣHM]=߱T!H@u;)o D`џGP_Ox/?H]9{O Z臫:}0^tMYD[4bc\u> jUےǵƭ Ԑ(y!6 `הNP"ۛkaH- ~z)bGuA (&=>Z|rYU@_iwQlnP׶6‡ EvlWGD, _&&\ۂMi~7~lzn轚Zpj1^_}Oz—gs]p WE/6z"eL- -=9nQWƝ;B9>.sonv:@G`m#^P(xCZ2'X8 "RTpmJо~PRBJo:$J4!eG-v'O D>2En&.ĭ H[,Ǣ.cb}svx(&mVUk$~ZoeA?>jmC#Hi{fIS_iWD: v-`@;]G݂ʎDڱh}-Д\w(C;ݭ Q"N[ztg) v՛]eFvn#?;o,,uN_S]cwf*G,FЮ菣:ME1An{Y݉vp>j<^6jGM3&A.FcǢI+њܮG-\-LTt:A۵W{H6?4skw"vom؁p[iYV1ٚ+ٹݣέv,rkb[(]n o>+R\A0^cAJe]ڎ浛i4zdmٹc _e$Ǒ#1ƐŝK~uA[}>+%[_-6 .@G#8ҹ l !EyQA~;-Z&t "-r@@WO!-t+ݖNo;Q])lE1ٔH{N\g-F-7jb7ڙ#H0u˱[&_>4k-[Hzo~<4 jD؝cJ؎]'ʦZAr{gZ "`!Yو'*QG9)bSn5ؾO;,<7([/M[`)r|18E'DBKK՝[(ҰU ѱ[aA9uq7@%6R;;EL&]Eܙ/6TA|u=mQ*XBka`glt.6Eu MQ%c2ؑ;lڅ7y3Z0.eی['w:@G`"}U3|Θ N O~=zߪ9 \+@ N_0LgH+( z!QcopA(@O]CJ)#x)ϣZǟ:1%El{'DH_pT_y.&Ew眝ñ]!i>ۣ0!ZҦWsG_="N]RR뢥Dx ;)}´O\p1y!FJ~vGBDvd.ڊdGV[T9sTz C#ywccC`hO$<96E D%}a׵ǖ`B؅X8+ Aش`0@Pd v_Jc4~ 씽#cyJ愶q(Rd6?eRmBRHol FoRwlQxK R_KG6mag(wɋ}m37 W.EoF^͎Շlba;]?;;͎E/0m]Q6mD,B1 !?W8t:5@'kJ@KKvm,Dd\ lgD:AQ$HP/lwȁ_6ԫ!3V|ݽC/?>Zv[+`a*A[x8|nRX%`2+x.Xh' [#.|Z$@bHC vțj:&yr$@LU4 ս} s _\cg[[v– &. ʢ-[?_:X@.MDaQ:k4;gACQ$A_%!}j,~CCl_9~D&`[A.:7cŦߘŦC;8RSz<(_f, F}nX.ֶG5ڪꁀ^=ZS+zH؎ 6yRT_YB@-8qRe|Ǜ^F+,%.|]Y!({K|۹n=?;ʎvM;l<"^`|hQ@G#I:]ݶ*- C wv@:*" (aQAYv+\숹ѥ膨`1E@ .Ȣ(ر@4eȧ@P7 9_=OvInؔ[~ >v`jA姞u{4"L}B1Atv K. 獋ZKe}~ AHv^@"lC"Cv+?}Kw5o> G6Gջ\RHόQ~ȔqPs\#re,ڽ5kF(< V u)YѶyb`Zc8lV>}^^{Y0c)-&MBvo1m>`Qȭa "a{/}[S>r9%|֖|J]ﲣ~|׿nXpS>H=c;R?\Q 3)_Elk?qԥ#t:kNndJ1 n` sJpkNJ}4q礑d G>ȅ|[^v-=o-Qv9V>Iàc egQ׵"R~V&F!o1;1Z唀z޵p(SԵ^Jh%ovԖ_쨔+}ݖ:9__TbS09_캶RoP_sF5~N뫬ԯe#SV'mTKSkm8g+mS3UeNS8ȷWI3cGۏpb][ Fu uWYpmk;fcSpvk ^T@G#tr߻W#k9J"IvH?]:#pUP]:@G#XCtr:WG[݆k: x}/E@=IGBT v:@G`-"Z^WE0K33^3:u큊WoWG`o"`q3E\tcԘt:A5QȬx#,cNuPo>V47#EMG#eMȞeG#t:{Nn&=郀ۏ8z۪vtVp{bsgׯt:@GF^^G`vXB%7.M{^CGBۂ1/yM7wt:@G` ^͎@G#t:@G#Fn@G#t:@G#vwao@G#t:@G#trm#t:@G#t<ܮ. t:@G#t:Nn t:@G#t:G5߅@G#t:@G#m@G#t:@G#Xtr滰7#t:@G#t:6t:@G#t:kNn|t:@G#t:@':@G#t:@G`#ހ@G#t:@G#@G#t:@G#y:]]t:@G#t:vt:@G#t:5@'k {:@G#t:@Gn@G#t:@G#vwao@G#t:@G#trm`_ .';"8s`O}L)??R'8G_˚sC0eoA· H6^4zUТ*茶 ܮNYU:K_vr::NƫW]ՙ['ū>>zS^9=nZ4:zYۃ‘$jXxdE*~7ylѿ5苣wU@'CauLp7>5裢>)ZkǶ WZ\ &ͭCE}{l==X\gџDo0B}'G.oUؑAjD5eSK םN6cwøTctJ39EMQw茉[Gߥ#@(oXCltԅ仮ݓWc^ѝܮ>[i"lrdSQE͗DO0Ǣ"jyEgWޟ,zt.nH~7,==菣X͕]u;k_*.n|.O] .~m҄D=oNoAG`#pmQ1q7oVz1hTtNnO'WA1y+.Wt躪~Vv0+6[6EG/p ;?_lp_gk6^YO~9Z/:!xo|;v>=2ǫF{>h'{f#KI#&>6͹xM:tr{-z00=r Q,#Dcjy _\Py.ѿX2=>E~3ѵ [Ki{6MRn)cUQ{K KG#p ]lY6FuTNn^pքSi),f@"Fhn?/Bgܖ췷4]engU9#`W\ݰ:hsx{g[3 vђIϤَg=Aq9+8mv;uu׆>Z.cu[D]n fiFrεЎ bgWeyEzn9WŪTIg=猖{;=Z0c _G4jnD~-+o]uc')`n޸7FƽYD`K}O0YV~BE[EmJ]ٔhs]/Mbtn%2k7U °ttGtgTڮ#k]s-WcmhO?Ծ502^|Şv1~Ǝz32֍{ǜq޵hLV|~VM?V?Z9Վkw8S/y[$YVlh3|6Hڱأc?z Az?қyQuNwψgPױͼ֫mDNnr`Qor[ 5zvtYM wѠu9o8[*5ljMWq0ώDפ|@}n'/@(;7I[EaÙ"yarQNBlgV@Jt]Գt$" eXG~ n"Q/nͼ7=yd7z~{k[-:ooV+ M[:`$cyGUs%뮖|?Z j Z;@DhV]e\1r}{zqTĶKBՓ/`#crw;oce5.vI"_oi;-RUcO -i^Q _?_ƂG}`Ѽ򘨀C^lvJu#cS(]_rJ}Gu>|ym0OQo{6SW}|'Q+ޭ> ǶE[_w!=rqc6`gSG+eX!dc0x^&7;Fͫ')װec+AuVb'6m~t~-\>׊"GEa(b j}̱|3[3/oi DεSrȜ la6=j8ODA ٢i-Qq鵣ŏe"3}͔KzeG,臇qcQS.I |i 2_\'EzwB&]./p#.cE Sc$Tw&шOM,*qpl_?jxS9t&DDq[>hSs樠|ѯ|JMlVG_mעچ j1لe1 4oRvDMPu>3hgݶwɗ#+BN&Dو`$s!CZ .ᯝ&/GM1AcrHnԜ ILv"v^Uw%VP#%HIiKT՟=}+z|usIF||;~sZzﵣ $j\Y09dS>hӖh[pUۓ%Yg1AIT]w|(ԕ=j4a{10^1ZX`/[}zTXQ1+*Ȁ}S zIc!ֶ&ouHd_Uѻˑ/UQ\_ʸGƝG~ڐߥ/:ߍ{^&xPYu]{,A\oApE#o /շ_F?ޒq?zhUɘO۪R"ոSgO`N AkӨ"7זh]/5QGA4;1<^}ݽΒb|[AM>6~o9 ׏̺|>|ai,͙XYQhYx7 ZT[4i(j^~ٜTAmC?2RqQi~)">QE*e+;T; X0Rc{Q{GWs*1.ZW_XZe#lh;{wTߕ]˵{W8C'b~؜T1?g8$|v8셣e=gk1Ψ޴iJYzzXGoI~WSY-PbNnWn %~ ւ\1?,GQ# &:_TNL$7n f gD/>ga^-zc\q-|Npl59+GEѺ狉46roB)yiv]'tYEuN^[_5+}T1En&6HI"(zK7S,YQ#^D$ea1#*-,~{Dfr|7q kQOcCъkG(hT-&QAT#.GDD0(I950"BM-X|!>'YÿuV6rZ6Rёlv2&+gL#~B0VebܳcB njC+|q?ׂ<wi fG}H \q8@R٣ ,w:pIƌT{T~2/vo^(HQ6JR8~*!*#g%x:1oNo-/cQXݨ@" Om`=z!:l"ß دmכ?_ls|JP^7^#zl#2[@>"E!6j׋#ʸSFlh+{akv⍧\wBZ52vy~CMd3oԉO4l/wOp3lD_?5Z1jlLbS5um7--`Kby_X;CE`^c36FQ%# [ʧT~lXfNlQĭOV>˵Qcn[t+sC4_Ü}CF+QuV_OPvo5P A#@ĵ &uXĄoѧE9YA'/)vؔaOlYA2vjʜ+k,Ah2c]TiSUk"i|cb8L^)jL\'8w--_11_"\E č[Φ7&ƋvdgcGS|~mQ*aszщzgtj, sT\1 Nnhv#ioYRxk|7[!@|00,"2%xmIzKT8漦ȭ`S`(FRTyE $ʢ#ռ:O+uJ-bMw!!sG\Wrȭgup|]ؘc1"EɭTYbR ,9]vUa;[&]EmWʑ4 ioUF#}Ȃ20"<+7!q+!u>5d"(q$B"6g5X-R TS1c1j #~Z;[im!)ˢΞH 2ƨ7v74j~eT|&9luo я?k6oKyjY :9iXȲ(<&w[5㳤STGD-q8<]X7m6-~ʂĮysxcU["v^9trHsգٝ9p8Id5ʹiu^`.n2RBn9)rkEd(8]IJ=hX^Rrȭ $>L[+ܗ Xܚhkh#T˙{S7\wϏ.ܺqQ {lGG]khB*?&[A]-yZQKlsV@`zWIC{Ի-5R[1Wlߛh{9||aSM[}[v>%lZ.R p,/ Dp#vHj1 Iu`;)V!nl;[/H"r$ r,_+nZbA{.% /X&)'}$&}An9WrkBL@5a-r}M*־+ߍ"NSbG̟]%@֬"13ܽg#vhVJn| Jݬk?O+!%˩Q_0񘡍1" vFE)} | ֞ " U JE0V} eOemjsh EE.~N x,ˎ]Z!."uG 1\T:c-"M Ef[mClfKGl!{ܪEv5dٸsy~m96y2߃/H/WSG̷ko8wM4Bn%E7+lĈ%㐒pf?Q>#o~O}^w^'/ BxVPyt d+[mXE ,h;K1 իW5Sv9IV1[xMn>4YepLp)'jd^6?9Ah?(Zvצ9Or_HUNF0kAVQud~?Z1yja|9̱_6*\ )oDd$(`C]hWX%*x,r|qg2{fBD^4:~i5g*֜aexy-cCݍ5ĥvX8]k N6D dHZZAե6=äϴ[%"cuhtjT5׍$4y'Ƕh;*;DTB`!Z^YA+QU9kY_ɱWF/Q s-S UU ym7]] 2=5u_cOEB<]5n t;cV(,X-*/Hw|L6xNKCZi>\\#F.7RۢS/LQlQcUz^q~@Je857Iؖq߷EaX/ڒLͥPzmޘ|9kJ QmncbYNIs_ͺE N]ϫ23m~G #svDOZO-bek~W9^47E٦EgqQ-_b0swhf3K?S1XpbqQ 6?e>,x$6]_i!G}?pΦEBPL ը1p7;81X~Unz'H;2lt[[! яɲZs@ۣĤ$rM945uX)ppN*[=U/(R1"^w'XguW_ʗF0LxE󳨀w;:Uw;$ 9"NʙC&H}|$B.' J A Un>H9חL&Y/@l t>TVWy>a$ZvFa5L(LQ)]{!V`VMSO;`&fdXt\^&sX0 )1O? :eb鶡ç_S!1\TBf -g|S;ٟq/`-=O朳#6u׮ ,ys{şO46؂oy-lP:׳#į J K9>*dQݍFeQfiʜZ򲘡/D图AOϵv-%/0`GwV򒧼Kh@P^~j=6PfGe@5@>[` sه!׋ /,>؜bAD( l;ux>Q0^-$ A5 u#Z6W^l^0`|Φ^UF͜U%#8KbHfxDg/ %⠺|ْP;k/sע)yq[WK-817kJW ]Q~NƋq5QvFͫlnٷP G |u#|s-](b&SwG _Ʒz i˂}+_o!S6~QG]V/&t N36sbK9)0~)~%RZ4An9_w J8GZ_ji_9_ Z]+hԄ^+$T{:[yS L" ԧԋ3_j+2S{J]u8!݂@%4)K| r׌rN>0GM֥Lo<'UPSjT0滠mɍP=M*egƺGEZiXɸD;r hFelr({e)?Lƚ =,uזt> A1<>Ty[Qڎ2nAP[-jr^cGm)wQĠO]ǶH^]'AԸ+DeR֖ؕ]w߈_W~^~^I`&@ZmmoA8ۺ=Xmzx~ԝm~|Q$خ?嗌27仱Ånjp)zhS/krZyKHIY|A12]h̛j;k~#pBP<ߑzzr~O(vKl;oNqg"- $;Ck.cx֨ ‚-R~/WΖ UT]lϽ]&yE×Lc 8]"FM-|яGKL7;d^T]ØoU7}!#jmWYT|XcQcxD|[|n;Wn?ھ-4!?7n,yCSLȾڿe#< (.b]Ttͣu|2un^ן!9S7fF[S_8n$o~\<έ_җxz +FM>SH#:OsCf`VQND ZuLP2)zMp2WVԹv"UVu}S j*@u J]7@~P7Oaz! ^g47Z0''ݎoN8i+&,} e(e!v0U0)kh_NтK)c蜇qd ;@ 4j`:&1rTec]X~7,Z}JU?76E .QcmC~5yۜ]E@>?F)\jL<< v,]Xcs5B+ ?Z[8G~VGnjY }uy{9|?L->1"qP]7|RyQb2ή'7e-|؎(90.ի\#`uZ/v^g̫5\N\<>`LS Q/Ue"O|w?5FnZsRO[N~*zJX(Mm!K2ޓwL/ZPtb[Q;_,I}vNyofthTx3>8"^>u]^A3>?N{69c6B'qAsojG`aw(~AQ;&cĵe1Hrk*'vFt:@q@nK^+ǁ|onM_Ol}gh ofc"'j.ܔ >_ o8ŅNnu@߹s,ܪ .ʨ[{:&P"n+C}Xosnr` 6Dq֥#p#wB/sד.r7=)rsGF/+y~tXexs}l3]:+E>Oz kg=c!ѩWZ޾nSgDs{^皽tϯ#@n=F躽}q?!Y-E?~. y;{vÊO o('ފܶ۾~:ڗnu0-Ndp w*:E2֟q/X;^"gVwEE}*^A?b,xAwEVj;;seR#Sݩ27%d?TMWn"ୁv4|3^Cߥ#OUo] -vV`zͲkM@G`-# qܡrz ᧯l}g1ry֓tiZ7?ڹ͹7G7RoCJ@G#t:@G#lvdS7{|Y2w09>ziU+t:@G#t:k6fۤyk۝rEGS6}\5$@G#t:@G#7=Cxѝ[91ل_#aBn8En19iβkt:@G#t:nz[vnhʯ?rsB\࿄nKy{NnWx7Y]oH@zYoJ8-mײ cL >_|4[q@jvy 6|Bd@O-6蜻A 'S-gnsIl. |.Y?(zPG`/#py0p/ֲM*|h'M7NZuߥmH7q?S+-Pt9y=sH=;Gn5r~c9έ7r~kH9@ j\0zi~h /=sv|!`^(/wu$ 65yW>S~ݨgO۱ Gn!;`saa! ?= u_3rBNP+^v:jG}p̪E}UT`tQ Gv[ݒy 2'ug?n%QwsW#>1njEk{\.l@w%2;3ƪm1wmioG׮i,paW)Pm houk{;S~zrKE4xŘ@ mݭ呜E^/QGupџ[4>nz?|^.> oK.R#qnXr[EHSt:ɳ}^J='RP,#uv­=QoXھ~9iSǒv%v4m{^}Q"PnY7VbkgTZKwee|%b9og? Iػ€˼`rS/21_z vϼ"gfrw^[DΎh(L"ƨ_Fg=X)Y+_SΔ__\6-vXuҢ;c3ಜ2Ϧ\۝լ){5+ߵ 9@k9_ܙGjݭwF(&CG}fޱy?.WX.qE*_tǬmrzUϝ9ߟ_dx)!2UN^";>Eu& Iw|mU*68Zs;ૢ򲤱y n&c`Y׼$) nzZʾUg}jqkA_ R7mSx㍢nyK?[h|/OnJܾ㭧ge5FaC}7W嫇~ha[m`䖪Z*RF[>݀Eŭmx&gvyߧI; ۩,2I_{Pts5:26,6)c zJ@^3OyA.e^Ψx(єMe{wۍ|ԭi湣l53Or g]?% 4|lX9p\9$dU\ŦRlHy6-[<s;ܲ׺,>{_ƾv3>b]W߈ 7VI-<}F3ܮ۞g(v*Ͽwu][Vn1ِY;Q޵M{N. ƣ6{81;cD€N <yŸ?,.,}'gϧG.2w̯D1C| F择eu-<ǧĸ/>ڮNgkkˇOKocv[?x-0 m|͔ܶ)Dsh](r)>hF-rxp=_[bej̲)z({y򠮹D鯉KOsC;xۣvnr߃ex=`7O+xzAL /D1HvRI]Pͦ{Ctߋ$#'T/ ͹Fn`uG'}IMՐ]5eA\LףH(G Q+e%b+zr@8v+_2K@*۠e5p 0 l#.u{G1*.TK yj#xoAxas[SM'F̥.\N9W>5&8`}> #F-QD~VǣYF D]G]UvN _KIr^pDŽM"?nmL: 7J>&t?K.߭gOE L좔|/6=F:r^`"*Srz8< ؝Tꈘ!|XWl(;7GX?nS>H0>*@d\|*zlT`r>}pt"Q]m3HFH-D<>/)ױDs!S%O$@8e ";~lU) HO0TEyU?lΐz!|;Ff,(\3Q<[/xK8E8zA)wsI-pQ/e5IvlL6m,i>şA)2 e^QLQ?%(߻K~X47D-TG6uVDٱ>n?|b#SCM ^l?G$O~/ؾ:U~-^cŮ!?srJO. vM]=1?xK,\Z)6ҦLcQ_l62i2#cdb_tLR=A+|e}Q1IQs!e'_}XQJe|HH:?u.{c81Wc?|eު7Ļ|UK1Q[x)GIMS-xӦo>qaT}a _im:q쨾nN68u*[7G٬>P?(|JoN]H!"wD3 i>,|;I߱zL5/m3@C3WXE{ӎCQϱVmQWwM+O^(7Ga5Ol_#ؽ(, &!?#jWvQ;oGs槏 i\[a?y֜(RZ}qikK`e\F-K{c)/ o`F@d|Zf6kGx_>xuJj熶~9?KgcbIߜϾI>("vog/ikv~X?nkZ[2nWƻq/uX9' )yOeܚZ1O5Mb'b&f8 G^EGq P;noInS>9zEŇ͏7M?ùcMoz]]V&l+V"Ad& $qbQmBDn>H=^!jY^QNQ )X1lM|(᫛"1XrweJ?O= 8`ʵ_ (|9Z/[9Qg716,C+A@¥D0^D}:s-l@vQ_& v& X="*E#PAND`H6ROL7( Б15kAD6^׏;v7uL6hi"\㛢l1EZ;_Zر4L&Qcگ.ʨ˗ 0+F/}I;OGYHZ lۢ^Sh]o8싏(sʘ.οkH_v{O:SSƬǣE*hC$Vش@/[% "/67~Wv5zp(?T5] 2g2$kQ&|1v;QvΏ%㮌/}tFk>#ccyHe"'m-3cx}^B$gk~1Fm Uh~NiE" x;n q<ۗ^_YU ۱`1F3B,U/n$X."|/h "2߽l$rLh.b.CvK:p#ĸׯy6SE5M1?a|1(V4w=/5%b~r|ejeP^|1?18z)wk>,ȿm8gL)D,It| nOžq|]?Ljg}rD&11^-^yZ<ڸdgڹO[k{{Rο+n|@arۮj@N1M@ 7aHdE8KDψ ER/AG\O@#PWje _ p&LՓ'55|ԵHê4׌:Ѳ>jrUFJk%pm[-s_m >_ĕ7i]oAc ̿ b3m h4'|"%=vr*G kMAuJLP_9 Ƅ**kE$wubXS~IΨW}jE4/}llA<ސkb/F͔}7ǐBVETq+l\?4R?ԯIv kh*`Gc$O[ tS4uCzcnV&;4ʆ^>GiӁmq wX$z2( jc?dC-ҏ,!;_DwC~CDؙqbqEQ~)cE&-"WI56v - FP_} |sH(E'G~Io淀\vڭ?&N.xsncsfWe{{-p1֦H,9<9Ɩ1&b%6ɇuu2D!b01\K5wk%Q1'F5gdocv("i{|85扸ܿa$![d⼖cu1_GOgI1+I4}|=1,0?^߲:gÝÿpGy::-6yodx ԖfdrJ.AȮ#V6 Y2dbr{ H׬]'7%EwF9'EM-';( vIDATB(Z;/TaBBMPcN>sF}SZU/|12ۣp J\`{$0e\'@u[‾wEȒtB] f 1l#'˔#̅lZ &[D[޳ȭ DOnb}t[D[Nme.%M ȂZIG'oۆ ?ZĿw+o5(BXr"TTs ,)=QbFcmqQ( $bJȆ|yc 5%#X9%z~mC p,Nl,z+_k^hE*\whKV^6o3j\$8tZ4ǗBY8„~@(@Oɺ;F˂/8HE(hșOnmGn8_u]*;ԷQq-[iB("僤C,F bљLnKۍđb ǵE܌V+H\:\bNQVW6j;/6-nx5KJdܚY6}!MNnCn7&ѷoѲsjqpZ9ʨeX ϒGn/? Ϩ`7I, ;&O #P8A `o2Mxv!kWe%H^Ҋ9'hYD[H^Nx8xX+&>xS"@2Dy#Ns|%!iR@#7ZT\LV}\v$P@k#M&fdfF7+Gnc;EnQUd6OvM &_">N?/vh}5CvFKn=?$vq_XϢ$Ŧ݉ UV2a^78 E, bλ(ȭ*cW!*"m"nn/`ws us@"Րxc>ے/(42e%Zva JvŅ}Mn-ꂸN >ji:ǐjd;S-{BniqbZY;-doF>Hh"lҳd,$N3Em6l$ڹ]R,ޘsRrk~2OCs zp;o~$NBvsW_ndZ{{I+[sshj-vܗt 5ڶQ}A\+8͛̌5[j]}"$bGG#ozwrƑ&Ļ@8!}e+k91"cqT I  դݒ_n\ aQgkXhqbc+θ>hSWv͜oM-l`>(%0~nώZ@Z5,z^古EAsȧK:D2":0*X_S)r;kf_lQq_Yļl/Q ~{"b٘*ZP-,hk[VGwvb܊}-b--69cwk~VWȭ׾xDny} g )/IcS¦ٮSh85S)\g$>,Dnc\D̸~rp`=w.G禐).}i22<'i\!jRٜon督C%* A.$Pgk\`cź]$lUzj8vh~7^JuSi~rUK 1(7E _dP.|uJ&=r?oP)-*z;&ʮe)?NWUBݻ$daC:9h̲#AW_.-[ڎO+'Sn'؜L%!5C ֧`(FU>T7;v!*K P 9 8y4 렡ߘ^Ĭb{]> }Tv4G*,vɎXW64uJL=,0SA會ѿ4TCDb+ƾ˾蕛<ϔި:-6$nhMFv7O)Ķ :[16|֖hK,^? "'cXA2?81?xU4ȝy~z][-hh X/֗^&6.כ;`eئnuzu"ۣ\$Պ=vC|X8rcݜ-(<4ԫinjcioc֦/EUQ_U|AOZ1NeEuΒOa2c6Q\8f7yT%HӾKڦuRб͟DjMrAU"V*wG:GȊ6tZu KQ&KmL O07Un()xzU?@"qEm\TQqi8ɾ<'_#iC6[tYp B?2w EmrԷy8 e+;5%oF7Gk;pἱl|zlg[%h3n Pl<9uiC0vDR!Ǵ_Dl@DK:]¦wE“aU-/?E+Q6V/ouQ9^Aȼܿ>w &3қ\5kmo~}mȗ˕"M#+-6mAR:j,HۚXw=|J{mV'Fge^uEl.k35O/GD#q(6wlkV~Q? e_+O]w1"[/FQ>7ȎWLy~7۶(}񇮕7d26կnX4_yv!|jԂ(ɦo؞3>ooO>9鶼4I|軒Iv\v-#Is.w4%qQ+yTV&KSLh&4E(lqQ͠h1 ϛ`%PNd+(P73bQ4\*#zRSC=#oO`[ n%G4#ԟuki\|c]Sd>1h_$fMmSa$@zVSC9 ^}甥ԑ;Fڥ/ HN oTV6R|Mx&ĒMI[Fr/ QAw-V孎4x;kMp^ zJp ~&R_p_D/ Ob|G1uQ AHt zG2ߣYŸ toUϧDuKeh{2 5FvKzɟP![T$,Fw9a]:N~߉Qâ9cLJ2Vȳ@sa*c0,._6F^u߂<7Ӽ c1>%a%&ӦE3Ww6q5&7(m(T7moblSCz6 ͫr`I!vln+2Pۓ гv0bKS7fG95a-TVOGT|M 8荛,巀A{Ϩi8k580}J8!J@Y)qj}&%[94 ϓU&2!̻6Eߙ&UڨƂS?"fq@u_c6Ae [b]p"O qAz 8B{籺ll a-PۑItL:;_?=lJk aA\3Ű[V)2{oΩߺ7黎/Pc1cF u!U/mc>ف4S kQH)X/Ō"v谻ëVm#~[2X g"x r:u!Y޵m~[ӈq;|(cs>lGݟ0ٖOR4UH_ꎬUݶ6?ȷaYrRƗk[r+hy!S ?6Ω"DrᑋύO6 ( @%'~ UQhHk qƄQu\G{='kc~eۂzc? ۗ^]`g^0'!^kꮙsۢcGβi2?J7 #6kNcRwA}ԥ९lIdq/6Nu!|b#v~._<0 E}{cZ?>lV=cf Z4a[\=+V\-k&]Y󒨻c]8hy}(T-&;s>"˖pMnݦLs9d> +,€ 9K'M60'VFrV#fu+ n]W.mql^|J5Hzik`]z.wv)Hc4iҖ6KMnԥh,m[4cǴ- z<욂<]}@Ky]~g{|7DY%]j"7? FϜQ[~ش-D̲yϳ2F nS2gKֶ..:ֵgK;g;{:-b-.k(25^31Dz_XݗeN)WXQ痸~̾뾪\_]5Fc~zQ"6=qVLQ u|6˵uYt,v2^yiV2]DKL8.c]ʞ秧Se.ͥ @哣_k[LkO _:nӶC]ycկ=+c=]5\pG`؅aԎA@G`#ܾ3=:ohs- =eKslQG-!]:D !6OO@l V-G%]juQWB^-U~رC_NŊ:0֭)\Q$>6ztt9wGjw $1x=w.z;U_tV@嵣do}+^M6cUFEB\mȿur3l=qG`m `m獺7^EFZ-*])軣noϾ#?6E5^ֱ}T8Hpw{'GOz+fvV;Uz4Jץ#J;)a4f@ 7R剷U|~ vw!'ZoU\^a=uG`u"9%sm}aguuת#6Jay[䶨78wtf#n7_:gG#X5 W <2\m8'y}yrGqĶ򐯷Yr! vKR풾wbE*cxWTV{Ɖ>g={N>B3BZ@w;.x跼*.ÖA? y=Tjv϶#t:@G#ga#i]_CspΣxoH OH!'{r`W2R}ެ@G#t:@G#`Ռ}llv}\^ld6=:?G6hc=}W]:n^$~8X^xTx߇moI=r{R<{ԜdrW.I#4?}pvY=:Uth*bGE_4<9U˕ 7F/@l|F=XN[ }ܦM9HD[a*kSyI|M_->gno]godoh#oc9^blsu _{\tK݆\[ E=9w=.g748藣F#y#ǼB9;~.|ڕ7.d=A1rvĊ,*HY H}f;W^ 1w_nzEݟVoѯGzD{of_?RM}| rm]@W? \rTl3?Z?En!y.#[)wvmN=`2:O {D{梨lky )vj_?8'/Tx&7⃼(|)!ۇLeumoXDQmɈ[x#?[GFԤeԶ/qCFW+?Lrlc일xj4(a'ޘ/y3<% n;m)˭ۧb2jxA}Eѱ?Bzpј؁FnZ0cù=+yY-ᆑJ;}Yή^ui(j|u[Y|jY\^{57;g= Enޜ{2{2G!~y쿇 m+9){5])H-4")vy:6=/Gsg\_z<7?̦gPrPsz}Ћ -pnFTi^,WkF&Ynqm0U-+kݢ.Zi<siUS?%?tؑu\iП5ʛվѱvϺ^vs 6뻶QL}z]Nk;,ۗG+oܶ~erNyqiߢv֫,mpwWSmߴlPltʱ7J ;[KӦ߫Ѿdk}u1n)m{˱YqQsmmɷqyny§1Z4.w HzRoҮ=}c:,g΀wqM/bGl>)r\?*>Ukvؔ|`lg%_EC?=mySҜ.пkPfL)[߁Ah.,zjH]N_ZP[]Dڹt|n{ ^Qdp-/8h]*CZ/Dr{St{n.}@HV[4yF^{ Ddq9h!KnC~mC/1?jm| :%&u}}po ڲy[g^.z(JW};T[nqK~O%zVYߙ}7^4"k|7OUh8JM{En/lm\-.`5:E/uk}ݢlːʙڭ~>Dn>+xh-q4#=߳vnWUu\|iԝ"˭ڸeto)g}yq;F?k/ck,j3kt J&p>EZv|ثs} \]6ؖv۾W^Ω=!oCUy'd-]f*d 6 #ߺzLM۪ 'n7ʻ4h=)S].<c.uωzUsc{bTE0*yܱI%%0Zt):s\ RA0n :!?e~2*u|uU eL$߽!fH^qh^xTLhlli\zIEȎ[>6pSp̚~"\<Ŵa` Ěw?n{_ \~BD3hziwF&+NOqukhY+++}'D4\#&"K]+ROQθ^gx۫kwm4] Q Xm&%S%R.5ͿO ԑg?E*Dz||!v uQ2aX `SJ`R>WUף&j.ȐI#FQ穬FS2)d;?"%e nԉt i.Vut :{cw9(W^ngQ}r@sST]F5i~#۪Aķ%ؐrmmHoE-pEr}k3`l5I T<"fD [O$lǗ:=87\řE]ED%{Lud% Rz]MMF1c9=ﰶ-1r +FDo?=H(V.Ƃ~gU׸Q̂Qb 9`ܝ=9 kWF[Vn!b%ٶC7e,h7hIQ(Y_룵=.->tgeunuaikqq:V6XS.эQ%M9HSYP';P2 vXk;cVjSЦ d][nZ{`_ZD6!/8зb#l]f:/6N㦌cS"&עU:.AMБ+IF-ߢwG1(O'U_D}xT9A蝚r QD6Q,**=z *j"¦7P g㐽cyT{\e0(;"q@ Kg xغF_d{iwME~}fGƴ҂Y L.kJl{tD¸CdKڻ绾+])ChTGrsRCYFo[1w i<"*n`c}g_}T jr&rsX1r{E- ggc {}2^:%~vkx4nkQ.Bިzir7-懺_MHպ /}Dߍ';45uE_c+ueǯ~)Kӄjh+bcB܍䐇8_@ߗOOr픘`6"R|3(smTΎC9n k|s p=*Zƺ9{[T xA;6k_+Syv}._6Ds6|VCABئ-mbSۢPw/s !?/u3f-9:FnKgq.2ckz{BlOh ny78>!rWrlɎ+ mS}OD9l[VL"#&)vNM$`5pƂZL${$sܵb1"Ec؄-^Dő kyd~ m{CzZ6?\#/@#BfuߕW8 SS& BpՎͣG3vADmH/80ѫ4 Qb<׈WlgL]6@ l٢Hx ktB@Dؠ }9AG4hg%%E?VlWEpӧd}U,!ȹ]TẺj#t_7+*`ǽ@U]gW޳HUV_vFm/;Fd/wi}'ZWUX ?ecoɭ6;$^"QGЋ Gu+brfbGrL`_ .z]:#8o-o":_]4:R*BJ:O2K"ƴ`m"ȗM!S!Hr4;cys> r,QМG ̭l2ߴ"_2%Qcs_EEZf̦cکZ̯|{׷xjs(__l_yS>9M)r!릮"u:~qe4V /sz[1W|b6ɢ]'W~-y=%>e;׹5]*V[\[9j?o~49c"EnZ823jY[OMskBi$, pӶhMn>-j?F9iXE#,#6G;DI[0z(aR xlnеo'5ǷG;yr@`;VlQk-x5.U'aa2hd@ۤ 0GHƄݩ?ԏU EDEG.b}~|$N '9ؔ#Pa&H5m1蓚a0 Trkx: em pl8VﵳL:0+o꯱Řlv7{@ 6[ז(2QWDB'x.EoyF+}W@P$lLaC[r[|]Z;'} EFX ?ڠ=( iY\eWtjQI:cJ 2ZaG:?7#C95h@YeTPuDk}WԂB+"I7L["Ղ:ԁ];WvgcHk=>jq_N[r\,r[?q$G5U;:%}+[#uuHzR};ًEc惥&"Q">EnԢvcj1a‡9C;)G vd Te? R![Θoo䉜?W!HCaGUe͏H>һ!;lVen)'ӧĸTO{|'E/"UBbQi/W5s_( O mkrf Fʘ/ӎWZxUzY'DkXci O+UBXom=W>~6;={6鋥2oC筇~"IWίߧ R +cbe{Jﺱ 9_Ix,y1mI<ؤ/pXJȭ2.=!jE$(7D7cҚD{|>5FnhKdFHAp#(cA&VM7i!ȗ}[+}E&pqRяF '5-`n%*0&WE-cuyȫ=!XgFD=m9*+h fI ƈz1rD_/}{ѩIxOȭ`n-G%Z@ϪK~]^( X n/;)Epܝ[A~F[r"Tj`TtDvlNu˜S:E5* TUu\/jqήU-n?9(R4LMr˗Fv/yxlSfvYEnc5Ug[8'vžfskQkmbSt:EV+[{ClĆ?wͫ >?wopvFnylw[I󵼧[)C:Z"E}|d᚜Vy޵kl|M[Y}- 7]'[}7No߶^F\[mt/Ay+ž(U뻐۱J%)9wB}^}޺5WuRc+vMm/Zp!%n;VoDaҜBnME\lZ笺us1DAh-Tr0uu6حU@X`z%1;m߭BS9p"K=hբ Wi+>'"ҧc#dLJ}Ul vHъm;X=ckvFXN vPr@p1rX ;OFaߎQX˫v*9@mة\."H"el`H_(e#MVW-j v7D1hLGlNEJڵjA5CRvZ߀@ /oqxLwOnl =7ղ K\N+b'  E~ _U%Zes|DNyֱśymvQZ,/"Ƃ"Z/@}mΰX_}sgG<1ا}eaUvnRiX^#gk@m8Q[;X;rQ- Ұ 3_<=?Z6bsiXY[c $݃=Х啰vxWp{sE栿D>%jAAQBA85Q+: YP}"H`܊`Dd7噸E~;*'7&ݲi@TS"uDmR !Ѱ 5'Q>W3&; ȎrEMc"P1\r@D_gd9XY 1o(=<!PsI+K j~?aCs9w0ڼj3!OəsTv|P"1(t*;"hjTZcƆEױYl~wdnnl-;DK{|%v@DZoE Sb;zQ 7%2xYx"lVef-P}'j6/ɱxX}Ĝa\!vˀq}W%^ψ~%h_)޳װX޶$+om ?xw5`"QiP]̱-y7 J9P9CzG"n_c¿ W9=)rS^C{kgMDŘrTӯ~9^_l)?#&bQMk40}?? DvdCpxsr!!]sTAgo-enOޕ4twLڈU;xj Q_--qεVz y bӵNpߌ7Z;S BwFMb%@Ѱ(FTabIT "KjvǃHC9\rLyXyd,$A_RTЦ^ڬ"L?thYp߂RIA8lMv**..#hd+h%&^$cȍ`Qv,Y8d 9bԥ'lO){@z 6$؀9r,230E}[ٟ~"!DU]#WDٿ1(PRƔ _0 5ޥ}GD urQIѓl6CvA<GZ4:n/.r|THӢFh}[ƝaV?תR{D eV_i çߎ;hYp:Orj1fN>;DY[C>0 No6ytq$n~x .|:i+G-9?o\,˨L cD>!GE-Ÿ-1e#ʾ:8"H?п 1Qs|*Ѻ|G^/ĔM#|r6{C5W$V3?}li>G".5aޘķ )?QŧG=_a91//l‹노cEכ6E'xf|Pw~LΟ|G.lOˏEل#yQv_*N:I>-Xhr]vMqZ1h= U<;9m{B^җΊ/xє!Ov}";@i/naPuw@ل)|6F8z2/51p`L@nrwkwSxAc!#S|~Q 9C02%Z!r jyt~h|JC ~:%I8!*zD'oL(GDDcIe"D6Tŵ?`ꁄ}h(˥&$d<$>Kc;J$QĘ$Q0ȂǪ@.d&璷O28fh~JrbCA.\C~UgƄ^hҲ%ZU:(=(janEqFLfQ1u!׭"1AL@5" J^ƪUlƨ(Ay];[;Q8ƐV gs|g׈B^$NھS kL;o'GƎȦq?+Zĥ|W|mzR}c?*XܬJc,yڳFb'4~o] >*[H3!jӅͪ}([CB3tQ>ϲH<WH1e #dk-TVwH|c\RhG#2d)j/]e7:vja+kG0s2E#i\daJQsLi"Yu~\j8ԍe# ߺN|,PgK|zE 7OU "!RӏDl2+ߋ?W?>ƻo]|9uF@|&>^qs٣gZ*>77EE)Mkƨ@~#rS U+_o xբ_<~A'[毺q)_gPb.1RYƩEdue4ԯ#/O؃rÊ/>Hy'?ڥ#"S`{íǧyo{|'avdSwĞRU>Nrou:rȬuOӯt:ҧY@o"wB]̏E.k.\g@G`x_SB8_#nU_hvpo]^F{4[J<5&rr,{\"{P~iG#'rkKG` `G̭.-P;o~8j׭KG#rqwtt@H??7"s/;oI.y_GuMSw-kܤySHe\ ڶ؇ApWO4ֈ6,mqUs_bH@G#t:@G`"7$db4o&cYѲ{!&||֛fW<ޫW]Cz:@G#t:@G`dGܬUN6?_?O|ޜ|[j{s2JgUFgnWYҼ#W\gIe7ys;C3 v:@G#t:!p衇.!=#^,Jކ7=4 Cąvo|ސq@G#t:@G#pև%R Fǹ#yUm۷*?8 |"glqHFr4F:@G#t:@G` b{Fz~RÏ!vZ%/9k*o1,O?^oZSv:@G#t:}9 mIٹH!æ]ҘW?Pia>ꨣ!#^BG#t:@G#؞'O ۑmfv#ѫfVZ~˥ qW>Ǻݢ.F:*w t:@G#t: ;Lvw a̱Hz^2[WW+Y4+XlKpWBLv{/f2;@G#t:ZC_]"uK\vl^y/ ;Zkvur4S0V/vzr~_p77#t:@G#szWݡ[|oM9Mo{Oݜ܋=CjOI%7#t:@G#Xn3:ٕ=qJHoxw?#ϻV>/dnO~I+\*@l{;~cBoLG#t:@G#Xxo%/ =y%RnSv>nG8ƼF<^=yg 7J>UОxֹ/;`\7#t:@G#Q>lT~$Ncu ߻69|6wvW];< t:@G#t:kԿ?_.|m9%R? {AޅؿzqVJmѷ~ا$ͮw^͎@G#t:@G#p@!Dž&/=g;ㆿ{%|_~=v!k @!ҽ'o~衇e!1@G#t:@G`#{٥\6)_ϟO@NO߾ZM; ?g룽=S;@m{ut'{KG#t:@G#XpW6&6oignmZU9|E> x[VCh ?qjn]Z퓣z#:@G#t:*G \bveO>kۑ~v#8wWynܰkD_@N=v6_&sOnMzn@G#t:@G#P#[`7l8)vf[VmΟp;vF>U_=y[ޑ7tw7@G#t:@G#xq8e ?DN;mCj=&@; <<|n@IxSO=7~7;@G#t:gfÞYmxw!{nAC{6`07#t:@G#eBXuXҎ=gku.< }9YFb~Öw)9vgt:@G#E8|2߶N3Dhg8(j۲{;s1}݊:@G#t:"["c :yx,t/[xdKb7=`>,yoRV@p9.#t:@G#t˭KGyû˭'ۑ[.6vν ]o} P:OI|Ϥ b{o unO/RVlrz@G#t:@G#p0#wã[d׬''}' Z΋_`ٹyyWvu I:m$ڱ};}v;ܛA9vU9Ї7,7f%bw:ọ(< fdewEval"0pPaEV@TAa/8 l lh8l" K`Xy~͵o߬}o?|竮z>{? H@$0Py=gB^15=e֙h u1Oy{0E^U}Ȃ:oW$  H@@;H*rt:$t?ґ8l!5 s>|"u#zn${P*|q^vV K"$  H@$ !ݰ >WfJM#ttڅh#g7ݧ 01 ܼi  YV$  H@:@zA ,–AC]G 4vzys`o(G#7zGl(&CC+v|wy璼Do4KQ ̙,d$  H@$0W PWB#K0DdeFF'Ѧ߃hozB5(wܸRˍcTz,skJ$  H@@{@}s8zҐ'Gff1YWa UK.8;7* ,%oϲiM1/M$  H@8?H33('ǽmG|F~;¸0%1b nō{+o'߳滗L1tE}3$  H@$h%f]Ms2ZIh[g1dT 07uKn/#p[0۾Zͅ7wv&E$  H@@#I!FnJf*Yͦ)زt4:]jW.7lncEnl̅{k*m$  H@$  ,Du{'PG{=m&{.e e@EA|DiW^o uG"vgs)M$  H@$ЁuqZ#.ci3g9jJa7|zgsfY K榭͍>c(yd\FxO gy$  H@$0O>VٮT}2Fjfy`YͺllpנMMVn|R 'M}R57)c( H@$  5tɧh_C\FڦSM4۝05's#ݍ!L-(iʙ4,o7Z$  H@$(+eM4'4 UC+aڟ$7?ߚG+ތ}\yQByrҔGn<:E+ H@$  H>a{DkhlSaM"̰"Ly7x$|d$Q"r#1G t7JAˑ$  H@ڈU5䋓\t-dl sxF-)gsCm\D{UH K?=IҎǝ{$  H@INLzdF&@vhrXN*4e 7j#Xw-XnS^$  H@"BOD^x-15YU$㶪1O];sɾ~;@)cgRLSqW"1J9W,!eJ@$  Hq!fL`l,mFW(R[F% 9@+D;jI27Ir&;Mo#FVg"naD mhޠIVJ@$  H Dk 2zHIAFKhUoDsL{q"Ppp~M;zސ4{RRK讨R7$  H@$ЙՉ68v!b6)=C!1 L0-!kGҐvuu-֙4~;v2W11q)VR]5r11U}2  H@$  (Yݰzb G6j55~c譆WlHR1ޤ*hWr 78B{T<[$7_;n$  H@>|"\pߴ} e,)?}3.9r9>Q V$K# xL\Δ(nTQL=t=oi~FG|p H@$  H`g_ }|BNܟhmIAݒ9_@  x%k_zRV[mX ʛǃ2'Gby-jv$  H@a|OooKj|%`UA̺Rb|lapk[T-˄'b O#p 'r9N X>1x/*l H@$  H`Ol*JK~c,Hm'YRF $Yvz!@u10aė?[%2AsjiUwOÙ~̙5~%fRO$7xPĈtRYY{LnI[fl^.mH pF4h$  H@hB Di񧿊?}z"@aݫ%۾Rez],9pid 7FƼ--e~mFN%X^}c&^%ƛc2/m+~{,ZڄI;폏m3Om|7?#j%x F!.2 LNjq%cMzcu)Ǹ(—ϗ_JKչ33΁ލ['ib}l2m@m`p@f@<'G?2(mUa߱_-qW[ըlo9(m6$~=p&t8d.1;~H@5Gpa{YD%[җ[}kT5Jg.9s~t*&m@m@ />]1';ExN}z~k+A2T6V3>St,g\J  H`.`,¢)emy8z[EgTBwFTl2m@m`@ߗ'Xχ,Z`M=^Ц6k*Q0dk>jjeI@0~Y"Q<&㶼qb8t_G<,V2nv{@a<d|1,13X m3kXx,Ϣ@˟n 7*Pn[\A.rm@`5SX_ۇswoӿAau/>'iTB֝ll( LSnTbNFqtg5K8?\HuiS|~4>gR*Ed hڀ6 h@g@|E"X??ZGI{v/`OG -mK|ҡWWO/ݽؠrн H``d֪";J30fݑ􇥱P> 'lpNo6 hڀ6 ho#C|x|Hԉٍ`+xtr=`!~L*QIENDB`$$If !vh585#v8#v:V l t06585a p$$If !vh585#v8#v:V l t06585a p}DyK _Toc110592372}DyK _Toc110592373}DyK _Toc110592374}DyK _Toc110592375}DyK _Toc110592376}DyK _Toc110592377}DyK _Toc110592378}DyK _Toc110592379}DyK _Toc110592380}DyK _Toc110592381}DyK _Toc110592382}DyK _Toc110592383}DyK _Toc110592384}DyK _Toc110592385}DyK _Toc110592386DyK yK 0http://www.medicare.gov}DyK _Toc110592397}DyK _Toc110592398$$If!vh55#v#v:V l t006,552V2 sytrDd$P\  3 S"`($88Dd$P\  3 S"`($88Dd$P\  3 S"`($88Dd$P\  3 S"`($88Dd$P\  3 S"`($88Dd$P\  3 S"`($88Dd$P\  3 S"`($88Dd$P\  3 S"`($88Dd$P\   3 S"`($88Dd$P\   3 S"`($88 Dd$P\   3 S"`($88 Dd$P\   3 S"`($88 Dd$P\   3 S"`($88 Dd$P\  3 S"`($88 ^ 666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH X`X huNormaldd[$\$!B*CJ_HaJmH phsH tH `@` hu Heading 1$$<@&a$5CJKH OJQJ\^JaJ V@V hu Heading 2$<@&5OJQJ\]^JaJVV hu Heading 3$<@&5CJOJQJ\^JaJJJ hu Heading 4$<@&5CJ\aJNN hu Heading 5 <@&56CJ\]aJRR hu Heading 6$x@&56CJOJQJhLL hu Heading 7$@&5>*B* CJaJph@@ hu Heading 8 <@&6]N N hu Heading 9 <@&CJOJQJ^JaJDA`D Default Paragraph FontRi@R  Table Normal4 l4a (k (No List dd huHeading 2 Char056CJOJQJ\]^J_HaJmH sH tH XX hu Char Char1*5CJOJQJ\^J_HaJmH sH tH JJ hu Char Char5CJ\_HaJmH sH tH <O!< hu 1 insertsfHq RO1R hu2 instructions:B*fHphq >OB> hu 0 bullet1  & FhPQP hu0 bullet1 CharCJ_HaJhmH sH tH 0U@a0 hu Hyperlink>*B*`r` huPDP Heading 2 F$hh@&5CJOJQJ^JaJP!P huPDP Heading 2 A hh 6\]aJvv huPDP Heading 3 A  (#1$"56B*OJQJ\^JaJphTT huH6 Bullet Under Bullet  & FaJ:: huPDP Heading 2 B:: huPDP Heading 3 BB@ huBody Text,Body Text Char,Body Text Char Char Char Char Char Char,Body Text Char Char Char,Body Text Char Char Char Char Char Char Char Char Char Char Char,Body Text Char Char Char Char Char Char Char Char Char Char Char Char Char5OJQJ^JaJ:: huPDP Heading 2 IB'B huComment ReferenceCJaJ^O^ hu Char Char2056CJOJQJ\]^J_HaJmH sH tH BB hu Bullet CharCJ_HmH sH tH RR@"R huBody Text Indent 2"hdx^h`2` huPDP Heading 2 E#$hh@&5CJOJQJ^JaJ<PB< hu Body Text 2 $dxvRv huPDP Heading 3 E%  (#1$"56B*OJQJ\^JaJphLbL huNotes in italic &x1$ 6aJh`r` huPDP Heading 2 D'$hh@&5CJOJQJ^JaJ\ @\ huFooter-( & F  !x1$^`aJhTT hu* Bullet Aligned with H6 ) & F`` huPDP Heading 2 C*$hh@&5CJOJQJ^JaJb^b hu Normal (Web) + & F *^`OJPJQJ^JTT hu Special 6,$hh@&>*CJOJQJ^JaJZZ huBullets Char Char- & FP1$ B*aJph>> hu 0 bullet2 . & FhPP huNumbers - normal / & FaJh<@< hu Comment Text0CJaJHH hu Balloon Text1CJOJQJ^JaJ! huOBody Text Char Char Char Char Char Char Char Char Char Char Char Char Char CharCJ_HhmH sH tH u2 husection subheading<3 ,hp@ P !1$"56B*CJOJQJaJhph:B: huPDP Heading 2 G4:R: huPDP Heading 3 G5b huSection subhead #3<6 ,hp@ P !xx1$"56B*CJOJQJaJhphRrR hu Numbered list7 hPP1$aJhVOV huNormal - block indent 8x1$aJhdd huNormal - block indent CharCJ_HhmH sH tH JJ huPDP Heading 4 G :5aJdd huHeading - no TOC ;5B* CJOJQJaJhph:O: huCM5<d7$8$H$OJ QJ HH huCM5 Char CJOJ QJ _HaJmH sH tH @ huHeader,Header Char,Header Char2 Char,Header Char Char1 Char,Header Char2 Char Char Char,Header Char Char1 Char Char1 Char,Header Char3 Char Char Char Char Char,Header Char2 Char Char Char Char Char Char,Header Char Char1 Char Char1 Char Char Char Char > !.)@. hu Page NumberFVF huFollowedHyperlink >*B* phZZ huHeading 4 Char&5CJOJQJ_HaJhmH sH tH h!h huHeading 3 Char35B* CJOJQJ^J_HaJhmH phsH tH J2J huNumbersC ^`hLC@BL huBody Text IndentDhx^haJ>QR> hu Body Text 3ExCJaJb hu Step headings-F  @ P !x1$&56B*CJKHOJQJaJhphXqX huPDP Heading 4 E Char5CJ_HmH sH tH @@ huBulletsH & Fx1$aJh>O> hupdpheading4echar5\DD hu notesinitalic JxG$6]00 hu Char Kd! huMHeading 2 + Times New Roman,(Latin) 20 pt,Not (Latin) Bold,Not (Latin) Ita...L56CJ(OJQJ^JHH hu 2instructions:phq DZD hu Plain TextNCJOJ QJ ^J aJVoV huDefault O7$8$H$!B*CJ_HaJmH phsH tH FOF hu Char Char3CJ_HaJmH sH tH 66 hu1inserts q :": hudefaultR7$8$ B*ph,2, hucm3 S7$8$`A` huHeading 3 Char1*5CJOJQJ\^J_HaJmH sH tH 6Q6 hu Footer CharCJhfObf huColorful List - Accent 12 V^m$ OJPJ QJNqN huBody Text Indent 2 CharCJaJ@@ huBody Text 2 CharCJaJzOz hu 15 paragraph after 15 pt headingYEdx]E CJ\aJ^O^ hu14 point heading Zdx5CJOJQJ^JaJ:: huComment Text Char:O: huPa6\dB*OJ QJ ph husection subheading Char CharB] ,hp@ P !1$[$\$"56B*CJOJQJaJhphtt huSection subhead #2^  (#1$[$\$5B*OJQJaJphRR huHeading 1 Char5CJ KH OJQJ\^JaJ 88 hu Footer Char1CJh>> huPa7adB*OJPJQJph66 huCM44b1$ B*_H ph O1  huBody Text Char Char Char Char Char Char Char,Body Text Char Char Char Char,Body Text Char Char Char Char Char Char Char Char Char Char Char Char,Body Text Char Char Char Char Char Char Char Char Char Char Char Char Char Char Char Char,Body Text Char15CJOJQJ^JT`BT hu No Spacingd$CJOJPJ QJ_HaJmH sH tH XQX hu Char Char8*5CJOJQJ\^J_HaJmH sH tH 6a6 hu Char Char5CJh6q6 hu Char Char7CJaJ66 hu Char Char6CJaJ\\ hu 15 pt headingidx\$5CJOJQJ^JaJzz huImportant Indented Paragraphj[$\$]5OJQJ_H RR hu TOC Heading 1k$[$\$a$>*CJ^J_H D!D hu TOC Heading 2l[$\$^J_H DD hunormailm56>*B*OJQJph\\ huTable Header 1n$[$\$a$5OJQJ_H pOp huChapter Heading%o$7$8$H$[$\$a$gds5>*CJOJQJP@P 2JpTOC 2+p $ `]^``gd2J\@\ 2JpTOC 1+q T$ T]^T`gd2J 5OJQJ.. hupTOC 3 r^.. hupTOC 4 s^.. hupTOC 5 t^.. hupTOC 6 u^.. hupTOC 7 v^.. hupTOC 8 w^.. hupTOC 9 x^O! huSection SubHeading 1 Ch 1fyp ,$d%d&d'dNOPQ[$\$^p` gdAv^J_H O huSection Heading Ch 1Nz$p,<$d&d @&NP [$\$^p`gdAv5CJKH OJQJ\_H aJ O  :Section Heading Ch 2P{$ $p<$d&d @&NP [$\$^p`5CJKH OJQJ\_H aJ O huSection Heading Ch 3N|$p,<$d&d @&NP [$\$^p`gdAv5CJKH OJQJ\_H aJ NON huSection SubHeading 1 Ch 3}DOD huSection Heading Ch 4~NON huSection SubHeading 1 Ch 4DOD huSection Heading Ch 5NON huSection SubHeading 1 Ch 5DO"D huSection Heading Ch 6NO2N huSection SubHeading 1 Ch 6DO!BD huSection Heading Ch 7NO1RN huSection SubHeading 1 Ch 7DOAbD huSection Heading Ch 8NOQrN huSection SubHeading 1 Ch 8FOaF huSection Heading Ch 10POqP huSection SubHeading 1 Ch 10FOF huSection Heading Ch 11Oa Part Heading Ch 9C$d&d-DM NPgdJOaJ Section Heading Ch 9gdTOqT Section SubHeading 1 Ch 9gdhOh Question Mark$[$\$a$gdCJ8OJQJmHnHuNON  Step Heading[$\$ 5OJQJtO t Section SubHeading 2 Ch 9hx[$\$`h6OJQJ^JBjB q.dComment SubjectCJaJ\O" \  Legal Terms$$[$\$`a$gdOJQJ<Y2 < qe0 Document MapOJQJJA J qe0Document Map CharCJOJQJaJPR P V Replace Text[$\$ B* _H phpfb f $aColorful List - Accent 11 ^m$ OJPJ QJJr J sG? TOC Heading 3p]pgdYR56  >a,Header Char1,Header Char Char,Header Char2 Char Char,Header Char Char1 Char Char,Header Char2 Char Char Char Char,Header Char Char1 Char Char1 Char Char,Header Char3 Char Char Char Char Char Char,Header Char2 Char Char Char Char Char Char CharCJ_HaJmH sH tH .O . 6/ list bulletb@ b cList Paragraph ^m$B*CJOJPJ QJaJphPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]  PPPPPP      P  GtjlS )2Apkz \ L\ \ \ ] I] ] ] ] 7^ o^ ^ ^ !_ Y_ _  :<>@BBDDDDDDK[]]]]w%%%%%%&(((* K.*"#$%'()+h27m;`? JOT]{bgmSsugds.>g5ʫt65q>- *^ s(P$}*8>qP[]3_bh^rQvwa|~#LjlG3`B9xB   zNPm'=16Z;AkGRP[`3it|w*@T׶r>\c?Ue @ `7:"*N9<1?H@M_lv)ލ:עP٩:9#GW|& #-5? G!LT^n}c̕x" w#3I;8DJLMOOP]UJ^cjstyzRSٚ yY4 U^    !"'+038=BFKPQW\^chmotx{   !#%')+,-./013468:<>?BGINPQSUWXY[]`bdefhkmnprsuwxyz|}~   !%(,Gr!^(/1A9-DcTvhF{SdKd;ޗsMΜ/p}¤a20fv|^(Kc} \[T,9,RGzw%j- S\(3FKWZ_hTvvwpx`|}~6ՃH1l)Mi:Gdٻf;^kk9> A$!+=FN_epf|*H =K }< p8n lx &2:kDHS^i zA 86<c->3 6;>CEHK7RQ\:`gmfou*x+ t;αɳ@7(^tb)] o 9v#&)-0z34V7=9;*?/A GPU3_h:pxjz+kRf ?FVs}[,  #$%&()*,-./1245679:;<>?@ACDEGHIJLMNORSTUVXYZ[]_`abdefgijklnpqrsuvwyz|}~   "$&(*2579;=@ACDEFHJKLMORTVZ\^_acgijloqtv{   "#$&')*+-g   /KN/KN8; $(9=?`|~ "e )+g9;"$s> Z \ B!^!`!!!!"""%"v""""bEbVbՀg;>Zvy"yфFbegװº*5`P"s-k#?B ),wOkn %(i9UX#?B ),.SST:T=TTTTU*U-UUUUUVV[VwVzVVVVW2W5WrWWWW/Gcf#&m\x{ '*]y|#?B~`|'CFy!=@)EH0LOOkn^z}$'_{~  V r u    3 O R        H69ç ),"qݩjxe %(׭ڭGcfخۮ=Y\Я7:l۰}WsvϲҲ-0D`c ]y}%AE*FJ>Z^`C22222333464:444455#555556666672767r777777#8?8C8E8n o7o^ВԒ*.Xtxғ:VZA]aƕ6RVЖԖ&BFf26ڙޙ37Ț̚-IMٛ9= y '+ '+w '+ڡFbfҢ^z~ʣ;? hԦئB^bd~A B%BABEBBBBBCCVCrCvCCDDDDDDEEREnErEEEEMFiFmFFFF4GPGTGGGGH$H(HHHHHXY&Yppq9q=qhqqqq %%%%%%%%%%%%̕ %%%%%%%%%%%%%%%%%%%%%X %%%%%%%%%̕XXXXXXXXX %%%%%%%%%%%%%%%%%%%%̕ %%%%%%%%%̕ %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%̕ %%%%%%%%%%%%%%%%%%%%%%%%%%%%%̕ %%%%%%%%%̕ %%%%%%%%%%%%̕X %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%̕X %%%%%%%%%%%%%%%̕X %%̕+CFKRVWorw~ ay} !`x|c{!!!!!!!!!!!!!!!!!!!!!X  ((2${?KEg¶kd_ B$G\;=X+|%R$?c\  #B$)XVٚ8ȟ" B$\>E^GC B$)0r B$0pa#IJH B$T<4si, 2$oP Ӕt/ B$/w~ Zh**B$_-ϞF ar"a+2$6789:;?@ABCDEFGKLMHIJNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<>=?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~@""""""""""""))))z*z*z*H,H,H,000000000333555,<,<,<~<~<~<AHHH0IwIwIwILLL?M?M?M2W2W2W'Y,Z,Z,ZqZqZqZ'\'\'\r\r\r\___-`-`-`nnnoooprrttzgnr `e ,g<%s> ] B!a!!!"&"v""g ?Zz#%EL5t@ttttt wwGwSwxxblÙ̙ -Z`krBOlru|qz~Y_ahnwܮ@E\a $)[[ 'CGSSos]z~\y_|'CSo]z\y_| `e ,g<%s> ] B!a!!!"&"v""g ?Zz#ܮ++yy  11ڙڙ88[[DD##>EP +'CGSYSos&1]z~+6\y_|46>96&^J.am&x!T<6JB4 5B2wnDꌐ)WRxjh^x;8!>y%u: $+ 8Zkz4{v LPf}015 zp ( s@zqJh{x>> lLMTt]` 2oqPgpW>x-0 :bmlF >r5 +\ &t:G\nvt(6@37r:x4\N $(]4C!*Y!T0/|!*fI")lP# G#DRcd# y%<d#%H(i%N::%Z'j&PZ:y&8UU3&z]J1&CUs'^:4z'j` R(X3<C}p(Lzmr(_ *`A)l6*bHc-,[s,CLQ,Pj$ ,V96- ;.̅<0Zq_R1УI1&a]4(bP;42cf4 si4 r5lwh6Bk"6 j6ĩ !Q7͆@37 Iq74$p,:]a; @;haY< Mtg@Fw~*]B_B\BLABP\yddD0ڥ5DWB+4E NsE AF 1^Fs. G "H ckI 6vJDmRJ qJkKsG5L$VrfLvl`YL,> x*NP j_N*tN<.O7]O*3-OιΈqn?OZjbzaQVx`RLUSLTN92T KU wU4C[YVTNv V\ \\ t\ `\ 2=[]ڷ`z]Р-)kczid$ OFeP !Ae )f F=Tgag1-Ai4o,^fo\pFDo 8'Loȇү"oIpf3zpdLR`rԚYXrhmSjsrx >u PKv?fYmw^B'x!jMx@i<.y T0={С}U.R|b^ gK2| +]}2'8 K(y4h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hH hh^h`OJQJo(h^`OJQJo(hHh^`OJ QJ o(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ o(hHohP^P`OJQJo(hHhp^p`OJQJo(hHh@ ^@ `OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHhP^P`OJQJo(hHh ^ `OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh\^`o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGCJ_HaJsH RwRwh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHhp@ @ ^@ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJQJ_HaJsH Jo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh8^8`OJQJo(hHh^`OJ QJ ^Jo(hHoh ^ `OJQJo(hHh ^ `OJQJo(hHhx^x`OJ QJ ^Jo(hHohH^H`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH. hh^h`OJQJo( hh^h`OJQJo(h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh ^ `OJQJo(hHh ^ `OJ QJ ^Jo(hHoh}^}`OJQJo(hHhM^M`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh] ^] `OJQJo(hHh^`OJQJo(hHh88^8`OJQJo(hH-ho^`4*56789:;<>*@EHH*KHEHOJQJS*TX[\^Jho(GCJsH tH _HhH.h@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHo  ^ `OJQJo(hH  ^ `OJQJo(hHxx^x`OJ QJ ^J o(hHoHH^H`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh8^8`OJQJo(hHh^`OJ QJ ^Jo(hHoh ^ `OJQJo(hHh ^ `OJQJo(hHhx^x`OJ QJ ^Jo(hHohH^H`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJ QJ ^Jo(hHoh@ ^@ `OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHhP^P`OJ QJ ^Jo(hHoh ^ `OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hH hh^h`OJQJo(h88^8`o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJOJ_HaJsH OQOJ OJQJo(hHJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHhp@ @ ^@ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJQJ_HaJsH Jo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJ QJ ^Jo(hHoh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh  ^ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh| | ^| `OJQJo(hHhLL^L`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHhx ^x `OJQJo(hHhH^H`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hH ^`OJQJo(h^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHhh^h`OJQJo(hH^`OJQJo(hH^`OJ QJ ^Jo(hHop^p`OJQJo(hH@ ^@ `OJQJo(hH^`OJ QJ ^Jo(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^Jo(hHoP^P`OJQJo(hHh   ^ `OJQJo(h ^`OJ QJ o(oh ^`OJQJo(h | | ^| `OJQJo(h LL^L`OJ QJ o(oh ^`OJQJo(h ^`OJQJo(h ^`OJ QJ o(oh ^`OJQJo(h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh8^8`OJQJo(hHh^`OJ QJ ^Jo(hHoh ^ `OJQJo(hHh ^ `OJQJo(hHhx^x`OJ QJ ^Jo(hHohH^H`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHhx  ^ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGCJJ QJ_HaJsH J OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHhp@ @ ^@ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJQJ_HaJsH Jo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHhs ^s `OJQJo(hHhC^C`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh8^8`OJQJo(hHh^`OJ QJ ^Jo(hHoh ^ `OJQJo(hHh ^ `OJQJo(hHhx^x`OJ QJ ^Jo(hHohH^H`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hH hh^h`OJQJo(h^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hH hh^h`OJQJo(h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hH 88^8`B*OJQJo(ph ^`OJ QJ o(o ^`OJQJo( hh^h`OJQJo( 88^8`OJ QJ o(o ^`OJQJo(   ^ `OJQJo(   ^ `B*CJOJQJo(ph xx^x`OJQJo(hx  ^ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGCJJ QJ_HaJsH J OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHhp@ @ ^@ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJQJ_HaJsH Jo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohe e ^e `OJQJo(hHh5 5 ^5 `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHhuu^u`OJ QJ ^J o(hHohEE^E`OJQJo(hHh ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH.h88^8`OJQJo(hHh^`OJ QJ ^Jo(hHoh  ^ `OJQJo(hHh  ^ `OJQJo(hHhxx^x`OJ QJ ^Jo(hHohHH^H`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHhhh^h`o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJOJ_HaJsH OQOJ OJQJo(hHJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHhppp^p`o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJQJ_HaJsH Jo(hHh@ @ ^@ `OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH ^`OJQJo(^`OJ QJ ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJ QJ ^Jo(o ^`OJQJo( ^`OJQJo(^`OJ QJ ^Jo(o P^P`OJQJo(h^`o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJOJ_HaJsH OQOJ OJQJo(hHJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHhp@ @ ^@ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJQJ_HaJsH Jo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh hh^h`OJQJo(h 88^8`OJ QJ o(oh ^`OJQJo(h   ^ `OJQJo(h   ^ `OJ QJ o(oh xx^x`OJQJo(h HH^H`OJQJo(h ^`OJ QJ o(oh ^`OJQJo(h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHhx  ^ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGCJJ QJ_HaJsH J OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHhp@ @ ^@ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJQJ_HaJsH Jo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ o(hHohPP^P`OJQJo(hH^`5o(. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hH hh^h`OJQJo(h88^8`OJQJo(hHh^`OJ QJ ^Jo(hHoh  ^ `OJQJo(hHh  ^ `OJQJo(hHhxx^x`OJ QJ ^Jo(hHohHH^H`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hH ^`OJQJo(h^`OJ QJ ^Jo(hHo p^p`OJQJo( @ ^@ `OJQJo(^`OJ QJ ^Jo(o ^`OJQJo( ^`OJQJo(^`OJ QJ ^Jo(o P^P`OJQJo(hq^q`OJQJo(hHhA^A`OJ QJ ^Jo(hHoh ^ `OJQJo(hHh ^ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHhQ^Q`OJQJo(hHh!^!`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh hh^h`OJQJo( 88^8`OJ QJ o(o ^`OJQJo(   ^ `OJQJo(   ^ `OJ QJ o(o xx^x`OJQJo( HH^H`OJQJo( ^`OJ QJ o(o ^`OJQJo(h^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH hh^h`OJQJo( hh^h`OJQJo(h^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH^`OJQJ^Jo(  ^ `OJ QJ ^Jo(o  ^ `OJQJ^Jo(xx^x`o(HH^H`OJ QJ ^Jo(o^`OJQJ^Jo(^`OJQJ^Jo(^`OJ QJ ^Jo(o^`OJQJ^Jo( hh^h`OJQJo(h  ^ `OJQJo(hHh ^`OJQJo(h  ^ `OJQJo(hHh  ^ `OJQJo(hHhxx^x`OJ QJ ^Jo(hHohHH^H`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hH hh^h`OJQJo(h^`OJQJo(hHh^`OJ QJ o(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ o(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH hh^h`OJQJo(h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJ QJ ^Jo(hHoh@ ^@ `OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHhP^P`OJ QJ ^Jo(hHoh ^ `OJQJo(hH hh^h`OJQJo(h^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJo(hHhpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh88^8`OJQJo(hHh^`OJ QJ ^Jo(hHoh  ^ `OJQJo(hHh  ^ `OJQJo(hHhxx^x`OJ QJ ^Jo(hHohHH^H`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHhT^T`OJ QJ ^Jo(hHoh$ ^$ `OJ QJ ^Jo(hHoh ^ `OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohd^d`OJQJo(hHh4^4`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hH^`OJQJo(hH hh^h`OJQJo( hh^h`OJQJo(h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hH hh^h`OJQJo(hh^h`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHhT^T`OJQJo(hHh$ ^$ `OJ QJ ^Jo(hHoh ^ `OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohd^d`OJQJo(hHh4^4`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hH88^8`OJQJo(hH^`OJ QJ o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ o(hHoPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJOJ_HaJsH OQOJ OJQJo(hHJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHhp@ @ ^@ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJQJ_HaJsH Jo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHhXX^X`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHhh^h`. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHhhh^h`OJQJo(hHh88^8`OJ QJ ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJ QJ ^Jo(hHohxx^x`OJQJo(hHhHH^H`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hH^`OJ QJ ^Jo(o pp^p`OJQJo( @ @ ^@ `OJQJo(^`OJ QJ ^Jo(o ^`OJQJo( ^`OJQJo(^`OJ QJ ^Jo(o PP^P`OJQJo(hh^h`OJQJo(hH^`OJ QJ ^J o(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHoPP^P`OJQJo(hH^`OJQJo(hH hh^h`OJQJo( ^`OJQJo( ^`OJ QJ o(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJQJo( ^`OJQJo( ^`OJ QJ o(o PP^P`OJQJo(h88^8`OJQJo(hHh^`OJ QJ ^Jo(hHoh  ^ `OJQJo(hHh  ^ `OJQJo(hHhxx^x`OJ QJ ^Jo(hHohHH^H`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hH^`OJQJo(hH hh^h`OJQJo( hh^h`OJQJo( ^`OJQJo( ^`OJQJo(^`OJ QJ ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJ QJ ^Jo(o ^`OJQJo( ^`OJQJo(^`OJ QJ ^Jo(o P^P`OJQJo(h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHhx  ^ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGCJJ QJ_HaJsH J OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHhp@ @ ^@ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJQJ_HaJsH Jo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHhT^T`OJQJo(hHh$ ^$ `OJ QJ ^Jo(hHoh ^ `OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohd^d`OJQJo(hHh4^4`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hH^`OJ QJ ^J o(hHo  ^ `OJQJo(hH  ^ `OJQJo(hHxx^x`OJ QJ ^J o(hHoHH^H`OJQJo(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJQJo(hH hh^h`OJQJo(hh^h`OJQJo(hHh88^8`OJQJo(hHh^`OJ QJ ^J o(hHoh  ^ `OJQJo(hHh  ^ `OJQJo(hHhxx^x`OJ QJ ^J o(hHohHH^H`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hH**^*`OJQJo(hH^`OJ QJ ^Jo(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJ QJ ^Jo(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^Jo(hHoPP^P`OJQJo(hH hh^h`OJQJo( hh^h`OJQJo(h^`CJOJQJaJo(hHh ^`OJQJo(hpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hH hh^h`OJQJo(h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHhL^L`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh ^ `OJ QJ ^Jo(hHoh\ ^\ `OJQJo(hHh,^,`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hH8^8`CJOJQJaJo(hH^`OJ QJ ^Jo(hHop^p`OJQJo(hH@ ^@ `OJQJo(hH^`OJ QJ ^Jo(hHo^`OJQJo(hH^`OJQJo(hH^`OJ QJ ^Jo(hHoP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ o(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ o(hHohP^P`OJQJo(hH ^`OJQJo(^`OJ QJ ^Jo(hHo  ^ `OJQJo(hH  ^ `OJQJo(hHxx^x`OJ QJ ^Jo(hHoHH^H`OJQJo(hH^`OJQJo(hH^`OJ QJ ^Jo(hHo^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hH hh^h`OJQJo(hh^h`OJQJo(hHh8^8`OJ QJ ^Jo(hHoh^`OJQJo(hHh ^ `OJQJo(hHh ^ `OJ QJ ^Jo(hHohx^x`OJQJo(hHhH^H`OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ o(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ o(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hH hh^h`OJQJo(hx^`o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGCJJ QJ_HaJsH J OJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJQJo(hHhp@ @ ^@ `o(GCJ_HaJsH tH G&B*CJo(;0,aOg.a0GGGJCJQJD_HaJsH Jo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJQJo(hHh ^`OJQJo(h ^`OJ QJ o(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJ QJ o(oh ^`OJQJo(h ^`OJQJo(h ^`OJ QJ o(oh PP^P`OJQJo( hh^h`OJQJo(h ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH.h^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohP^P`OJQJo(hHfLoqd#%agv 3TkMxvt8Iq7H n<0mRJ6*>y;"o+]}2=[] x*NkKY!j$ ,lLMqJ  n` R(,^fo`z]]OI1`RMtg@]4C!wUU3&YXrj6p 7)kcs,a]4qn?O*`A) j_NTY=ckI8 mkx-96LosG5LC}p(!Q7:%SjsI"s' +1^Fi4oIpwh6q_R1:b*]B@;PKvyG#LAB&t:`8 m3zpB'xid5D:xLQ,;.yddD[YV )W>3-OwnD\N &aQi%c-,Dox!TJy% KYL:y&YmwR`r5B p,:mr(.aTz'si4T0={+4EK2|cd#AF`\92TgpWj&\BOFeP;4aY<r5GAe37U.R|NuA>>)flP#@ V\ivJmlk\\NsE5 F=Tg6-"HB4cf4KUi<.yt\US3$+. G"6u:a;O/|!                                                      $                                                              2|AB6GOGVVI9dJvKRPQSX}SU-U]UGV WGMX Y`ZX][xT]p\]r_a!b}c7dP0e2fk' ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~  Oh+'0  8 D P \hpx[Insert date]Kelly MoriartyNormalMichael Canonico17Microsoft Office Word@$@H@M5@v<h՜.+,D՜.+,L hp  Hewlett-Packard Company  [Insert date] Title, 8@ _PID_HLINKSANI]http://www.medicare.gov/I]http://www.medicare.gov/{vhttp://www.minnesotahelp.info/c*http://www.rrb.gov/mt www.mnaging.org./admin/ooom.htmg&;http://www.dhs.state.mn.us/healthcare/managedcareombudsmang&;http://www.dhs.state.mn.us/healthcare/managedcareombudsman<`www.dhs.state.mn.us/healthcareb(http://www.ssa.gov/ Dhttp://www.stratishealth.org/rrwww.minnesotahelp.infoI]http://www.medicare.gov/I]ihttp://www.medicare.gov/  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~        !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGIJKLMNOQRSTUVWxRoot Entry F@$<zData cED1TableWordDocument SummaryInformation(HDocumentSummaryInformation8PCompObjy  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q